---
document_datetime: 2023-09-21 19:45:33
document_pages: 193
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/keytruda-h-c-3820-ii-0069-epar-assessment-report-variation_en.pdf
document_name: keytruda-h-c-3820-ii-0069-epar-assessment-report-variation_en.pdf
version: success
processing_time: 513.3755614
conversion_datetime: 2025-12-31 02:28:03.966687
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

25 July 2019 EMA/CHMP/455620/2019 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Keytruda

International non-proprietary name: pembrolizumab

Procedure No. EMEA/H/C/003820/II/0069

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                  | ..............................................6                                                           |
|-----------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................6  |                                                                                                           |
| 1.2. Steps taken for the assessment of the product.........................................................7                |                                                                                                           |
| 2. Scientific discussion                                                                                                    | ................................................................................7                         |
| 2.1. Introduction.........................................................................................................7 |                                                                                                           |
| 2.2. Non-clinical aspects                                                                                                   | ............................................................................................11            |
| 2.2.1. Ecotoxicity/environmental risk assessment                                                                            | .........................................................11                                               |
| 2.2.2. Discussion and Conclusion on non-clinical aspects                                                                    | ...............................................11                                                         |
| 2.3. Clinical aspects                                                                                                       | ..................................................................................................11      |
| 2.3.1. Introduction....................................................................................................11   |                                                                                                           |
| 2.3.2. Pharmacokinetics.............................................................................................12      |                                                                                                           |
| 2.3.3. Pharmacodynamics..........................................................................................23         |                                                                                                           |
| 2.3.4. PK/PD modelling..............................................................................................27      |                                                                                                           |
| 2.3.5. Discussion on clinical pharmacology...................................................................27             |                                                                                                           |
| 2.3.6. Conclusions on clinical pharmacology.................................................................28              |                                                                                                           |
| 2.4. Clinical efficacy                                                                                                      | ..................................................................................................28      |
| 2.4.1. Dose response study(ies)                                                                                             | .................................................................................28                       |
| 2.4.2. Main study(ies)                                                                                                      | ...............................................................................................29         |
| 2.4.3. Discussion on clinical efficacy............................................................................85        |                                                                                                           |
| 2.4.4. Conclusions on the clinical efficacy.....................................................................90          |                                                                                                           |
| 2.5. Clinical safety                                                                                                        | ....................................................................................................91    |
| 2.5.1. Discussion on clinical safety ............................................................................           | 172                                                                                                       |
| 2.5.2. Conclusions on clinical safety ..........................................................................            | 182                                                                                                       |
| 2.5.3. PSUR cycle                                                                                                           | ................................................................................................... 182   |
| 2.6. Risk management plan......................................................................................             | 182                                                                                                       |
| 2.7. Update of the Product information                                                                                      | ...................................................................... 187                                |
| 2.7.1. User consultation...........................................................................................         | 187                                                                                                       |
| 3. Benefit-Risk Balance............................................................................187                      |                                                                                                           |
| 3.1. Therapeutic Context .........................................................................................          | 187                                                                                                       |
| 3.1.1. Disease or condition.......................................................................................          | 187                                                                                                       |
| 3.1.2. Available therapies and unmet medical need.....................................................                      | 187                                                                                                       |
| 3.1.3. Main clinical studies .......................................................................................        | 188                                                                                                       |
| 3.2. Favourable effects ............................................................................................        | 188                                                                                                       |
| 3.3. Uncertainties and limitations about favourable effects...........................................                      | 188                                                                                                       |
| 3.4. Unfavourable effects.........................................................................................          | 189                                                                                                       |
| 3.5. Uncertainties and limitations about unfavourable effects                                                               | ....................................... 190                                                               |
| 3.6. Effects Table....................................................................................................      | 190                                                                                                       |
| 3.7. Benefit-risk assessment and discussion...............................................................                  | 191                                                                                                       |
| 3.7.1. Importance of favourable and unfavourable effects............................................                        | 191                                                                                                       |
| 3.7.2. Balance of benefits and risks...........................................................................             | 191                                                                                                       |
| 3.7.3. Additional considerations on the benefit-risk balance                                                                | ......................................... 191                                                             |
| 3.8. Conclusions                                                                                                            | ..................................................................................................... 191 |

<div style=\"page-break-after: always\"></div>

## 4. Recommendations ...............................................................................  191 5. EPAR changes  ......................................................................................  193

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| Abbreviation   | Definition                                             |
|----------------|--------------------------------------------------------|
| 1L             | First-line                                             |
| 2L             | Second-line                                            |
| ADA            | Antidrug antibody                                      |
| AE             | Adverse event                                          |
| AEOSI          | Adverse event of special interest                      |
| ALT            | Alanine aminotransferase                               |
| AST            | Aspartate aminotransferase                             |
| ATP            | Adenosine triphosphate                                 |
| BICR           | Blinded independent central review                     |
| BID            | Twice daily                                            |
| ccRCC          | Clear cell renal cell carcinoma                        |
| CD8            | Cluster of differentiation 8                           |
| cHL            | Chronic Hodgkin's lymphoma                             |
| CI             | Confidence interval                                    |
| CHMP           | Committee for Medicinal Products for Human Use         |
| CR             | Complete response                                      |
| CPS            | Combined proportion score                              |
| CSR            | Clinical Study Report                                  |
| DCR            | Disease control rate                                   |
| DFG-out        | Asparagine-phenylalanine-glycine out                   |
| DOR            | Duration of response                                   |
| EC50           | Half maximal effective concentration                   |
| ECOG           | Eastern Cooperative Oncology Group                     |
| ESMO           | European Society for Medical Oncology                  |
| EU             | European Union                                         |
| FDA            | US Food and Drug Administration                        |
| FoxP3          | Forkhead box P3                                        |
| HNSCC          | Head and neck squamous cell carcinoma                  |
| HR             | Hazard ratio                                           |
| IA1            | Interim analysis 1                                     |
| IFNα -2b       | Interferon alpha 2b                                    |
| IFNγ           | Interferon gamma Immunoglobulin G4                     |
| IgG4           |                                                        |
| IL-2           | Interleukin 2 Metastatic Renal Cell Carcinoma Database |
| IMDC ITT       | International Intent-to-treat                          |
| IV             | Intravenous                                            |
| KEYNOTE(-426)  | KN(426)                                                |
| KM             | Kaplan-Meier                                           |
| KPS            | Karnofsk Performance Status                            |
| MSI-H          | Microsatellite instability-high                        |
| MSKCC          | Memorial Sloan Kettering Cancer Center                 |
| mTOR           | Mammalian target of rapamycin                          |
| NCCN           | National Comprehensive Cancer Network                  |
| nccRCC         | Non-clear cell renal cell carcinoma                    |
| NSCLC          | Non-small cell lung cancer                             |
| ORR            | Objective response rate                                |
| OS             | Overall survival                                       |
| PD             | Progressive disease                                    |
| PD-1           | Programmed cell death 1                                |
| PDGFR- β       | Platelet-derived growth factor receptor beta           |
| PD-L1          | Programmed cell death 1 ligand 1                       |
| PD-L2          | Programmed cell death 1 ligand 2                       |
| PFS            | Progression-free survival                              |
| PK             | Pharmacokinetics                                       |
| PMBCL          | Primary mediastinal large B-cell lymphoma              |
| PR             | Partial response                                       |

<div style=\"page-break-after: always\"></div>

| Abbreviation   | Definition                                               |
|----------------|----------------------------------------------------------|
| Q3W            | Every 3 weeks                                            |
| Q6W            | Every 6 weeks                                            |
| Q8W            | Every 8 weeks                                            |
| Q12W           | Every 12 weeks                                           |
| QD             | Once daily                                               |
| RCC            | Renal cell carcinoma                                     |
| RECIST 1.1     | Response Evaluation Criteria in Solid Tumors version 1.1 |
| RIP-Tag        | Rat insulin promoter-SV40 T/t antigen                    |
| RSD            | Reference Safety Dataset                                 |
| RTK            | Receptor tyrosine kinase                                 |
| SAE            | Serious adverse event                                    |
| SAWP           | Scientific Advice Working Party                          |
| SD             | Stable disease                                           |
| TILs           | Tumor infiltrating lymphocyte                            |
| TNFα           | Tumor necrosis factor alpha                              |
| TKI            | Tyrosine kinase inhibitor                                |
| TPS            | Tumor proportion score                                   |
| TTR            | Time to reponse                                          |
| US             | United States                                            |
| VEGF           | Vascular endothelial growth factor                       |
| VEGFR          | Vascular endothelial growth factor receptor              |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Merck Sharp &amp; Dohme B.V. submitted to the European Medicines Agency on 9 January 2019 an application for a variation.

The following variation was requested:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of Indication to include first line treatment of advanced or metastatic renal cell carcinoma (RCC) as combination therapy of pembrolizumab together with axitinib based on the results of the first Interim Analysis (IA1) from the pivotal study, KN426, an ongoing, Phase 3, randomized, open-label, multicenter, global study, to evaluate the efficacy and safety of pembrolizumab in combination with axitinib versus sunitinib in previously untreated subjects with advanced/metastatic RCC. It also includes supportive data from KEYNOTE-427 Cohort A (pembrolizumab monotherapy) and a Sponsored Study A4061051 (axitinib monotherapy). As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance.

In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet.

The risk management plan (RMP) Version 24.1 is submitted.

The requested variation proposed amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision(s) P/0043/2018 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0043/2018 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

Scientific advice has been obtained from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) pertained to clinical aspects of the dossier regarding the design of the Keynote 426/427; Procedure No.: EMEA/H/SA/2437/13/2016/II. Objections were raised regarding the

<div style=\"page-break-after: always\"></div>

choice of combination TKI (axitinib) and comparator (sunitinib). The CHMP did not support the proposed use of different TKI as comparator (sunitinib) and backbone treatment (axitinib in combination with pembrolizumab). A pure add-on trial with either sunitinib or axitinib as the comparator and backbone treatment  was  advised.  In  addition,  the  Applicant  was  advised  to  consider  including  a  third  arm, pembrolizumab monotherapy.

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Daniela Melchiorri

Co-Rapporteur:

Jan Mueller-Berghaus

| Timetable                                                                                  | Actual dates    |
|--------------------------------------------------------------------------------------------|-----------------|
| Submission date                                                                            | 9 January 2019  |
| Start of procedure                                                                         | 27 January 2019 |
| CHMP Rapporteur's preliminary assessment report circulated on                              | 25 March 2019   |
| CHMP Co-Rapporteur's preliminary assessment report circulated on                           | 22 March 2019   |
| PRAC Rapporteur's preliminary assessment report circulated on                              | 27 March 2019   |
| PRAC RMP advice and assessment overview adopted by PRAC on                                 | 11 April 2019   |
| CHMP Rapporteurs' updated joint assessment report circulated on                            | 19 April 2019   |
| Request for supplementary information adopted by the CHMP on                               | 26 April 2019   |
| MAH's responses submitted to the CHMP on                                                   | 1 May 2019      |
| CHMP Rapporteurs' preliminary joint assessment report on the MAH's responses circulated on | 3 June 2019     |
| 2 nd Request for supplementary information adopted by the CHMP on                          | 27 June 2019    |
| MAH's responses submitted to the CHMP on                                                   | 2 July 2019     |
| CHMP Rapporteurs' preliminary joint assessment report on the MAH's responses circulated on | 11 July 2019    |
| CHMP Opinion                                                                               | 25 July 2019    |

## 2. Scientific discussion

## 2.1. Introduction

This application concerns an extension of indication to include the first-line combination treatment with pembrolizumab and axitinib of adult patients with advanced or metastatic renal cell carcinoma (RCC).

## Pembrolizumab

Keytruda (pembrolizumab) is a humanized mAb of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade enhances functional activity of the target lymphocytes to facilitate tumor regression and, ultimately, immune rejection. In vitro and in vivo experiences have shown that PD-1 and PD-L1 blockade using a mAb can result in activation of antitumor T cells and subsequent tumor regression. In T-cell activation assays using human donor blood cells, the EC50 was in the range of 0.1 to 0.3 nM. Pembrolizumab also modulates the level of IL2, TNFα,

<div style=\"page-break-after: always\"></div>

IFNγ,  and  other  cytokines.  The  antibody  potentiates  existing  immune  responses  in  the  presence  of antigen  only;  it  does  not  nonspecifically  activate  T  cells.  The  PD-1  pathway,  especially  the  PD-1 receptor-ligand interaction, represents a major immune-control switch that may be engaged by ligands expressed  in  the  tumor  microenvironment  to  overcome  active  antitumor-specific  T  cell  immune surveillance.

Keytruda  is  approved  in  EU  for  melanoma,  NSCLC  (both  monotherapy  and  in  combination  with chemotherapy), refractory classical Hodgkin lymphoma, urothelial carcinoma, and HNSCC.

Clinical studies are being conducted in these tumor types, as well as in several other advanced solid tumor indications and hematologic malignancies.

## Axitinib

Inlyta (axitinib) is an oral, potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor  receptors  (VEGFR)-1,  VEGFR-2  and  VEGFR-3.  These  receptors  are  implicated  in  pathologic angiogenesis, tumour growth, and metastatic progression of cancer. Axitinib has been shown to potently inhibit VEGFR-mediated endothelial cell proliferation and survival. Axitinib inhibited the phosphorylation of VEGFR-2 in xenograft tumour vasculature that expressed the target in vivo and produced tumour growth delay, regression, and inhibition of metastases in many experimental models of cancer

Inlyta is approved in EU for the treatment of advanced RCC after failure of 1 prior treatment with sunitinib or a cytokine.

## Renal Cell Carcinoma (RCC)

RCC is the seventh most common cancer in men and the ninth most common in women, accounting for 2% to 4% of all adult malignancies. Approximately 85% of renal tumors are RCC and approximately 70% of  these  are  of  clear  cell  histology.  Other  less  common  histologies  include  papillary,  chromophobe, translocation, and collecting duct tumors [NCCN Clinical Practice Guidelines in Oncology: kidney cancer: version  3.2019].  Smoking,  obesity  and  hypertension  are  established  risk  factors  for  RCC.  Several hereditary conditions, such as von Hippel-Lindau disease, predispose patients to having an increased risk of developing RCC [NCCN Clinical Practice Guidelines in Oncology: kidney cancer: version 3.2019]. At the initial diagnosis, approximately 65% of patients have localized disease; 16% have regional spread, and 16% have distant metastasis [Siegel RL, et al. Cancer statistics, 2018. CA Cancer J Clin. 2018].

In Europe, the expected number of new cases and deaths from kidney cancer for 2018 is 136,500 and 54,700,  respectively  [Ferlay  J,  et  al.  Eur  J  Cancer  2018;103:356-87.].  The  5-year  survival  rate  for advanced RCC is still poor, approximately 12% [NCCN Clinical Practice Guidelines in Oncology: kidney cancer: version 3.2019].

## Current Therapies for First-Line Advanced RCC

A number of medicines are approved in EU for the first-line treatment of advanced RCC.

According to the main guidelines (RCC: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, update January 2019; NCCN Clinical Practice Guidelines in Oncology: kidney cancer: version 3.2019) tumor histology and risk stratification is important in treatment selection. The Memorial Sloan Kettering Cancer Center (MSKCC) Prognostic Model has been the most widely used until recently to define risk  groups  of  patients  by  combining  five  independent  prognostic  factors  for  survival  (interval  from diagnosis to treatment less than 1 year, Karnofski PS&lt;80%, serum lactate dehydrogenase [LDH]&gt;1.5 ULN, corrected serum calcium&gt;ULN and serum hemoglobin&lt;ULN). A prognostic model derived from a population of patients with metastatic RCC treated with VEGF-targeted treatment has been more recently developed, known as International Metastatic RCC Database Consortium (IMDC) score: this model take into  consideration  six  clinical  parameters  to  stratify  patients  into  favourable,  intermediate  and  poor

<div style=\"page-break-after: always\"></div>

prognosis groups: interval from diagnosis to treatment less than 1 year, Karnofski PS&lt;80%, corrected serum calcium&gt;ULN, serum hemoglobin&lt;ULN, absolute neutrophil count&gt;ULN and platelets&gt;ULN. The IMDC model has been derived from a retrospective study of 645 patients treated with VEGF-targeted agents (Heng DY, et al. J Clin Oncol 2009), and validated in an independent dataset (Heng DY, et al.Lancet Oncol 2013). The 2-year OS ranges from 75% in the favourable risk group (none of the 6 factors identified) to 7% in the poor-risk group (3 to 6 factors identified).

In the EU, the following agents targeting the VEGF/VEGFR signaling pathway are approved for the 1L treatment of advanced RCC: sunitinib, pazopanib, bevacizumab + IFNα, tivozanib and cabozantinib (in patients who are considered to be intermediate and poor risk).

In addition to agents that target VEGFR and VEGF, other approved agents for advanced RCC include the mTOR inhibitor temsirolimus for patients considered to be poor risk (per the MSKCC risk category) in the 1L setting and the mTOR inhibitor everolimus.

Recently, the combination of nivolumab + ipilimumab was approved in the EU for use in treatment-naïve patients with advanced RCC who were considered to be intermediate or poor risk per the IMDC criteria.

Axitinib  and  the  mTOR  inhibitor  everolimus,  as  single  agent  or  in  combination  with  lenvatinib,  are approved for patients with advanced RCC who have received prior treatment for their advanced disease. Nivolumab was also approved in the EU for the 2L+ setting after demonstrating a statistically significant and clinically meaningful improvement in OS compared with everolimus in patients who had received 1 or 2 prior anti angiogenic agents; however, this study failed to demonstrate an improvement in PFS.

The current ESMO clinical practice guidelines recommend the following treatments for treatment-naïve patients with advanced RCC:

<!-- image -->

Axitinib is only approved for the 2L treatment of advanced RCC. In a Phase 3 randomized study of axitinib versus sorafenib in treatment-naïve patients with advanced RCC (N = 288, randomized 2:1), axitinib failed to demonstrate a statistically significant improvement in the primary endpoint of PFS; however, axitinib demonstrated a clinically meaningful improvement in ORR [Hutson TE, et al. Lancet Oncol 2013; Hutson TE, et al., Clin Genitourin Cancer. 2017]. Based on these results, axitinib is considered by the NCCN as a treatment option (category 2B) for advanced RCC patients in the 1L setting [NCCN Clinical Practice Guidelines in Oncology: kidney cancer: version 3.2019].

<div style=\"page-break-after: always\"></div>

## Approved or Recommended First-Line Treatments for Advanced RCC

| Study (N)                                        | Median PFS (mos)/ HR (95% CI, p value)      | Median OS (mos)/ HR (95% CI, p value)                 | ORR (%) (p value)       | Reference                                                                             |
|--------------------------------------------------|---------------------------------------------|-------------------------------------------------------|-------------------------|---------------------------------------------------------------------------------------|
| Sunitinib vs. IFNα (N = 750)                     | 11.0 vs. 5 / 0.42 (0.32 - 0.54, p<0.001)    | 26.4 vs. 21.8 / 0.82 (0.67 - 1.00, p=0.051)           | 31 vs. 6 (p <0.001)     | Motzer RC, et al., N Engl J Med. 2007 Motzer RJ, et al., J Clin Oncol. 2009           |
| Pazopanib vs. Placebo (N = 233) a                | 11.1 vs. 2.8 / 0.40 (0.27 - 0.60, p<0.0001) | 22.9 vs. 23.5 / 1.01 (0.72 - 1.42)                    | 32 vs. 4                | Sternberg CN, et al., J Clin Oncol. 2010 Sternberg CN, et al., Eur J Cancer. 2013     |
| Bevacizumab + IFNα vs. IFNα (N = 649)            | 10.2 vs. 5.4 / 0.63 (0.52 - 0.75, p=0.0001) | 23.3 vs. 21.3 / 0.91 (0.76 - 1.10, p=0.3360)          | 31 vs. 13 (p=0.0001)    | Escudier B, et al., Lancet 2007 Escudier B, et al., J Clin Oncol. 2010                |
| Sunitinib vs. pazopanib (N = 1110) b             | 9.5 vs. 8.4 / 1.05 (0.90 - 1.22)            | 29.3 vs. 28.4 / 0.91 (0.76 - 1.08, p=0.28)            | 25 vs. 31 (p=0.03)      | Motzer RJ, et al., N Engl J Med. 2013                                                 |
| Temsirolimus vs. IFNα (N = 416) c                | 5.5 vs. 3.1 / NR                            | 10.9 vs. 7.3 / 0.73 (0.58 - 0.92, p=0.008)            | 8.6 vs. 4.8             | Hudes G, et al., N Engl J Med. 2007                                                   |
| Cabozantinib vs. Sunitinib (N = 157) d           | 8.2 vs. 5.6 / 0.66 (0.46 - 0.95, p=0.012)   | 30.3 vs. 21.8 / 0.80 (0.50 - 1.26)                    | 46 vs. 18               | Choueiri TK, et al. J Clin Oncol. 2017                                                |
| Nivolumab + Ipilimumab vs. Sunitinib (N = 847) d | 11.6 vs. 8.4 / 0.82 (0.64 - 1.05, p=0.03) e | Not reached vs. 26.0 / 0.63 (0.44 - 0.89, p <0.001) e | 42 vs. 27 (p <0.001)    | Motzer RJ, et al., N Engl J Med. 2018                                                 |
| Tivozanib vs sorafenib (N=517)                   | 11.9 v 9.1 / 0.797 ( 0.639- 0.993, p= .042) | 29.3 v 28.8 / 1.245 (0.954- 1.624, p=.105)            | 33.1 vs. 23.3 (p=0.014) | Motzer RJ, et al., J clin Oncol. 2013                                                 |
| Axitinib vs. sorafenib (N = 288)                 | 10.1 vs. 6.5 / 0.77 (0.56 - 1.05, p=0.038)  | 21.7 vs. 23.3 / 0.995 (0.731 - 1.356, p=0.4883)       | 32 vs. 15 (p=0.0006)    | Hutson TE, et al., Lancet Oncol. 2013 Hutson TE, et al., Clin Genitourin Cancer. 2017 |

Abbreviations: HR = hazard ratio; IFNα = interferon alpha; mos = months; NR = not reported; ORR = objective response rate; OS = overall survival; PFS = progression-free survival; RCC = renal cell carcinoma.

- a. Treatment-naïve population.
- b. The sunitinib versus pazopanib study used a non-inferiority design which demonstrated that pazopanib was noninferior to sunitinib with the primary endpoint PFS meeting the predefined non-inferiority margin
- c. Study enrolled a poor-prognosis population.
- d. Data demonstrated in IMDC intermediate and poor risk populations.
- e. Reported as 99.1% CI and 99.8% CI for PFS and OS, respectively.

## Rationale for the combination of pembrolizumab and axitinib

Angiogenesis is integral to the biology of RCC. As such, anti-angiogenic agents targeting VEGF/VEGFR have substantially improved clinical outcomes in patients with advanced RCC, and are considered among the standard 1L treatment option for advanced RCC.

RCC has long been considered an immune-reactive tumor based on anecdotal reports of spontaneous remissions in advanced RCC patients with evidence of antigen specific lymphocyte infiltration of tumor tissues [Wierecky J, et al. Cancer Res 2006] and the fact that high dose IL-2 could produce durable

<div style=\"page-break-after: always\"></div>

long-term responses in a small subset of advanced RCC patients. In RCC, upregulation of the PD-1 receptor on TILs and its ligand PD-L1 on tumors is associated with more aggressive disease and poor prognosis [Pedoeem A, et al. Clin Immunol 2014; Ahmadzadeh M, et al. Blood 2009]. In addition to pro angiogenic functions, VEGF has been shown to have immunosuppressive effects [Johnson BF, et al. Expert Opin Biol Ther 2007] and inhibition of VEGF signaling has been shown to enhance antigen-specific T-cell migration in RCC [Wallin JJ, et al. Nat Commun 2016]. The evidence supports targeting RCC with an immunotherapeutic approach in combination with inhibitors of the VEGF/VEGFR signaling axis.

The clinical activity of an anti-PD-1 agent in advanced RCC was first demonstrated by nivolumab in patients  who  had  received  prior  anti-angiogenic  agents  [Motzer  RJ,  et  al.  N  Engl  J  Med  2015]. Pembrolizumab has shown clinical efficacy when administered as a monotherapy for the 1L treatment of advanced RCC (Study KEYNOTE-427 - Cohort A). Given the clinical success of targeting the either the VEGFR or PD-1 axis independently, targeting these 2 pathways could provide a significant benefit to patients  with  advanced  RCC.  Specifically,  KEYNOTE-035  (Study  A4061079),  which  evaluated  the combination of axitinib and pembrolizumab in treatment-naive advanced RCC, demonstrated substantial clinical efficacy with an apparently acceptable safety profile.

Based on the scientific rationale of targeting angiogenesis and immune-check point pathways, as well as the promising data from KEYNOTE-035, the combination of pembrolizumab and axitinib was tested in the pivotal Phase 3 KEYNOTE-426 study.

## 2.2. Non-clinical aspects

No new non-clinical data have been submitted in this application, which was considered acceptable by the CHMP.

## 2.2.1. Ecotoxicity/environmental risk assessment

Pembrolizumab is a protein, which is expected to be metabolised in the body and biodegrade in the environment. Thus, according to the 'Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use' (EMEA/CHMP/SWP/4447/00), pembrolizumab is exempt from the submission of an Environmental Risk Assessment as the product and excipients do not expect to pose a significant risk to the environment.

## 2.2.2. Discussion and Conclusion on non-clinical aspects

The applicant did not submit studies for the ERA. According to the guideline, in the case of products containing proteins as active pharmaceutical ingredient(s), the lack of ERA studies is acceptable.

## 2.3. Clinical aspects

## 2.3.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

<div style=\"page-break-after: always\"></div>

| Study Number Status                       | Design                                                                                                                                                        | Population                                                                               | Dosage Regimen                                                                                                                | Primary Endpoint(s)                      |
|-------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|
| KN426 Ongoing; closed for enrollment      | Phase 3, open-label, multicenter, global study to evaluate the efficacy and safety of pembrolizumab in combination with axitinib versus sunitinib monotherapy | Treatment-naïve participants with advanced ccRCC                                         | Arm 1: Pembrolizumab 200 mg Q3W + axitinib 5 mg BID Arm 2: Sunitinib 50 mg QD; 4 weeks on and 2 weeks off                     | OS, PFS                                  |
| KN427 Ongoing; closed for enrollment      | Phase 2, open-label, multicenter, global study to evaluate the efficacy and safety of pembrolizumab                                                           | Treatment-naïve participants with advanced ccRCC (Cohort A) or nccRCC (Cohort B)         | Pembrolizumab 200 mg Q3W                                                                                                      | ORR                                      |
| A4061051 c Ongoing, enrollment terminated | Phase 3, randomized, open-label, multicenter study to evaluate the efficacy and safety of axitinib vs sorafenib                                               | Participants with advanced ccRCC who have not received prior systemic first-line therapy | Axitinib 5 mg BID vs Sorafenib 400 mg BID                                                                                     | PFS                                      |
| KN035 (Study A4061079) c                  | Phase 1b, open-label, dose finding study to evaluate the safety, pharmacokinetics, and pharmacodynamics of axitinib in combination with pembrolizumab         | Participants with previously untreated advanced ccRCC                                    | Dose-finding: Axitinib: 5 mg BID a + pembrolizumab 2 mg/kg Q3W Dose Expansion Axitinib 5 mg BID b + pembrolizumab 2 mg/kg Q3W | Determination of MTD for axitinib Safety |

Abbreviations: BID = twice daily; ccRCC = clear cell renal cell carcinoma; KN = KEYNOTE; MTD = maximum tolerated dose; nccRCC = non clear cell renal cell carcinoma; ORR = objective response rate; OS = overall survival; PFS = progression-free survival; Q3W = every 3 weeks; QD = once daily; RCC = renal cell carcinoma.

a. The starting dose of axitinib was 5 mg but could be reduced based on dose-limiting toxicities.

b. The MTD was determined to be 5 mg BID.

c. Sponsored by Pfizer Inc.

## 2.3.2. Pharmacokinetics

Clinical  pharmacology  results  for  the  combination  therapy  of  Pembrolizumab  together  with  axitinib, specific to support approval for first line treatment of advanced or metastatic renal cell carcinoma (RCC), are available from the pivotal study KEYNOTE-426 and the Pfizer-sponsored study KEYNOTE-035 (Study A4061079).

The updated clinical pharmacology results specific to this submission include:

- PK  data  of  pembrolizumab  at  200  mg  Q3W  in  combination  with  axitinib  at  5  mg  BID  from KEYNOTE-426.
- A comparison of KN426 observed PK data with reference model (TDPK) predicted PK.
- PK data of axitinib at 5 mg BID alone and in combination with 2 mg/kg Q3W pembrolizumab from KEYNOTE-035.

<div style=\"page-break-after: always\"></div>

## Pharmacokinetic in target population

Axitinib, as monotherapy, is approved for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy.

Based  on  the  existing  robust  characterization  of  pembrolizumab  PK,  a  comparison  was  conducted between the observed PK of pembrolizumab for the current indication (RCC) in combination with axitinib and the predictions from the reference PK model developed with pembrolizumab monotherapy data (KEYNOTE-001, -002, -006, -010, and -024). This analysis is presented in the PK report (Report 052Z0C).

DDI between pembrolizumab and Axitinib are unlikely, considering the divergent metabolic pathways for both compounds. However, axitinib could be considered to have immunomodulatory effects and PK and/or immunogenicity assessments are planned in cases where pembrolizumab is combined with another agent with potential immunomodulatory effect.

New data related to characterization of pharmacokinetics for the combination of pembrolizumab and axitinib, and a characterization of immunogenicity for pembrolizumab following co-administration with axitinib have been presented in this submission.

## Pembrolizumab PK data from KEYNOTE-426 (KN426) study

PK samples were collected and measured for 423 subjects in KN0426 RCC (200 mg Q3W).

PK sample schedule in KN426: Predose pembrolizumab serum concentrations (Ctrough) were obtained within 24 hours prior to dosing at cycles 1, 3, 5 and every 4 cycles (12 weeks) thereafter. Postdose serum concentrations (Cmax) were drawn within approximately 30 minutes after the end of the infusion in cycle 1 and cycle 9.

Phoenix™ WinNonlin® (Version 6.3.0.395) software was used for pharmacokinetic analysis.

## OverviewofPembrolizumabCohortsIncludedinKN426PKAnalysis

| Indication   | Arm   | Treatment                         |   Numberof Subjects providingPKa | Datacutoff   |
|--------------|-------|-----------------------------------|----------------------------------|--------------|
| RCC          |       | MK3475200mgQ3W+ axitinib 5 mg BID |                              423 | 24-Aug-2018  |

number of unique subjects from arm 1 in dataset DataSource:[052Z0C:analysis-P426pkdm0usfiling0v3.csv]

Summary statistics of the observed pembrolizumab trough (pre-dose) and post-dose concentrations in RCC subjects from KN0426 are presented in the table below:

<div style=\"page-break-after: always\"></div>

## Summary Statistics of Pembrolizumab Predose (Ctrough) and Postdose (Cmax) Serum Concentration Values Following Administration of Multiple I.V. Doses 200 mg Q3W in KN426

<!-- image -->

| Cycle                                              | NOMTAFD day                                        | N                                                  | GM (%CV)                                           | GM (SD)                                            | AM (SD) (μg/mL)                                    | Min                                                | Median                                             | Max                                                |
|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
| Predose (Ctrough)                                  |                                                    |                                                    |                                                    |                                                    |                                                    |                                                    |                                                    |                                                    |
| Cycle 3 (Week 6)                                   | 42                                                 | 354                                                | 20.4 (43.5)                                        | 20.4 (8.4)                                         | 22.1 (8.4)                                         | 4.07                                               | 21.2                                               | 50.4                                               |
| Cycle 5 (Week 12)                                  | 84                                                 | 319                                                |                                                    |                                                    | 30.4 (12.3)                                        | 0.00                                               | 28.8                                               | 76.6                                               |
| Cycle 9 (Week 24)                                  | 168                                                | 248                                                |                                                    |                                                    | 36.4 (13.8)                                        | 0.00                                               | 35.6                                               | 75.7                                               |
| Cycle 13 (Week 36)                                 | 252                                                | 205                                                | 35.8 (57.5)                                        | 35.8 (16.0)                                        | 39.9 (16.0)                                        | 2.83                                               | 37.9                                               | 86.4                                               |
| Cycle 17 (Week 48)                                 | 336                                                | 142                                                | 39.0 (39.2)                                        | 39.0 (15.2)                                        | 41.7 (15.2)                                        | 11.7                                               | 39.2                                               | 89.5                                               |
| Cycle 21 (Week 60)                                 | 420                                                | 90                                                 | 38.5 (41.7)                                        | 38.5 (16.0)                                        | 41.5 (16.0)                                        | 7.66                                               | 39.8                                               | 96.8                                               |
| Cycle 25 (Week 72)                                 | 504                                                | 48                                                 | 38.0 (40.6)                                        | 38.0 (14.4)                                        | 40.6 (14.4)                                        | 10.5                                               | 38.7                                               | 76.2                                               |
| Cycle 29 (Week 84)                                 | 588                                                | 7                                                  | 47.3 (32.5)                                        | 47.3 (14.1)                                        | 49.2 (14.1)                                        | 26.2                                               | 48.5                                               | 66.9                                               |
| Postdose (Cma)(vithin 30 min post end of infusion) | Postdose (Cma)(vithin 30 min post end of infusion) | Postdose (Cma)(vithin 30 min post end of infusion) | Postdose (Cma)(vithin 30 min post end of infusion) | Postdose (Cma)(vithin 30 min post end of infusion) | Postdose (Cma)(vithin 30 min post end of infusion) | Postdose (Cma)(vithin 30 min post end of infusion) | Postdose (Cma)(vithin 30 min post end of infusion) | Postdose (Cma)(vithin 30 min post end of infusion) |
| Cycle 1 (Week 0)                                   | 0                                                  | 378                                                | 61.2 (28.4)                                        | 61.2 (17.8)                                        | 63.6 (17.8)                                        | 27.3                                               | 61.7                                               | 152                                                |
| Cycle 9 (Week 24)                                  | 168                                                | 240                                                | 106 (27.4)                                         | 106 (28.9)                                         | 110 (28.9)                                         | 46.3                                               | 108                                                | 230                                                |

[052Z0C: analysis-P426pkdm0usfiling0v3.csv]

<div style=\"page-break-after: always\"></div>

The following figures show the individual and mean predose concentration-time profiles:

IndividualandArithmeticMean(SE)PenbrolizumabConcentrationTimeProfilesFollowingMultipleI.V.Dosesof 200mgQ3WinStudy KN426 (a) Linear' scale, (b) Log scale

<!-- image -->

Note: Grey linesrepresent individual concentration observations.Black dashedlinesrepresent arithmeticmean concentrations anderrorbars areassociated+/-SE(Standard Error) DataSource:[052Z0C: analysis-P426pkdm0usfiling0v3.csv]

Arithmetic Mean (SD) Pembrolizumab Concentration -Time Profiles Following Multiple I.V. Doses of 200 mg Q3W to Subjects in Study KN426 (Linear' scale)

<!-- image -->

Note: This plot is Arithmetic Mean with Standard Deviation (SD). X-axis unit is in weeks. Data Source: [052Z0C: analysis-P426pkdm0usfiling0v3.csv]

The  observed  and  predicted  pembrolizumab  concentration-time  profiles  following  200  mg  Q3W administration at postdose cycle 1 and predose cycle 3 and at steady state with a time since last dose of maximum 22 days are illustrated in the following figure:

<div style=\"page-break-after: always\"></div>

## Observed Concentration Datawith a cutoff of 22 days after last dosing of KN426 Subjects Receiving 200 mg Q3W Pembrolizumab with Reference Model-Predicted Pharmacokinetic Profile for 200mg Q3W Dose Regimen

KN426Postdose C1,Predose C3 with a Time since last dose of maximum 22 days

KN426SteadyStatewith aTime sincelast doseof maximum of 22days

<!-- image -->

Postdose cycle1 and cycle 9, predose before cycle 3 dosing and predose at steady state on log scale. Red and blue symbols are individual observed data(nominal time) from subjects with renal cell carcinoma in KN426; black line is median predicted concentrations from the model for a regimen of 200 mg Q3W and the grey shaded area represents the 90% prediction interval.

Data Source: [052Z0C: analysis-P426pkdm0usfiling0v3.csv]

Predose pembrolizumab serum concentrations (Ctrough) were obtained within 24 hours prior to dosing at cycles 1, 3, 5 and every 4 cycles (12 weeks) thereafter. Postdose serum concentrations (Cmax) were obtained about 30 minutes after the end of the infusion in cycle 1 and cycle 9.

The observed concentrations in RCC patients treated with Pembrolizumab in combination with Axitinib generally fall within the range of predicted concentrations, both after first dose and at steady state, although some low concentrations don't fall in the 90% PI.

<div style=\"page-break-after: always\"></div>

Tabular summaries  of descriptive statistics and boxplots comparing observed pembrolizumab concentrations  of  200  mg  every  3  weeks  (Q3W)  from  participants  with  RCC  in  KEYNOTE-426  in combination with axitinib with those obtained with the 200 mg Q3W flat dose for other tumor types in the monotherapy setting were provided as requested. (see below)

Table 6 Summary Statistics of Observed Pembrolizumab Concentrations at 200 mg Q3W in Various Monotherapy Trials (KEYNOTE-024, -045, -052, -055, -087, -158, -164) and in Combination with Axitinib (KEYNOTE-426)

| Time point      | Dose   | Study/ Indication   |   N | GMCV (g/mL)   | AMSD (μg/mL)   |   Min (μg/mL) |   Median (μg/mL) |   Max (μg/mL) |
|-----------------|--------|---------------------|-----|---------------|----------------|---------------|------------------|---------------|
| Cycle1Postdose  | 200mg  | KN024NSCLC          | 147 | 67.5 (23)     | 69.27 (16)     |         36.6  |             66.8 |         132   |
|                 |        | KN045 UC            | 247 | 65.7 (26)     | 67.93 (18)     |         33.9  |             65.9 |         144   |
|                 |        | KN052 UC            | 298 | 58 (28)       | 60.18 (17)     |         22.8  |             57.4 |         148   |
|                 |        | KN055 HNSCC         |  43 | 56.5 (28)     | 58.94 (21)     |         33.1  |             54.9 |         162   |
|                 |        | KN087 HL            | 195 | 60.7 (28)     | 63.06 (18)     |         31.2  |             61.3 |         183   |
|                 |        | KN158 MSIH          |  90 | 64.4 (27)     | 66.65 (18)     |         31.2  |             65.2 |         133   |
|                 |        | KN164 MSIH          |  56 | 62.2 (28)     | 64.59 (19)     |         34.9  |             61.2 |         150   |
|                 |        | KN426 RCC           | 378 | 61.2 (28)     | 63.58 (18)     |         27.3  |             61.7 |         152   |
| Cycle 8 Predose |        | KN024NSCLC          |  82 | 30.6 (50)     | 33.61 (13)     |          5.26 |             32.7 |          64.1 |
|                 |        | KN045 UC            | 104 | 33.4 (64)     | 37.83 (17)     |          1.13 |             37.5 |          95.6 |
|                 |        | KN052 UC            |  59 | 28 (38)       | 29.86 (10)     |          8.15 |             27.9 |          59.8 |
|                 |        | KNO55HNSCC          |   7 | 27.8 (41)     | 29.64 (11)     |         16.8  |             24.5 |          43.3 |
|                 |        | KN087 HL            |  68 | 43.9 (43)     | 47.37 (17)     |         13.9  |             47.5 |          92.4 |
|                 |        | KN164 MSIH          |  34 | 33.6 (43)     | 36.23 (14)     |          8.4  |             33.7 |          78.8 |
| Cycle 9 Predose |        | KN426 RCC           | 248 |               | 36.43 (14)     |          0    |             35.6 |          75.7 |

Figure 12 Observed Peak Pembrolizumab Concentrations Post Cycle 1 in Various Monotherapy Trials (KEYNOTE-024, -045, -052, -055, -087, -158, -164) and in the Combination Trial with Axitinib (KEYNOTE-426)

Cycle 1Postdose

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 13Observed Trough Pembrolizumab Concentrations at Cycle 8 or Cycle 9 Pre-dose in Various Monotherapy Trials (KEYNOTE-024, -045, -052, -055, -087, -158, -164) and in the Combination Trial with Axitinib (KEYNOTE-426)

<!-- image -->

## Axitinib PK data (Alone and in Combination with Pembrolizumab) from KEYNOTE-035 (Study A4061079)

The single sequence DDI assessment in this study was conducted using a 7-day in Lead-in Cycle where daily 5 mg or 3 mg doses of axitinib were to be administered alone for 7 days, with axitinib full PK profile assessment  conducted  on  Day  7  of  the  Lead-in  Cycle.  Following  the  Lead-in  Cycle,  axitinib  was co-administered with MK-3475 continuously, with another axitinib full profile PK assessment conducted on Day 1 of Cycle 7. This design allowed comparison of the multiple dose PK of axitinib administered alone (Lead-in  Day  7)  to  the  multiple  dose  PK  of  axitinib  administered  in  combination  with  multiple  dose MK-3475 (Cycle 7 Day 1) to assess the potential effect of MK-3475 DDI on axitinib PK.

Summary of Plasma Axitinib Pharmacokinetic Parameters Following Daily 5 mg or 3 mg Oral Doses of Axitinib Alone and in Combination with MK-3475 in Study A4061079

| Parameter [Units]      | ParameterSummaryStatistics?byTreatment   | ParameterSummaryStatistics?byTreatment   |
|------------------------|------------------------------------------|------------------------------------------|
|                        | Axitinib Alone Lead-in Day 7             | Axitinib+MK-3475 Cycle 7 Day 1           |
| N                      | 7                                        | 7                                        |
| AUC12 [ng:hr/mL]       | 88.51 (71)                               | 101.3 (63)                               |
| AUC2(dn) [ng:hr/mL/mg] | 17.70 (71)                               | 21.79 (50)                               |
| Cmax [ng/mL]           | 23.98 (58)                               | 20.95 (52)                               |
| Cmax(dn) [ng/mL/mg]    | 4.797 (58)                               | 4.507 (46)                               |
| Tmax [hr]              | 2.00 (0.00-3.00)                         | 3.00 (1.00-6.00)                         |

Parameters are defined in Table 1.

Source:Table 14.4.3.1

<div style=\"page-break-after: always\"></div>

Treatment Comparison For Axitinib Pharmacokinetic Parameters in Study

A4061079

Source:Table14.4.3.1

| Parameter [units]      |   Axitinib+MK-3475 (Cycle 7 Day 1) (Test) |   AxitinibAlone (Lead-in Day 7) (Reference) |   Ratio%(Test/Reference) |
|------------------------|-------------------------------------------|---------------------------------------------|--------------------------|
| AUC2(dn) [ng:hr/mL/mg] |                                    21.79  |                                      17.7   |                   123.11 |
| Cmax(dn) [ng/mL/mg]    |                                     4.507 |                                       4.797 |                    93.95 |

Median axitinib plasma concentration-time profiles were similar when axitinib was administered alone and with  MK-3475  dose-normalized  AUC12  and  Cmax,  geometric  ratios  of  1.23  and  0.94  respectively indicating no clinically meaningful DDI effect.

<!-- image -->

Upper and lower panels are linear and semi-logarithmic scales, respectively. Axitinib+MK 3475(Cycle 7Day 1) and AxitinibAlone (Lead in Day 7) Source:[Ref.5.3.5.4:P1079V01:Figure 14.4.2.2.1] [Ref.5.3.5.4:P1079V01:Figure 14.4.2.2.2]

<div style=\"page-break-after: always\"></div>

## Overview of bioanalytical methods and assay validation

## Pembrolizumab (MK-3475) Quantification Method Validation

The assay was originally developed and validated at Merck Research Laboratories (Oss, The Netherlands) in  September  2010.  A  full  assay  validation  was  performed  that  evaluated  assay  performance characteristics typical for validation of ligand binding assay methods.

This first generation validated assay was not used to support quantitative bioanalysis of pembrolizumab concentrations in serum samples collected from clinical studies. This assay served as the foundation for later method transfer validation to the CRO, Intertek (San Diego, CA).

Following transfer of the first generation Oss assay to Intertek, the method underwent refinement and transfer validation in August 2011

The method (2nd generation assay, Report 4020) was used to support bioanalysis of MK-3475 in serum samples from clinical study P001.

This  second  generation  method  validated  at  the  CRO  Intertek  was  updated  and  underwent  further validation in May 2013 to become the third generation assay. Method selectivity in normal and disease populations was one of the key performance characteristics investigated during partial re-validation to meet the guidance requirement to perform selectivity assessments using control samples prepared at the Lower Limit of Quantitation (LLOQ=10 ng/mL).

This  third  generation  method  was  later  transferred  and  cross-lab  validated  at  a  second  CRO,  PPD (Richmond, VA) to increase the level of automation, increase of sample throughput and reduce variability.

During the continued use of the 3rd generation assay at PPD it was noticed that variability at the LLOQ level of 10 ng/mL prevented the appropriate assessment of the influence of new disease states on the assay. Therefore, it was decided to raise the LLOQ of the assay and change the concentration of the QCs to appropriately span the new range of the assay.

Accuracy and precision of the new QCs were assessed and appeared to be within the already established accuracy and precision. Moreover, due to the logistical difficulties in shipping clinical serum samples collected in China from China to PPD laboratories in USA, the 3rd generation assay at PPD was transferred and cross-validated at Wuxi AppTec laboratories in Shanghai, China.

The validated method at Wuxi is utilized to support Pembrolizumab drug concentration analysis for study protocols where Chinese subjects are enrolled through clinical sites in China.

## Pembrolizumab (MK-3475) ADA Method Validation

The  ADA  assay  was  originally  developed  and  validated  at  Merck  Research  Laboratories  (Oss,  The Netherlands) in November 2010, with a full assay validation. The assay was transferred to Intertek (San Diego, CA) and underwent method transfer validation in September 2011.

The method was later transferred and re-validated at a second CRO, PPD (Richmond, VA) to perform ADA analysis at the same lab conducting quantitation of pembrolizumab in serum samples.

Due to the logistical difficulties in shipping clinical serum sample out of China for bioanalytical testing, ADA method was fully validated at Wuxi AppTec laboratory in Shanghai, China to perform ADA analysis of samples for studies in which Chinese subjects are enrolled through clinical sites in China.

With method developed at Intertek, the anti-CDR enriched ADA positive control at 250 ng/mL can tolerate up to 25 μ g/mL of pembrolizumab. The method at PPD, which includes extended overnight incubation times and optimized acid neutralization timing for further drug tolerance enhancement, can tolerate up to 124 μ g/mL drug in an ADA positive control spiked at 250 ng/mL of anti-CDR enriched ADA.

The method used at Wuxi achieved comparable drug tolerance to PPD; the method can tolerate up to 9 μ g/mL drug in an ADA positive control spiked at 250 ng/mL of anti-CDR enriched ADA.

<div style=\"page-break-after: always\"></div>

## Pembrolizumab (MK-3475) Nab Method Validation

The first generation assay was originally developed and validated at Merck's Oss site (The Netherlands) in January 2011. A full assay validation evaluated assay performance characteristics typical for neutralizing ADA assays.  The Oss assay method was transferred to the CRO, Intertek (San Diego, CA), and was transfer validated in December 2011.  The NAb assay method was redesigned and validated at a second CRO, PPD (Richmond, VA) as a second generation assay. The assay was validated at PPD in September 2016.

This  assay  was  later  transfer  validated  at  Wuxi  AppTec  in  Shanghai,  China  to  evaluate  neutralizing capacity of samples tested positive for ADA at Wuxi.

## Bioanalytical report related to study KEYNOTE-426

## Report 054620 : Analysis of Samples Using an ECL Method for the Quantification of MK-3475 in Human Serum.

This analysis was conducted for Merck Sharp &amp; Dohme Corp. by PPD® Laboratories.

Two thousand eight hundred thirty-nine (2839) original and two thousand seven hundred sixty-five (2765) replicate human serum samples were received frozen and in good condition in 45 shipments from Q2 Solutions (Valencia, California and Bath Gate, United Kingdom) between 21 December 2016 and 06 September 2018. The samples were stored frozen at -80°C ± 10°C and all samples  were analyzed within the 1218 days demonstrated long-term storage stability in human serum at -80°C ± 10°C.

The assay used in the analysis of study samples is a quantitative assay designed to quantify MK-3475 in human serum.

A nominal MK-3475 concentration range of 25.0 to 800 ng/mL in 100% human serum was chosen to quantitate samples. The calibration standards ranged from 1.00 to 125 ng/mL, with anchor calibrators at 1.00 and 125 ng/mL after correction for the 1:10 MRD. This assay required a minimum 20 μL human serum aliquot (or more for TECAN use). Calibration standards and quality control samples were prepared using  reference.  Standards  and  Certificates  of  Analysis  for  these  standards  are  attached  to  the bioanalytical report.

Analysis of the human serum samples began on 25 April 2017 and was completed on 28 September 2018. Regression equations and correlation coefficients were calculated. The  Average Correlation Coefficient was  0.9976. Back-calculated calibration data are found in the following table:

|                 | AverageBack-calculatedCalibrationStandards   | AverageBack-calculatedCalibrationStandards   | AverageBack-calculatedCalibrationStandards   | AverageBack-calculatedCalibrationStandards   | AverageBack-calculatedCalibrationStandards   | AverageBack-calculatedCalibrationStandards   | AverageBack-calculatedCalibrationStandards   |                 |
|-----------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|----------------------------------------------|-----------------|
| Run ID RGTQ     | CAL 11* (ng/mL)                              | CAL 12 (ng/mL)                               | CAL 13 (ng/mL)                               | CAL 14 (ng/mL)                               | CAL 15 (ng/mL)                               | CAL 16 (ng/mL)                               | CAL 17 (ng/mL)                               | CAL 18* (ng/mL) |
| N               | 97                                           | 98                                           | 98                                           | 98                                           | 98                                           | 98                                           | 98                                           | 98              |
| Theoretical     |                                              |                                              |                                              |                                              |                                              |                                              |                                              |                 |
| Concentration   | 1.00                                         | 2.50                                         | 5.00                                         | 10.0                                         | 20.0                                         | 40.0                                         | 80.0                                         | 125             |
| Mean            | 1.00                                         | 2.49                                         | 5.02                                         | 10.0                                         | 20.2                                         | 40.1                                         | 79.7                                         | 126             |
| SD              | 0.0170                                       | 0.0693                                       | 0.102                                        | 0.235                                        | 0.457                                        | 0.784                                        | 1.60                                         | 2.48            |
| %CV             | 1.70                                         | 2.78                                         | 2.03                                         | 2.34                                         | 2.27                                         | 1.96                                         | 2.01                                         | 1.97            |
| %Difference     |                                              |                                              |                                              |                                              |                                              |                                              |                                              |                 |
| fromTheoretical | 0.238                                        | -0.200                                       | 0.307                                        | 0.378                                        | 0.790                                        | 0.267                                        | -0.437                                       | 0.548           |

Legend:

串 Denotesanchorcalibrators.

a Cal deactivated per SOP.

Precision  and  accuracy  were  evaluated  by  replicate  analyses  of  human  serum  quality  control  pools prepared at three concentrations spanning the calibration range. Precision was measured as the percent

<div style=\"page-break-after: always\"></div>

coefficient of variation (%CV) of the set of values for each pool. Accuracy was expressed as the percent difference  of  the  mean  value  for  each  pool  from  the  theoretical  concentration.  Inter-assay  data  are presented in the following table:

## Inter-assayPrecisionandAccuracy

| Run ID RGTO     | QC 11 Dil 10 (ng/mL)   | QC 12 Dil 10 (ng/mL)   | QC 13 Di1 10 (ng/mL)   |
|-----------------|------------------------|------------------------|------------------------|
| N               | 194                    | 192                    | 196                    |
| Theoretical     |                        |                        |                        |
| Concentration   | 70.0                   | 150                    | 600                    |
| Mean            | 69.1                   | 151                    | 594                    |
| SD              | 5.46                   | 18.8                   | 39.2                   |
| %CV             | 7.90                   | 12.4                   | 6.60                   |
| %Difference     |                        |                        |                        |
| fromTheoretical | -1.30                  | 0.458                  | -0.984                 |
| Low Limit       | 56.0                   | 120                    | 480                    |
| High Limit      | 84.0                   | 180                    | 720                    |

## Legend:

rcV Replicatecoeficientofvariationunacceptable

## Report 054622 : Analysis of Samples Using an Electrochemiluminescent (ECL) Method for the Detection of Anti-MK-3475 Antibodies (ADA) in Human

Human  serum  samples  were  analyzed  for  anti-MK-3475  antibodies  in  support  of  Protocol  Number MK-3475-426. Two thousand one hundred sixty-six (2166) original and three thousand one hundred sixty-two (3162) replicate human serum samples were received frozen and in good condition from Q2 Solutions (Valencia, California and Bath Gate, United Kingdom) between 21 December 2016 and 06 September 2018. The samples were stored frozen at -80°C ± 10°C. Project samples were analyzed according to the bioanalytical plan and PPD Method ICDIM 201 V 1.02, entitled 'An Electrochemiluminescent (ECL) Method for the Detection of Anti-MK-3475 Antibodies in Human Serum,' This method employs a three-tiered approach consisting of a screening assay, confirmatory assay, and titration assay.

Sample results are acceptable if the %C.V. between duplicate responses is less than or equal to 20%. A higher %C.V. between duplicate responses is acceptable if the responses for both wells are above the assay cut point or if both responses are below the assay cut point.

## Report 054623 : Analysis of Samples Using an Electrochemiluminescent (ECL) Method for the Detection of Anti-MK-3475 Neutralizing Antibodies in Human Serum

Human serum samples were analyzed to detect anti-MK-3475 neutralizing antibodies (NAb) in support of Protocol Number MK-3475-426.

Two thousand one hundred sixty-six (2166) original and three thousand one hundred sixty-two (3162) replicate human serum samples were received frozen and in good condition in 42 shipments from Q2 Solutions (Valencia, California and Bath Gate, United Kingdom) between 21 December 2016 and 06 September 2018. These samples were first tested in the electro-chemiluminescent immunoassay for the detection of anti-MK-3475 antibodies. Samples that were confirmed to be positive for anti-MK-3475 antibodies were tested for neutralizing capacity. The assay for the detection of neutralizing antibodies to MK-3475 (ICDIM 202 V 2.01) from Protocol MK-3475-426 was assigned the unique PPD project code 'RGTS.'

<div style=\"page-break-after: always\"></div>

All samples from project RGTR which confirmed positive in the ADA immunoassay to date were analyzed for the presence of neutralizing antibodies. Sample analysis was conducted under Project Code 'RGTS' using method ICDIM 202 V 2.01.

The  NAb  assay  method,  entitled  'An  ECL  Method  for  the  Detection  of  Anti-MK-3475  Neutralizing Antibodies in Human Serum,' was validated under Project Code 'RFRI2' and is described under PPD Method ICDIM 202 V 2.01.

Analysis of human serum samples took place in six runs beginning on 19 December 2017 and ending on 28 September 2018.  See below in section 'Immunogenicity'.

## 2.3.3. Pharmacodynamics

## Mechanism of action

KEYTRUDA  is  an  antibody  that  binds  to  the  programmed  death-1  (PD-1)  receptor  and  blocks  its interaction with ligands PD-L1 and PD-L2. The PD-1 receptor is a negative regulator of T-cell activity that has been shown to be involved in the control of T-cell immune responses. KEYTRUDA potentiates T-cell responses, including anti-tumour responses, through blockade of PD-1 binding to PD-L1 and PD-L2, which are expressed in antigen presenting cells and may be expressed by tumours or other cells in the tumour microenvironment.

## Primary and secondary pharmacology

## Immunogenicity

The existing immunogenicity assessment for pembrolizumab for the monotherapy setting is based on a sufficiently large dataset of patients across several indications, with very low observed rates of total treatment emergent ADA (1.4 - 3.8%) as well as of neutralizing antibodies (0.4 - 1.6%). This analysis has not demonstrated impact on efficacy or safety, as currently summarized in the USPI and EU SmPC. This low rate of immunogenicity has been shown to be consistent across tumor type and no clinical consequences have been observed in the subjects with a positive immunogenicity reading.

## Immunogenicity evaluation for study KEYNOTE-426

For  pembrolizumab  combination  therapy  (200  mg  pembrolizumab  Q3W  +  5  mg  axitinib  BID),  ADA samples were available from 434 subjects. A subset of the subjects was not assessable for drug-induced immunogenicity  because  the  subjects  were  not  treated  with  pembrolizumab  (N=12)  or  only  a pre-treatment ADA sample was available (N=16). The remaining 406 subjects were included in the immunogenicity assessment.

<div style=\"page-break-after: always\"></div>

## Overview of SubjectsIncluded in theImmunogenicity Analysis after Pembrolizumab Combination Therapy, 200 mg Pembrolizumab Q3W + 5 mg Axitinib BID (KN426)

|                                 |                                 | Subjects                      | Subjects                          | Subjects                                                                     |
|---------------------------------|---------------------------------|-------------------------------|-----------------------------------|------------------------------------------------------------------------------|
| Study                           | Indication                      | Subjects providing ADASamples | Subjects Dosed with Pembrolizumab | AssessableSubjects SubjectsDosed with Pembrolizumab andPostTreatment Samples |
| PembrolizumabCombinationTherapy | PembrolizumabCombinationTherapy |                               |                                   |                                                                              |
| KN426                           | RenalCell Carcinoma             | 434                           | 422                               | 406                                                                          |

Data source [053033: analysis-p426pkada0usfilingv5]

The table below presents an overview of the immunogenicity status of all assessable subjects. To evaluate immunogenicity, the overall immunogenicity was defined as the proportion of emergent positive subjects to the total number of evaluable subjects (treatment emergent positive, non-treatment emergent positive and negative immunogenicity status).

## SummaryofSubjectImmunogenicityResultsafterPembrolizumab Combination Therapy, 200 mg Pembrolizumab Q3W + 5 mg Axitinib BID (KN426)

| Stratified by treatment          | Stratified by treatment                                    |
|----------------------------------|------------------------------------------------------------|
| Immunogenicity status            | Renal Cell Carcinoma 200mgpembrolizumabQ3W+5mg axitinibBID |
| Assessable subjectsa             | 406                                                        |
| Inconclusive subjectsb           | 17                                                         |
| Evaluable subjectsc              | 389                                                        |
| Negatived                        | 358 (92.0%)                                                |
| Non-Treatment emergent positived | 7 (1.8%)                                                   |
| Neutralizing negative            | 5 (1.3%)                                                   |
| Neutralizing positive            | 2 (0.5%)                                                   |
| Treatment emergent positived     | 24 (6.2%)                                                  |
| Neutralizing negative            | 21 (5.4%)                                                  |
| Neutralizing positive            | 3 (0.8%)                                                   |

Data source [053033: analysis-p426pkada0usfilingv5]

The  observed  incidence  of  treatment  emergent  ADA  in  evaluable  subjects  after  pembrolizumab combination therapy is 6.2% (24 out of 389), based on 24 subjects with treatment emergent positive, 7 with non-treatment emergent positive and 358 with negative immunogenicity status. Three of the 24 treatment emergent positive subjects, had antibodies with neutralizing capacity, yielding an incidence of treatment emergent neutralizing positive subjects of 0.8% (3 out of 389).

## Impact of ADA on Pembrolizumab Exposure

The effect of ADA on pembrolizumab levels, for the subjects with ADA positive samples, is compared with the subjects treated with the same regimen that only have ADA negative samples.

<div style=\"page-break-after: always\"></div>

Effect of ADA on Pembrolizumab Exposure, for Subjects Treated with 200 mg Pembrolizumab Q3W + 5 mg Axitinib BID (KN426)

<!-- image -->

Footnote: Figure includes ADA samples with corresponding PK concentrations. Samples taken &gt; 42 days after last dose (&gt; 2 times the scheduled time) are excluded.

Individual pembrolizumab concentrations for the ADA negative subjects (grey dot), mean value of the negative neutralizing positive subjects (blue dot), treatment emergent neutralizing negative subjects (orange dot), treatment emergent neutralizing positive subjects (red dot).

If a subject is determined to be ADA positive (TE or non-TE, based on one or more positive samples), all datapoints belonging to that subject are shown in the color of the corresponding ADA status group.

Data source [053033: analysis-p426pkada0usfilingv5]

For all of the ADA positive subjects, the pembrolizumab exposure was similar to that for other subjects treated with the same regimen.

## Impact of ADA on Pembrolizumab Safety

The  ADA  positive  subjects  (treatment  emergent  and  non-treatment  emergent),  were  evaluated  for potential  impact  on  safety.  The  safety  profile  in  ADA  positive  subjects  was  compared  with  negative subjects. (see table below)

Overview of Impact of ADA on Adverse Events Incidence after Pembrolizumab Combination Therapy, 2o0 mg PembrolizumabQ3W+5mgAxitinibBID(KN426)

|                                                             | negative   | negative   | non-TE nAB Neg   | non-TE nAB Neg   | non-TE nAB Pos   | non-TE nAB Pos   | TE nAB Neg   | TE nAB Neg   | TE nAB Pos   | TE nAB Pos   |
|-------------------------------------------------------------|------------|------------|------------------|------------------|------------------|------------------|--------------|--------------|--------------|--------------|
|                                                             | n          | (%)        | n                | (%)              | n                | (%)              | n            | (%)          | n            | (%)          |
| Subjects in population                                      | 358        |            | 5                |                  | 2                |                  | 21           |              | 3            |              |
| with one ormore adverse events                              | 354        | (98.9)     | 5                | (100.0)          | 2                | (100.0)          | 21           | (100.0)      | 3            | (100.0)      |
| with no adverse event                                       | 4          | (1.1)      | 0                | (0.0)            | 0                | (0.0)            | 0            | (0.0)        | 0            | (0.0)        |
| with drug-relatedadverseevents                              | 349        | (97.5)     | 4                | (80.0)           | 2                | (100.0)          | 21           | (100.0)      | 3            | (100.0)      |
| with toxicitygrade3-5adverse events                         | 269        | (75.1)     | 4                | (80.0)           | 2                | (100.0)          | 17           | (81.0)       | 3            | (100.0)      |
| with toxicity grade 3-5 drug-related adverse events         | 221        | (61.7)     | 3                | (60.0)           | 2                | (100.0)          | 16           | (76.2)       | 2            | (66.7)       |
| with serious adverse events                                 | 147        | (41.1)     | 3                | (60.0)           | 1                | (50.0)           | 10           | (47.6)       | 2            | (66.7)       |
| with serious drug-related adverseevents                     | 84         | (23.5)     | 3                | (60.0)           | 1                | (50.0)           | 6            | (28.6)       | 1            | (33.3)       |
| who died                                                    | 13         | (3.6)      | 0                | (0.0)            | 0                | (0.0)            | 0            | (0.0)        | 0            | (0.0)        |
| whodieddue toadrug-related adverse event                    | 2          | (0.6)      | 0                | (0.0)            | 0                | (0.0)            | 0            | (0.0)        | 0            | (0.0)        |
| discontinueddrugdue toan adverse event                      | 100        | (27.9)     | 3                | (60.0)           | 2                | (100.0)          | 11           | (52.4)       | 1            | (33.3)       |
| discontinueddrugduetoadrug-relatedadverseevent              | 81         | (22.6)     | 1                | (20.0)           | 2                | (100.0)          | 9            | (42.9)       | 1            | (33.3)       |
| discontinued drugduetoaserious adverseevent                 | 61         | (17.0)     | 2                | (40.0)           | 1                | (50.0)           | 5            | (23.8)       | 1            | (33.3)       |
| discontinued drug duetoa serious drug-related adverse event | 41         | (11.5)     | 1                | (20.0)           | 1                | (50.0)           | 3            | (14.3)       | 1            | (33.3)       |

Grades are based on NCI CTCAE version 4.0.

Non-serious adverse events up to30days of last dose and serious adverse eventsup to90days of last dose areincluded.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

DatabaseCutoff Date:24Aug2018.

Subjects with inconclusive ADA results are excluded

Source:[P426V01MK3475: adam-adsl; adae;adbase]

<div style=\"page-break-after: always\"></div>

## Impact of ADA on Pembrolizumab  Efficacy

Only an exploratory impact of ADA on overall survival (OS) over time was visually examined, considering that there are only three subjects with TE Nab positive status. The figure shows that OS was similar across all ADA subgroups.

Kaplan-MeierEstimates of Overall Survival CurvesforSubjectsTreated with 200 mg Pembrolizumab Q3W + 5 mg Axitinib BID (KN426)

<!-- image -->

DatabaseCutoffDate:'24AUG2018'd

<div style=\"page-break-after: always\"></div>

## 2.3.4. PK/PD modelling

No new information regarding PK/PD modelling for pembrolizumab is available within this extension of indication.

## 2.3.5. Discussion on clinical pharmacology

Clinical pharmacology results for the combination therapy of Pembrolizumab together with axitinib specific to support approval for first line treatment of advanced or metastatic renal cell carcinoma (RCC), are available from the pivotal study KEYNOTE-426 and the Pfizer-sponsored study KEYNOTE-035 (Study A4061079).

A substantial characterization of the key clinical pharmacology and immunogenicity findings of pembrolizumab as monotherapy have been provided in previous submissions. Axitinib, as monotherapy, is approved for the treatment of advanced renal cell carcinoma after failure of one prior systemic therapy.

Based on the existing robust characterization of pembrolizumab PK, a comparison was conducted between the observed PK of pembrolizumab for the current indication (RCC) in combination with axitinib and the predictions from the reference PK model developed with pembrolizumab monotherapy data (KEYNOTE-001, -002, -006, -010, and -024).

Predose pembrolizumab serum concentrations (Ctrough) were obtained within 24 hours prior to dosing at cycles 1, 3, 5 and every 4 cycles (12 weeks) thereafter. Postdose serum concentrations (Cmax) were obtained about 30 minutes after the end of the infusion in cycle 1 and cycle 9.

The observed concentrations in RCC patients treated with Pembrolizumab in combination with Axitinib generally fall within the range of predicted concentrations, both after first dose and at steady state, although some low concentrations don't fall in the 90% PI.

As requested, the MAH provided tabular summaries of descriptive statistics and boxplots comparing observed pembrolizumab concentrations of 200 mg every 3 weeks (Q3W) from participants with RCC in KEYNOTE-426 in combination with axitinib with those obtained with the 200 mg Q3W flat dose for other tumor types in the monotherapy setting. These data showed the consistency among exposure obtained in monotherapy with those obtained in combination therapy.

Treatment comparison for axitinib PK parameters (study A4061079) showed that median axitinib plasma concentration-time profiles were comparable when axitinib was administered alone and with pembrolizumab. In addition, comparison of axitinib exposures, as assessed by the PK parameters dose-normalized AUC12 and Cmax, when axitinib was administered alone or in combination, yielded geometric ratios of 1.23 and 0.94 respectively, indicating no clinically meaningful DDI effect.

The exposures observed in this study with or without co-administration of pembrolizumab are within the range of exposures historically observed with axitinib.

The existing immunogenicity assessment for pembrolizumab for the monotherapy setting is based on a sufficiently large dataset of patients across several indications, with very low observed rates of total treatment emergent ADA (1.4 - 3.8%) as well as of neutralizing antibodies (0.4 - 1.6%).

For pembrolizumab combination therapy (200 mg pembrolizumab Q3W + 5 mg axitinib BID), ADA samples were available from 434 subjects (only 406 subjects were included in the final immunogenicity assessment).

<div style=\"page-break-after: always\"></div>

The incidence of treatment-emergent ADA to pembrolizumab in subjects with RCC treated with pembrolizumab in combination with axitinib was ~6% (24 out of 389 total evaluable samples) that is higher compared to the overall incidence in the monotherapy setting (1.8%).

Three out of 24 treatment emergent ADA positive patients had neutralising antibodies against pembrolizumab (0.8%). The percentage of ADA positive patients with neutralising properties is similar with the overall incidence in the monotherapy setting.

There was no evidence of an altered pharmacokinetic or safety profile with anti-pembrolizumab binding or neutralising antibody development.

## 2.3.6. Conclusions on clinical pharmacology

The observed concentration from KEYNOTE-426 falls within the 90% CI of the model predicted median concentration. Although the number of treatment emergent ADA is higher when pembrolizumab is combined with axitinib, treatment emergent ADA status is not found to alter the PK, efficacy and safety of the combination regimen.

## 2.4. Clinical efficacy

The proposed indication is based on the results from KEYNOTE-426, an on-going randomized, multi-center, open-label, global phase 3 study investigating pembrolizumab in combination with axitinib vs sunitinib monotherapy as first-line treatment for locally advanced or metastatic RCC.

Data from KEYNOTE-427 (Phase 2 study of pembrolizumab monotherapy in participants with RCC) for participants with clear cell RCC (Cohort A), and the Pfizer-sponsored Study A4061051 (Phase 3 study of axitinib versus sorafenib in treatment-naïve RCC patients) are submitted as supportive with the aim to provide the contribution of each of the components to the efficacy of the pembrolizumab + axitinib regimen, together with the results of the Pfizer sponsored study KEYNOTE-035/A4061079 (Phase 1b of pembrolizumab + axitinib in RCC), which provided the rationale for evaluating pembrolizumab in combination with axitinib in participants with advanced RCC.

## 2.4.1. Dose response study(ies)

Study KN-035 was a Phase 1b, open label, single-arm, multi-center, multiple-dose, safety, efficacy, PK and  pharmacodynamics  study  of  axitinib  in  combination  with  pembrolizumab  in  adult  patients  with previously untreated advanced RCC. This clinical study comprised of a Dose Finding Phase and a Dose Expansion Phase. In this trial, the axitinib starting dose was 5 mg BID with or without food, i.e. the dose approved for the indication of second-line treatment of adults with advanced RCC. The pembrolizumab starting dose was 2 mg/kg to be administered Q3W.

This study estimated an MTD of axitinib 5 mg BID and pembrolizumab 2 mg/kg intravenously (IV). During the dose-finding phase, there were 3 (27.3%) out of 11 patients who experienced DLTs during the first 2 cycles or 6 weeks post C1D1. One patient had transient ischemic attack (TIA) and two patients were unable to complete ≥ 75% of planned axitinib dose due to treatment-related toxicity (one due to grade 2/3 headache and the other due to grade 2 headache, fatigue, asthenia, and dehydration).

A total of 52 patients were enrolled into the study from 16 September 2014, including the first 11 patients enrolled in the Dose Finding Phase.

Overall, the combination of axitinib and pembrolizumab was safe and tolerable. No new safety signals were identified with axitinib in combination with pembrolizumab in patients with previously untreated

<div style=\"page-break-after: always\"></div>

advanced RCC; the safety profile of either study drug was consistent with the known safety profile when used as single agent.

The most frequently reported AEs such as diarrhea and fatigue were similar to those found in monotherapy trials. No treatment-related deaths during the study was reported.

At the data cut-off date of 31 March 2017, the confirmed ORR was 73.1% (95% CI [59.0, 84.4]), with a best overall response of CR reported for 4 patients and PR reported for 34 patients. The median duration of tumor response was 18.6 months (95% CI [15.1, NR]).The median TTR was 2.8 months (range: 0.7 15.2 months).

The median PFS was 20.9 months (15.4, NR) among all the treated patients. The median OS in the current study was not reached at the minimum follow-up period of 17.6 months; the majority of patients [43 (82.7%) patients] were still alive at the time of data cut-off.

Overall, 48 patients had their tumor tissue evaluated for PD-L1 status. Nine (18.8%) patients had a tumor PD-L1 status positive; 34 (70.8%) patients had a tumor PD-L1 status negative. Four (8.3%) patients had a tumor PD-L1 status of not evaluable, while 1 (2.1%) patient was missing the PD-L1 status. Of the 9 patients with tumor PD-L1 status positive, 8 (88.9%) patients had partial response and 1 (11.1%) had indeterminate response. Of the 34 patients with tumor PD-L1 status negative, 4 (11.8%) patients had complete response, 20 (58.8%) patients had partial response, 6 (17.6%) patients had stable disease, 2 (5.9%) patient had progressive disease, and 2 (5.9%) patients had intermediate response. Of the 4 patients without tumor PD-L1 status available, 3 (75%) patients had PR, and 1 patient had SD, while the patient missing the PD-L1 status had a PR.

Based on these data suggesting the tolerability and anti-tumor efficacy of the combination of axitinib and pembrolizumab, the MAH designed Study KN-426. In this trial, the pembrolizumab dose was 200 mg Q3W. The rational is based on the fact that an integrated body of evidence suggests that 200 mg Q3W is expected to provide similar response to 2 mg/kg Q3W, 10 mg/kg Q3W, and 10 mg/kg Q2W.  Exposures for 200 mg Q3W are expected to lie within this range and close to those obtained with the 2 mg/kg Q3W dose.

The 200 mg Q3W dose currently recommended for all the approved indications of pembrolizumab (as monotherapy or in combination with chemotherapy), and is being evaluated in multiple clinical studies.

## 2.4.2. Main study(ies)

A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) - KEYNOTE-426

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Methods

## Study participants

Key inclusion criteria were:

- Histologically confirmed diagnosis of RCC with clear cell component with or without sarcomatoid features.
- Locally advanced/metastatic disease, i.e. newly diagnosed stage IV RCC per AJCC or recurrent disease.
- Measurable disease per RECIST 1.1 as assessed by the investigator/site radiologist.
- No prior systemic therapy for advanced RCC.
- KPS ≥ 70%, as assessed within 10 days prior to randomization.
- Subjects receiving bone resorptive therapy (including but not limited to bisphosphonate or RANK-L inhibitor) must have therapy initiated at least 2 weeks prior to randomization.
- Adequate organ function.

## Key exclusion criteria were:

- Major surgery within 4 weeks, radiation therapy within 2 weeks prior to randomization, or has not recovered (i.e., ≤ Grade 1 or at baseline) from AEs due to prior treatment
- Prior treatment with any anti-PD-1, or PD-L1, or PD-L2 agent or an antibody targeting any other immune-regulatory receptors or mechanisms. Examples of such antibodies include (but are not limited to) antibodies against IDO, PD -L1, IL-2R, and GITR.
- Prior systemic anticancer therapy for RCC (e.g., VEGF/VEGFR, chemotherapy, or mTOR-targeting agents).
- o Prior neoadjuvant/adjuvant therapy for RCC was acceptable if completed &gt;12 months prior to randomization.
- Diagnosis of immunodeficiency OR is receiving a systemic steroid therapy exceeding physiologic corticosteroid dose or any other form of immunosuppressive therapy within 7 days prior to randomization, except in the case of central nervous system (CNS) metastases-
- Active autoimmune disease requiring systemic treatment within the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs) OR with a documented history of clinically severe autoimmune disease
- o Note: Subjects with vitiligo, Sjögren's syndrome, Type 1 diabetes, or resolved childhood asthma/atopy will not be excluded from the study. Subjects requiring intermittent use of bronchodilators, inhaled steroids, or local steroid injections will not be excluded from the study. Subjects with hypothyroidism, or adrenal or pituitary insufficiency who are stable on hormone replacement will not be excluded from the study.
- Known active CNS metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are radiologically stable, clinically stable and without requirement of steroid treatment for at least 14 days prior to randomization.
- Clinically significant GI abnormality.
- QTc ≥ 480 msec.

<div style=\"page-break-after: always\"></div>

- History of any of the following cardiovascular conditions within 12 months of randomization:
- o myocardial infarction, unstable angina pectoris, cardiac angioplasty or stenting, coronary/peripheral artery bypass graft, Class III or IV congestive heart failure per New York Heart Association criteria, or cerebrovascular accident or transient ischemic attack.
- History of deep vein thrombosis or pulmonary embolism within 6 months of screening.
- Has poorly controlled hypertension defined as systolic blood pressure (SBP) ≥ 150 mm Hg and/or diastolic blood pressure (DBP) ≥ 90 mm Hg.
- Evidence of inadequate wound healing.
- Active bleeding disorder or other history of significant bleeding episodes within 30 days of randomization.
- Hemoptysis within 6 weeks prior to randomization.

## Treatments

The study treatments are outlined in the table below:

<!-- image -->

| Treatment                                                                                                                                                                                                                                                                                                                                                                                    | Regimen                                                                                                                                                                                                                                                                                                                                                                                      | Route of Administration                                                                                                                                                                                                                                                                                                                                                                      | Duration of Treatment                                                                                                                                                                                                                                                                                                                                                                        | Use in Study                                                                                                                                                                                                                                                                                                                                                                                 |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pembrolizumab+Axitinib                                                                                                                                                                                                                                                                                                                                                                       | Pembrolizumab+Axitinib                                                                                                                                                                                                                                                                                                                                                                       | Pembrolizumab+Axitinib                                                                                                                                                                                                                                                                                                                                                                       | Pembrolizumab+Axitinib                                                                                                                                                                                                                                                                                                                                                                       | Pembrolizumab+Axitinib                                                                                                                                                                                                                                                                                                                                                                       |
| Pembrolizumab                                                                                                                                                                                                                                                                                                                                                                                | 200 mg Q3W                                                                                                                                                                                                                                                                                                                                                                                   | IV infusion                                                                                                                                                                                                                                                                                                                                                                                  | Up to 35 doses (about 24 months) or until PD is BICR verifiedorfurther confirmed by the investigator                                                                                                                                                                                                                                                                                         | Experimental                                                                                                                                                                                                                                                                                                                                                                                 |
| Axitinib                                                                                                                                                                                                                                                                                                                                                                                     | 5 mg BID                                                                                                                                                                                                                                                                                                                                                                                     | PO                                                                                                                                                                                                                                                                                                                                                                                           | Continued treatment until PD is BICR verified of further confirmed by the investigator                                                                                                                                                                                                                                                                                                       | Experimental                                                                                                                                                                                                                                                                                                                                                                                 |
| Sunitinib                                                                                                                                                                                                                                                                                                                                                                                    | Sunitinib                                                                                                                                                                                                                                                                                                                                                                                    | Sunitinib                                                                                                                                                                                                                                                                                                                                                                                    | Sunitinib                                                                                                                                                                                                                                                                                                                                                                                    | Sunitinib                                                                                                                                                                                                                                                                                                                                                                                    |
| Sunitinib                                                                                                                                                                                                                                                                                                                                                                                    | 50 mg QD 4 weeks on, 2 weeks off                                                                                                                                                                                                                                                                                                                                                             | PO                                                                                                                                                                                                                                                                                                                                                                                           | Continued treatment until PD is BICR verified or further confirmed by the investigator                                                                                                                                                                                                                                                                                                       | Comparator (standard of care)                                                                                                                                                                                                                                                                                                                                                                |
| Abbreviations: BICR = blinded independent central review, BID = twice daily; IV = intravenous; PD = progressive disease; PO = per os/by mouth; QD = once daily; Q3 W = every 3 weeks. a. Subjectsinthe pembrolizumab+axitinib armmayreceive a second course of treatment with an additional 17 doses of pembrolizumab. Details are described in Section 5.8.3 of the shudy protocol [16.1.1] | Abbreviations: BICR = blinded independent central review, BID = twice daily; IV = intravenous; PD = progressive disease; PO = per os/by mouth; QD = once daily; Q3 W = every 3 weeks. a. Subjectsinthe pembrolizumab+axitinib armmayreceive a second course of treatment with an additional 17 doses of pembrolizumab. Details are described in Section 5.8.3 of the shudy protocol [16.1.1] | Abbreviations: BICR = blinded independent central review, BID = twice daily; IV = intravenous; PD = progressive disease; PO = per os/by mouth; QD = once daily; Q3 W = every 3 weeks. a. Subjectsinthe pembrolizumab+axitinib armmayreceive a second course of treatment with an additional 17 doses of pembrolizumab. Details are described in Section 5.8.3 of the shudy protocol [16.1.1] | Abbreviations: BICR = blinded independent central review, BID = twice daily; IV = intravenous; PD = progressive disease; PO = per os/by mouth; QD = once daily; Q3 W = every 3 weeks. a. Subjectsinthe pembrolizumab+axitinib armmayreceive a second course of treatment with an additional 17 doses of pembrolizumab. Details are described in Section 5.8.3 of the shudy protocol [16.1.1] | Abbreviations: BICR = blinded independent central review, BID = twice daily; IV = intravenous; PD = progressive disease; PO = per os/by mouth; QD = once daily; Q3 W = every 3 weeks. a. Subjectsinthe pembrolizumab+axitinib armmayreceive a second course of treatment with an additional 17 doses of pembrolizumab. Details are described in Section 5.8.3 of the shudy protocol [16.1.1] |

Study treatment was to begin on the day of randomization or within 3 days of randomization in the 2 treatment groups. Subsequently, the treatment was to be administered on Day 1 of each treatment cycle. For participants in the pembrolizumab + axitinib group, each treatment cycle was 21 days (+/- 3 days) to correspond with the dosing schedule of pembrolizumab. The first dose of axitinib was to start on the same day when first dose of pembrolizumab was administered or on the following day. For participants in the sunitinib group, each treatment cycle was 42 days.

<div style=\"page-break-after: always\"></div>

Pembrolizumab, axitinib, and sunitinib were withheld for drug-related toxicities and severe or life-threatening AEs. The axitinib dose could be adjusted by a dosing interruption with or without dose reduction as indicated. The dose modification could occur independently for the 2 drugs used in the pembrolizumab plus axitinib arm. If axitinib dose reduction from 5 mg BID was required, the next recommended dose levels were 3 mg BID and 2 mg BID. Axitinib was permanently discontinued if subjects could not tolerate 2 mg BID.

Subjects who tolerated axitinib 5 mg BID for 2 consecutive treatment cycles (i.e. 6 weeks) with no &gt; Grade 2 treatment-related AEs to axitinib and with BP well controlled to ≤ 150/90 mm Hg could have axitinib dose increased to 7 mg BID, and further increased to 10 mg BID using the same criteria.

For sunitinib, the study used the label-recommended dose and schedule for RCC (50 mg QD 4 weeks on, 2 weeks off). Dose interruption and/or dose modification in 12.5 -mg increments or decrements was recommended based on individual safety and tolerability, as per label recommendations.

Study treatments continue until progressive disease (PD) is BICR-verified or further confirmed by the investigator, unacceptable adverse events (AEs) or intercurrent illness prevents further administration of treatment, death or withdrawal of consent. For both arms, in the event that a complete response (CR) has been observed in a subject, study treatment may be discontinued at the discretion of the investigator after the CR has been confirmed and after a minimum of 8 cycles of treatment (~24 weeks) in the pembrolizumab plus axitinib arm or 4 cycles of treatment (~24 weeks) in the sunitinib arm have been received. In the combination arm, treatment could continue with one drug if the other had been discontinued due to adverse reactions. Pembrolizumab is administered for a maximum of 35 doses.

## Objectives

## Primary Objectives :

- To evaluate and compare PFS per RECIST 1.1 as assessed by BICR in participants treated with pembrolizumab + axitinib versus sunitinib.
- o Hypothesis:  The  combination  therapy  of  pembrolizumab  plus  axitinib  is  superior  to sunitinib monotherapy with respect to PFS as assessed by BICR per RECIST 1.1.
- To  evaluate  and  compare  OS  in  participants  treated  with  pembrolizumab  +  axitinib  versus sunitinib.
- o Hypothesis:  The  combination  therapy  of  pembrolizumab  plus  axitinib  is  superior  to sunitinib monotherapy with respect to OS.

## Secondary Objectives :

- To compare ORR and DCR per RECIST 1.1 as assessed by BICR in participants treated with pembrolizumab + axitinib versus sunitinib. DOR per RECIST 1.1 will also be evaluated.
- o Hypothesis:  The  combination  therapy  of  pembrolizumab  plus  axitinib  is  superior  to sunitinib monotherapy with respect to ORR as assessed by BICR per RECIST 1.1.
- To evaluate PFS rate per RECIST 1.1 as assessed by BICR at 12, 18, and 24 months based on data adequacy; to evaluate OS rates at 12, 18, and 24 months based on data adequacy.
- To evaluate and compare  safety and tolerability profiles in participants treated with

<div style=\"page-break-after: always\"></div>

pembrolizumab + axitinib versus sunitinib.

- To compare TTD based on the FKSI-DRS scale in participants treated with pembrolizumab + axitinib versus sunitinib.
- To assess the longitudinal score changes from baseline to 42 weeks as measured by EORTC QLQ-C30 global health status/quality of life scale

In  addition,  pembrolizumab  +  axitinib  was  compared  to  sunitinib  for  the  following Exploratory Objectives :

- To evaluate PFS, ORR, DOR, and DCR per irRECIST as assessed by BICR in participants treated with pembrolizumab + axitinib versus sunitinib.
- To characterize utility in participants using the EQ-5D-3L.
- To characterize the PK of pembrolizumab in participants treated with pembrolizumab + axitinib. To  identify  molecular  (genomic,  metabolic  and/or  proteomic)  determinants  of  response  or resistance to pembrolizumab + axitinib treatments in this study, so as to define novel predictive and pharmacodynamic biomarkers and understand the mechanism of action of the pembrolizumab + axitinib combination.

## Outcomes/endpoints

## Primary endpoints

- Progression-free Survival (PFS) - RECIST 1.1 by Blinded Central Imaging Vendor Review
- o Progression-free  survival  is  defined  as  the  time  from  randomization  to  the  first documented disease progression per RECIST 1.1 based on BICR or death due to any cause, whichever occurs first.
- Overall Survival (OS)
- o Overall survival is defined as the time from randomization to death due to any cause. Subjects without documented death at the time of the final analysis will be censored at the date of the last follow up.

## Secondary endpoints

- Objective Response Rate (ORR) - RECIST 1.1 by BICR
- o Objective  response  rate  is  defined  as  the  proportion  of  the  subjects  in  the  analysis population who have a CR or PR per RECIST 1.1.
- Duration of Response (DOR) - RECIST 1.1 by BICR
- o For  subjects  who  demonstrate  CR  or  PR,  DOR  is  defined  as  the  time  from  first documented evidence of CR or PR per RECIST 1.1 until disease progression per RECIST 1.1 or death due to any cause, whichever occurs first.
- Disease Control Rate (DCR) - RECIST 1.1 by BICR
- o Disease control rate is defined as the percentage of subjects who have achieved CR, PR, or SD of ≥ 6 months based on assessments by BICR per RECIST 1.1.

<div style=\"page-break-after: always\"></div>

## Sample size

The study was event-driven and planned to randomize approximately 840 subjects with 1:1 ratio into the two treatment groups pembrolizumab plus axitinib and sunitinib.

Both PFS and OS are primary endpoints for this study. For the PFS endpoint, based on a target number of 487 PFS events and one interim analysis at approximately 75% of the target number of events, the study has ~99% power to detect an HR of 0.60 (pembrolizumab+axitinib combination versus sunitinib) at alpha=0.2% (1-sided). The calculation assumes an HSD alphaspending function with γ= -2 to control the overall Type I error rate for this endpoint at 0.2% (1-sided). The target numbers of PFS events for the first interim and final analysis are projected to occur at 22 and 31 months respectively. The IA1 was triggered when 305 PFS events had accrued and all participants were followed for at least 7 months after randomization. For the OS endpoint, based on a target number of 404 final OS events and 2 interim analyses (with approximately 48% of final OS events at IA1 and 74% of the final OS events at IA2), the study has approximately 80% power to detect an HR of 0.75 at an overall alpha level of 2.3% (1-sided). The calculation assumes that a linear alpha-spending function with a fixed alpha-spending of 0.0001 at IA1 and the rest alpha-spending approximated by an HSD alphaspending function withγ= -4 to control the overall Type I error rate for this endpoint at 2.3% (1-sided). The target number of OS events is projected to occur at 43 months after the start of the study. The target numbers of OS events for the first and second interim analyses are projected to occur at 22 months and 31 months respectively. The calculations assume an exponential distribution with a median of 13 months for PFS and a median of 33 months for OS for the control group respectively, a yearly dropout rate of 10% for PFS and 1% for OS, and an enrollment of 15 months, with monthly accrual of 40 to 60 patients in the first 3 months and monthly accrual of ~60 patients after the first 3 months. The median PFS and median OS assumptions in the control group are based on emerging data of sunitinib from the CheckMate 214 study.

## Randomisation

Treatment randomization occurred centrally using an interactive voice response system/integrated web response system (IVRS/IWRS). Subjects were assigned randomly in a 1:1 ratio to the pembrolizumab plus axitinib combination arm or the sunitinib monotherapy arm.

Prior to randomization subjects will be stratified according to the following factors:

1. International Metastatic RCC Database Consortium (IMDC) risk group: favourable versus intermediate versus poor risk groups

2. Geographic region: North America versus Western Europe versus 'Rest of the World'.

IMDC risk category for each subject was determined first by assessing 6 risk factors as shown in the table below:

<div style=\"page-break-after: always\"></div>

| Assessments                                                                                                                                                                                                                                                            | Risk Factor                                                                                                                                                                                                                                                            |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| BaselineKamofskyPerformanceStatus                                                                                                                                                                                                                                      | ≤ 80%                                                                                                                                                                                                                                                                  |
| Interval between initial diagnosis of RCC to start of first-line systemic treatment for advanced disease (noteforthis shudy, dateofrandomizationwill be used as the start offirst- line systemic treaiment)                                                            | < lyear                                                                                                                                                                                                                                                                |
| Baseline Hemoglobin                                                                                                                                                                                                                                                    | ≤ Lower limit ofnonmal                                                                                                                                                                                                                                                 |
| BaselinePlatelet Couut                                                                                                                                                                                                                                                 | >Upper limit of normal                                                                                                                                                                                                                                                 |
| Baseline Corrected Calcium'                                                                                                                                                                                                                                            | > Upper limit of nonmal                                                                                                                                                                                                                                                |
| Baseline Neutrophil                                                                                                                                                                                                                                                    | > Upper limit of nomal                                                                                                                                                                                                                                                 |
| The IMDC risk group is determined by totaling the existing nisk factors per subject.                                                                                                                                                                                   | The IMDC risk group is determined by totaling the existing nisk factors per subject.                                                                                                                                                                                   |
| MDC Risk Group                                                                                                                                                                                                                                                         | MDC Category                                                                                                                                                                                                                                                           |
| Favorable                                                                                                                                                                                                                                                              | No risk factors                                                                                                                                                                                                                                                        |
| Intemediate                                                                                                                                                                                                                                                            | 1 or2risk factors                                                                                                                                                                                                                                                      |
| Poor                                                                                                                                                                                                                                                                   | 3 or more risk factors                                                                                                                                                                                                                                                 |
| Corected calcim cam be calculated based o1 the following formula: Correctedcalcium (mg/dl)=0.8x[4.0-subject'salbumin (g/dll] 1+ subject's calcium (mg/dl). A subject's conrected calcium will be compared with the upper limit of nommal of inshitution serum calcium. | Corected calcim cam be calculated based o1 the following formula: Correctedcalcium (mg/dl)=0.8x[4.0-subject'salbumin (g/dll] 1+ subject's calcium (mg/dl). A subject's conrected calcium will be compared with the upper limit of nommal of inshitution serum calcium. |

## Blinding (masking)

The study was conducted in an open-label fashion, with a blinded independent radiologist review of responses.

## Statistical methods

The primary efficacy analysis was performed on Intention-to-Treat (ITT) population.

The  non-parametric  Kaplan-Meier  method  was  used  to  estimate  the  OS  and  the  PFS  curve  in  each treatment group including the PFS rates at 12, 18, and 24 months. The treatment difference in PFS was assessed by the stratified log -rank test. A stratified Cox proportional hazard model with Efron's method of tie handling was used to estimate the magnitude of the treatment difference between the treatment arms. The hazard ratio and its 95% confidence interval from the stratified Cox model with Efron's method of tie handling and with a single treatment covariate was reported. The stratification factors used for randomization was applied to both the stratified log-rank test and the stratified Cox model.

The true date of disease progression was approximated by the date of the first assessment at which PD is objectively documented per RECIST 1.1 by BICR. Death was always considered as a confirmed PD event. Subjects who did not experience a PFS event were censored at the last disease assessment.  The censoring rules for primary and sensitivity analyses* are summarized in the following table.

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Situation                                                                                                              | Primary Analysis                                                                                                                            | Sensitivity Analysis 1                    | Sensitivity Analysis 2                                                                                                                                                                    |
|------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PDordeathdocumented after ≤ 1 missed disease assessment, and before new anti-cancer therapy, if any                    | Progressed at date of documented PDor death                                                                                                 | Progressed at date of documentedPDordeath | Progressed at date of documentedPDordeath                                                                                                                                                 |
| PD or death documented immediately after≥2 consecutive missed disease assessmentsor afternew anti-cancertherapy,if any | Censored at last disease assessment prior to the earlier date of ≥2 consecuive missed disease assessment and new anti-cancer therapy,if any | Progressed at date of documentedPDordeath | Progressed at date of documentedPDordeath                                                                                                                                                 |
| No PD and no death; and newanticancer treammentis not initiated                                                        | Censored at last disease assessment                                                                                                         | Censored at last disease assessment       | Progressed at treatment discontinuation due to reasons other than complete response; otherwise censored at last disease assessmentif still onstudy treatment orcompleted shudy treatment. |
| No PD and no death; new anticancer treatment iS initiated                                                              | Censoredatlast disease assessment before new anticancer treatment                                                                           | Censored at last disease assessment       | Progressed at date of new anticancertreahment                                                                                                                                             |

PD = progressive divease, PFS =progession-fiee suvival

* The Sensitivity analysis was performed for comparison of PFS based on investigator's assessment using primary censoring rule.

Stratified Miettinen and Nurminens method with weights proportional to the stratum size was used for comparison of the objective response rates (ORR) and of the DCR between the treatment arms. A 95% CI for the difference in response rates between the treatment arms was provided. The stratification factors used for randomization were applied to the analysis. Sensitivity analyses were performed to assess ORR and DCR based on investigator's assessment.

The non-parametric Kaplan-Meier method was used to estimate the DOR curve in each treatment group; estimates of the percentage of subjects still in response and 95% CIs at specific duration time points was provided. Sensitivity analyses were performed to assess DOR based on investigator's assessment.

The overall Type I error across the testing of the OS, PFS, and ORR hypotheses was strongly controlled at 2.5% (1-sided) with 0.2% initially allocated to PFS and 2.3% initially allocated to OS. If a hypothesis was rejected, then the corresponding alpha level of that test could be shifted using the graphical approach of Maurer and Bretz (see figure below).

<!-- image -->

Two interim analyses were planned for OS and one planned interim analysis for PFS for the study. A group sequential approach was used to allocate alpha between the interim and final analyses. The study was considered a success if either PFS or OS is demonstrated to be statistically significant under multiplicity control.

<div style=\"page-break-after: always\"></div>

The following table show the strategies for each interim and final analysis in this trial based on model assumptions.

Table 20 Summary of Interim and Final Analyses Strategies

<!-- image -->

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Expected Months after Study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Hypo- thesis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Infor- mation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Type I Error (Overall                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | EfficacyBoundaryCrossing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | EfficacyBoundaryCrossing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | EfficacyBoundaryCrossing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | EfficacyBoundaryCrossing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | FutilityBoundaryCrossing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | FutilityBoundaryCrossing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | FutilityBoundaryCrossing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | FutilityBoundaryCrossing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Start                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Tested in the Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | True Hazard Ratio                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Fraction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | α                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Nominal C.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Z- value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Statistics+                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | Powers                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | Nominal a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Z- value                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | Hazard Ratio                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Cumulative Type II Error                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 22 Months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | PFS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 0.6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 365                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 0.75                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0.20%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0.11%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 3.06                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0.73                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | ~96.5%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 22.1%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | -0.77                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 1.08                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | <0.01%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 22 Months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | PFS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 0.6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 365                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 0.75                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 1.35%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 0.74%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 2.44                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0.77                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | ~99.2%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 21.8%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | -0.78                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 1.08                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | <0.01%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 22 Months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | PFS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 0.6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 365                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 0.75                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 2.5%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 1.36%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 2.21                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0.79                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | %9'66~                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 21.6%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | -0.79                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 1.08                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | <0.01%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 22 Months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | OS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0.75                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 195                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 0.48                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 2.3%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0.01%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 3.72                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0.59                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | ~4.3%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 4.1%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | -1.74                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 1.28                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | ~0.01%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 22 Months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | OS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0.75                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 195                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 0.48                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 2.5%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0.01%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 3.70                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0.59                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | ~4.5%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 4.1%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | -1.74                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 1.28                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | ~0.01%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 22 Months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | ORR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 860                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 1.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 0.2% 1.15%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 0.2% 1.15%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 2.88 2.27                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 9.4%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | %6'66<                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 22 Months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | ORR                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 860                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 1.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 2.5%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 2.5%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 1.96                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 7.4% 6.4%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | %6'66< >99.9%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 31 Months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | PFS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 0.6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 487                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 1.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 0.2%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0.14%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 3.00                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0.76                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | >99.9%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 99.8%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 3.00                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0.76                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | ~3.9%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 31 Months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | PFS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 0.6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 487                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 1.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 1.35%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 1.02%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 2.32                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0.81                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | >99.9%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 98.7%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 2.32                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0.81                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | ~0.04%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 31 Months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | PFS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 0.6                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 487                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 1.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 2.5%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 1.95%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 2.06                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0.83                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | %666<                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 97.5%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 2.06                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0.83                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | ~0.02%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 31 Months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | oS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0.75                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 299                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 0.74                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 2.3%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0.78%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 2.42                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0.76                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | ~52.7%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 20.3%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | -0.84                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 1.10                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | ~0.05%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 31 Months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | oS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0.75                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 299                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 0.74                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 2.5%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0.92%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 2.36                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 0.76                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | ~55.1%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 20.2%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | -0.85                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 1.10                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | ~0.05%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Months 43                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | OS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 0.75                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 404                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 1.0                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 2.3% 2.5%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 2.22% 2.07%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 2.04 2.01                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 0.82 0.82                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | ~81.7% ~80.8%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 97.7% 97.5%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 2.01 2.04                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | ~0.82 ~0.82                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | ~19.2% ~18.3%                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| + n means expected events at the time of corresponding analysis for PFS and OS based on model assumption. In the rare case if PFS events accumulate slower than expected, a minimumof 305eventsisrequired at 22months to triggerIA1;n means totalsamplesizeforORR. + The statistics used here are hazard ratio for PFS and OS, and ORR △ for ORR where ORR  = ORR in (pembrolizumab+axitinib group)- ORR in sunitinib group.  The power calculated for OS is cumulative power. For the power calculation, the target ORR in the pembrolizuab+axitinib group and the reference ORR assumed in the sunitinib groups are 55% and 31%, respectively. For OS, a linear spending function with a fixed alpha spending of 0.oo01 at IA1 and the rest alpha spending approximated by a Hwang-Shih-DeCani (HSD) alpha-spending function with gamma parameter (-4) is used to construct Haybittle-Peto type of group sequential boundaries to control the overall Type Ierrorrate for this endpoint at 2.3% or 2.5% (1-sided).Futility spending is done by controlling the probability of crossing the futility bound under the null hypothesis (total of 1-α=97.5%); an HSD alpha-spending function with gamma parameter (-6)isused to construct group sequential boundariesforfutility.TheType Ierrorrate to spend at IA2 andFAwill bedetermined by the spendingfunctionevaluated at the exact number of deaths at each analysis. | + n means expected events at the time of corresponding analysis for PFS and OS based on model assumption. In the rare case if PFS events accumulate slower than expected, a minimumof 305eventsisrequired at 22months to triggerIA1;n means totalsamplesizeforORR. + The statistics used here are hazard ratio for PFS and OS, and ORR △ for ORR where ORR  = ORR in (pembrolizumab+axitinib group)- ORR in sunitinib group.  The power calculated for OS is cumulative power. For the power calculation, the target ORR in the pembrolizuab+axitinib group and the reference ORR assumed in the sunitinib groups are 55% and 31%, respectively. For OS, a linear spending function with a fixed alpha spending of 0.oo01 at IA1 and the rest alpha spending approximated by a Hwang-Shih-DeCani (HSD) alpha-spending function with gamma parameter (-4) is used to construct Haybittle-Peto type of group sequential boundaries to control the overall Type Ierrorrate for this endpoint at 2.3% or 2.5% (1-sided).Futility spending is done by controlling the probability of crossing the futility bound under the null hypothesis (total of 1-α=97.5%); an HSD alpha-spending function with gamma parameter (-6)isused to construct group sequential boundariesforfutility.TheType Ierrorrate to spend at IA2 andFAwill bedetermined by the spendingfunctionevaluated at the exact number of deaths at each analysis. | + n means expected events at the time of corresponding analysis for PFS and OS based on model assumption. In the rare case if PFS events accumulate slower than expected, a minimumof 305eventsisrequired at 22months to triggerIA1;n means totalsamplesizeforORR. + The statistics used here are hazard ratio for PFS and OS, and ORR △ for ORR where ORR  = ORR in (pembrolizumab+axitinib group)- ORR in sunitinib group.  The power calculated for OS is cumulative power. For the power calculation, the target ORR in the pembrolizuab+axitinib group and the reference ORR assumed in the sunitinib groups are 55% and 31%, respectively. For OS, a linear spending function with a fixed alpha spending of 0.oo01 at IA1 and the rest alpha spending approximated by a Hwang-Shih-DeCani (HSD) alpha-spending function with gamma parameter (-4) is used to construct Haybittle-Peto type of group sequential boundaries to control the overall Type Ierrorrate for this endpoint at 2.3% or 2.5% (1-sided).Futility spending is done by controlling the probability of crossing the futility bound under the null hypothesis (total of 1-α=97.5%); an HSD alpha-spending function with gamma parameter (-6)isused to construct group sequential boundariesforfutility.TheType Ierrorrate to spend at IA2 andFAwill bedetermined by the spendingfunctionevaluated at the exact number of deaths at each analysis. | + n means expected events at the time of corresponding analysis for PFS and OS based on model assumption. In the rare case if PFS events accumulate slower than expected, a minimumof 305eventsisrequired at 22months to triggerIA1;n means totalsamplesizeforORR. + The statistics used here are hazard ratio for PFS and OS, and ORR △ for ORR where ORR  = ORR in (pembrolizumab+axitinib group)- ORR in sunitinib group.  The power calculated for OS is cumulative power. For the power calculation, the target ORR in the pembrolizuab+axitinib group and the reference ORR assumed in the sunitinib groups are 55% and 31%, respectively. For OS, a linear spending function with a fixed alpha spending of 0.oo01 at IA1 and the rest alpha spending approximated by a Hwang-Shih-DeCani (HSD) alpha-spending function with gamma parameter (-4) is used to construct Haybittle-Peto type of group sequential boundaries to control the overall Type Ierrorrate for this endpoint at 2.3% or 2.5% (1-sided).Futility spending is done by controlling the probability of crossing the futility bound under the null hypothesis (total of 1-α=97.5%); an HSD alpha-spending function with gamma parameter (-6)isused to construct group sequential boundariesforfutility.TheType Ierrorrate to spend at IA2 andFAwill bedetermined by the spendingfunctionevaluated at the exact number of deaths at each analysis. | + n means expected events at the time of corresponding analysis for PFS and OS based on model assumption. In the rare case if PFS events accumulate slower than expected, a minimumof 305eventsisrequired at 22months to triggerIA1;n means totalsamplesizeforORR. + The statistics used here are hazard ratio for PFS and OS, and ORR △ for ORR where ORR  = ORR in (pembrolizumab+axitinib group)- ORR in sunitinib group.  The power calculated for OS is cumulative power. For the power calculation, the target ORR in the pembrolizuab+axitinib group and the reference ORR assumed in the sunitinib groups are 55% and 31%, respectively. For OS, a linear spending function with a fixed alpha spending of 0.oo01 at IA1 and the rest alpha spending approximated by a Hwang-Shih-DeCani (HSD) alpha-spending function with gamma parameter (-4) is used to construct Haybittle-Peto type of group sequential boundaries to control the overall Type Ierrorrate for this endpoint at 2.3% or 2.5% (1-sided).Futility spending is done by controlling the probability of crossing the futility bound under the null hypothesis (total of 1-α=97.5%); an HSD alpha-spending function with gamma parameter (-6)isused to construct group sequential boundariesforfutility.TheType Ierrorrate to spend at IA2 andFAwill bedetermined by the spendingfunctionevaluated at the exact number of deaths at each analysis. | + n means expected events at the time of corresponding analysis for PFS and OS based on model assumption. In the rare case if PFS events accumulate slower than expected, a minimumof 305eventsisrequired at 22months to triggerIA1;n means totalsamplesizeforORR. + The statistics used here are hazard ratio for PFS and OS, and ORR △ for ORR where ORR  = ORR in (pembrolizumab+axitinib group)- ORR in sunitinib group.  The power calculated for OS is cumulative power. For the power calculation, the target ORR in the pembrolizuab+axitinib group and the reference ORR assumed in the sunitinib groups are 55% and 31%, respectively. For OS, a linear spending function with a fixed alpha spending of 0.oo01 at IA1 and the rest alpha spending approximated by a Hwang-Shih-DeCani (HSD) alpha-spending function with gamma parameter (-4) is used to construct Haybittle-Peto type of group sequential boundaries to control the overall Type Ierrorrate for this endpoint at 2.3% or 2.5% (1-sided).Futility spending is done by controlling the probability of crossing the futility bound under the null hypothesis (total of 1-α=97.5%); an HSD alpha-spending function with gamma parameter (-6)isused to construct group sequential boundariesforfutility.TheType Ierrorrate to spend at IA2 andFAwill bedetermined by the spendingfunctionevaluated at the exact number of deaths at each analysis. | + n means expected events at the time of corresponding analysis for PFS and OS based on model assumption. In the rare case if PFS events accumulate slower than expected, a minimumof 305eventsisrequired at 22months to triggerIA1;n means totalsamplesizeforORR. + The statistics used here are hazard ratio for PFS and OS, and ORR △ for ORR where ORR  = ORR in (pembrolizumab+axitinib group)- ORR in sunitinib group.  The power calculated for OS is cumulative power. For the power calculation, the target ORR in the pembrolizuab+axitinib group and the reference ORR assumed in the sunitinib groups are 55% and 31%, respectively. For OS, a linear spending function with a fixed alpha spending of 0.oo01 at IA1 and the rest alpha spending approximated by a Hwang-Shih-DeCani (HSD) alpha-spending function with gamma parameter (-4) is used to construct Haybittle-Peto type of group sequential boundaries to control the overall Type Ierrorrate for this endpoint at 2.3% or 2.5% (1-sided).Futility spending is done by controlling the probability of crossing the futility bound under the null hypothesis (total of 1-α=97.5%); an HSD alpha-spending function with gamma parameter (-6)isused to construct group sequential boundariesforfutility.TheType Ierrorrate to spend at IA2 andFAwill bedetermined by the spendingfunctionevaluated at the exact number of deaths at each analysis. | + n means expected events at the time of corresponding analysis for PFS and OS based on model assumption. In the rare case if PFS events accumulate slower than expected, a minimumof 305eventsisrequired at 22months to triggerIA1;n means totalsamplesizeforORR. + The statistics used here are hazard ratio for PFS and OS, and ORR △ for ORR where ORR  = ORR in (pembrolizumab+axitinib group)- ORR in sunitinib group.  The power calculated for OS is cumulative power. For the power calculation, the target ORR in the pembrolizuab+axitinib group and the reference ORR assumed in the sunitinib groups are 55% and 31%, respectively. For OS, a linear spending function with a fixed alpha spending of 0.oo01 at IA1 and the rest alpha spending approximated by a Hwang-Shih-DeCani (HSD) alpha-spending function with gamma parameter (-4) is used to construct Haybittle-Peto type of group sequential boundaries to control the overall Type Ierrorrate for this endpoint at 2.3% or 2.5% (1-sided).Futility spending is done by controlling the probability of crossing the futility bound under the null hypothesis (total of 1-α=97.5%); an HSD alpha-spending function with gamma parameter (-6)isused to construct group sequential boundariesforfutility.TheType Ierrorrate to spend at IA2 andFAwill bedetermined by the spendingfunctionevaluated at the exact number of deaths at each analysis. | + n means expected events at the time of corresponding analysis for PFS and OS based on model assumption. In the rare case if PFS events accumulate slower than expected, a minimumof 305eventsisrequired at 22months to triggerIA1;n means totalsamplesizeforORR. + The statistics used here are hazard ratio for PFS and OS, and ORR △ for ORR where ORR  = ORR in (pembrolizumab+axitinib group)- ORR in sunitinib group.  The power calculated for OS is cumulative power. For the power calculation, the target ORR in the pembrolizuab+axitinib group and the reference ORR assumed in the sunitinib groups are 55% and 31%, respectively. For OS, a linear spending function with a fixed alpha spending of 0.oo01 at IA1 and the rest alpha spending approximated by a Hwang-Shih-DeCani (HSD) alpha-spending function with gamma parameter (-4) is used to construct Haybittle-Peto type of group sequential boundaries to control the overall Type Ierrorrate for this endpoint at 2.3% or 2.5% (1-sided).Futility spending is done by controlling the probability of crossing the futility bound under the null hypothesis (total of 1-α=97.5%); an HSD alpha-spending function with gamma parameter (-6)isused to construct group sequential boundariesforfutility.TheType Ierrorrate to spend at IA2 andFAwill bedetermined by the spendingfunctionevaluated at the exact number of deaths at each analysis. | + n means expected events at the time of corresponding analysis for PFS and OS based on model assumption. In the rare case if PFS events accumulate slower than expected, a minimumof 305eventsisrequired at 22months to triggerIA1;n means totalsamplesizeforORR. + The statistics used here are hazard ratio for PFS and OS, and ORR △ for ORR where ORR  = ORR in (pembrolizumab+axitinib group)- ORR in sunitinib group.  The power calculated for OS is cumulative power. For the power calculation, the target ORR in the pembrolizuab+axitinib group and the reference ORR assumed in the sunitinib groups are 55% and 31%, respectively. For OS, a linear spending function with a fixed alpha spending of 0.oo01 at IA1 and the rest alpha spending approximated by a Hwang-Shih-DeCani (HSD) alpha-spending function with gamma parameter (-4) is used to construct Haybittle-Peto type of group sequential boundaries to control the overall Type Ierrorrate for this endpoint at 2.3% or 2.5% (1-sided).Futility spending is done by controlling the probability of crossing the futility bound under the null hypothesis (total of 1-α=97.5%); an HSD alpha-spending function with gamma parameter (-6)isused to construct group sequential boundariesforfutility.TheType Ierrorrate to spend at IA2 andFAwill bedetermined by the spendingfunctionevaluated at the exact number of deaths at each analysis. | + n means expected events at the time of corresponding analysis for PFS and OS based on model assumption. In the rare case if PFS events accumulate slower than expected, a minimumof 305eventsisrequired at 22months to triggerIA1;n means totalsamplesizeforORR. + The statistics used here are hazard ratio for PFS and OS, and ORR △ for ORR where ORR  = ORR in (pembrolizumab+axitinib group)- ORR in sunitinib group.  The power calculated for OS is cumulative power. For the power calculation, the target ORR in the pembrolizuab+axitinib group and the reference ORR assumed in the sunitinib groups are 55% and 31%, respectively. For OS, a linear spending function with a fixed alpha spending of 0.oo01 at IA1 and the rest alpha spending approximated by a Hwang-Shih-DeCani (HSD) alpha-spending function with gamma parameter (-4) is used to construct Haybittle-Peto type of group sequential boundaries to control the overall Type Ierrorrate for this endpoint at 2.3% or 2.5% (1-sided).Futility spending is done by controlling the probability of crossing the futility bound under the null hypothesis (total of 1-α=97.5%); an HSD alpha-spending function with gamma parameter (-6)isused to construct group sequential boundariesforfutility.TheType Ierrorrate to spend at IA2 andFAwill bedetermined by the spendingfunctionevaluated at the exact number of deaths at each analysis. | + n means expected events at the time of corresponding analysis for PFS and OS based on model assumption. In the rare case if PFS events accumulate slower than expected, a minimumof 305eventsisrequired at 22months to triggerIA1;n means totalsamplesizeforORR. + The statistics used here are hazard ratio for PFS and OS, and ORR △ for ORR where ORR  = ORR in (pembrolizumab+axitinib group)- ORR in sunitinib group.  The power calculated for OS is cumulative power. For the power calculation, the target ORR in the pembrolizuab+axitinib group and the reference ORR assumed in the sunitinib groups are 55% and 31%, respectively. For OS, a linear spending function with a fixed alpha spending of 0.oo01 at IA1 and the rest alpha spending approximated by a Hwang-Shih-DeCani (HSD) alpha-spending function with gamma parameter (-4) is used to construct Haybittle-Peto type of group sequential boundaries to control the overall Type Ierrorrate for this endpoint at 2.3% or 2.5% (1-sided).Futility spending is done by controlling the probability of crossing the futility bound under the null hypothesis (total of 1-α=97.5%); an HSD alpha-spending function with gamma parameter (-6)isused to construct group sequential boundariesforfutility.TheType Ierrorrate to spend at IA2 andFAwill bedetermined by the spendingfunctionevaluated at the exact number of deaths at each analysis. | + n means expected events at the time of corresponding analysis for PFS and OS based on model assumption. In the rare case if PFS events accumulate slower than expected, a minimumof 305eventsisrequired at 22months to triggerIA1;n means totalsamplesizeforORR. + The statistics used here are hazard ratio for PFS and OS, and ORR △ for ORR where ORR  = ORR in (pembrolizumab+axitinib group)- ORR in sunitinib group.  The power calculated for OS is cumulative power. For the power calculation, the target ORR in the pembrolizuab+axitinib group and the reference ORR assumed in the sunitinib groups are 55% and 31%, respectively. For OS, a linear spending function with a fixed alpha spending of 0.oo01 at IA1 and the rest alpha spending approximated by a Hwang-Shih-DeCani (HSD) alpha-spending function with gamma parameter (-4) is used to construct Haybittle-Peto type of group sequential boundaries to control the overall Type Ierrorrate for this endpoint at 2.3% or 2.5% (1-sided).Futility spending is done by controlling the probability of crossing the futility bound under the null hypothesis (total of 1-α=97.5%); an HSD alpha-spending function with gamma parameter (-6)isused to construct group sequential boundariesforfutility.TheType Ierrorrate to spend at IA2 andFAwill bedetermined by the spendingfunctionevaluated at the exact number of deaths at each analysis. | + n means expected events at the time of corresponding analysis for PFS and OS based on model assumption. In the rare case if PFS events accumulate slower than expected, a minimumof 305eventsisrequired at 22months to triggerIA1;n means totalsamplesizeforORR. + The statistics used here are hazard ratio for PFS and OS, and ORR △ for ORR where ORR  = ORR in (pembrolizumab+axitinib group)- ORR in sunitinib group.  The power calculated for OS is cumulative power. For the power calculation, the target ORR in the pembrolizuab+axitinib group and the reference ORR assumed in the sunitinib groups are 55% and 31%, respectively. For OS, a linear spending function with a fixed alpha spending of 0.oo01 at IA1 and the rest alpha spending approximated by a Hwang-Shih-DeCani (HSD) alpha-spending function with gamma parameter (-4) is used to construct Haybittle-Peto type of group sequential boundaries to control the overall Type Ierrorrate for this endpoint at 2.3% or 2.5% (1-sided).Futility spending is done by controlling the probability of crossing the futility bound under the null hypothesis (total of 1-α=97.5%); an HSD alpha-spending function with gamma parameter (-6)isused to construct group sequential boundariesforfutility.TheType Ierrorrate to spend at IA2 andFAwill bedetermined by the spendingfunctionevaluated at the exact number of deaths at each analysis. | + n means expected events at the time of corresponding analysis for PFS and OS based on model assumption. In the rare case if PFS events accumulate slower than expected, a minimumof 305eventsisrequired at 22months to triggerIA1;n means totalsamplesizeforORR. + The statistics used here are hazard ratio for PFS and OS, and ORR △ for ORR where ORR  = ORR in (pembrolizumab+axitinib group)- ORR in sunitinib group.  The power calculated for OS is cumulative power. For the power calculation, the target ORR in the pembrolizuab+axitinib group and the reference ORR assumed in the sunitinib groups are 55% and 31%, respectively. For OS, a linear spending function with a fixed alpha spending of 0.oo01 at IA1 and the rest alpha spending approximated by a Hwang-Shih-DeCani (HSD) alpha-spending function with gamma parameter (-4) is used to construct Haybittle-Peto type of group sequential boundaries to control the overall Type Ierrorrate for this endpoint at 2.3% or 2.5% (1-sided).Futility spending is done by controlling the probability of crossing the futility bound under the null hypothesis (total of 1-α=97.5%); an HSD alpha-spending function with gamma parameter (-6)isused to construct group sequential boundariesforfutility.TheType Ierrorrate to spend at IA2 andFAwill bedetermined by the spendingfunctionevaluated at the exact number of deaths at each analysis. |

The MAH planned to update the boundary using the actual number of PFS and of OS events at the interim and final analyses and the same spending function used to derive the design.

The results of the study are based on the IA1 that was performed after enrollment completion, when a minimum of 305 PFS events had accrued and all participants were followed for at least 7 months after randomization.

For  PRO  endpoints  no  formal  hypothesis  testing,  nominal  p-values  were  provided  for  treatment comparisons of pembrolizumab + axitinib vs. sunitinib. No multiplicity adjustment was performed. The following table summarizes the planned PRO analyses.

<div style=\"page-break-after: always\"></div>

Table 9PlannedStatisticalAnalysisforPRO

| Endpoint/ Analysis                                                                | Instrument Scale/Sub-Scale                                                                                                                                                           | Analysis Population   | Method                                                | Statistics                                                   |
|-----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|-------------------------------------------------------|--------------------------------------------------------------|
| Summary ofPRO Compliance                                                          | ·FKSI-DRS ·EORTC QLQ-C30 ·EQ-5D-3L                                                                                                                                                   | PROFAS                |                                                       |                                                              |
| Mean score changefrom baseline through the primary analysis time point            | ·FKSI-DRS ·EORTC QLQ-C30 Global Health status/QoL ·EORTC QLQ-C30 physical functional scale,role functional scale,nausea and vomiting symptom scale,Diarrhea symptom scale ·EQ-5D VAS | PRO FAS               | cLDA                                                  | Difference in Lsmean estimate (95% C.1.) and nominal p-value |
| Time todeterioration                                                              | ·FKSI-DRS ·EORTCQLQ-C30Global Health status/QoL ·EQ-5DVAS                                                                                                                            | PRO FAS               | Stratified Cox model with Efron's tie handling method | Hazard ratio (95% C.I., p-value); Kaplan-Meier plot          |
| Proportion of overall improvement                                                 | ·FKSI-DRS ·EORTC QLQ-C30 Global Health status/QoL ·EQ-5D VAS                                                                                                                         | PROFAS                | Stratified Miettinen and method Nurminen's            | Differencein overall improvement rates (95% C.I)             |
| Proportion of ment at theprimary analysis time point deterioration/stable/improve | ·FKSI-DRS ·EORTC QLQ-C30Global Health status/QoL ·EORTC QLQ-C30 physical functional scale,role functional scale,nausea and vomiting symptom scaleDiarrheasymptom scale               | PRO FAS               | Difference in proportions imputation with base on MAR | Diffeerence by treatment group and visit estimate (95% C.1)  |

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow for KEYNOTE-426

<!-- image -->

## Recruitment

A total of 1062 participants were screened (first participant screened on 06-OCT-2016) and 861 were randomly allocated from 24-OCT-2016 to 24-JAN-2018 across 124 global study sites in 16 countries. First and last participant visits were respectively 06-OCT-2018 and 23-AUG-2018.

Data cut-off for IA1 occurred on 24-AUG-2018. During the evaluation, the MAH provided efficacy data from KN426, with a data cutoff date of 2 January 2019.

<div style=\"page-break-after: always\"></div>

## Conduct of the study

## Protocol amendments

The original protocol is dated 10 June 2016. A total of 6 protocol amendments, including 4 global and 2 country-specific amendments, were implemented during the study. In addition to the original protocol this resulted in a total of 7 protocol versions. Amendment versions 6 and 7 were never finalized for distribution, hence the numbers are not in the table below.

The key changes introduced by the protocol amendments are summarized below:

| Protocol Amendment     | Most relevant changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| #01 (21 July 2016)     | Country specific (Japan)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| #2 (3 October 2016)    | Country specific (France)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| # 3 (13 Mar 2017)      | First Global Amendment - Inclusion criteria: changed the allowed time period for starting bone resorptive therapy from 4 weeks to 2 weeks prior to randomization. - Exclusion criteria: clarify that subjects who have had chemotherapy as neoadjuvant or adjuvant therapy for RCC qualify for the study. - Exclusion criteria: revised the timeframe of active autoimmune disease exclusion from 3 months to 2 years. Added language on excluded therapies and allowed replacement therapies. - Exclusion criteria: clarify that subjects with brain metastasis who have been treated with steroid treatment at least 14 days (changed '4 weeks' to '14 days') prior to randomization in order to show stability qualify for the study. - Exclusion criteria: exclude subjects with a known history of hepatitis B. - Exclusion criteria: removal of exclusion for 'GI perforation\": repaired GI perforation is not excluded.                                                     |
| #4 (21 Mar 2017)       | Country specific (Japan) version of global amendment #3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| #5 (21 Mar 2017)       | Country specific (France) version of global amendment #3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| #8 (28 August 2017)    | Second Global Amendment To further refine general guidance on evaluation and management of overlapping AEs potentially associated with either pembrolizumab and axitinib or both in the combination arm and include a new subsection detailing evaluation and management of transaminase elevations during axitinib and pembrolizumab combination therapy (Section 5.2.2.3). The rational for this change was to provide detailed guidelines on how to systemically approach treatment-emergent alanine aminotransferase [ALT]/aspartate aminotransferase [AST] elevations in the pembrolizumab + axitinib group as there are no specific markers to differentiate drug-induced liver injury from axitinib versus immune-mediated hepatitis from pembrolizumab versus ALT/AST elevations due to other reasons. The amedment also provided detailed algorithms regarding study drug rechallenge for different scenarios following recovery from an initial ALT/AST elevation event. |
| #9 (07 September 2017) | Country specific (France) version of global amendment #8                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| #10 (19 October 2017)   | Third Global Amendment The primary reason for the amendment was to revise Table 6 in Section 5.2.2.1 (Dose Modification and Toxicity Management Guidelines for Adverse Events Potentially Associated with Pembrolizumab Treatment), to include: 1) myocarditis as a new immunerelated AE (irAE); and 2) under all the ' other immune-related AEs ' , any Grade 3 AE was separated from intolerable Grade 2 as a standalone category. These updates were required to be consistent with the guidelines provided in the IB and product label that were current at that time.                                                                                                                                                                                                                                                                                                                                                                      |
|-------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| #11 (26 October 2017)   | Country specific (France) version of global amendment #10                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| #12 (03 May 2018)       | Fourth Global Amendment - Statistical Analysis Plan: 1) Revised assumptions on control arm median PFS and OS 2) Revised IA1 trigger from 50% final OS events to once achieving 305 PFS events and 7 months of minimum follow up. 3) Added one interim analysis for PFS to have earlier chance of observing positive efficacy of PFS with relatively mature data. 4) Initial alpha to PFS and OS changed from 0.1% and 2.4% to 0.2% and 2.3% respectively. Slightly higher alpha is reallocated to PFS to ensure adequate power for this important primary endpoint without compromising the power of OS 5) Secondary objectives: landmark analyses on PFS and OS are added to compare and characterize the tail of the curve (PFS rate per RECIST 1.1 as assessed by BICR at 12, 18, and 24 months, and OS rates at 12, 18, and 24 months, based on data adequacy). 6) Updated the censoring rules for primary and sensitivity analyses of PFS. |
| #13 (11 May 2018)       | Country specific (France) version of global amendment #12                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |

Note: There was only 1 country-specific protocol amendment for Japan, which was protocol amendment 426-01. Protocol amendment 426-04 was global amendment 426-03 with changes from 426-01 carried over.

There was only 1 country-specific protocol amendment for France, which was amendment 426-02.

Protocol amendments 426-05, -09, -11 and -13 were global amendments 426-03, -08, -10 and -12 with changes from 426-02 carried over.

## Protocol deviations

The percentage of participants with important deviations, defined as deviations that could significantly impact the quality (ie, completeness, accuracy, and reliability) or integrity of key study data; or that could significantly affect a participant's rights, safety, or well-being, was similar in the 2 groups (14.2% in the pembrolizumab + axitinib group and 12.9% in the sunitinib group).

Deviations were reported across the following categories:

- Discontinuation criteria (n=0 for pembrolizumab + axitinib; n=1 for sunitinib)
- Inclusion/exclusion criteria (n=14 for pembrolizumab + axitinib; n=12 for sunitinib)
- Informed consent form (n=0 for pembrolizumab + axitinib; n=1 for sunitinib)
- Prohibited medications (n=2 for pembrolizumab + axitinib; n=1 for sunitinib)
- Safety reporting (n=19 for pembrolizumab + axitinib; n=14 for sunitinib)
- Study intervention (n=6 for pembrolizumab + axitinib; n=3 for sunitinib)
- Trial procedures (n=27 for pembrolizumab + axitinib; n=27 for sunitinib)

Of these important protocol deviations, one was deemed to be clinically significant. One participant in the pembrolizumab + axitinib group experienced an SAE (peritonitis) that was reported to the Sponsor more

<div style=\"page-break-after: always\"></div>

than  90  days  after  the  SAE  occurred.  The  SAE  resolved  with  no  action  taken  with  regard  to  study treatment,  and  the  participant  continued  in  the  study.  The  participant  was  not  excluded  from  any analyses.

Of  note  is  that  2  patients  in  the  experimental  arm  received  prohibited  medication  defined  as \" Antineoplastic systemic chemotherapy, biologic therapy, immunotherapy, other investigational agents given while on treatment (unless allowed per protocol) \".  The  prohibited  medication  received  by  the patients in the control arm was instead a drug having pro-arrhythmic potential. The rate of patients with \" 2 consecutive Imaging Scans up to week 54 or 1 imaging scan after Week 54, not performed for all anatomical locations required or missed entirely \" was slightly higher in the experimental arm (5.1% vs 4%).

## Baseline data

Table: Subject Characteristics (ITT Population)

|                                     | Pembrolizumab + Axitinib   | Pembrolizumab + Axitinib   | Sunitinib   | Sunitinib   | Total   | Total   |
|-------------------------------------|----------------------------|----------------------------|-------------|-------------|---------|---------|
|                                     | n                          | (%)                        | n           | (%)         | n       | (%)     |
| Subjects in population              | 432                        |                            | 429         |             | 861     |         |
| Gender                              |                            |                            |             |             |         |         |
| Male                                | 308                        | (71.3)                     | 320         | (74.6)      | 628     | (72.9)  |
| Female                              | 124                        | (28.7)                     | 109         | (25.4)      | 233     | (27.1)  |
| Age (Years)                         |                            |                            |             |             |         |         |
| < 65                                | 260                        | (60.2)                     | 278         | (64.8)      | 538     | (62.5)  |
| ≥ 65                                | 172                        | (39.8)                     | 151         | (35.2)      | 323     | (37.5)  |
| Subjects with data                  | 432                        |                            | 429         |             | 861     |         |
| Mean                                | 61.2                       |                            | 60.8        |             | 61.0    |         |
| SD                                  | 10.0                       |                            | 10.2        |             | 10.1    |         |
| Median                              | 62.0                       |                            | 61.0        |             | 62.0    |         |
| Range                               | 30 to 89                   |                            | 26 to 90    |             | 26 to   | 90      |
| Race                                |                            |                            |             |             |         |         |
| Asian                               | 66                         | (15.3)                     | 71          | (16.6)      | 137     | (15.9)  |
| Black Or African American           | 10                         | (2.3)                      | 8           | (1.9)       | 18      | (2.1)   |
| White                               | 343                        | (79.4)                     | 341         | (79.5)      | 684     | (79.4)  |
| Other                               | 4                          | (0.9)                      | 4           | (0.9)       | 8       | (0.9)   |
| Missing                             | 9                          | (2.1)                      | 5           | (1.2)       | 14      | (1.6)   |
| Ethnicity                           |                            |                            |             |             |         |         |
| Hispanic Or Latino                  | 19                         | (4.4)                      | 18          | (4.2)       | 37      | (4.3)   |
| Not Hispanic Or Latino              | 377                        | (87.3)                     | 387         | (90.2)      | 764     | (88.7)  |
| Not Reported                        | 14                         | (3.2)                      | 12          | (2.8)       | 26      | (3.0)   |
| Unknown                             | 21                         | (4.9)                      | 11          | (2.6)       | 32      | (3.7)   |
| Missing                             | 1                          | (0.2)                      | 1           | (0.2)       | 2       | (0.2)   |
| Geographic Region of Enrolling Site |                            |                            |             |             |         |         |
| North America                       | 104                        | (24.1)                     | 103         | (24.0)      | 207     | (24.0)  |
| Western Europe                      | 106                        | (24.5)                     | 104         | (24.2)      | 210     | (24.4)  |
| Rest of the World                   | 222                        | (51.4)                     | 222         | (51.7)      | 444     | (51.6)  |

861

628

(72.9)

233

(27.1)

538

(62.5)

323

(37.5)

861

61.0

10.1

62.0

26 to 90

137

(15.9)

18

684

(79.4)

8

14

37

764

(88.7)

26

32

2

207

(24.0)

210

(24.4)

444

(51.6)

<div style=\"page-break-after: always\"></div>

317

(36.8)

544

(63.2)

688

(79.9)

172

(20.0)

1

269

(31.2)

484

(56.2)

108

(12.5)

269

(31.2)

592

(68.8)

497

(57.7)

325

(37.7)

6

33

621

(72.1)

240

(27.9)

396

(46.0)

465

(54.0)

206

(23.9)

655

(76.1)

143

(16.6)

718

(83.4)

137

(15.9)

724

|                              | Pembrolizumab + Axitinib   | Pembrolizumab + Axitinib   | Sunitinib   | Sunitinib   | Total   | Total   |
|------------------------------|----------------------------|----------------------------|-------------|-------------|---------|---------|
|                              | n                          | (%)                        | n           | (%)         | n       | (%)     |
| Region                       |                            |                            |             |             |         |         |
| EU                           | 161                        | (37.3)                     | 156         | (36.4)      | 317     | (36.8)  |
| Ex-EU                        | 271                        | (62.7)                     | 273         | (63.6)      | 544     | (63.2)  |
| Karnofsky Performance Scale  |                            |                            |             |             |         |         |
| 90/100                       | 347                        | (80.3)                     | 341         | (79.5)      | 688     | (79.9)  |
| 70/80                        | 84                         | (19.4)                     | 88          | (20.5)      | 172     | (20.0)  |
| Missing                      | 1                          | (0.2)                      | 0           | (0.0)       | 1       | (0.1)   |
| IMDC Risk Category           |                            |                            |             |             |         |         |
| Favorable                    | 138                        | (31.9)                     | 131         | (30.5)      | 269     | (31.2)  |
| Intermediate                 | 238                        | (55.1)                     | 246         | (57.3)      | 484     | (56.2)  |
| Poor                         | 56                         | (13.0)                     | 52          | (12.1)      | 108     | (12.5)  |
| IMDC Risk Category 2         |                            |                            |             |             |         |         |
| Favorable                    | 138                        | (31.9)                     | 131         | (30.5)      | 269     | (31.2)  |
| Intermediate or Poor         | 294                        | (68.1)                     | 298         | (69.5)      | 592     | (68.8)  |
| PD-L1 Status                 |                            |                            |             |             |         |         |
| CPS ≥ 1                      | 243                        | (56.3)                     | 254         | (59.2)      | 497     | (57.7)  |
| CPS < 1                      | 167                        | (38.7)                     | 158         | (36.8)      | 325     | (37.7)  |
| Not Available                | 4                          | (0.9)                      | 2           | (0.5)       | 6       | (0.7)   |
| Missing                      | 18                         | (4.2)                      | 15          | (3.5)       | 33      | (3.8)   |
| Sites of Metastatic Disease* |                            |                            |             |             |         |         |
| Lung                         |                            |                            |             |             |         |         |
| Yes                          | 312                        | (72.2)                     | 309         | (72.0)      | 621     | (72.1)  |
| No                           | 120                        | (27.8)                     | 120         | (28.0)      | 240     | (27.9)  |
| Lymph Node                   |                            |                            |             |             |         |         |
| Yes                          | 199                        | (46.1)                     | 197         | (45.9)      | 396     | (46.0)  |
| No                           | 233                        | (53.9)                     | 232         | (54.1)      | 465     | (54.0)  |
| Bone                         |                            |                            |             |             |         |         |
| Yes                          | 103                        | (23.8)                     | 103         | (24.0)      | 206     | (23.9)  |
| No                           | 329                        | (76.2)                     | 326         | (76.0)      | 655     | (76.1)  |
| Adrenal Gland                |                            |                            |             |             |         |         |
| Yes                          | 67                         | (15.5)                     | 76          | (17.7)      | 143     | (16.6)  |
| No                           | 365                        | (84.5)                     | 353         | (82.3)      | 718     | (83.4)  |
| Liver                        |                            |                            |             |             |         |         |
| Yes                          | 66                         | (15.3)                     | 71          | (16.6)      | 137     | (15.9)  |
| No                           | 366                        | (84.7)                     | 358         | (83.4)      | 724     | (84.1)  |

(84.1)

210

(24.4)

646

(75.0)

5

804

(93.4)

55

2

105

(12.2)

473

(54.9)

|                                                    | Pembrolizumab + Axitinib                           | Pembrolizumab + Axitinib                           | Sunitinib                                          | Sunitinib                                          | Total                                              | Total                                              |
|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|----------------------------------------------------|
|                                                    | n                                                  | (%)                                                | n                                                  | (%)                                                | n                                                  | (%)                                                |
| Number of Organs Involved with Disease at Baseline | Number of Organs Involved with Disease at Baseline | Number of Organs Involved with Disease at Baseline | Number of Organs Involved with Disease at Baseline | Number of Organs Involved with Disease at Baseline | Number of Organs Involved with Disease at Baseline | Number of Organs Involved with Disease at Baseline |
| 1                                                  | 114                                                | (26.4)                                             | 96                                                 | (22.4)                                             | 210                                                | (24.4)                                             |
| ≥ 2                                                | 315                                                | (72.9)                                             | 331                                                | (77.2)                                             | 646                                                | (75.0)                                             |
| Missing                                            | 3                                                  | (0.7)                                              | 2                                                  | (0.5)                                              | 5                                                  | (0.6)                                              |
| RCC Histology                                      |                                                    |                                                    |                                                    |                                                    |                                                    |                                                    |
| Clear Cell                                         | 403                                                | (93.3)                                             | 401                                                | (93.5)                                             | 804                                                | (93.4)                                             |
| Clear Cell Component                               | 28                                                 | (6.5)                                              | 27                                                 | (6.3)                                              | 55                                                 | (6.4)                                              |
| Other                                              | 1                                                  | (0.2)                                              | 1                                                  | (0.2)                                              | 2                                                  | (0.2)                                              |
| Sarcomatoid Feature                                |                                                    |                                                    |                                                    |                                                    |                                                    |                                                    |
| Yes                                                | 51                                                 | (11.8)                                             | 54                                                 | (12.6)                                             | 105                                                | (12.2)                                             |
| No                                                 | 234                                                | (54.2)                                             | 239                                                | (55.7)                                             | 473                                                | (54.9)                                             |

<div style=\"page-break-after: always\"></div>

281

(32.6)

2

47

265

(30.8)

258

(30.0)

197

(22.9)

94

(10.9)

469

(54.5)

392

(45.5)

130

(15.1)

93

197

(22.9)

436

(50.6)

5

81

780

(90.6)

715

(83.0)

146

(17.0)

|                                                                                                                                                                 | Pembrolizumab + Axitinib                                                                                                                                        | Pembrolizumab + Axitinib                                                                                                                                        | Sunitinib                                                                                                                                                       | Sunitinib                                                                                                                                                       | Total                                                                                                                                                           | Total                                                                                                                                                           |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                 | n                                                                                                                                                               | (%)                                                                                                                                                             | n                                                                                                                                                               | (%)                                                                                                                                                             | n                                                                                                                                                               | (%)                                                                                                                                                             |
| Unknown                                                                                                                                                         | 146                                                                                                                                                             | (33.8)                                                                                                                                                          | 135                                                                                                                                                             | (31.5)                                                                                                                                                          | 281                                                                                                                                                             | (32.6)                                                                                                                                                          |
| Missing                                                                                                                                                         | 1                                                                                                                                                               | (0.2)                                                                                                                                                           | 1                                                                                                                                                               | (0.2)                                                                                                                                                           | 2                                                                                                                                                               | (0.2)                                                                                                                                                           |
| RCC Tumor Fuhrman Grade                                                                                                                                         |                                                                                                                                                                 |                                                                                                                                                                 |                                                                                                                                                                 |                                                                                                                                                                 |                                                                                                                                                                 |                                                                                                                                                                 |
| Grade 1                                                                                                                                                         | 23                                                                                                                                                              | (5.3)                                                                                                                                                           | 24                                                                                                                                                              | (5.6)                                                                                                                                                           | 47                                                                                                                                                              | (5.5)                                                                                                                                                           |
| Grade 2                                                                                                                                                         | 138                                                                                                                                                             | (31.9)                                                                                                                                                          | 127                                                                                                                                                             | (29.6)                                                                                                                                                          | 265                                                                                                                                                             | (30.8)                                                                                                                                                          |
| Grade 3                                                                                                                                                         | 120                                                                                                                                                             | (27.8)                                                                                                                                                          | 138                                                                                                                                                             | (32.2)                                                                                                                                                          | 258                                                                                                                                                             | (30.0)                                                                                                                                                          |
| Grade 4                                                                                                                                                         | 104                                                                                                                                                             | (24.1)                                                                                                                                                          | 93                                                                                                                                                              | (21.7)                                                                                                                                                          | 197                                                                                                                                                             | (22.9)                                                                                                                                                          |
| Missing                                                                                                                                                         | 47                                                                                                                                                              | (10.9)                                                                                                                                                          | 47                                                                                                                                                              | (11.0)                                                                                                                                                          | 94                                                                                                                                                              | (10.9)                                                                                                                                                          |
| Disease Status at Baseline                                                                                                                                      |                                                                                                                                                                 |                                                                                                                                                                 |                                                                                                                                                                 |                                                                                                                                                                 |                                                                                                                                                                 |                                                                                                                                                                 |
| Recurrent                                                                                                                                                       | 238                                                                                                                                                             | (55.1)                                                                                                                                                          | 231                                                                                                                                                             | (53.8)                                                                                                                                                          | 469                                                                                                                                                             | (54.5)                                                                                                                                                          |
| Newly Diagnosed                                                                                                                                                 | 194                                                                                                                                                             | (44.9)                                                                                                                                                          | 198                                                                                                                                                             | (46.2)                                                                                                                                                          | 392                                                                                                                                                             | (45.5)                                                                                                                                                          |
| RCC Stage at Initial Diagnosis                                                                                                                                  |                                                                                                                                                                 |                                                                                                                                                                 |                                                                                                                                                                 |                                                                                                                                                                 |                                                                                                                                                                 |                                                                                                                                                                 |
| I                                                                                                                                                               | 68                                                                                                                                                              | (15.7)                                                                                                                                                          | 62                                                                                                                                                              | (14.5)                                                                                                                                                          | 130                                                                                                                                                             | (15.1)                                                                                                                                                          |
| II                                                                                                                                                              | 55                                                                                                                                                              | (12.7)                                                                                                                                                          | 38                                                                                                                                                              | (8.9)                                                                                                                                                           | 93                                                                                                                                                              | (10.8)                                                                                                                                                          |
| III                                                                                                                                                             | 96                                                                                                                                                              | (22.2)                                                                                                                                                          | 101                                                                                                                                                             | (23.5)                                                                                                                                                          | 197                                                                                                                                                             | (22.9)                                                                                                                                                          |
| IV                                                                                                                                                              | 209                                                                                                                                                             | (48.4)                                                                                                                                                          | 227                                                                                                                                                             | (52.9)                                                                                                                                                          | 436                                                                                                                                                             | (50.6)                                                                                                                                                          |
| Missing                                                                                                                                                         | 4                                                                                                                                                               | (0.9)                                                                                                                                                           | 1                                                                                                                                                               | (0.2)                                                                                                                                                           | 5                                                                                                                                                               | (0.6)                                                                                                                                                           |
| Prior Oncologic Radiation                                                                                                                                       |                                                                                                                                                                 |                                                                                                                                                                 |                                                                                                                                                                 |                                                                                                                                                                 |                                                                                                                                                                 |                                                                                                                                                                 |
| Yes                                                                                                                                                             | 41                                                                                                                                                              | (9.5)                                                                                                                                                           | 40                                                                                                                                                              | (9.3)                                                                                                                                                           | 81                                                                                                                                                              | (9.4)                                                                                                                                                           |
| No                                                                                                                                                              | 391                                                                                                                                                             | (90.5)                                                                                                                                                          | 389                                                                                                                                                             | (90.7)                                                                                                                                                          | 780                                                                                                                                                             | (90.6)                                                                                                                                                          |
| Prior Nephrectomy                                                                                                                                               |                                                                                                                                                                 |                                                                                                                                                                 |                                                                                                                                                                 |                                                                                                                                                                 |                                                                                                                                                                 |                                                                                                                                                                 |
| Yes                                                                                                                                                             | 357                                                                                                                                                             | (82.6)                                                                                                                                                          | 358                                                                                                                                                             | (83.4)                                                                                                                                                          | 715                                                                                                                                                             | (83.0)                                                                                                                                                          |
| No                                                                                                                                                              | 75                                                                                                                                                              | (17.4)                                                                                                                                                          | 71                                                                                                                                                              | (16.6)                                                                                                                                                          | 146                                                                                                                                                             | (17.0)                                                                                                                                                          |
| *The sites are five most common metastatic sites and ordered decreasingly by the frequency in total of the two treatment arms. Database Cutoff Date: 24Aug2018. | *The sites are five most common metastatic sites and ordered decreasingly by the frequency in total of the two treatment arms. Database Cutoff Date: 24Aug2018. | *The sites are five most common metastatic sites and ordered decreasingly by the frequency in total of the two treatment arms. Database Cutoff Date: 24Aug2018. | *The sites are five most common metastatic sites and ordered decreasingly by the frequency in total of the two treatment arms. Database Cutoff Date: 24Aug2018. | *The sites are five most common metastatic sites and ordered decreasingly by the frequency in total of the two treatment arms. Database Cutoff Date: 24Aug2018. | *The sites are five most common metastatic sites and ordered decreasingly by the frequency in total of the two treatment arms. Database Cutoff Date: 24Aug2018. | *The sites are five most common metastatic sites and ordered decreasingly by the frequency in total of the two treatment arms. Database Cutoff Date: 24Aug2018. |

## Numbers analysed

Efficacy analyses were based on the ITT population, which included participants in the treatment group to which they were randomly assigned, regardless of whether or not they received study treatment.

Table: Study Population

|                                                                | Pembrolizumab+ Axitinib   | Sumitinib   | Total   |
|----------------------------------------------------------------|---------------------------|-------------|---------|
| NumberofSubjectsScreened                                       |                           |             | 1062    |
| Number of SubjectsRandomized (Planned Treatment) (ITT)         | 432                       | 429         | 861     |
| Number of Subjects Received Treatment (Actual Treatment)(ASaT) | 429                       | 425         | 854     |
| NumberofSubjectsRandomizedandDidnotReceiveTreatment            | 3                         | 4           | 7       |
| DatabaseCutoffDate:24Aug2018                                   |                           |             |         |

PRO analyses were based on the FAS population, which consisted of all randomized participants who received at least 1 dose of study medication and completed at least 1 PRO assessment.

<div style=\"page-break-after: always\"></div>

Table: Disposition of Subjects

|                                                                                                                                                                                                                                    | Pembrolizumab + Axitinib                                                                                                                                                                                                           | Pembrolizumab + Axitinib                                                                                                                                                                                                           | Sunitinib                                                                                                                                                                                                                          | Sunitinib                                                                                                                                                                                                                          | Total                                                                                                                                                                                                                              | Total                                                                                                                                                                                                                              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                    | n                                                                                                                                                                                                                                  | (%)                                                                                                                                                                                                                                | n                                                                                                                                                                                                                                  | (%)                                                                                                                                                                                                                                | n                                                                                                                                                                                                                                  | (%)                                                                                                                                                                                                                                |
| Subjects in population                                                                                                                                                                                                             | 432                                                                                                                                                                                                                                |                                                                                                                                                                                                                                    | 429                                                                                                                                                                                                                                |                                                                                                                                                                                                                                    | 861                                                                                                                                                                                                                                |                                                                                                                                                                                                                                    |
| Status for Trial                                                                                                                                                                                                                   |                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                    |
| Discontinued                                                                                                                                                                                                                       | 64                                                                                                                                                                                                                                 | (14.8)                                                                                                                                                                                                                             | 104                                                                                                                                                                                                                                | (24.2)                                                                                                                                                                                                                             | 168                                                                                                                                                                                                                                | (19.5)                                                                                                                                                                                                                             |
| Death                                                                                                                                                                                                                              | 59                                                                                                                                                                                                                                 | (13.7)                                                                                                                                                                                                                             | 95                                                                                                                                                                                                                                 | (22.1)                                                                                                                                                                                                                             | 154                                                                                                                                                                                                                                | (17.9)                                                                                                                                                                                                                             |
| Withdrawal By Subject                                                                                                                                                                                                              | 5                                                                                                                                                                                                                                  | (1.2)                                                                                                                                                                                                                              | 9                                                                                                                                                                                                                                  | (2.1)                                                                                                                                                                                                                              | 14                                                                                                                                                                                                                                 | (1.6)                                                                                                                                                                                                                              |
| Trial Ongoing                                                                                                                                                                                                                      | 368                                                                                                                                                                                                                                | (85.2)                                                                                                                                                                                                                             | 325                                                                                                                                                                                                                                | (75.8)                                                                                                                                                                                                                             | 693                                                                                                                                                                                                                                | (80.5)                                                                                                                                                                                                                             |
| StatusforStudyMedicationinTrial                                                                                                                                                                                                    |                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                    |
| Started                                                                                                                                                                                                                            | 429                                                                                                                                                                                                                                | (100.0)                                                                                                                                                                                                                            | 425                                                                                                                                                                                                                                | (100.0)                                                                                                                                                                                                                            | 854                                                                                                                                                                                                                                | (100.0)                                                                                                                                                                                                                            |
| Discontinued                                                                                                                                                                                                                       | 176                                                                                                                                                                                                                                | (41.0)                                                                                                                                                                                                                             | 242                                                                                                                                                                                                                                | (56.9)                                                                                                                                                                                                                             | 418                                                                                                                                                                                                                                | (48.9)                                                                                                                                                                                                                             |
| Adverse Event                                                                                                                                                                                                                      | 52                                                                                                                                                                                                                                 | (12.1)                                                                                                                                                                                                                             | 57                                                                                                                                                                                                                                 | (13.4)                                                                                                                                                                                                                             | 109                                                                                                                                                                                                                                | (12.8)                                                                                                                                                                                                                             |
| Clinical Progression                                                                                                                                                                                                               | 12                                                                                                                                                                                                                                 | (2.8)                                                                                                                                                                                                                              | 16                                                                                                                                                                                                                                 | (3.8)                                                                                                                                                                                                                              | 28                                                                                                                                                                                                                                 | (3.3)                                                                                                                                                                                                                              |
| Complete Response                                                                                                                                                                                                                  | 3                                                                                                                                                                                                                                  | (0.7)                                                                                                                                                                                                                              | 0                                                                                                                                                                                                                                  | (0.0)                                                                                                                                                                                                                              | 3                                                                                                                                                                                                                                  | (0.4)                                                                                                                                                                                                                              |
| Excluded Medication                                                                                                                                                                                                                | 1                                                                                                                                                                                                                                  | (0.2)                                                                                                                                                                                                                              | 0                                                                                                                                                                                                                                  | (0.0)                                                                                                                                                                                                                              | 1                                                                                                                                                                                                                                  | (0.1)                                                                                                                                                                                                                              |
| Non-Compliance With Study Drug                                                                                                                                                                                                     | 0                                                                                                                                                                                                                                  | (0.0)                                                                                                                                                                                                                              | 1                                                                                                                                                                                                                                  | (0.2)                                                                                                                                                                                                                              | 1                                                                                                                                                                                                                                  | (0.1)                                                                                                                                                                                                                              |
| Physician Decision                                                                                                                                                                                                                 | 3                                                                                                                                                                                                                                  | (0.7)                                                                                                                                                                                                                              | 8                                                                                                                                                                                                                                  | (6:1)                                                                                                                                                                                                                              | 11                                                                                                                                                                                                                                 | (1.3)                                                                                                                                                                                                                              |
| Progressive Disease                                                                                                                                                                                                                | 90                                                                                                                                                                                                                                 | (21.0)                                                                                                                                                                                                                             | 141                                                                                                                                                                                                                                | (33.2)                                                                                                                                                                                                                             | 231                                                                                                                                                                                                                                | (27.0)                                                                                                                                                                                                                             |
| Withdrawal By Subject                                                                                                                                                                                                              | 15                                                                                                                                                                                                                                 | (3.5)                                                                                                                                                                                                                              | 19                                                                                                                                                                                                                                 | (4.5)                                                                                                                                                                                                                              | 34                                                                                                                                                                                                                                 | (4.0)                                                                                                                                                                                                                              |
| Treatment Ongoing                                                                                                                                                                                                                  | 253                                                                                                                                                                                                                                | (59.0)                                                                                                                                                                                                                             | 183                                                                                                                                                                                                                                | (43.1)                                                                                                                                                                                                                             | 436                                                                                                                                                                                                                                | (51.1)                                                                                                                                                                                                                             |
| Each subject is counted once for Trial Status based on the latest Survival Follow-up record. Eachsubjectis counted onceforStudyMedicationStatus based on thelatest correspondingdisposition record. DatabaseCutoff Date:24Aug2018. | Each subject is counted once for Trial Status based on the latest Survival Follow-up record. Eachsubjectis counted onceforStudyMedicationStatus based on thelatest correspondingdisposition record. DatabaseCutoff Date:24Aug2018. | Each subject is counted once for Trial Status based on the latest Survival Follow-up record. Eachsubjectis counted onceforStudyMedicationStatus based on thelatest correspondingdisposition record. DatabaseCutoff Date:24Aug2018. | Each subject is counted once for Trial Status based on the latest Survival Follow-up record. Eachsubjectis counted onceforStudyMedicationStatus based on thelatest correspondingdisposition record. DatabaseCutoff Date:24Aug2018. | Each subject is counted once for Trial Status based on the latest Survival Follow-up record. Eachsubjectis counted onceforStudyMedicationStatus based on thelatest correspondingdisposition record. DatabaseCutoff Date:24Aug2018. | Each subject is counted once for Trial Status based on the latest Survival Follow-up record. Eachsubjectis counted onceforStudyMedicationStatus based on thelatest correspondingdisposition record. DatabaseCutoff Date:24Aug2018. | Each subject is counted once for Trial Status based on the latest Survival Follow-up record. Eachsubjectis counted onceforStudyMedicationStatus based on thelatest correspondingdisposition record. DatabaseCutoff Date:24Aug2018. |

Source: [P426V01MK3475: adam-adsl; adpm]

A breakdown of the disposition of participants by individual component in the pembrolizumab + axitinib group shows that the percentage of participants who discontinued either pembrolizumab or axitinib (with or without discontinuation of the other drug) was similar.

## Outcomes and estimation

The MAH provided the results of IA1. As of the data cutoff date (24-AUG-2018) for IA1, the median duration of follow up was 13.2 months (range: 0.1 to 21.5 months) in the pembrolizumab + axitinib group and 12.1 months (range: 0.4 to 22.0 months) in the sunitinib group.

<div style=\"page-break-after: always\"></div>

## Table: Summary of Follow-up Duration

| Follow-upduration(months)                                                                                                                                               | Pembrolizumab+Axitinib (N=432)                                                                                                                                          | Suuitinib (N=429)                                                                                                                                                       | Total (N=861)                                                                                                                                                           |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Median(Range)                                                                                                                                                           | 13.2 (0.1,21.5)                                                                                                                                                         | 12.1 (0.4, 22.0)                                                                                                                                                        | 12.8 (0.1,22.0)                                                                                                                                                         |
| Mean (SD)                                                                                                                                                               | 13.2 (4.5)                                                                                                                                                              | 12.2 (5.0)                                                                                                                                                              | 12.7 (4.8)                                                                                                                                                              |
| Follow-up durationis defined as the time from randomization to the date of death or the database cutoff date if the subjectis still alive. DatabaseCutoffDate:24Aug2018 | Follow-up durationis defined as the time from randomization to the date of death or the database cutoff date if the subjectis still alive. DatabaseCutoffDate:24Aug2018 | Follow-up durationis defined as the time from randomization to the date of death or the database cutoff date if the subjectis still alive. DatabaseCutoffDate:24Aug2018 | Follow-up durationis defined as the time from randomization to the date of death or the database cutoff date if the subjectis still alive. DatabaseCutoffDate:24Aug2018 |

Source:[P426V01MK3475:adam-adsl]

## Primary endpoints

## Overall Survival

## Table: Analysis of Overall Survival (ITT population)

| Treatment                          | N                                  | Number of Events (%)               | Person- Months                     | Event Rate/ 100 Person- Months     | Median Os 1 (Months) (95% CI)   | OS Rate at Months 12 in % 1 (95% CI)   |
|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|---------------------------------|----------------------------------------|
| Pembrolizumab+Axitinib             | 432                                | 59 (13.7)                          | 5670.0                             | 1.0                                | Not Reached (, .)               | 89.9 (86.4, 92.4)                      |
| Sunitinib                          | 429                                | 97 (22.6)                          | 5183.8                             | 1.9                                | Not Reached (., )               | 78.3 (73.8,82.1)                       |
| PairwiseComparisons                | PairwiseComparisons                | PairwiseComparisons                | PairwiseComparisons                | PairwiseComparisons                | Hazard Ratio(95%CI)             | p-Values                               |
| Pembrolizumab+Axitinibvs.Suuitinib | Pembrolizumab+Axitinibvs.Suuitinib | Pembrolizumab+Axitinibvs.Suuitinib | Pembrolizumab+Axitinibvs.Suuitinib | Pembrolizumab+Axitinibvs.Suuitinib | 0.53 (0.38, 0.74)               | 0.00005                                |

Source:[P426V01MK3475:adam-adsl; adtte]

## Table: Summary of Overall Survival Rate over time (ITT population)

|                                                                                              | Pembrolizumab+Axitinib (N=432)   | Sunitinib (N=429)   |
|----------------------------------------------------------------------------------------------|----------------------------------|---------------------|
| OSrate at6 Months in %(95%CI)                                                                | 94.9 (92.3,96.6)                 | 89.0 (85.6, 91.6)   |
| OS rate at 12 Months in % (95% CI)                                                           | 89.9 (86.4, 92.4)                | 78.3 (73.8,82.1)    |
| OSrate at 18 Months in %(95% CI)                                                             | 82.3 (77.2,86.3)                 | 72.1 (66.3, 77.0)   |
| From the product-limit (Kaplan-Meier) method for censored data. DatabaseCutoffDate:24Aug2018 |                                  |                     |

Source:[P426V01MK3475:adam-adsl;adtte]

<div style=\"page-break-after: always\"></div>

Figure: Kaplan-Meier Estimates of Overall Survival (ITT Population)

<!-- image -->

DatabaseCutoffDate:24Aug2018.

Source:[P426V01MK3475:adam-adsl;adtte]

Progression-Free Survival

Table: Analysis of Progression-Free Survival (Primary Censoring Rule) Based on BICR Assessment per RECIST 1.1 (ITT population)

| Treatment                          | N                                  | Number of Events (%)               | Person- Months                     | EventRate/ 100 Person- Months      | MedianPFS↑ (Months) (95% CI)   | PFSRate at Months12in%t (95%CI)   |
|------------------------------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|--------------------------------|-----------------------------------|
| Pembrolizumab+Axitinib             | 432                                | 183 (42.4)                         | 3949.7                             | 4.6                                | 15.1 (12.6, 17.7)              | 59.6 (54.3, 64.5)                 |
| Sunitinib                          | 429                                | 213 (49.7)                         | 3280.7                             | 6.5                                | 11.0 (8.7, 12.5)               | 46.1 (40.5, 51.5)                 |
| PairwiseComparisons                | PairwiseComparisons                | PairwiseComparisons                | PairwiseComparisons                | PairwiseComparisons                | HazardRatio(95%CI)+            | p-Values                          |
| Pembrolizumab+Axitinibvs.Sunitinib | Pembrolizumab+Axitinibvs.Sunitinib | Pembrolizumab+Axitinibvs.Sunitinib | Pembrolizumab+Axitinibvs.Sunitinib | Pembrolizumab+Axitinibvs.Sunitinib | 0.69 (0.56,0.84)               | 0.00012                           |

DatabaseCutoffDate:24Aug2018.

Source:[P426V01MK3475:adam-adsl][P426V01MK3475:sdtm-\\_adtte]

## Table: Summary of Progression-Free Survival Rate over time (Primary Censoring Rule) Based on BICR Assessment per RECIST 1.1 (ITT population)

|                                                                                                                                               | Pembrolizumab + Axitinib (N=432)                                                                                                              | Sunitinib (N=429)                                                                                                                             |
|-----------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| PFS rate at 6 Months in %(95% CI) †                                                                                                           | 74.0 (69.5, 77.9)                                                                                                                             | 65.8 (60.9, 70.2)                                                                                                                             |
| PFS rate at 12 Months in %(95% CI) †                                                                                                          | 59.6 (54.3, 64.5)                                                                                                                             | 46.1 (40.5, 51.5)                                                                                                                             |
| PFS rate at 18 Months in %(95% CI) †                                                                                                          | 41.1 (33.5, 48.5)                                                                                                                             | 32.8 (25.4, 40.4)                                                                                                                             |
| † From the product-limit (Kaplan-Meier) method for censored data. BICR = Blinded independent central review. Database Cutoff Date: 24Aug2018. | † From the product-limit (Kaplan-Meier) method for censored data. BICR = Blinded independent central review. Database Cutoff Date: 24Aug2018. | † From the product-limit (Kaplan-Meier) method for censored data. BICR = Blinded independent central review. Database Cutoff Date: 24Aug2018. |

Source:  [P426V01MK3475: adam-adsl; adtte]

<div style=\"page-break-after: always\"></div>

Table: Summary of Event and Censoring Description for Progression-Free Survival (Primary Censoring Rule) Based on BICR Assessment per RECIST 1.1 (ITT Population)

213 (49.7)

29 (6.8)

184 (42.9)

216 (50.3)

7 (1.6)

155 (36.1)

41 (9.6)

13 (3.0)

|                                                        | Pembrolizumab + Axitinib (N=432)           | Sunitinib (N=429)                          |
|--------------------------------------------------------|--------------------------------------------|--------------------------------------------|
| Number of Events (%)                                   | 183 (42.4)                                 | 213 (49.7)                                 |
| Death                                                  | 21 (4.9)                                   | 29 (6.8)                                   |
| Documented Progression                                 | 162 (37.5)                                 | 184 (42.9)                                 |
| Number of Censored (%) †                               | 249 (57.6)                                 | 216 (50.3)                                 |
| ≥ 2 Missing Assessments Immediately Before Death or PD | 2 (0.5)                                    | 7 (1.6)                                    |
| Last Radiologic Assessment Showing No Progression      | 219 (50.7)                                 | 155 (36.1)                                 |
| New Anti- Cancer Therapy                               | 20 (4.6)                                   | 41 (9.6)                                   |
| No Post Baseline Imaging Assessment                    | 8 (1.9)                                    | 13 (3.0)                                   |
| BICR = Blinded independent central review.             | BICR = Blinded independent central review. | BICR = Blinded independent central review. |

Source:  [P426V01MK3475: adam-adsl; adtte]

<div style=\"page-break-after: always\"></div>

Figure: Kaplan-Meier Estimates of Progression-Free Survival (Primary Censoring Rule) Based on BICR Assessment per RECIST 1.1 (ITT Population)

<!-- image -->

Database CutoffDate:24Aug2018.

Source: [P426V01MK3475: adam-adsl; adtte]

## Secondary endpoints

## Objective Response Rate

Table: Analysis of Objective Response Rate (Confirmed) Based on BICR Assessment per RECIST 1.1 (ITT population)

<!-- image -->

|                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                       | Differencein%vs.Sunitinib                                                                                                                                                                                                                                                                             | Differencein%vs.Sunitinib                                                                                                                                                                                                                                                                             |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Treatment                                                                                                                                                                                                                                                                                             | N                                                                                                                                                                                                                                                                                                     | NumberofObjective Responses                                                                                                                                                                                                                                                                           | ObjectiveResponse Rate (%) (95% CI)                                                                                                                                                                                                                                                                   | Estimate (95%CI)                                                                                                                                                                                                                                                                                      | p-Valuelf                                                                                                                                                                                                                                                                                             |
| Pembrolizumab+Axitinib Sunitinib                                                                                                                                                                                                                                                                      | 432 429                                                                                                                                                                                                                                                                                               | 256 153                                                                                                                                                                                                                                                                                               | 59.3 (54.5,63.9) 35.7 (31.1,40.4)                                                                                                                                                                                                                                                                     | 23.6 (17.2,29.9)                                                                                                                                                                                                                                                                                      | ≤0.0001                                                                                                                                                                                                                                                                                               |
| BasedonMiettinen&NurminenmethodstratifiedbyIntemational MetastaticRCCDatabaseConsortium(IMDC)riskgroup(favorablevs.intermediate vs. poor)andgeographicregion(NorthAmericavs.WestemEuropevs.RestoftheWorld). If One-sided p-value for testing. HO: difference in % = 0 versus H1: difference in % > 0. | BasedonMiettinen&NurminenmethodstratifiedbyIntemational MetastaticRCCDatabaseConsortium(IMDC)riskgroup(favorablevs.intermediate vs. poor)andgeographicregion(NorthAmericavs.WestemEuropevs.RestoftheWorld). If One-sided p-value for testing. HO: difference in % = 0 versus H1: difference in % > 0. | BasedonMiettinen&NurminenmethodstratifiedbyIntemational MetastaticRCCDatabaseConsortium(IMDC)riskgroup(favorablevs.intermediate vs. poor)andgeographicregion(NorthAmericavs.WestemEuropevs.RestoftheWorld). If One-sided p-value for testing. HO: difference in % = 0 versus H1: difference in % > 0. | BasedonMiettinen&NurminenmethodstratifiedbyIntemational MetastaticRCCDatabaseConsortium(IMDC)riskgroup(favorablevs.intermediate vs. poor)andgeographicregion(NorthAmericavs.WestemEuropevs.RestoftheWorld). If One-sided p-value for testing. HO: difference in % = 0 versus H1: difference in % > 0. | BasedonMiettinen&NurminenmethodstratifiedbyIntemational MetastaticRCCDatabaseConsortium(IMDC)riskgroup(favorablevs.intermediate vs. poor)andgeographicregion(NorthAmericavs.WestemEuropevs.RestoftheWorld). If One-sided p-value for testing. HO: difference in % = 0 versus H1: difference in % > 0. | BasedonMiettinen&NurminenmethodstratifiedbyIntemational MetastaticRCCDatabaseConsortium(IMDC)riskgroup(favorablevs.intermediate vs. poor)andgeographicregion(NorthAmericavs.WestemEuropevs.RestoftheWorld). If One-sided p-value for testing. HO: difference in % = 0 versus H1: difference in % > 0. |

<div style=\"page-break-after: always\"></div>

## Table: Summary of Objective Response Rate (Confirmed) Based on BICR Assessment per RECIST 1.1 (ITT population)

| Response Evaluation               | Pembrolizumab+Axitinib   | Pembrolizumab+Axitinib   | Pembrolizumab+Axitinib   | Sunitinib   | Sunitinib   | Sunitinib    |
|-----------------------------------|--------------------------|--------------------------|--------------------------|-------------|-------------|--------------|
|                                   | n                        | %                        | 95%CIt                   | n           | %           | 95%CIt       |
| Subjects in population            | 432                      |                          |                          | 429         |             |              |
| CompleteResponse(CR)              | 25                       | 5.8                      | (3.8, 8.4)               | 8           | 1.9         | (0.8, 3.6)   |
| Partial Response (PR)             | 231                      | 53.5                     | (48.6, 58.3)             | 145         | 33.8        | (29.3, 38.5) |
| Objective Response (CR+PR)        | 256                      | 59.3                     | (54.5, 63.9)             | 153         | 35.7        | (31.1, 40.4) |
| Stable Disease (SD)               | 106                      | 24.5                     | (20.5, 28.9)             | 168         | 39.2        | (34.5, 44.0) |
| Disease Control(CR+PR+SD≥6months) | 309                      | 71.5                     | (67.0, 75.7)             | 260         | 60.6        | (55.8, 65.3) |
| Progressive Disease (PD)          | 47                       | 10.9                     | (8.1, 14.2)              | 74          | 17.2        | (13.8, 21.2) |
| Non-evaluable (NE)                | 8                        | 1.9                      | (0.8, 3.6)               | 6           | 1.4         | (0.5, 3.0)   |
| No Assessment                     | 15                       | 3.5                      | (2.0, 5.7)               | 28          | 6.5         | (4.4, 9.3)   |

Forbest overall responseofCRandPR,onlyconfirmed responses areincluded.

BICR=Blinded independent central review.

Database CutoffDate:24Aug2018.

## Disease Control Rate

## Table: Analysis of Disease Control Rate (Confirmed) Based on BICR Assessment per RECIST 1.1 (ITT population)

| Treatment              |   N |   Number ofSubjects WithDiseaseControl | DiseaseControlRate (%) (95% CI)   | Differencein%vs.Sunitinib Estimate (95% CI)   |
|------------------------|-----|----------------------------------------|-----------------------------------|-----------------------------------------------|
| Pembrolizumab+Axitinib | 432 |                                    309 | 71.5 (67.0,75.7)                  | 11.0 (4.8,17.0)                               |
| Sunitinib              | 429 |                                    260 | 60.6 (55.8,65.3)                  |                                               |

Based on Miettinen &amp; Nurminen method stratified by Intemational Metastatic RCC Database Consortium (IMDC) risk group (favorable vs. intermediate Vs. poor) and geographic region (North America vs. Westem Europe vs. Rest of the World).

Responses arebasedonBICR assessmentper RECIST 1.1.

BICR=Blinded independentcentralreview.

DiseasecontrolincludesconfimedCR,confirmedPRandSD&gt;6months

DatabaseCutoffDate:24Aug2018.

Source:[P426V01MK3475:adam-adsl;adrs;adintdt]

Source:[P426V01MK3475:adam-adsl;adrs;adintdt]

<div style=\"page-break-after: always\"></div>

## Duration of Response

Table: Time to Response and Duration of Response Based on Response in Subjects with Confirmed Response Based on BICR Assessment per RECIST 1.1 (ITT Population)

|                                                                                                                                                                                                                                       | Pembrolizumab+Axitinib (N=432)   | Sunitinib (N=429)        |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|--------------------------|
| Number of subjects with response!                                                                                                                                                                                                     | 256                              | 153                      |
| Time toResponse(months)                                                                                                                                                                                                               |                                  |                          |
| Mean (SD) Median (Range)                                                                                                                                                                                                              | 3.5 (1.8) 2.8 (1.5-16.6)         | 4.0 (2.1) 2.9 (2.1-15.1) |
| Response Duration (months)                                                                                                                                                                                                            |                                  |                          |
| Median (Range)                                                                                                                                                                                                                        | NR (1.4+ - 18.2+)                | 15.2 (1.1+ - 15.4+)      |
| Number(%+)of Subjects withExtended ResponseDuration:                                                                                                                                                                                  |                                  |                          |
| ≥6 months ≥12 months                                                                                                                                                                                                                  | 161 (88.4) 58 (70.6)             | 84 (81.2) 26 (61.6)      |
| Includessubjectswith confirmed complete response orpartialresponse. From product-limit (Kaplan-Meier) method for censored data. \"+\" indicates there is no progressive disease by the time of last disease assessment. NR=Not Reached. |                                  |                          |

Source:[P426V01MK3475:adam-adsl;adtte;adrs]

Figure: Kaplan-Meier Estimates of Duration of Response in Subjects With Confirmed Response Based on BICR Assessment per RECIST 1.1 (ITT Population)

<!-- image -->

Database Cutoff Date:24Aug2018.

## Patient Reported Outcomes

In the pembrolizumab + axitinib group, PROs were assessed on Day 1 of each cycle. In the sunitinib group, PROs were assessed on Days 1 and 29 of each cycle up to Cycle 4, then on Day 1 of each subsequent cycle following the 2-week-off treatment period. Compliance rates for the FKSI-DRS by visit and by treatment at baseline through Week 30 were high (range: 85.9% through 97.1%) in both groups. The compliance rates for EORTC QLQ-C30 [Table 14.2-55] and EQ-5D-3L [Table 14.2-56] were similar to that for the FKSI-DRS. As expected, completion rates generally decreased at each time point as more participants discontinued the study treatment.

## Time to True Deterioration from Baseline in the FKSI-DRS

The time to true deterioration (time to first onset of 3 or more decrease from baseline with confirmation under right-censoring rule) in the FKSI-DRS differed between the 2 groups in favor of sunitinib (HR 1.44;

<div style=\"page-break-after: always\"></div>

95% CI: 1.14, 1.82; nominal p=0.999).  At the time of data cutoff, the median time to true deterioration was not reached in either treatment group.

Figure: Kaplan-Meier Estimates of Time to True Deterioration for FKSI-DRS (Primary Analysis) (FAS Population)

<!-- image -->

Database Cutoff Date: 24Aug2018. Source:[P426V01MK3475: adam-adpro, adttd]

## EORTC QLQ-C30 Global Health Status/Quality of Life Change From Baseline to Week 30

There were no clinically meaningful differences from baseline to Week 30 in the EORTC QLQ-C30 global health status/QoL score for participants in both the pembrolizumab + axitinib group and the sunitinib group.  Greater  worsening  (ie,  increase  in  score)  from  baseline  to  Week  30  in  the  EORTC  QLQ-C30 symptom  scale  for  diarrhea  was  observed  for  participants  in  the  pembrolizumab  +  axitinib  group compared with those in the sunitinib group. Diarrhea is an AE associated with both pembrolizumab and axitinib.

<div style=\"page-break-after: always\"></div>

Figure: Change from Baseline for EORTC QLQ-C30 Global Health Status/QoL and Selected Functional and Symptom Scales at Week 30 LS Mean Change and 95% CI (FAS Population)

<!-- image -->

Forglobalhealthstatus/qualityoflifescoreandallfunctionalscales:ahigherscoredenotes better health related quality of life (HRQOL) or function.

For symptoms scales: a higher score denotes worse symptoms.

DatabaseCutoffDate:24Aug2018.

Source:[P426V01MK3475:adam-adplda]

## Ancillary analyses

PFS Sensitivity Analyses

## Table: Analysis of Progression-Free Survival (Sensitivity Censoring Rule 1) Based on BICR Assessment per RECIST 1.1 (ITT Population)

| Treatment                           | N                                   | Number of Events (%)   | Person- Months   | Event Rate/ 100 Person- Months   | MedianPFS (Months) (95% CI)   | PFS Rate at Months 12 in %1 (95%CI)   |
|-------------------------------------|-------------------------------------|------------------------|------------------|----------------------------------|-------------------------------|---------------------------------------|
| Pembrolizumab+Axitinib              | 432                                 | 185 (42.8)             | 3962.6           | 4.7                              | 15.1 (12.5, 17.7)             | 59.4 (54.1, 64.3)                     |
| Suuitinib                           | 429                                 | 223 (52.0)             | 3346.8           | 6.7                              | 10.2 (8.5, 12.4)              | 45.3 (39.8, 50.7)                     |
| PairwiseComparisons                 |                                     |                        |                  |                                  | Hazard Ratio+(95%CI)          | p-Values                              |
| Pembrolizuumab+Axitinibvs.Suuitinib | Pembrolizuumab+Axitinibvs.Suuitinib |                        |                  |                                  | 0.68 (0.56, 0.82)             | 0.00005                               |

Source:[P426V01MK3475: adam-adsl;adlte]

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table: Analysis of Progression-Free Survival (Sensitivity Censoring Rule 2) Based on BICR Assessment per RECIST 1.1 (ITT Population)

| Treatment                                                                                                                                                                                                | N                                                                                                                                                                                                        | Number of Events (%)                                                                                                                                                                                     | Person- Months                                                                                                                                                                                           | Event Rate/ 100Person- Months                                                                                                                                                                            | MedianPFS (Months) (95% CI)                                                                                                                                                                              | PFSRate at Months 12in %1 (95% CI)                                                                                                                                                                       |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pembrolizmab+Axitinib                                                                                                                                                                                    | 432                                                                                                                                                                                                      | 230 (53.2)                                                                                                                                                                                               | 3936.6                                                                                                                                                                                                   | 5.8                                                                                                                                                                                                      | 12.4 (10.7, 14.5)                                                                                                                                                                                        | 52.4 (47.3, 57.2)                                                                                                                                                                                        |
| Suuitinib                                                                                                                                                                                                | 429                                                                                                                                                                                                      | 289 (67.4)                                                                                                                                                                                               | 3377.1                                                                                                                                                                                                   | 8.6                                                                                                                                                                                                      | 8.2 (7.1, 9.2)                                                                                                                                                                                           | 35.9 (31.0,40.8)                                                                                                                                                                                         |
| PairwiseComparisons                                                                                                                                                                                      | PairwiseComparisons                                                                                                                                                                                      | PairwiseComparisons                                                                                                                                                                                      | PairwiseComparisons                                                                                                                                                                                      | PairwiseComparisons                                                                                                                                                                                      | Hazard Ratio(95%CI)                                                                                                                                                                                      | p-Values                                                                                                                                                                                                 |
| Pembrolizumab+Axitinibvs.Suuitinib                                                                                                                                                                       | Pembrolizumab+Axitinibvs.Suuitinib                                                                                                                                                                       | Pembrolizumab+Axitinibvs.Suuitinib                                                                                                                                                                       | Pembrolizumab+Axitinibvs.Suuitinib                                                                                                                                                                       | Pembrolizumab+Axitinibvs.Suuitinib                                                                                                                                                                       | 0.65 (0.55, 0.78)                                                                                                                                                                                        | 0.00000                                                                                                                                                                                                  |
| Fromproduct-limit(Kaplan-Meier)methodforcensoreddata. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Intemational Metastatic RCC Database | Fromproduct-limit(Kaplan-Meier)methodforcensoreddata. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Intemational Metastatic RCC Database | Fromproduct-limit(Kaplan-Meier)methodforcensoreddata. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Intemational Metastatic RCC Database | Fromproduct-limit(Kaplan-Meier)methodforcensoreddata. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Intemational Metastatic RCC Database | Fromproduct-limit(Kaplan-Meier)methodforcensoreddata. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Intemational Metastatic RCC Database | Fromproduct-limit(Kaplan-Meier)methodforcensoreddata. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Intemational Metastatic RCC Database | Fromproduct-limit(Kaplan-Meier)methodforcensoreddata. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Intemational Metastatic RCC Database |

Souurce:[P426V01MK3475: adam-adsl;adtte]

PFS Analyses based on Investigator Assessment

Table: Analysis of Progression-Free Survival (Primary Censoring Rule) Based on Investigator Assessment per RECIST 1.1 (ITT Population)

| Treatment                                                                                                                                                                                                  | N                                                                                                                                                                                                          | Numberof Events (%)                                                                                                                                                                                        | Person- Months                                                                                                                                                                                             | Event Rate/ 100Person- Months                                                                                                                                                                              | Median PFS (Months) (95% CI)                                                                                                                                                                               | PFS Rate at Months 12 in % t (95% CI)                                                                                                                                                                      |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pembrolizumab+Axitinib                                                                                                                                                                                     | 432                                                                                                                                                                                                        | 190 (44.0)                                                                                                                                                                                                 | 3925.4                                                                                                                                                                                                     | 4.8                                                                                                                                                                                                        | 14.5 (12.5, 17.7)                                                                                                                                                                                          | 58.6 (53.4, 63.4)                                                                                                                                                                                          |
| Sunitinib                                                                                                                                                                                                  | 429                                                                                                                                                                                                        | 207 (48.3)                                                                                                                                                                                                 | 3503.2                                                                                                                                                                                                     | 5.9                                                                                                                                                                                                        | 11.9 (10.1,15.0)                                                                                                                                                                                           | 49.9 (44.4, 55.2)                                                                                                                                                                                          |
| PairwiseComparisons                                                                                                                                                                                        | PairwiseComparisons                                                                                                                                                                                        | PairwiseComparisons                                                                                                                                                                                        | PairwiseComparisons                                                                                                                                                                                        | PairwiseComparisons                                                                                                                                                                                        | Hazard Ratio+(95%C1)                                                                                                                                                                                       | p-Values                                                                                                                                                                                                   |
| Pembrolizumab+Axitinibvs.Suuitinib                                                                                                                                                                         | Pembrolizumab+Axitinibvs.Suuitinib                                                                                                                                                                         | Pembrolizumab+Axitinibvs.Suuitinib                                                                                                                                                                         | Pembrolizumab+Axitinibvs.Suuitinib                                                                                                                                                                         | Pembrolizumab+Axitinibvs.Suuitinib                                                                                                                                                                         | 0.82 (0.67,1.00)                                                                                                                                                                                           | 0.02200                                                                                                                                                                                                    |
| Fromproduct-limit (Kaplan-Meier)methodforcensored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Intemational Metastatic RCC Database | Fromproduct-limit (Kaplan-Meier)methodforcensored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Intemational Metastatic RCC Database | Fromproduct-limit (Kaplan-Meier)methodforcensored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Intemational Metastatic RCC Database | Fromproduct-limit (Kaplan-Meier)methodforcensored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Intemational Metastatic RCC Database | Fromproduct-limit (Kaplan-Meier)methodforcensored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Intemational Metastatic RCC Database | Fromproduct-limit (Kaplan-Meier)methodforcensored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Intemational Metastatic RCC Database | Fromproduct-limit (Kaplan-Meier)methodforcensored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Intemational Metastatic RCC Database |

Source: [P426V01MK3475: adam-adsl; adte]

Figure: Kaplan-Meier Estimates of Progression-Free Survival (Primary Censoring Rule) Based on Investigator Assessment per RECIST 1.1 (ITT Population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table: Concordance of Progression Events (Investigator vs. BICR) (ITT Population)

<!-- image -->

|                                                                                                                                                                                                           | Pembrolizumab+Axitinib (N=432)                                                | Sunitinib (N=429)                                                            | Total (N=861)                                                                  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| Investigator Assessment - PD BICR Agreed BICR andInvestigator agreed ontime BICRhas earliertime BICRhaslatertime BICR Disagreed NoBICR Assessment InvestigatorAssessment-NonPD BICR Agreed BICR Disagreed | 169 136(80%) 71(42%) 43(25%) 22(13%) 33(20%) 0(0%) 245 219(89%) 26(11%) 0(0%) | 183 137(75%) 77(42%) 45(25%) 15(8%) 46(25%) 0(0%) 215 168(78%) 47(22%) 0(0%) | 352 273(78%) 148(42%) 88(25%) 37(11%) 79(22%) (%0)0 460 387(84%) 73(16%) (%0)0 |
| PD:Progressive Disease. BICR:Blindedindependent centralreview. DatabaseCutoffDate:24Aug2018.                                                                                                              |                                                                               |                                                                              |                                                                                |

Source:[P426V01MK3475:adam-adsl;adrs;adintdt]

Duration of Response based on Investigator Assessment

Table: Summary of Time to Response and Duration of Response Based on Response in Subjects with Confirmed Response Based on Investigator Assessment per RECIST 1.1 (ITT Population)

|                                                                                                        | Pembrolizumab+Axitinib (N=432)   | Sunitinib (N=429)   |
|--------------------------------------------------------------------------------------------------------|----------------------------------|---------------------|
| Number of subjects with response                                                                       | 245                              | 149                 |
| Time toResponse(months)                                                                                |                                  |                     |
| Mean (SD)                                                                                              | 3.5 (1.4)                        | 4.3 (2.3)           |
| Median (Range)                                                                                         | 2.8 (1.5-11.4)                   | 3.0 (2.4-15.1)      |
| Response Duration (months)                                                                             |                                  |                     |
| Median (Range)                                                                                         | 18.0 (1.3+ -18.2+)               | 15.2 (1.2+ - 15.4)  |
| Nunber(%)of Subjectswith Extended ResponseDuration:                                                    |                                  |                     |
| ≥6 months                                                                                              | 153 (85.2)                       | 87 (83.8)           |
| ≥12months                                                                                              | 53 (67.0)                        | 23 (61.7)           |
| ≥18months                                                                                              | 2 (34.9)                         | 0 (NR)              |
| Includes subjects with confirmed complete response or partialresponse.                                 |                                  |                     |
| From product-limit (Kaplan-Meier) method for censored data.                                            |                                  |                     |
| \"+\" indicates there is no progressive disease by the time of last disease assessment. NR =Not Reached. |                                  |                     |
| DatabaseCutoffDate:24Aug2018.                                                                          |                                  |                     |

Source:[P426V01MK3475:adam-adsl;adltte;adrs]

<div style=\"page-break-after: always\"></div>

Figure: Kaplan-Meier Estimates of Duration of Response in Subjects With Confirmed Response Based on Investigator Assessment per RECIST 1.1 (ITT Population)

<!-- image -->

DatabaseCutoffDate:24Aug2018 Source:[P426V01MK3475: adam-adsl; adtte]

## Subgroups analyses

OS subgroups analysis

Figure: Forest Plot of OS Hazard Ratio by Subgroup Factors (ITT Population)

<!-- image -->

BasedonCoxregressionmodeltreatmentasacovariatestratifiedbyIntermationalMetastatic RCC Database Consortium (IMDC) risk group (favorable vs. intermediate vs. poor) and Geographic Region (North America vs. Westerm Europe vs. Rest ofthe World).

Subjects with PD-L1 not evaluable are not included in the subgroup analysis.

DatabaseCutoffDate:24Aug2018.

Source:[P426V01MK3475: adam-adsl; adtte]

<div style=\"page-break-after: always\"></div>

## PFS subgroups analysis

Figure: Forest Plot of PFS Hazard Ratio by Subgroup Factors (Primary Censoring Rule) Based on BICR Assessment per RECIST 1.1 (ITT Population)

<!-- image -->

BasedonCoxregressionmodeltreatmentasacovariatestratifiedbyInternationalMetastatic RCC Database Consortium (IMDC) risk group (favorable vs. intermediate vs. poor) and Geographic Region (North America vs. Westem Europe vs. Rest of the World). Subjects with PD-L1 not evaluable are not included in the subgroup analysis. Database Cutoff Date: 24Aug2018.Source:[P426V01MK3475: adam-adsl; adtte]

IMDC Favourable Risk

Table 4.4.2.15 : Analysis of Overall Survival Subjects with IMDC Favorable Risk (ITT Population)

| Treatment                                                                                                                                                                                                                                                                                                                                                         | N                                                                                                                                                                                                                                                                                                                                                                 | Number of Events (%)                                                                                                                                                                                                                                                                                                                                              | Person- Months                                                                                                                                                                                                                                                                                                                                                    | Event Rate/ 100 Person- Months                                                                                                                                                                                                                                                                                                                                    | Median Os t (Months) (95% CI)                                                                                                                                                                                                                                                                                                                                     | OS Rate at Months 12 in % t (95% CI)                                                                                                                                                                                                                                                                                                                              |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pembrolizumab+Axitinib                                                                                                                                                                                                                                                                                                                                            | 138                                                                                                                                                                                                                                                                                                                                                               | 7 (5.1)                                                                                                                                                                                                                                                                                                                                                           | 1878.6                                                                                                                                                                                                                                                                                                                                                            | 0.4                                                                                                                                                                                                                                                                                                                                                               | Not Reached (., .)                                                                                                                                                                                                                                                                                                                                                | 95.2 (89.6, 97.9)                                                                                                                                                                                                                                                                                                                                                 |
| Sunitinib                                                                                                                                                                                                                                                                                                                                                         | 131                                                                                                                                                                                                                                                                                                                                                               | 10 (7.6)                                                                                                                                                                                                                                                                                                                                                          | 1775.9                                                                                                                                                                                                                                                                                                                                                            | 0.6                                                                                                                                                                                                                                                                                                                                                               | Not Reached (.. .)                                                                                                                                                                                                                                                                                                                                                | 93.8 (87.4, 97.0)                                                                                                                                                                                                                                                                                                                                                 |
| PairwiseComparisons                                                                                                                                                                                                                                                                                                                                               | PairwiseComparisons                                                                                                                                                                                                                                                                                                                                               | PairwiseComparisons                                                                                                                                                                                                                                                                                                                                               | PairwiseComparisons                                                                                                                                                                                                                                                                                                                                               | PairwiseComparisons                                                                                                                                                                                                                                                                                                                                               | Hazard Ratio (95% CI)t                                                                                                                                                                                                                                                                                                                                            | p-Values                                                                                                                                                                                                                                                                                                                                                          |
| Pembrolizumab+Axitinibvs.Sunitinib                                                                                                                                                                                                                                                                                                                                | Pembrolizumab+Axitinibvs.Sunitinib                                                                                                                                                                                                                                                                                                                                | Pembrolizumab+Axitinibvs.Sunitinib                                                                                                                                                                                                                                                                                                                                | Pembrolizumab+Axitinibvs.Sunitinib                                                                                                                                                                                                                                                                                                                                | Pembrolizumab+Axitinibvs.Sunitinib                                                                                                                                                                                                                                                                                                                                | 0.64 (0.24,1.68)                                                                                                                                                                                                                                                                                                                                                  | 0.18047                                                                                                                                                                                                                                                                                                                                                           |
| From product-limit (Kaplan-Meier)method for censored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by International Metastatic RCC Database Consortium (IMDC) risk group (favorable vs. intermediate vs. poor) and geographic region (North America vs. Western Europe vs. Rest of the World). | From product-limit (Kaplan-Meier)method for censored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by International Metastatic RCC Database Consortium (IMDC) risk group (favorable vs. intermediate vs. poor) and geographic region (North America vs. Western Europe vs. Rest of the World). | From product-limit (Kaplan-Meier)method for censored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by International Metastatic RCC Database Consortium (IMDC) risk group (favorable vs. intermediate vs. poor) and geographic region (North America vs. Western Europe vs. Rest of the World). | From product-limit (Kaplan-Meier)method for censored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by International Metastatic RCC Database Consortium (IMDC) risk group (favorable vs. intermediate vs. poor) and geographic region (North America vs. Western Europe vs. Rest of the World). | From product-limit (Kaplan-Meier)method for censored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by International Metastatic RCC Database Consortium (IMDC) risk group (favorable vs. intermediate vs. poor) and geographic region (North America vs. Western Europe vs. Rest of the World). | From product-limit (Kaplan-Meier)method for censored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by International Metastatic RCC Database Consortium (IMDC) risk group (favorable vs. intermediate vs. poor) and geographic region (North America vs. Western Europe vs. Rest of the World). | From product-limit (Kaplan-Meier)method for censored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by International Metastatic RCC Database Consortium (IMDC) risk group (favorable vs. intermediate vs. poor) and geographic region (North America vs. Western Europe vs. Rest of the World). |

Source:[P426V01MK3475:adam-adsl;adtte]

<div style=\"page-break-after: always\"></div>

Figure 4.4.2.7: Kaplan-Meier Estimates of Overall Survival Subjects with IMDC Favorable Risk (ITT Population)

Database Cutoff Date: 24Aug2018.

Source: [P426V01MK3475: adam-adsl; adtte]

<!-- image -->

Table 4.4.2.16:  Analysis of Progression-Free Survival (Primary Censoring Rule) Based on BICR Assessment per RECIST 1.1 Subjects with IMDC Favorable Risk (ITT Population)

| Treatment                                                   | N                                                           | Number of Events (%)                                        | Person- Months                                              | Event Rate/ 100Person- Months                               | Median PFS (Months) (95% CI)                                | PFS Rate at Months 12 in % t (95% CI)                       |
|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
| Pembrolizumab+Axitinib                                      | 138                                                         | 43 (31.2)                                                   | 1380.9                                                      | 3.1                                                         | 17.7 (15.2, )                                               | 68.0 (58.4, 75.9)                                           |
| Sunitinib                                                   | 131                                                         | 47 (35.9)                                                   | 1192.3                                                      | 3.9                                                         | 12.7 (11.5, .)                                              | 60.0 (48.9, 69.4)                                           |
| PairwiseComparisons                                         | PairwiseComparisons                                         | PairwiseComparisons                                         | PairwiseComparisons                                         | PairwiseComparisons                                         | Hazard Ratio+(95% CI)                                       | p-Values                                                    |
| Pembrolizumab+Axitinibvs.Sunitinib                          | Pembrolizumab+Axitinibvs.Sunitinib                          | Pembrolizumab+Axitinibvs.Sunitinib                          | Pembrolizumab+Axitinibvs.Sunitinib                          | Pembrolizumab+Axitinibvs.Sunitinib                          | 0.81 (0.53,1.24)                                            | 0.16572                                                     |
| From product-limit (Kaplan-Meier) method for censored data. | From product-limit (Kaplan-Meier) method for censored data. | From product-limit (Kaplan-Meier) method for censored data. | From product-limit (Kaplan-Meier) method for censored data. | From product-limit (Kaplan-Meier) method for censored data. | From product-limit (Kaplan-Meier) method for censored data. | From product-limit (Kaplan-Meier) method for censored data. |

Source:[P426V01MK3475:adam-adsl;adtte]

<div style=\"page-break-after: always\"></div>

Figure 4.4.2.8:  Kaplan-Meier Estimates of Progression-Free Survival (Primary Censoring Rule) Based on BICR Assessment per RECIST 1.1 Subjects with IMDC Favorable Risk (ITT Population)

<!-- image -->

PD-L1 Expression Subgroups

Table 4.4.2.17:  Analysis of Overall Survival Subjects with CPS &lt; 1 (ITT Population)

| Treatment                                                                                                                                                                                                       | N                                                                                                                                                                                                               | Number of Events (%)                                                                                                                                                                                            | Person- Months                                                                                                                                                                                                  | Event Rate/ 100Person- Months                                                                                                                                                                                   | Median Os t (Months) (95% CI)                                                                                                                                                                                   | OS Rate at Months 12 in % (95% CI)                                                                                                                                                                              |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pembrolizumab+Axitinib                                                                                                                                                                                          | 167                                                                                                                                                                                                             | 21 (12.6)                                                                                                                                                                                                       | 2235.9                                                                                                                                                                                                          | 0.9                                                                                                                                                                                                             | Not Reached (., .)                                                                                                                                                                                              | 91.5 (85.8, 95.0)                                                                                                                                                                                               |
| Sunitinib                                                                                                                                                                                                       | 158                                                                                                                                                                                                             | 33 (20.9)                                                                                                                                                                                                       | 1963.8                                                                                                                                                                                                          | 1.7                                                                                                                                                                                                             | Not Reached (., .)                                                                                                                                                                                              | 78.3 (70.6, 84.2)                                                                                                                                                                                               |
| PairwiseComparisons                                                                                                                                                                                             | PairwiseComparisons                                                                                                                                                                                             | PairwiseComparisons                                                                                                                                                                                             | PairwiseComparisons                                                                                                                                                                                             | PairwiseComparisons                                                                                                                                                                                             | Hazard Ratio+(95% CI)t                                                                                                                                                                                          | p-Values                                                                                                                                                                                                        |
| Pembrolizumab+Axitinibvs.Sunitinib                                                                                                                                                                              | Pembrolizumab+Axitinibvs.Sunitinib                                                                                                                                                                              | Pembrolizumab+Axitinibvs.Sunitinib                                                                                                                                                                              | Pembrolizumab+Axitinibvs.Sunitinib                                                                                                                                                                              | Pembrolizumab+Axitinibvs.Sunitinib                                                                                                                                                                              | 0.59 (0.34, 1.03)                                                                                                                                                                                               | 0.03082                                                                                                                                                                                                         |
| From product-limit (Kaplan-Meier) method for censored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by International Metastatic RCC Database | From product-limit (Kaplan-Meier) method for censored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by International Metastatic RCC Database | From product-limit (Kaplan-Meier) method for censored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by International Metastatic RCC Database | From product-limit (Kaplan-Meier) method for censored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by International Metastatic RCC Database | From product-limit (Kaplan-Meier) method for censored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by International Metastatic RCC Database | From product-limit (Kaplan-Meier) method for censored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by International Metastatic RCC Database | From product-limit (Kaplan-Meier) method for censored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by International Metastatic RCC Database |

Source:[P426V01MK3475:adam-adsl;adtte]

Table 4.4.2.18:  Analysis of Overall Survival Subjects with CPS ≥ 1 (ITT Population)

| Treatment                                                   | N                                                           | Number of Events (%)                                        | Person- Months                                              | Event Rate 100Person- Months                                | Median Os t (Months) (95% CI)                               | OS Rate at Months 12 in % t (95% CI)                        |
|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
| Pembrolizumab+Axitinib                                      | 243                                                         | 32 (13.2)                                                   | 3156.5                                                      | 1.0                                                         | Not Reached (., .)                                          | 90.1 (85.5, 93.3)                                           |
| Sunitinib                                                   | 254                                                         | 58 (22.8)                                                   | 3050.3                                                      | 1.9                                                         | Not Reached (., .)                                          | 78.4 (72.4,83.2)                                            |
| PairwiseComparisons                                         | PairwiseComparisons                                         | PairwiseComparisons                                         | PairwiseComparisons                                         | PairwiseComparisons                                         | Hazard Ratio+(95% CI)                                       | p-Values                                                    |
| Pembrolizumab+Axitinibvs.Sunitinib                          | Pembrolizumab+Axitinibvs.Sunitinib                          | Pembrolizumab+Axitinibvs.Sunitinib                          | Pembrolizumab+Axitinibvs.Sunitinib                          | Pembrolizumab+Axitinibvs.Sunitinib                          | 0.54 (0.35,0.84)                                            | 0.00272                                                     |
| From product-limit (Kaplan-Meier) method for censored data. | From product-limit (Kaplan-Meier) method for censored data. | From product-limit (Kaplan-Meier) method for censored data. | From product-limit (Kaplan-Meier) method for censored data. | From product-limit (Kaplan-Meier) method for censored data. | From product-limit (Kaplan-Meier) method for censored data. | From product-limit (Kaplan-Meier) method for censored data. |

Source:[P426V01MK3475:adam-adsl;adtte]

<div style=\"page-break-after: always\"></div>

Figure 4.4.2.9: Kaplan-Meier Estimates of Overall Survival Subjects with CPS &lt; 1 (ITT Population)

<!-- image -->

Figure 4.4.2.10:  Kaplan-Meier Estimates of Overall Survival Subjects with CPS &gt;= 1 (ITT Population)

<!-- image -->

## Subsequent Anticancer Treatments for RCC

A lower percentage of participants in the pembrolizumab + axitinib group compared with the sunitinib group received any subsequent systemic anti-cancer therapy by type or across lines for advanced RCC. The most common type of subsequent anticancer therapy administered in the pembrolizumab + axitinib group was a VEGF/VEGR inhibitor (most commonly cabozantinib, sunitinib, axitinib, or pazopanib), with a frequency that was similar to that in the sunitinib group. A higher percentage of participants in the sunitinib group received a PD-1 or PD-L1 checkpoint inhibitor (most commonly nivolumab) as subsequent anticancer therapy compared with the pembrolizumab + axitinib group.

<div style=\"page-break-after: always\"></div>

Table: Subsequent Systemic Anti-Cancer Treatment (ITT Population)

<!-- image -->

|                                                                                                                      | Pembrolizumab +Axitinib (N=432)                                                                                      | Sunitinib (N=429)                                                                                                    | Total (N=861)                                                                                                        |
|----------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|
| StartedStudyTreatment                                                                                                | 429 (99.3)                                                                                                           | 425 (99.1)                                                                                                           | 854 (99.2)                                                                                                           |
| Discontinued Study Treatment                                                                                         | 176 (40.7)                                                                                                           | 242 (56.4)                                                                                                           | 418 (48.5)                                                                                                           |
| Received Any Subsequent Systemic Anti-cancerTherapy                                                                  | 88 (20.4)                                                                                                            | 147 (34.3)                                                                                                           | 235 (27.3)                                                                                                           |
| Subsequent systemic therapy by type                                                                                  |                                                                                                                      |                                                                                                                      |                                                                                                                      |
| Any PD1/PD-L1 checkpoint inhibitor                                                                                   | (6'D) 8                                                                                                              | 91 (21.2)                                                                                                            | (S'11) 66                                                                                                            |
| atezolizumab                                                                                                         | 0 (0.0)                                                                                                              | 1(0.2)                                                                                                               | 1 (0.1)                                                                                                              |
| duvalumab                                                                                                            | 0 (0.0)                                                                                                              | 2 (0.5)                                                                                                              | 2 (0.2)                                                                                                              |
| nivolumab                                                                                                            | (6'D) 8                                                                                                              | 88 (20.5)                                                                                                            | 96 (11.1)                                                                                                            |
| pembrolizumab                                                                                                        | 0 (0.0)                                                                                                              | 1(0.2)                                                                                                               | 1 (0.1)                                                                                                              |
| Any VEGF/VEGFR inhibitor                                                                                             | 78 (18.1)                                                                                                            | 86 (20.0)                                                                                                            | 164 (19.0)                                                                                                           |
| axitinib                                                                                                             | 7 (1.6)                                                                                                              | 28 (6.5)                                                                                                             | 35 (4.1)                                                                                                             |
| bevacizumab                                                                                                          | 0 (0.0)                                                                                                              | 1(0.2)                                                                                                               | 1 (0.1)                                                                                                              |
| cabozantinib                                                                                                         | 33 (7.6)                                                                                                             | 22 (5.1)                                                                                                             | 55 (6.4)                                                                                                             |
| lenvatinib                                                                                                           | 9 (2.1)                                                                                                              | 5 (1.2)                                                                                                              | 14 (1.6)                                                                                                             |
| pazopanib                                                                                                            | 13 (3.0)                                                                                                             | 21 (4.9)                                                                                                             | 34 (3.9)                                                                                                             |
| sorafenib                                                                                                            | 0 (0.0)                                                                                                              | 2 (0.5)                                                                                                              | 2 (0.2)                                                                                                              |
| sunitinib                                                                                                            | 29 (6.7)                                                                                                             | 18 (4.2)                                                                                                             | 47 (5.5)                                                                                                             |
| Other                                                                                                                | 21 (4.9)                                                                                                             | 26 (6.1)                                                                                                             | 47 (5.5)                                                                                                             |
| everolimus                                                                                                           | 16 (3.7)                                                                                                             | 14 (3.3)                                                                                                             | 30 (3.5)                                                                                                             |
| glutaminase inhibitor (unspecified)                                                                                  | 2 (0.5)                                                                                                              | 2 (0.5)                                                                                                              | 4 (0.5)                                                                                                              |
| hypoxia inducible factor 2 alpha inhibitor (unspecified)                                                             | 1 (0.2)                                                                                                              | 0 (0.0)                                                                                                              | 1 (0.1)                                                                                                              |
| ibrutinib                                                                                                            | 0 (0.0)                                                                                                              | 1 (0.2)                                                                                                              | 1 (0.1)                                                                                                              |
| interferon (unspecified)                                                                                             | 3 (0.7)                                                                                                              | 2 (0.5)                                                                                                              | 5 (0.6)                                                                                                              |
| interferon alfa-2a                                                                                                   | 0 (0.0)                                                                                                              | 1 (0.2)                                                                                                              | 1 (0.1)                                                                                                              |
| interferon gamma                                                                                                     | 1 (0.2)                                                                                                              | 0 (0.0)                                                                                                              | 1 (0.1)                                                                                                              |
| investigational drug (unspecified)                                                                                   | 0 (0.0)                                                                                                              | 2 (0.5)                                                                                                              | 2 (0.2)                                                                                                              |
| ipilimumab                                                                                                           | 2 (0.5)                                                                                                              | 6 (1.4)                                                                                                              | 8 (0.9)                                                                                                              |
| savolitinib                                                                                                          | 0 (0.0)                                                                                                              | 1 (0.2)                                                                                                              | 1 (0.1)                                                                                                              |
| vinblastine                                                                                                          | 2 (0.5)                                                                                                              | 0 (0.0)                                                                                                              | 2 (0.2)                                                                                                              |
| Subsequent systemic therapy by lines                                                                                 |                                                                                                                      |                                                                                                                      |                                                                                                                      |
| 1 subsequent line                                                                                                    | 88 (20.4)                                                                                                            | 141 (32.9)                                                                                                           | 229 (26.6)                                                                                                           |
| 2 subsequent lines                                                                                                   | 18 (4.2)                                                                                                             | 46 (10.7)                                                                                                            | 64 (7.4)                                                                                                             |
| ≥3 subsequent lines                                                                                                  | 4 (0.9)                                                                                                              | 8 (1.9)                                                                                                              | 12 (1.4)                                                                                                             |
| Every subjectis counted a single time for each applicable specific anti-cancer treatment.                            | Every subjectis counted a single time for each applicable specific anti-cancer treatment.                            | Every subjectis counted a single time for each applicable specific anti-cancer treatment.                            | Every subjectis counted a single time for each applicable specific anti-cancer treatment.                            |
| A subject with multiple anti-cancer treatments within a therapy category is counted a single time for that category. | A subject with multiple anti-cancer treatments within a therapy category is counted a single time for that category. | A subject with multiple anti-cancer treatments within a therapy category is counted a single time for that category. | A subject with multiple anti-cancer treatments within a therapy category is counted a single time for that category. |
| DatabaseCutoffDate:24Aug2018.                                                                                        | DatabaseCutoffDate:24Aug2018.                                                                                        | DatabaseCutoffDate:24Aug2018.                                                                                        | DatabaseCutoffDate:24Aug2018.                                                                                        |

Sowrce:[P426V01MK3475:adam-adsl; adcm]

## UPDATED DATA

As per CHMP request, the MAH provided updated efficacy data from KEYNOTE-426, using a data cutoff of 02-JAN-2019.

Median follow up duration (ITT population) was 17.4 months (range 0.1, 25.6) in pembrolizumab + axitinib arm, and 15.7 months (0.4, 26.3) in the sunitinib arm.

<div style=\"page-break-after: always\"></div>

## Overall survival

## Table: Analysis of Overall Survival and Summary Over Time (ITT Population) - 02-JAN-2019 Cutoff

| Endpoint                            | Pembrolizumab Axitinib n=432   | Sunitinib n=429      |
|-------------------------------------|--------------------------------|----------------------|
| OS (ITT)                            |                                |                      |
| Number of events (%)                | 84 (19.4%)                     | 122 (28.4%)          |
| Median in months (95% CI)           | Not reached ( 25.2 , NA)       | Not reached (NA, NA) |
| Hazard ratio * (95% CI)             | 0.59 (0.45, 0.78)              | 0.59 (0.45, 0.78)    |
| p-Value †                           | 0.00010                        | 0.00010              |
| OS rate at 6 Months in %(95% CI) †  | 94.9 (92.3, 96.6)              | 89.0 (85.6, 91.6)    |
| OS rate at 12 Months in %(95% CI) † | 89.5 (86.2, 92.1)              | 78.8 (74.7, 82.4)    |
| OS rate at 18 Months in %(95% CI) † | 81.0 (76.7, 84.6)              | 70.7 (65.8, 75.1)    |

## Table: Overall Survival in IMDC Risk Category - 02-JAN-2019 Cutoff

| Endpoint                  | Pembrolizumab Axitinib n=432   | Sunitinib n=429      |
|---------------------------|--------------------------------|----------------------|
| OS (IMDC Risk category 1) |                                |                      |
| Favorable                 | n=138                          | n=131                |
| Number of events (%)      | 13 (9.4%)                      | 12 (9.2%)            |
| Median in months (95% CI) | Not reached (NA, NA)           | Not reached (NA, NA) |
| Hazard ratio * (95% CI)   | 0.94 (0.43, 2.07)              | 0.94 (0.43, 2.07)    |
| Intermediate              | n=238                          | n=246                |
| Number of events (%)      | 45 (18.9%)                     | 78 (31.7%)           |
| Median in months (95% CI) | Not reached (NA, NA)           | Not reached (NA, NA) |
| Hazard ratio * (95% CI)   | 0.52 (0.36, 0.75)              | 0.52 (0.36, 0.75)    |
| Poor                      | n=56                           | n=52                 |
| Number of events (%)      | 26 (46.4%)                     | 32 (61.5%)           |
| Median in months (95% CI) | 21.8 (14.7, 25.2)              | 10.1 (7.0, 17.6)     |
| Hazard ratio * (95% CI)   | 0.50 (0.29, 0.87)              | 0.50 (0.29, 0.87)    |

<div style=\"page-break-after: always\"></div>

Figure: Kaplan-Meier Estimates of Overall Survival (ITT Population) Database Cutoff Date: 02Jan2019.

<!-- image -->

Figure: Forest Plot of OS Hazard Ratio by Subgroup Factors (ITT Population) - Database Cutoff Date: 02Jan2019.

<!-- image -->

Based on Cox regression model treatment as a covariate stratified by International Metastatic RCC Database Consortium (IMDC) risk group (favorable vs. intermediate vs. poor) and Geographic Region (North America vs. Western Europe vs. Rest of the World). Subjects with PDL1 not evaluable are not included in the subgroup analysis.

<div style=\"page-break-after: always\"></div>

Figure:  Kaplan-Meier Estimates of Overall Survival Subjects with IMDC Favorable Risk (ITT Population) Database Cutoff Date: 02Jan2019

<!-- image -->

131

129

125

88

39

3

0

Sunitinib

Figure:  Kaplan-Meier Estimates of Overall Survival Subjects with IMDC Intermediate Risk (ITT Population) Database Cutoff Date: 02Jan2019.

<!-- image -->

Pembrolizumab + Axitinib

Sunitinib

238

246

230

224

219

194

149

129

71

64

6

3

0

0

Figure:  Kaplan-Meier Estimates of Overall Survival Subjects with IMDC Poor Risk (ITT Population) Database Cutoff Date: 02Jan2019.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Progression-free Survival

Table: Analysis of Progression-Free Survival (Primary Censoring Rule) Based on BICR Assessment per RECIST 1.1 (ITT Population) Database Cutoff Date: 02Jan2019.

60.1 (55.1, 64.7)

47.7 (42.5, 52.7)

0.69 (0.57, 0.83)

0.00005

| Treatment                              | N                                      | Number of Events (%)                   | Person- Months                         | Event Rate/ 100 Person- Months         | Median PFS † (Months) (95% CI)   | PFS Rate at Months 12 in% † (95% CI)   |
|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------|----------------------------------------|
| Pembrolizumab + Axitinib               | 432                                    | 207 (47.9)                             | 4789.2                                 | 4.3                                    | 17.1 (13.6, 18.9)                | 60.1 (55.1, 64.7)                      |
| Sunitinib                              | 429                                    | 232 (54.1)                             | 3775.2                                 | 6.1                                    | 11.1 (8.7, 12.5)                 | 47.7 (42.5, 52.7)                      |
| Pairwise Comparisons                   | Pairwise Comparisons                   | Pairwise Comparisons                   | Pairwise Comparisons                   | Pairwise Comparisons                   | Hazard Ratio ‡ (95% CI) ‡        | p-Value §                              |
| Pembrolizumab + Axitinib vs. Sunitinib | Pembrolizumab + Axitinib vs. Sunitinib | Pembrolizumab + Axitinib vs. Sunitinib | Pembrolizumab + Axitinib vs. Sunitinib | Pembrolizumab + Axitinib vs. Sunitinib | 0.69 (0.57, 0.83)                | 0.00005                                |

‡ Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by International Metastatic RCC Database Consortium (IMDC) risk group (favorable vs. intermediate vs. poor) and geographic region (North America vs. Western Europe vs. Rest of the World).

§ One-sided p-value based on logrank test stratified by the same strata as above.

Database Cutoff Date: 02Jan2019.

Figure: Kaplan-Meier Estimates of Progression-Free Survival (Primary Censoring Rule) Based on BICR Assessment per RECIST 1.1 (ITT Population) Database Cutoff Date: 02Jan2019.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure: Forest Plot of PFS Hazard Ratio by Subgroup Factors (Primary Censoring Rule) Based on BICR Assessment per RECIST 1.1 (ITT Population) Database Cutoff Date: 02Jan2019.

<!-- image -->

Based on Cox regression model treatment as a covariate stratified by International Metastatic RCC Database Consortium (IMDC) risk group (favorable vs. intermediate vs. poor) and Geographic Region (North America vs. Western Europe vs. Rest of the World).

Subjects with PDL1 not evaluable are not included in the subgroup analysis. Database Cutoff Date: 02Jan2019.

Figure:  Kaplan-Meier Estimates of Progression-Free Survival (Primary Censoring Rule) Based on BICR Assessment per RECIST 1.1 Subjects with IMDC Favorable Risk (ITT Population)

Database Cutoff Date: 02Jan2019.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure: Kaplan-Meier Estimates of Progression-Free Survival (Primary Censoring Rule) Based on BICR Assessment per RECIST 1.1 Subjects with IMDC Intermediate Risk (ITT Population) Database Cutoff Date: 02Jan2019.

Figure: Kaplan-Meier Estimates of Progression-Free Survival (Primary Censoring Rule) Based on BICR Assessment per RECIST 1.1 Subjects with IMDC Poor Risk (ITT Population)

<!-- image -->

Database Cutoff Date: 02Jan2019.

Objective Response Rate

<!-- image -->

Table: Analysis of Objective Response (Confirmed) Based on BICR Assessment per RECIST 1.1 (ITT Population) Database Cutoff Date: 02Jan2019.

|                 |     |                               |                                      | Difference in %vs. Sunitinib   | Difference in %vs. Sunitinib   |
|-----------------|-----|-------------------------------|--------------------------------------|--------------------------------|--------------------------------|
| Treatment       | N   | Number of Objective Responses | Objective Response Rate (%) (95% CI) | Estimate (95% CI) †            | p-Value ††                     |
| Pembrolizumab + | 432 | 259                           | 60.0 (55.2,64.6)                     | 21.5 (15.1,27.8)               | <0.0001                        |
| Sunitinib       | 429 | 165                           | 38.5 (33.8,43.2)                     |                                |                                |

<div style=\"page-break-after: always\"></div>

Figure: Forest Plot of Objective Response Rate by Subgroup Factors (Confirmed) Based on BICR Assessments per RECIST 1.1 (ITT Population) Database Cutoff Date: 02Jan2019.

<!-- image -->

Analysis (ORR difference and 95% CI) in the overall population is based on the stratified Miettinen and Nurminen method; analysis in the subgroups is based on the unstratified Miettinen &amp; Nurminen method.

Subjects with PD-L1 not evaluable are not included in the subgroup analysis.

Database Cutoff Date: 02Jan2019.

## Additonal subgroup analysis

## RCC with sarcomatoid features:

## Figure:Kaplan-Meier Estimates of Overall Survival Subjects with Sarcomatoid Feature (ITT Population)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure Kaplan-Meier Estimates of Progression-Free Survival (Primary Censoring Rule) Based on BICR Assessment per RECIST 1.1 Subjects with Sarcomatoid Feature (ITT Population)

<!-- image -->

## Recurrent vs. newly diagnosed RCC

For OS, the HRs (95% CIs) are 0.43 (0.26, 0.73) and 0.65 (0.42, 0.99) for the subgroups with recurrent and newly diagnosed disease, respectively. For PFS, the HRs (95% CIs) are 0.74 (0.55, 0.99) and 0.66 (0.50, 0.87) for these same subgroups. These results indicate a comparable treatment effect in OS and PFS in both subgroups.

Figure: Kaplan-Meier Estimates of Overall Survival Subjects with Recurrent (left) and Newly Diagnosed Stage IV /right  RCC

(ITT Population)

<!-- image -->

Subsequent Anticancer Treatments for RCC in Subjects who Discontinued Treatment due to AEs

<div style=\"page-break-after: always\"></div>

As of the data cutoff of 02 JAN 2019, 65 / 429 (15.2%) participants from the pembrolizumab plus axitinib arm and 61 / 425 (14.4%) participants from the sunitinib arm had discontinued study treatment(s) completely due to adverse events (AEs). Subsequent anticancer treatment in these subjects is described in the tables below:

Table 1 Subsequent Systemic Anti-Cancer Treatment (ITT Population) (SubjectsWho Discontinued Study Treatment Due to AE)

|                                                                                            | Pembrolizumab +Axitinib (N=65)   | Sunitinib (N=61)   | Tota1 (N=126)   |
|--------------------------------------------------------------------------------------------|----------------------------------|--------------------|-----------------|
| DiscontinuedStudyTreatmentDue toAEs                                                        | 65 (100.0)                       | 61 (100.0)         | 126 (100.0)     |
| DiscontinuedStudyTreatmentDue toAEsandReceived Any Subsequent Systemic Anti-cancer Therapy | 24 (36.9)                        | 30 (49.2)          | 54 (42.9)       |
| Subsequentsystemic therapyby type                                                          |                                  |                    |                 |
| Any PD1/PD-L1 checkpoint inhibitor                                                         | 3 (4.6)                          | 21 (34.4)          | 24 (19.0)       |
| nivolumab                                                                                  | 3 (4.6)                          | 21 (34.4)          | 24 (19.0)       |
| pembrolizumab                                                                              | 0 (0.0)                          | 1 (1.6)            | 1 (0.8)         |
| AnyVEGF/VEGFRinhibitor                                                                     | 19 (29.2)                        | 18 (29.5)          | 37 (29.4)       |
| axitinib                                                                                   | 4 (6.2)                          | 5 (8.2)            | 9 (7.1)         |
| bevacizumab                                                                                | 0 (0.0)                          | 1 (1.6)            | 1 (0.8)         |
| cabazantinib                                                                               | 5 (7.7)                          | 2 (3.3)            | 7 (5.6)         |
| lenvatinib                                                                                 | 0 (0.0)                          | 1 (1.6)            | 1 (0.8)         |
| pazopanib                                                                                  | 5 (7.7)                          | 5 (8.2)            | 10 (7.9)        |
| sunitinib                                                                                  | 9 (13.8)                         | 6 (9.8)            | 15 (11.9)       |
| Other                                                                                      | 7 (10.8)                         | 2 (3.3)            | 9 (7.1)         |
| doxorubicin                                                                                | 1 (1.5)                          | 0 (0.0)            | 1 (0.8)         |
| everolimus                                                                                 | 6 (9.2)                          | 2 (3.3)            | 8 (6.3)         |
| glutaminase inhibitor (unspecified)                                                        | 1 (1.5)                          | 0 (0.0)            | 1 (0.8)         |
| interferon (unspecified)                                                                   | 1 (1.5)                          | 0 (0.0)            | 1 (0.8)         |
| vinblastine                                                                                | 1 (1.5)                          | 0 (0.0)            | 1 (0.8)         |
| Subsequentsystemictherapybynumberoflines                                                   |                                  |                    |                 |
| 1 subsequent line                                                                          | 24 (36.9)                        | 28 (45.9)          | 52 (41.3)       |
| 2 subsequentlines                                                                          | 7 (10.8)                         | 10 (16.4)          | 17 (13.5)       |
| ≥3subsequent lines                                                                         | 2 (3.1)                          | 2 (3.3)            | 4 (3.2)         |

Every subjectis counted asingle time for each applicable specific anti-cancertreatment.

A subject with multiple anti-cancertreatments within a therapy category is counted a single time for that category.

Database CutoffDate:02Jan2019.

<div style=\"page-break-after: always\"></div>

Table 2 Summary of TreatmentDuration of thefirst subsequent anti-cancer therapy (ASaT Population)

(SubjectsWhoDiscontinuedStudyTreatmentDuetoAE)

|                                                       | Pembrolizumab+Axitinib N =65   | Sunitimib N =61   |
|-------------------------------------------------------|--------------------------------|-------------------|
| Subjects with first subsequentanti-cancertherapy (2L) | 24                             | 28*               |
| TreatmentDuration(days)                               |                                |                   |
| Mean                                                  | 183.3                          | 137.7             |
| SD                                                    | 145.58                         | 138.83            |
| Median                                                | 102.5                          | 74.0              |
| Range                                                 | 13 to 535                      | 2 to 551          |

*Twoparticipants whohadsubsequent sunitinib afterhavingdiscontinued sunitinibasstudy treatmentcould not be included dueto data entry didn't indicate this as2L therapy.

DatabaseCutoffDate:02Jan2019.

Treatment duration= last dose date(or data cutoff date if still ongoing)-first dose date+1

Table3 Reason for Discontinuation of the first Subsequent Anti-cancer Therapy (2L) (Subjects WhoDiscontinued Study Treatment Due to AE)

|                                                    | Pembrolizumab + Axitinib N =65   | Sunitinib N =61               |
|----------------------------------------------------|----------------------------------|-------------------------------|
| Subjectswithfirst subsequentanti-cancertherapy(2L) | 24                               | 28                            |
| Discontinued                                       |                                  |                               |
| Death                                              | 0                                | 1                             |
| Progression OfDisease                              | 5                                | 6                             |
| Toxicity                                           | 4                                | 10                            |
| Unknown                                            | 1                                | 0                             |
| Treatment Ongoing                                  | 14                               | 11                            |
| DatabaseCutoffDate:02Jan2019.                      | DatabaseCutoffDate:02Jan2019.    | DatabaseCutoffDate:02Jan2019. |

Of the 41 participants in the pembrolizumab + axitinib group who discontinued study treatment(s) due to an AE and received no further anti-cancer treatments, 24 participants were still alive and 17 participants had died; of the 31 participants from the sunitinib group who discontinued study treatment(s) due to an AE and received no further anti-cancer treatments, 13 participants were still alive and 18 participants had died.

## Summary of main study(ies)

The  following  tables  summarise  the  efficacy  results  from  the  main  studies  supporting  the  present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 1. Summary of Efficacy for trial KEYNOTE-426

| Title: A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC)   | Title: A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC)   | Title: A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC)   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                | KEYNOTE-426 EudraCT NUMBER: 2016-000588-17                                                                                                                                                                                                                      | KEYNOTE-426 EudraCT NUMBER: 2016-000588-17                                                                                                                                                                                                                      |
| Design                                                                                                                                                                                                                                                          | Phase III randomized (1:1), open-label, multicenter, global trial of pembrolizumab in combination with axitinib versus sunitinib monotherapy as a first-line treatment for advanced/metastatic renal cell carcinoma (mRCC).                                     | Phase III randomized (1:1), open-label, multicenter, global trial of pembrolizumab in combination with axitinib versus sunitinib monotherapy as a first-line treatment for advanced/metastatic renal cell carcinoma (mRCC).                                     |
| Design                                                                                                                                                                                                                                                          | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                  | Enrolment started on 24-OCT-2016; study ongoing not applicable not applicable                                                                                                                                                                                   |
| Hypothesis                                                                                                                                                                                                                                                      | Superiority                                                                                                                                                                                                                                                     | Superiority                                                                                                                                                                                                                                                     |
| Treatments groups                                                                                                                                                                                                                                               | Pembrolizumab + Axitinib                                                                                                                                                                                                                                        | Pembrolizumab 200 mg every 3 weeks (Q3W) up to 35 doses or until PD in combination with Axitinib 5 mg twice daily (BID) until PD. 432 subjects randomized                                                                                                       |
| Treatments groups                                                                                                                                                                                                                                               | Sunitinib                                                                                                                                                                                                                                                       | Sunitinib 50 mg QD 4 weeks on, 2 weeks off until PD 429 subjects randomized                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| Endpoints and definitions                                                                                           | Co-Primary endpoint                                                                                                                              | Co-Primary endpoint                                                                                                                              | Overall Survival (OS)                                                                                                                            | Time from randomization to death due to any cause                                                                                                | Time from randomization to death due to any cause                                                                                                | Time from randomization to death due to any cause                                                                                                | Time from randomization to death due to any cause                                                                                                | Time from randomization to death due to any cause                                                                                                | Time from randomization to death due to any cause                                                                                                | Time from randomization to death due to any cause                                                                                                | Time from randomization to death due to any cause                                                                                                | Time from randomization to death due to any cause                                                                                                | Time from randomization to death due to any cause                                                                                                | Time from randomization to death due to any cause                                                                                                | Time from randomization to death due to any cause                                                                                                | Time from randomization to death due to any cause                                                                                                | Time from randomization to death due to any cause                                                                                                |                                                                                                                                                  |
|---------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|
| Endpoints and definitions                                                                                           | Co-Primary endpoint ree                                                                                                                          | Co-Primary endpoint ree                                                                                                                          | Progression-F Survival (PFS)                                                                                                                     | Time from randomization to first PD (per RECIST 1.1 based on BICR) or death due to any cause, whichever occur first.                             | Time from randomization to first PD (per RECIST 1.1 based on BICR) or death due to any cause, whichever occur first.                             | Time from randomization to first PD (per RECIST 1.1 based on BICR) or death due to any cause, whichever occur first.                             | Time from randomization to first PD (per RECIST 1.1 based on BICR) or death due to any cause, whichever occur first.                             | Time from randomization to first PD (per RECIST 1.1 based on BICR) or death due to any cause, whichever occur first.                             | Time from randomization to first PD (per RECIST 1.1 based on BICR) or death due to any cause, whichever occur first.                             | Time from randomization to first PD (per RECIST 1.1 based on BICR) or death due to any cause, whichever occur first.                             | Time from randomization to first PD (per RECIST 1.1 based on BICR) or death due to any cause, whichever occur first.                             | Time from randomization to first PD (per RECIST 1.1 based on BICR) or death due to any cause, whichever occur first.                             | Time from randomization to first PD (per RECIST 1.1 based on BICR) or death due to any cause, whichever occur first.                             | Time from randomization to first PD (per RECIST 1.1 based on BICR) or death due to any cause, whichever occur first.                             | Time from randomization to first PD (per RECIST 1.1 based on BICR) or death due to any cause, whichever occur first.                             | Time from randomization to first PD (per RECIST 1.1 based on BICR) or death due to any cause, whichever occur first.                             | Time from randomization to first PD (per RECIST 1.1 based on BICR) or death due to any cause, whichever occur first.                             |                                                                                                                                                  |
| Endpoints and definitions                                                                                           | Secondary endpoint                                                                                                                               | Secondary endpoint                                                                                                                               | Objective Response rate (ORR)                                                                                                                    | Proportion of subjects in the analysis population with a CR or PR, based on blinded independent radiologists' assessment per RECIST              | Proportion of subjects in the analysis population with a CR or PR, based on blinded independent radiologists' assessment per RECIST              | Proportion of subjects in the analysis population with a CR or PR, based on blinded independent radiologists' assessment per RECIST              | Proportion of subjects in the analysis population with a CR or PR, based on blinded independent radiologists' assessment per RECIST              | Proportion of subjects in the analysis population with a CR or PR, based on blinded independent radiologists' assessment per RECIST              | Proportion of subjects in the analysis population with a CR or PR, based on blinded independent radiologists' assessment per RECIST              | Proportion of subjects in the analysis population with a CR or PR, based on blinded independent radiologists' assessment per RECIST              | Proportion of subjects in the analysis population with a CR or PR, based on blinded independent radiologists' assessment per RECIST              | Proportion of subjects in the analysis population with a CR or PR, based on blinded independent radiologists' assessment per RECIST              | Proportion of subjects in the analysis population with a CR or PR, based on blinded independent radiologists' assessment per RECIST              | Proportion of subjects in the analysis population with a CR or PR, based on blinded independent radiologists' assessment per RECIST              | Proportion of subjects in the analysis population with a CR or PR, based on blinded independent radiologists' assessment per RECIST              | Proportion of subjects in the analysis population with a CR or PR, based on blinded independent radiologists' assessment per RECIST              | Proportion of subjects in the analysis population with a CR or PR, based on blinded independent radiologists' assessment per RECIST              |                                                                                                                                                  |
| Endpoints and definitions                                                                                           | Secondary endpoint                                                                                                                               | Secondary endpoint                                                                                                                               | Duration of Response (DoR)                                                                                                                       | Duration of Response (DoR)                                                                                                                       | 1.1. Time from first documented evidence of CR or PR until disease progression or death, whichever occur first.                                  | 1.1. Time from first documented evidence of CR or PR until disease progression or death, whichever occur first.                                  | 1.1. Time from first documented evidence of CR or PR until disease progression or death, whichever occur first.                                  | 1.1. Time from first documented evidence of CR or PR until disease progression or death, whichever occur first.                                  | 1.1. Time from first documented evidence of CR or PR until disease progression or death, whichever occur first.                                  | 1.1. Time from first documented evidence of CR or PR until disease progression or death, whichever occur first.                                  | 1.1. Time from first documented evidence of CR or PR until disease progression or death, whichever occur first.                                  | 1.1. Time from first documented evidence of CR or PR until disease progression or death, whichever occur first.                                  | 1.1. Time from first documented evidence of CR or PR until disease progression or death, whichever occur first.                                  | 1.1. Time from first documented evidence of CR or PR until disease progression or death, whichever occur first.                                  | 1.1. Time from first documented evidence of CR or PR until disease progression or death, whichever occur first.                                  | 1.1. Time from first documented evidence of CR or PR until disease progression or death, whichever occur first.                                  | 1.1. Time from first documented evidence of CR or PR until disease progression or death, whichever occur first.                                  |                                                                                                                                                  |
| Endpoints and definitions                                                                                           | Secondary endpoint                                                                                                                               | Secondary endpoint                                                                                                                               | Disease Control Rate (DCR)                                                                                                                       | Percentage of subjects who have achieved CR, PR or SD of ≥ 6 months based on blinded independent radiologists' assessment per RECIST             | Percentage of subjects who have achieved CR, PR or SD of ≥ 6 months based on blinded independent radiologists' assessment per RECIST             | Percentage of subjects who have achieved CR, PR or SD of ≥ 6 months based on blinded independent radiologists' assessment per RECIST             | Percentage of subjects who have achieved CR, PR or SD of ≥ 6 months based on blinded independent radiologists' assessment per RECIST             | Percentage of subjects who have achieved CR, PR or SD of ≥ 6 months based on blinded independent radiologists' assessment per RECIST             | Percentage of subjects who have achieved CR, PR or SD of ≥ 6 months based on blinded independent radiologists' assessment per RECIST             | Percentage of subjects who have achieved CR, PR or SD of ≥ 6 months based on blinded independent radiologists' assessment per RECIST             | Percentage of subjects who have achieved CR, PR or SD of ≥ 6 months based on blinded independent radiologists' assessment per RECIST             | Percentage of subjects who have achieved CR, PR or SD of ≥ 6 months based on blinded independent radiologists' assessment per RECIST             | Percentage of subjects who have achieved CR, PR or SD of ≥ 6 months based on blinded independent radiologists' assessment per RECIST             | Percentage of subjects who have achieved CR, PR or SD of ≥ 6 months based on blinded independent radiologists' assessment per RECIST             | Percentage of subjects who have achieved CR, PR or SD of ≥ 6 months based on blinded independent radiologists' assessment per RECIST             | Percentage of subjects who have achieved CR, PR or SD of ≥ 6 months based on blinded independent radiologists' assessment per RECIST             | Percentage of subjects who have achieved CR, PR or SD of ≥ 6 months based on blinded independent radiologists' assessment per RECIST             |                                                                                                                                                  |
| Database lock                                                                                                       | 1.1.. 24 August 2018                                                                                                                             | 1.1.. 24 August 2018                                                                                                                             | 1.1.. 24 August 2018                                                                                                                             | 1.1.. 24 August 2018                                                                                                                             | 1.1.. 24 August 2018                                                                                                                             | 1.1.. 24 August 2018                                                                                                                             | 1.1.. 24 August 2018                                                                                                                             | 1.1.. 24 August 2018                                                                                                                             | 1.1.. 24 August 2018                                                                                                                             | 1.1.. 24 August 2018                                                                                                                             | 1.1.. 24 August 2018                                                                                                                             | 1.1.. 24 August 2018                                                                                                                             | 1.1.. 24 August 2018                                                                                                                             | 1.1.. 24 August 2018                                                                                                                             | 1.1.. 24 August 2018                                                                                                                             | 1.1.. 24 August 2018                                                                                                                             | 1.1.. 24 August 2018                                                                                                                             | 1.1.. 24 August 2018                                                                                                                             |
| Results and Analysis                                                                                                | Results and Analysis                                                                                                                             | Results and Analysis                                                                                                                             | Results and Analysis                                                                                                                             | Results and Analysis                                                                                                                             | Results and Analysis                                                                                                                             | Results and Analysis                                                                                                                             | Results and Analysis                                                                                                                             | Results and Analysis                                                                                                                             | Results and Analysis                                                                                                                             | Results and Analysis                                                                                                                             | Results and Analysis                                                                                                                             | Results and Analysis                                                                                                                             | Results and Analysis                                                                                                                             | Results and Analysis                                                                                                                             | Results and Analysis                                                                                                                             | Results and Analysis                                                                                                                             | Results and Analysis                                                                                                                             | Results and Analysis                                                                                                                             |
| Analysis description Analysis population and time point description Descriptive statistics and estimate variability | Primary Analysis (Interim Analysis 1)                                                                                                            | Primary Analysis (Interim Analysis 1)                                                                                                            | Primary Analysis (Interim Analysis 1)                                                                                                            | Primary Analysis (Interim Analysis 1)                                                                                                            | Primary Analysis (Interim Analysis 1)                                                                                                            | Primary Analysis (Interim Analysis 1)                                                                                                            | Primary Analysis (Interim Analysis 1)                                                                                                            | Primary Analysis (Interim Analysis 1)                                                                                                            | Primary Analysis (Interim Analysis 1)                                                                                                            | Primary Analysis (Interim Analysis 1)                                                                                                            | Primary Analysis (Interim Analysis 1)                                                                                                            | Primary Analysis (Interim Analysis 1)                                                                                                            | Primary Analysis (Interim Analysis 1)                                                                                                            | Primary Analysis (Interim Analysis 1)                                                                                                            | Primary Analysis (Interim Analysis 1)                                                                                                            | Primary Analysis (Interim Analysis 1)                                                                                                            | Primary Analysis (Interim Analysis 1)                                                                                                            | Primary Analysis (Interim Analysis 1)                                                                                                            |
|                                                                                                                     | Intent to treat Median follow-up 12.8 months                                                                                                     | Intent to treat Median follow-up 12.8 months                                                                                                     | Intent to treat Median follow-up 12.8 months                                                                                                     | Intent to treat Median follow-up 12.8 months                                                                                                     | Intent to treat Median follow-up 12.8 months                                                                                                     | Intent to treat Median follow-up 12.8 months                                                                                                     | Intent to treat Median follow-up 12.8 months                                                                                                     | Intent to treat Median follow-up 12.8 months                                                                                                     | Intent to treat Median follow-up 12.8 months                                                                                                     | Intent to treat Median follow-up 12.8 months                                                                                                     | Intent to treat Median follow-up 12.8 months                                                                                                     | Intent to treat Median follow-up 12.8 months                                                                                                     | Intent to treat Median follow-up 12.8 months                                                                                                     | Intent to treat Median follow-up 12.8 months                                                                                                     | Intent to treat Median follow-up 12.8 months                                                                                                     | Intent to treat Median follow-up 12.8 months                                                                                                     | Intent to treat Median follow-up 12.8 months                                                                                                     | Intent to treat Median follow-up 12.8 months                                                                                                     |
|                                                                                                                     | Treatment group Pembrolizumab + Axitinib Sunitinib                                                                                               | Treatment group Pembrolizumab + Axitinib Sunitinib                                                                                               | Treatment group Pembrolizumab + Axitinib Sunitinib                                                                                               | Treatment group Pembrolizumab + Axitinib Sunitinib                                                                                               | Treatment group Pembrolizumab + Axitinib Sunitinib                                                                                               | Treatment group Pembrolizumab + Axitinib Sunitinib                                                                                               | Treatment group Pembrolizumab + Axitinib Sunitinib                                                                                               | Treatment group Pembrolizumab + Axitinib Sunitinib                                                                                               | Treatment group Pembrolizumab + Axitinib Sunitinib                                                                                               | Treatment group Pembrolizumab + Axitinib Sunitinib                                                                                               | Treatment group Pembrolizumab + Axitinib Sunitinib                                                                                               | Treatment group Pembrolizumab + Axitinib Sunitinib                                                                                               | Treatment group Pembrolizumab + Axitinib Sunitinib                                                                                               | Treatment group Pembrolizumab + Axitinib Sunitinib                                                                                               | Treatment group Pembrolizumab + Axitinib Sunitinib                                                                                               | Treatment group Pembrolizumab + Axitinib Sunitinib                                                                                               | Treatment group Pembrolizumab + Axitinib Sunitinib                                                                                               | Treatment group Pembrolizumab + Axitinib Sunitinib                                                                                               |
|                                                                                                                     | Number of subject 432 429 OS N. with events 59 (13.7) 97 (22.6)                                                                                  | Number of subject 432 429 OS N. with events 59 (13.7) 97 (22.6)                                                                                  | Number of subject 432 429 OS N. with events 59 (13.7) 97 (22.6)                                                                                  | Number of subject 432 429 OS N. with events 59 (13.7) 97 (22.6)                                                                                  | Number of subject 432 429 OS N. with events 59 (13.7) 97 (22.6)                                                                                  | Number of subject 432 429 OS N. with events 59 (13.7) 97 (22.6)                                                                                  | Number of subject 432 429 OS N. with events 59 (13.7) 97 (22.6)                                                                                  | Number of subject 432 429 OS N. with events 59 (13.7) 97 (22.6)                                                                                  | Number of subject 432 429 OS N. with events 59 (13.7) 97 (22.6)                                                                                  | Number of subject 432 429 OS N. with events 59 (13.7) 97 (22.6)                                                                                  | Number of subject 432 429 OS N. with events 59 (13.7) 97 (22.6)                                                                                  | Number of subject 432 429 OS N. with events 59 (13.7) 97 (22.6)                                                                                  | Number of subject 432 429 OS N. with events 59 (13.7) 97 (22.6)                                                                                  | Number of subject 432 429 OS N. with events 59 (13.7) 97 (22.6)                                                                                  | Number of subject 432 429 OS N. with events 59 (13.7) 97 (22.6)                                                                                  | Number of subject 432 429 OS N. with events 59 (13.7) 97 (22.6)                                                                                  | Number of subject 432 429 OS N. with events 59 (13.7) 97 (22.6)                                                                                  | Number of subject 432 429 OS N. with events 59 (13.7) 97 (22.6)                                                                                  |
|                                                                                                                     | n (%) Median OS months (95% CI) NR (.., ..) NR (.., ..)                                                                                          | n (%) Median OS months (95% CI) NR (.., ..) NR (.., ..)                                                                                          | n (%) Median OS months (95% CI) NR (.., ..) NR (.., ..)                                                                                          | n (%) Median OS months (95% CI) NR (.., ..) NR (.., ..)                                                                                          | n (%) Median OS months (95% CI) NR (.., ..) NR (.., ..)                                                                                          | n (%) Median OS months (95% CI) NR (.., ..) NR (.., ..)                                                                                          | n (%) Median OS months (95% CI) NR (.., ..) NR (.., ..)                                                                                          | n (%) Median OS months (95% CI) NR (.., ..) NR (.., ..)                                                                                          | n (%) Median OS months (95% CI) NR (.., ..) NR (.., ..)                                                                                          | n (%) Median OS months (95% CI) NR (.., ..) NR (.., ..)                                                                                          | n (%) Median OS months (95% CI) NR (.., ..) NR (.., ..)                                                                                          | n (%) Median OS months (95% CI) NR (.., ..) NR (.., ..)                                                                                          | n (%) Median OS months (95% CI) NR (.., ..) NR (.., ..)                                                                                          | n (%) Median OS months (95% CI) NR (.., ..) NR (.., ..)                                                                                          | n (%) Median OS months (95% CI) NR (.., ..) NR (.., ..)                                                                                          | n (%) Median OS months (95% CI) NR (.., ..) NR (.., ..)                                                                                          | n (%) Median OS months (95% CI) NR (.., ..) NR (.., ..)                                                                                          | n (%) Median OS months (95% CI) NR (.., ..) NR (.., ..)                                                                                          |
|                                                                                                                     | PFS N. with events n (%) 183 (42.4) 213 (50) Median PFS 15.1 11.0 (8.7, 12.5)                                                                    | PFS N. with events n (%) 183 (42.4) 213 (50) Median PFS 15.1 11.0 (8.7, 12.5)                                                                    | PFS N. with events n (%) 183 (42.4) 213 (50) Median PFS 15.1 11.0 (8.7, 12.5)                                                                    | PFS N. with events n (%) 183 (42.4) 213 (50) Median PFS 15.1 11.0 (8.7, 12.5)                                                                    | PFS N. with events n (%) 183 (42.4) 213 (50) Median PFS 15.1 11.0 (8.7, 12.5)                                                                    | PFS N. with events n (%) 183 (42.4) 213 (50) Median PFS 15.1 11.0 (8.7, 12.5)                                                                    | PFS N. with events n (%) 183 (42.4) 213 (50) Median PFS 15.1 11.0 (8.7, 12.5)                                                                    | PFS N. with events n (%) 183 (42.4) 213 (50) Median PFS 15.1 11.0 (8.7, 12.5)                                                                    | PFS N. with events n (%) 183 (42.4) 213 (50) Median PFS 15.1 11.0 (8.7, 12.5)                                                                    | PFS N. with events n (%) 183 (42.4) 213 (50) Median PFS 15.1 11.0 (8.7, 12.5)                                                                    | PFS N. with events n (%) 183 (42.4) 213 (50) Median PFS 15.1 11.0 (8.7, 12.5)                                                                    | PFS N. with events n (%) 183 (42.4) 213 (50) Median PFS 15.1 11.0 (8.7, 12.5)                                                                    | PFS N. with events n (%) 183 (42.4) 213 (50) Median PFS 15.1 11.0 (8.7, 12.5)                                                                    | PFS N. with events n (%) 183 (42.4) 213 (50) Median PFS 15.1 11.0 (8.7, 12.5)                                                                    | PFS N. with events n (%) 183 (42.4) 213 (50) Median PFS 15.1 11.0 (8.7, 12.5)                                                                    | PFS N. with events n (%) 183 (42.4) 213 (50) Median PFS 15.1 11.0 (8.7, 12.5)                                                                    | PFS N. with events n (%) 183 (42.4) 213 (50) Median PFS 15.1 11.0 (8.7, 12.5)                                                                    | PFS N. with events n (%) 183 (42.4) 213 (50) Median PFS 15.1 11.0 (8.7, 12.5)                                                                    |
| Effect estimate per comparison                                                                                      | OS Comparison groups Pembrolizumab + axitinib vs.                                                                                                | OS Comparison groups Pembrolizumab + axitinib vs.                                                                                                | OS Comparison groups Pembrolizumab + axitinib vs.                                                                                                | OS Comparison groups Pembrolizumab + axitinib vs.                                                                                                | OS Comparison groups Pembrolizumab + axitinib vs.                                                                                                | OS Comparison groups Pembrolizumab + axitinib vs.                                                                                                | OS Comparison groups Pembrolizumab + axitinib vs.                                                                                                | OS Comparison groups Pembrolizumab + axitinib vs.                                                                                                | OS Comparison groups Pembrolizumab + axitinib vs.                                                                                                | OS Comparison groups Pembrolizumab + axitinib vs.                                                                                                | OS Comparison groups Pembrolizumab + axitinib vs.                                                                                                | OS Comparison groups Pembrolizumab + axitinib vs.                                                                                                | OS Comparison groups Pembrolizumab + axitinib vs.                                                                                                | OS Comparison groups Pembrolizumab + axitinib vs.                                                                                                | OS Comparison groups Pembrolizumab + axitinib vs.                                                                                                | OS Comparison groups Pembrolizumab + axitinib vs.                                                                                                | OS Comparison groups Pembrolizumab + axitinib vs.                                                                                                | OS Comparison groups Pembrolizumab + axitinib vs.                                                                                                |
| Effect estimate per comparison                                                                                      | sunitinib HR 0.53 95% CI (0.38, 0.74)                                                                                                            | sunitinib HR 0.53 95% CI (0.38, 0.74)                                                                                                            | sunitinib HR 0.53 95% CI (0.38, 0.74)                                                                                                            | sunitinib HR 0.53 95% CI (0.38, 0.74)                                                                                                            | sunitinib HR 0.53 95% CI (0.38, 0.74)                                                                                                            | sunitinib HR 0.53 95% CI (0.38, 0.74)                                                                                                            | sunitinib HR 0.53 95% CI (0.38, 0.74)                                                                                                            | sunitinib HR 0.53 95% CI (0.38, 0.74)                                                                                                            | sunitinib HR 0.53 95% CI (0.38, 0.74)                                                                                                            | sunitinib HR 0.53 95% CI (0.38, 0.74)                                                                                                            | sunitinib HR 0.53 95% CI (0.38, 0.74)                                                                                                            | sunitinib HR 0.53 95% CI (0.38, 0.74)                                                                                                            | sunitinib HR 0.53 95% CI (0.38, 0.74)                                                                                                            | sunitinib HR 0.53 95% CI (0.38, 0.74)                                                                                                            | sunitinib HR 0.53 95% CI (0.38, 0.74)                                                                                                            | sunitinib HR 0.53 95% CI (0.38, 0.74)                                                                                                            | sunitinib HR 0.53 95% CI (0.38, 0.74)                                                                                                            | sunitinib HR 0.53 95% CI (0.38, 0.74)                                                                                                            |
| Effect estimate per comparison                                                                                      | P-value 0.00005                                                                                                                                  | P-value 0.00005                                                                                                                                  | P-value 0.00005                                                                                                                                  | P-value 0.00005                                                                                                                                  | P-value 0.00005                                                                                                                                  | P-value 0.00005                                                                                                                                  | P-value 0.00005                                                                                                                                  | P-value 0.00005                                                                                                                                  | P-value 0.00005                                                                                                                                  | P-value 0.00005                                                                                                                                  | P-value 0.00005                                                                                                                                  | P-value 0.00005                                                                                                                                  | P-value 0.00005                                                                                                                                  | P-value 0.00005                                                                                                                                  | P-value 0.00005                                                                                                                                  | P-value 0.00005                                                                                                                                  | P-value 0.00005                                                                                                                                  | P-value 0.00005                                                                                                                                  |
| Effect estimate per comparison                                                                                      | PFS Comparison groups Pembrolizumab + axitinib vs.                                                                                               | PFS Comparison groups Pembrolizumab + axitinib vs.                                                                                               | PFS Comparison groups Pembrolizumab + axitinib vs.                                                                                               | PFS Comparison groups Pembrolizumab + axitinib vs.                                                                                               | PFS Comparison groups Pembrolizumab + axitinib vs.                                                                                               | PFS Comparison groups Pembrolizumab + axitinib vs.                                                                                               | PFS Comparison groups Pembrolizumab + axitinib vs.                                                                                               | PFS Comparison groups Pembrolizumab + axitinib vs.                                                                                               | PFS Comparison groups Pembrolizumab + axitinib vs.                                                                                               | PFS Comparison groups Pembrolizumab + axitinib vs.                                                                                               | PFS Comparison groups Pembrolizumab + axitinib vs.                                                                                               | PFS Comparison groups Pembrolizumab + axitinib vs.                                                                                               | PFS Comparison groups Pembrolizumab + axitinib vs.                                                                                               | PFS Comparison groups Pembrolizumab + axitinib vs.                                                                                               | PFS Comparison groups Pembrolizumab + axitinib vs.                                                                                               | PFS Comparison groups Pembrolizumab + axitinib vs.                                                                                               | PFS Comparison groups Pembrolizumab + axitinib vs.                                                                                               | PFS Comparison groups Pembrolizumab + axitinib vs.                                                                                               |
| Effect estimate per comparison                                                                                      | sunitinib HR 0.69 95% CI (0.56, 0.84)                                                                                                            | sunitinib HR 0.69 95% CI (0.56, 0.84)                                                                                                            | sunitinib HR 0.69 95% CI (0.56, 0.84)                                                                                                            | sunitinib HR 0.69 95% CI (0.56, 0.84)                                                                                                            | sunitinib HR 0.69 95% CI (0.56, 0.84)                                                                                                            | sunitinib HR 0.69 95% CI (0.56, 0.84)                                                                                                            | sunitinib HR 0.69 95% CI (0.56, 0.84)                                                                                                            | sunitinib HR 0.69 95% CI (0.56, 0.84)                                                                                                            | sunitinib HR 0.69 95% CI (0.56, 0.84)                                                                                                            | sunitinib HR 0.69 95% CI (0.56, 0.84)                                                                                                            | sunitinib HR 0.69 95% CI (0.56, 0.84)                                                                                                            | sunitinib HR 0.69 95% CI (0.56, 0.84)                                                                                                            | sunitinib HR 0.69 95% CI (0.56, 0.84)                                                                                                            | sunitinib HR 0.69 95% CI (0.56, 0.84)                                                                                                            | sunitinib HR 0.69 95% CI (0.56, 0.84)                                                                                                            | sunitinib HR 0.69 95% CI (0.56, 0.84)                                                                                                            | sunitinib HR 0.69 95% CI (0.56, 0.84)                                                                                                            | sunitinib HR 0.69 95% CI (0.56, 0.84)                                                                                                            |
| Effect estimate per comparison                                                                                      | P-value 0.00012                                                                                                                                  | P-value 0.00012                                                                                                                                  | P-value 0.00012                                                                                                                                  | P-value 0.00012                                                                                                                                  | P-value 0.00012                                                                                                                                  | P-value 0.00012                                                                                                                                  | P-value 0.00012                                                                                                                                  | P-value 0.00012                                                                                                                                  | P-value 0.00012                                                                                                                                  | P-value 0.00012                                                                                                                                  | P-value 0.00012                                                                                                                                  | P-value 0.00012                                                                                                                                  | P-value 0.00012                                                                                                                                  | P-value 0.00012                                                                                                                                  | P-value 0.00012                                                                                                                                  | P-value 0.00012                                                                                                                                  | P-value 0.00012                                                                                                                                  | P-value 0.00012                                                                                                                                  |
| Effect estimate per comparison                                                                                      | ORR Comparison groups Pembrolizumab + axitinib vs. sunitinib Difference in ORR 23.6 95% CI (17.2, 29.9)                                          | ORR Comparison groups Pembrolizumab + axitinib vs. sunitinib Difference in ORR 23.6 95% CI (17.2, 29.9)                                          | ORR Comparison groups Pembrolizumab + axitinib vs. sunitinib Difference in ORR 23.6 95% CI (17.2, 29.9)                                          | ORR Comparison groups Pembrolizumab + axitinib vs. sunitinib Difference in ORR 23.6 95% CI (17.2, 29.9)                                          | ORR Comparison groups Pembrolizumab + axitinib vs. sunitinib Difference in ORR 23.6 95% CI (17.2, 29.9)                                          | ORR Comparison groups Pembrolizumab + axitinib vs. sunitinib Difference in ORR 23.6 95% CI (17.2, 29.9)                                          | ORR Comparison groups Pembrolizumab + axitinib vs. sunitinib Difference in ORR 23.6 95% CI (17.2, 29.9)                                          | ORR Comparison groups Pembrolizumab + axitinib vs. sunitinib Difference in ORR 23.6 95% CI (17.2, 29.9)                                          | ORR Comparison groups Pembrolizumab + axitinib vs. sunitinib Difference in ORR 23.6 95% CI (17.2, 29.9)                                          | ORR Comparison groups Pembrolizumab + axitinib vs. sunitinib Difference in ORR 23.6 95% CI (17.2, 29.9)                                          | ORR Comparison groups Pembrolizumab + axitinib vs. sunitinib Difference in ORR 23.6 95% CI (17.2, 29.9)                                          | ORR Comparison groups Pembrolizumab + axitinib vs. sunitinib Difference in ORR 23.6 95% CI (17.2, 29.9)                                          | ORR Comparison groups Pembrolizumab + axitinib vs. sunitinib Difference in ORR 23.6 95% CI (17.2, 29.9)                                          | ORR Comparison groups Pembrolizumab + axitinib vs. sunitinib Difference in ORR 23.6 95% CI (17.2, 29.9)                                          | ORR Comparison groups Pembrolizumab + axitinib vs. sunitinib Difference in ORR 23.6 95% CI (17.2, 29.9)                                          | ORR Comparison groups Pembrolizumab + axitinib vs. sunitinib Difference in ORR 23.6 95% CI (17.2, 29.9)                                          | ORR Comparison groups Pembrolizumab + axitinib vs. sunitinib Difference in ORR 23.6 95% CI (17.2, 29.9)                                          | ORR Comparison groups Pembrolizumab + axitinib vs. sunitinib Difference in ORR 23.6 95% CI (17.2, 29.9)                                          |
| Effect estimate per comparison                                                                                      | P-value <0.0001 The analysis indicates a statistical significant superiority of pembrolizumab + axitinib vs sunitinib with regard to OS and PFS. | P-value <0.0001 The analysis indicates a statistical significant superiority of pembrolizumab + axitinib vs sunitinib with regard to OS and PFS. | P-value <0.0001 The analysis indicates a statistical significant superiority of pembrolizumab + axitinib vs sunitinib with regard to OS and PFS. | P-value <0.0001 The analysis indicates a statistical significant superiority of pembrolizumab + axitinib vs sunitinib with regard to OS and PFS. | P-value <0.0001 The analysis indicates a statistical significant superiority of pembrolizumab + axitinib vs sunitinib with regard to OS and PFS. | P-value <0.0001 The analysis indicates a statistical significant superiority of pembrolizumab + axitinib vs sunitinib with regard to OS and PFS. | P-value <0.0001 The analysis indicates a statistical significant superiority of pembrolizumab + axitinib vs sunitinib with regard to OS and PFS. | P-value <0.0001 The analysis indicates a statistical significant superiority of pembrolizumab + axitinib vs sunitinib with regard to OS and PFS. | P-value <0.0001 The analysis indicates a statistical significant superiority of pembrolizumab + axitinib vs sunitinib with regard to OS and PFS. | P-value <0.0001 The analysis indicates a statistical significant superiority of pembrolizumab + axitinib vs sunitinib with regard to OS and PFS. | P-value <0.0001 The analysis indicates a statistical significant superiority of pembrolizumab + axitinib vs sunitinib with regard to OS and PFS. | P-value <0.0001 The analysis indicates a statistical significant superiority of pembrolizumab + axitinib vs sunitinib with regard to OS and PFS. | P-value <0.0001 The analysis indicates a statistical significant superiority of pembrolizumab + axitinib vs sunitinib with regard to OS and PFS. | P-value <0.0001 The analysis indicates a statistical significant superiority of pembrolizumab + axitinib vs sunitinib with regard to OS and PFS. | P-value <0.0001 The analysis indicates a statistical significant superiority of pembrolizumab + axitinib vs sunitinib with regard to OS and PFS. | P-value <0.0001 The analysis indicates a statistical significant superiority of pembrolizumab + axitinib vs sunitinib with regard to OS and PFS. | P-value <0.0001 The analysis indicates a statistical significant superiority of pembrolizumab + axitinib vs sunitinib with regard to OS and PFS. | P-value <0.0001 The analysis indicates a statistical significant superiority of pembrolizumab + axitinib vs sunitinib with regard to OS and PFS. |
| Effect estimate per comparison                                                                                      | Secondary analysis                                                                                                                               | Secondary analysis                                                                                                                               | Secondary analysis                                                                                                                               | Secondary analysis                                                                                                                               | Secondary analysis                                                                                                                               | Secondary analysis                                                                                                                               | Secondary analysis                                                                                                                               | Secondary analysis                                                                                                                               | Secondary analysis                                                                                                                               | Secondary analysis                                                                                                                               | Secondary analysis                                                                                                                               | Secondary analysis                                                                                                                               | Secondary analysis                                                                                                                               | Secondary analysis                                                                                                                               | Secondary analysis                                                                                                                               | Secondary analysis                                                                                                                               | Secondary analysis                                                                                                                               | Secondary analysis                                                                                                                               |
| Effect estimate per comparison                                                                                      | Intent to treat                                                                                                                                  | Intent to treat                                                                                                                                  | Intent to treat                                                                                                                                  | Intent to treat                                                                                                                                  | Intent to treat                                                                                                                                  | Intent to treat                                                                                                                                  | Intent to treat                                                                                                                                  | Intent to treat                                                                                                                                  | Intent to treat                                                                                                                                  | Intent to treat                                                                                                                                  | Intent to treat                                                                                                                                  | Intent to treat                                                                                                                                  | Intent to treat                                                                                                                                  | Intent to treat                                                                                                                                  | Intent to treat                                                                                                                                  | Intent to treat                                                                                                                                  | Intent to treat                                                                                                                                  | Intent to treat                                                                                                                                  |
| Analysis population and time point description Descriptive statistics and estimate variability                      | Treatment                                                                                                                                        |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |
| Effect estimate per comparison                                                                                      | ORR,%                                                                                                                                            |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |
|                                                                                                                     |                                                                                                                                                  | (n = 432) 59.3 % 35.7 % (54.5, 63.9) (31.1, 40.4)                                                                                                | (n = 432) 59.3 % 35.7 % (54.5, 63.9) (31.1, 40.4)                                                                                                | (n = 432) 59.3 % 35.7 % (54.5, 63.9) (31.1, 40.4)                                                                                                | (n = 432) 59.3 % 35.7 % (54.5, 63.9) (31.1, 40.4)                                                                                                | (n = 432) 59.3 % 35.7 % (54.5, 63.9) (31.1, 40.4)                                                                                                | (n = 432) 59.3 % 35.7 % (54.5, 63.9) (31.1, 40.4)                                                                                                | (n = 432) 59.3 % 35.7 % (54.5, 63.9) (31.1, 40.4)                                                                                                | (n = 432) 59.3 % 35.7 % (54.5, 63.9) (31.1, 40.4)                                                                                                | (n = 432) 59.3 % 35.7 % (54.5, 63.9) (31.1, 40.4)                                                                                                | (n = 432) 59.3 % 35.7 % (54.5, 63.9) (31.1, 40.4)                                                                                                | (n = 432) 59.3 % 35.7 % (54.5, 63.9) (31.1, 40.4)                                                                                                | (n = 432) 59.3 % 35.7 % (54.5, 63.9) (31.1, 40.4)                                                                                                | (n = 432) 59.3 % 35.7 % (54.5, 63.9) (31.1, 40.4)                                                                                                | (n = 432) 59.3 % 35.7 % (54.5, 63.9) (31.1, 40.4)                                                                                                | (n = 432) 59.3 % 35.7 % (54.5, 63.9) (31.1, 40.4)                                                                                                | (n = 432) 59.3 % 35.7 % (54.5, 63.9) (31.1, 40.4)                                                                                                | (n = 432) 59.3 % 35.7 % (54.5, 63.9) (31.1, 40.4)                                                                                                |
|                                                                                                                     | %                                                                                                                                                | +Axitinib (n = 429)                                                                                                                              | +Axitinib (n = 429)                                                                                                                              | +Axitinib (n = 429)                                                                                                                              | +Axitinib (n = 429)                                                                                                                              | +Axitinib (n = 429)                                                                                                                              | +Axitinib (n = 429)                                                                                                                              | +Axitinib (n = 429)                                                                                                                              | +Axitinib (n = 429)                                                                                                                              | +Axitinib (n = 429)                                                                                                                              | +Axitinib (n = 429)                                                                                                                              | +Axitinib (n = 429)                                                                                                                              | +Axitinib (n = 429)                                                                                                                              | +Axitinib (n = 429)                                                                                                                              | +Axitinib (n = 429)                                                                                                                              | +Axitinib (n = 429)                                                                                                                              | +Axitinib (n = 429)                                                                                                                              | +Axitinib (n = 429)                                                                                                                              |
|                                                                                                                     |                                                                                                                                                  | Pembrolizumab Sunitinib                                                                                                                          | Pembrolizumab Sunitinib                                                                                                                          | Pembrolizumab Sunitinib                                                                                                                          | Pembrolizumab Sunitinib                                                                                                                          | Pembrolizumab Sunitinib                                                                                                                          | Pembrolizumab Sunitinib                                                                                                                          | Pembrolizumab Sunitinib                                                                                                                          | Pembrolizumab Sunitinib                                                                                                                          | Pembrolizumab Sunitinib                                                                                                                          | Pembrolizumab Sunitinib                                                                                                                          | Pembrolizumab Sunitinib                                                                                                                          | Pembrolizumab Sunitinib                                                                                                                          | Pembrolizumab Sunitinib                                                                                                                          | Pembrolizumab Sunitinib                                                                                                                          | Pembrolizumab Sunitinib                                                                                                                          | Pembrolizumab Sunitinib                                                                                                                          | Pembrolizumab Sunitinib                                                                                                                          |
|                                                                                                                     | group                                                                                                                                            |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |
|                                                                                                                     | 95%-CI,                                                                                                                                          |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

|                                | DCR                                                                                                                                                     | 71.5 %                                                                                                                                                  | 60.6 %                                                                                                                                                  |
|--------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                | 95%-CI, %                                                                                                                                               | (67.9, 75.7)                                                                                                                                            | (55.8, 65.3)                                                                                                                                            |
|                                | DOR (Median (months))                                                                                                                                   | Not reached                                                                                                                                             | 15.2                                                                                                                                                    |
|                                | 95%-CI                                                                                                                                                  | (1.4+, 18.2+)                                                                                                                                           | (1.1+, 15.4+)                                                                                                                                           |
| Effect estimate per comparison | ORR                                                                                                                                                     | Comparison groups                                                                                                                                       | Pembrolizumab + Axitinib vs. Sunitinib                                                                                                                  |
|                                |                                                                                                                                                         | Difference                                                                                                                                              | 23.6 %                                                                                                                                                  |
|                                |                                                                                                                                                         | 95%-CI,%                                                                                                                                                | (17.2, 29.9)                                                                                                                                            |
|                                |                                                                                                                                                         | P-value                                                                                                                                                 | <0.0001                                                                                                                                                 |
|                                | DCR                                                                                                                                                     | Difference                                                                                                                                              | 11.0%                                                                                                                                                   |
|                                |                                                                                                                                                         | 95%-CI,%                                                                                                                                                | (4.8, 17.0)                                                                                                                                             |
|                                |                                                                                                                                                         | P-value                                                                                                                                                 |                                                                                                                                                         |
|                                | DOR                                                                                                                                                     | HR                                                                                                                                                      | NA                                                                                                                                                      |
|                                |                                                                                                                                                         | 95%-CI                                                                                                                                                  | NA                                                                                                                                                      |
|                                |                                                                                                                                                         | P-value                                                                                                                                                 | NA                                                                                                                                                      |
| Notes                          | HR was not applicable for DOR at the time point of data cutoff date. Updated results (data cut-off 2 Jan 2019) have been provided during the procedure. | HR was not applicable for DOR at the time point of data cutoff date. Updated results (data cut-off 2 Jan 2019) have been provided during the procedure. | HR was not applicable for DOR at the time point of data cutoff date. Updated results (data cut-off 2 Jan 2019) have been provided during the procedure. |

## Clinical studies in special populations

The Applicant provided data (PFS, OS, ORR, DOR) using the following age subgroups: &lt;65 years and ≥ 65 years

## Table: Subgroup Analysis of Overall Survival and Progression-free Survival (ITT Population)

432

260

432

260

|                  | Pembrolizumab + Axitinib (N=432)   | Pembrolizumab + Axitinib (N=432)   | Pembrolizumab + Axitinib (N=432)   | Sunitinib (N=429)   | Sunitinib (N=429)   | Sunitinib (N=429)   | Pembrolizumab + Axitinib vs. Sunitinib   |
|------------------|------------------------------------|------------------------------------|------------------------------------|---------------------|---------------------|---------------------|------------------------------------------|
| Overall Survival | N                                  | Number of Events                   | (%)                                | N                   | Number of Events    | (%)                 | Hazard Ratio (95% CI) †                  |
| Overall          |                                    |                                    | (13.7)                             |                     | 97                  | (22.6)              |                                          |
|                  | 432                                | 59                                 |                                    | 429                 |                     |                     | 0.53 (0.38, 0.74)                        |
| < 65 years       | 260                                | 31                                 | (11.9)                             | 278                 | 60                  | (21.6)              | 0.47 (0.30, 0.73)                        |
| ≥ 65 years       | 172                                | 28                                 | (16.3)                             | 151                 | 37                  | (24.5)              | 0.59 (0.36, 0.97)                        |
| Progression-free |                                    |                                    |                                    |                     |                     |                     |                                          |
| Survival         | Survival                           | Survival                           | Survival                           | Survival            | Survival            | Survival            | Survival                                 |
| Overall          | 432                                | 183                                | (42.4)                             | 429                 | 212                 | (49.4)              | 0.69 (0.57, 0.84)                        |
| < 65 years       | 260                                | 108                                | (41.5)                             | 278                 | 140                 | (50.4)              | 0.70 (0.54, 0.90)                        |
| ≥ 65 years       | 172                                | 75                                 | (43.6)                             | 151                 | 72                  | (47.7)              | 0.63 (0.45, 0.88)                        |

Database Cutoff Date: 24Aug2018.

Table  Subgroup Analysis of Objective Response (Confirmed) Based on BICR Assessment per RECIST 1.1 (ITT Population)

<div style=\"page-break-after: always\"></div>

(23.6)

|            | Pembrolizumab + Axitinib (N=432)   | Pembrolizumab + Axitinib (N=432)   | Pembrolizumab + Axitinib (N=432)   | Pembrolizumab + Axitinib (N=432)   | Sunitinib (N=429)   | Sunitinib (N=429)   | Sunitinib (N=429)   | Sunitinib (N=429)   | Difference †   | Difference †   |
|------------|------------------------------------|------------------------------------|------------------------------------|------------------------------------|---------------------|---------------------|---------------------|---------------------|----------------|----------------|
|            | N                                  | n                                  | (%)                                | 95% CI (%)                         | N                   | n                   | (%)                 | 95% CI (%)          | (%)            | 95% CI (%)     |
| Overall    | 432                                | 256                                | (59.3)                             | (54.5, 63.9)                       | 429                 | 153                 | (35.7)              | (31.1, 40.4)        | (23.6)         | (17.2, 29.9)   |
| < 65 years | 260                                | 146                                | (56.2)                             | (49.9, 62.3)                       | 278                 | 104                 | (37.4)              | (31.7, 43.4)        | (18.7)         | (10.3, 26.9)   |
| ≥ 65 years | 172                                | 110                                | (64.0)                             | (56.3, 71.1)                       | 151                 | 49                  | (32.5)              | (25.1, 40.5)        | (31.5)         | (20.8, 41.4)   |

Overall response is based on best overall response using BICR assessment per RECIST 1.1 with confirmation.

† Analysis (ORR difference and 95% CI) in the overall population is based on the stratified Miettinen &amp; Nurminen method; analysis in the subgroups is based on the unstratified Miettinen &amp; Nurminen method.

Subjects with PD-L1 not evaluable are not included in the subgroup analysis.

Database Cutoff Date: 24Aug2018.

Source:  [P426V01MK3475: adam-adsl; adrs]

The benefit of pembrolizumab + axitinib over sunitinib was seen across the above specified age subgroups, supporting the benefit of pembrolizumab + axitinib in the proposed indication.

## Supportive study(ies)

## Study KEYNOTE-427

KEYNOTE-427 is an ongoing, Phase 2, nonrandomized, open-label, 2-cohort, multicenter, global study of pembrolizumab monotherapy to evaluate the efficacy and safety of pembrolizumab as 1L treatment for locally advanced/metatsatic ccRCC (Cohort A) and nccRCC (Cohort B) in adult participants who had not previously received systemic therapy for metastatic disease. Patients were required to have measurable disease per RECIST 1.1. as assessed by BICR. Key exclusion criteria were prior treatment with any anti-PD-1, or PD-L1, or PD-L2 agent or an antibody targeting any other immune-regulatory receptors or mechanisms, diagnosis of immunodeficiency, treatment with systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to allocation (except in the case of central nervous system metastases), active autoimmune disease requiring systemic treatment within the past 2 years OR a documented history of clinically severe autoimmune disease, and known active central nervous system metastases and/or carcinomatous meningitis.

<!-- image -->

Eligible participants in Cohort A (N=110) were treated with pembrolizumab 200 mg Q3W until a total of 35  doses  had  been  administered  or  until  documented  PD,  unacceptable  AEs,  or  any  of  the  other discontinuation  criteria  were  met,  as  outlined  in  the  protocol.  Participants  were  evaluated  with radiographic imaging to assess response to treatment at baseline, after randomization at Week 12, then Q6W until Week 54, and Q12W thereafter. All participants are being followed for survival (by phone contact or clinic visit) until death, withdrawal of consent, being lost to follow-up, or until the study is concluded or terminated early, whichever occurs first.

The primary endpoint is ORR per RECIST 1.1 by BICR. Key secondary endpoints include DOR, DCR and PFS per RECIST 1.1 by BICR, and OS. There will be no formal hypothesis testing in this study. The overall sample size selection is based on the confidence interval (CI) width that will provide the appropriate level

<div style=\"page-break-after: always\"></div>

of precision needed for estimation. The planned sample size is approximately 105 subjects in ccRCC cohort. With a sample size of 105 subjects with clear cell renal cell carcinoma, the half-width of 95% confidence interval varies between 8% and 10% when the observed response rates vary from 20% to 60%. No power calculation is provided. Efficacy analyses were based on the ASaT population, which consisted of 110 allocated participants in Cohort A who received at least 1 dose of study treatment. The analysis population for DOR consisted of responders.

Figure: Disposition of participants in Cohort A

<!-- image -->

BICR confirmed ORR of 36.4% was achieved; 3 (2.7%) participants had a CR and 37 (33.6%) participants had PR.

Table: Summary of Best Overall Response (Confirmed) Based on BICR per RECIST 1.1 Cohort A: ccRCC (ASaT Population)

<!-- image -->

| Response Evalwation                                                                                                                                                                                                                                                            | Cohort A                                                                                                                                                                                                                                                                       | Cohort A                                                                                                                                                                                                                                                                       | Cohort A                                                                                                                                                                                                                                                                       |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                | %                                                                                                                                                                                                                                                                              | 95%6 C1                                                                                                                                                                                                                                                                        |
| Subjects in population                                                                                                                                                                                                                                                         | 110                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                |
| Complete Responio (CR)                                                                                                                                                                                                                                                         | 3                                                                                                                                                                                                                                                                              | 2.7                                                                                                                                                                                                                                                                            | (0.6, 7.8)                                                                                                                                                                                                                                                                     |
| Partisl Responwe (PR)                                                                                                                                                                                                                                                          | 37                                                                                                                                                                                                                                                                             | 33.6                                                                                                                                                                                                                                                                           | (24.9,43.3)                                                                                                                                                                                                                                                                    |
| Objective Response(CR+PR)                                                                                                                                                                                                                                                      | 40                                                                                                                                                                                                                                                                             | 36.4                                                                                                                                                                                                                                                                           | (27.4, 46.1)                                                                                                                                                                                                                                                                   |
| Stablo Disoaso (SD)                                                                                                                                                                                                                                                            | 35                                                                                                                                                                                                                                                                             | 31.8                                                                                                                                                                                                                                                                           | (23.3,41.4)                                                                                                                                                                                                                                                                    |
| DieassControl(CR+PR+SD26mouths)                                                                                                                                                                                                                                                | 63                                                                                                                                                                                                                                                                             | 57.3                                                                                                                                                                                                                                                                           | (47.5, 66.7)                                                                                                                                                                                                                                                                   |
| Progessive Diseie (PD)                                                                                                                                                                                                                                                         | EE                                                                                                                                                                                                                                                                             | 30.0                                                                                                                                                                                                                                                                           | (21.6,39.5)                                                                                                                                                                                                                                                                    |
| No Asrwment                                                                                                                                                                                                                                                                    | 2                                                                                                                                                                                                                                                                              | 1.8                                                                                                                                                                                                                                                                            | (0.2, 6.4)                                                                                                                                                                                                                                                                     |
| Based on binomial exact confidenco intorval mothod for binomial data.  No Awwowment' includes subjects discontinuing or death before the first post-baroline scan. For best overall response of CR snd PR, only confiwed reaponsen ae inchded. Dathbaso Cutoff Date: 07Sep2018 | Based on binomial exact confidenco intorval mothod for binomial data.  No Awwowment' includes subjects discontinuing or death before the first post-baroline scan. For best overall response of CR snd PR, only confiwed reaponsen ae inchded. Dathbaso Cutoff Date: 07Sep2018 | Based on binomial exact confidenco intorval mothod for binomial data.  No Awwowment' includes subjects discontinuing or death before the first post-baroline scan. For best overall response of CR snd PR, only confiwed reaponsen ae inchded. Dathbaso Cutoff Date: 07Sep2018 | Based on binomial exact confidenco intorval mothod for binomial data.  No Awwowment' includes subjects discontinuing or death before the first post-baroline scan. For best overall response of CR snd PR, only confiwed reaponsen ae inchded. Dathbaso Cutoff Date: 07Sep2018 |

Source: [P427V01MK3475: adam-adsl: adrs, adintdt]

<div style=\"page-break-after: always\"></div>

Overall, the ORR was consistent across demographic and other predetermined subgroups with the exception of the analyses by gender and PD-L1 status. ORR is lower in females (16.7%) compared with males (41.9%); however, the small sample size precludes a meaningful analysis.

As the cutpoint for PD-L1 status (positive vs negative) was chosen in an attempt to discriminate response by CPS score based on results from an earlier database lock, the ORR was higher for participants with CPS ≥ 1 (44.2%) compared with CPS &lt;1 (29.3%) with overlapping 95% CIs.

Analysis results, based on investigator assessment, were consistent with the primary analysis results, based on BICR.

As of the data cutoff date, the median DOR was not reached; 63.6% (18 of the 40 responders) of participants had an extended response duration of ≥ 12 months. Disease control was achieved by 57.3% (63 of 110) of participants. The median PFS for participants was 7.1 months; the PFS rate at 12 months was 37.6%. As of the data cutoff date, the median OS was not reached; the OS rate at 12 months was 88.2%.

Figure 4.4.2.13: Forest Plot of Objective Response Rate (Confirmed) Based on BICR per RECIST 1.1 Cohort A: ccRCC (ASaTPopulation)

<!-- image -->

Table Comparison of Efficacy Results from Participants with PD-L1 Positive and Negative Tumors in KEYNOTE-426 and KEYNOTE-427

| PD-L1 Status   | PD-L1 CPS ≥1   | PD-L1 CPS ≥1   | PD-L1 CPS <1   | PD-L1 CPS <1   |
|----------------|----------------|----------------|----------------|----------------|
| Study          | KEYNOTE-426    | KEYNOTE-427    | KEYNOTE-426    | KEYNOTE-427    |

<div style=\"page-break-after: always\"></div>

| Parameter                                                                                                                                                                                                                                                                                                      | Pembrolizumab + Axitinib (N=243)                                                                                                                                                                                                                                                                               | Pembrolizumab (N=52)                                                                                                                                                                                                                                                                                           | Pembrolizumab + Axitinib (N=167)                                                                                                                                                                                                                                                                               | Pembrolizumab (N=58)                                                                                                                                                                                                                                                                                           |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Confirmed Response                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                |
| ORR (CR + PR),% (95% CI)                                                                                                                                                                                                                                                                                       | 60.5 (54.0, 66.7)                                                                                                                                                                                                                                                                                              | 44.2 (30.5, 58.7)                                                                                                                                                                                                                                                                                              | 56.3 (48.4, 63.9)                                                                                                                                                                                                                                                                                              | 29.3 (18.1, 42.7)                                                                                                                                                                                                                                                                                              |
| CR, n (%)                                                                                                                                                                                                                                                                                                      | 15 (6.2)                                                                                                                                                                                                                                                                                                       | 2 (3.8)                                                                                                                                                                                                                                                                                                        | 8 (4.8)                                                                                                                                                                                                                                                                                                        | 1 (1.7)                                                                                                                                                                                                                                                                                                        |
| PR, n (%)                                                                                                                                                                                                                                                                                                      | 132 (54.3)                                                                                                                                                                                                                                                                                                     | 21 (40.4)                                                                                                                                                                                                                                                                                                      | 86 (51.5)                                                                                                                                                                                                                                                                                                      | 16 (27.6)                                                                                                                                                                                                                                                                                                      |
| PFS                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                |
| Median (95% CI), months                                                                                                                                                                                                                                                                                        | 15.3 (12.6, -)                                                                                                                                                                                                                                                                                                 | 9.7 (6.7 to 16.4)                                                                                                                                                                                                                                                                                              | 15.0 (12.4, -)                                                                                                                                                                                                                                                                                                 | 6.9 (3.3, 10.9)                                                                                                                                                                                                                                                                                                |
| 12-month PFS rate, %(95% CI)                                                                                                                                                                                                                                                                                   | 58.7 (51.7, 65.1)                                                                                                                                                                                                                                                                                              | 40.3 (26.4, 53.7)                                                                                                                                                                                                                                                                                              | 60.4 (51.6, 68.0)                                                                                                                                                                                                                                                                                              | 35.3 (22.9, 47.9)                                                                                                                                                                                                                                                                                              |
| OS                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                                                                                |
| Median (95% CI), months                                                                                                                                                                                                                                                                                        | Not reached                                                                                                                                                                                                                                                                                                    | Not reached                                                                                                                                                                                                                                                                                                    | Not reached                                                                                                                                                                                                                                                                                                    | Not reached                                                                                                                                                                                                                                                                                                    |
| 12-month OS rate, %(95% CI)                                                                                                                                                                                                                                                                                    | 90.1 (85.5, 93.3)                                                                                                                                                                                                                                                                                              | 92.3 (80.79, 97.04)                                                                                                                                                                                                                                                                                            | 91.5 (85.8, 95.0)                                                                                                                                                                                                                                                                                              | 84.5 (72.30, 91.61)                                                                                                                                                                                                                                                                                            |
| Abbreviations: CI = confidence interval; CPS = combined positive score; CR = complete response; ORR = objective response rate; OS = overall survival; PFS = progression-free survival; PR = partial response. Database Cutoff Date for KEYNOTE-426: 24Aug2018; Database Cutoff Date for KEYNOTE-427: 07Sep2018 | Abbreviations: CI = confidence interval; CPS = combined positive score; CR = complete response; ORR = objective response rate; OS = overall survival; PFS = progression-free survival; PR = partial response. Database Cutoff Date for KEYNOTE-426: 24Aug2018; Database Cutoff Date for KEYNOTE-427: 07Sep2018 | Abbreviations: CI = confidence interval; CPS = combined positive score; CR = complete response; ORR = objective response rate; OS = overall survival; PFS = progression-free survival; PR = partial response. Database Cutoff Date for KEYNOTE-426: 24Aug2018; Database Cutoff Date for KEYNOTE-427: 07Sep2018 | Abbreviations: CI = confidence interval; CPS = combined positive score; CR = complete response; ORR = objective response rate; OS = overall survival; PFS = progression-free survival; PR = partial response. Database Cutoff Date for KEYNOTE-426: 24Aug2018; Database Cutoff Date for KEYNOTE-427: 07Sep2018 | Abbreviations: CI = confidence interval; CPS = combined positive score; CR = complete response; ORR = objective response rate; OS = overall survival; PFS = progression-free survival; PR = partial response. Database Cutoff Date for KEYNOTE-426: 24Aug2018; Database Cutoff Date for KEYNOTE-427: 07Sep2018 |

## Table: Overall Summary of Efficacy Outcome with Confirmed Responses Cohort B: nccRCC (ASaT Population)

165

24.8 (18.5, 32.2)

40.6 (33.0, 48.5)

8 (4.8)

33 (20.0)

53 (32.1)

61 (37.0)

2 (1.2)

8 (4.8)

41

NR (2.8 - 15.2+)

2.8 (0.1-8.3)

4.1 (2.8,5.6)

41.6 (33.9, 49.1)

NR NR

91.5 (86.09,94.89)

86.6 (80.41,90.99)

|                                                                                       | Cohort B                                                                              |
|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|
| Number of Subjects                                                                    | 165                                                                                   |
| ORR Analysis (Central Radiology Assessment per RECIST v1.1, Confirmed Responses)      | ORR Analysis (Central Radiology Assessment per RECIST v1.1, Confirmed Responses)      |
| ORR, %(95% CI † )                                                                     | 24.8 (18.5, 32.2)                                                                     |
| DCR, %(95% CI † )                                                                     | 40.6 (33.0, 48.5)                                                                     |
| Overall response, n (%)                                                               | Overall response, n (%)                                                               |
| CR                                                                                    | 8 (4.8)                                                                               |
| PR                                                                                    | 33 (20.0)                                                                             |
| SD                                                                                    | 53 (32.1)                                                                             |
| PD                                                                                    | 61 (37.0)                                                                             |
| Non-evaluable (NE)                                                                    | 2 (1.2)                                                                               |
| No Assessment                                                                         | 8 (4.8)                                                                               |
| Response Duration (Central Radiology Assessment per RECIST v1.1, Confirmed Responses) | Response Duration (Central Radiology Assessment per RECIST v1.1, Confirmed Responses) |
| Subjects with a Response (n)                                                          | 41                                                                                    |
| Median duration of response in months (range) ‡                                       | NR (2.8 - 15.2+)                                                                      |
| Median time to response (range), months                                               | 2.8 (0.1-8.3)                                                                         |
| PFS (Central Radiology Assessment per RECIST v1.1)                                    | PFS (Central Radiology Assessment per RECIST v1.1)                                    |
| Median in months (95% CI) ‡                                                           | 4.1 (2.8,5.6)                                                                         |
| PFS rate at Month 6 (%) ‡                                                             | 41.6 (33.9, 49.1)                                                                     |
| OS                                                                                    | OS                                                                                    |
| Median in months (95% CI) ‡                                                           | NR NR 91.5 (86.09,94.89)                                                              |
| OS rate at Month 3 (%) ‡                                                              |                                                                                       |
| OS rate at Month 6 (%) ‡                                                              | 86.6 (80.41,90.99)                                                                    |

<div style=\"page-break-after: always\"></div>

- CR=complete response; DCR=disease control rate; ORR=overall response rate; OS=overall survival; PD=progressive disease; PFS= progression-free survival; PR=partial response; SD=stable disease;
- † Based on binomial exact confidence interval method for binomial data.
- ‡ From product-limit (Kaplan-Meier) method for censored data.
- \"+\" indicates there was no progressive disease by the time of last disease assessment.

NR = Not reached

Database Cutoff Date: 07Sep2018

## Waterfall Plot of Subjects with Maximum Target Lesion Change from Baseline Based on BICR Cohort B: nccRCC (ASaT Population)

<!-- image -->

## Study A4061051 (Pfizer Sponsored):

Study  A4064051  was  a  Phase  3,  randomized,  open-label,  multicenter  study  sponsored  by  Pfizer  to evaluate the efficacy and safety of axitinib versus sorafenib as a 1L treatment for metastatic RCC. Key eligibiity criteria were

Eligible participants were required to meet eligibility criteria, i.e. histologically or cytologically confirmed ccRCC with metastasis, with no prior systemic first-line therapy (prior adjuvant therapy with interferon (IFN) and/or interleukin allowed if recurrence occurred &gt;6 months after the last dose), ECOG PS 0-1, no evidence  of  pre-existing  uncontrolled  hypertension,  no  active  seizure  disorder  or  evidence  of  brain metastases, spinal cord compression, or carcinomatous meningitis.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Patients  were  enrolled  beginning  on  15-JUN-2010  and  stratified  by  ECOG  status  (0  versus  1),  then randomly assigned in a 2:1 ratio to either axitinib (5 mg BID; N=192) or sorafenib (400 mg BID; N=96).

Participants continued to receive study treatment until documented PD, unacceptable AEs, or any of the other  discontinuation  criteria  were  met,  as  outlined  in  the  protocol.  Participants  with  PD  who  were experiencing a clinical  benefit  with  either  axitinib  or  sorafenib  were  eligible  for  continued  treatment provided  that  the  treating  physician  had  assessed  the  risk/benefit  of  taking  such  an  approach  and provided that the sum of longest diameters of measurable lesions remained less than or equal to the baseline sum of longest diameters and no alternative treatment was available.

Participants were evaluated with radiographic imaging to assess response to treatment at baseline, after randomization at Week 6 and Week 12, then Q8W thereafter. All participants were followed for survival.

The primary endpoint was PFS per RECIST 1.0 by central radiology assessment. Key secondary endpoints included OS, ORR, and DOR.

A total of 148 patients with progressive disease or death were required for a log-rank test with an overall 1-sided significance level of 0.025 to have power of 0.90. This assumed a 78% improvement in median PFS from 5.5 months to 9.8 months in treatment-naïve mRCC patients randomized to receive axitinib. Applying  a  2:1  randomization  and  a  planned  accrual  period  of  16  months,  a  follow-up  period  of approximately 6 months, and assuming 20% of patients dropped out at 24 months in each arm, it was estimated that approximately 247 patients needed to be enrolled in order to observe 148 patients with progressive disease or death by the end of the follow-up period. The nominal significance level for the interim  and  final  efficacy  analyses  was  determined  using  the  Lan-DeMets  procedure  with  an O'Brien-Fleming  stopping  rule.  The  final  analysis  was  to  take  place  when  the  148th  patient  had documented progressive disease or death. The overall Type I error rate was preserved at the nominal 0.025 level.

The sample size described above also allowed the assessment of differences in the secondary endpoint of OS with a high level of significance. Median OS in treatment-naïve mRCC patients treated with sorafenib was estimated to be 17.3 months. A total of 178 deaths were required for a log-rank test with an overall 1-sided  significance  level  of  0.025  to  have  power  of  0.80.  This  assumed  an  approximately  59% improvement in median OS from 17 months to 27 months in mRCC patients who had received no prior systemic therapy randomized to receive axitinib and a follow-up period of approximately 37 months, assuming a 0% drop out rate. The estimated sample size of 247 patients for PFS was also sufficient to observe the 178 deaths needed for comparing median OS.

<div style=\"page-break-after: always\"></div>

Table: Overall Summary of Patient Disposition by Treatment

<!-- image -->

In the first line portion of this study in treatment naïve patients with mRCC, the study did not achieve its primary objective, although there was a 23.3% reduction in the risk of disease progression or death (HR=0.767; 95% CI [0.559, 1.053]; p-value=0.0377) for axitinib vs sorafenib.

<div style=\"page-break-after: always\"></div>

OS,  a  secondary  efficacy  endpoint,  was  immature  at  the  time  of  the  final  PFS  analysis,  with  only approximately 40% of patients having died. The currently estimated survival probability at 12 months was 72.0% (95% CI [65.0%, 77.9%]) for axitinib and 73.5% (95% CI [63.4%, 81.2%]) for sorafenib. The observed HR was 1.136 (95% CI [0.765, 1.687]) with a 1-sided p-value of 0.7370.

ORR, a secondary endpoint was superior for axitinib compared to sorafenib (ORR of 32.3% and 14.6%, respectively, the risk ratio (axitinib:sorafenib) was 2.214 (95% CI [1.306, 3.753]) with a 1-sided p-value of 0.0006. DoR, a secondary efficacy endpoint, was similar between treatments; the median DoR was 14.7 and 14.3 months for axitinib and sorafenib, respectively.

'Summary table of the contribution of each component in the combination regimen':

|                                | KN426 (Ph3 vs. Sunitinib) Pembrolizumab + axitinib   | KN427 Ph2 Cohort A Pembrolizumab monotherapy   | Study A4061051 (Ph3 vs. sorafenib) Axitinib monotherapy   |
|--------------------------------|------------------------------------------------------|------------------------------------------------|-----------------------------------------------------------|
| Study population               | 1L advanced RCC Clear cell                           | 1L advanced RCC Clear cell                     | 1L advanced RCC Clear cell                                |
| Samples size (ITT)             | 432                                                  | 110                                            | 192                                                       |
| PFS, median, mos (95% CI)      | 15.1 (12.6, 17.7)                                    | 7.1 (5.6, 11.0)                                | 10.1 (7.2, 12.1)                                          |
| PFS rate at 12 months (95% CI) | 59.6 % (54.3, 64.5)                                  | 37.6 % (28.2, 46.9)                            | NA                                                        |
| OS, median, mos (95% CI)       | NR (NR,NR)                                           | NR (NR,NR)                                     | 21.7 (18.0, 31.7)                                         |
| OS rate at 12 months (95% CI)  | 89.9 % (86.4, 92.4)                                  | 88.2 % (80.5, 93.0)                            | 83.8% (75.3, 89.6)                                        |
| Confirmed ORR, % (95% CI)      | 59.3% (54.5, 63.9),                                  | 36.4% (27.4, 46.1),                            | 32.3% (25.7, 39.4),                                       |

## Comparison and analyses of results across studies

A  comparison  of  the  results  from  KEYNOTE-427  and  Study  A4061051  with  KEYNOTE-426  has  been presented by the MAH to provide the contribution of each component of the combination regimen to the overall efficacy of pembrolizumab + axitinib for the 1L treatment of advanced RCC.

## Study design

The separate studies, KEYNOTE-426, KEYNOTE-427 Cohort A (ccRCC), and Study A4061051, were similar in  terms  of  criteria  defining  the  eligible  participant  population.  The  following  differences  were  also notable:

- KEYNOTE-426 and KEYNOTE-427 enrolled participants with KPS ≥ 70%, which is similar to an ECOG  performance  status  of  0  to  2.  Study  A4061051  enrolled  participants  with  an  ECOG performance status of 0 or 1.
- Stratification to study intervention was based on IMDC risk category and geographical region in KEYNOTE-426 and ECOG performance status in Study A4061051. Because KEYNOTE-427 is a single arm study, no stratification was applicable, although outcomes were analyzed by IMDC risk category.

<div style=\"page-break-after: always\"></div>

- Randomization to  study  intervention  was  1:1  in  KEYNOTE-426  and  2:1  in  Study  A4061051. Eligible participants with ccRCC were allocated to Cohort A of KEYNOTE-427.
- KEYNOTE-427 was single-arm study and used ORR per RECIST 1.1 by BICR as the primary endpoint.
- In KEYNOTE-426 and KEYNOTE-427, participants were evaluated with radiographic imaging at baseline, after randomization at Week 12, then Q6W until Week 54, and Q12W thereafter. In Study  A4061051,  participants  were  evaluated  with  radiographic  imaging  at  baseline,  after randomization at Week 6 and Week 12, then Q8W thereafter.

<div style=\"page-break-after: always\"></div>

## Participant Characteristics

## Table: Key Baseline Demographics from KEYNOTE-426, KEYNOTE-427, and Study A4061051

| Study                             | KEYNOTE-426                       | KEYNOTE-426                       | KEYNOTE-427                       | Study A4061051                    | Study A4061051                    |
|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
|                                   | Pembrolizumab + Axitinib          | Sunitinib                         | Pembrolizumab                     | Axitinib                          | Sorafenib                         |
| Participants in Population        | 432                               | 429                               | 110                               | 192                               | 96                                |
| Gender, n (%)                     | Gender, n (%)                     | Gender, n (%)                     | Gender, n (%)                     | Gender, n (%)                     | Gender, n (%)                     |
| Male                              | 308 (71.3)                        | 320 (74.6)                        | 86 (78.2)                         | 134 (69.8)                        | 74 (77.1)                         |
| Female                            | 124 (28.7)                        | 109 (25.4)                        | 24 (21.8)                         | 58 (30.2)                         | 22 (22.9)                         |
| Age, n (%)                        | Age, n (%)                        | Age, n (%)                        | Age, n (%)                        | Age, n (%)                        | Age, n (%)                        |
| <65                               | 260 (60.2)                        | 278 (64.8)                        | 58 (52.7)                         | 142 (74.0)                        | 77 (80.2)                         |
| ≥65                               | 172 (39.8)                        | 151 (35.2)                        | 52 (47.3)                         | 50 (26.0)                         | 19 (19.8)                         |
| Median (range)                    | 62.0 (30 to 89)                   | 61.0 (26 to 90)                   | 64.0 (29 to 87)                   | 58 (23 to 83)                     | 58 (20 to 77)                     |
| KPS, n (%)                        | KPS, n (%)                        | KPS, n (%)                        | KPS, n (%)                        | KPS, n (%)                        | KPS, n (%)                        |
| 90/100                            | 347 (80.3)                        | 341 (79.5)                        | 88 (80.0)                         | -                                 | -                                 |
| 70/80                             | 84 (19.4)                         | 88 (20.5)                         | 22 (20.0)                         | -                                 | -                                 |
| Missing                           | 1 (0.2)                           | 0                                 | -                                 | -                                 | -                                 |
| ECOG, n (%)                       | ECOG, n (%)                       | ECOG, n (%)                       | ECOG, n (%)                       | ECOG, n (%)                       | ECOG, n (%)                       |
| 0                                 | -                                 | -                                 | -                                 | 114 (59.4)                        | 53 (55.2)                         |
| 1                                 | -                                 | -                                 | -                                 | 78 (40.6)                         | 43 (44.8)                         |
| >1                                | -                                 | -                                 | -                                 | 0                                 | 0                                 |
| IMDC Risk Category, n (%)         | IMDC Risk Category, n (%)         | IMDC Risk Category, n (%)         | IMDC Risk Category, n (%)         | IMDC Risk Category, n (%)         | IMDC Risk Category, n (%)         |
| Favorable                         | 138 (31.9)                        | 131 (30.5)                        | 42 (38.2)                         | -                                 | -                                 |
| Intermediate                      | 238 (55.1)                        | 246 (57.3)                        | 52 (47.3)                         | -                                 | -                                 |
| Poor                              | 56 (13.0)                         | 52 (12.1)                         | 16 (14.5)                         | -                                 | -                                 |
| MSKCC Risk Group, n (%)           | MSKCC Risk Group, n (%)           | MSKCC Risk Group, n (%)           | MSKCC Risk Group, n (%)           | MSKCC Risk Group, n (%)           | MSKCC Risk Group, n (%)           |
| Favorable                         | -                                 | -                                 | -                                 | 94 (49.0)                         | 53 (55.2)                         |
| Intermediate                      | -                                 | -                                 | -                                 | 84 (43.8)                         | 40 (41.7)                         |
| Poor                              | -                                 | -                                 | -                                 | 7 (3.6)                           | 2 (2.1)                           |
| Missing                           | -                                 | -                                 | -                                 | 7 (3.6)                           | 1 (1.0)                           |
| Site of Metastatic Disease, n (%) | Site of Metastatic Disease, n (%) | Site of Metastatic Disease, n (%) | Site of Metastatic Disease, n (%) | Site of Metastatic Disease, n (%) | Site of Metastatic Disease, n (%) |
| Lung                              | 312 (72.2)                        | 309 (72.0)                        | 73 (66.4)                         | 137 (71.4)                        | 72 (75.0)                         |
| Lymph Node                        | 199 (46.1)                        | 197 (45.9)                        | 46 (41.8)                         | 99 (51.6)                         | 55 (57.3)                         |
| Bone                              | 103 (23.8)                        | 103 (24.0)                        | 23 (20.9)                         | 56 (29.2)                         | 24 (25.0)                         |
| Liver                             | 66 (15.3)                         | 71 (16.6)                         | 14 (12.7)                         | 52 (27.1)                         | 25 (26.0)                         |
| RCC Histology, n (%)              | RCC Histology, n (%)              | RCC Histology, n (%)              | RCC Histology, n (%)              | RCC Histology, n (%)              | RCC Histology, n (%)              |
| Clear cell                        | 403 (93.3)                        | 401 (93.5)                        | 100 (30.9)                        | 192 (100)                         | 96 (100)                          |

<div style=\"page-break-after: always\"></div>

| Study                | KEYNOTE-426              | KEYNOTE-426   | KEYNOTE-427   | Study A4061051   | Study A4061051   |
|----------------------|--------------------------|---------------|---------------|------------------|------------------|
|                      | Pembrolizumab + Axitinib | Sunitinib     | Pembrolizumab | Axitinib         | Sorafenib        |
| Clear cell component | 28 (6.5)                 | 27 (6.3)      | 4 (3.6)       | -                | -                |
| Unknown              |                          |               | 6 (5.5)       | -                | -                |
| Other                | 1 (0.2)                  | 1 (0.2)       | -             | 19 (9.9)         | 13 (13.5)        |

## Efficacy summary of all studies

KEYNOTE-427 and Study A4061051 demonstrate the individual contributions of pembrolizumab and axitinib relative to that of the combination. Cohort A (ccRCC) of KEYNOTE-427 was specifically designed to  evaluate  the  efficacy  and  safety  of  pembrolizumab  monotherapy  to  support  the  development  of pembrolizumab + axitinib in KEYNOTE-426. Study A4061051 was a multicenter, randomized Phase 3 study of axitinib monotherapy versus sorafenib monotherapy conducted in a similar patient population as that of KEYNOTE-426.

Pembrolizumab and axitinib both demonstrated clinical activity in advanced RCC in KEYNOTE-427 and Study A4061051, respectively. The ORR and PFS results of pembrolizumab + axitinib in KEYNOTE-426 were markedly greater (in some cases doubled) relative to what was observed in either KEYNOTE-427 or Study A4061051 [Table 2.7.3-rcc1: 12]. Even acknowledging that these are cross-study comparisons, the MAH claims that the results from the combination of pembrolizumab and axitinib in KEYNOTE-426 represent  substantial  improvements  in  ORR  and  PFS  relative  to  either  component  administered  as monotherapy as shown by non-overlapping 95% CIs. These data demonstrate the contribution of each of the components to the efficacy of the pembrolizumab and axitinib combination regimen.

## Table: Comparison of Efficacy Results from KEYNOTE-426, KEYNOTE-427, and Study A4061051

| Study                                        | KEYNOTE-426               | KEYNOTE-426               | KEYNOTE-427         | Study A4061051              | Study A4061051              |
|----------------------------------------------|---------------------------|---------------------------|---------------------|-----------------------------|-----------------------------|
| Treatment Parameter                          | Pembrolizumab + Axitinib  | Sunitinib                 | Pembrolizuma b      | Axitinib                    | Sorafenib                   |
| ORR, %(95% CI)                               |                           |                           |                     |                             |                             |
| CR + PR p-value                              | 59.3 (54.5, 63.9)         | 35.7 (31.1, 40.4)         | 36.4 (27.4, 46.1)   | 32.3 (25.7, 39.4)           | 14.6 (8.2, 23.3)            |
| CR + PR p-value                              | <0.0001                   | <0.0001                   | N/A                 | 0.0006                      | 0.0006                      |
| CR, n (%)                                    | 25 (5.8)                  | 8 (1.9)                   | 3 (2.7)             | 0                           | 0                           |
| PR, n (%)                                    | 231 (53.5)                | 145 (33.8)                | 37 (33.6)           | 62 (32.3)                   | 14 (14.6)                   |
| PFS                                          |                           |                           |                     |                             |                             |
| Median (95% CI), months HR (95% CI), p-value | 15.1 (12.6, 17.7)         | 11.0 (8.7, 12.5)          | 7.1 (5.6 to 11.0)   | 10.1 (7.2 to 12.1)          | 6.5 (4.7 to 8.3)            |
| Median (95% CI), months HR (95% CI), p-value | 0.69 (0.56, 0.84) 0.00012 | 0.69 (0.56, 0.84) 0.00012 | N/A                 | 0.768 (0.566, 1.042) 0.0441 | 0.768 (0.566, 1.042) 0.0441 |
| OS                                           |                           |                           |                     |                             |                             |
| Median (95% CI), months HR (95% CI), p-value | Not reached               | Not reached               | Not reached         | 21.7 (18.0 to 31.7)         | 23.3 (18.1 to 33.2)         |
| Median (95% CI), months HR (95% CI), p-value | 0.53 (0.38, 0.74) 0.00005 | 0.53 (0.38, 0.74) 0.00005 | N/A                 | 1.136 (0.765, 1.687) 0.7370 | 1.136 (0.765, 1.687) 0.7370 |
| OS rate, 6 Months % (95% CI)                 | 94.9 (92.3, 96.6)         | 89.0 (85.6, 91.6)         | 92.7 (85.98, 96.29) | N/A                         | N/A                         |
| OS rate, 12 Months % (95% CI)                | 89.9 (86.4, 92.4)         | 78.3 (73.8, 82.1)         | 88.2 (80.52, 92.96) | 72.0 (65.0, 77.9)           | 73.3 (63.1, 81.0)           |
| OS rate, 18 Months % (95% CI)                | 82.3 (77.2, 86.3)         | 72.1 (66.3, 77.0)         | N/A                 | N/A                         | N/A                         |

<div style=\"page-break-after: always\"></div>

## 2.4.3. Discussion on clinical efficacy

A type II Variation for the extension of Keytruda therapeutic indication for the first-line treatment of advanced renal cell carcinoma (RCC) in adults in combination with axitinib has been submitted by the MAH based on the IA1 results of the pivotal phase III trial KEYNOTE-426. Updated data with cut-off date of 2 Jan 2019 have been further submitted upon CHMP request.

Data from KEYNOTE-427 (Phase 2 study of pembrolizumab monotherapy in participants with RCC) for participants with clear cell RCC (Cohort A), and the Pfizer-sponsored Study A4061051 (Phase 3 study of axitinib versus sorafenib) have been submitted as supportive with the aim to provide the contribution of each of the components to the efficacy of the pembrolizumab + axitinib regimen.

The  results  of  the  Pfizer  sponsored  study  KEYNOTE-035/A4061079  (Phase  1b  of  pembrolizumab  + axitinib in RCC), which provided the rationale for evaluating pembrolizumab in combination with axitinib in participants with advanced RCC, have been also submitted.

## Design and conduct of clinical studies

## Study KEYNOTE-426

KEYNOTE-426 is an ongoing, Phase 3, randomized, multicenter, active-controlled, 2 arms, open-label clinical  study  in  first  line  adult  patients  with  advanced  renal  cell  carcinoma  (RCC),  comparing  the combination of pembrolizumab 200mg Q3W + axitinib 5 mg BID with sunitinib 50 mg QD 4 weeks n 2 weeks off.

Adult patients with newly diagnosed stage IV per AJCC (locally advanced/metastatic disease) or recurrent histologically  confirmed  RCC  with  clear  cell  component  (with  or  without  sarcomatoid  features)  were eligible  provided  they  had  not  received  prior  systemic  therapy  for  advanced  renal  cancer  (prior neoadjuvant/adjuvant therapy for RCC was acceptable if completed &gt;12 months prior to randomization).

Due to the small sample size in both treatment groups and the limited number of events at the time of the data cutoff, a meaningful analysis of OS and PFS in participants with sarcomatoid features cannot be performed at this time. Nevertheless results seem to be consistent with the ITT population.

Patients with non-clear cell RCC were not included in the trial, even though they are not excluded by the sought indication. This is not rejected in principle. To support the activity of pembrolizumab and axitinib in non-clear cell RCC, the MAH provided data from KN-427 cohort B for pembrolizumab, and shortly discussed the results of a multicenter phase II trial of axitinib in patients with recurrent or metastatic nccRCC who had failed prior treatment with temsirolimus (Park, 2018) arguing that these data support the activity of axitinib in nccRCC. Overall, it is considered that there is some evidence supporting the potential activity of both pembrolizumab and axitinib as single agents in nccRCC. No combination data are available. In the SmPC it has been added that patients enrolled in KN-426 trial have clear cell component.

Patients were enrolled regardless of PD-L1 expression. This is not questioned, taking into account that responses had been observed in both PD-L1 positive and PD-L1 negative patients in the phase Ib study KN-035 with the combination of pembrolizumab and axitinib, and also in the phase II study KN-427 with pembrolizumab  monotherapy  (although  more  pronounced  in  PD-L1  CPS ≥ 1).  Subgroup  analyses according to PD-L1 expression have been included in the protocol.

There was no restriction based on IMDC risk category: this is acceptable, although the heterogeneity of the patient population in terms of prognosis is noted. This was considered as a stratification factor.

<div style=\"page-break-after: always\"></div>

Patients should have KPS ≥ 70% and disease was to be measurable. Other key eligibility criteria to account for the known safety profile of pembrolizumab, axitinib and sunitinib.

Sunitinib  is  considered  an  acceptable  comparator  in  the  target  population  of  this  study,  and  is administered at the recommended dose for RCC (Sutent SmPC).

With regard to the experimental arm, the main issue is related to the assessment of the contribution of each component of the combination treatment. According the Guideline on the evaluation of anticancer medicinal products in man (EMA/CHMP/205/95 Rev.5), when a new combination is tested against a reference  regimen,  clinical  phase  I/II  data  should  support  the  need  for  both  components  in  the experimental regimen. The documented activity of the individual components of the combination regimen should be taken into account, and if one of the components is regarded as an acceptable treatment regimen in monotherapy, a randomised phase II study comparing the monotherapy regimen with the combination should be considered. This is deemed important since the combination regimen is expected to  be  more  toxic  compared  to  monotherapy  with  each  of  the  components.  The  study  design  of KEYNOTE-426 (with different TKIs in the control and comparator arm) does not allow to evaluate the contribution of the TKI axitinib to the superiority of the combination therapy compared to sunitib. Axitinib could be regarded as comparable to sunitinib with regard to efficacy, but a recent real-world analysis showed that compared with sunitinib, axitinib significantly prolonged OS (Konishi et al. Med Oncol 2018). In other words, the efficacy benefit for the combination could be attributed in part to a higher level of activity with axitinib than with sunitinib, this should be considered.

It is acknowledged that efficacy results from Study KN-035 showed high activity of the combination, with confirmed ORR of 73.1% (95% CI [59.0, 84.4]) that compares favourably with observed ORR with axitinib (32.3%; 95% CI 25.7, 39.4) and pembrolizumab (36.4; 95% CI 27.4, 46.1%)  in separate studies (Study A4061061 and Study KN-427). However, no direct comparison has been performed. This is particularly relevant for pembrolizumab, since for immunotherapies there is no evidence of a clear correlation  between  ORR  and  long  term  benefit,  and  conventional  response  evaluation  criteria  may underestimate the long-term benefit from immunotherapies (Anagnostou V et al. Clin Cancer Res 2017, Hodi F et al. J Clin Oncol 2016, Kaufman H et al. J Clin Oncol 2017). Furthermore, it cannot be excluded that pembrolizumab monotherapy could represent a valid treatment option for at least a subgroup of patients  (e.g.  high  PD-L1  expression).  In  this  regard,  the  MAH  was  asked  to  justify  the  lack  of  a pembrolizumab  monotherapy  arm  based  on  all  available  nonclinical  and  clinical  data.  The  MAH  has provided comparative efficacy data of pembrolizumab in combination with axitinib vs pembrolizumab monotherapy, according to PD-L1 status, from Study KEYNOTE-426 and Study KEYNOTE-427 Cohort A, respectively. Besides the intrinsic limitations of such cross-study comparison, it is acknowledged that data suggests that the combination is more efficacious than pembrolizumab as monotherapy in subjects with PD-L1 CPS&lt;1, with a trend (95%CI overlapping) suggesting a higher benefit even in the CPS ≥ 1 subgroup in terms of ORR and PFS. Indeed, in the CPS ≥ 1 subgroup ORR was 60.5% (95% CI 54.0, 66.7) and 44.2% 95%CI 30.5, 58.7) in the combination and monotherapy, respectively. Median PFS was 15.3 (95% CI 12.6,-) and 9.7 (95%CI 6.7, 16.4). OS data are too immature. No definitive conclusion can be drawn due to the lack of a direct comparison between the combination and pembrolizumab monotherapy in subjects with high PD-L1 expression. However, it is acknowledged that the combination of these two agents with distinct mechanisms of action tend to provide a higher benefit in terms of ORR and PFS.

The rationale for the proposed doses and schedule of the combination is adequately justified based on PK and clinical results of phase Ib Study KN-035 that demonstrated the safety and tolerability feasibility of pembrolizumab 2 mg/Kg Q3W plus axitinib 5 mg BID, and the integrated body of evidence suggesting that 200 mg Q3w is expected to provide similar response and exposures to that expected with the 2 mg/Kg Q3W.

<div style=\"page-break-after: always\"></div>

The open-label design is justified on the basis of the different route and schedule of administration of drugs in the two arms. In view of the risk of bias due to the open label-design, the assessment of response has been performed based on blinded independent central review (BICR).

Participants were stratified according to International Metastatic RCC Database Consortium (IMDC) risk group  (favourable  versus  intermediate  versus  poor),  and  Geographic  region  (North  America  versus Western Europe versus 'Rest of the World'). Stratification factors appear appropriate.

The  primary  objectives  of  the  study  were  to  compare  the  OS  and  PFS  per  RECIST  1.1  by  BICR  in participants treated with pembrolizumab + axitinib vs sunitinib. ORR, DCR, DoR, safety and tolerability profile  of  pembrolizumab,  PFS  and  OS  rate  at  12,  24  and  18  months,  and  PROs  were  secondary objectives. The choice of OS and PFS as primary objectives can be considered appropriate.

The expected median PFS time in the control group was 13 months. Based on 487 PFS events, the study had ~99% power to detect a hazard ratio of 0.60 for PFS at alpha=0.2% (1-sided). The expected median OS time in the control group was 33 months. Based on 404 death events, the study had 80% power to detect  a  hazard  ratio  of  0.75  for  OS  at  alpha=2.3%  (1-sided).  The  sample  size  calculations  result congruent with the assumptions made.

Efficacy analyses were conducted using the intention-to-treat (ITT) population. The statistical methods used  for  time  to  events  and  binary  endpoints  are  considered  adequate.  Two  interim  analyses  were planned for OS and one for PFS. A group sequential approach was used to allocate alpha between the interim and final analyses. The IA1 (first interim analysis for PFS and OS) was planned after enrollment completion, when a minimum of 305 PFS events had accrued and all participants were followed for at least  7  months  after  randomization,  and  it  was  expected  to  be  22  months  after  the  first  subject randomized. Approximately 48% of the final required OS events (or 195 deaths) were expected at that time. The study met its primary endpoints at IA1. The approaches, to control Type I error is appropriate.

A total of 1062 participants were screened (first participant screened on 06-OCT-2016) and 861 were randomly allocated from 24-OCT-2016 to 24-JAN-2018 across 124 global study sites in 16 countries. Screen failure was mostly due to not meeting specific eligibility criteria. No new concern arises regarding the conduction of the study.

Important  protocol  deviations  were  reported  in  a  similar  rate  in  the  2  groups  (14.2%  in  the pembrolizumab + axitinib group and 12.9% in the sunitinib group), and it is considered unlikely that they impacted on the results.

Overall,  there  were  no  meaningful  imbalances  in  patients'  baseline  characteristics  among  treatment arms, and the enrolled population is overall representative of real life EU patients. In the experimental arm there were few more women (28.7% vs 25.4%) and subjects aged ≥ 65 years (39.8% vs 35.2%) and less subjects with ≥ 2 organs involved with disease at baseline (72.9% vs 77.2%) than in the control arm. The percentage of participants in the IMDC risk categories of favorable, intermediate, and poor risk was 31.2%, 56.2% and 12.5%, respectively. A total of 57.7% of participants had a tumor tissue PD-L1 expression score of CPS ≥ 1.

The supportive trial Keynote 427 is a phase 2, open-label trial of pembrolizumab monotherapy to evaluate the efficacy and safety of pembrolizumab as 1L treatment for advanced ccRCC (Cohort A) and nccRCC (Cohort B). Data from Cohort A which included 110 patients are supportive of the present submission. Data up to the DBL of 07-Sep-2018 including a medium follow-up of 18 months are presented. No mature OS data was available and an update should be provided (OC). In Keynote 427, the PD-L1 positive subgroup was constituted by 52 (53.7%) out of the 110 randomised subjects. The OS rates at 3 months, 6 months, and 12 months were 97.3%, 92.7%, and 88.2%, respectively.

<div style=\"page-break-after: always\"></div>

## Efficacy data and additional analyses

The results submitted by the MAH are based on the pre-planned IA1 for PFS and OS (0.75 information fraction to PFS and 0.48 information fraction to OS) with a data cut-off date 24-AUG-2018. The median duration of follow up was 13.2 months (range: 0.1 to 21.5 months) in the pembrolizumab + axitinib group and 12.1 months (range: 0.4 to 22.0 months) in the sunitinib group. As per CHMP request, updated efficacy  data  with  cut-off  date  2  Jan  2019  have  been  submitted,  with  an  additional  4.3  months  of follow-up  compared to the IA1. The median follow up is now 17.4 months and 15.7 months in the experimental arm and in the control arm, respectively.

The ITT population included 432 patients randomized to pembro combo and 429 to sunitinib.

## Primary endpoints

A statistically significant benefit in OS has been observed for pembrolizumab + axitinib over sunitinib (HR of 0.53, 95% CI 0.38, 0.74; p=0.00005) with 59 (13.7%) and 97 (22.6%) events in the experimental and the control arm, respectively. The median OS for both arms was not reached. The estimated percentage of patients who were alive at 12 months was 89.9% (95% CI, 86.4 to 92.4) in the pembrolizumabaxitinib group and 78.3% (95% CI, 73.8 to 82.1) in the sunitinib group. The corresponding estimates for 18 months were 82.3% (95% CI, 77.2 to 86.3) and 72.1% (95% CI, 66.3 to 77.0). Data are considered rather immature, with an OS event rate of 13.7% and 22.6% for the combination and sunitinib arm. The amount of censoring was high in the tail of the K-M curves, starting at month 7.  In order to have estimations regarding OS more precise, updated OS data were requested. Since a statistically significant improvement had been demonstrated at IA1, only descriptive OS and PFS data, not formally tested for statistical significance, were provided. Overall, 50 additional OS events (25 in each arm) were observed. A clear benefit is still observed in the overall population as well as in the IMDC poor (HR= 0.50, 95%CI 0.29, 0.87) and intermediate (HR= 0.52, 95%CI 0.36,0.75) risk categories. With a total of 25 OS events (13 and 12 in the experimental and control arm, respectively), it is not possible to draw any sound conclusion with regard to the IMDC favourable risk group (HR 0.94, 95%CI 0.43, 2.07). The OS KM curves in this subgroup are, as expected, superimposable at this stage.

Overall, OS subgroup analyses show results consistent with the primary analysis, although very few events are observed in specific subgroups such as in the favourable IMDC risk group.

A  statistically  significant  benefit  in  PFS  has  been  also  observed  for  pembrolizumab  +  axitinib  over sunitinib (HR of 0.69, 95% CI 0.56, 0.84; p=0.00014) with 183 (42.4%) and 213 (49.7%) events in the experimental and the control arm, respectively. The median PFS is 15.1 (95% CI 12.6, 17.7) and 11.0 (95% CI 8.7, 12.5) in the experimental and the control arm, respectively. The KM curves tend to separate quite early and tend to remain parallel over time. The censoring due to≥ 2 missing assessment/New Anticancer Therapy/No Post-Baseline Assessment are much more frequent in the control arm (14.8%) than in the experimental arm (7%). PFS sensitivity analysis based on different censoring rules show a consistent effect. In the updated PFS data, a total of 43 additional PFS events (24 in the experimental arm and 19 in the control arm) were reported. As observed for OS, a clear benefit in terms of PFS is also observed in the ITT population (HR 0.69, 95%CI 0.57, 0.83), as well as in the IMDC poor (HR= 0.57, 95%CI 0.35, 0.92) and intermediate (HR= 0.70, 95%CI 0.55,0.90) risk categories. With 13 additional PFS events observed in the IMDC favourable risk group (now occurred in 103/269 patients, i.e. 38.2% of the subjects with baseline favourable IMDC risk) the HR is 0.73 (95% CI 0.49, 1.09) slightly improved compared to the previous report (HR 0.81, 95%CI 0.53, 1.24). The PFS KM curves in this subgroup tend to separate after 7 months.

Overall, PFS subgroup analyses show results consistent with the primary analysis, although a lower effect is observed in the favourable IMDC risk group and in subjects with CPS&lt;1%.

<div style=\"page-break-after: always\"></div>

Interestingly, PFS based on investigator assessment is not statistically significant with an HR of 0.82 (95% CI 0.67, 1.00) and a median PFS of 14.5 (95% CI 12.5, 17.7) and 11.9 (95% CI 10.1, 15.0) in the experimental and the control arm, respectively. The concordance between Investigator and BICR, show an overall agreement around 80%. Compared to Investigator BICR assigned PD at a later time in 13% and 8% for the experimental arm and the control arm, but disagreed in 20% and 25%. Among subjects with no PD based on Investigators' Assessment, BICR detected much more frequently in the control arm (22%) than in the experimental arm (11%). This substantial discrepancy is somewhat unexpected and raises concern with regard to the robustness of the results.

Objective response rate based on BICR assessment were observed in 59.3% (95% CI 54.5,63.9) of the patients treated with the combination compared to 35.7% (95% CI 31.1,40.4) in the control arm. The median time to response is similar in the two arms, while the duration of response tend to be longer in the experimental arm with 70.6% of patients still in response at 12 months in the control arm vs 61.6% in the control  arm.  At  the  updated  analysis,  with  only  15  more  objective  responses  reported  (3  in  the experimental arm and 12 in the control arm), results are very similar to those reported at the IA1. The ORR difference of 20.71% (95% CI 9.00, 31.90) in the IMDC favourable risk group, quite consistent with other IMDC risk subgroups, is noted.

With regard to PROs, Time to true deterioration in the Functional Assessment of Cancer Therapy - Kidney Symptom Index - Disease related Symptoms (FKSI-DRS) differed between the two arms with a worse outcome for the experimental arm (HR 1.44; 95% CI 1.14, 1.82; nominal p:0.999). A worsening from baseline to Week 30 was observed for diarrhea in the EORTC QLQ-C30 symptom scale.

## Contribution of each component in the combination regimen.

The absence of a well designed clinical trial testing the combination and monotherapies (pembrolizumab and axitinib) leads to uncertainties when it comes to reaching a benefit risk conclusion. Beneficial result of the comparison of pembrolizumab + axitinib versus sunitinib can be reasoned by each of the two components. It could be possible that the whole treatment effect might be reasoned by axitinib without an additional effect of pembrolizumab or vice versa. Pembrolizumab and axitinib are two different drugs with different  action  and  independent  activities.  The  applicant  provides  the  supportive  phase  3  study A4061051, where 288 patients were randomly assigned in a 2:1 ratio to either axitinib or sorafenib. The confirmed  ORR  for  pembrolizumab  +  axitinib  in  KEYNOTE-426  (60.0%  [55.2,  64.6])  from  the 02-JAN-2019 cutoff was   higher relative to what was observed for axitinib in Study A4061051 (32.3% [95% CI: 25.7, 39.4]) (Table 24). This was also the case for the median PFS (17.1 months [13.6, 18.9] vs.  10.1  months  [95% CI: 7.2, 12.1], respectively).  The  median  OS  was  still  not  reached  with  the updated data for KEYNOTE-426 in comparison to 21.7 months (95% CI: 18.0, 31.7) for axitinib in Study A4061051. The observed OS rate at 12 months in the pembrolizumab + axitinib group continued to be higher relative to what was observed for axitinib in Study A4061051 (89.5% versus 72.0%).

In addition, the applicant provides the supportive phase 2 Keynote-427, where 110 patients with ccRCC were  included  in  a  pembrolizumab  monotherapy  cohort  A.  The  results  for  the  pembrolizumab monotherapy arm of this study showed an ORR of 36.4 % (95%CI: (27.4, 46.1)), a median PFS of 7.1 months (95%CI: (5.6, 11.0)) and an OS rate at 12 month of 88.2%.

Considering  the  ORR  and  PFS  data  described  in  the  supportive  studies,  these  results  support  the hypothesis that each component is contributing to the treatment effect in the combination regimen, ORR and PFS results of both monotherapies were lower compared to the results of the combination therapy. However,  no  meaningful  differences  could  be  observed  between  the  preliminary  OS  data  for pembrolizumab monotherapy, axitinib monotherapy and the combination of pembrolizumab and axitinib. Even if acknowledging the differences in comparing OS data across different trials, there remains an uncertainty whether both components would be needed in the 1L treatment of RCC.

<div style=\"page-break-after: always\"></div>

## Analyses of efficacy endpoints according to PD-L1 expression:

Results in terms of OS for patients with PDL1 CPS≥1% showed a median not reached at the time of the analysis (HR: 0.54 (95%CI: 0.35, 0.84). For patients with PD-L1&lt;1 no medians were reached in either study arm, too (HR: 0.59 (95%CI: 0.34, 1.03). Superior efficacy of pembrolizumab+ axitinib combination over sunitinib therapy has been observed regardless PD-L1 expression.

## Favourable risk patients

Efficacy regarding OS benefit is demonstrated for the overall study population based on the first IA with a median follow-up of 13.2 months. OS data are too immature to support efficacy in the favourable risk group which comprises 1/3 of the ITT population (with only 7 events in the pembrolizumab+ axitinib vs. 10 events in the sunitinib group, observed so far).

The MAH was requested to provide updated efficacy data to justify the use this combination in the proposed patient population. Updated OS data do not provide any additional information. Differently, updated PFS data show a trend to an improved effect in the IDMC favourable risk subgroup compared to data initially submitted. Overall, based on the updated data it can be agreed that a benefit in terms of PFS and  ORR  is  observed  across  all  IMDC  risk  group,  including  the  favourable.  There  is  no  apparent detrimental effect in terms of OS in the IMDC favourable risk subgroup, although also updated data are quite immature. It is reassuring that most of the patients (11/15, 73%) who discontinued treatment with pembrolizumab and axitinib due to hepatic AEs received subsequent anti-cancer treatment, which is even higher than the rate of patients (88/176, 50%) who received a subsequent anti-cancer treatment therapy after discontinuing pembrolizumab + axitinib for any reason. Unfortunately, PFS2 data does not seem to have been captured. Taking into account the clearly worse safety profile of the combination, in order to provide further reassurance, the MAH was asked to provide comparative data on the ability to receive subsequent anticancer therapy in all subjects who discontinued treatment due to any AEs in the two arms. While the rate in the two arms appears to be similar (65/429 [15.2%] and 61/425 [14.4%] in the pembrolizumab plus axitinib arm and the sunitinib arm, respectively), less subjects in the experimental arm received subsequent systemic treatments (24/65 [36.9%] and 30/61 [49.2%] in the pembrolizumab plus axitinib arm and the sunitinib arm, respectively). Looking at those patients who received subsequent systemic treatments, it seems that treatment with pembrolizumab and axitinib does not negatively affect the outcome or the ability to tolerate subsequent treatment: indeed, treatment duration of the first subsequent anti-cancer therapy tended to be longer for patients in the experimental arm compared to the control arm, and no relevant differences were observed between the two arms in terms of reason for discontinuation  of  the  first  subsequent  anti-cancer  therapy  with  the  exception  of  discontinuation  for toxicity  that  were  less  frequently  observed  in  the  experimental  arm  (4/24)  than  in  the  control  arm (10/28). Looking at those patients who discontinued study treatment(s) due to an AE and received no further anti-cancer treatments, the rate of patients still alive at the data cutoff of the submitted analysis (02 JAN 2019) was higher in the experimental arm (24/41, corresponding to 58.5%) compared to the sunitinib arm (13/31 corresponding to 41.9%).

## Special populations

The benefit of pembrolizumab + axitinib over sunitinib was seen across the age subgroups: &lt;65 years and ≥ 65 years.

## 2.4.4. Conclusions on the clinical efficacy

The combination of pembrolizumab and axitinib demonstrated superiority vs sunitinib in terms of PFS and OS in patients with advanced RCC, supported by an advantage in terms of ORR. The lack of monotherapy experimental arms in study KN-426 hampers the assessment of the contribution of each component of the combination treatment. Even though exploratory data show higher ORR with the combination

<div style=\"page-break-after: always\"></div>

compared to both pembrolizumab and axitinib, only indirect comparisons are available. This is particularly relevant for pembrolizumab, since conventional response evaluation criteria may underestimate the long-term benefit and it cannot be excluded that pembrolizumab monotherapy could represent a valid treatment option for at least a subgroup of patients (e.g. high PD-L1 expression).  Overall, based on the updated data, a benefit in terms of PFS and ORR is observed across all IMDC risk group, including the favourable. Additionally, there is no apparent detrimental effect in terms of OS in the IMDC favourable risk subgroup, although data are quite immature.

The following measures are considered necessary to address issues related to clinical efficacy: the final CSR of the pivotal Keynote-426 study is to be provided post-approval as Annex II condition, in particular to further characterize the benefit of the combination treatment in the favourable IDMC risk group based on data with longer follow-up.

## 2.5. Clinical safety

## Introduction

The safety evaluation provided to support the claimed indication of pembrolizumab in combination with axitinib (Inlyta®, AG-013736) for 1L treatment of subjects with advanced RCC is based on the first interim analysis (IA1) of the KEYNOTE-426 study. This is an ongoing, Phase 3, randomized, open-label, multicenter, global study to evaluate the efficacy and safety of Pembrolizumab+Axitinib versus Sunitinib for the 1L treatment for advanced RCC with clear cell component. Participants were stratified by IMDC risk category and geographic region and then randomized in a 1:1 ratio between treatment arms. IA1 was a combined event- and time-driven analysis with data cut-off date 24-AUG-2018 and a median duration of follow-up of 12.8 months [range: 0.1, 22.0].

Provided safety summary tables including all subjects as treated (ASaT) population show side-by-side safety results of the following four datasets:

- KEYNOTE-426 Pembrolizumab plus Axitinib Safety Dataset (N = 429)
- KEYNOTE-426 Sunitinib Safety Dataset (N = 425)
- Pembrolizumab Monotherapy Reference Safety Dataset (N = 4439): to enable a comparison of safety data  from  KEYNOTE  426  with  the  established  safety  profile  for  pembrolizumab  monotherapy.  It included all subjects who received at least one dose of pembrolizumab in KEYNOTE-001 Part B1, B2, B3, D, C, F1, F2, F3, KEYNOTE-002 (original phase), KEYNOTE-006, KEYNOTE-010, KEYNOTE-012 Cohorts  B  and  B2,  KEYNOTE-013  Cohort  3,  KEYNOTE-024,  KEYNOTE-040,  KEYNOTE-045, KEYNOTE-052, KEYNOTE-055 and KEYNOTE-087.
- Cumulative Running Safety Dataset for Pembrolizumab Monotherapy (N = 6436): to evaluate the consistency of the pembrolizumab safety profile across indications. It included safety data collected as of the data cut-off (07-SEP-2018) for KEYNOTE-427 Cohort A (RCC monotherapy) and participants treated  with  pembrolizumab  from  the  pembrolizumab  monotherapy  RSD  and  studies  previously submitted for review in the following indications: KEYNOTE-001 Part B1, B2, B3, D, C, F1, F2, F3; KEYNOTE-002 (original phase); KEYNOTE-006; KEYNOTE-010; KEYNOTE-012 Cohort B and B2 (head and  neck  cancer),  Cohort C  (urothelial  tract  cancer  cancer),  and  Cohort D  (gastric  cancer); KEYNOTE-013 Cohort 3 (classical Hodgkin lymphoma) and Cohort 4a (primary mediastinal large B-cell lymphoma); KEYNOTE-017; KEYNOTE-024, KEYNOTE-028 Cohort B4; KEYNOTE-040; KEYNOTE-042; KEYNOTE-045 and KEYNOTE-052 (urothelial cancer); KEYNOTE-054; KEYNOTE-055,

<div style=\"page-break-after: always\"></div>

KEYNOTE-059  Cohort 1  (gastric  cancer);  KEYNOTE-087;  KEYNOTE-158;  KEYNOTE-164  Cohort A (colorectal cancer); KEYNOTE-170; KEYNOTE-224.

Additional supportive safety data is provided to understand the contribution of each drug to the safety profile of the combination in the claimed indication:

- Axitinib monotherapy arm: data from the Pfizer-Sponsored, Phase 3, randomized, open-label, multicenter Study A4061051 (Axitinib vs Sorafenib study) for the 1L treatment of metastatic RCC (data cut-off date 27 July 2012; N = 189)
- Pembrolizumab monotherapy Cohort A of  the  ongoing,  Phase  2,  nonrandomized, open-label, 2-cohort, multicenter, global KEYNOTE-427 study for the 1L treatment of advanced ccRCC (data cut-off date 07 Sept 2018; N =110)

The  safety  data  from  the  52 participants  enrolled  in  the  Phase  1b  study  (Study  A4061079)  of pembrolizumab+axitinib  were  not  pooled  with  KEYNOTE-426  for  this  summary  and  are  presented separately in the dossier.

<div style=\"page-break-after: always\"></div>

## Demographic and other baseline characteristics

Table 2.7.4-rcc1: 4 Subject Characteristics (ASaT Population)

|                                           | KN426 Data for Pembrolizumab+ Axitinibl   | KN426 Data for Pembrolizumab+ Axitinibl   | KN426 Sumitinibl   | KN426 Sumitinibl   | Reference Safety Dataset for Pembrolizmab Monotherapy   | Reference Safety Dataset for Pembrolizmab Monotherapy   | Cumulative Rumning Safety Dataset for Pembrolizumab Monotherapy   | Cumulative Rumning Safety Dataset for Pembrolizumab Monotherapy   |
|-------------------------------------------|-------------------------------------------|-------------------------------------------|--------------------|--------------------|---------------------------------------------------------|---------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|
|                                           |                                           | (%)                                       |                    | (%)                |                                                         | (%)                                                     | n                                                                 | (%)                                                               |
| Subjects in population                    | 429                                       |                                           | 425                |                    | 4,439                                                   |                                                         | 6,436                                                             |                                                                   |
| Gender                                    |                                           |                                           |                    |                    |                                                         |                                                         |                                                                   |                                                                   |
| Male                                      | 306                                       | (71.3)                                    | 318                | (74.8)             | 2,869                                                   | (64.6)                                                  | 4,159                                                             | (64.6)                                                            |
| Female                                    | 123                                       | (28.7)                                    | 107                | (25.2)             | 1,570                                                   | (35.4)                                                  | 2,277                                                             | (35.4)                                                            |
| Age (Years)                               |                                           |                                           |                    |                    |                                                         |                                                         |                                                                   |                                                                   |
| ≤65                                       | 257                                       | (59.9)                                    | 277                | (65.2)             | 2,453                                                   | (55.3)                                                  | 3,709                                                             | (57.6)                                                            |
| >=65                                      | 172                                       | (40.1)                                    | 148                | (34.8)             | 1,986                                                   | (44.7)                                                  | 2,727                                                             | (42.4)                                                            |
| Mean                                      | 61.2                                      |                                           | 60.7               |                    | 61.1                                                    |                                                         | 60.2                                                              |                                                                   |
| SD                                        | 10.0                                      |                                           | 10.1               |                    | 13.5                                                    |                                                         | 13.6                                                              |                                                                   |
| Median                                    | 62.0                                      |                                           | 61.0               |                    | 63.0                                                    |                                                         | 62.0                                                              |                                                                   |
| Range                                     | 30 to 89                                  |                                           | 26to 88            |                    | 15 to 94                                                |                                                         | 15 to 94                                                          |                                                                   |
| Race                                      |                                           |                                           |                    |                    |                                                         |                                                         |                                                                   |                                                                   |
| American Indian Or Alaska Native          | 2                                         | (0.5)                                     | 2                  | (0.5)              | 14                                                      | (0.3)                                                   | 27                                                                | (0.4)                                                             |
| Asian                                     | 66                                        | (15.4)                                    | 70                 | (16.5)             | 411                                                     | (9.3)                                                   | 721                                                               | (11.2)                                                            |
| Black Or African American                 | 9                                         | (2.1)                                     | 8                  | (61)               | 6                                                       | (2.1)                                                   | 117                                                               | (1.8)                                                             |
| Missing                                   | 8                                         | (61)                                      | 5                  | (7D)               | 9                                                       | (1.4)                                                   | 600                                                               | (9.3)                                                             |
| Multiracial                               | 1                                         | (0.2)                                     | 2                  | (0.5)              | 24                                                      | (0.5)                                                   | 58                                                                | (0.9)                                                             |
| Native Hawaiian Or Other Pacific Islander | 1                                         | (0.2)                                     | 0                  | (0.0)              | 4                                                       | (0.1)                                                   | 6                                                                 | (0.1)                                                             |
| White                                     | 342                                       | (79.7)                                    | 338                | (S'6L)             | 3,829                                                   | (86.3)                                                  | 4,907                                                             | (76.2)                                                            |
| Ethnicity                                 |                                           |                                           |                    |                    |                                                         |                                                         |                                                                   |                                                                   |
| Hispanic Or Latino                        | 18                                        | (4.2)                                     | 18                 | (4.2)              | 222                                                     | (5.0)                                                   | 377                                                               | (5.9)                                                             |
| Not Hispanic Or Latino                    | 375                                       | (87.4)                                    | 383                | (90.1)             | 3,952                                                   | (89.0)                                                  | 5,206                                                             | (80.9)                                                            |
| Not Reported                              | 14                                        | (3.3)                                     | 12                 | (2.8)              | 151                                                     | (3.4)                                                   | 197                                                               | (3.1)                                                             |
| Unknown                                   | 21                                        | (4.9)                                     | 11                 | (2.0)              | 109                                                     | (2.5)                                                   | 135                                                               | (2.1)                                                             |
| Missing                                   | 1                                         | (0.2)                                     | 1                  | (0.2)              | 5                                                       | (0.1)                                                   | 521                                                               | (8.1)                                                             |
| Geographic Region                         |                                           |                                           |                    |                    |                                                         |                                                         |                                                                   |                                                                   |
| US                                        | 80                                        | (18.6)                                    | 80                 | (18.8)             | 1,911                                                   | (43.1)                                                  | 2,242                                                             | (34.8)                                                            |
| Ex-US                                     | 349                                       | (81.4)                                    | 345                | (81.2)             | 2,528                                                   | (56.9)                                                  | 4,194                                                             | (65.2)                                                            |
| Geographic Region                         |                                           |                                           |                    |                    |                                                         |                                                         |                                                                   |                                                                   |
| EU                                        | 161                                       | (37.5)                                    | 154                | (36.2)             | 1,537                                                   | (34.6)                                                  | 2,298                                                             | (35.7)                                                            |
| Ex-EU                                     | 268                                       | (62.5)                                    | 271                | (63.8)             | 2,902                                                   | (65.4)                                                  | 4,138                                                             | (64.3)                                                            |
| GeographicRegion                          |                                           |                                           |                    |                    |                                                         |                                                         |                                                                   |                                                                   |
| East Asia                                 | 62                                        | (14.5)                                    | 67                 | (15.8)             | 303                                                     | (6.8)                                                   | 601                                                               | (9.3)                                                             |
| Non-Est Asia                              | 367                                       | (85.5)                                    | 358                | (84.2)             | 4,136                                                   | (93.2)                                                  | 5.835                                                             | (90.7)                                                            |

Inclndes allsubjecta who recoived at least ons doso of Sunitinib in KN426.

Include: all subjects who reccived at least ons dor of Pembrolizumab and/or Axitinib in KN426.

nclude allubjects who receivdat least one dose ofpmbrolizumab in KN001 PartB1, B2, B3, D, C,Fl,F2,F3, KN002 (original phavo). KN006, KN010, KN012 Cohorts B amd B2 (HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN045,RN052,KN055andKN0S7.

ncludos all subjocts who roccived at loast ono doso of pombrolizumab in KN001 Part B1, B2, B3. D,C,F1,F2,F3, KN002 (original phave), KN006, KN010, KN012 Cohorts B and B2 (HNSCC), Cohort C (Urothelial Tract Cancer) amd Cobort D (Gastic Camcer), KN013 Cohort3 (Hodgkin Lymphomn)and Cohort 4A (MLBCL), KN017, KN024, KN028 Cohort B4, KN040,KN042,KN045,KN052,KN054,KN055,KN059 Cohort 1, KN0S7,KN158,KN164 CohortA,KN170, KN224 and KN427 Cohort A.

Databaso cutoff dato for Lumg (KN001-NSCLC: 23IAN2015,KN010: 30SEP2015,KN024: 10JUL2017,KN042:26FEB2018)

- Databaso cutoff dato for Molamoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 020CT2017)

Databaso cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN055: 22APR2016)

Databaso cutoff date for cHL (KN013-Cohort 3: 27SEP2016, KN0S7: 25SEP2016)

Databaso cutoff dato for Gastric (KN012-Gastic: 26APR2016, KN059-Cohort 1: 21APR2017)

Databaso cutoff dato for Bladder (KN012-Urothelisl: 01SEP2015, KN045: 260CT2017,KN052: 09MAR2017)

Database cutoff date for Colorectal (KN164-Cobort A: 03AUG2016)

Databaro cutoff dato for MLBCL (KN013-Cohort 4A: 04AIUG2017, KN170: 19JAN2018)

Databaso cutoff date for Corviesl (KN028-Cohort B4: 20FEB2017, KN158: 15JAN2018)

Databaso cutoff date for HCC (KN224: 15MAY2018)

Databat9 cutoff dato for RCC (KN426: 24AUG2018,KN427-Cchort A: 07SEP2018)

Databaso cutoff dato for MCC (KN017: 06FEB2018)

Sowee: [ISS: adhm-ad:]

With regards to disease characteristics (KPS, IMDC Risk Category, PD-L1 Status, Sites of Metastatic Disease, Number of Organs Involved, Recurrent/Newly Diagnosed, RCC Stage), treatment arms of the KEYNOTE-426 study were well balanced. Liver metastases were found in approximately 15% of subjects of both treatment arms. In both treatment arms, most subjects (approximately 83%) had undergone prior nephrectomy and only a small proportion (approximately 9%) had received prior radiation therapy.

<div style=\"page-break-after: always\"></div>

## Patient exposure

## Range

Table 2.7.4-rcc1: 2 Summary of Drug Exposure (ASaT Population)

|                                       | KN426 Data for Pembrolizumab + Axitinibl (N=429)   | KN426 Sumitinib (N=425)   | Reference Safety Dataset for PembrolizumabMonotherapy (N=4439)   | CumulativeRuningSafety DatasetforPembrolizumab Monotherapy (N=6436)   |
|---------------------------------------|----------------------------------------------------|---------------------------|------------------------------------------------------------------|-----------------------------------------------------------------------|
| Duration On Therapy (month)           |                                                    |                           |                                                                  |                                                                       |
| Mean                                  | 10.5 10.42 5.36                                    | 8.4 7.82 5.44             | 6.4 4.17 6.08                                                    | 6.8 4.83 6.22                                                         |
| Median                                |                                                    |                           |                                                                  |                                                                       |
| SD                                    |                                                    |                           |                                                                  |                                                                       |
| Range                                 | 0.03 to 21.22                                      | 0.07 to 20.47             | 0.03 to 30.39                                                    | 0.03 to 30.39                                                         |
| Number of PembrolizumabAdministration |                                                    |                           |                                                                  |                                                                       |
| Mean                                  | 13.8                                               | 0.0                       | 10.7                                                             | 11.0                                                                  |
| Median                                | 14.00                                              | 0.00                      | 7.00                                                             | 8.00                                                                  |
| SD                                    | 8.04                                               | 0.00                      | 9.56                                                             | 9.52                                                                  |
|                                       | 1.00 to 31.00                                      | 0.00 to 0.00              | 1.00 to 59.00                                                    | 1.00 to 59.00                                                         |

Each subjectis counted once on each applicable duation category row.

IIncludes all subjects who received at least one dose of Pembrolizumab and/or Axitinib in KN426.

Duration of Exposure is calculated as (last dose date -first dose date +1)/30.4367(months).

I Includes all subjects who received at least one dose ofSunitinib in KN426.

Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C,F1, F2, F3, KN002 (oniginal phase), KN006, KN010, KN012 Cohorts B and B2 (HNSCC), Cohort C (Urothelial TractCancer)andCohortD (Gastric Cancer),KN013 Cohort3(Hodgkin Lymphoma)and Cohort 4A (MLBCL),KN017,KN024,KN028Cohort B4,KN040,KN042,

Includes allsubjects who received at least one dose ofpembrolizumab in KN001 Part B12,B3,D, C,F1,F2,F3,KN002 (original phase), KN006,KN010, KN012 Cohorts B and B2 (HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN045, KN052, KN055 and KN087.

KN045,KN052,KN054,KN055,KN059 Cohort 1,KN087,KN158,KN164 CohortA,KN170,KN224 andKN427 Cohort A.

Database cutoff date for Melanoma (KN001-Melanoma:18APR2014,KN002: 28FEB2015,KN006: 03MAR2015,KN054: 020CT2017)

Database cutoff date forLumg (KN001-NSCLC: 23JAN2015,KN010: 30SEP2015,KN024:10JUL2017,KN042: 26FEB2018)

Database cutoff date forHNSCC (KN012-HNSCC: 26APR2016,KN040: 15MAY2017, KN055: 22APR2016)

Database cutoff date for Gastic (KN012-Gastric: 26APR2016,KN059-Cohort 1: 21APR2017)

Database cutoff date for cHL(KN013-Cohort 3: 27SEP2016,KN087: 25SEP2016)

Database cutoff dateforBladder (KN012-Urothelial:01SEP2015,KN045:26OCT2017,KN052:09MAR2017)

Database cutoff date for Colorectal (KN164-Cohort A:03AUG2016)

Database cutoff date forMLBCL (KN013-Cohort 4A:04AUG2017,KN170: 19JAN2018)

Database cutoff date for Cervical (KN028-Cohort B4: 20FEB2017,KN158:15JAN2018)

Databasecutoff dateforHCC (KN224:15MAY2018)

Database cutoff date forRCC (KN426: 24AUG2018,KN427-Cohort A:07SEP2018)

Databasecutoff dateforMCC (KN017:06FEB2018)

Source:[ISS: adam-adsl; adexsum]

Table 2.7.4-rcc1: 3 Drug Exposure by Duration (ASaT Population)

|                      | KN426Data forPembrolizumab+ Axitinibl (N=429)   | KN426Data forPembrolizumab+ Axitinibl (N=429)   | KN426Data forPembrolizumab+ Axitinibl (N=429)   | KN426 Sunitinibtt (N=425)   | KN426 Sunitinibtt (N=425)   | KN426 Sunitinibtt (N=425)   | ReferenceSafetyDataset for Pembrolizumab Monotherapy (N=4439)   | ReferenceSafetyDataset for Pembrolizumab Monotherapy (N=4439)   | ReferenceSafetyDataset for Pembrolizumab Monotherapy (N=4439)   | CumulativeRunningSafetyDataset for Pembrolizumab Monotherapy (N=6436)   | CumulativeRunningSafetyDataset for Pembrolizumab Monotherapy (N=6436)   | CumulativeRunningSafetyDataset for Pembrolizumab Monotherapy (N=6436)   |
|----------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|
|                      | n                                               | (%)                                             | Person-years                                    | n                           | (%)                         | Person-years                | n                                                               | (%)                                                             | Person-years                                                    | n                                                                       | (%)                                                                     | Person-years                                                            |
| Duration of Exposure |                                                 |                                                 |                                                 |                             |                             |                             |                                                                 |                                                                 |                                                                 |                                                                         |                                                                         |                                                                         |
| >0m                  | 429                                             | (100.0)                                         | (376.6)                                         | 425                         | (100.0)                     | (297.5)                     | 4,439                                                           | (100.0)                                                         | (2.385.6)                                                       | 6,436                                                                   | (100.0)                                                                 | (3,638.4)                                                               |
| >=1 m                | 418                                             | (97.4)                                          | (376.0)                                         | 387                         | (91.1)                      | (295.3)                     | 3,747                                                           | (84.4)                                                          | (2,362.6)                                                       | 5,466                                                                   | (84.9)                                                                  | (3,606.1)                                                               |
| >=3 m                | 382                                             | (89.0)                                          | (370.1)                                         | 333                         | (78.4)                      | (285.4)                     | 2,608                                                           | (58.8)                                                          | (2,173.2)                                                       | 3,900                                                                   | (60.6)                                                                  | (3,346.5)                                                               |
| >=6m                 | 334                                             | (77.9)                                          | (352.1)                                         | 270                         | (63.5)                      | (262.5)                     | 1,816                                                           | (40.9)                                                          | (1,885.9)                                                       | 2,794                                                                   | (43.4)                                                                  | (2,945.5)                                                               |
| >=12m                | 173                                             | (40.3)                                          | (230.3)                                         | 108                         | (25.4)                      | (142.9)                     | 851                                                             | (7'61)                                                          | (1,189.9)                                                       | 1,253                                                                   | (561)                                                                   | (1,773.6)                                                               |
| >=18m                | 41                                              | (9.6)                                           | (64.9)                                          | 18                          | (4.2)                       | (28.9)                      | 256                                                             |                                                                 | (468.2)                                                         | 430                                                                     |                                                                         | (783.4)                                                                 |

Each subject is counted once on each applicable duration category row.

Includes all subjects who received at least one dose of Pembrolizumab and/or Axitinib in KN426.

Duration of Exposure is calculated as (last dose date -first dose date +1)/30.4367(months).

I Includes all subjects who received at least one dose of Sunitinib in KN426.

Includes all subjects who received atleast one dose ofpembrolizumab in KN001 Part B1, B2,B3,D,C,F1,F2,F3,KN002(original phase),KN006,KN010,KN012 Cohorts B and B2(HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN045, KN052,KN055 and KN087.

Cohort C (UrothelialTract Cancer)and Cohort D(Gastric Cancer),KN013 Cohort3(HodgkinLymphoma)and Cohort4A (MLBCL),KN017,KN024,KN028 Cohort B4,KN040,KN042,

Includes all subjects who received at least one dose ofpembrolizumab in KN001 Part B1, B2,B3,D,C,F1, F2,F3, KN002 (oniginal phase),KN006,KN010, KN012 Cohorts B and B2 (HNSCC),

KN045, KN052,KN054, KN055, KN059 Cohort 1, KN087, KN158, KN164 Cohort A,KN170, KN224 and KN427 Cohort A.

Databasecutoff dateforMelanoma(KN001-Melanoma:18APR2014,KN002:28FEB2015,KN006:03MAR2015,KN054:020CT2017)

Databasecutoff dateforLung(KN001-NSCLC:23JAN2015,KN010:30SEP2015,KN024:10JUL2017,KN042:26FEB2018)

Database cutoff date forHNSCC (KN012-HNSCC: 26APR2016,KN040:15MAY2017,KN055:22APR2016)

Database cutoff date for Gastric (KN012-Gastric: 26APR2016,KN059-Cohort 1: 21APR2017)

Database cutoff date forcHL(KN013-Cohort3:27SEP2016,KN087:25SEP2016)

Database cutoff date for Bladder (KN012-Urothelial: 01SEP2015, KN045: 26OCT2017, KN052:09MAR2017)

Database cutoff date for Colorectal (KN164-Cohort A:03AUG2016)

Database cutoff date forMLBCL (KN013-Cohort 4A:04AUG2017,KN170:19JAN2018)

Database cutoff date forCervical(KN028-Cohort B4:20FEB2017,KN158:15JAN2018)

Database cutoff date for HCC (KN224: 15MAY2018)

Database cutoff date for RCC(KN426: 24AUG2018,KN427-Cohort A:07SEP2018)

Database cutoff date for MCC (KN017:06FEB2018)

Source: [ISS: adam-adsl; adexsum]

(5.8)

(6.7)

<div style=\"page-break-after: always\"></div>

## Extent of Exposure Summary of Days on Drug or Doses (ASaT Population)

|                                        | Pembrolizumab + Axitinib   | Pembrolizumab + Axitinib   | Sunitinib         |
|----------------------------------------|----------------------------|----------------------------|-------------------|
|                                        | Pembrolizumab              | Axitinib                   | Sunitinib         |
| Subjects in population                 | 429                        | 429                        | 425               |
| Number of Days on Drug †               |                            |                            |                   |
| N                                      | -                          | 429                        | 425               |
| Mean (SD)                              | -                          | 275.6 (164.1)              | 168.9 (107.8)     |
| Median                                 | -                          | 274.0                      | 162.0             |
| Range                                  | -                          | 1.0 to 618.0               | 2.0 to 421.0      |
| Total Dose Administered (mg) †         |                            |                            |                   |
| N                                      | -                          | 429                        | 425               |
| Mean (SD)                              | -                          | 2,535.0 (1,835.2)          | 7,494.1 (5,012.9) |
| Median                                 | -                          | 2,245.0                    | 6,650.0           |
| Range                                  | -                          | 10.0 to 9,948.0            | 100.0 to 21,000.0 |
| Average Daily Dose Administered (mg) † |                            |                            |                   |
| N                                      | -                          | 429                        | 425               |
| Mean (SD)                              | -                          | 9.1 (2.4)                  | 45.1 (6.5)        |
| Median                                 | -                          | 9.8                        | 50.0              |
| Range                                  | -                          | 4.2 to 18.7                | 25.6 to 50.0      |
| Number of Doses Received §             |                            |                            |                   |
| N                                      | 429                        | -                          | -                 |
| Mean (SD)                              | 13.8 (8.0)                 | -                          | -                 |
| Median                                 | 14.0                       | -                          | -                 |
| Range                                  | 1.0 to 31.0                | -                          | -                 |

'Number of Days on Drug' for a subject is the total number of days when the subject took non -zero doses. 'Total Dose Administered' for a subject is the total doses that the subject took.

'Average Daily Dose Administered' for a subject is calculated by (Total Dose Administered) / (Number of Days on Drug).

† Only apply for Axitinib and Sunitinib.

§ Only apply for Pembrolizumab.

Database Cutoff Date: 24Aug2018.

Source: [P426V01MK3475: adam-adsl; adexsum]

<div style=\"page-break-after: always\"></div>

## Adverse events

The primary safety analyses of IA1 were based on data from the ASaT population. In all tables, individuals are counted only once for a specific AE term by the worst severity recorded.

MedDRA Version 21.0 was used in the generation of AE tables.

## Overall and exposure-adjusted Adverse Events

Table 5.3.5.3.3-rcc1:4

## Adverse Event Summary (ASaT Population)

|                                                                   | KN426 Data for Pembrolizumab + Axitinibl   | KN426 Data for Pembrolizumab + Axitinibl   | KN426 Sunitinib1t   | KN426 Sunitinib1t   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Cunulative Running Safety Dataset for Pembrolizumab Monotherapy'   | Cunulative Running Safety Dataset for Pembrolizumab Monotherapy'   |
|-------------------------------------------------------------------|--------------------------------------------|--------------------------------------------|---------------------|---------------------|----------------------------------------------------------|----------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|
|                                                                   |                                            | (%)                                        | n                   | (%)                 | n                                                        | (%)                                                      | n                                                                  | (%)                                                                |
| Subjects in population                                            | 429                                        |                                            | 425                 |                     | 4,439                                                    |                                                          | 6,436                                                              |                                                                    |
| with one or more adverse events                                   | 422                                        | (98.4)                                     | 423                 | (99.5)              | 4,313                                                    | (97.2)                                                   | 6,225                                                              | (96.7)                                                             |
| with no adverse event                                             | 7                                          | (1.6)                                      | 2                   | (0.5)               | 126                                                      | (2.8)                                                    | 211                                                                | (3.3)                                                              |
| with drug-related' adverse events                                 | 413                                        | (96.3)                                     | 415                 | (97.6)              | 3,140                                                    | (70.7)                                                   | 4,512                                                              | (70.1)                                                             |
| with toxicity grnade 3-5 adverse events                           | 325                                        | (75.8)                                     | 300                 | (70.6)              | 2,153                                                    | (48.5)                                                   | 3,107                                                              | (48.3)                                                             |
| with toxicity grade 3-5 drug-related adverse events               | 270                                        | (62.9)                                     | 247                 | (58.1)              | 660                                                      | (14.9)                                                   | 1,018                                                              | (15.8)                                                             |
| with serious adverse events                                       | 173                                        | (40.3)                                     | 133                 | (31.3)              | 1,729                                                    | (39.0)                                                   | 2,472                                                              | (38.4)                                                             |
| with serious drug-related adverse events                          | 102                                        | (23.8)                                     | 60                  | (14.1)              | 464                                                      | (10.5)                                                   | 720                                                                | (11.2)                                                             |
| who died                                                          | 11                                         | (2.0)                                      | 15                  | (3.5)               | 211                                                      | (4.8)                                                    | 329                                                                | (5.1)                                                              |
| who died due to a drug-related adverse event                      | 4                                          | (0.9)                                      | 7                   | (1.6)               | 22                                                       | (0.5)                                                    | 41                                                                 | (0.6)                                                              |
| discontinued any drug due to an adverse event                     | 131                                        | (30.5)                                     | 59                  | (13.9)              | 538                                                      | (12.1)                                                   | 828                                                                | (12.9)                                                             |
| discontinued Pembrolizumab                                        | 89                                         | (20.7)                                     | 0                   | (0.0)               | 538                                                      | (12.1)                                                   | 828                                                                | (12.9)                                                             |
| discontinued allregimen components                                | 33                                         | (7.7)                                      | 59                  | (13.9)              | 538                                                      | (12.1)                                                   | 828                                                                | (12.9)                                                             |
| discontinued any drug due to a drug-related adverse event         | 111                                        | (25.9)                                     | 43                  | (10.1)              | 259                                                      | (5.8)                                                    | 423                                                                | (6.6)                                                              |
| discontinued Pembrolizumab                                        | 80                                         | (18.6)                                     | 0                   | (0.0)               | 259                                                      | (5.8)                                                    | 423                                                                | (6.6)                                                              |
| discontinued allregimen components                                | 27                                         | (6.3)                                      | 43                  | (10.1)              | 259                                                      | (5.8)                                                    | 423                                                                | (6.6)                                                              |
| discontinued any drug due to a serious adverse event              | 73                                         | (17.0)                                     | 42                  | (9.9)               | 407                                                      | (9.2)                                                    | 608                                                                | (9.4)                                                              |
| discontinued Pembrolizumab                                        | 50                                         | (11.7)                                     | 0                   | (0.0)               | 407                                                      | (9.2)                                                    | 608                                                                | (9.4)                                                              |
| discontinued allregimen components                                | 25                                         | (5.8)                                      | 42                  | (9.9)               | 407                                                      | (9.2)                                                    | 608                                                                | (9.4)                                                              |
| discontinued any drug due to a serious drug-related adverse event | 53                                         | (12.4)                                     | 28                  | (6.6)               | 172                                                      | (3.9)                                                    | 261                                                                | (4.1)                                                              |
| discontinued Pembrolizumab                                        | 42                                         | (9.8)                                      | 0                   | (0.0)               | 172                                                      | (3.9)                                                    | 261                                                                | (4.1)                                                              |
| discontinued allregimen components                                | 19                                         | (4.4)                                      | 28                  | (6.6)               | 172                                                      | (3.9)                                                    | 261                                                                | (4.1)                                                              |

Non-serious adverse events up to 30 days following the last dose and serious adverse events up to 90 days following the last dose are included.

MedDRA preferred terms Neoplasm Progression\", *Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

IInchudes allsubjects who received at least one dose of Sunitinib in KN426.

IInchudes all subjects who received atleast one dose of Pembrolizumab and/or Axitinib in KN426.

Includes all subjects who received at least one dose ofpembrolizumab in KN001 Part B1. B2. B3, D. C, F1. F2, F3, KN002 (oniginal phase), KN006. KN010, KN012 Cohorts B and B2 (HNSCC). KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN045, KN052, KN055 and KN087.

CohortC(Urothelial Tract Cancer) and Cohort D (Gastric Cancer),KN013 Cohort 3 (Hodgkin Lymphoma) and Cohort 4A (MLBCL).KN017,KN024,KN028 Cohort B4,KN040,KN042. KN045, KN052, KN054, KN055, KN059 Cohort 1, KN087,KN158, KN164 Cohort A, KN170, KN224 and KN427 Cohort A.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014,KN002: 28FEB2015, KN006:03MAR2015,KN054: 02OCT2017)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN055: 22APR2016)

Database cutoff date for Gastric (KN012-Gastric: 26APR2016,KN059-Cohort 1: 21APR2017)

Database cutoff date forcHL(KN013-Cohort 3: 27SEP2016,KN087:25SEP2016)

Database cutoff date for Bladder (KN012-Urothelial:01SEP2015,KN045: 26OCT2017,KN052: 09MAR2017)

Database cutoff date for Colorectal (KN164-Cohort A: 03AUG2016)

Database cutoff date for MLBCL (KN013-Cohort4A:04AUG2017,KN170: 19JAN2018)

Database cutoff date for Cervical (KN028-Cohort B4: 20FEB2017, KN158: 15JAN2018)

Database cutoff date for HCC (KN224: 15MAY2018)

Database cutoff date for RCC (KN426: 24AUG2018, KN427-Cohort A: 07SEP2018)

Database cutoff date for MCC (KN017: 06FEB2018)

Souce: [ISS:adam-adsl; adae]

<div style=\"page-break-after: always\"></div>

Table 12-2 Exposure-Adjusted AdverseEventSummary (IncludingMultiple Occurrences of Events) (ASaT Population)

|                                                                                                                                                                                                        | Event Coumt andRate(Events/l00 person-months)                                                                                                                                                          | Event Coumt andRate(Events/l00 person-months)                                                                                                                                                          | Event Coumt andRate(Events/l00 person-months)                                                                                                                                                          | Event Coumt andRate(Events/l00 person-months)                                                                                                                                                          |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                        | Pembrolizumab + Axitinib                                                                                                                                                                               | Pembrolizumab + Axitinib                                                                                                                                                                               | Sumitinib                                                                                                                                                                                              | Sumitinib                                                                                                                                                                                              |
| Number of Subjects exposed Total exposure in person-months                                                                                                                                             | 429 4766.94                                                                                                                                                                                            |                                                                                                                                                                                                        | 425 3924.64                                                                                                                                                                                            |                                                                                                                                                                                                        |
| Total events (rate)                                                                                                                                                                                    |                                                                                                                                                                                                        |                                                                                                                                                                                                        |                                                                                                                                                                                                        |                                                                                                                                                                                                        |
| adverse events drug-related adverse events                                                                                                                                                             | 7,017 3,992 846 551                                                                                                                                                                                    | (147.20) (83.74) (17.75) (11.56)                                                                                                                                                                       | 7,052 4,955 823 565 201                                                                                                                                                                                | (179.69) (126.25) (20.97)                                                                                                                                                                              |
| toxicity grade 3-5 adverse events                                                                                                                                                                      |                                                                                                                                                                                                        |                                                                                                                                                                                                        |                                                                                                                                                                                                        |                                                                                                                                                                                                        |
| toxicity grade 3-5 drug-related adverse events serious adverse events                                                                                                                                  | 284                                                                                                                                                                                                    | (5.96)                                                                                                                                                                                                 |                                                                                                                                                                                                        | (14.40) (5.12)                                                                                                                                                                                         |
| serious drug-related adverse events                                                                                                                                                                    | 137                                                                                                                                                                                                    | (2.87)                                                                                                                                                                                                 | 78                                                                                                                                                                                                     | (661)                                                                                                                                                                                                  |
| adverse events leading to death                                                                                                                                                                        | 11                                                                                                                                                                                                     | (0.23)                                                                                                                                                                                                 | 16                                                                                                                                                                                                     | (0.41)                                                                                                                                                                                                 |
| drug-related adverse events leading to death                                                                                                                                                           | 4                                                                                                                                                                                                      |                                                                                                                                                                                                        | 7                                                                                                                                                                                                      |                                                                                                                                                                                                        |
| adverse events resulting in drug discontinuation                                                                                                                                                       | 180                                                                                                                                                                                                    | (0.08) (3.78)                                                                                                                                                                                          | 65                                                                                                                                                                                                     | (0.18) (99'1)                                                                                                                                                                                          |
| drug-related adverse events resulting in drug                                                                                                                                                          | 152                                                                                                                                                                                                    | (3.19)                                                                                                                                                                                                 | 47                                                                                                                                                                                                     | (1.20)                                                                                                                                                                                                 |
| discontinuation serious adverse events resulting in dng                                                                                                                                                | 80                                                                                                                                                                                                     | (1.68)                                                                                                                                                                                                 | 43                                                                                                                                                                                                     | (1.10)                                                                                                                                                                                                 |
| discontinuation serious drug-related adverse events resulting in drug discontinuation                                                                                                                  | 59                                                                                                                                                                                                     | (1.24)                                                                                                                                                                                                 | 28                                                                                                                                                                                                     | (0.71)                                                                                                                                                                                                 |
| t Dnug exposure is defined as the between the first dose date + 1 day and the earlier of the last dose date +30 or the database cutoff date. Determined by the investigator to be related to the drug. | t Dnug exposure is defined as the between the first dose date + 1 day and the earlier of the last dose date +30 or the database cutoff date. Determined by the investigator to be related to the drug. | t Dnug exposure is defined as the between the first dose date + 1 day and the earlier of the last dose date +30 or the database cutoff date. Determined by the investigator to be related to the drug. | t Dnug exposure is defined as the between the first dose date + 1 day and the earlier of the last dose date +30 or the database cutoff date. Determined by the investigator to be related to the drug. | t Dnug exposure is defined as the between the first dose date + 1 day and the earlier of the last dose date +30 or the database cutoff date. Determined by the investigator to be related to the drug. |

5owce: [P426V01MK3475: adam-adsl; adae]

## Adverse Events (AEs)

## All AEs

Subjects With Adverse Events

By Decreasing Frequency of Preferred Term

(Incidence ≥ 10% in One or More Treatment Groups)

(ASaT Population)

|                                             | KN426 Data for Pembrolizumab+ Axitinibl   | KN426 Data for Pembrolizumab+ Axitinibl   | KN426 Sunitinib   | KN426 Sunitinib   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Cumulative Running Safety Dataset for Pembrolizumab Monotherapy   | Cumulative Running Safety Dataset for Pembrolizumab Monotherapy   |
|---------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------|-------------------|----------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|
|                                             | n                                         | (%)                                       | n                 | (%)               |                                                          | (%)                                                      | n                                                                 | (%)                                                               |
| Subjects in population                      | 429                                       |                                           | 425               |                   | 4.439                                                    |                                                          | 6,436                                                             |                                                                   |
| with one or more adverse events             | 422                                       | (98.4)                                    | 423               | (5'66)            | 4,313                                                    | (97.2)                                                   | 6,225                                                             | (96.7)                                                            |
| with no adverse events                      | 7                                         | (91)                                      | 2                 | (0.5)             | 126                                                      | (2.8)                                                    | 211                                                               | (3.3)                                                             |
| Diarrhoea                                   | 233                                       | (54.3)                                    | 161               | (44.9)            | 925                                                      | (20.8)                                                   | 1,311                                                             | (20.4)                                                            |
| Hypertension                                | 161                                       | (44.5)                                    | 193               | (45.4)            | 165                                                      | (3.7)                                                    | 311                                                               | (4.8)                                                             |
| Fatigue                                     | 165                                       | (38.5)                                    | 161               | (37.9)            | 1,518                                                    | (34.2)                                                   | 2,058                                                             | (32.0)                                                            |
| Hypothyroidism                              | 152                                       | (35.4)                                    | 134               | (31.5)            | 439                                                      | (9.9)                                                    | 666                                                               | (10.3)                                                            |
| Decreased appetite                          | 127                                       | (29.6)                                    | 125               | (29.4)            | 927                                                      | (20.9)                                                   | 1,254                                                             | (19.5)                                                            |
| Palmar-plantar erythrodysaesthesia syndrome | 120                                       | (28.0)                                    | 170               | (40.0)            | 12                                                       | (0.3)                                                    | 21                                                                | (0.3)                                                             |
| Nausea                                      | 119                                       | (27.7)                                    | 134               | (31.5)            | 987                                                      | (22.2)                                                   | 1,332                                                             | (20.7)                                                            |
| Alanine aminotransferase increased          | 115                                       | (26.8)                                    | 64                | (15.1)            | 268                                                      | (6.0)                                                    | 444                                                               | (6.9)                                                             |
| Aspartate aminotransferase increased        | 112                                       | (26.1)                                    | 69                | (16.2)            | 273                                                      | (6.2)                                                    | 469                                                               | (EL)                                                              |
| Dysphonia                                   | 109                                       | (25.4)                                    | 14                | (3.3)             | 104                                                      | (2.3)                                                    | 140                                                               | (2.2)                                                             |
| Cough                                       | 16                                        | (21.2)                                    | 58                | (13.6)            | 908                                                      | (20.5)                                                   | 1,228                                                             | (19.1)                                                            |
| Constipation                                | 89                                        | (20.7)                                    | 62                | (14.0)            | 814                                                      | (18.3)                                                   | 1,085                                                             | (16.9)                                                            |
| Arthralgia                                  | 78                                        | (18.2)                                    | 26                | (6.1)             | 692                                                      | (15.0)                                                   | 929                                                               | (14.4)                                                            |
| Weight decreased                            | 76                                        | (17.7)                                    | 47                | (11.1)            | 392                                                      | (8.8)                                                    | 585                                                               | (9.1)                                                             |
| Proteinuria                                 | 75                                        | (17.5)                                    | 47                | (11.1)            | 38                                                       | (0.9)                                                    | 58                                                                | (60)                                                              |
| Dyspnoea                                    | 69                                        | (16.1)                                    | 46                | (10.8)            | 785                                                      | (17.7)                                                   | 1,054                                                             | (16.4)                                                            |
| Headache                                    | 68                                        | (15.9)                                    | 69                | (16.2)            | 527                                                      | (611)                                                    | 737 155                                                           | (11.5)                                                            |
| Stomatitis                                  | 67                                        | (15.6)                                    | 89                | (20.9)            | 111                                                      | (2.5)                                                    |                                                                   | (2.4)                                                             |
| Asthenia                                    | 65                                        | (15.2)                                    | 63                | (14.8)            | 518                                                      | (11.7)                                                   | 745                                                               | (11.6)                                                            |
| Pruritus                                    | 65                                        | (15.2)                                    | 25                | (5.9)             | 819                                                      | (18.5)                                                   | 1,113                                                             | (17.3)                                                            |
| Vomiting                                    | 65                                        | (15.2)                                    | 79                | (18.0)            | 596                                                      | (13.4)                                                   | 807                                                               | (12.5)                                                            |
| Rash                                        | 61                                        | (14.2)                                    | 47                | (11.1)            | 712                                                      | (16.0)                                                   | 933                                                               | (14.5)                                                            |
| Back pain                                   | 57                                        | (13.3)                                    | 43                | (10.1)            | 530                                                      | (611)                                                    | 711                                                               | (0'11)                                                            |
| Mucosal inflammation                        | 57                                        | (13.3)                                    | 93                | (21.9)            | 77                                                       | (1.7)                                                    | 90 272                                                            | (1.4)                                                             |
| Hyperthyroidism                             | 55                                        | (12.8)                                    | 16                | (3.8)             | 145 602                                                  | (3.3)                                                    | 816                                                               | (4.2)                                                             |
| Pyrexia                                     | 55                                        | (12.8)                                    | 43                | (10.1)            | 323                                                      | (13.0)                                                   |                                                                   | (12.7)                                                            |
| Pain in extemity                            | 51                                        | (611)                                     | 42                | (9.9)             |                                                          | (7.3)                                                    | 416                                                               | (6.5)                                                             |
| Abdominal pain                              | 49                                        | (11.4)                                    | 29                | (6.8)             | 411                                                      | (9.3)                                                    | 616                                                               | (9.6)                                                             |
| Blood creatinine increased                  |                                           | (11.2)                                    |                   |                   |                                                          |                                                          |                                                                   |                                                                   |
|                                             | 48                                        |                                           | 51                | (12.0)            | 207                                                      | (4.7)                                                    | 303                                                               | (4.7)                                                             |
| Dysgeusia Anaemia                           | 47 34                                     | (11.0) (7.9)                              | 131 100           | (30.8) (23.5)     | 117 649                                                  | (2.6) (14.6)                                             | 156 923                                                           | (2.4) (14.3)                                                      |
| Dyspepsia                                   | 22                                        | (5.1)                                     | 62                | (14.0)            | 101                                                      | (2.3)                                                    | 165                                                               | (2.6)                                                             |
| Gastrooesophageal reflux disense            | 18                                        | (4.2)                                     | 48                | (11.3)            | 98                                                       | (2.2)                                                    | 135                                                               | (2.1)                                                             |
| Platelet count decreased                    | 16                                        | (3.7)                                     | 77                | (18.1)            | 59                                                       | (1.3)                                                    | 83                                                                | (ED)                                                              |
| Thrombocytopenia                            | 11                                        | (2.6)                                     | 99                | (23.3)            |                                                          |                                                          | 105                                                               | (1.6)                                                             |
|                                             |                                           |                                           |                   |                   | 73                                                       | (1.6)                                                    |                                                                   |                                                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

Source: [ISS: adam-adsl; adae]

Figure 12-1

Between-Treatment Comparisons in AdverseEvents Selected Adverse Events (&gt;= 10% Incidence) and Sorted by Risk Difference (ASaT Population) A (N=429) vs. B (N=425)

<!-- image -->

AstandsforPembrolizumab+Axitiniband BstandsforSuunitinib

DatabaseCutoffDate:24Aug2018.

Source:[P426V01MK3475:adam-adsl;adae]

<div style=\"page-break-after: always\"></div>

Table 14.3-18 Exposure-AdjustedAdverseEvents (IncludingMultiple Occurrences ofEvents) (Incidence≥10% in One or MoreTreatment Groups) (ASaT Population)

|                                                                                 | Event Count and Rate (Events/100 person-months)   | Event Count and Rate (Events/100 person-months)   |
|---------------------------------------------------------------------------------|---------------------------------------------------|---------------------------------------------------|
|                                                                                 | Pembrolizumab Sunitinib                           | Pembrolizumab Sunitinib                           |
|                                                                                 | + Axitinib                                        |                                                   |
| Number of subjects exposed                                                      | 429                                               | 425                                               |
| Total exposure* in person-months                                                | 4766.9                                            | 3924.6                                            |
| Total events (rate)                                                             | 7,017 (147.2)                                     | 7,052 (179.7)                                     |
| Bloodandlymphaticsystemdisorders                                                | (61) 16                                           | 577 (14.7)                                        |
| Anaemia                                                                         | 36 (0.8)                                          | 155 (3.9)                                         |
| Neutropenia                                                                     | 11 (0.2)                                          | 152 (3.9)                                         |
| Thrombocytopenia                                                                | 13 (0.3) 64 (1.3)                                 | 168 (4.3) 45 (1.1)                                |
| Cardiac disorders Endocrine disorders                                           | 278 (5.8)                                         | 196 (5.0)                                         |
| Hyperthyroidism                                                                 | 60 (1.3)                                          | 18 (0.5)                                          |
| Hypothyroidism                                                                  | 178 (3.7)                                         | 174 (4.4)                                         |
| Eye disorders                                                                   | 69 (1.4)                                          | 87 (2.2)                                          |
| Gastrointestinaldisorders                                                       | 1,402 (29.4)                                      | 1,407 (35.9)                                      |
| Abdominal pain                                                                  | 66 (1.4)                                          | 33 (0.8)                                          |
| Constipation Diarhoea                                                           | 107 (2.2) 508 (10.7)                              | 70 (1.8) 384 (9.8)                                |
|                                                                                 | 26 (0.5)                                          | 73 (1.9)                                          |
| Dyspepsia                                                                       | 18 (0.4)                                          | 61 (1.6)                                          |
| Gastrooesophageal reflux disease Nausea                                         | 176 (3.7)                                         | 205 (5.2)                                         |
| Stomatitis                                                                      | 86 (1.8)                                          | 111 (2.8)                                         |
| Vomiting                                                                        | 99 (2.1)                                          | 127 (3.2)                                         |
| General disorders andadministrationsiteconditions                               | 622 (13.0)                                        | 711 (18.1)                                        |
| Asthenia                                                                        | 88 (1.8)                                          | 81 (2.1) 214 (5.5)                                |
| Fatigue                                                                         | 208 (4.4)                                         |                                                   |
| Mucosalinflammation                                                             | 78 (1.6)                                          | 145 (3.7)                                         |
| Pyrexia                                                                         | 68 (1.4)                                          | 47 (1.2)                                          |
| Hepatobiliary disorders                                                         | 60 (1.3)                                          | 61 (1.0)                                          |
| Infectionsandinfestations                                                       | 364 (7.6)                                         | 266 (6.8) 49 (1.2)                                |
| Injury,poisoningandproceduralcomplications                                      | 61 (1.3)                                          | 944 (24.1)                                        |
| Investigations                                                                  | 866 (18.2)                                        |                                                   |
| Alanine aminotransferase increased                                              | 164 (3.4)                                         | 81 (2.1)                                          |
| Investigations                                                                  | 866 (18.2)                                        | 944 (24.1)                                        |
| Aspartate aminotransferaseincreased                                             | 168 (3.5)                                         | 95 (2.4) 72 (1.8)                                 |
| Bloodcreatinineincreased Neutrophil count decreased                             | 79 (1.7) 6 (0.1)                                  | 109 (2.8)                                         |
| Platelet count decreased                                                        | 21 (0.4)                                          | 151 (3.8)                                         |
| Weight decreased                                                                | 86 (1.8)                                          | 54 (1.4)                                          |
| Whitebloodcellcountdecreased                                                    | 2 (0.0)                                           | 97 (2.5)                                          |
| Metabolismandnutritiondisorders                                                 | 539 (11.3)                                        | 436 (11.1)                                        |
| Decreased appetite                                                              | 174 (3.7)                                         | 156 (4.0)                                         |
| Musculoskeletalandconnectivetissuedisorders                                     | 453 (9.5)                                         | 281 (7.2)                                         |
| Arthralgia                                                                      | 96 (2.0)                                          | 34 (0.9)                                          |
| Back pain                                                                       | 66 (1.4)                                          | 46 (1.2)                                          |
| Pain in extremity                                                               | 69 (1.4)                                          | 48 (1.2)                                          |
| Nervoussystem disorder's                                                        | 322 (6.8)                                         | 419 (10.7)                                        |
| Dysgeusia                                                                       | 52 (1.1)                                          | 185 (4.7)                                         |
|                                                                                 | 95 (2.0)                                          | 88 (2.2)                                          |
| Headache                                                                        | 110 (2.3)                                         | 85 (2.2)                                          |
| Psychiatric disorders                                                           | 215 (4.5)                                         | 156 (4.0)                                         |
| Renalandurinarydisorders Proteinuria                                            | 105 (2.2) 500 (10.5)                              | 77 (2.0)                                          |
|                                                                                 | 108 (2.3)                                         | 315 (8.0) 66 (1.7)                                |
| Respiratory,thoracic and mediastinal disorders Cough Dysphonia                  |                                                   |                                                   |
|                                                                                 | 126 (2.6)                                         | 18 (0.5)                                          |
| Dyspnoea                                                                        | 83 (1.7)                                          | 51 (1.3)                                          |
| Skin andsubcutaneoustissuedisorders Palmar-plantar erythrodysaesthesia syndrome | 555 (11.0) 142 (3.0)                              | 638 (16.3) 236 (6.0)                              |
|                                                                                 | 78 (1.6)                                          | 33 (0.8)                                          |
| Pruritus Rash                                                                   | 84 (1.8)                                          | 60 (1.5)                                          |
| Vasculardisorders                                                               | 366 (7.7)                                         | 317 (8.1)                                         |
|                                                                                 | 366 (7.7)                                         | 317 (8.1)                                         |
| Vasculardisorders Hypertension                                                  | 319 (6.7)                                         | 280 (7.1)                                         |

Eventrateper100person-monthsofexposure=event count*100/person-monthsofexposure.

Drug exposure is defined as the interval between the first dose date + 1 day and the earlier of the last dose date+30orthe database cutoff date.

Non-serious adverse events upto30daysoflastdose andseriousadverseeventsupto90days of last dose are included.

MedDRA preferred tems Neoplasm progression', Malignant neoplasm progression' and Disease progression'notrelated to thedrug are excluded.

Includingadverseeventsthatoccurredin≥10%ofsubjectsinASaTpopulationinoneormoretreatment groups.

DatabaseCutoffDate:24Aug2018

Source:[P426V01MK3475:adam-adsl;adae]

<div style=\"page-break-after: always\"></div>

Hypertension

Table 14.3-20 Exposure-Adjusted AdverseEvents by ObservationPeriod (Including Multiple Occurrences of Events) (Incidence ≥ 10% in One or More Treatment Groups) (ASaT Population)

|                                                                                    | Event Count and Rate (Events/100 person-months) 1   | Event Count and Rate (Events/100 person-months) 1   | Event Count and Rate (Events/100 person-months) 1   | Event Count and Rate (Events/100 person-months) 1   | Event Count and Rate (Events/100 person-months) 1   | Event Count and Rate (Events/100 person-months) 1   | Event Count and Rate (Events/100 person-months) 1   | Event Count and Rate (Events/100 person-months) 1   |
|------------------------------------------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
| Observation period of drug                                                         | 0-3                                                 |                                                     | Pembrolizumab + Axitinib 6-12                       | Beyond 12                                           | 0-3                                                 | 3-6                                                 | Sunitinib 6-12                                      | Beyond 12                                           |
| exposure                                                                           | months                                              | 3-6 months                                          | months                                              | months                                              | months                                              | months                                              | months                                              | months                                              |
| Number of subjects exposed                                                         | 429                                                 | 400                                                 | 349                                                 | 187                                                 | 425                                                 | 375                                                 | 295                                                 | 126                                                 |
| Total exposure in person-months                                                    | 1261.3                                              | 1121.4                                              | 1624.1                                              | 760.1                                               | 1219.6                                              | 966.2                                               | 1237.1                                              | 501.8                                               |
| Total events (rate)                                                                | 3096 (245.5)                                        | 1561 (139.2)                                        | 1660 (102.2)                                        | 700 (92.1)                                          | 4148 (340.1)                                        | 1395 (144.4)                                        | 1102 (89.1)                                         | 407 (81.1)                                          |
| Blood and lymphaticsystem disorders                                                | 28(2.2)                                             | 23(2.1)                                             | 28(1.7)                                             | 12(1.6)                                             | 285(23.4)                                           | 137(14.2)                                           | 117(9.5)                                            | 38(7.6)                                             |
| Anaemia                                                                            | 11(0.9)                                             | 11(1.0)                                             | 9(0.6)                                              | 5(0.7)                                              | 71(5.8)                                             | 44(4.6)                                             | 26(2.1)                                             | 14(2.8)                                             |
| Neutropenia                                                                        | 2(0.2)                                              | 3(0.3)                                              | 5(0.3)                                              | 1(0.1)                                              | 67(5.5)                                             | 31(3.2)                                             | 43(3.5)                                             | 11(2.2)                                             |
| Thrombocytopenia                                                                   | 6(0.5)                                              | 2(0.2)                                              | 3(0.2)                                              | 2(0.3)                                              | 98(8.0)                                             | 45(4.7)                                             | 24(1.9)                                             | 1(0.2)                                              |
| Cardiac disorders                                                                  | 36(2.9)                                             | 8(0.7)                                              | 11(0.7)                                             | 9(1.2)                                              | 24(2.0)                                             | 11(1.1)                                             | 7(0.6)                                              | 3(0.6)                                              |
| Endocrine disorders                                                                | 140(11.1)                                           | 71(6.3)                                             | 43(2.6)                                             | 24(3.2)                                             | 97(8.0)                                             | 46(4.8)                                             | 37(3.0)                                             | 16(3.2)                                             |
| Hyperthyroidism                                                                    | 47(3.7)                                             | 3(0.3)                                              | 5(0.3)                                              | 5(0.7)                                              | 6(0.5)                                              | 4(0.4)                                              | 6(0.5)                                              | 2(0.4)                                              |
| Hypothyroidism                                                                     |                                                     |                                                     | 27(1.7)                                             |                                                     | 89(7.3)                                             | 41(4.2)                                             | 30(2.4)                                             | 14(2.8)                                             |
| Eye disorders                                                                      | 77(6.1)                                             | 58(5.2)                                             |                                                     | 16(2.1) 12(1.6)                                     |                                                     | 21(2.2)                                             | 7(0.6)                                              | 5(1.0)                                              |
|                                                                                    | 25(2.0)                                             | 13(1.2)                                             | 19(1.2) 378(23.3)                                   | 159(20.9)                                           | 54(4.4) 847(69.4)                                   | 266(27.5)                                           | 223(18.0)                                           | 71(14.1)                                            |
| Gastrointestinal disorders Abdominal pain                                          | 516(40.9) 18(1.4)                                   | 349(31.1) 13(1.2)                                   | 27(1.7)                                             | 8(1.1)                                              | 16(1.3)                                             | 5(0.5)                                              | 10(0.8)                                             | 2(0.4)                                              |
| Constipation                                                                       | 52(4.1)                                             | 30(2.7)                                             | 20(1.2)                                             | 5(0.7)                                              | 49(4.0)                                             | 12(1.2)                                             | 7(0.6)                                              | 2(0.4)                                              |
| Diarhoea                                                                           | 144(11.4)                                           | 123(11.0)                                           | 158(9.7)                                            | 83(10.9)                                            | 188(15.4)                                           | 92(9.5)                                             | 80(6.5)                                             | 24(4.8)                                             |
| Dyspepsia                                                                          | 13(1.0)                                             | 6(0.5)                                              | 5(0.3)                                              | 2(0.3)                                              | 54(4.4)                                             | 12(1.2)                                             | 6(0.5)                                              | 1(0.2)                                              |
|                                                                                    |                                                     |                                                     |                                                     |                                                     |                                                     |                                                     | 10(0.8)                                             |                                                     |
| Gastrooesophageal reflux disease                                                   | 6(0.5)                                              | 4(0.4)                                              | 4(0.2)                                              | 4(0.5)                                              | 35(2.9)                                             | 11(1.1)                                             |                                                     | 5(1.0)                                              |
| Nausea                                                                             | 82(6.5)                                             | 44(3.9)                                             | 39(2.4)                                             | 11(1.4)                                             | 124(10.2)                                           | 41(4.2)                                             | 27(2.2)                                             | 13(2.6) 3(0.6)                                      |
| Stomatitis                                                                         | 49(3.9)                                             | 18(1.6)                                             | 12(0.7)                                             | 7(0.9)                                              | 89(7.3)                                             | 7(0.7)                                              | 12(1.0)                                             |                                                     |
| Vomiting                                                                           | 31(2.5)                                             | 24(2.1)                                             | 33(2.0)                                             | 11(1.4)                                             | 69(5.7)                                             | 27(2.8)                                             | 25(2.0)                                             | 6(1.2)                                              |
| General disorders and administration site conditions                               | 317(25.1)                                           | 120(10.7)                                           | 140(8.6)                                            | 45(5.9)                                             | 466(38.2)                                           | 114(11.8)                                           | 105(8.5)                                            | 26(5.2)                                             |
| Asthenia                                                                           | 43(3.4)                                             | 18(1.6)                                             | 22(1.4)                                             | 5(0.7)                                              | 57(4.7)                                             | 9(0.9)                                              | 11(0.9)                                             | 4(0.8) 7(1.4)                                       |
| Fatigue                                                                            | 122(9.7)                                            | 42(3.7)                                             | 32(2.0)                                             | 12(1.6)                                             | 147(12.1)                                           | 35(3.6)                                             | 25(2.0)                                             |                                                     |
| Mucosal inflammation                                                               | 47(3.7)                                             | 14(1.2)                                             | 14(0.9)                                             | 3(0.4)                                              | 101(8.3)                                            | 26(2.7)                                             | 16(1.3)                                             | 2(0.4)                                              |
| Pyrexia                                                                            | 29(2.3)                                             | 14(1.2)                                             | 19(1.2)                                             | 6(0.8)                                              | 36(3.0)                                             | 0(0.0)                                              | 10(0.8)                                             | 1(0.2)                                              |
| Hepatobiliary disorders                                                            | 34(2.7)                                             | 14(1.2)                                             | 9(0.6)                                              | 3(0.4)                                              | 38(3.1)                                             | 15(1.6)                                             | 7(0.0)                                              | 1(0.2)                                              |
| Infections and infestations                                                        | 111(8.8)                                            | 98(8.7)                                             | 109(6.7)                                            | 46(6.1)                                             | 137(11.2)                                           | 60(6.2)                                             | 54(4.4)                                             | 15(3.0)                                             |
| Injury, poisoning and procedural                                                   | 26(2.1)                                             |                                                     | 16(1.0)                                             | 8(1.1)                                              | 22(1.8)                                             | 15(1.0)                                             | 9(0.7)                                              | 3(0.6)                                              |
| complications                                                                      |                                                     | 11(1.0)                                             |                                                     |                                                     |                                                     |                                                     |                                                     |                                                     |
| Investigations Alanine aminotransferase increased                                  | 337(26.7) 66(5.2)                                   | 225(20.1) 53(4.7)                                   | 208(12.8) 33(2.0)                                   | 96(12.0) 12(1.6)                                    | 522(42.8) 54(4.4)                                   | 199(20.6) 13(1.3)                                   | 141(11.4) 11(0.9)                                   | 82(16.3) 3(0.6)                                     |
| Aspartate aminotransferase increased                                               | 66(5.2)                                             | 54(4.8)                                             | 35(2.2)                                             | 13(1.7)                                             | 56(4.6)                                             | 19(2.0)                                             | 14(1.1)                                             | 6(1.2)                                              |
| Blood creatinine increased                                                         | 21(1.7)                                             | 15(1.3)                                             | 23(1.4)                                             | 20(2.6)                                             | 35(2.9)                                             | 20(2.1)                                             | 8(0.0)                                              | 9(1.8)                                              |
| Neutrophil coumt decreased                                                         | 1(0.1)                                              | 1(0.1)                                              | 2(0.1)                                              | 2(0.3)                                              | 44(3.6)                                             | 29(3.0)                                             | 22(1.8)                                             | 14(2.8)                                             |
| Platelet count decreased                                                           | 6(0.5)                                              | 6(0.5)                                              | 7(0.4)                                              | 2(0.3)                                              | 90(7.4)                                             | 26(2.7)                                             | 25(2.0)                                             | 10(2.0)                                             |
| Weight decreased                                                                   | 32(2.5)                                             | 23(2.1)                                             | 22(1.4)                                             | (7D)6                                               | 27(2.2)                                             | 20(2.1)                                             | 4(0.3)                                              | 3(0.6)                                              |
| White blood cell coumt decreased                                                   | 0(0.0)                                              | 2(0.2)                                              | 0(0.0)                                              | 0(0.0)                                              | 46(3.8)                                             | 22(2.3)                                             | 18(1.5)                                             | 11(2.2)                                             |
| Mfetabolism and nutrition disorders                                                | 193(15.3)                                           | 123(11.0)                                           | 144(8.9)                                            | 79(10.4)                                            | 247(20.3)                                           | 81(8.4)                                             | 78(6.3)                                             | 30(6.0)                                             |
| Decreased appetite                                                                 | 65(5.2)                                             | 43(3.8)                                             | 49(3.0)                                             | 17(2.2)                                             | 101(8.3)                                            | 34(3.5)                                             | 17(1.4)                                             | 4(0.8)                                              |
| Mfusculoskeletaland connective tissue                                              |                                                     |                                                     |                                                     |                                                     |                                                     |                                                     |                                                     |                                                     |
| disorders                                                                          | 210(16.0)                                           | 94(8.4)                                             | 107(6.6)                                            | 42(5.5)                                             | 159(13.0)                                           | 54(5.6)                                             | 51(4.1)                                             | 17(3.4)                                             |
| Mfusculoskeletal and connective tissue                                             | 210(16.0)                                           | 94(8.4)                                             | 107(6.6)                                            | 42(5.5)                                             | 159(13.0)                                           | 54(5.6)                                             | 51(4.1)                                             | 17(3.4)                                             |
| disorders Arthralgia                                                               | 49(3.9) 29(2.3)                                     | 20(1.8)                                             | 15(0.9)                                             | 12(1.6) 4(0.5)                                      | 19(1.6) 30(2.5)                                     | 4(0.4) 7(0.7)                                       | 8(0.0) 5(0.4)                                       | 3(0.6)                                              |
| Back pain                                                                          | 27(2.1)                                             | 15(1.3) 14(1.2)                                     | 18(1.1)                                             | 6(0.8)                                              | 22(1.8)                                             |                                                     | 8(0.6)                                              | 4(0.8)                                              |
| Pain in extremity Nervous system disorders                                         | 154(12.2)                                           | 72(6.4)                                             | 22(1.4) 64(3.9)                                     | 32(4.2)                                             | 277(22.7)                                           | 15(1.6)                                             | 47(3.8)                                             | 3(0.6) 18(3.6)                                      |
| Dysgeusia                                                                          | 26(2.1)                                             |                                                     | 10(0.6)                                             | 2(0.3)                                              | 136(11.2)                                           | 77(8.0)                                             | 15(1.2)                                             |                                                     |
|                                                                                    | 56(4.4)                                             | 14(1.2)                                             |                                                     |                                                     |                                                     | 27(2.8)                                             |                                                     | 7(1.4)                                              |
| Headache                                                                           |                                                     | 21(1.9)                                             | 11(0.7)                                             | 7(0.9)                                              | 60(4.9)                                             | 16(1.7)                                             | 9(0.7)                                              | 3(0.6)                                              |
| Psychintric disorders                                                              | 52(4.1) 103(8.2)                                    | 23(2.1)                                             | 26(1.6)                                             | 9(1.2)                                              | 51(4.2)                                             | 18(1.9)                                             | 9(0.7)                                              | 7(1.4)                                              |
| Renal and urinary disorders                                                        |                                                     | 43(3.8)                                             | 49(3.0)                                             | 20(2.6)                                             | 95(7.8)                                             | 29(3.0)                                             | 16(1.3)                                             | 16(3.2)                                             |
| Proteinwia                                                                         | 55(4.4) 274(21.7)                                   | 16(1.4)                                             | 23(1.4)                                             | 11(1.4)                                             | 44(3.6)                                             | 15(1.6)                                             |                                                     | 11(2.2)                                             |
| Respiratory, thoracic and mediastinal                                              |                                                     |                                                     |                                                     |                                                     | 188(15.4)                                           |                                                     | 7(0.6) 41(3.3)                                      |                                                     |
| disorders                                                                          |                                                     | 89(7.9)                                             | 86(5.3)                                             | 51(6.7)                                             |                                                     | 61(6.3)                                             |                                                     | 25(5.0)                                             |
| Cough                                                                              | 55(4.4) 95(7.5)                                     | 22(2.0)                                             | 22(1.4)                                             | (7D)6                                               | 39(3.2)                                             | 15(1.6)                                             | 9(0.7)                                              | 3(0.6) 0(0.0)                                       |
| Dysphonia                                                                          | 39(3.1)                                             | 18(1.6)                                             | 9(0.6)                                              | 4(0.5)                                              | 12(1.0) 30(2.5)                                     | 2(0.2) (60)6                                        | 4(0.3) 8(0.0)                                       |                                                     |
| Dyspnoea                                                                           | 273(21.0)                                           | 13(1.2) 110(9.8)                                    | 17(1.0) 131(8.1)                                    | 14(1.8)                                             |                                                     |                                                     |                                                     | 4(0.8)                                              |
| Skin and subcutaneous tissue disorders Palmar-plantar erythrodysaesthesia syndrome | 84(6.7)                                             | 26(2.3)                                             | 24(1.5)                                             | 41(5.4) 8(1.1)                                      | 378(31.0) 127(10.4)                                 | 143(14.8) 65(6.7)                                   | 88(7.1) 34(2.7)                                     | 29(5.8) 10(2.0)                                     |
|                                                                                    |                                                     |                                                     |                                                     |                                                     |                                                     |                                                     |                                                     | 1(0.2)                                              |
| Pruritus                                                                           | 40(3.2) 36(2.9)                                     | 16(1.4)                                             | 18(1.1) 21(1.3)                                     | 4(0.5) 8(1.1)                                       | 23(1.9) 41(3.4)                                     | 5(0.5) 9(0.9)                                       | 4(0.3) 8(0.0)                                       | 2(0.4)                                              |
| Rash                                                                               | 229(18.2)                                           | 19(1.7)                                             |                                                     | 10(1.3)                                             | 227(18.0)                                           |                                                     | 47(3.8)                                             | 5(1.0)                                              |
| Vascular disorders                                                                 |                                                     | 58(5.2)                                             | 69(4.2)                                             |                                                     |                                                     | 38(3.9)                                             |                                                     |                                                     |
|                                                                                    | 229(18.2)                                           |                                                     | 69(4.2)                                             | 10(1.3)                                             | 227(18.0)                                           |                                                     |                                                     | 5(1.0)                                              |
| Vascular disorders                                                                 |                                                     | 58(5.2)                                             |                                                     | 5(0.7)                                              | 204(16.7)                                           | 38(3.9) 31(3.2)                                     | 47(3.8)                                             |                                                     |
|                                                                                    |                                                     | 47(4.2)                                             |                                                     |                                                     |                                                     |                                                     | 42(3.4)                                             | 3(0.6)                                              |

211(16.7)

Number of subjects exposed to dng at the start of indicated time interval.

56(3.4)

Drug exposureis defined as the interval between the first dose date + 1 day and the earlier ofthe last dose date + 30 or the database cutoff date.

Non-serious adverse events up to 30 days oflast dose and serious adverse events up to 90 days oflast dose are included.

Including adverse events that occured in &gt; 10% of subjects in ASaT population in one or more treatment groups.

DatabaseCutoffDate:24Aug2018.

Source:[P426V01MK3475: adam-adsl; adae]

<div style=\"page-break-after: always\"></div>

In the next tables safety data of monotherapy with either pembrolizumab (KN427 Cohort A) or with axitinib (Study A4061051) are provided:

## KN427 Cohort A (Pembrolizumab monotherapy)

Table 14.3-) Subjects WithAdverseEvents By Decreasing Incidence (Incidence ≥ 5%) CohortA:ccRCC (ASaT Population)

|                                                                                                                                                                                                                                                  | CohontA                                                                                                                                                                                                                                          | CohontA                                                                                                                                                                                                                                          |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                  | (9%6)                                                                                                                                                                                                                                            |
| Subjects in population                                                                                                                                                                                                                           | 110 108                                                                                                                                                                                                                                          | (98.2)                                                                                                                                                                                                                                           |
| with one or more adverse events with no adverse events                                                                                                                                                                                           | 2                                                                                                                                                                                                                                                | (1.8)                                                                                                                                                                                                                                            |
| Fatigue                                                                                                                                                                                                                                          | 42                                                                                                                                                                                                                                               | (38.2)                                                                                                                                                                                                                                           |
| Prwritus                                                                                                                                                                                                                                         | 39                                                                                                                                                                                                                                               | (35.5)                                                                                                                                                                                                                                           |
| Dianhoea                                                                                                                                                                                                                                         | 36                                                                                                                                                                                                                                               | (32.7)                                                                                                                                                                                                                                           |
| Arthralgia                                                                                                                                                                                                                                       | 25                                                                                                                                                                                                                                               | (22.7)                                                                                                                                                                                                                                           |
| Cough                                                                                                                                                                                                                                            | 25                                                                                                                                                                                                                                               | (22.7)                                                                                                                                                                                                                                           |
| Constipation                                                                                                                                                                                                                                     | 22                                                                                                                                                                                                                                               | (20.0)                                                                                                                                                                                                                                           |
| Nausea                                                                                                                                                                                                                                           | 21                                                                                                                                                                                                                                               | (19.1)                                                                                                                                                                                                                                           |
| Decressed appetite                                                                                                                                                                                                                               | 20                                                                                                                                                                                                                                               | (18.2)                                                                                                                                                                                                                                           |
| Blood creatinine increased                                                                                                                                                                                                                       | 17                                                                                                                                                                                                                                               | (15.5)                                                                                                                                                                                                                                           |
| Dyspuoea                                                                                                                                                                                                                                         | 16                                                                                                                                                                                                                                               | (14.5)                                                                                                                                                                                                                                           |
| Asthenia                                                                                                                                                                                                                                         | 15                                                                                                                                                                                                                                               | (13.6)                                                                                                                                                                                                                                           |
| Anaemia                                                                                                                                                                                                                                          | 13                                                                                                                                                                                                                                               | (11.8)                                                                                                                                                                                                                                           |
| Dry mouth                                                                                                                                                                                                                                        | 13                                                                                                                                                                                                                                               | (11.8)                                                                                                                                                                                                                                           |
| Hypothyroidism                                                                                                                                                                                                                                   | 13                                                                                                                                                                                                                                               | (11.8)                                                                                                                                                                                                                                           |
| Rash                                                                                                                                                                                                                                             | 13                                                                                                                                                                                                                                               | (11.8)                                                                                                                                                                                                                                           |
| Alanine aminotransferase increased                                                                                                                                                                                                               | 12                                                                                                                                                                                                                                               | (10.9)                                                                                                                                                                                                                                           |
| Headache                                                                                                                                                                                                                                         | 12                                                                                                                                                                                                                                               | (10.9)                                                                                                                                                                                                                                           |
| Musculoskeletal pain                                                                                                                                                                                                                             | 12                                                                                                                                                                                                                                               | (10.9)                                                                                                                                                                                                                                           |
| Aspartate aminotransferase increased                                                                                                                                                                                                             | 11                                                                                                                                                                                                                                               | (10.0)                                                                                                                                                                                                                                           |
| Myalgia                                                                                                                                                                                                                                          | 11                                                                                                                                                                                                                                               | (10.0)                                                                                                                                                                                                                                           |
| Abdominal pain                                                                                                                                                                                                                                   | 10                                                                                                                                                                                                                                               | (9.1)                                                                                                                                                                                                                                            |
| Back pain                                                                                                                                                                                                                                        | 10                                                                                                                                                                                                                                               | (9.1) (9.1)                                                                                                                                                                                                                                      |
| Pyrexia                                                                                                                                                                                                                                          | 10                                                                                                                                                                                                                                               | (8.2)                                                                                                                                                                                                                                            |
| Hyperglycaemia                                                                                                                                                                                                                                   | 9 9                                                                                                                                                                                                                                              | (8.2)                                                                                                                                                                                                                                            |
| Hypertension Infuenza like illness                                                                                                                                                                                                               | 9                                                                                                                                                                                                                                                | (8.2)                                                                                                                                                                                                                                            |
| Insommia                                                                                                                                                                                                                                         | 9                                                                                                                                                                                                                                                | (8.2)                                                                                                                                                                                                                                            |
| Dizziness                                                                                                                                                                                                                                        | 8                                                                                                                                                                                                                                                | (7.3)                                                                                                                                                                                                                                            |
|                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                  | (7.3)                                                                                                                                                                                                                                            |
| Dyspepsia                                                                                                                                                                                                                                        | 8                                                                                                                                                                                                                                                | (7.3)                                                                                                                                                                                                                                            |
| Hyperkalaemia                                                                                                                                                                                                                                    | 8                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                  |
| Rash maculo-papular                                                                                                                                                                                                                              | 8                                                                                                                                                                                                                                                | (7.3)                                                                                                                                                                                                                                            |
| Vomiting                                                                                                                                                                                                                                         | 8                                                                                                                                                                                                                                                | (7.3)                                                                                                                                                                                                                                            |
| Blood akaline phosphatase increased                                                                                                                                                                                                              | 7                                                                                                                                                                                                                                                | (6.4)                                                                                                                                                                                                                                            |
| Depression                                                                                                                                                                                                                                       | 7                                                                                                                                                                                                                                                | (6.4)                                                                                                                                                                                                                                            |
| Hypercalcaemia Nasopharyngitis                                                                                                                                                                                                                   | 7 7                                                                                                                                                                                                                                              | (6.4)                                                                                                                                                                                                                                            |
|                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                  | (6.4)                                                                                                                                                                                                                                            |
| Oedema penipheral                                                                                                                                                                                                                                | 7 7                                                                                                                                                                                                                                              | (6.4) (6.4)                                                                                                                                                                                                                                      |
| Pneumonia Upper respiatory tact infection                                                                                                                                                                                                        | 7                                                                                                                                                                                                                                                | (6.4)                                                                                                                                                                                                                                            |
| Chest pain                                                                                                                                                                                                                                       | 6 6                                                                                                                                                                                                                                              | (5.5) (5.5)                                                                                                                                                                                                                                      |
| Debydration                                                                                                                                                                                                                                      | 6                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                  |
| Dry skin                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                  | (5.5)                                                                                                                                                                                                                                            |
| Haematuia                                                                                                                                                                                                                                        | 6                                                                                                                                                                                                                                                | (5.5)                                                                                                                                                                                                                                            |
| Hyperthyroidism                                                                                                                                                                                                                                  | 6                                                                                                                                                                                                                                                | (5.5)                                                                                                                                                                                                                                            |
| Hyponatraemia                                                                                                                                                                                                                                    | 6                                                                                                                                                                                                                                                | (5.5)                                                                                                                                                                                                                                            |
| Lymphocyte count decresed                                                                                                                                                                                                                        | 6                                                                                                                                                                                                                                                | (5.5)                                                                                                                                                                                                                                            |
| Pain in extremity                                                                                                                                                                                                                                | 6                                                                                                                                                                                                                                                | (5.5)                                                                                                                                                                                                                                            |
|                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                  | (5.5)                                                                                                                                                                                                                                            |
| Sinusitis                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                                  |
| Every subjectiscounted a single time foreach applicable specificadverse event.                                                                                                                                                                   | 6                                                                                                                                                                                                                                                |                                                                                                                                                                                                                                                  |
| Aspecifcrvetpearnhiselifitsdmeetstideeeti afterroumding. Non-seriousadveseventsupt30daysflastdoseandseriousadverseeventsuto90dayflastdoseare included. MedDRA preferedtems Neoplasm Progesion”,Maliguant Neoplasm ProgessionadDisease Progession | Aspecifcrvetpearnhiselifitsdmeetstideeeti afterroumding. Non-seriousadveseventsupt30daysflastdoseandseriousadverseeventsuto90dayflastdoseare included. MedDRA preferedtems Neoplasm Progesion”,Maliguant Neoplasm ProgessionadDisease Progession | Aspecifcrvetpearnhiselifitsdmeetstideeeti afterroumding. Non-seriousadveseventsupt30daysflastdoseandseriousadverseeventsuto90dayflastdoseare included. MedDRA preferedtems Neoplasm Progesion”,Maliguant Neoplasm ProgessionadDisease Progession |

## Study A4061051 (Axitinib monotherapy)

Table 32. SummaryofTreatment-EmergentAdverseEventsExperiencedby≥5%of PatientsbyPreferredTerm(AllCausalities);SafetyAnalysisSet

| Preferred Term                               | Axitinib N=189    | Axitinib N=189   | Sorafenib N=96    | Sorafenib N=96   |
|----------------------------------------------|-------------------|------------------|-------------------|------------------|
| Preferred Term                               | n (%)             | No.of Events     | n (%)             | No.ofEvents      |
| Page 1 of2                                   |                   |                  |                   |                  |
| Any AE                                       | 178 (94.2)        | 2226             | 92 (95.8)         | 746              |
| Diarhea                                      | 94 (49.7)         | 297              | 38 (39.6)         | 81               |
| Hypertension                                 | 92 (48.7)         | 210              | 28 (29.2)         | 41               |
| Weight decreased                             | 69 (36.5)         | 140              | 23 (24.0)         | 43               |
| Fatigue                                      | 62 (32.8)         | 113              | 25 (26.0)         | 32               |
| Decreased appetite                           | 54 (28.6)         | 85               | 18 (18.8)         | 22               |
| Palmar-plantar erythrodysesthesiasyndrome    | 50 (26.5)         | 128              | 37 (38.53)        | 87               |
| Dysphonia                                    | 44 (23.3)         | 58               | 10 (10.4)         | 10               |
| Asthenia                                     | 39 (20.6)         | 63               | 15 (15.6)         | 20               |
| Hypothyroidism                               | 39 (20.6)         | 46               | 7 (7.3)           | 7                |
| Nausea                                       | 37 (19.6)         | 84               | 14 (14.6)         | 19               |
| Vomiting                                     | (S81)S5           | 90               | 10 (10.4)         | 12               |
| Abdominal pain upper                         | 31 (16.4)         | 44               | 6 (6.3)           | 8                |
| Cough                                        | 31 (16.4)         | 38               | 16 (16.7)         | 24               |
| Stomatitis                                   | (6'S1) 05         | 76               | 6 (6.3)           | 8                |
| Back pain                                    | 28 (14.8)         | 43               | 12 (12.5)         | 15               |
| Headache                                     | 25 (13.2)         | 35               | 6 (6.3)           | 6                |
| Dyspnea                                      | 22 (11.6)         | 30               | 8 (8.3)           | 11               |
| Proteinuria                                  | 22 (11.6)         | 64               | 12 (12.5)         | 14               |
| Disease progression                          | 21 (11.1)         | 23               | 7 (7.3)           | 7                |
| Mucosal inflammation Pain in extremity       | 21 (11.1)         | 36               | 8 (8.3)           | 10 8             |
|                                              | 21 (11.1)         | 32               | 6 (6.3)           |                  |
| Alanine aminotransferase increased           | 20 (10.6)         | 28               | 7 (7.3)           | 12               |
| Constipation                                 | 20 (10.6)         | 29               | 13 (13.5)         | 17               |
| Arthralgia                                   | 19 (10.1)         | 27               | 9 (9.4)           | 17               |
| Rash                                         | 18 (9.5)          | 23               | 19 (19.8)         | 28               |
| Upperrespiratory tract                       | 17 (9.0)          | 21               | (01)1             | 1                |
| infection Blood thyroid stimulating          | 16 (8.5)          | 22               | 2 (2.1)           | 2                |
| homone increased Aspartate aminotransferase  | 15 (7.9)          | 18               | 7 (7.3)           | 11               |
| increased Abdominal pain                     | 14 (7.4) 14 (7.4) | 24 22            | 11 (11.5) 5 (5.2) | 15               |
| Oropharyngeal pain Dizziness                 | 13 (6.9)          | 18               | 2 (2.1)           | 5 3              |
|                                              |                   |                  | 5 (5.2)           | 6                |
| Blood creatinine increased                   | 12 (6.3)          | 27               |                   |                  |
| Dyspepsia Hypotension                        | 12 (6.3) 12 (6.3) | 15 14            | 2 (2.1) 3 (3.1)   | 2 4              |
| Drymouth                                     | 11 (5.8)          | 14               | 1 (1.0)           | 1                |
| Musculoskeletal pain                         | 11 (5.8)          | 17               | 3 (3.1)           | 3                |
|                                              | 11 (5.8)          |                  | 2 (2.1)           | 2                |
| Urinary tract infection Abdominal distension | 10 (5.3)          | 14 13            | 2 (2.1)           | 2                |
| Amylase increased                            |                   |                  |                   |                  |
|                                              | 10 (5.3)          | 22               | (01)1             | 2                |
| Anxiety                                      | 10 (5.3)          | 14               | 0                 | 0                |
| Alopecia                                     | 8 (4.2)           | 10               | 18 (18.8)         | 21               |
| Erythema                                     | 5 (2.6) 9 (4.8)   | 6                | 18 (18.8)         | 20               |
| Insomnia                                     | 8 (4.2)           | 10 9             | 5 (5.2) 5 (5.2)   | 5 5              |
| Pyrexia Epistaxis                            | 5 (2.6)           | 6                | 5 (5.2)           | 5                |
|                                              |                   |                  |                   | 9                |
| Hyperglycemia                                | 4 (2.1)           | 7                | 5 (5.2)           | 6                |
| Chest pain Edema peripheral                  | 9 (4.8) 9 (4.8)   | 14 13            | 6 (6.3) 6 (6.3)   | 8                |
| Blood alkaline phosphatase                   | 5 (2.6)           | 5                | 6 (6.3)           | 7                |
| increased                                    | (91)              | 3                | 6 (6.3)           | 8                |
| Skin exfoliation                             |                   |                  |                   |                  |
| Anemia                                       | 9 (4.8)           | 13               | 7 (7.3)           | 14               |
| Pruritus                                     | 7 (3.7)           | 7                | 8 (8.3)           | 11 9             |
| Pleural effusion                             | 6 (3.2)           | 6                |                   |                  |
|                                              |                   |                  | 9 (9.4)           |                  |

%=(n/N) x 100.

Source:Table 14.3.1.2.3a

MedDRA (v15.0) coding dictionary applied.

Datacutoffdate:27July2012.

Abbreviations:MedDRA=Medical Dictionary for Regulatory Activities;v=version;N=number ofpatients;

n=number of patients meeting prespecified criteria; No.=number

<div style=\"page-break-after: always\"></div>

## Grade 3-5 AEs

## Table 5.3.5.3.3-rcc1: 10

Subjects With Grade 3-5 Adverse Events

(Incidence ≥ 5% in the Preferred Term)

By Decreasing Frequency of Preferred Term

(ASaT Population)

(modified by the Assessor)

<!-- image -->

|                                                                               | KN426 Data for Pembrolizuab+ Axitinibl   | KN426 Data for Pembrolizuab+ Axitinibl   | KN426 Sumitinib   | KN426 Sumitinib   | Reference Safety Dataset for Pembrolizwab Monotherapy   | Reference Safety Dataset for Pembrolizwab Monotherapy   | Cumulative Rumning Safety Dataset for Pembrolizmab Monotherapy   | Cumulative Rumning Safety Dataset for Pembrolizmab Monotherapy   |
|-------------------------------------------------------------------------------|------------------------------------------|------------------------------------------|-------------------|-------------------|---------------------------------------------------------|---------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|
|                                                                               |                                          | (%)                                      | n                 | (%)               |                                                         | (%)                                                     |                                                                  | (%)                                                              |
| Subjects in population with one or more adverse events with no adverse events | 429 325 104                              | (75.8) (24.2)                            | 425 300 125       | (70.6) (29.4)     | 4,439 2,153 2,286                                       | (48.5) (51.5)                                           | 6,436 3,107 3,329                                                | (48.3) (51.7)                                                    |
| Hypertension                                                                  | 95 57                                    | (22.1)                                   | 82                | (19.3)            | 55 41                                                   | (7) (0.9)                                               | 103 79                                                           | (1.0) (1.2)                                                      |
| Alanine aminotansferase increased Diarrhoea                                   | 39                                       | (13.3) (9.1)                             | 13 20             | (3.1) (4.7)       | 65                                                      | (1.5)                                                   | 88                                                               | (1.4)                                                            |
|                                                                               | 22                                       |                                          | 16                | (3.8)             |                                                         |                                                         | 1                                                                |                                                                  |
| Aspartate aminotransferase increased Palmar-plantar erythrodysaesthesia       | 30                                       | (7.0)                                    | 10                | (2.4)             | 52                                                      | (1.2) (0.0)                                             | 103                                                              | (1.6) (0.0)                                                      |
| syudrome Fatigue Thrombocytopenia                                             | 12 0                                     | (5.1) (2.8) (0.0)                        | 28 25             | (6.6) (5.9)       | 1 118 15                                                | (2.7) (0.3)                                             | 166 18                                                           | (2.6) (0.3)                                                      |
| Neutropenia                                                                   | 1                                        | (0.2)                                    |                   | (6.6)             | 13                                                      | (0.3)                                                   |                                                                  | (0.4)                                                            |
| Neutrophil count decreased                                                    |                                          |                                          |                   |                   |                                                         |                                                         |                                                                  |                                                                  |
|                                                                               |                                          |                                          | 28                |                   |                                                         |                                                         | 27                                                               |                                                                  |
|                                                                               | 1                                        | (0.2)                                    | 29                | (6.8)             | 6                                                       | (0.1)                                                   | 11                                                               | (0.2)                                                            |
| Plateletcount decreased                                                       |                                          | (0.2)                                    | 31                | (7.3)             | 6                                                       | (0.1)                                                   | 8                                                                | (0.1)                                                            |

Figure 14.3-3 Between-Treatment Comparisons in Grade 3-5 Adverse Events Selected Adverse Events (&gt;= 5% Incidence) and Sorted by Risk Difference (ASaT Population) A (N=429) vs. B (N=425)

<!-- image -->

A stands for Pembrolizumab + Axitinib and B stands for Sunitinib.

Database Cutoff Date: 24Aug2018.

Source: [P426V01MK3475: adam-adsl; adae]

<div style=\"page-break-after: always\"></div>

Table 14.3-28 Analysis of Time to First Grade 3, 4 or 5 Adverse Events (ASaT Population)

| Treatment                                                                                                                                                                                                     | N                                                                                                                                                                                                             | Number of Events (%)                                                                                                                                                                                          | Person- Weeks                                                                                                                                                                                                 | Event Rate/ 100 Person- Weeks                                                                                                                                                                                 | Median Time (Weeks) (95% CI)                                                                                                                                                                                  | Event Free Rate at Weeks 12 in % I (95% CI)                                                                                                                                                                   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pembrolizumab+Axitinib                                                                                                                                                                                        | 429                                                                                                                                                                                                           | 325 (75.8)                                                                                                                                                                                                    | 9411.9                                                                                                                                                                                                        | 3.5                                                                                                                                                                                                           | 13.1 (12.0, 16.1)                                                                                                                                                                                             | 52.7 (47.9, 57.4)                                                                                                                                                                                             |
| Sunitinib                                                                                                                                                                                                     | 425                                                                                                                                                                                                           | 300 (70.6)                                                                                                                                                                                                    | 8313.3                                                                                                                                                                                                        | 3.6                                                                                                                                                                                                           | 10.1 (7.0, 11.6)                                                                                                                                                                                              | 43.7 (38.9,48.3)                                                                                                                                                                                              |
| Pairwise Comparisons                                                                                                                                                                                          | Pairwise Comparisons                                                                                                                                                                                          | Pairwise Comparisons                                                                                                                                                                                          | Pairwise Comparisons                                                                                                                                                                                          | Pairwise Comparisons                                                                                                                                                                                          | Hazard Ratio (95% CI                                                                                                                                                                                          | p-Value?                                                                                                                                                                                                      |
| Pembrolizumab + Axitinib vs.Sunitinib                                                                                                                                                                         | Pembrolizumab + Axitinib vs.Sunitinib                                                                                                                                                                         | Pembrolizumab + Axitinib vs.Sunitinib                                                                                                                                                                         | Pembrolizumab + Axitinib vs.Sunitinib                                                                                                                                                                         | Pembrolizumab + Axitinib vs.Sunitinib                                                                                                                                                                         | 0.96 (0.82, 1.13)                                                                                                                                                                                             | 0.3184                                                                                                                                                                                                        |
| From product-limit (Kaplan-Meier) method for censored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Intermational MetastaticRCCDatabase | From product-limit (Kaplan-Meier) method for censored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Intermational MetastaticRCCDatabase | From product-limit (Kaplan-Meier) method for censored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Intermational MetastaticRCCDatabase | From product-limit (Kaplan-Meier) method for censored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Intermational MetastaticRCCDatabase | From product-limit (Kaplan-Meier) method for censored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Intermational MetastaticRCCDatabase | From product-limit (Kaplan-Meier) method for censored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Intermational MetastaticRCCDatabase | From product-limit (Kaplan-Meier) method for censored data. Based on Cox regression model with Efron's method of tie handling with treatment as a covariate stratified by Intermational MetastaticRCCDatabase |

Source:[P426V01MK3475:adam-adsl;adttae]

Figure 14.3-4 Kaplan-Meier Estimates of Time to First Grade 3, 4 or 5 Adverse Events (ASaT Population)

<!-- image -->

Database Cutoff Date:24Aug2018.

Source:[P426V01MK3475:adam-adsl; adttae]

<div style=\"page-break-after: always\"></div>

## Drug-related AEs

Table 5.3.5.3.3-rcc1: 8 SubjectsWithDrug-Related AdverseEvents (Incidence ≥ 5% in One or More Treatment Groups) By Decreasing Frequency of PreferredTerm

## (ASaT Population)

|                                            | KN426 Data for Pembrolizumab+ Axitinbl   | KN426 Data for Pembrolizumab+ Axitinbl   | KN426 Sunitinib   | KN426 Sunitinib   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Cumulative Running Safety Dataset for Pembrolizumab Monotherapy'   | Cumulative Running Safety Dataset for Pembrolizumab Monotherapy'   |
|--------------------------------------------|------------------------------------------|------------------------------------------|-------------------|-------------------|----------------------------------------------------------|----------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|
|                                            | n                                        | (%)                                      | n                 | (%)               | n                                                        | (%)                                                      | n                                                                  | (%)                                                                |
| Subjects in population                     | 429                                      |                                          | 425               |                   | 4,439                                                    |                                                          | 6,436                                                              |                                                                    |
| with one or more adverse events            | 413                                      | (96.3)                                   | 415               | (97.6)            | 3,140                                                    | (70.7)                                                   | 4,512                                                              | (70.1)                                                             |
| with no adverse events                     | 16                                       | (3.7)                                    | 10                | (2.4)             | 1,299                                                    | (29.3)                                                   | 1,924                                                              | (29.9)                                                             |
| Dianhoea                                   | 210                                      | (49.0)                                   | 175               | (41.2)            | 480                                                      | (10.8)                                                   | 690                                                                | (10.7)                                                             |
| Hypertension                               | 179                                      | (41.7)                                   | 184               | (43.3)            | 19                                                       | (0.4)                                                    | 36                                                                 | (0.6)                                                              |
| Hypothyroidism                             | 135                                      | (31.5)                                   | 119               | (28.0)            | 378                                                      | (8.5)                                                    | 584                                                                | (9.1)                                                              |
| Fatigue                                    | 130                                      | (30.3)                                   | 142               | (33.4)            | 929                                                      | (20.9)                                                   | 1,285                                                              | (20.0)                                                             |
| Paimar-planar erythrodysaesthesia syndrome | 119                                      | (27.7)                                   | 168               | (39.5)            | 10                                                       | (0.2)                                                    | 17                                                                 | (0.3)                                                              |
| Alanine aminotransferase increased         | 102                                      | (23.8)                                   | 54                | (12.7)            | 149                                                      | (3.4)                                                    | 262                                                                | (4.1)                                                              |
| Dysphonia                                  | 98                                       | (22.8)                                   | 12                | (2.8)             | 14                                                       | (0.3)                                                    | 19                                                                 | (0.3)                                                              |
| Aspartate aminotransferase increased       | 97                                       | (22.6)                                   | 59                | (6E1)             | 147                                                      | (3.3)                                                    | 261                                                                | (4.1)                                                              |
| Decreased appetite                         | 94                                       | (21.9)                                   | 106               | (24.9)            | 377                                                      | (8.5)                                                    | 499                                                                | (7.8)                                                              |
| Nausea                                     | 16                                       | (21.2)                                   | II1               | (26.1)            | 430                                                      | (9.7)                                                    | 579                                                                | (9.0)                                                              |
| Proteinuria                                | 66                                       | (15.4)                                   | 39                | (9.2)             | 7                                                        | (0.2)                                                    | 15                                                                 | (0.2)                                                              |
| Stomatitis                                 | 19                                       | (14.2)                                   | 86                | (20.2)            | 58                                                       | (1.3)                                                    | 78                                                                 | (CD)                                                               |
| Mucosalinfammation                         | 55                                       | (12.8)                                   | 90                | (21.2)            | 39                                                       | (0.9)                                                    | 49                                                                 | (0.8)                                                              |
| Pruritus                                   | 53                                       | (12.4)                                   | 18                | (4.2)             | 644                                                      | (14.5)                                                   | 871                                                                | (13.5)                                                             |
| Arthralgia                                 | 52                                       | (12.1)                                   | 15                | (3.5)             | 349                                                      | (62)                                                     | 489                                                                | (9L)                                                               |
| Hyperthyroidism                            | 52                                       | (12.1)                                   | 14                | (3.3)             | 125                                                      | (2.8)                                                    | 243                                                                | (3.8)                                                              |
| Asthenia                                   | 50                                       | (11.7)                                   | 54                | (12.7)            | 279                                                      | (6.3)                                                    | 396                                                                | (6.2)                                                              |
| Rash                                       | 46                                       | (10.7)                                   | 38                | (8.9)             | 531                                                      | (12.0)                                                   | 688                                                                | (10.7)                                                             |
| Weight decreased                           | 41                                       | (9.0)                                    | 36                | (8.5)             | 100                                                      | (2.3)                                                    | 142                                                                | (2.2)                                                              |
| Dysgeusia                                  | 40                                       | (9.3)                                    | 129               | (30.4)            | 66                                                       | (1.5)                                                    | 16                                                                 | (+1)                                                               |
| Headache                                   | 35                                       | (8.2)                                    | 33                | (7.8)             | 141                                                      | (3.2)                                                    |                                                                    | (3.1)                                                              |
| Vomiting                                   | 34                                       | (7.9)                                    | 56                | (13.2)            | 157                                                      | (3.5)                                                    | 220                                                                | (3.4)                                                              |
| Cough                                      | 32                                       | (7.5)                                    | 12                | (2.8)             | 159                                                      | (3.0)                                                    | 204                                                                | (3.2)                                                              |
| Constipation                               | 31                                       | (7.2)                                    | 29                | (6.8)             | 127                                                      | (2.9)                                                    | 172                                                                | (2.7)                                                              |
| Dyspnoea                                   | 28                                       | (6.5)                                    | 16                | (3.8)             | 148                                                      | (3.3)                                                    | 216                                                                | (3.4)                                                              |
| Dry skin                                   | 27                                       | (6.3)                                    | 35                | (8.2)             | 134                                                      | (3.0)                                                    | 189                                                                | (2.9)                                                              |
| Blood creatinine increased                 | 24                                       | (5.0)                                    | 30                | (7.1)             | 53                                                       | (1.2)                                                    | 75                                                                 | (1.2)                                                              |
| Abdominal pain Myalgia                     | 23                                       | (5.4)                                    | 16                | (3.8)             | 16                                                       | (2.1)                                                    | 134                                                                | (2.1)                                                              |
|                                            | 23                                       | (5.4)                                    | 16                | (3.8)             | 183                                                      | (4.1)                                                    | 262                                                                | (4.1)                                                              |
| Blood thyroid stinulating homone increased | 22                                       | (5.1)                                    | 22                | (5.2)             | 47                                                       | (1.1)                                                    | 72                                                                 | (1.1)                                                              |
| Epistaxis                                  | 19                                       | (4.4)                                    | 32                | (7.5)             | 5                                                        | (0.1)                                                    | 7                                                                  | (0.1)                                                              |
| Dry mouth                                  | 17                                       | (4.0)                                    | 22                | (5.2)             | 104                                                      | (2.3)                                                    |                                                                    |                                                                    |
| Pyrexia                                    | 16                                       | (3.7)                                    | 24                | (5.6)             | 216                                                      | (4.9)                                                    | 153 280                                                            | (2.4) (4.4)                                                        |
| Platelet count decreased                   | 14                                       | (3.3)                                    | 76                | (17.9)            | 27                                                       | (0.0)                                                    | 34                                                                 | (0.5)                                                              |
| Anaenia                                    | 12                                       | (2.8)                                    | 69                | (16.2)            | 152                                                      | (3.4)                                                    | 223                                                                | (3.5)                                                              |
| Dyspepsia Thrombocytopenia                 | 12 8                                     | (2.8) (1.9)                              | 48 94             | (11.3) (22.1)     | 18 29                                                    | (F0) (0.7)                                               | 36 43                                                              | (9:0) (0.7)                                                        |
| Gastrooesophagealreflux disease            | 6                                        | (1)                                      | 34                | (8.0)             | 12                                                       | (0.3)                                                    | 20                                                                 | (0.3)                                                              |
| Hypophosphataenia                          | 6                                        |                                          | 26                | (6.1)             |                                                          | (0.7)                                                    | 45                                                                 |                                                                    |
|                                            |                                          | (1.4)                                    |                   |                   | 31                                                       |                                                          |                                                                    | (0.7)                                                              |
| Neuropenia                                 | 6                                        | (1.4)                                    | 79                | (18.6)            | 20                                                       | (0.5)                                                    | 45 34                                                              | (0.7)                                                              |
| Leukopenia Neutophil count decreased       | 5 3                                      | (T1) (0.7)                               | 37 48             | (8.7) (11.3)      | 18 21                                                    | (0.4) (0.5)                                              | 27                                                                 | (0.5) (0.4)                                                        |

Whitebloodcell count decreased

(0.2)

37

Every subjectis counted a single time for each applicable row and column.

Non-serious adverse events up to 30 days following the last dose and serious adverse events up to 90 days following the last dose are included.

(8.7)

23

(0.5)

30

(0.5)

A system organ clhss or specific adverse event appears on this report only ifits incidence in one or more of the columns meets the incidence criterion in the report tile, after rouding.

MedDRA preferred temmsNeoplasm Progression'\"Malignant Neoplasm Progression\"and\"Disease Progression\"not related to the drug are excluded.

'Includes all subjects who received at least one dose of Sunitinib in KN426.

IIncludes all subjects who received at least one dose of Pembrolizumab and/or Axitinib in KN426.

Includes all subjects who received atleast one dose of pembrolizumab in KN001 Part B1, B2,B3, D. C, F1. F2, F3, KN002 (original phase).KN006,KN010.KN012 Cohorts B and B2(HNSCC).KN013 Cohort3(HodgkinLymphoma).KN024,KN040. KN045, KN052, KN055 and KN087.

Includes all subjects who received at least one dose ofpembrolizumab in KN001 Part B1,B2,B3,D.C,F1,F2,F3.KN002 (originalphase).KN006,KN010,KN012 Cohorts B and B2(HNSCC),Cohort C(UrothelialTractCancer)）and Cohort D （GastricCancer).KN013 Cohort3(Hodgkin Lymphoma)and Cohort 4A (MLBCL).KN017,KN024,KN028 Cohort B4, KN040,KN042,KN045,KN052,KN054,KN055,KN059 Cohort 1,KN087,KN158,KN164 CohortA,KN170,KN224 and KN427 Cohort A.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014,KN002: 28FEB2015, KN006: 03MAR2015, KN054: 020CT2017)

Database cutoff date forLung (KN001-NSCLC: 23JAN2015,KN010: 30SEP2015,KN024:10JUL2017,KN042:26FEB2018) Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN055: 22APR2016)

Database cutoff date for Gastric (KN012-Gastric: 26APR2016,KN059-Cohort 1: 21APR2017)

Database cutoff date for cHL (KN013-Cohort 3: 27SEP2016, KN087: 25SEP2016)

Database cutoff date for Bladder (KN012-Urothelial: 01SEP2015, KN045: 26OCT2017, KN052: 09MAR2017)

Database cutoff date for Colorectal (KN164-Cohort A: 03AUG2016)

Database cutoff date for MLBCL (KN013-Cohort 4A: 04AUG2017,KN170: 19JAN2018)

Database cutoff date for Cervical(KN028-Cohort B4: 20FEB2017,KN158: 15JAN2018)

Database cutoff date for HCC (KN224: 15MAY2018)

Database cutoff date for RCC (KN426: 24AUG2018, KN427-Cohort A: 07SEP2018)

Database cutoff date for MCC (KN017: 06FEB2018)

Source: [ISS: adam-adsl; adae]

<div style=\"page-break-after: always\"></div>

Figure 14.3-2 Between-Treatment Comparisons in Drug-Related Adverse Events Selected Adverse Events (&gt;= 5% Incidence) and Sorted by Risk Difference (ASaT Population) A (N=429) vs. B (N=425)

<!-- image -->

AstandsforPembrolizumab+AxitinibandBstandsforSunitinib.

Database Cutoff Date:24Aug2018. Source:[P426V01MK3475:adam-adsl;adae]

<div style=\"page-break-after: always\"></div>

## KN427 Cohort A (Pembrolizumab monotherapy)

Table 14.3-8 Subjects WithDrug-RelatedAdverseEvents By DecreasingIncidence (Incidence≥5%) Cohort A: ccRCC (ASaT Population)

|                                                                                                                                                                                                                         | CohortA                                                                                                                                                                                                                 | CohortA                                                                                                                                                                                                                 |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                         |                                                                                                                                                                                                                         | (%)                                                                                                                                                                                                                     |
| Subjects in population                                                                                                                                                                                                  | 110                                                                                                                                                                                                                     |                                                                                                                                                                                                                         |
| with one or more drug-related adverse events                                                                                                                                                                            | 89                                                                                                                                                                                                                      | (80.9)                                                                                                                                                                                                                  |
| with no drug-related adverse events                                                                                                                                                                                     | 21                                                                                                                                                                                                                      | (19.1)                                                                                                                                                                                                                  |
| Fatigue                                                                                                                                                                                                                 | 31                                                                                                                                                                                                                      | (28.2)                                                                                                                                                                                                                  |
| Prwrius                                                                                                                                                                                                                 | 31                                                                                                                                                                                                                      | (28.2)                                                                                                                                                                                                                  |
| Dianhoea                                                                                                                                                                                                                | 25                                                                                                                                                                                                                      | (22.7)                                                                                                                                                                                                                  |
| Arthralgia                                                                                                                                                                                                              | 15                                                                                                                                                                                                                      | (13.0)                                                                                                                                                                                                                  |
| Hypothyroidism                                                                                                                                                                                                          | 12                                                                                                                                                                                                                      | (10.9)                                                                                                                                                                                                                  |
| Rash                                                                                                                                                                                                                    | 9                                                                                                                                                                                                                       | (8.2)                                                                                                                                                                                                                   |
| Alanine aminotransferase increased                                                                                                                                                                                      | 8                                                                                                                                                                                                                       | (EL)                                                                                                                                                                                                                    |
| Aspartate aminotransferase increased                                                                                                                                                                                    | 8                                                                                                                                                                                                                       | (7.3)                                                                                                                                                                                                                   |
| Asthenia                                                                                                                                                                                                                | 8                                                                                                                                                                                                                       | (7.3)                                                                                                                                                                                                                   |
| Decreased appetite                                                                                                                                                                                                      | 8                                                                                                                                                                                                                       | (7.3)                                                                                                                                                                                                                   |
| Dry mouth                                                                                                                                                                                                               | 7                                                                                                                                                                                                                       | (6.4)                                                                                                                                                                                                                   |
| Infuenza like ilness                                                                                                                                                                                                    | 7                                                                                                                                                                                                                       | (6.4)                                                                                                                                                                                                                   |
| Rash maculo-papular                                                                                                                                                                                                     | 7                                                                                                                                                                                                                       | (6.4)                                                                                                                                                                                                                   |
| Dyspnoea                                                                                                                                                                                                                | 6                                                                                                                                                                                                                       | (5.5)                                                                                                                                                                                                                   |
| Hyperthyroidism                                                                                                                                                                                                         | 6                                                                                                                                                                                                                       | (5.5)                                                                                                                                                                                                                   |
| Nausea                                                                                                                                                                                                                  | 6                                                                                                                                                                                                                       | (5.5)                                                                                                                                                                                                                   |
| Every subjectis coumted a single time for each applicable specific adverse event. A specific adverse event appears on this report only if its incidence meets the incidence criterion in the reportile, after rounding. | Every subjectis coumted a single time for each applicable specific adverse event. A specific adverse event appears on this report only if its incidence meets the incidence criterion in the reportile, after rounding. | Every subjectis coumted a single time for each applicable specific adverse event. A specific adverse event appears on this report only if its incidence meets the incidence criterion in the reportile, after rounding. |
| Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included. MedDRA version used is 21.0. Database Cutoff Date: 07Sep2018                                  | Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included. MedDRA version used is 21.0. Database Cutoff Date: 07Sep2018                                  | Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included. MedDRA version used is 21.0. Database Cutoff Date: 07Sep2018                                  |

Sowrce: [P427V01MK3475: adam-adsl; adae]

## Study A4061051 (Axitinib monotherapy)

Table35. Summary of Treatment-Related Adverse Events Experienced by ≥5% of PatientsbyTreatment andPreferredTerm;SafetyAnalysisSet

| Preferred Term                              | Axitinib N=189   | Axitinib N=189   | Sorafenib N=96   | Sorafenib N=96   |
|---------------------------------------------|------------------|------------------|------------------|------------------|
| Preferred Term                              | n (%)            | No. of Events    | n (%)            | No. of Events    |
| Any AE                                      | 163 (86.2)       | 1527             | 84 (87.5)        | 490              |
| Hypertension                                | 87 (46.0)        | 201              | 27 (28.1)        | 40               |
| Diarrhea                                    | 85 (45.0)        | 260              | 32 (33.3)        | 56               |
| Weight decreased                            | 52 (27.5)        | 95               | 17 (17.7)        | 33               |
| Fatigue                                     | 51 (27.0)        | 95               | 20 (20.8)        | 23               |
| Palmar-plantar erythrodysesthesia syndrome  | 50 (26.5)        | 128              | 37 (38.5)        | 87               |
| Dysphonia                                   | 44 (23.3)        | 57               | 9 (9.4)          | 9                |
| Decreased appetite                          | 42 (22.2)        | 69               | 15 (15.6)        | 19               |
| Hypothyroidism                              | 39 (20.6)        | 46               | 7 (7.3)          | 7                |
| Nausea                                      | 32 (16.9)        | 69               | 11 (11.5)        | 13               |
| Stomatitis                                  | 29 (15.3)        | 74               | 6 (6.3)          | 8                |
| Vomiting                                    | 25 (13.2)        | 54               | 3 (3.1)          | 5                |
| Asthenia                                    | 23 (12.2)        | 34               | 7 (7.3)          | 9                |
| Mucosalinflammation                         | 21 (11.1)        | 36               | 8 (8.3)          | 10               |
| Proteinuria                                 | 19 (10.1)        | 52               | 9 (9.4)          | 11               |
| Headache                                    | 18 (19.5)        | 20               | 4 (4.2)          | 4                |
| Abdominal pain upper                        | 17 (9.0)         | 19               | 4 (4.2)          | 6                |
| Rash                                        | 17 (9.0)         | 22               | 19 (19.8)        | 26               |
| Alanine aminotransferase increased          | 16 (8.5)         | 23               | 7 (7.3)          | 12               |
| Blood thyroid stimulating hormone increased | 16 (8.5)         | 22               | 2 (2.1)          | 2                |
| Aspartate aminotransferase increased        | 12 (6.3)         | 15               | 7 (7.3)          | 11               |
| Arthralgia                                  | 11 (5.8)         | 15               | 3 (3.1)          | 3                |
| Drymouth                                    | 11 (5.8)         | 13               | 1 (1.0)          | 1                |
| Oropharyngeal pain                          | 11 (5.8)         | 17               | 4 (4.2)          | 4                |
| Pain in extremity                           | 11 (5.8)         | 21               | 3 (3.1)          | 3                |
| Constipation                                | 10 (5.3)         | 12               | 9 (9.4)          | 13               |
| Dyspepsia                                   | 10 (5.3)         | 13               | 2 (2.1)          | 2                |
| Cough                                       | 9 (4.8)          | 10               | 7 (7.3)          | 7                |
| Alopecia                                    | 8 (4.2)          | 10               | 18 (18.8)        | 21               |
| Abdominal pain                              | 7 (3.7)          | 14               | 5 (5.2)          | 6                |
| Pruritus                                    | 5 (2.6)          | 5                | 8 (8.3)          | 11               |
| Erythema                                    | 3 (1.6)          | 3                | 18 (18.8)        | 20               |
| Skin exfoliation                            | 3 (1.6)          | 3                | 6 (6.3)          | 8                |

Source:Table 14.3.1.3.3a

%=(n/N) × 100

MedDRA (v15.0) coding dictionary applied.

Data cutoff date:27July 2012.

Abbreviations:AE=adverse event;MedDRA=MedicalDictionaryforRegulatoryActivities;v=version;

N=number of patients; n=number of patients meeting prespecified criteria; No.=number

## Drug-related Grade 3 to 5 Adverse Events

Table 14.3-24 Subjects With Drug-Related Adverse Events by System Organ Class and Preferred Term by Maximum Toxicity Grade (Incidence&gt;O%inOneorMoreTreatmentGroups) (ASaTPopulation)

|                            | Pembrolizumab+Axitinib                 | Pembrolizumab+Axitinib                 | Pembrolizumab+Axitinib                     | Pembrolizumab+Axitinib                     | Pembrolizumab+Axitinib   | Pembrolizumab+Axitinib   | Pembrolizumab+Axitinib   | Pembrolizumab+Axitinib   | Suitinib   | Suitinib   |
|----------------------------|----------------------------------------|----------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|------------|------------|
|                            | Related to Pembrolizmab and/orAxitinib | Related to Pembrolizmab and/orAxitinib | Related to both Pembrolizuumaband Axitinib | Related to both Pembrolizuumaband Axitinib | Related to Pembrolizumab | Related to Pembrolizumab | Related to Axitinib      | Related to Axitinib      |            |            |
|                            | n                                      | (%)                                    | n                                          | (%)                                        | n                        | (%)                      |                          | (%)                      | n          | (%)        |
| Subjects inpopulation      | 429                                    |                                        | 429                                        |                                            | 429                      |                          | 429                      |                          | 425        |            |
| withoneormoreadverseevents | 413                                    | (96.3)                                 | 305                                        | (71.1)                                     | 365                      | (85.1)                   | 409                      | (95.3)                   | 415        | (97.6)     |
| Grade 1                    | 38                                     | (8.9)                                  | 73                                         | (17.0)                                     | 70                       | (16.3)                   | 47                       | (11.0)                   | 49         | (11.5)     |
| Grade 2                    | 105                                    | (24.5)                                 | 120                                        | (28.0)                                     | 136                      | (31.7)                   | 118                      | (27.5)                   | 119        | (28.0)     |
| Grade3                     | 242                                    | (56.4)                                 | 102                                        | (23.8)                                     | 141                      | (32.9)                   | 224                      | (52.2)                   | 220        | (51.8)     |
| Grade 4                    | 24                                     | (5.6)                                  | 10                                         | (2.3)                                      | 14                       | (3.3)                    | 20                       | (4.7)                    | 20         | (4.7)      |
| Grade5                     | 4                                      | (0.9)                                  | 0                                          | (0.0)                                      | 4                        | (0.9)                    | 0                        | (0.0)                    | 7          | (1.6)      |
| withnoadverseevents        | 16                                     | (3.7)                                  | 124                                        | (28.9)                                     | 64                       | (14.9)                   | 20                       | (4.7)                    | 10         | (2.4)      |

<div style=\"page-break-after: always\"></div>

Table 2.7.4-rcc1: 9 Subjects With Grade 3-5 Drug-related Adverse Events (Incidence ≥ 1% in One or More Treatment Groups) By Decreasing Frequency of Preferred Term (ASaT Population)

|                                             | KN426 Data for Pembrolizmab+ Axitinibl   | KN426 Data for Pembrolizmab+ Axitinibl   | KN426 Sumitinib!   | KN426 Sumitinib!   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Cumulative Running Safety Dataset for Pembrolizumab Monotherapy*   | Cumulative Running Safety Dataset for Pembrolizumab Monotherapy*   |
|---------------------------------------------|------------------------------------------|------------------------------------------|--------------------|--------------------|----------------------------------------------------------|----------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|
|                                             | n                                        | (%)                                      |                    | (%)                |                                                          | (9%)                                                     |                                                                    | (%)                                                                |
| Subjects in population                      | 429                                      |                                          | 425                |                    | 4,439                                                    |                                                          | 6,436                                                              |                                                                    |
| with one or more adverse events             | 270                                      | (62.9)                                   | 247                | (58.1)             | 660                                                      | (14.9)                                                   | 1,018                                                              | (15.8)                                                             |
| with no adverse events                      | 159                                      | (37.1)                                   | 178                | (41.9)             | 3,779                                                    | (85.1)                                                   | 5,418                                                              | (84.2)                                                             |
| Hypertension                                | 91                                       | (21.2)                                   | 78                 | (18.4)             | 8                                                        | (0.2)                                                    | 11                                                                 | (0.2)                                                              |
| Alanine aminotransferase increased          | 52                                       | (12.1)                                   | 11                 | (2.6)              | 23                                                       | (0.5)                                                    | 47                                                                 | (0.7)                                                              |
| Diarhoea                                    | 31                                       | (7.2)                                    | 19                 | (4.5)              | 45                                                       | (1.0)                                                    | 62                                                                 | (1.0)                                                              |
| Aspartate aminotransferase increased        | 29                                       | (6.8)                                    | 7                  | (91)               | 29                                                       | (0.7)                                                    | 53                                                                 | (0.8)                                                              |
| Palmar-plantar erythrodysaesthesia syudrome | 22                                       | (5.1)                                    | 15                 | (3.5)              | 1                                                        | (0.0)                                                    | 1                                                                  | (0.0)                                                              |
| Proteinuria                                 | 11                                       | (2.6)                                    | 6                  | (1.4)              | 0                                                        | (0.0)                                                    | 1                                                                  | (0.0)                                                              |
| Faigue                                      | 10                                       | (2.3)                                    | 21                 | (4.9)              | 52                                                       | (71)                                                     | 77                                                                 | (1.2)                                                              |
| Decreased appetite                          | 9                                        | (2.1)                                    | 2                  | (0.5)              | 14                                                       | (0.3)                                                    | 21                                                                 | (0.3)                                                              |
| Asthenia                                    | 6                                        | (1.4)                                    | 12                 | (2.8)              | 18                                                       | (0.4)                                                    | 27                                                                 | (0.4)                                                              |
| Blood pressure increased                    | 6                                        | (1.4)                                    | 1                  | (0.2)              | 0                                                        | (0.0)                                                    | 0                                                                  | (0.0)                                                              |
| Hepatic fimction abnomal                    | 6                                        | (1.4)                                    | 0                  | (0.0)              | 1                                                        | (0.0)                                                    | 5                                                                  | (0.1)                                                              |
| Hepatitis                                   | 6                                        | (1.4)                                    | 0                  | (0.0)              | 8                                                        | (0.2)                                                    | 14                                                                 | (0.2)                                                              |
| Hyperglycaemia                              | 6                                        | (1.4)                                    | 0                  | (0.0)              | 10                                                       | (0.2)                                                    | 16                                                                 | (0.2)                                                              |
| Weight decreased                            | 6                                        | (1.4)                                    | 0                  | (0.0)              | 4                                                        | (0.1)                                                    | 7                                                                  | (0.1)                                                              |
| Blood alkaline phosphatase increased        | 5                                        | (71)                                     | 3                  | (0.7)              | 12                                                       | (0.3)                                                    | 15                                                                 | (0.2)                                                              |
| Colitis                                     | 5                                        | (71)                                     | 0                  | (0.0)              | 43                                                       | (1.0)                                                    | 61                                                                 | (0.9)                                                              |
| Hyponatraemia                               | 5                                        | (71)                                     | 8                  | (61)               | 19                                                       | (0.4)                                                    | 28                                                                 | (0.4)                                                              |
| Dehydration                                 | 4                                        | (6'0)                                    | 5                  | (1.2)              | 7                                                        | (0.2)                                                    | 13                                                                 | (0.2)                                                              |
| Mucosalinflammation                         | 4                                        | (6'0)                                    | 7                  | (91)               | 3                                                        | (0.1)                                                    | 5                                                                  | (0.1)                                                              |
| Stomatitis                                  | 3                                        | (0.7)                                    | 9                  | (2.1)              | 5                                                        | (0.1)                                                    | 5                                                                  | (0.1)                                                              |
| Hypophosphataemia                           | 2                                        | (0.5)                                    | 11                 | (2.6)              | 9                                                        | (0.2)                                                    | 14                                                                 | (0.2)                                                              |
| Anaemia                                     | 1                                        | (0.2)                                    | 13                 | (3.1)              | 23                                                       | (0.5)                                                    | 36                                                                 | (0.6)                                                              |
| Neutropenia                                 |                                          | (0.2)                                    | 28                 | (6.6)              | 8                                                        | (0.2)                                                    | 20                                                                 | (0.3)                                                              |
| Neutrophil count decreased                  | 1                                        | (0.2)                                    | 29                 | (6.8)              | 4                                                        | (0.1)                                                    | 5                                                                  | (0.1)                                                              |
| Platelet count decreased                    | 1                                        | (0.2)                                    | 31                 | (7.3)              | 2                                                        | (0.0)                                                    | 2                                                                  | (0.0)                                                              |
| Pneumonitis                                 | 1                                        | (0.2)                                    | 0                  | (0.0)              | 51                                                       | (1.1)                                                    | 79                                                                 | (1.2)                                                              |
| Leukopenia                                  | 0                                        | (0.0)                                    | 6                  | (1.4)              | 3                                                        | (0.1)                                                    | 3                                                                  | (0.0)                                                              |
| Thrombocytopenia                            | 0                                        | (0.0)                                    | 22                 | (5.2)              | 4                                                        | (0.1)                                                    | 6                                                                  | (0.1)                                                              |
| White blood cell coumt decreased            | 0                                        | (0.0)                                    | 11                 | (2.6)              | 1                                                        | (0.0)                                                    | 1                                                                  | (0.0)                                                              |

Every subjectis counted a single time for each applicable row and column.

- A system organ class or specific adverse event appears on this report only ifits incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.
- Non-serious adverse events up to 30 days following the last dose and serious adverse events up to 90 days following the last dose are included.

MedDRA preferred tenmsNeoplasm Progression\",\"Maliguant Neoplasm Progression\"and\"Disease Progression\"notrelated to the dnug are excluded.

I'Includes allsubjects who received at least one dose of Sunitinib in KN426.

IImcludes all subjects who received at least one dose of Pembrolizumab and/or Axitinib in KN426.

- Imcludesall subjects whoreceivedatleastone doseofpembrolizumab inKN001Part B1,B2,B3,D,CF1,F2,F3,KN002 (original phase), KN006, KN010, KN012 Cohorts B and B2 (HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN045, KN052, KN055 and KN087.
- mcludes all subjects whoreceived atleast one dose ofpembrolizumab inKN001 PartB1,B2B3,D,C,F1,F2,F3,KN002 (originalphase),KN006,KN010,KN012 Cohorts Band B2(HNSCC),Cohort C (Urothelial Tract Cancer)and Cohort D (Gastric Cancer),KN013 Cohort 3 (Hodgkin Lymphoma) and Cohort 4A (MLBCL),KN017,KN024,KN028 Cohort B4, KN040,KN042, KN045, KN052, KN054, KN055, KN059 Cohort 1, KN087, KN158, KN164 Cohort A, KN170, KN224 and KN427 Cohort A.
- Database cutoff date for Melanoma(KN001-Melanoma:18APR2014,KN002:28FEB2015,KN006:03MAR2015,KN054: 020CT2017)

Database cutoff date forLumg(KN001-NSCLC: 23JAN2015, KN010:30SEP2015, KN024:10JUL2017,KN042: 26FEB2018)

Database cutoff date for HNSCC(KN012-HNSCC: 26APR2016,KN040:15MAY2017,KN055:22APR2016)

Database cutoff date for Gastric (KN012-Gastic: 26APR2016, KN059-Cohort 1: 21APR2017)

Database cutoff date for cHL (KN013-Cohort3: 27SEP2016,KN087:25SEP2016)

Database cutoff date for Bladder (KN012-Urothelial:01SEP2015,KN045: 26OCT2017, KN052: 09MAR2017)

Database cutoff date for Colorectal (KN164-Cohort A: 03AUG2016)

Database cutoff date for MLBCL (KN013-Cohort 4A: 04AUG2017, KN170: 19JAN2018)

Database cutoff date for Cervical (KN028-Cohort B4: 20FEB2017,KN158: 15JAN2018)

Database cutoff date forHCC (KN224: 15MAY2018)

Database cutoff date for RCC (KN426:24AUG2018,KN427-Cohort A:07SEP2018)

Database cutoff date for MCC (KN017: 06FEB2018)

Source: [ISS:adam-adsl; adae]

<div style=\"page-break-after: always\"></div>

## Serious Adverse Events

All SAEs

Table 5.3.5.3.3-rcc1: 16

## Subjects With Serious Adverse Events Up to 90 Days of Last Dose (Incidence ≥ 1% in One or More Treatment Groups) By Decreasing Frequency of Preferred Term

(ASaT Population)

|                                                       | KN426 Data for Pembrolizmab + Axitinibl   | KN426 Data for Pembrolizmab + Axitinibl   | KN426 Sunitinib   | KN426 Sunitinib   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Cumlative Rumning Safety Dataset for Pembrolizumab Monotherapy'   | Cumlative Rumning Safety Dataset for Pembrolizumab Monotherapy'   |
|-------------------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------|-------------------|----------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|
|                                                       | n                                         | (%)                                       | n                 | (%)               | n                                                        | (%)                                                      | n                                                                 | (%)                                                               |
| Subjects inpopulation with one or more adverse events | 429                                       |                                           | 425               |                   | 4,439                                                    |                                                          | 6,436                                                             |                                                                   |
|                                                       | 173                                       | (40.3)                                    | 133               | (31.3)            | 1,729                                                    | (39.0)                                                   | 2,472                                                             | (38.4)                                                            |
| with no adverse events                                | 256                                       | (59.7)                                    | 292               | (68.7)            | 2,710                                                    | (61.0)                                                   | 3,964                                                             | (61.6)                                                            |
| Dianhoea                                              | 12                                        | (2.8)                                     | 4                 | (0.9)             | 46                                                       | (0'1)                                                    | 66                                                                | (1.0)                                                             |
| Acute kidney injuy                                    | 7                                         | (9'1)                                     | 3                 | (0.7)             | 42                                                       | (0.9)                                                    | 58                                                                | (0.9)                                                             |
| Alanine aminotransferase increased                    | 6                                         | (1.4)                                     | 0                 | (0.0)             | 9                                                        | (0.2)                                                    | 20                                                                | (0.3)                                                             |
| Dehydration                                           | 6                                         | (1.4)                                     | 5                 | (1.2)             | 39                                                       | (0.9)                                                    | 54                                                                | (0.8)                                                             |
| Aspartate aminotransferase increased                  | 5                                         | (71)                                      | 0                 | (0.0)             | 11                                                       | (0.2)                                                    | 27                                                                | (0.4)                                                             |
| Hepaticfimction abnormal                              | 5                                         | (7)                                       | 0                 | (0.0)             | 1                                                        | (0.0)                                                    | 5                                                                 | (0.1)                                                             |
| Pneumonitis                                           | 5                                         | (71)                                      | 0                 | (0.0)             | 80                                                       | (1.8)                                                    | 120                                                               | (6 )                                                              |
| Pneumonia                                             | 4                                         | (0.9)                                     | 10                | (2.4)             | 153                                                      | (3.4)                                                    | 211                                                               | (3.3)                                                             |
| Pulmonary embolism                                    | 4                                         | (0.9)                                     | 7                 | (1.6)             | 54                                                       | (7D)                                                     | 82                                                                | (1.3)                                                             |
| Colitis                                               | 3                                         | (0.7)                                     | 0                 | (0.0)             | 46                                                       | (0'1)                                                    | 67                                                                | (1.0)                                                             |
| Dyspnoea                                              | 3                                         | (0.7)                                     | 2                 | (0.5)             | 69                                                       | (9'1)                                                    | 86                                                                | (1.3)                                                             |
| Pyrexia                                               | 3                                         | (0.7)                                     | 1                 | (0.2)             | 56                                                       | (1.3)                                                    | 78                                                                | (1.2)                                                             |
| Urinary tact infection                                | 3                                         | (0.7)                                     | 3                 | (0.7)             | 57                                                       | (1.3)                                                    | 68                                                                | (1.1)                                                             |
| Anaemia                                               | 2                                         | (0.5)                                     | 3                 | (0.7)             | 55                                                       | (7D)                                                     | 76                                                                | (7D)                                                              |
| Hyponatraemia                                         | 2                                         | (0.5)                                     | 5                 | (71)              | 34                                                       | (0.8)                                                    | 42                                                                | (0.7)                                                             |
| Plewaleffusion                                        | 2                                         | (0.5)                                     | 1                 | (0.2)             | 66                                                       | (1.5)                                                    | 98                                                                | (SD)                                                              |

Every subject is counted a single time for each applicable row and column.

A system organ class or specific adverse event appears on this report only ifits incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-senious adverse events up to 30 days following the last dose and serious adverse events up to 90 days following the last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

Includes all subjects who received at least one dose of Sunitinib in KN426.

I Includes all subjects who received at least one dose of Pembrolizumab and/or Axitinib in KN426.

Includes allsubjects who received at least one dose ofpembrolizumab in KN001 Pait B1, B2, B3, D, C, F1, F2, F3, KN002 (oniginal phase), KN006, KN010, KN012 Cohorts B and B2 (HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN045, KN052, KN055 and KN087.

Includes all subjects who received at least one dose ofpembrolizumab in KN001 Part B1,B2,B3,D,C,F1, F2,F3,KN002 (oniginal phase),KN006,KN010, KN012 Cohorts B and B2 (HNSCC), Cohort C (Urothelial Tract Cancer) and Cohort D (Gashic Cancer),KN013 Cohort 3 (Hodgkin Lymphoma) and Cohort 4A (MLBCL), KN017, KN024, KN028 Cohort B4, KN040, KN042, KN045, KN052, KN054, KN055, KN059 Cohort 1, KN087, KN158, KN164 Cohort A, KN170, KN224 and KN427Cohort A.

Database cutoff date for Melanoma (KN001-Melanoma:18APR2014,KN002: 28FEB2015,KN006:03MAR2015, KN054: 020CT2017)

Database cutoff date forLumg (KN001-NSCLC:23JAN2015,KN010:30SEP2015,KN024:10JUL2017,KN042:26FEB201S)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN055: 22APR2016)

Database cutoff date for Gashic (KN012-Gashic: 26APR2016, KN059-Cohort 1: 21APR2017)

Database cutoff date for cHL (KN013-Cohort 3: 27SEP2016, KN087: 25SEP2016)

Database cutoff date for Bladder (KN012-Urothelial: 01SEP2015, KN045: 26OCT2017, KN052: 09MAR2017)

Database cutoff date for Colorectal (KN164-Cohort A: 03AUG2016)

Database cutoff date for MLBCL (KN013-Cohort 4A:04AUG2017,KN170:19JAN2018)

Database cutoff datefor Cervical (KN028-Cohort B4:20FEB2017,KN158:15JAN2018)

Database cutoff date for HCC (KN224: 15MAY2018)

Database cutoff date for RCC (KN426: 24AUG2018, KN427-Cohort A: 07SEP2018)

Database cutoff date forMCC (KN017:06FEB2018)

Source:[ISS:adam-adsl; adae]

Page 108/193

<div style=\"page-break-after: always\"></div>

Figure 14.3-5 Between-TreatmentComparisonsinSeriousAdverseEventsupto90Days ofLastDose Selected Adverse Events (&gt;= 1% Incidence) and Sorted by Risk Difference (ASaT Population)

A (N=429) vs. B (N=425)

<!-- image -->

AstandsforPembrolizumab+AxitinibandBstandsforSunitinib

Database CutoffDate: 24Aug2018.

Source: [P426V01MK3475: adam-adsl; adae]

When adjusted for exposure, the overall event rate of SAEs was similar for pembrolizumab+axitinib (6.0 events/100  person-months)  compared  with  sunitinib  (5.1  events/100  person-months);  however differences with higher rates for pembrolizumab+axitinib vs. sunitinib remained for diarrhoea (0.3 vs. 0.1), hepatobiliary disorders (0.4 vs. 0.2), investigations (0.4 vs. 0.1 mainly due to increase of ALT, AST, blood  bilirubin,  hepatic  enzyme,  liver  function  test  and  transaminases  increased),  musculoskeletal disorders (0.3 vs. 0.1), nervous system disorders (0.4. vs. 0.2), and renal and urinary disorders (0.4 vs. 0.2 events/100 person-months).

Rates of exposure-adjusted SAEs were highest in the first three months (10 events/100 person-months in both treatment arms) and then decreased subsequently (with higher rates in the pembrolizumab+axitinib arm from 3 months onwards).

Table 4.5.10: Exposure-Adjusted SAEs Up to 90 Days of Last Dose by Observation Period; (Including Multiple Occurrences of Events); (Incidence &gt; 0% in One or More Treatment Groups) Excerpt

|                               | Event Count andRate(Events/100person-months)   | Event Count andRate(Events/100person-months)   | Event Count andRate(Events/100person-months)   | Event Count andRate(Events/100person-months)   | Event Count andRate(Events/100person-months)   | Event Count andRate(Events/100person-months)   | Event Count andRate(Events/100person-months)   | Event Count andRate(Events/100person-months)   |
|-------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|------------------------------------------------|
|                               | Pembrolizumab+Axitinib                         | Pembrolizumab+Axitinib                         | Pembrolizumab+Axitinib                         | Pembrolizumab+Axitinib                         | Sunitinib                                      | Sunitinib                                      | Sunitinib                                      | Sunitinib                                      |
| Observationperiodofdrug       | 0-3                                            | 3-6                                            | 6-12                                           | Beyond12                                       | 0-3                                            | 3-6                                            | 6-12                                           | Beyond12                                       |
| exposure                      | months                                         | months                                         | months                                         | months                                         | months                                         | months                                         | months                                         | months                                         |
| Number of subjects exposedt   | 429                                            | 400                                            | 349                                            | 187                                            | 425                                            | 375                                            | 295                                            | 126                                            |
| Total exposureinperson-months | 1261.3                                         | 1121.4                                         | 1624.1                                         | 760.1                                          | 1219.6                                         | 966.2                                          | 1237.1                                         | 501.8                                          |
| Totalevents(rate)             | 129 (10.2)                                     | 59 (5.3)                                       | 73 (4.5)                                       | 23 (3.0)                                       | 123 (10.1)                                     | 38 (3.9)                                       | 32 (2.6)                                       | 8 (1.6)                                        |

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                                                                                                      | Cohort A                                                                                                                                                                                                                             | Cohort A                                                                                                                                                                                                                             |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                      | n                                                                                                                                                                                                                                    | (%)                                                                                                                                                                                                                                  |
| Subjects in population                                                                                                                                                                                                               | 110                                                                                                                                                                                                                                  |                                                                                                                                                                                                                                      |
| with one or more serious drug-related adverse events                                                                                                                                                                                 | 20                                                                                                                                                                                                                                   | (18.2)                                                                                                                                                                                                                               |
| with no serious drug-related adverse events                                                                                                                                                                                          | 90                                                                                                                                                                                                                                   | (81.8)                                                                                                                                                                                                                               |
| Blood and lymphatic system disorders                                                                                                                                                                                                 | 1                                                                                                                                                                                                                                    | (0.9)                                                                                                                                                                                                                                |
| Lymphadenopathy                                                                                                                                                                                                                      | 1                                                                                                                                                                                                                                    | (0.9)                                                                                                                                                                                                                                |
| Endocrine disorders                                                                                                                                                                                                                  | 2                                                                                                                                                                                                                                    | (1.8)                                                                                                                                                                                                                                |
| Adrenal insufficiency                                                                                                                                                                                                                | 1                                                                                                                                                                                                                                    | (0.9)                                                                                                                                                                                                                                |
| Secondary adrenocortical insufficiency                                                                                                                                                                                               | 1                                                                                                                                                                                                                                    | (0.9)                                                                                                                                                                                                                                |
| Gastrointestinal disorders                                                                                                                                                                                                           | 6                                                                                                                                                                                                                                    | (5.5)                                                                                                                                                                                                                                |
| Colitis                                                                                                                                                                                                                              | 3                                                                                                                                                                                                                                    | (2.7)                                                                                                                                                                                                                                |
| Diarrhoea                                                                                                                                                                                                                            | 3                                                                                                                                                                                                                                    | (2.7)                                                                                                                                                                                                                                |
| General disordersand administrationsiteconditions                                                                                                                                                                                    | 2                                                                                                                                                                                                                                    | (1.8)                                                                                                                                                                                                                                |
| Asthenia                                                                                                                                                                                                                             | 1                                                                                                                                                                                                                                    | (0.9)                                                                                                                                                                                                                                |
| Pyrexia                                                                                                                                                                                                                              | 1                                                                                                                                                                                                                                    | (0.9)                                                                                                                                                                                                                                |
| Hepatobiliary disorders                                                                                                                                                                                                              | 2                                                                                                                                                                                                                                    | (1.8)                                                                                                                                                                                                                                |
| Hepatitis                                                                                                                                                                                                                            | 2                                                                                                                                                                                                                                    | (1.8)                                                                                                                                                                                                                                |
| Immune system disorders                                                                                                                                                                                                              | 1                                                                                                                                                                                                                                    | (0.9)                                                                                                                                                                                                                                |
| Contrast media allergy                                                                                                                                                                                                               | 1                                                                                                                                                                                                                                    | (0.9)                                                                                                                                                                                                                                |
| Metabolism and nutrition disorders                                                                                                                                                                                                   | 4                                                                                                                                                                                                                                    | (3.0)                                                                                                                                                                                                                                |
| Hyperglycaemia                                                                                                                                                                                                                       | 1                                                                                                                                                                                                                                    | (0.9)                                                                                                                                                                                                                                |
| Hyponatraemia                                                                                                                                                                                                                        | 1                                                                                                                                                                                                                                    | (0.9)                                                                                                                                                                                                                                |
| Hypophosphataemia                                                                                                                                                                                                                    | 1                                                                                                                                                                                                                                    | (0.9)                                                                                                                                                                                                                                |
| Type 1 diabetes mellitus                                                                                                                                                                                                             | 1                                                                                                                                                                                                                                    | (0.9)                                                                                                                                                                                                                                |
| Musculoskeletal and connective tissue disorders                                                                                                                                                                                      | 1                                                                                                                                                                                                                                    | (0.9)                                                                                                                                                                                                                                |
| Muscular weakness                                                                                                                                                                                                                    | 1                                                                                                                                                                                                                                    | (0.9)                                                                                                                                                                                                                                |
| Nervous system disorders                                                                                                                                                                                                             | 1                                                                                                                                                                                                                                    | (0.9)                                                                                                                                                                                                                                |
| Nervous system disorders                                                                                                                                                                                                             | 1                                                                                                                                                                                                                                    | (0.9)                                                                                                                                                                                                                                |
| Myelopathy                                                                                                                                                                                                                           | 1                                                                                                                                                                                                                                    | (0.9)                                                                                                                                                                                                                                |
| Neuropathy peripheral                                                                                                                                                                                                                | 1                                                                                                                                                                                                                                    | (0.9)                                                                                                                                                                                                                                |
| Respiratory,thoracic and mediastinaldisorders                                                                                                                                                                                        | 4                                                                                                                                                                                                                                    | (3.0)                                                                                                                                                                                                                                |
| Pneumonitis                                                                                                                                                                                                                          | 2                                                                                                                                                                                                                                    | (1.8)                                                                                                                                                                                                                                |
| Atelectasis                                                                                                                                                                                                                          | 1                                                                                                                                                                                                                                    | (0.9)                                                                                                                                                                                                                                |
| Pulmonary embolism                                                                                                                                                                                                                   | 1                                                                                                                                                                                                                                    | (0.9)                                                                                                                                                                                                                                |
| Every subjectis counted a single time for each applicable row and column. A system organ class or specific adverse event appears on thiseport only ifits incidence meets the incidence criterion in the report title,after rounding. | Every subjectis counted a single time for each applicable row and column. A system organ class or specific adverse event appears on thiseport only ifits incidence meets the incidence criterion in the report title,after rounding. | Every subjectis counted a single time for each applicable row and column. A system organ class or specific adverse event appears on thiseport only ifits incidence meets the incidence criterion in the report title,after rounding. |
| MedDRA version used is 21.0.                                                                                                                                                                                                         | MedDRA version used is 21.0.                                                                                                                                                                                                         | MedDRA version used is 21.0.                                                                                                                                                                                                         |
| DatabaseCutoffDate:07Sep2018                                                                                                                                                                                                         | DatabaseCutoffDate:07Sep2018                                                                                                                                                                                                         | DatabaseCutoffDate:07Sep2018                                                                                                                                                                                                         |

| System Organ Class PreferredTerm                                         | Axitinib N=189                                                           | Axitinib N=189                                                           |
|--------------------------------------------------------------------------|--------------------------------------------------------------------------|--------------------------------------------------------------------------|
|                                                                          | n (%)                                                                    | No.of Events                                                             |
| Any serious AE                                                           | 64 (33.9)                                                                | 104                                                                      |
| Cardiac disorders                                                        |                                                                          |                                                                          |
| Acutemyocardialinfarction                                                | 0                                                                        | 0                                                                        |
| Cardiac arrest                                                           | 3 (1.6)                                                                  | 4                                                                        |
| Cardio-respiratory arrest                                                | 2 (1.1)                                                                  | 2                                                                        |
| Gastrointestinaldisorders                                                |                                                                          |                                                                          |
| Abdominalpain                                                            | 1 (0.5)                                                                  | 1                                                                        |
| Diarrhea                                                                 | 5 (2.6)                                                                  | 5                                                                        |
| Nausea                                                                   | 1 (0.5)                                                                  | 1                                                                        |
| Rectal hemorrhage                                                        | 2 (1.1)                                                                  | 2                                                                        |
| General disorders and administration site conditions                     |                                                                          |                                                                          |
| Asthenia                                                                 | 2 (1.1)                                                                  | 2                                                                        |
| Chest pain                                                               | 2 (1.1)                                                                  | 2                                                                        |
| Disease progression                                                      | 20 (10.6)                                                                | 20                                                                       |
| Infections andinfestations                                               |                                                                          |                                                                          |
| Pneumonia                                                                | 2 (1.1)                                                                  | 2                                                                        |
| Urinary tractinfection                                                   | 2 (1.1)                                                                  | 2                                                                        |
| Metabolismandnutritiondisorders                                          |                                                                          |                                                                          |
| Dehydration                                                              | 1 (0.5)                                                                  | 2                                                                        |
| Musculoskeletal andconnectivetissuedisorder                              | Musculoskeletal andconnectivetissuedisorder                              | Musculoskeletal andconnectivetissuedisorder                              |
| Pathologicalfracture                                                     | 1 (0.5)                                                                  | 1                                                                        |
| Neoplasms benign, malignant and unspecified (including cysts and polyps) | Neoplasms benign, malignant and unspecified (including cysts and polyps) | Neoplasms benign, malignant and unspecified (including cysts and polyps) |
| Renal cancer metastatic                                                  | 2 (1.1)                                                                  | 2                                                                        |
| Nervous system disorders                                                 | Nervous system disorders                                                 | Nervous system disorders                                                 |
| Cerebralischemia                                                         | 2 (1.1)                                                                  | 2                                                                        |
| Respiratory,thoracic andmediastinaldisorders                             | Respiratory,thoracic andmediastinaldisorders                             | Respiratory,thoracic andmediastinaldisorders                             |
| Hemoptysis                                                               | 1 (0.5)                                                                  | 1                                                                        |
| Pleuraleffusion                                                          | 3 (1.6)                                                                  | 3                                                                        |

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Drug-related SAEs

Table 5.3.5.3.3-rcc1: 18

## Subjects With Drug-related Serious Adverse Events Up to 90 Days of Last Dose (Incidence ≥ 1% in One or More Treatment Groups) By Decreasing Frequency of Preferred Term

(ASaT Population)

|                                                                                                                                                                                                                                                                                                                                                                                                                                                   | KN426 Data for Pembrolizumab + Axitinib                                                                                                                                                                                                                                                                                                                                                                                                           | KN426 Data for Pembrolizumab + Axitinib                                                                                                                                                                                                                                                                                                                                                                                                           | KN426 Sumitinibll                                                                                                                                                                                                                                                                                                                                                                                                                                 | KN426 Sumitinibll                                                                                                                                                                                                                                                                                                                                                                                                                                 | Reference Safety Dataset for Pembrolizumab Monotherapy                                                                                                                                                                                                                                                                                                                                                                                            | Reference Safety Dataset for Pembrolizumab Monotherapy                                                                                                                                                                                                                                                                                                                                                                                            | Cumulative Rumning Safety Dataset for Pembrolizumab Monotherapy                                                                                                                                                                                                                                                                                                                                                                                   | Cumulative Rumning Safety Dataset for Pembrolizumab Monotherapy                                                                                                                                                                                                                                                                                                                                                                                   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                   | n                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (%)                                                                                                                                                                                                                                                                                                                                                                                                                                               | n                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (%)                                                                                                                                                                                                                                                                                                                                                                                                                                               | n                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (%)                                                                                                                                                                                                                                                                                                                                                                                                                                               | n                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (%)                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Subjects in population                                                                                                                                                                                                                                                                                                                                                                                                                            | 429                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 425                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 4,439                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 6,436                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| with one or more adverse events                                                                                                                                                                                                                                                                                                                                                                                                                   | 102                                                                                                                                                                                                                                                                                                                                                                                                                                               | (23.8)                                                                                                                                                                                                                                                                                                                                                                                                                                            | 60                                                                                                                                                                                                                                                                                                                                                                                                                                                | (14.1)                                                                                                                                                                                                                                                                                                                                                                                                                                            | 464                                                                                                                                                                                                                                                                                                                                                                                                                                               | (10.5)                                                                                                                                                                                                                                                                                                                                                                                                                                            | 720                                                                                                                                                                                                                                                                                                                                                                                                                                               | (11.2)                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| with no adverse events                                                                                                                                                                                                                                                                                                                                                                                                                            | 327                                                                                                                                                                                                                                                                                                                                                                                                                                               | (76.2)                                                                                                                                                                                                                                                                                                                                                                                                                                            | 365                                                                                                                                                                                                                                                                                                                                                                                                                                               | (85.9)                                                                                                                                                                                                                                                                                                                                                                                                                                            | 3,975                                                                                                                                                                                                                                                                                                                                                                                                                                             | (89.5)                                                                                                                                                                                                                                                                                                                                                                                                                                            | 5,716                                                                                                                                                                                                                                                                                                                                                                                                                                             | (88.8)                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Dianhoea                                                                                                                                                                                                                                                                                                                                                                                                                                          | 8                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (6'1)                                                                                                                                                                                                                                                                                                                                                                                                                                             | 3                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (0.7)                                                                                                                                                                                                                                                                                                                                                                                                                                             | 30                                                                                                                                                                                                                                                                                                                                                                                                                                                | (0.7)                                                                                                                                                                                                                                                                                                                                                                                                                                             | 43                                                                                                                                                                                                                                                                                                                                                                                                                                                | (0.7)                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Alanine aminohransferase increased                                                                                                                                                                                                                                                                                                                                                                                                                | 6                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (1.4)                                                                                                                                                                                                                                                                                                                                                                                                                                             | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                             | 8                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (0.2)                                                                                                                                                                                                                                                                                                                                                                                                                                             | 15                                                                                                                                                                                                                                                                                                                                                                                                                                                | (0.2)                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Aspartate aminotransferase increased                                                                                                                                                                                                                                                                                                                                                                                                              | 5                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (71)                                                                                                                                                                                                                                                                                                                                                                                                                                              | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                             | 8                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (0.2)                                                                                                                                                                                                                                                                                                                                                                                                                                             | 20                                                                                                                                                                                                                                                                                                                                                                                                                                                | (0.3)                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Pneumonitis                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 0                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 5                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (71)                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                   | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                             | 74                                                                                                                                                                                                                                                                                                                                                                                                                                                | (1.7)                                                                                                                                                                                                                                                                                                                                                                                                                                             | 113                                                                                                                                                                                                                                                                                                                                                                                                                                               | (1.8)                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Every subjectis couted a single time for each applicable row and column A system organ class or specific adverse event appears on this report only ifits incidence in one or more of the columns meets the                                                                                                                                                                                                                                        | Every subjectis couted a single time for each applicable row and column A system organ class or specific adverse event appears on this report only ifits incidence in one or more of the columns meets the                                                                                                                                                                                                                                        | Every subjectis couted a single time for each applicable row and column A system organ class or specific adverse event appears on this report only ifits incidence in one or more of the columns meets the                                                                                                                                                                                                                                        | Every subjectis couted a single time for each applicable row and column A system organ class or specific adverse event appears on this report only ifits incidence in one or more of the columns meets the                                                                                                                                                                                                                                        | Every subjectis couted a single time for each applicable row and column A system organ class or specific adverse event appears on this report only ifits incidence in one or more of the columns meets the                                                                                                                                                                                                                                        | Every subjectis couted a single time for each applicable row and column A system organ class or specific adverse event appears on this report only ifits incidence in one or more of the columns meets the                                                                                                                                                                                                                                        | Every subjectis couted a single time for each applicable row and column A system organ class or specific adverse event appears on this report only ifits incidence in one or more of the columns meets the                                                                                                                                                                                                                                        | Every subjectis couted a single time for each applicable row and column A system organ class or specific adverse event appears on this report only ifits incidence in one or more of the columns meets the                                                                                                                                                                                                                                        | Every subjectis couted a single time for each applicable row and column A system organ class or specific adverse event appears on this report only ifits incidence in one or more of the columns meets the                                                                                                                                                                                                                                        |
| incidence critenion in the report title, after roumding. Non-senious adverse events up to 30 days following the last dose and serious adverse events up to 90 days following the last dose are included.                                                                                                                                                                                                                                          | incidence critenion in the report title, after roumding. Non-senious adverse events up to 30 days following the last dose and serious adverse events up to 90 days following the last dose are included.                                                                                                                                                                                                                                          | incidence critenion in the report title, after roumding. Non-senious adverse events up to 30 days following the last dose and serious adverse events up to 90 days following the last dose are included.                                                                                                                                                                                                                                          | incidence critenion in the report title, after roumding. Non-senious adverse events up to 30 days following the last dose and serious adverse events up to 90 days following the last dose are included.                                                                                                                                                                                                                                          | incidence critenion in the report title, after roumding. Non-senious adverse events up to 30 days following the last dose and serious adverse events up to 90 days following the last dose are included.                                                                                                                                                                                                                                          | incidence critenion in the report title, after roumding. Non-senious adverse events up to 30 days following the last dose and serious adverse events up to 90 days following the last dose are included.                                                                                                                                                                                                                                          | incidence critenion in the report title, after roumding. Non-senious adverse events up to 30 days following the last dose and serious adverse events up to 90 days following the last dose are included.                                                                                                                                                                                                                                          | incidence critenion in the report title, after roumding. Non-senious adverse events up to 30 days following the last dose and serious adverse events up to 90 days following the last dose are included.                                                                                                                                                                                                                                          | incidence critenion in the report title, after roumding. Non-senious adverse events up to 30 days following the last dose and serious adverse events up to 90 days following the last dose are included.                                                                                                                                                                                                                                          |
| MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.                                                                                                                                                                                                                                                                                                   | MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.                                                                                                                                                                                                                                                                                                   | MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.                                                                                                                                                                                                                                                                                                   | MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.                                                                                                                                                                                                                                                                                                   | MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.                                                                                                                                                                                                                                                                                                   | MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.                                                                                                                                                                                                                                                                                                   | MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.                                                                                                                                                                                                                                                                                                   | MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.                                                                                                                                                                                                                                                                                                   | MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.                                                                                                                                                                                                                                                                                                   |
| I Includes all subjects who received at least one dose of Pembrolizumab and/or Axitinb in KN426. I Includes all subjects who received at least one dose of Sunitinib in KN426.                                                                                                                                                                                                                                                                    | I Includes all subjects who received at least one dose of Pembrolizumab and/or Axitinb in KN426. I Includes all subjects who received at least one dose of Sunitinib in KN426.                                                                                                                                                                                                                                                                    | I Includes all subjects who received at least one dose of Pembrolizumab and/or Axitinb in KN426. I Includes all subjects who received at least one dose of Sunitinib in KN426.                                                                                                                                                                                                                                                                    | I Includes all subjects who received at least one dose of Pembrolizumab and/or Axitinb in KN426. I Includes all subjects who received at least one dose of Sunitinib in KN426.                                                                                                                                                                                                                                                                    | I Includes all subjects who received at least one dose of Pembrolizumab and/or Axitinb in KN426. I Includes all subjects who received at least one dose of Sunitinib in KN426.                                                                                                                                                                                                                                                                    | I Includes all subjects who received at least one dose of Pembrolizumab and/or Axitinb in KN426. I Includes all subjects who received at least one dose of Sunitinib in KN426.                                                                                                                                                                                                                                                                    | I Includes all subjects who received at least one dose of Pembrolizumab and/or Axitinb in KN426. I Includes all subjects who received at least one dose of Sunitinib in KN426.                                                                                                                                                                                                                                                                    | I Includes all subjects who received at least one dose of Pembrolizumab and/or Axitinb in KN426. I Includes all subjects who received at least one dose of Sunitinib in KN426.                                                                                                                                                                                                                                                                    | I Includes all subjects who received at least one dose of Pembrolizumab and/or Axitinb in KN426. I Includes all subjects who received at least one dose of Sunitinib in KN426.                                                                                                                                                                                                                                                                    |
| Includes all subjects who received atleast one dose ofpembrolizumab in KN001 Pant B1, B2,B3, D,C,F1, F2,F3, KN002 (oniginal phase), KN006, KN010, KN012 Cohorts B and B2 (HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN045, KN052,KN055 and KN087.                                                                                                                                                                                  | Includes all subjects who received atleast one dose ofpembrolizumab in KN001 Pant B1, B2,B3, D,C,F1, F2,F3, KN002 (oniginal phase), KN006, KN010, KN012 Cohorts B and B2 (HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN045, KN052,KN055 and KN087.                                                                                                                                                                                  | Includes all subjects who received atleast one dose ofpembrolizumab in KN001 Pant B1, B2,B3, D,C,F1, F2,F3, KN002 (oniginal phase), KN006, KN010, KN012 Cohorts B and B2 (HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN045, KN052,KN055 and KN087.                                                                                                                                                                                  | Includes all subjects who received atleast one dose ofpembrolizumab in KN001 Pant B1, B2,B3, D,C,F1, F2,F3, KN002 (oniginal phase), KN006, KN010, KN012 Cohorts B and B2 (HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN045, KN052,KN055 and KN087.                                                                                                                                                                                  | Includes all subjects who received atleast one dose ofpembrolizumab in KN001 Pant B1, B2,B3, D,C,F1, F2,F3, KN002 (oniginal phase), KN006, KN010, KN012 Cohorts B and B2 (HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN045, KN052,KN055 and KN087.                                                                                                                                                                                  | Includes all subjects who received atleast one dose ofpembrolizumab in KN001 Pant B1, B2,B3, D,C,F1, F2,F3, KN002 (oniginal phase), KN006, KN010, KN012 Cohorts B and B2 (HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN045, KN052,KN055 and KN087.                                                                                                                                                                                  | Includes all subjects who received atleast one dose ofpembrolizumab in KN001 Pant B1, B2,B3, D,C,F1, F2,F3, KN002 (oniginal phase), KN006, KN010, KN012 Cohorts B and B2 (HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN045, KN052,KN055 and KN087.                                                                                                                                                                                  | Includes all subjects who received atleast one dose ofpembrolizumab in KN001 Pant B1, B2,B3, D,C,F1, F2,F3, KN002 (oniginal phase), KN006, KN010, KN012 Cohorts B and B2 (HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN045, KN052,KN055 and KN087.                                                                                                                                                                                  | Includes all subjects who received atleast one dose ofpembrolizumab in KN001 Pant B1, B2,B3, D,C,F1, F2,F3, KN002 (oniginal phase), KN006, KN010, KN012 Cohorts B and B2 (HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN045, KN052,KN055 and KN087.                                                                                                                                                                                  |
| $Includes all subjects who received at least one dose ofpembrolizumab in KN001 Pait B1, B2, B3, D, C, Fl, F2, F3, KN002 (oniginal phase),KN006, KN010, KN012 Cohorts B and B2 (HNSCC),Cohort C (Urothelial Tract Cancer) and Cohort D (Gashic Cancer),KN013 Cohort 3 (Hodgkin Lymphoma)and Cohort 4A (MLBCL),KN017, KN024,KN028 Cohort B4, KN040,KN042,KN045,KN052,KN054,KN055,KN059Cohort1,KN087,KN158,KN164CohortA,KN170,KN224and KN427CohortA. | $Includes all subjects who received at least one dose ofpembrolizumab in KN001 Pait B1, B2, B3, D, C, Fl, F2, F3, KN002 (oniginal phase),KN006, KN010, KN012 Cohorts B and B2 (HNSCC),Cohort C (Urothelial Tract Cancer) and Cohort D (Gashic Cancer),KN013 Cohort 3 (Hodgkin Lymphoma)and Cohort 4A (MLBCL),KN017, KN024,KN028 Cohort B4, KN040,KN042,KN045,KN052,KN054,KN055,KN059Cohort1,KN087,KN158,KN164CohortA,KN170,KN224and KN427CohortA. | $Includes all subjects who received at least one dose ofpembrolizumab in KN001 Pait B1, B2, B3, D, C, Fl, F2, F3, KN002 (oniginal phase),KN006, KN010, KN012 Cohorts B and B2 (HNSCC),Cohort C (Urothelial Tract Cancer) and Cohort D (Gashic Cancer),KN013 Cohort 3 (Hodgkin Lymphoma)and Cohort 4A (MLBCL),KN017, KN024,KN028 Cohort B4, KN040,KN042,KN045,KN052,KN054,KN055,KN059Cohort1,KN087,KN158,KN164CohortA,KN170,KN224and KN427CohortA. | $Includes all subjects who received at least one dose ofpembrolizumab in KN001 Pait B1, B2, B3, D, C, Fl, F2, F3, KN002 (oniginal phase),KN006, KN010, KN012 Cohorts B and B2 (HNSCC),Cohort C (Urothelial Tract Cancer) and Cohort D (Gashic Cancer),KN013 Cohort 3 (Hodgkin Lymphoma)and Cohort 4A (MLBCL),KN017, KN024,KN028 Cohort B4, KN040,KN042,KN045,KN052,KN054,KN055,KN059Cohort1,KN087,KN158,KN164CohortA,KN170,KN224and KN427CohortA. | $Includes all subjects who received at least one dose ofpembrolizumab in KN001 Pait B1, B2, B3, D, C, Fl, F2, F3, KN002 (oniginal phase),KN006, KN010, KN012 Cohorts B and B2 (HNSCC),Cohort C (Urothelial Tract Cancer) and Cohort D (Gashic Cancer),KN013 Cohort 3 (Hodgkin Lymphoma)and Cohort 4A (MLBCL),KN017, KN024,KN028 Cohort B4, KN040,KN042,KN045,KN052,KN054,KN055,KN059Cohort1,KN087,KN158,KN164CohortA,KN170,KN224and KN427CohortA. | $Includes all subjects who received at least one dose ofpembrolizumab in KN001 Pait B1, B2, B3, D, C, Fl, F2, F3, KN002 (oniginal phase),KN006, KN010, KN012 Cohorts B and B2 (HNSCC),Cohort C (Urothelial Tract Cancer) and Cohort D (Gashic Cancer),KN013 Cohort 3 (Hodgkin Lymphoma)and Cohort 4A (MLBCL),KN017, KN024,KN028 Cohort B4, KN040,KN042,KN045,KN052,KN054,KN055,KN059Cohort1,KN087,KN158,KN164CohortA,KN170,KN224and KN427CohortA. | $Includes all subjects who received at least one dose ofpembrolizumab in KN001 Pait B1, B2, B3, D, C, Fl, F2, F3, KN002 (oniginal phase),KN006, KN010, KN012 Cohorts B and B2 (HNSCC),Cohort C (Urothelial Tract Cancer) and Cohort D (Gashic Cancer),KN013 Cohort 3 (Hodgkin Lymphoma)and Cohort 4A (MLBCL),KN017, KN024,KN028 Cohort B4, KN040,KN042,KN045,KN052,KN054,KN055,KN059Cohort1,KN087,KN158,KN164CohortA,KN170,KN224and KN427CohortA. | $Includes all subjects who received at least one dose ofpembrolizumab in KN001 Pait B1, B2, B3, D, C, Fl, F2, F3, KN002 (oniginal phase),KN006, KN010, KN012 Cohorts B and B2 (HNSCC),Cohort C (Urothelial Tract Cancer) and Cohort D (Gashic Cancer),KN013 Cohort 3 (Hodgkin Lymphoma)and Cohort 4A (MLBCL),KN017, KN024,KN028 Cohort B4, KN040,KN042,KN045,KN052,KN054,KN055,KN059Cohort1,KN087,KN158,KN164CohortA,KN170,KN224and KN427CohortA. | $Includes all subjects who received at least one dose ofpembrolizumab in KN001 Pait B1, B2, B3, D, C, Fl, F2, F3, KN002 (oniginal phase),KN006, KN010, KN012 Cohorts B and B2 (HNSCC),Cohort C (Urothelial Tract Cancer) and Cohort D (Gashic Cancer),KN013 Cohort 3 (Hodgkin Lymphoma)and Cohort 4A (MLBCL),KN017, KN024,KN028 Cohort B4, KN040,KN042,KN045,KN052,KN054,KN055,KN059Cohort1,KN087,KN158,KN164CohortA,KN170,KN224and KN427CohortA. |
| Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 2SFEB2015, KN006: 03MAR2015, KN054:                                                                                                                                                                                                                                                                                                                                          | Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 2SFEB2015, KN006: 03MAR2015, KN054:                                                                                                                                                                                                                                                                                                                                          | Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 2SFEB2015, KN006: 03MAR2015, KN054:                                                                                                                                                                                                                                                                                                                                          | Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 2SFEB2015, KN006: 03MAR2015, KN054:                                                                                                                                                                                                                                                                                                                                          | Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 2SFEB2015, KN006: 03MAR2015, KN054:                                                                                                                                                                                                                                                                                                                                          | Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 2SFEB2015, KN006: 03MAR2015, KN054:                                                                                                                                                                                                                                                                                                                                          | Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 2SFEB2015, KN006: 03MAR2015, KN054:                                                                                                                                                                                                                                                                                                                                          | Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 2SFEB2015, KN006: 03MAR2015, KN054:                                                                                                                                                                                                                                                                                                                                          | Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 2SFEB2015, KN006: 03MAR2015, KN054:                                                                                                                                                                                                                                                                                                                                          |
| 020CT2017)                                                                                                                                                                                                                                                                                                                                                                                                                                        | 020CT2017)                                                                                                                                                                                                                                                                                                                                                                                                                                        | 020CT2017)                                                                                                                                                                                                                                                                                                                                                                                                                                        | 020CT2017)                                                                                                                                                                                                                                                                                                                                                                                                                                        | 020CT2017)                                                                                                                                                                                                                                                                                                                                                                                                                                        | 020CT2017)                                                                                                                                                                                                                                                                                                                                                                                                                                        | 020CT2017)                                                                                                                                                                                                                                                                                                                                                                                                                                        | 020CT2017)                                                                                                                                                                                                                                                                                                                                                                                                                                        | 020CT2017)                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Database cutoff date forLumg (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015,KN024: 10JUL2017,KN042: 26FEB2018)                                                                                                                                                                                                                                                                                                                                         | Database cutoff date forLumg (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015,KN024: 10JUL2017,KN042: 26FEB2018)                                                                                                                                                                                                                                                                                                                                         | Database cutoff date forLumg (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015,KN024: 10JUL2017,KN042: 26FEB2018)                                                                                                                                                                                                                                                                                                                                         | Database cutoff date forLumg (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015,KN024: 10JUL2017,KN042: 26FEB2018)                                                                                                                                                                                                                                                                                                                                         | Database cutoff date forLumg (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015,KN024: 10JUL2017,KN042: 26FEB2018)                                                                                                                                                                                                                                                                                                                                         | Database cutoff date forLumg (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015,KN024: 10JUL2017,KN042: 26FEB2018)                                                                                                                                                                                                                                                                                                                                         | Database cutoff date forLumg (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015,KN024: 10JUL2017,KN042: 26FEB2018)                                                                                                                                                                                                                                                                                                                                         | Database cutoff date forLumg (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015,KN024: 10JUL2017,KN042: 26FEB2018)                                                                                                                                                                                                                                                                                                                                         | Database cutoff date forLumg (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015,KN024: 10JUL2017,KN042: 26FEB2018)                                                                                                                                                                                                                                                                                                                                         |
| Database cutoff date for Gashic (KN012-Gashic: 26APR2016, KN059-Cohort 1: 21APR2017)                                                                                                                                                                                                                                                                                                                                                              | Database cutoff date for Gashic (KN012-Gashic: 26APR2016, KN059-Cohort 1: 21APR2017)                                                                                                                                                                                                                                                                                                                                                              | Database cutoff date for Gashic (KN012-Gashic: 26APR2016, KN059-Cohort 1: 21APR2017)                                                                                                                                                                                                                                                                                                                                                              | Database cutoff date for Gashic (KN012-Gashic: 26APR2016, KN059-Cohort 1: 21APR2017)                                                                                                                                                                                                                                                                                                                                                              | Database cutoff date for Gashic (KN012-Gashic: 26APR2016, KN059-Cohort 1: 21APR2017)                                                                                                                                                                                                                                                                                                                                                              | Database cutoff date for Gashic (KN012-Gashic: 26APR2016, KN059-Cohort 1: 21APR2017)                                                                                                                                                                                                                                                                                                                                                              | Database cutoff date for Gashic (KN012-Gashic: 26APR2016, KN059-Cohort 1: 21APR2017)                                                                                                                                                                                                                                                                                                                                                              | Database cutoff date for Gashic (KN012-Gashic: 26APR2016, KN059-Cohort 1: 21APR2017)                                                                                                                                                                                                                                                                                                                                                              | Database cutoff date for Gashic (KN012-Gashic: 26APR2016, KN059-Cohort 1: 21APR2017)                                                                                                                                                                                                                                                                                                                                                              |
| Database cutoff date for cHL (KN013-Cohort 3: 27SEP2016, KN087: 25SEP2016)                                                                                                                                                                                                                                                                                                                                                                        | Database cutoff date for cHL (KN013-Cohort 3: 27SEP2016, KN087: 25SEP2016)                                                                                                                                                                                                                                                                                                                                                                        | Database cutoff date for cHL (KN013-Cohort 3: 27SEP2016, KN087: 25SEP2016)                                                                                                                                                                                                                                                                                                                                                                        | Database cutoff date for cHL (KN013-Cohort 3: 27SEP2016, KN087: 25SEP2016)                                                                                                                                                                                                                                                                                                                                                                        | Database cutoff date for cHL (KN013-Cohort 3: 27SEP2016, KN087: 25SEP2016)                                                                                                                                                                                                                                                                                                                                                                        | Database cutoff date for cHL (KN013-Cohort 3: 27SEP2016, KN087: 25SEP2016)                                                                                                                                                                                                                                                                                                                                                                        | Database cutoff date for cHL (KN013-Cohort 3: 27SEP2016, KN087: 25SEP2016)                                                                                                                                                                                                                                                                                                                                                                        | Database cutoff date for cHL (KN013-Cohort 3: 27SEP2016, KN087: 25SEP2016)                                                                                                                                                                                                                                                                                                                                                                        | Database cutoff date for cHL (KN013-Cohort 3: 27SEP2016, KN087: 25SEP2016)                                                                                                                                                                                                                                                                                                                                                                        |
| Database cutoff date forBladder (KN012-Urothelial:01SEP2015,KN045: 26OCT2017,KN052: 09MAR2017) Database cutoff date for Colorectal (KN164-Cohort A: 03AUG2016)                                                                                                                                                                                                                                                                                    | Database cutoff date forBladder (KN012-Urothelial:01SEP2015,KN045: 26OCT2017,KN052: 09MAR2017) Database cutoff date for Colorectal (KN164-Cohort A: 03AUG2016)                                                                                                                                                                                                                                                                                    | Database cutoff date forBladder (KN012-Urothelial:01SEP2015,KN045: 26OCT2017,KN052: 09MAR2017) Database cutoff date for Colorectal (KN164-Cohort A: 03AUG2016)                                                                                                                                                                                                                                                                                    | Database cutoff date forBladder (KN012-Urothelial:01SEP2015,KN045: 26OCT2017,KN052: 09MAR2017) Database cutoff date for Colorectal (KN164-Cohort A: 03AUG2016)                                                                                                                                                                                                                                                                                    | Database cutoff date forBladder (KN012-Urothelial:01SEP2015,KN045: 26OCT2017,KN052: 09MAR2017) Database cutoff date for Colorectal (KN164-Cohort A: 03AUG2016)                                                                                                                                                                                                                                                                                    | Database cutoff date forBladder (KN012-Urothelial:01SEP2015,KN045: 26OCT2017,KN052: 09MAR2017) Database cutoff date for Colorectal (KN164-Cohort A: 03AUG2016)                                                                                                                                                                                                                                                                                    | Database cutoff date forBladder (KN012-Urothelial:01SEP2015,KN045: 26OCT2017,KN052: 09MAR2017) Database cutoff date for Colorectal (KN164-Cohort A: 03AUG2016)                                                                                                                                                                                                                                                                                    | Database cutoff date forBladder (KN012-Urothelial:01SEP2015,KN045: 26OCT2017,KN052: 09MAR2017) Database cutoff date for Colorectal (KN164-Cohort A: 03AUG2016)                                                                                                                                                                                                                                                                                    | Database cutoff date forBladder (KN012-Urothelial:01SEP2015,KN045: 26OCT2017,KN052: 09MAR2017) Database cutoff date for Colorectal (KN164-Cohort A: 03AUG2016)                                                                                                                                                                                                                                                                                    |
| Database cutoff date for MLBCL (KN013-Cohort 4A: 04AUG2017, KN170: 19JAN2018)                                                                                                                                                                                                                                                                                                                                                                     | Database cutoff date for MLBCL (KN013-Cohort 4A: 04AUG2017, KN170: 19JAN2018)                                                                                                                                                                                                                                                                                                                                                                     | Database cutoff date for MLBCL (KN013-Cohort 4A: 04AUG2017, KN170: 19JAN2018)                                                                                                                                                                                                                                                                                                                                                                     | Database cutoff date for MLBCL (KN013-Cohort 4A: 04AUG2017, KN170: 19JAN2018)                                                                                                                                                                                                                                                                                                                                                                     | Database cutoff date for MLBCL (KN013-Cohort 4A: 04AUG2017, KN170: 19JAN2018)                                                                                                                                                                                                                                                                                                                                                                     | Database cutoff date for MLBCL (KN013-Cohort 4A: 04AUG2017, KN170: 19JAN2018)                                                                                                                                                                                                                                                                                                                                                                     | Database cutoff date for MLBCL (KN013-Cohort 4A: 04AUG2017, KN170: 19JAN2018)                                                                                                                                                                                                                                                                                                                                                                     | Database cutoff date for MLBCL (KN013-Cohort 4A: 04AUG2017, KN170: 19JAN2018)                                                                                                                                                                                                                                                                                                                                                                     | Database cutoff date for MLBCL (KN013-Cohort 4A: 04AUG2017, KN170: 19JAN2018)                                                                                                                                                                                                                                                                                                                                                                     |
| Database cutoff date for Cervical (KN028-Cohort B4: 20FEB2017, KN158:15JAN2018)                                                                                                                                                                                                                                                                                                                                                                   | Database cutoff date for Cervical (KN028-Cohort B4: 20FEB2017, KN158:15JAN2018)                                                                                                                                                                                                                                                                                                                                                                   | Database cutoff date for Cervical (KN028-Cohort B4: 20FEB2017, KN158:15JAN2018)                                                                                                                                                                                                                                                                                                                                                                   | Database cutoff date for Cervical (KN028-Cohort B4: 20FEB2017, KN158:15JAN2018)                                                                                                                                                                                                                                                                                                                                                                   | Database cutoff date for Cervical (KN028-Cohort B4: 20FEB2017, KN158:15JAN2018)                                                                                                                                                                                                                                                                                                                                                                   | Database cutoff date for Cervical (KN028-Cohort B4: 20FEB2017, KN158:15JAN2018)                                                                                                                                                                                                                                                                                                                                                                   | Database cutoff date for Cervical (KN028-Cohort B4: 20FEB2017, KN158:15JAN2018)                                                                                                                                                                                                                                                                                                                                                                   | Database cutoff date for Cervical (KN028-Cohort B4: 20FEB2017, KN158:15JAN2018)                                                                                                                                                                                                                                                                                                                                                                   | Database cutoff date for Cervical (KN028-Cohort B4: 20FEB2017, KN158:15JAN2018)                                                                                                                                                                                                                                                                                                                                                                   |
| Database cutoff date for HCC (KN224: 15MAY2018)                                                                                                                                                                                                                                                                                                                                                                                                   | Database cutoff date for HCC (KN224: 15MAY2018)                                                                                                                                                                                                                                                                                                                                                                                                   | Database cutoff date for HCC (KN224: 15MAY2018)                                                                                                                                                                                                                                                                                                                                                                                                   | Database cutoff date for HCC (KN224: 15MAY2018)                                                                                                                                                                                                                                                                                                                                                                                                   | Database cutoff date for HCC (KN224: 15MAY2018)                                                                                                                                                                                                                                                                                                                                                                                                   | Database cutoff date for HCC (KN224: 15MAY2018)                                                                                                                                                                                                                                                                                                                                                                                                   | Database cutoff date for HCC (KN224: 15MAY2018)                                                                                                                                                                                                                                                                                                                                                                                                   | Database cutoff date for HCC (KN224: 15MAY2018)                                                                                                                                                                                                                                                                                                                                                                                                   | Database cutoff date for HCC (KN224: 15MAY2018)                                                                                                                                                                                                                                                                                                                                                                                                   |
| Database cutoff date for RCC (KN426: 24AUG2018,KN427-Cohort A: 07SEP2018) Database cutoff date for MCC (KN017: 06FEB2018)                                                                                                                                                                                                                                                                                                                         | Database cutoff date for RCC (KN426: 24AUG2018,KN427-Cohort A: 07SEP2018) Database cutoff date for MCC (KN017: 06FEB2018)                                                                                                                                                                                                                                                                                                                         | Database cutoff date for RCC (KN426: 24AUG2018,KN427-Cohort A: 07SEP2018) Database cutoff date for MCC (KN017: 06FEB2018)                                                                                                                                                                                                                                                                                                                         | Database cutoff date for RCC (KN426: 24AUG2018,KN427-Cohort A: 07SEP2018) Database cutoff date for MCC (KN017: 06FEB2018)                                                                                                                                                                                                                                                                                                                         | Database cutoff date for RCC (KN426: 24AUG2018,KN427-Cohort A: 07SEP2018) Database cutoff date for MCC (KN017: 06FEB2018)                                                                                                                                                                                                                                                                                                                         | Database cutoff date for RCC (KN426: 24AUG2018,KN427-Cohort A: 07SEP2018) Database cutoff date for MCC (KN017: 06FEB2018)                                                                                                                                                                                                                                                                                                                         | Database cutoff date for RCC (KN426: 24AUG2018,KN427-Cohort A: 07SEP2018) Database cutoff date for MCC (KN017: 06FEB2018)                                                                                                                                                                                                                                                                                                                         | Database cutoff date for RCC (KN426: 24AUG2018,KN427-Cohort A: 07SEP2018) Database cutoff date for MCC (KN017: 06FEB2018)                                                                                                                                                                                                                                                                                                                         | Database cutoff date for RCC (KN426: 24AUG2018,KN427-Cohort A: 07SEP2018) Database cutoff date for MCC (KN017: 06FEB2018)                                                                                                                                                                                                                                                                                                                         |

Souce:[ISS:adam-adsl; adae]

In  the  pembrolizumab+axitinib  arm,  aside  from Diarrhoea , ALT  increased,  AST  increased, and Pneumonitis (see table above), also Colitis (3 subjects), Hepatic function abnormal (4 subjects), Hepatitis (3 subjects), Hepatocellular injury (3 subjects), Cerebrovascular accident (3 subjects), Myasthenia gravis (4  subjects), Acute  kidney  injury (4  subjects), Pulmonary  embolism (3  subjects), Dehydration (3 subjects) were recorded.

Overall , drug-related SAEs with PTs related to Hepatobiliar disorders were reported in a total of 31 subjects (7.2%) : ALT increased (6 subjects) , AST increased (5 subjects) , Hepatic function abnormal (4 subjects), Hepatitis (3  subjects), Hepatocellular  injury (3  subjects), Hepatic  enzyme  increased (2 subjects), Liver function test increased (2 subjects), Transaminases increased (2 subjects), Autoimmune hepatitis (1 subject), Blood bilirubin increased (1 subject), Hepatotoxicity (1 subject), Immune mediated hepatitis (1 subject)

<div style=\"page-break-after: always\"></div>

## Deaths Due to AEs

Table 4.5.12: Subjects With AEs Resulting in Death Up to 90 Days of Last Dose (Excerpt Incidence &gt;0 in Pembrolizumab + Axitinib Group)

|                                 | KN426 Data for Pembrolizumab + Axitinibll   | KN426 Data for Pembrolizumab + Axitinibll   | KN426 Sunitinibtt   | KN426 Sunitinibtt   | Reference Safety Dataset for Pembrolizumab Monotherapy'   | Reference Safety Dataset for Pembrolizumab Monotherapy'   | Cumulative Running Safety Dataset for Pembrolizumab Monotherapy$   | Cumulative Running Safety Dataset for Pembrolizumab Monotherapy$   |
|---------------------------------|---------------------------------------------|---------------------------------------------|---------------------|---------------------|-----------------------------------------------------------|-----------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|
|                                 | 1n                                          | (%)                                         | 1n                  | (%)                 | n                                                         | (%)                                                       |                                                                    | (%)                                                                |
| Subjects in population          | 429                                         |                                             | 425                 |                     | 4,439                                                     |                                                           | 6,436                                                              |                                                                    |
| with one or more adverse events | 11                                          | (2.6)                                       | 15                  | (3.5)               | 211                                                       | (4.8)                                                     | 329                                                                | (5.1)                                                              |
| with no adverse events          | 418                                         | (97.4)                                      | 410                 | (96.5)              | 4,228                                                     | (95.2)                                                    | 6,107                                                              | (94.9)                                                             |
| Cardiac arrest                  | 1                                           | (0.2)                                       | 1                   | (0.2)               | 7                                                         | (0.2)                                                     | 11                                                                 | (0.2)                                                              |
| Death                           | 1                                           | (0.2)                                       | 1                   | (0.2)               | 30                                                        | (0.7)                                                     | 46                                                                 | (0.7)                                                              |
| Myasthenia gravis               | 1                                           | (0.2)                                       | 0                   | (0.0)               | 0                                                         | (0.0)                                                     | 0                                                                  | (0.0)                                                              |
| Myocarditis                     | 1                                           | (0.2)                                       | 0                   | (0.0)               | 0                                                         | (0.0)                                                     | 0                                                                  | (0.0)                                                              |
| Necrotising fasciitis           | 1                                           | (0.2)                                       | 0                   | (0.0)               | 0                                                         | (0.0)                                                     | 0                                                                  | (0.0)                                                              |
| Plasma cell myeloma             | 1                                           | (0.2)                                       | 0                   | (0.0)               | 0                                                         | (0.0)                                                     | 0                                                                  | (0.0)                                                              |
| Pneumonitis                     | 1                                           | (0.2)                                       | 0                   | (0.0)               | 6                                                         | (0.1)                                                     | 8                                                                  | (0.1)                                                              |
| Pulmonary embolism              | 1                                           | (0.2)                                       | 0                   | (0.0)               | 4                                                         | (0.1)                                                     | 12                                                                 | (0.2)                                                              |
| Pulmonary thrombosis            | 1                                           | (0.2)                                       | 0                   | (0.0)               | 0                                                         | (0.0)                                                     | 0                                                                  | (0.0)                                                              |
| Respiratory failure             | 1                                           | (0.2)                                       | 0                   | (0.0)               | 14                                                        | (0.3)                                                     | 18                                                                 | (0.3)                                                              |
| Sudden cardiac death            |                                             | (0.2)                                       | 0                   | (0.0)               | 0                                                         | (0.0)                                                     | 0                                                                  | (0.0)                                                              |

Table 14.3-32 Subjects With Adverse Events Resulting in Death By Decreasing Incidence (Incidence &gt; 0% in One or More Treatment Groups)

(ASaT Population)

|                                | Pembrolizumab + Axitinib   | Pembrolizumab + Axitinib   | Sunitinib   | Sunitinib   |
|--------------------------------|----------------------------|----------------------------|-------------|-------------|
|                                | n                          | (%)                        |             | (%)         |
| Subjects in population         | 429                        |                            | 425         |             |
| with one ormore adverse events | 11                         | (2.6)                      | 15          | (3.5)       |
| with no adverse events         | 418                        | (97.4)                     | 410         | (96.5)      |
| Cardiac alrest                 | 1                          | (0.2)                      | 1           | (0.2)       |
| Death                          | 1                          | (0.2)                      | 1           | (0.2)       |
| Myasthenia gravis              | 1                          | (0.2)                      | 0           | (0.0)       |
| Myocarditis                    | 1                          | (0.2)                      | 0           | (0.0)       |
| Necrotising fasciitis          | 1                          | (0.2)                      | 0           | (0.0)       |
| Plasma cell myeloma            | 1                          | (0.2)                      | 0           | (0.0)       |
| Pneumonitis                    | 1                          | (0.2)                      | 0           | (0.0)       |
| Pulmonary embolism             | 1                          | (0.2)                      | 0           | (0.0)       |
| Pulmonary thrombosis           | 1                          | (0.2)                      | 0           | (0.0)       |
| Respiratory failure            | 1                          | (0.2)                      | 0           | (0.0)       |
| Sudden cardiac death           | 1                          | (0.2)                      | 0           | (0.0)       |
| Acute myocardial infarction    | 0                          | (0.0)                      | 1           | (0.2)       |
| Cardiac amyloidosis            | 0                          | (0.0)                      | 1           | (0.2)       |
| Cardiac failure chronic        | 0                          | (0.0)                      | 1           | (0.2)       |
| Gastric haemonhage             | 0                          | (0.0)                      | 1           | (0.2)       |
| Gastrointestinal haemonhage    | 0                          | (0.0)                      | 1           | (0.2)       |
| Haemorhage intracranial        | 0                          | (0.0)                      | 1           | (0.2)       |
| Hepatitis fulminant            | 0                          | (0.0)                      | 1           | (0.2)       |
| Malignant neoplasm progression | 0                          | (0.0)                      | 1           | (0.2)       |
| Pneumonia                      | 0                          | (0.0)                      | 3           | (0.7)       |
| Sepsis                         | 0                          | (0.0)                      | 1           | (0.2)       |
| Sudden death                   | 0                          | (0.0)                      | 1           | (0.2)       |

<div style=\"page-break-after: always\"></div>

Urinary tract infection

0

(0.0)

1

(0.2)

Every subjectis counted a single timeforeach applicable row and column.

- A system organ class orspecific adverse event appears onthis report only ifits incidence inone ormore of the columns meets the incidence criterion in the report title, afterroumding.

The adverse events are ordered decreasingly by the incidence in the first column.

- MedDRA preferred terms \"Neoplasm progression\", \"Malignant neoplasm progression\" and \"Disease progression\" not related to the drug are excluded.
- Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

DatabaseCutoffDate:24Aug2018

Source: [P426V01MK3475: adam-adsl; adae]

Table 14.3-34 Subjects With Drug-Related Adverse Events Resulting in Death By Decreasing Incidence (Incidence &gt; O% in One or More Treatment Groups)

(ASaT Population)

|                                 | Pembrolizumab + Axitinib   | Pembrolizumab + Axitinib   | Sunitinib   | Sunitinib   |
|---------------------------------|----------------------------|----------------------------|-------------|-------------|
|                                 | n                          | (%)                        |             | (%)         |
| Subjects in population          | 429                        |                            | 425         |             |
| with one or more adverse events | 4                          | (0.9)                      | 7           | (1.6)       |
| withno adverseevents            | 425                        | (99.1)                     | 418         | (98.4)      |
| Myasthenia gravis               | 1                          | (0.2)                      | 0           | (0.0)       |
| Myocarditis                     | 1                          | (0.2)                      | 0           | (0.0)       |
| Necrotising fasciitis           | 1                          | (0.2)                      | 0           | (0.0)       |
| Pneumonitis                     | 1                          | (0.2)                      | 0           | (0.0)       |
| Acute myocardial infarction     | 0                          | (0.0)                      | 1           | (0.2)       |
| Cardiac alrest                  | 0                          | (0.0)                      | 1           | (0.2)       |
| Gastrointestinal haemonhage     | 0                          | (0.0)                      | 1           | (0.2)       |
| Haemonhage intracranial         | 0                          | (0.0)                      | 1           | (0.2)       |
| Hepatitisfulminant              | 0                          | (0.0)                      | 1           | (0.2)       |
| Malignant neoplasm progression  | 0                          | (0.0)                      | 1           | (0.2)       |
| Pneumonia                       | 0                          | (0.0)                      |             | (0.2)       |

- A system organ class or specific adverse event appears on this report only ifits incidence in one or more of the columns meets the incidence criterion in the report title, after roumding.

The adverse events are ordered decreasingly by the incidence in the fist column.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

Database Cutoff Date: 24Aug2018.

Source:[P426V01MK3475:adam-adsl;adae]

Narratives were provided for all the 11 subjects with AEs leading to death up to 90 days after last dose that occurred in the pembrolizumab-axitinib arm of KN426. Based on the information provided (data not shown), in 6 out of 11 patients experienced also Hepatic AE or Hepatic injury during treatment exposure (Grade 4 in 1 case, Grade 3 in 4 cases and Grade 1 in the remaining case).

## Adverse Events of Special Interest

AEOSI are categories comprised of groups of PTs developed by the Sponsor during the pembrolizumab monotherapy program to assess the frequency of immune-related events considered by the Sponsor to be  causally  related  to  pembrolizumab.  Each  AEOSI  represents  a  single  medical  concept  (e.g., immune-related hypothyroidism) and is comprised of multiple PTs (hypothyroidism, hypothyroidism, myxoedema, myxoedema coma, primary hypothyroidism). When pembrolizumab is combined with other drugs, the other drug(s) in the combination may have an AE profile whose ADRs overlap with particular PTs contained in 1 or more AEOSI categories (e.g., axitinib is causally associated with hypothyroidism).

Under  these  circumstances,  those  AEs  reported  using  these  overlapping  PTs  may  not  always  be immune-mediated. Furthermore, an active control (eg, sunitinib) may have an AE profile that includes ADRs whose PTs overlap with PTs contained in 1 or more AEOSI categories. Unless the control drug(s) are immunomodulatory  agents,  these  ADRs,  although  reported  using  PTs  that  overlap  with  some  PTs contained in the AEOSI categories, are not immune-related.

Table 5.3.5.3.3-rcc1: 36

<div style=\"page-break-after: always\"></div>

## Adverse Event Summary for AEOSI (ASaT Population)

|                                                                  | KN426 Data for Pembrolizmab+ Axitinibl   | KN426 Data for Pembrolizmab+ Axitinibl   | KN426 Sunitinibl   | KN426 Sunitinibl   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Cumlative Running Safety Dataset for Pembrolizumab Monotherapy   | Cumlative Running Safety Dataset for Pembrolizumab Monotherapy   |
|------------------------------------------------------------------|------------------------------------------|------------------------------------------|--------------------|--------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|
|                                                                  | n                                        | (%)                                      | n                  | (%)                | n                                                        | (%)                                                      | n                                                                | (%)                                                              |
| Subjects in population                                           | 429                                      |                                          | 425                |                    | 4,439                                                    |                                                          | 6,436                                                            |                                                                  |
| with one or more adveise events                                  | 220                                      | (51.3)                                   | 154                | (36.2)             | 1,007                                                    | (22.7)                                                   | 1,535                                                            | (23.9)                                                           |
| with no adverse event                                            | 209                                      | (48.7)                                   | 271                | (63.8)             | 3,432                                                    | (77.3)                                                   | 4,901                                                            | (76.1)                                                           |
| with drug-related adverse events                                 | 202                                      | (47.1)                                   | 137                | (32.2)             | 860                                                      | (19.4)                                                   | 1,341                                                            | (20.8)                                                           |
| with toxicity grade 3-5 adverse events                           | 46                                       | (10.7)                                   | 8                  | (61)               | 255                                                      | (5.7)                                                    | 395                                                              | (6.1)                                                            |
| with toxicity grade 3-5 drug-related adverse events              | 38                                       | (8.9)                                    | 5                  | (71)               | 217                                                      | (4.9)                                                    | 346                                                              | (5.4)                                                            |
| with non-serious adverse events                                  | 200                                      | (46.6)                                   | 150                | (35.3)             | 827                                                      | (18.6)                                                   | 1,279                                                            | (19.9)                                                           |
| with serious adverse events                                      | 42                                       | (9.8)                                    | 6                  | (1.4)              | 256                                                      | (5.8)                                                    | 393                                                              | (6.1)                                                            |
| with serious dhug-related adverse events                         | 34                                       | (7.9)                                    | 5                  | (1.2)              | 223                                                      | (5.0)                                                    | 349                                                              | (5.4)                                                            |
| with any dose modification due to an adverse event               | 73                                       | (17.0)                                   | 13                 | (3.1)              | 346                                                      | (7.8)                                                    | 546                                                              | (8.5)                                                            |
| Pembrolizumab dose modification                                  | 63                                       | (14.7)                                   | 0                  | (0.0)              | 346                                                      | (7.8)                                                    | 546                                                              | (8.5)                                                            |
| all regimen components dose modification                         | 46                                       | (10.7)                                   | 13                 | (3.1)              | 346                                                      | (7.8)                                                    | 546                                                              | (8.5)                                                            |
| who died                                                         | 3                                        | (0.7)                                    | 1                  | (0.2)              | 6                                                        | (0.2)                                                    | 11                                                               | (0.2)                                                            |
| who died due to a dug-related adverse event                      | 3                                        | (0.7)                                    | 1                  | (0.2)              | 9                                                        | (0.2)                                                    | 11                                                               | (0.2)                                                            |
| discontinued any drug due to an adverse event                    | 26                                       | (6.1)                                    | 4                  | (0.9)              | 142                                                      | (3.2)                                                    | 230                                                              | (3.6)                                                            |
| discontinued Pembrolizumab                                       | 23                                       | (5.4)                                    | 0                  | (0.0)              | 142                                                      | (3.2)                                                    | 230                                                              | (3.6)                                                            |
| discontinued allregimen components                               | 6                                        | (2.1)                                    | 4                  | (0.9)              | 142                                                      | (3.2)                                                    | 230                                                              | (3.6)                                                            |
| discontinued any drug due to a drug- related adverse event       | 23                                       | (5.4)                                    | 4                  | (0.9)              | 140                                                      | (3.2)                                                    | 228                                                              | (3.5)                                                            |
| discontinued Pembrolizumab                                       | 21                                       | (4.9)                                    | 0                  | (0.0)              | 140                                                      | (3.2)                                                    | 228                                                              | (3.5)                                                            |
| discontinued allregimen components                               | 8                                        | (6'1)                                    | 4                  | (6'0)              | 140                                                      | (3.2)                                                    | 228                                                              | (3.5)                                                            |
| discontinued any diug due to a senious adverse event             | 22                                       | (5.1)                                    | 3                  | (0.7)              | 109                                                      | (2.5)                                                    | 159                                                              | (2.5)                                                            |
| discontinued Pembrolizumab                                       | 19                                       | (4.4)                                    | 0                  | (0.0)              | 109                                                      | (2.5)                                                    | 159                                                              | (2.5)                                                            |
| disconfinued allregimen components                               | 8                                        | (6 1)                                    | 3                  | (0.7)              | 109                                                      | (2.5)                                                    | 159                                                              | (2.5)                                                            |
| discontinued any dug due to a senious dhug-related adverse event | 19                                       | (4.4)                                    | 3                  | (0.7)              | 107                                                      | (2.4)                                                    | 157                                                              | (2.4)                                                            |
| discontinued Pembrolizumab                                       | 17                                       | (4.0)                                    | 0                  | (0.0)              | 107                                                      | (2.4)                                                    | 157                                                              | (2.4)                                                            |
| discontinued all regimen components                              | 7                                        | (9'1)                                    | 3                  | (0.7)              | 107                                                      | (2.4)                                                    | 157                                                              | (2.4)                                                            |

Defined as an action taken of dose reduced, drug intemupted or drug withdraw.

Non-senious adverse events up to 30 days following the last dose and serious adverse events up to 90 days following the last dose are included.

Includes allsubjects who received at least one dose of Pembrolizumab and/or Axitinib in KN426.

Includes allsubjects who received at least one dose of pembrolizumab in KN001 Part Bl, B2, B3, D, C, Fl, F2, F3, KN002 (originalphase), KN006, KN010, KN012 Cohorts B and B2 (HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN045,KN052,KN055 andKN087.

I Includes all subjects who received at least one dose of Sumitinib in KN426.

Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (oniginal phase),KN006,KN010,KN012 Cohorts B and B2 (HNSCC), Cohort C (Urothelial TractCancer)and Cohort D (Gashic Cancer), KN013 Cohort 3 (Hodgkin Lymphoma) and Cohort 4A (MLBCL), KN017, KN024, KN028 Cohort B4, KN040,KN042,KN045,KN052,KN054,KN055,KN059 Cohort1,KN087,KN158,KN164CohortA,KN170,KN224 amd KN427 Cohort A.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 020CT2017)

Database cutoff date for Lumg (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 26FEB2018)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MA Y2017, KN055: 22APR2016)

Database cutoff date for Gashic (KN012-Gashic: 26APR2016, KN059-Cohort 1: 21APR2017)

Database cutoff date for cHL (KN013-Cohort 3: 27SEP2016,KN087: 25SEP2016)

Database cutoff date for Bladder (KN012-Urothelial: 01SEP2015, KN045: 26OCT2017, KN052: 09MAR2017)

Database cutoff date for Colorectal (KN164-Cohort A: 03AUG2016)

Database cutoff date for MLBCL (KN013-Cohort 4A: 04AUG2017, KN170: 19JAN2018)

Database cutoff date for Cervical (KN028-Cohort B4: 20FEB2017, KN158: 15JAN2018)

Database cutoff date for HCC (KN224: 15MAY2018)

Database cutoff date forRCC（KN426:24AUG2018,KN427-CohortA:07SEP2018)

Database cutoff date for MCC (KN017: 06FEB2018)

Source: [ISS: adam-adsl; adae]

<div style=\"page-break-after: always\"></div>

## Subjects With Adverse Events of Special Interest (AEOSI) (Incidence &gt; 0% in One or More Treatment Groups) By AEOSI Category and Preferred Term

Table 5.3.5.3.3-rcc1: 37 (ASaT Population)

|                                                       | KN426 Data for Pembrolizumab + Axitinbl   | KN426 Data for Pembrolizumab + Axitinbl   | KN426 Sunitinibl   | KN426 Sunitinibl   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Cumulative Running Safety Dataset for Pembrolizumab Monotherapy   | Cumulative Running Safety Dataset for Pembrolizumab Monotherapy   |
|-------------------------------------------------------|-------------------------------------------|-------------------------------------------|--------------------|--------------------|----------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|
|                                                       | n                                         | (%)                                       | n                  | (%)                | n                                                        | (%)                                                      | n                                                                 | (%)                                                               |
| Subjects inpopulation with one or more adverse events | 429 220 607                               | (51.3)                                    | 425 154 271        | (36.2)             | 4,439 1,007                                              | (22.7)                                                   | 6,436 1,535                                                       | (23.9)                                                            |
| with no adverse events                                |                                           | (48.7)                                    |                    | (63.8)             | 3,432                                                    | (77.3)                                                   | 4,901                                                             | (76.1)                                                            |
|                                                       | 13                                        | (3.0)                                     | 1                  | (0.2)              | 34                                                       | (0.8)                                                    | 51                                                                | (0.8)                                                             |
| Adrenal Insufficieney Adrenal insuficiency            | 12                                        | (2.8)                                     |                    | (0.2)              | 32                                                       | (0.7)                                                    | 47                                                                | (0.7)                                                             |
|                                                       | 1                                         | (0.2)                                     | 0                  | (0.0)              | 1                                                        | (0.0)                                                    | 2                                                                 | (0.0)                                                             |
| Adrenocorticalinsufficiency acute                     | 0                                         | (0.0)                                     | 0                  | (0.0)              | 1                                                        | (0.0)                                                    | 2                                                                 | (0.0)                                                             |
| Colitis                                               | 11                                        | (2.6)                                     | 3                  | (0.7)              | 79                                                       | (1.8)                                                    | 125                                                               | (1.9)                                                             |
| Colitis                                               | 8                                         | (61)                                      | 1                  | (0.2)              | 73                                                       | (9'1)                                                    | 109                                                               | (1.7)                                                             |
| Enterocolitis                                         | 2                                         | (0.5)                                     | 2                  | (0.5)              | 5                                                        | (0.1)                                                    | 8                                                                 | (0.1)                                                             |
| Enterocolitis haemonhagic                             | 1                                         | (0.2)                                     | 0                  | (0.0)              | 0                                                        | (0.0)                                                    | 0                                                                 | (0.0)                                                             |
| Autoimmune colitis                                    | 0                                         | (0.0)                                     | 0                  | (0.0)              | 1                                                        | (0.0)                                                    | 7                                                                 | (0.1)                                                             |
| Colitis microscopic                                   | 0                                         | (0.0)                                     | 0                  | (0.0)              | 2                                                        | (0.0)                                                    | 4                                                                 | (0.1)                                                             |
| Encephalitis                                          | 0                                         | (0.0)                                     | 0                  | (0.0)              | 1                                                        | (0.0)                                                    | 2                                                                 | (0.0)                                                             |
| Encephalitis                                          | 0                                         | (0.0)                                     | 0                  | (0.0)              | 1                                                        | (0.0)                                                    | 2                                                                 | (0.0)                                                             |
| Guillain-BarreSyndrome                                | 0                                         | (0.0)                                     | 0                  | (0.0)              |                                                          | (0.1)                                                    | 5                                                                 | (0.1)                                                             |
| Axonal neuropathy                                     | 0                                         | (0.0)                                     | 0                  | (0.0)              | 1                                                        | (0.0)                                                    | 1                                                                 | (0.0)                                                             |
| Demyelinating polymeuropathy                          | 0                                         | (0.0)                                     | 0                  | (0.0)              | 1                                                        | (0.0)                                                    | 1                                                                 | (0.0)                                                             |
| Guillain-Bare syndrome                                | 0                                         | (0.0)                                     | 0                  | (0.0)              | 2                                                        | (0.0)                                                    | 3                                                                 | (0.0)                                                             |
| Hepatitis                                             | 12                                        | (2.8)                                     |                    | (0.5)              | 30                                                       | (0.7)                                                    | 52                                                                | (0.8)                                                             |
| Hepatitis                                             | 7                                         | (1.6)                                     | 1                  | (0.2)              | 13                                                       | (0.3)                                                    | 25                                                                | (0.4)                                                             |
| Autoimmune hepatitis                                  | 3                                         | (0.7)                                     | 0                  | (0.0)              | 14                                                       | (0.3)                                                    | 21                                                                | (0.3)                                                             |
| Drug-induced liver injury                             |                                           | (0.2)                                     | 0                  | (0.0)              | 4                                                        | (0.1)                                                    | 5                                                                 | (0.1)                                                             |
| Immune-mediated hepatitis                             | 1 0                                       | (0.2) (0.0)                               | 0 0                | (0.0)              | 0                                                        | (0.0)                                                    | 1 1                                                               | (0.0) (0.0)                                                       |
| Hepatiis acute                                        |                                           |                                           |                    | (0.0)              | 0                                                        | (0.0)                                                    | 0                                                                 | (0.0)                                                             |
| Hepatitis fulminant                                   | 0                                         | (0.0)                                     | 1                  | (0.2)              | 0                                                        | (0.0)                                                    |                                                                   |                                                                   |
| Hyperthyroidism                                       | 55                                        | (12.8)                                    | 16                 | (3.8)              | 145                                                      | (3.3)                                                    | 272                                                               | (4.2)                                                             |
| Hyperthyroidism                                       | 55                                        | (12.8)                                    | 16                 | (3.8)              | 145                                                      | (3.3)                                                    | 272                                                               | (4.2)                                                             |
| Hypophysitis                                          | 5                                         | (1.2)                                     | 0                  | (0.0)              | 21                                                       | (0.5) (0.3)                                              | 36 22                                                             | (0.6) (0.3)                                                       |
| Hypophysitis                                          | 5                                         | (71)                                      | 0                  | (0.0)              | 12                                                       |                                                          | 14                                                                |                                                                   |
| Hypopiuitansm                                         | 0                                         | (0.0)                                     | 0                  |                    | 9                                                        | (0.2)                                                    |                                                                   | (0.2)                                                             |
| Hypothyroidism                                        |                                           |                                           |                    | (0.0)              |                                                          |                                                          |                                                                   |                                                                   |
| Hypothyroidism                                        | 152 152                                   | (35.4) (35.4)                             | 134 134            | (31.5) (31.5)      | 440 439                                                  | (9.9) (9.9)                                              | 667 666                                                           | (10.4) (10.3)                                                     |
| Myxoedema                                             | 0                                         | (0.0)                                     | 0 0                | (0.0)              | 1                                                        | (0.0)                                                    | 1 1                                                               | (0.0)                                                             |
| Primary hypothyroidism                                | 0                                         | (0.0)                                     | 4                  | (0.0)              | 1                                                        | (0.0)                                                    | 142                                                               | (0.0) (2.2)                                                       |
| Infusion Reactions Hypersensitivity                   | 7                                         | (1.6)                                     |                    | (0.9) (0.5)        | 113 37                                                   | (2.5) (0.8)                                              | 43                                                                | (0.7)                                                             |
| Infusion relatedreaction                              | 3 2                                       | (0.7) (0.5)                               | 2 0                | (0.0)              | 48                                                       | (1.1)                                                    | 63                                                                | (1.0)                                                             |
| Anaphylactic reaction                                 |                                           | (0.2)                                     | 2                  | (0.5) (0.0)        | 5 16                                                     | (0.1)                                                    | 9 20                                                              | (0.1) (0.3)                                                       |
| Drug hypersensitivity                                 | 1                                         | (0.2)                                     | 0                  |                    |                                                          | (0.4)                                                    | 1                                                                 |                                                                   |
| Anaphylactoid reaction                                | 0                                         | (0.0)                                     | 0                  | (0.0)              | 1                                                        | (0.0)                                                    |                                                                   | (0.0)                                                             |
| Cytokine release syndrome                             | 0                                         | (0.0)                                     | 0                  | (0.0)              | 8                                                        | (0.2)                                                    | 8 4                                                               | (0.1) (0.1)                                                       |
| Myasthenic Syndrome                                   | 4                                         | (0.9)                                     | 0                  | (0.0)              | 2                                                        | (0.0)                                                    |                                                                   |                                                                   |
| Myasthenia gravis Myasthenic syndrome                 | 4                                         | (0.9)                                     | 0                  | (0.0) (0.0)        | 0                                                        | (0.0) (0.0)                                              | 1                                                                 | (0.0) (0.0)                                                       |
|                                                       | 0                                         | (0.0)                                     | 0                  |                    | 2                                                        |                                                          | 3 6                                                               |                                                                   |
| Myocarditis                                           | 2                                         | (0.5)                                     | 0                  | (0.0)              | 3                                                        | (0.1)                                                    |                                                                   | (0.1)                                                             |
| Myocarditis                                           | 2                                         | (0.5)                                     | 0                  | (0.0)              | 3                                                        | (0.1)                                                    | 6                                                                 | (0.1)                                                             |
| Mfyositis                                             |                                           | (0.9)                                     |                    | (0.0)              | 18                                                       | (0.4)                                                    |                                                                   | (0.4)                                                             |
| Myositis                                              | 4 4                                       | (0.9)                                     | 0 0                | (0.0)              | 13                                                       | (0.3)                                                    | 26 20                                                             | (0.3)                                                             |
| Myopathy                                              | 0                                         | (0.0)                                     | 0                  | (0.0)              |                                                          | (0.1)                                                    | 4                                                                 |                                                                   |
| Rhabdomyolysis                                        | 0                                         | (0.0)                                     | 0                  | (0.0)              | 4 1                                                      | (0.0)                                                    | 3                                                                 | (0.1) (0.0)                                                       |
| Nephritis                                             | 6 4                                       | (1.4)                                     | 1                  | (0.2)              | 15                                                       | (0.3)                                                    | 21                                                                | (0.3)                                                             |
| Nephritis                                             | 1                                         | (0.9)                                     | 0 0                | (0.0) (0.0)        |                                                          | (0.0) (0.0)                                              |                                                                   | (0.1) (0.0)                                                       |
| Autoimmune nephritis                                  |                                           | (0.2)                                     |                    |                    | 1 2                                                      |                                                          | 4 3                                                               |                                                                   |
| Tubulointerstitial nephritis                          | 1                                         | (0.2)                                     | 0                  | (0.0)              |                                                          | (0.2)                                                    | 8                                                                 | (0.1)                                                             |
| Acute kidney injuy                                    | 0                                         | (0.0)                                     | 0                  | (0.0)              | 7 2                                                      | (0.0)                                                    | 2                                                                 | (0.0)                                                             |
| Glomerulonephritis membranous                         | 0                                         | (0.0)                                     | 0                  | (0.0)              | 1                                                        | (0.0)                                                    | 1                                                                 | (0.0)                                                             |
| Nephrotic syndrome                                    | 0                                         | (0.0)                                     | 1                  | (0.2)              | 0                                                        | (0.0)                                                    |                                                                   | (0.0)                                                             |
| Renal failure                                         | 0                                         | (0.0)                                     | 0                  | (0.0)              | 2                                                        | (0.0)                                                    | 1 2                                                               | (0.0)                                                             |
| Pancrea titis                                         | 2                                         | (0.5)                                     |                    | (0.5)              | 11                                                       | (0.2)                                                    | 21                                                                | (0.3)                                                             |
|                                                       | 2                                         | (0.5)                                     | 2                  | (0.5)              | 9                                                        | (0.2)                                                    | 18                                                                | (0.3)                                                             |
| Pancreatitis                                          |                                           | (0.0)                                     | 0                  | (0.0)              | 1                                                        | (0.0)                                                    | 1                                                                 | (0.0)                                                             |
| Autoimmune pancreatitis                               | 0 0                                       | (0.0)                                     | 0                  | (0.0)              | 1                                                        | (0.0)                                                    | 3                                                                 | (0.0)                                                             |
| Pancreatitis acute                                    |                                           |                                           |                    |                    |                                                          |                                                          |                                                                   |                                                                   |

<div style=\"page-break-after: always\"></div>

| Pneumonitis                        | 12   | (2.8)   |   1 | (0.2)   | 166   | (3.7)   | 254   | (3.9)   |
|------------------------------------|------|---------|-----|---------|-------|---------|-------|---------|
| Pneumonitis                        | 11   | (2.6)   |   1 | (0.2)   | 154   | (3.5)   | 233   | (3.6)   |
| Interstitial lung disease          | 1    | (0.2)   |   0 | (0.0)   | 13    | (0.3)   | 22    | (0.3)   |
| Organising pneumonia               | 0    | (0.0)   |   0 | (0.0)   | 0     | (0.0)   | 1     | (0.0)   |
| Sarcoidosis                        | 0    | (0.0)   |   0 | (0.0)   | 3     | (0.1)   | 11    | (0.2)   |
| Sarcoidosis                        | 0    | (0.0)   |   0 | (0.0)   | 3     | (0.1)   | 11    | (0.2)   |
| Severe Skin Reactions              | 8    | (1.9)   |   6 | (1.4)   | 63    | (1.4)   | 96    | (1.5)   |
| Exfoliative rash                   | 2    | (0.5)   |   1 | (0.2)   | 2     | (0.0)   | 2     | (0.0)   |
| Rash maculo-papular                | 2    | (0.5)   |   0 | (0.0)   | 10    | (0.2)   | 21    | (0.3)   |
| Dematitis bullous                  | 1    | (0.2)   |   4 | (0.9)   | 5     | (0.1)   | 6     | (0.1)   |
| Pruitus                            |      | (0.2)   |   0 | (0.0)   | 6     | (0.1)   | 9     | (0.1)   |
| Rash                               |      | (0.2)   |   2 | (0.5)   | 18    | (0.4)   | 27    | (0.4)   |
| Rash generalised                   |      | (0.2)   |   0 | (0.0)   | 3     | (0.1)   | 5     | (0.1)   |
| Dermatitis exfoliative             | 0    | (0.0)   |   0 | (0.0)   | 3     | (0.1)   | 5     | (0.1)   |
| Dermatitis exfoliative generalised | 0    | (0.0)   |   0 | (0.0)   | 2     | (0.0)   | 2     | (0.0)   |
| Erythema multifome                 | 0    | (0.0)   |   0 | (0.0)   | 3     | (0.1)   | 6     | (0.1)   |
| Pemphigoid                         | 0    | (0.0)   |   0 | (0.0)   | 3     | (0.1)   | 5     | (0.1)   |
| Pemphigus                          | 0    | (0.0)   |   0 | (0.0)   | 1     | (0.0)   | 2     | (0.0)   |
| Prwihus generalised                | 0    | (0.0)   |   0 | (0.0)   | 1     | (0.0)   | 2     | (0.0)   |
| Prwitus genital                    | 0    | (0.0)   |   0 | (0.0)   | 1     | (0.0)   | 一     | (0.0)   |
| Rash erythematous                  | 0    | (0.0)   |   0 | (0.0)   |       | (0.0)   | 1     | (0.0)   |
| Rash pruitic                       | 0    | (0.0)   |   0 | (0.0)   |       | (0.0)   | 2     | (0.0)   |
| Rash pustular                      | 0    | (0.0)   |   0 | (0.0)   | 1     | (0.0)   |       | (0.0)   |
| Skin necrosis                      | 0    | (0.0)   |   0 | (0.0)   | 1     | (0.0)   | 1     | (0.0)   |
| Stevens-Johnson syndrome           | 0    | (0.0)   |   0 | (0.0)   | 3     | (0.1)   | 3     | (0.0)   |
| Toxic skin eruption                | 0    | (0.0)   |   0 | (0.0)   | 2     | (0.0)   | 2     | (0.0)   |
| Thyroiditis                        | 12   | (2.8)   |   2 | (0.5)   | 30    | (0.7)   | 65    | (1.0)   |
| Thyroiditis                        | 11   | (2.6)   |   1 | (0.2)   | 22    | (0.5)   | 48    | (0.7)   |
| Autoimmune thyroiditis             | 1    | (0.2)   |   0 | (0.0)   | 7     | (0.2)   | 14    | (0.2)   |
| Thyroid disorder                   | 0    | (0.0)   |   1 | (0.2)   | 1     | (0.0)   | 5     | (0.1)   |
| Iype 1 DiabetesMfellitus           | 1    | (0.2)   |   0 | (0.0)   | 15    | (0.3)   | 22    | (0.3)   |
| Diabetic ketoacidosis              | 1    | (0.2)   |   0 | (0.0)   | 7     | (0.2)   | 9     | (0.1)   |
| Iype 1 diabetes mellitus           | 0    | (0.0)   |   0 | (0.0)   | 11    | (0.2)   | 18    | (0.3)   |
| Uveitis                            | 2    | (0.5)   |   0 | (0.0)   | 17    | (0.4)   | 22    | (0.3)   |
| Ureitis                            | 2    | (0.5)   |   0 | (0.0)   | 17    | (0.4)   | 22    | (0.3)   |
| Uveitis                            | 2    | (0.5)   |   0 | (0.0)   | 11    | (0.2)   | 15    | (0.2)   |
| Inidocyclitis                      | 0    | (0.0)   |   0 | (0.0)   | 3     | (0.1)   | 4     | (0.1)   |
| Initis                             | 0    | (0.0)   |   0 | (0.0)   | 3     | (0.1)   | 3     | (0.0)   |

Source: [ISS: adam-adsl; adae]

<!-- image -->

## Table 5.3.5.3.3-rcc1: 118

<div style=\"page-break-after: always\"></div>

## Subjects With Adverse Events of Special Interest (AEOSI) by Maximum Toxicity Grade (Incidence &gt; 0% in One or More Treatment Groups) (ASaT Population)

|                                 | KN426 Data for Pembrolizumnb + Axiinibl   | KN426 Data for Pembrolizumnb + Axiinibl   | KN426 Sumitinib   | KN426 Sumitinib   | Reference Safety Dataset for Pembrolizuwnb Monotherapy   | Reference Safety Dataset for Pembrolizuwnb Monotherapy   | Cumulative Rumning Safety Dataset for Pembrolizimab Monotherapy'   | Cumulative Rumning Safety Dataset for Pembrolizimab Monotherapy'   |
|---------------------------------|-------------------------------------------|-------------------------------------------|-------------------|-------------------|----------------------------------------------------------|----------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|
|                                 | n                                         | (6)                                       |                   | (6)               |                                                          | (6)                                                      | n                                                                  | (6)                                                                |
| Subjects in population          | 429                                       |                                           | 425               |                   | 4.439                                                    |                                                          | 6,436                                                              |                                                                    |
| with one or more adverse events | 220                                       | (51.3)                                    | 154               | (36.2)            | 1,007                                                    | (22.7)                                                   | 1,535                                                              | (23.9)                                                             |
| Grade 1                         | 58                                        | (13.5)                                    | 64                | (15.1)            | 259                                                      | (5.8)                                                    | 372                                                                | (5.8)                                                              |
| Grade 2                         | 116                                       | (27.0)                                    | 82                | (19.3)            | 493                                                      | (11.1)                                                   | 768                                                                | (11.9)                                                             |
| Gnde 3                          | 36                                        | (8.4)                                     | 7                 | (1.6)             | 217                                                      | (4.9)                                                    | 341                                                                | (5.3)                                                              |
| Grade 4                         | 7                                         | (1.0)                                     | 0                 | (0.0)             | 29                                                       | (0.7)                                                    | 43                                                                 | (0.7)                                                              |
| Gnade 5                         | 3                                         | (0.7)                                     | 1                 | (0.2)             | 9                                                        | (0.2)                                                    | 11                                                                 | (0.2)                                                              |
| with no adverse events          | 209                                       | (48.7)                                    | 271               | (63.8)            | 3.432                                                    | (77.3)                                                   | 4.901                                                              | (76.1)                                                             |

Table 14.3-60 Summary of Outcome for SubjectsWithAEOSI (Incidence &gt; 0% in One or More Treatment Groups) (ASaT Population)

|                        |              | Pembrolizumab + Axitinib   | Pembrolizumab + Axitinib   | Suitinib   | Suitinib   |
|------------------------|--------------|----------------------------|----------------------------|------------|------------|
|                        | Outcome      | n                          | (%)                        | n          | (%)        |
| Subjects in population |              | 429                        |                            | 425        |            |
| With one or more AEOSI | Overall      | 220                        | (51.3)                     | 154        | (36.2)     |
|                        | Fatal        | 3                          | (1.4)                      | 1          | (0.6)      |
|                        | Not Resolved | 118                        | (53.6)                     | 80         | (51.9)     |
|                        | Resolving    | 27                         | (12.3)                     | 25         | (16.2)     |
|                        | Unknown      | 0                          | (0.0)                      | 0          | (0.0)      |
|                        | Sequelae     | 7                          | (3.2)                      | 1          | (0.6)      |
|                        | Resolved     | 65                         | (29.5)                     | 47         | (30.5)     |
| Hypothyroidism         | Overall      | 152                        | (35.4)                     | 134        | (31.5)     |
|                        | Fatal        | 0                          | (0.0)                      | 0          | (0.0)      |
|                        | Not Resolved | 95                         | (62.5)                     | 72         | (53.7)     |
|                        | Resolving    | 19                         | (12.5)                     | 21         | (15.7)     |
|                        | Unknown      | 0                          | (0.0)                      | 0          | (0.0)      |
|                        | Sequelae     | 0                          | (0.0)                      | 0          | (0.0)      |
|                        | Resolved     | 38                         | (25.0)                     | 41         | (30.6)     |
| Hyperthyroidism        | Overall      | 55                         | (12.8)                     | 16         | (3.8)      |
|                        | Fatal        | 0                          | (0.0)                      | 0          | (0.0)      |
|                        | Not Resolved | 7                          | (12.7)                     | 4          | (25.0)     |
|                        | Resolving    | 1                          | (1.8)                      | 4          | (25.0)     |
|                        | Unknown      | 0                          | (0.0)                      | 0          | (0.0)      |
|                        | Sequelae     | 0                          | (0.0)                      | 0          | (0.0)      |
|                        | Resolved     | 47                         | (85.5)                     | 8          | (50.0)     |
| Adrenal Insufficiency  | Overall      | 13                         | (3.0)                      |            | (0.2)      |
|                        | Fatal        | 0                          | (0.0)                      | 0          | (0.0)      |
|                        | Not Resolved | 4                          | (30.8)                     | 1          | (100.0)    |
|                        | Resolving    | 2                          | (15.4)                     | 0          | (0.0)      |
|                        | Unknown      | 0                          | (0.0)                      | 0          | (0.0)      |
|                        | Sequelae     | 5                          | (38.5)                     | 0          | (0.0)      |

<div style=\"page-break-after: always\"></div>

| Adrenal Insufficiency   | Resolved               | 2   | (15.4)       | 0   | (0.0)         |
|-------------------------|------------------------|-----|--------------|-----|---------------|
| Colitis                 | Overall                | 11  | (2.6)        | 3   | (0.7)         |
|                         | Fatal                  | 0   | (0.0)        | 0   | (0.0)         |
|                         | Not Resolved           | 1   | (9.1)        | 2   | (66.7)        |
|                         | Resolving              | 1   | (9.1)        | 0   | (0.0)         |
|                         | Unknown                | 0   | (0.0)        | 0   | (0.0)         |
|                         | Sequelae               | 1   | (9.1)        | 0   | (0.0)         |
|                         | Resolved               | 8   | (72.7)       | 1   | (33.3)        |
| Hepatitis               | Overall                | 12  | (2.8)        |     | (0.5)         |
|                         | Fatal                  | 0   | (0.0)        | 1   | (50.0)        |
|                         | Not Resolved           | 0   | (0.0)        | 0   | (0.0)         |
|                         | Resolving              | 2   | (16.7)       | 0   | (0.0)         |
|                         | Unknown                | 0   | (0.0)        | 0   | (0.0)         |
|                         | Sequelae               | 1   | (8.3)        | 0   | (0.0)         |
|                         | Resolved               | 9   | (75.0)       |     | (50.0)        |
| Severe Skin Reactions   |                        | 8   | (1.9)        | 6   | (1.4)         |
|                         | Overall Fatal          | 0 1 | (0.0) (12.5) | 0 2 | (0.0) (33.3)  |
|                         | Not Resolved Resolving | 1   | (12.5)       | 0   | (0.0)         |
|                         | Unknown                | 0   | (0.0)        | 0   | (0.0)         |
|                         | Sequelae               | 0   | (0.0)        | 1   | (16.7)        |
|                         | Resolved               |     |              |     |               |
|                         |                        | 6   | (75.0)       |     | (50.0)        |
| Thyroiditis             |                        | 0   | (2.8)        | 3   | (0.5)         |
|                         | Overall Fatal          | 12  | (0.0) (58.3) | 0 0 | (0.0) (0.0)   |
|                         | Not Resolved Resolving | 7 1 | (8.3)        | 0   | (0.0)         |
|                         | Unknown                | 0   | (0.0)        | 0   | (0.0)         |
|                         | Sequelae               | 0   | (0.0)        | 0   | (0.0)         |
| Thyroiditis             | Resolved               |     | (33.3)       | 2   | (100.0)       |
|                         |                        | 4   |              |     |               |
| Pneumonitis             | Overall                | 12  | (2.8)        | 1   | (0.2)         |
|                         | Fatal                  | 1   | (8.3)        | 0   | (0.0)         |
|                         | Not Resolved           | 2   | (16.7)       | 1   | (100.0)       |
|                         | Resolving              | 2   | (16.7)       | 0   | (0.0)         |
|                         | Unknown                | 0   | (0.0)        | 0   | (0.0)         |
|                         | Sequelae               | 0   | (0.0)        | 0   | (0.0)         |
|                         | Resolved               |     |              | 0   |               |
|                         |                        | 7   | (58.3)       |     | (0.0)         |
| Infusion Reactions      | Overall Fatal          | 0   | (1.6) (0.0)  | 0   | (0.9) (0.0)   |
|                         | Not Resolved           | 1   | (14.3) (0.0) | 0 0 | (0.0)         |
|                         | Resolving              | 0   |              | 0   | (0.0)         |
|                         | Unknow                 | 0   | (0.0)        |     | (0.0)         |
|                         | Sequelae               | 0   | (0.0)        | 0   | (0.0)         |
|                         | Resolved               | 6   | (85.7)       | 4   | (100.0)       |
| Nephritis               | Overall Fatal          | 6 0 | (1.4) (0.0)  | 0   | (0.2) (0.0)   |
|                         | Not Resolved Resolving | 2 0 | (33.3) (0.0) | 1 0 | (100.0) (0.0) |
|                         | Unknown                | 0   | (0.0)        | 0   | (0.0)         |
|                         | Sequelae               | 0   | (0.0)        | 0   | (0.0)         |
|                         | Resolved               | 4   | (66.7)       |     | (0.0)         |
|                         |                        |     |              | 0   |               |
| Hypophysitis            | Overall                | 5   | (71)         | 0   | (0.0)         |
|                         | Fatal Not Resolved     | 0 2 | (0.0) (40.0) | 0 0 | (0.0) (0.0)   |
|                         | Resolving Unknow       | 1   | (20.0)       | 0   | (0.0)         |
|                         |                        | 0   | (0.0)        | 0   | (0.0)         |
|                         | Sequelae               | 0   | (0.0)        | 0   | (0.0)         |

<div style=\"page-break-after: always\"></div>

| Hypophysitis             | Resolved               | 2   | (40.0)       | 0   | (0.0)       |
|--------------------------|------------------------|-----|--------------|-----|-------------|
| MyasthenicSyndrome       | Overall                | 4   | (0.9)        | 0   | (0.0)       |
|                          | Fatal                  | 1   | (25.0)       | 0   | (0.0)       |
|                          | Not Resolved           | 1   | (25.0)       | 0   | (0.0)       |
|                          | Resolving              | 0   | (0.0)        | 0   | (0.0)       |
|                          | Unknowm                | 0   | (0.0)        | 0   | (0.0)       |
|                          | Sequelae               | 2   | (50.0)       | 0   | (0.0)       |
|                          | Resolved               | 0   | (0.0)        | 0   | (0.0)       |
| Myositis                 | Overall                |     | (0.9)        | 0   | (0.0)       |
|                          | Fatal                  | 0   | (0.0)        | 0   | (0.0)       |
|                          | Not Resolved           | 1   | (25.0)       | 0   | (0.0)       |
|                          | Resolving              | 0   | (0.0)        | 0   | (0.0)       |
|                          | Unknown                | 0   | (0.0)        | 0   | (0.0)       |
|                          | Sequelae               | 1   | (25.0)       | 0   | (0.0)       |
|                          | Resolved               | 2   | (50.0)       | 0   | (0.0)       |
| Pancreatitis             | Overall                | 2   | (0.5)        |     | (0.5)       |
|                          | Fatal                  | 0   | (0.0)        | 0   | (0.0)       |
|                          | Not Resolved           | 1   | (50.0)       | 0   | (0.0)       |
|                          | Resolving              | 0   | (0.0)        | 0   | (0.0)       |
|                          | Unknown                | 0   | (0.0)        | 0   | (0.0)       |
|                          | Sequelae               | 1   | (50.0)       | 0   | (0.0)       |
|                          | Resolved               | 0   | (0.0)        |     | (100.0)     |
| Myocarditis              | Overall                | 2   | (0.5)        | 0   | (0.0)       |
|                          | Fatal                  | 1   | (50.0)       | 0   | (0.0)       |
|                          | Not Resolved           | 1   | (50.0)       | 0   | (0.0)       |
|                          | Resolving              | 0   | (0.0)        | 0   | (0.0)       |
|                          | Unknown                | 0   | (0.0)        | 0   | (0.0)       |
|                          | Sequelae               | 0   | (0.0)        | 0   | (0.0)       |
| Myocarditis              | Resolved               | 0   | (0.0)        | 0   | (0.0)       |
| Uveitis                  | Overall                | 2   | (0.5)        | 0   | (0.0)       |
|                          | Fatal                  | 0   | (0.0)        | 0 0 | (0.0) (0.0) |
|                          | Not Resolved           | 1   | (50.0) (0.0) | 0   | (0.0)       |
|                          | Resolving Unknown      | 0 0 | (0.0)        | 0   | (0.0)       |
|                          | Sequelae               | 0   | (0.0)        | 0   | (0.0)       |
|                          | Resolved               | 1   |              | 0   |             |
|                          |                        |     | (50.0)       |     | (0.0)       |
| Type 1 Diabetes Mellitus | Overall                | 1   | (0.2)        | 0   | (0.0)       |
|                          | Fatal                  | 0   | (0.0)        | 0   | (0.0)       |
|                          | Not Resolved Resolving | 0 0 | (0.0) (0.0)  | 0 0 | (0.0) (0.0) |
|                          | Unknow                 | 0   | (0.0)        | 0   | (0.0)       |
|                          |                        | 1   |              |     | (0.0)       |
|                          | Sequelae               |     | (100.0)      | 0   |             |
|                          | Resolved               | 0   | (0.0)        | 0   | (0.0)       |

Outcome: Resolved = RECOVERED/RESOLVED, Resolving =RECOVERING/RESOLVING, Sequelae = RECOVERED/RESOLVED WITH SEQUELAE, Notresolved =NOT RECOVERED/NOTRESOLVED.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

DatabaseCutoff Date: 24Aug2018.

Source:[P426V01MK3475: adam-adsl; adae]

There  were  3  deaths  (0.7%)  due  to  AEOSIs  in  the  pembrolizumab  +  axitinib  (myasthenia  gravis, myocarditis, and pneumonitis) that were considered by the investigator to be related to pembrolizumab; 1 participant in the sunitinib died due to hepatitis fulminant (0.2%).

<div style=\"page-break-after: always\"></div>

## Adrenal Insufficiency

Table 5.3.3.3.3-rccl: 38

## Adverse Event Summary AEOSI-Adrenal Insufficiency (ASaT Population)

|                                                                  | KN426 Dan for Pembrolizumub + Axiinib!   | KN426 Smitinibl   | Refaence Sufely Dulsetfor Penboliamsb Menedenpy   | Refaence Sufely Dulsetfor Penboliamsb Menedenpy   | Cunuline Runing Sufety Dalret for Penbrolizumab Menotenpy   | Cunuline Runing Sufety Dalret for Penbrolizumab Menotenpy   |
|------------------------------------------------------------------|------------------------------------------|-------------------|---------------------------------------------------|---------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|
|                                                                  | ()                                       | (2)               |                                                   |                                                   |                                                             |                                                             |
| Suljeusin popuhtion With cne or more sdherse events              | 429 13 (3.0)                             | 425 (2o)          | 4,439 34                                          | (0.8)                                             | 6,436 51                                                    | (0.8)                                                       |
| with no sdverse event                                            | 416 (97.0)                               | 424 (99.8)        | 4,405                                             | (99.2)                                            | 6,385                                                       | (99.2)                                                      |
| wilh dug-rclled' adverse cventls                                 | 10 (23)                                  | 1 (0.2)           | 24                                                | (0.5)                                             | 39                                                          | (0.6)                                                       |
| Wih mxiclty gnde 3-5 mdvese events                               | 3 (0.7)                                  | 0 (0.0)           | 17                                                | (0.4)                                             |                                                             | (0.4)                                                       |
| wih mdidity pmde 3-5 dug-rehied sdverse cwents                   | 1 (0.2)                                  | 0 (0.0)           | 11                                                | (0.2)                                             | 19                                                          | (Eo)                                                        |
| with mon-serious adverse cvents                                  | 8 (1.9)                                  | 1 (0.2)           | 21                                                | (50)                                              | 30                                                          | (50)                                                        |
| With serious sdverse cvents                                      | 5 (1.2)                                  | 0                 | 17                                                | (0.4)                                             |                                                             | (0.4)                                                       |
| with serious drug-reled adverse cvent                            | E (0.7)                                  | (0.0) 0 (0.0)     | 12                                                | (ED)                                              | 20                                                          | (Eo)                                                        |
| Whh any dose modifention dhe to am Slverse cwent                 | 4 (0.9)                                  | 0 (0.0)           | 16                                                | 中)                                                | 2                                                           | (0.4)                                                       |
| Penbolizmsh dose moifiention                                     | 3 (0.7)                                  | 0 (oro)           | 16                                                | (0.4)                                             | 2                                                           | (0.4)                                                       |
| all regimcn conponents docc modifiention                         | 2 (0.5)                                  | 0 (0.0)           | 16                                                | (中)                                               | 2                                                           | (0.4)                                                       |
| wlodied                                                          | 0 (0.0)                                  | 0 (0.0)           | 0                                                 | (0.0)                                             | 0                                                           | (0.0)                                                       |
| Who died dre to a drug-relted ndverse cvenl                      | D (0.0)                                  | 0 (0.0)           |                                                   | (0.0)                                             | 0                                                           | (0.0)                                                       |
| disoontimed eny dng dhe to umsverse event                        | 0 (0.0)                                  | 0 (0.0)           | 1                                                 | (0.0)                                             | 3                                                           | (0.1)                                                       |
| discontinned Penbroliaumab                                       | (0.0)                                    | 0 (0.0)           |                                                   | (0.0)                                             | 5                                                           | (0.1)                                                       |
| discontinned all regimen components                              | (0.0)                                    | 0 (0.0)           |                                                   | (0.0)                                             | 5                                                           | (0.1)                                                       |
| discontinued any drug dhe toa dmg- relted adverse cvent          | 0 (0.0)                                  | 0 (0.0)           |                                                   | (0.0)                                             | 5                                                           | (0.1)                                                       |
| discontinved Pembrolizumab                                       | (0.0)                                    | 0 (0.0)           |                                                   | (oo)                                              | 5                                                           | (0.1)                                                       |
| discontinved all regimen components                              | (0.0)                                    | 0 (oro)           |                                                   | (0.0)                                             | 5                                                           | (0.1)                                                       |
| discontinued any dnug due lon serious Mlverse cvent              | (0.0)                                    | (0.0)             |                                                   | (0.0)                                             | 4                                                           | (0.1)                                                       |
| discontinnedPenbrolizumab                                        | 0 (0.0)                                  | 0 (0.0)           |                                                   | (o0)                                              | 4                                                           | (0.1)                                                       |
| discontinmed all egimen components                               | (0.0)                                    | 0 (0.0)           |                                                   | (0.0)                                             | 4                                                           | (0.1)                                                       |
| discontinued any dnug doe ton seriora drug-reliled sdverse event | 0 (0.0)                                  | 0 (0.0)           |                                                   | (0.0)                                             | 4                                                           | (0.1)                                                       |
| discontined Penbroliaumab                                        | 0 (0.0)                                  | (0.0)             |                                                   | 1 (0.0)                                           | 4                                                           | (0.1) (0.1)                                                 |
| discontinved all regimen components                              | (0.0)                                    | 0 (0.0)           | 1                                                 | (0.0)                                             | 4                                                           |                                                             |

I Defned es mm sction tken of dose redhced, dmgintemupted or dug gildrawn.

Deemired by le invesligror to berelaed to the dug.

Non-serionsndverse evenls up lo 30 days following the lst doce ud serousiedverse cvents up to 90 drys following dhe lst doce ane inclided.

Incldes all sbjees who received at least one dese of Suntinib in KN426.

IIncludes all suljes who receired atles cne dose cf Penbmliamtb andor Axitinibs in KN426.

hcdesllsubjcwhoreccivedatlestone dos of pemrdiumb nKN0o1 PutB1,B2, B3,D, C,F1,F2,F3, KN0m (original phwe), KN006, KNO10, KN012 Coou B and B2 (HNSOC), KN013 Cohon3 (Hokin Lymphomn), KN024, KN040, KN04S,KN052,KN0550d KN087.

deall subje who reccie alestone dose opemrolizmab i KN001 Pa B1,B2, B3, D, C, F1,F2,F3, KN002 (original phase),KN006, KN010, KN012 Colors B amd B2 (HNSCC). Cohon C (Uclelial TracL Chncer)and Cohot D (Gaiie Cance),KN013 Cohon3 (Hodkin Lymphomn and Cohon4A (MLBCL),KN017, KN024,KN028Cohon B4, KN040,KN042,KN045,KN052,KN054,KN055,KN059CooT1,KN087,KN158,KN164CooA,KN170,KN224amd KN427 CohotA

Daalicc culolT dile forMelmoma(KN001-Melnomt 18APR2014,KN002: 28FEB2015, KN006: 03MAR2015, KN054: 020CT2017)

DHI8ecuIoITdale forLmg(KN001-NSCLC:23IAN2015,KN010:30SEP2015,KN024:10JUL2017,KN042:26FEB2018)

Daabi8 cuiol daIe forHNSCC (KN012-HNSCC:26APR2016KN040:15MAY2017,KN055:22APR2016)

Daubce culolT date for Gaatie (KN012-Gatrie: 26APR2016, KN059-Cohon 1: 21APR2017)

Dal8e culolT da1e forcHL.(KN013-Colom3:27SEP2016,KN087:25SEP2016)

Daabise culnlT daie forBldde (KN012-Urothelial:01SEP2015, KN045:260CT2017, KN052: 09MAR2017)

Daabise culolf dhle for Colorccal (KN164-Colet A:03AuG2016)

Datl8 cunlT dale forMLBCL (KN013-Cohort4A:04AUG2017,KN170: 19JAN2018)

Daalise cuiolf date for Cerviee (KN028-Cohont B4:20FEB2017, KN158:15IAN2018)

Dalbiss culolT dileforHCC (KN224: 15MAY2018)

Daabiwe cuIolT dale for RCC (KN426:24AUG2018, KN427-Oohot A:07SFP2018)

Databive culolf dite for MCC (KN017: 06FEB2018)

Somree: [sS: cdm-adsl, ade]

<div style=\"page-break-after: always\"></div>

Table 5.3.5.3.3-rccl: 39 Time to Onset and Duration of AEOSI - Adrenal Insufficiency (ASaT Population)

|                                                                       | KN426 Datafor Penboliamb + Axiinitl   | KN426 Sunitinib (m)    | Penbrolizmmab Monotenpy ()   | Cumulstive Rurning Safery Daaset for Pembrolizumab Monotlenpy, 16)   |
|-----------------------------------------------------------------------|---------------------------------------|------------------------|------------------------------|----------------------------------------------------------------------|
| Subjeets n popolailon                                                 | 429                                   | 425                    | 4439 34                      | 6436 51                                                              |
| Subjects with Adreul humlfhcienry                                     | 13 (3.0)                              | (0.2)                  | (0.8) 180.0 (136.8) 160.0    | (0.8) 189.1 (1323)                                                   |
| Time lo Onsst of Fist Adreal hsullicieicy (days)t Mem (S) Medim Range | 215.8(148.8) 168.0 64 10 491          | 276.0 276.0 276 10 276 | 110 539                      | 162.0 1 10 539 53                                                    |
| Toal episodes or Adrenl hsulfieieney                                  | 13                                    |                        | 36                           | 1.04                                                                 |
| Avenge Episodes per pitient Epbede duntion (day)t                     | 1.00                                  | 1.00                   | 1.06                         |                                                                      |
| Medlim                                                                | 204.0                                 | Not reched             | Not recled                   | Not rencled                                                          |

Source: [Iss: adm-adel, mdhe]

<!-- image -->

In the pembrolizumab+axitinib arm, Adrenal insufficiency AEOSI presented after a median of 168 days (range, 64-491) of exposure. An average of 1 episode was reported per patient with a median duration of 204 days. Corticosteroid treatment was given to 92.3% of subjects.

<div style=\"page-break-after: always\"></div>

discontimued allregimen components

Table 5.3.5.3.3-1cc1: 54

## Adverse Event Summary AEOSI -Hepatitis (ASaT Population)

|                                                                   | KN426 Data for Pembrolizumab + Axitinibl   | KN426 Sumitinib   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Cumulative Rumning Safety Dataset for Pembrolizmab Monotherapy'   | Cumulative Rumning Safety Dataset for Pembrolizmab Monotherapy'   |
|-------------------------------------------------------------------|--------------------------------------------|-------------------|----------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|
|                                                                   | n (%)                                      | ()                |                                                          | ()                                                       |                                                                   | ()                                                                |
| Subjects in population                                            | 429                                        | 425               | 4.439                                                    |                                                          | 6,436                                                             |                                                                   |
| with one or more adverse events                                   | 12 (2.8)                                   | 2 (s0)            | 30                                                       | (0.7)                                                    | 52                                                                | (0.8)                                                             |
| with no adverse event                                             | 417 (97.2)                                 | 423 (99.5)        | 4,409                                                    | (99.3)                                                   | 6.384                                                             | (99.2)                                                            |
| with drug-related adverse events                                  | 10 (2.3)                                   | (0.5)             | 25                                                       | (0.6)                                                    | 41                                                                | (0.6)                                                             |
| with toxicity grade 3-5 adverse events                            | 10 (2.3)                                   | 2 1 (0.2)         | 23                                                       | (0.5)                                                    | 40                                                                | (90)                                                              |
| with toxicity grade 3-5 drug-related adverse events               | 9 (2.1)                                    | 1 (0.2)           | 19                                                       | (0.4)                                                    | 32                                                                | (0.5)                                                             |
| with non-serious adverse events                                   | 5 (1.2)                                    | 1 (0.2)           | 13                                                       | (0.3)                                                    | 23                                                                | (0.4)                                                             |
| with serious adverse events                                       | 7 (1.6)                                    | 1 (0.2)           | 17                                                       | (0.4)                                                    | 31                                                                | (0.5)                                                             |
| with serious drug-related adverse events                          | 6 (1.4)                                    | (0.2)             | 17                                                       | (0.4)                                                    | 27                                                                | (0.4)                                                             |
| with any dose modification* due to an adverse event               | 10 (2.3)                                   | (0.2)             | 21                                                       | (0.5)                                                    |                                                                   | (0.5)                                                             |
| Pembrolizumab dose modification                                   | 9 (2.1)                                    | 0 (0.0)           | 21                                                       | (0.5)                                                    | E                                                                 | (0.5)                                                             |
| all regimen components dose modification                          | 8 (1.9)                                    | 1 (0.2)           | 21                                                       | (0.5)                                                    | tE                                                                | (0.5)                                                             |
| who died                                                          | 0 (0.0)                                    | (0.2)             | 0                                                        | (0.0)                                                    | 0                                                                 | (0°0)                                                             |
| Who died due to a drug-related adverse event                      | 0 (0.0)                                    | (0.2)             | 0                                                        | (0.0)                                                    | 0                                                                 | (0.0)                                                             |
| discontinued any drug due to an adverse event                     | 8 (1.9)                                    | 1 (0.2)           | 9                                                        | (0.2)                                                    | 19                                                                | (0.3)                                                             |
| discontinued Pembrolizumab                                        | 7 (1.6)                                    | 0 (0.0)           | 9                                                        | (0.2)                                                    | 19                                                                | (0.3)                                                             |
| discontimued allregimen components                                | 3 (0.7)                                    | 1 (0.2)           | 9                                                        | (0.2)                                                    | 19                                                                | (0.3)                                                             |
| discontimued any drug due to a drug- related adverse event        | 7 (1.6)                                    | (0.2)             | 9                                                        | (0.2)                                                    | 19                                                                | (0.3)                                                             |
| discontimued Pembrolizimab                                        | 6 (1.4)                                    | 0 (0.0)           | 9                                                        | (0.2)                                                    | 19                                                                | (0.3)                                                             |
| discontimued allregimen components                                | 3 (0.7)                                    | 1 (0.2)           | 9                                                        | (0.2)                                                    | 19                                                                | (0.3)                                                             |
| discontinued any dnug due to a serious adverse event              | 6 (1.4)                                    | 1 (0.2)           | 8                                                        | (0.2)                                                    | 14                                                                | (0.2)                                                             |
| discontinued Pembrolizumab                                        | 5 (1.2)                                    | 0 (0.0)           | 8                                                        | (0.2)                                                    | 14                                                                | (0.2)                                                             |
| discontinued allregimen components                                | 2 (0.5)                                    | 1 (0.2)           | 8                                                        | (0.2)                                                    | 14                                                                | (0.2)                                                             |
| discontinued any drug due to a serious dnug-related adverse event | 5 (1.2)                                    | 1 (0.2)           | 8                                                        | (0.2)                                                    | 14                                                                | (0.2)                                                             |
| discontinued Pembrolizumab                                        | 4 (0.9)                                    | 0 (0.0)           | 8                                                        | (0.2)                                                    | 14                                                                | (0.2)                                                             |

2

I Determined by the investigator to be related to the drug.

(0.5)

(0.2)

I Defined as an action taken of dose reduced, drug interrupted or drug withdrawn.

IIncludes all subjects who received at least one dose of Pembrolizumab and/or Axiinib in KN426.

(0.2)

(0.2)

Non-serious adverse events up to 30 days following the last dose and serious adverse events up to 90 days following the last dose are included.

+Includes all subjects who received at least one dose of Sunitinib in KN426.

- Includes all subjects who received at least one dose ofpembrolizumab in KN001 Part B1,B2,B3,D,C,F1,F2,F3,KN002 (oniginal phase). KN006, KN010. KN012 Cohorts B and B2 (HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040. KN045, KN052, KN055 and KN087.

Includes all subjects who received atleast one dose ofpembrolizumab inKN001 Part B1,B2,B3,D,CF1,F2,F3,KN002 (original phase),KN006,KN010, KN012 Cohorts B and B2 (HNSCC), Cohort C (Urothelial Tract Cancer) and Cohort D (Gastric Cancer).KN013 Cohort 3 (Hodgkin Lymphoma) and Cohort 4A (MLBCL).KN017, KN024,KN028 Cohort B4, KN040, KN042, KN045, KN052, KN054, KN055, KN059 Cohort 1, KN087, KN158, KN164 Cohort A, KN170, KN224 and KN427 CohortA.

Database cutoff date for Melanoma (KN001-Melanoma:18APR2014.KN002: 28FEB2015.KN006:03MAR2015,KN054: 020CT2017)

Database cutoff date forLung(KN001-NSCLC: 23JAN2015,KN010: 30SEP2015,KN024: 10JUL2017,KN042: 26FEB2018)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017,KN055: 22APR2016)

Database cutoff date for Gastric (KN012-Gastric: 26APR2016, KN059-Cohort 1: 21APR2017)

Database cutoff date for cHL(KN013-Cohort 3:27SEP2016,KN087: 25SEP2016)

Database cutoff date for Bladder (KN012-Urothelial: 01SEP2015,KN045: 26OCT2017,KN052: 09MAR2017)

Database cutoff date for Colorectal (KN164-Cohort A: 03AUG2016)

Database cutoff date for MLBCL (KN013-Cohort 4A: 04AUG2017,KN170: 19JAN2018)

Database cutoff date for Cervical (KN028-Cohort B4: 20FEB2017, KN158: 15JAN2018)

Database cutoff date for HCC (KN224: 15MAY2018)

Database cutoff date for RCC (KN426: 24AUG2018,KN427-Cohort A: 07SEP2018)

Database cutoff date for MCC (KN017: 06FEB2018)

Source: [ISS: adam-adsl; adae]

8

14

<div style=\"page-break-after: always\"></div>

Table 5.3.5.3.3-rcc1: 55

## Time to Onset and Duration of AEOSI - Hepatitis (ASaT Population)

|                                                                  | KN426 Data for Pembrolizumab + Axitinib (7.)   | KN426 Sunitinibt Ⅱ (70)      | Reference Safety Dataset for Pembrolizumab Monotherapy (%)   | Cumulative Rumning Safety Dataset for Pembrolizumab Monotherapy' I (%)   |
|------------------------------------------------------------------|------------------------------------------------|------------------------------|--------------------------------------------------------------|--------------------------------------------------------------------------|
| Subjects in population                                           | 429                                            | 425                          | 4439                                                         | 6436                                                                     |
| Subjects with Hepatitis                                          | 12 (2.8)                                       | 2 (0.5)                      | 30 (0.7)                                                     | 52 (0.8)                                                                 |
| Time to Onset of First Hepatitis (days)T Mean (Std) Median Range | 79.8 (71.3) 54.0 16 to 252                     | 113.0 (72.1) 113.0 62 to 164 | 99.4 (125.9) 61.0 8 to 651                                   | 144.9 (145.6) 108.0 8 to 651                                             |
| Total episodes of Hepatitis                                      | 12                                             | 4                            | 32                                                           | 69                                                                       |
| Average Episodes per patient Episode duation (days)t             | 1.00                                           | 2.00                         | 1.07                                                         | 1.33                                                                     |
| Median                                                           | 47.0                                           | 13.0                         | 46.0                                                         | 33.0                                                                     |

Range

7 to 457+

(/) = Number of subjects with Hepatitis/ Number of subjects in population.

↑ Time to onset statistics are based on number of subjects with Hepatitis.

↑ From product-limit (Kaplan-Meier) method for censored data. If an adverse event is not resolved at the time of analysis or the subject died without adverse event resolved, the duration is censored at either data cutoff date or date of death, whichever occured first.

+ indicates the AE episode is not recovered/resolved by the time of the cutoff date or date of death.

Std = Standard Deviation.

Grades are based on NCI CTCAE 4.0.

IIncludes allsubjects who received at least one dose of Pembrolizumab and/or Axitinib in KN426.

Includes allsubjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 Cohorts B and B2 (HNSCC). KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN045, KN052, KN055 and KN087.

I Includes all subjects who received at least one dose of Sumitinib in KN426.

Inchdes allsubjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3. KN002 (original phase). KN006, KN010, KN012 Cohorts B and B2 (HNSCC). Cohort C (Urothelial Tract Cancer)and Cohort D (Gastic Cancer).KN013 Cohort 3 (Hodgkin Lymphoma) and Cohort 4A (MLBCL).KN017, KN024, KN028 Cohort B4,KN040, KN042.

KN045, KN052, KN054, KN055, KN059 Cohort 1, KN087, KN158, KN164 Cohort A, KN170, KN224 and KN427 Cohort A.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 020CT2017)

Database cutoff date for Lug (KN001-NSCLC: 23IAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 26FEB2018)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016. KN040: 15MAY2017. KN055: 22APR2016)

Database cutoff date for Gastic (KN012-Gastric: 26APR2016, KN059-Cohort 1: 21APR2017)

Database cutoff date for cHL (KN013-Cohort 3: 27SEP2016, KN087: 25SEP2016)

Database cutoff date for Bladder (KN012-Urothelial: 01SEP2015, KN045: 260CT2017, KN052: 09MAR2017)

Database cutoff date for Colorectal (KN164-Cohort A: 03AUG2016)

Database cutoff date for MLBCL (KN013-Cohort 4A: 04AUG2017, KN170: 19JAN2018)

Database cutoff date for Cervical (KN028-Cohort B4: 20FEB2017, KN158: 15JAN2018)

Database cutoff date for HCC (KN224: 15MAY2018)

Database cutoff date for RCC (KN426: 24AUG2018, KN427-Cohort A: 07SEP2018)

Database cutoff date for MCC (KN017: 06FEB2018)

Source: [ISS: adam-adsl; adae]

In the pembrolizub+axitinib arm, median time to Hepatitis AEOSI was 54 days (range, 16-252). An average of 1.0 episode was reported per patient with a median duration of 47 days. In 66.7% of subjects concomitant  corticosteroids  were  given;  all  received  high  starting  dose  (&gt;40  mg/day  prednisone  or equivalent).

4+ to 43

8 to 635+

1 to 635+

## Table 5.3.5.3.3-rcc1: 58

<div style=\"page-break-after: always\"></div>

## Adverse Event Summary AEOSI - Hyperthyroidism

(ASaT Population)

|                                                                   | KN426 Data for Pembrolizumab + Axitinibl   | KN426 Sumitinib   | KN426 Sumitinib   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Cumulative Rumning Safety Dataset for Pembrolizimab Monotherapy'   | Cumulative Rumning Safety Dataset for Pembrolizimab Monotherapy'   |
|-------------------------------------------------------------------|--------------------------------------------|-------------------|-------------------|----------------------------------------------------------|----------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|
|                                                                   | I ()                                       | n                 | ()                | n                                                        | ()                                                       |                                                                    | (%0)                                                               |
| Subjects in population                                            | 429                                        | 425               |                   | 4.439                                                    |                                                          | 6,436                                                              |                                                                    |
| with one or more adverse events                                   | 55                                         | 16                | (3.8)             | 145                                                      | (3.3)                                                    | 272                                                                | (4.2)                                                              |
| with no adverse event                                             | (12.8) 374 (87.2)                          | 409               | (96.2)            | 4.294                                                    | (96.7)                                                   | 6,164                                                              | (95.8)                                                             |
| with drug-related' adverse events                                 | 52 (12.1)                                  | 14                | (3.3)             | 125                                                      | (2.8)                                                    | 243                                                                | (3.8)                                                              |
| with toxicity grade 3-5 adverse events                            | 5 (1.2)                                    | 0                 | (0.0)             | 4                                                        | (0.1)                                                    | 6                                                                  | (0.1)                                                              |
| with toxicity grade 3-5 drug-related adverse events               | 4 (0.9)                                    | 0                 | (0.0)             | 4                                                        | (0.1)                                                    | 6                                                                  | (0.1)                                                              |
| with non-serious adverse events                                   | 53 (12.4)                                  | 16                | (3.8)             | 138                                                      | (3.1)                                                    | 263                                                                | (4.1)                                                              |
| with serious adverse events                                       | 2 (0.5)                                    | 0                 | (0.0)             | 8                                                        | (0.2)                                                    | 10                                                                 | (0.2)                                                              |
| with serious drug-related adverse events                          | 1 (0.2)                                    | 0                 | (0.0)             | 8                                                        | (0.2)                                                    | 10                                                                 | (0.2)                                                              |
| with any dose modification* due to an adverse event               | 11 (2.0)                                   | 0                 | (0.0)             | 10                                                       | (0.2)                                                    | 18                                                                 | (0.3)                                                              |
| Pembrolizumab dose modification                                   | 10 (2.3)                                   | 0                 | (0.0)             | 10                                                       | (0.2)                                                    | 18                                                                 | (0.3)                                                              |
| allregimen components dose modification                           | 6 (1.4)                                    | 0                 | (0.0)             | 10                                                       | (0.2)                                                    | 18                                                                 | (0.3)                                                              |
| who died                                                          | 0 (0.0)                                    | 0                 | (0.0)             | 0                                                        | (0.0)                                                    | 0                                                                  | (0.0)                                                              |
| who died due to a drug-related adverse event                      | 0 (0.0)                                    | 0                 | (0.0)             | 0                                                        | (0.0)                                                    | 0                                                                  | (0.0)                                                              |
| discontinued any dnug due to an adverse event                     | 0 (0.0)                                    | 0                 | (0.0)             | 2                                                        | (0.0)                                                    | 3                                                                  | (0.0)                                                              |
| discontinued Pembrolizumab                                        | 0 (0.0)                                    | 0                 | (0.0)             | 2                                                        | (0.0)                                                    | 3                                                                  | (0.0)                                                              |
| discontinued all regimen components                               | 0 (0.0)                                    | 0                 | (0.0)             | 2                                                        | (0.0)                                                    | 3                                                                  | (0.0)                                                              |
| discontinued any drug due to a drug- related adverse event        | 0 (0.0)                                    | 0                 | (0.0)             | 2                                                        | (0.0)                                                    | m                                                                  | (0.0)                                                              |
| discontinued Pembrolizumab                                        | 0 (0.0)                                    | 0                 | (0.0)             | 2                                                        | (0.0)                                                    | m                                                                  | (0.0)                                                              |
| discontinued all regimen components                               | 0 (0.0)                                    | 0                 | (0.0)             | 2                                                        | (0.0)                                                    | 3                                                                  | (0.0)                                                              |
| discontinued any drug due to a serious adverse event              | 0 (0.0)                                    | 0                 | (0.0)             | 2                                                        | (0.0)                                                    | 2                                                                  | (0.0)                                                              |
| discontinued Pembrolizumnb                                        | 0 (0.0)                                    | 0                 | (0.0)             | 2                                                        | (0.0)                                                    | 2                                                                  | (0.0)                                                              |
| discontinued all regimen components                               | 0 (0.0)                                    | 0                 | (0.0)             | 2                                                        | (0.0)                                                    | 2                                                                  | (0.0)                                                              |
| discontinued any drug due to a serious drug-related adverse event | 0 (0.0)                                    | 0                 | (0.0)             | 2                                                        | (0.0)                                                    | 2                                                                  | (0.0)                                                              |
| discontinued Pembrolizumnb                                        | 0 (0.0)                                    | 0                 | (0.0)             | 2                                                        | (0.0)                                                    | 2                                                                  | (0.0)                                                              |
| discontinued allregimen components                                | 0 (0.0)                                    | 0                 | (0.0)             | 2                                                        | (0.0)                                                    | 2                                                                  | (0.0)                                                              |

Defined as an action taken of dose reduced, drug intemupted or drug withdrawn.

Determined by the investigator to be related to the drug.

Non-serious adverse events up to 30 days following the last dose and serious adverse events up to 90 days following the hst dose are included.

I'Includes all subjects who received at least one dose of Sumitinib in KN426.

IInchudes allsubjects who received atleast one dose of Pembrolizumab and/or Axitinib in KN426.

Includes all subjects who receivedat least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase). KN006, KN010, KN012 Cohorts B and B2 (HNSCC). KN013 Cohort 3 (Hodgkin Lymphoma). KN024, KN040, KN045, KN052, KN055 and KN087.

Includes allsubjects who received at least one dose of pembrolizumab in KN001 Paut B1,B2,B3,D,C,F1,F2,F3,KN002 (original phase). KN006, KN010, KN012 Cohorts B and B2 (HNSCC). Cohort C (Urothelial Tract Cancer) and Cohort D (Gastric Cancer). KN013 Cohort 3 (Hodgkin Lymphoma) and Cohort 4A (MLBCL). KN017, KN024, KN028 Cohort B4. KN040, KN042, KN045, KN052, KN054, KN055. KN059 Cohort 1, KN087, KN158, KN164 Cohort A, KN170, KN224 and KN427 Cohort A.

Database cutoffdate forMelanoma（KN001-Melanoma:18APR2014.KN002:28FEB2015.KN006:03MAR2015.KN054: 020CT2017)

Database cutoff date for Lumg (KN001-NSCLC: 23IAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 26FEB2018)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN055: 22APR2016)

Database cutoff date for Gastric (KN012-Gastric: 26APR2016, KN059-Cohort 1: 21APR2017)

Database cutoff date for cHL (KN013-Cohort 3: 27SEP2016, KN087: 25SEP2016)

Database cutoff date for Bladder (KN012-Urothelial: 01SEP2015, KN045: 26OCT2017, KN052: 09MAR2017)

Database cutoff date for Colorectal (KN164-Cohort A: 03AUG2016)

Database cutoff date for MLBCL (KN013-Cohort 4A: 04AUG2017, KN170: 19JAN2018)

Database cutoff date for Cervical (KN028-Cohort B4: 20FEB2017, KN158: 15JAN2018)

Database cutoff date for HCC (KN224: 15MAY2018)

Database cutoff date for RCC (KN426: 24AUG2018, KN427-Cohort A: 07SEP2018)

Database cutoff date for MCC (KN017: 06FEB2018)

Sowce: [ISS: adhm-adsl; adhe]

<div style=\"page-break-after: always\"></div>

Range

Table 5.3.5.3.3-rcc1: 59

## Time to Onset and Duration of AEOSI -- Hyperthyroidism (ASaT Population)

|                                                                        | KN426 Data for Pembrolizumab + Axitinib n (%:)   | KN426 Sunitinib (%)           | Reference Safety Dataset for Pembrolizumab Monotherapy (6)   | Cumulative Runing Safety Dataset forPembrolizumab Monotherapy' (/)   |
|------------------------------------------------------------------------|--------------------------------------------------|-------------------------------|--------------------------------------------------------------|----------------------------------------------------------------------|
| Subjects in population                                                 | 429                                              | 425                           | 4439                                                         | 6436                                                                 |
| Subjects with Hyperthyroidism                                          | 55 (12.8)                                        | 16 (3.8)                      | 145 (3.3)                                                    | 272 (4.2)                                                            |
| Time to Onset of First Hyperthyroidism (days)t Mean (Std) Median Range | 70.3 (91.9) 43.0 11 to 440                       | 166.8 (138.5) 114.0 29 to 483 | 70.1 (98.1) 43.0 1 to 707                                    | 67.4 (81.8) 43.0 1 to 707                                            |
| Total episodes of Hyperthyroidism                                      | 60                                               | 18                            | 155                                                          | 292                                                                  |
| Average Episodes per patient                                           | 1.09                                             | 1.13                          | 1.07                                                         | 1.07                                                                 |
| Episode duration (days)t Median                                        | 43.0                                             | 85.0                          | 62.0                                                         | 57.0                                                                 |

3 to 634

↑ Time to onset statistics are based on number of subjects with Hyperthyroidism.

↑ From product-limit (Kaplan-Meier) method for censored data. If an adverse event is notresolved at the time of analysis or the subject died without adverse event resolved, the duration is censored at either data cutoff date or date of death, whichever occured first.

+ indicates the AE episode is not recovered/resolved by the time of the cutoff date or date of death.

Std = Standard Deviation

Grades are based on NCI CTCAE 4.0.

Includes allsubjects who received at least one dose of Sunitinib in KN426.

Includes all subjects who received at least one dose of Pembrolizumab and/or Axitinib in KN426.

Includes allsubjects who received at least one dose ofpembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 Cohorts B and B2 (HNSCC). KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KIN040, KN045, KN052, KN055 and KN087.

*Includes allsubjects who received at least one dose ofpembrolizumab in KN001 Paut B1. B2. B3, D. C, F1. F2. F3. KN002 (original phase). KN006, KN010. KN012 Cohorts B and B2 (HNSCC).

KN045, KN052, KN054, KN055, KN059 Cohort 1, KN087, KN158, KN164 Cohort A, KN170, KN224 and KN427 Cohort A.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 02OCT2017)

Database cutoff date for HNSOC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN055: 22APR2016)

Database cutoff date for cHL (KN013-Cohort 3: 27SEP2016,KN087: 25SEP2016)

Database cutoff date for Gastic (KN012-Gastic: 26APR2016, KN059-Cohort 1: 21APR2017)

Database cutoff date for Bladder (KN012-Urothelial:01SEP2015.KN045: 26OCT2017.KN052:09MAR2017)

Database cutoff date for Colorectal (KN164-Cohort A: 03AUG2016)

Database cutoff date for MLBCL (KN013-Cohort 4A: 04AUG2017, KN170: 19JAN2018)

Database cutoff date for Cervical (KN028-Cohort B4: 20FEB2017, KN158: 15JAN2018)

Database cutoff date for HCC (KN224: 15MAY2018)

Database cutoff date for RCC (KN426: 24AUG2018, KN427-Cohort A: 07SEP2018)

Database cutoff date for MCC (KN017: 06FEB2018)

Source: [ISS: adam-adsl; adhe]

In the pembrolizub+axitinib arm, median time to Hyperthyroidism AEOSI was 142 days (range, 61-245). An average of 1.1 episodes were reported per patient with a median duration of 43 days.  Corticosteroids were given at high doses in 1.7% and low doses in 6.7%.

4+ to 578+

10 to 471+

4 to 887+

<div style=\"page-break-after: always\"></div>

## Table 5.3.5.3.3-rcc1: 66 Adverse Event Summary AEOSI - Hypothyroidism (ASaT Population)

|                                                                   | KN426 Data for Pembrolizumab + Axitinibl   | KN426 Sumitinibl   | KN426 Sumitinibl   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Cumulative Running Safety Dataset for Pembrolizumab Monotherapy'   | Cumulative Running Safety Dataset for Pembrolizumab Monotherapy'   |
|-------------------------------------------------------------------|--------------------------------------------|--------------------|--------------------|----------------------------------------------------------|----------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|
|                                                                   | n (.)                                      |                    | (6)                | n                                                        | ()                                                       |                                                                    | ()                                                                 |
| Subjects in population                                            | 429                                        | 425                |                    | 4,439                                                    |                                                          | 6,436                                                              |                                                                    |
| with one or more adverse events                                   | 152 (35.4)                                 | 134                | (31.5)             | 440                                                      | (9.9)                                                    | 667                                                                | (10.4)                                                             |
| with no adverse event                                             | 277 (64.6)                                 | 16t                | (68.5)             | 3.999                                                    | (90.1)                                                   | 5,769                                                              | (89.6)                                                             |
| with drug-related adverse events                                  | 135                                        | 119                | (28.0)             | 379                                                      | (8.5)                                                    | 585                                                                | (9.1)                                                              |
| with toxicity grade 3-5 adverse events                            | (31.5) 1 (0.2)                             | 1                  | (0.2)              | 7                                                        | (0.2)                                                    | 10                                                                 | (0.2)                                                              |
| with toxicity grade 3-5 dnug-related adverse events               | 1 (0.2)                                    | 0                  | (0.0)              | 7                                                        | (0.2)                                                    | 10                                                                 | (0.2)                                                              |
| with non-serious adverse events                                   | 152 (35.4)                                 | 133                | (31.3)             | 436                                                      | (9.8)                                                    | 661                                                                | (10.3)                                                             |
| with serious adverse events                                       | 1 (0.2)                                    | 2                  | (0.5)              | 5                                                        | (0.1)                                                    | 7                                                                  | (0.1)                                                              |
| with serious dnug-related adverse events                          | 1 (0.2)                                    | 1                  | (0.2)              | 5                                                        | (0.1)                                                    | 7                                                                  | (0.1)                                                              |
| with any dose modification due to an adverse event                | 8 (1.9)                                    | 5                  | (1.2)              | 27                                                       | (0.6)                                                    | 47                                                                 | (0.7)                                                              |
| Pembrolizumab dose modification                                   | 5 (1.2)                                    | 0                  | (0.0)              | 27                                                       | (0.6)                                                    | 47                                                                 | (0.7)                                                              |
| all regimen components dose modification                          | 5 (1.2)                                    | 5                  | (1.2)              | 27                                                       | (0.6)                                                    | 47                                                                 | (0.7)                                                              |
| who died                                                          | 0 (0.0)                                    | 0                  | (0.0)              | 0                                                        | (0.0)                                                    | 0                                                                  | (0.0)                                                              |
| who died due to a drug-related adverse event                      | 0 (0.0)                                    | 0                  | (0.0)              | 0                                                        | (0.0)                                                    | 0                                                                  | (0.0)                                                              |
| discontinued any drug due to an adverse event                     | 1 (0.2)                                    | 0                  | (0.0)              | 1                                                        | (0.0)                                                    | 2                                                                  | (0.0)                                                              |
| discontinued Pembrolizumab                                        | 1 (0.2)                                    | 0                  | (0.0)              | 1                                                        | (0.0)                                                    | 2                                                                  | (0.0)                                                              |
| discontinued allregimen components                                | 0 (0.0)                                    | 0                  | (0.0)              | 1                                                        | (0.0)                                                    | 2                                                                  | (0.0)                                                              |
| discontinued any drug due to a drug- related adverse event        | 1 (0.2)                                    | 0                  | (0.0)              | 1                                                        | (0.0)                                                    | 2                                                                  | (0.0)                                                              |
| discontinued Pembrolizumab                                        | 1 (0.2)                                    |                    | (0.0)              | 1                                                        | (0.0)                                                    | 2                                                                  | (0.0)                                                              |
| discontinued allregimen components                                | 0 (0.0)                                    | 0                  | (0.0)              | 1                                                        | (0.0)                                                    | 2                                                                  | (0.0)                                                              |
| discontinued any drug due to a serious adverse event              | 0 (0.0)                                    | 0                  | (0.0)              | 0                                                        | (0.0)                                                    | 0                                                                  | (0.0)                                                              |
| discontinued Pembrolizumab                                        | 0 (0.0)                                    | 0                  | (0.0)              | 0                                                        | (0.0)                                                    | 0                                                                  | (0.0)                                                              |
| discontinued allregimen components                                | 0 (0.0)                                    | 0                  | (0.0)              | 0                                                        | (0.0)                                                    | 0                                                                  | (0.0)                                                              |
| discontinued any drug due to a serious dnug-related adverse event | 0 (0.0)                                    | 0                  | (0.0)              | 0                                                        | (0.0)                                                    | 0                                                                  | (0.0)                                                              |
| discontinued Pembrolizumab                                        | 0 (0.0)                                    | 0                  | (0.0)              | 0                                                        | (0.0)                                                    | 0                                                                  | (0.0)                                                              |
| 0                                                                 |                                            |                    |                    | 0                                                        |                                                          | 0                                                                  |                                                                    |

discontinued all regimen components

Determined by the investigator to be related to the drug.

(0.0)

0

(0.0)

Defined as an action talken of dose reduced, drug interrupted or drug withdrawn.

Non-serious adverse events up to 30 days following the last dose and serious adverse events up to 90 days following the last dose are included.

ncludes all subjects who received at least one dose of Pembrolizumab and/or Axitinib in KN426.

Includes all subjects who received at least one dose of pembrolizumab in KN001 Paut B1, B2, B3, D, C, Fl, F2, F3, KN002 （original phase).KN006.KN010.KN012 Cohorts B and B2（HNSCC).KN013 Cohort 3 (HodgkinLymphoma）.KN024.KN040. KN045, KN052, KN055 and KN087.

Includes allsubjects who received at least one dose of Sumitinib in KN426.

*Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, Fl, F2, F3, KN002 (original phase), KN006. KN010. KN012 Cohorts B and B2 (HNSCC). Cohort C (Urothelial Tract Cancer and Cohort D (Gastric Cancer). KN013 Cohort 3 (Hodgkin Lymphoma) and Cohort 4A (MLBCL). KN017, KN024, KN028 Cohort B4, KN040, KN042, KN045, KN052, KN054, KN055. KN059 Cohort 1, KN087, KN158, KN164 Cohort A, KN170, KN224 and KN427 Cohort .A.

Database cutoff date for Melanoma (KN001-Melanoma:18APR2014,KN002:28FEB2015,KN006:03MAR2015.KN054: 020CT2017)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015. KIN010: 30SEP2015, KN024: 10JUL2017, KN042: 26FEB2018)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN055: 22APR2016)

Database cutoff date for Gastric (KN012-Gastric: 26APR2016, KN059-Cohort 1: 21APR2017)

Database cutoff date for cHL (KN013-Cohort 3: 27SEP2016, KN087: 25SEP2016)

Database cutoff date for Bladder (KN012-Urothelial: 01SEP2015, KN045: 260CT2017,KN052: 09MAR2017)

Database cutoff date for Colorectal (KN164-Cohort A: 03AUG2016)

Database cutoff date for MLBCL (KN013-Cohort 4A: 04AUG2017, KN170: 19JAN2018)

Database cutoff date for Cervical (KN028-Cohort B4: 20FEB2017, KN158: 15IAN2018)

Database cutoff date for HCC (KN224: 15MAY2018)

Database cutoff date for RCC (KN426:24AUG2018,KN427-Cohort A:07SEP2018)

Database cutoff date for MCC (KN017: 06FEB2018)

Souce: [ISS: adam-adsl; adae]

(0.0)

(0.0)

<div style=\"page-break-after: always\"></div>

## Table 5.3.5.3.3-rcc1: 67

## Time to Onset and Duration of AEOSI - Hypothyroidism (ASaT Population)

|                                                                       | KN426 Data for Pembrolizumab + Axitinibl (%)   | KN426 Sunitinib n ()         | Reference Safety Dataset for Pembrolizumab Monotherapy (%)   | Cumulative Running Safety Dataset for Pembrolizumab Monotherapy' (76)   |
|-----------------------------------------------------------------------|------------------------------------------------|------------------------------|--------------------------------------------------------------|-------------------------------------------------------------------------|
| Subjects in population Subjects with Hypothyroidism                   | 429 152 (35.4)                                 | 425 134 (31.5)               | 4439 440 (9.9)                                               | 6436 667 (10.4)                                                         |
| Time to Onset of First Hypothyroidism (days)t Mean (Std) Median Range | 122.0 (99.1) 94.0 2 to 491                     | 123.4 (129.7) 71.0 15 to 587 | 116.2 (87.0) 105.0 1 to 623                                  | 116.8 (87.7) 104.0 1 to 623                                             |
| Total episodes of Hypothyroidism Average Episodes per patient         | 178 1.17                                       | 174 1.30                     | 460 1.05                                                     | 730 1.09                                                                |

## Range

7 to 592+

(/%) = Number of subjects with Hypothyroidism/ Number of subjects in population.

Time to onset statistics are based on number of subjects with Hypothyroidism.

↑ From product-limit (Kaplan-Meier) method for censored data. If an adverse eventis not resolved at the time of analysis or the subject died without adverse event resolved, the duration is censored at either data cutoff date or date of death, whichever occuwred furst.

+ indicates the AE episode is not recovered/resolved by the time of the cutoff date or date of death.

Grades are based on NCI CTCAE 4.0.

Std = Standard Deviation.

IIncludes all subjects who received at least one dose of Pembrolizumab and/or Axitinib in KN426.

Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 Cohoris B and B2 (HNSCC). KN013 Cohort 3 (Hodgkin Lymphoma)., KN024, KN040, KN045, KN052, KN055 and KN087.

+Includes allsubjects who received at least one dose of Sunitinib in KN426.

*Includes all subjects who received at least one dose of pembrolizumab in KN001 Part Bl, B2, B3, D, C, F1, F2, F3, KN002 (onginal phase), KN006, KN010, KN012 Cohorts B and B2 (HNSCC). Cohort C (Urothelial Tract Cancer) and Cohort D (Gastic Cancer). KN013 Cohort 3 (Hodgkin Lymphoma) and Cohort 4A (MLBCL). KN017. KN024. KN028 Cohort B4, KN040. KN042. KN045, KN052, KN054, KN055, KN059 Cohort i, KN087, KN158, KN164 Cohort A, KN170, KN224 and KN427 Cohort A.

Database cutoff date for Melanoma (KN001-Melanomn: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 020CT2017)

Database cutoff date for Lumg (KN001-NSCLC: 23IAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 26FEB2018)

Database cutoff date for Gastic (KN012-Gastric: 26APR2016, KN059-Cohort 1: 21APR2017)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN055: 22APR2016)

Database cutoff date for cHL (KN013-Cohort 3: 27SEP2016, KN087: 25SEP2016)

Database cutoff date for Bladder (KN012-Urothelial: 01SEP2015, KN045: 260CT2017, KN052: 09MAR2017)

Database cutoff date for Colorectal (KN164-Cohort A: 03AUG2016)

Database cutoff date for MLBCL (KN013-Cohort 4A: 04AUG2017. KN170: 19JAN2018)

Database cutoff date for Cervical (KN028-Cohort B4: 20FEB2017, KN158: 15IAN2018)

Database cutoff date for HCC (KN224: 15MAY2018)

Database cutoff date for RCC (KN426: 24AUG2018, KN427-Cohort A: 07SEP2018)

Database cutoff date for MCC (KN017: 06FEB2018)

Source: [ISS: adam-adsl: adae]

In the pembrolizub+axitinib arm, median time to Hypothyroidism AEOSI was 94 days (range, 2-491). An average of 1.2 episodes were reported per patient with a not reached median duration (range, 7-592+). Overall 5.3% of subjects with one or more Hypothyroidism AEOSIs received concomitant corticosteroid treatment (high and low starting dose in 2.2% each).

7 to 599+

2 to 909+

1+ to 992+

<div style=\"page-break-after: always\"></div>

## AEOSI-Myasthenic Syndrome

Table 5.3.5.3.3-rcc1: 74 Adverse Event Summary (ASaT Population)

|                                                                                                                                                                                           | KN426 Data for Pembrolizumab + Axitinibl                                             | KN426 Sumitinib                                                                                     | Reference Safety Dataset for Pembrolizumab Monotherapy                                    | Cumulative Running Safety Dataset for Pembrolizumab Monotherapy'                                   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                           |                                                                                      | n (%) 425                                                                                           | n (%)                                                                                     | (%)                                                                                                |
| Subjects in population with one or more adverse events with no adverse event with drug-related adverse events with toxicity grade 3-5 adverse events with toxicity grade 3-5 drug-related | n (/) 429 4 (0.9) 425 (99.1) 4 (0.9) 2 (0.5) 2 (0.5) 0 (0.0) 4 (0.9) 4 (0.9) 4 (0.9) | 0 (0.0) 425 (0'001) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) | 4,439 2 (0.0) 4,437 (100.0) 2 (0.0) 1 (0.0) 1 (0.0) (0.0) 1 (0.0) 1 (0.0) 2 (0.0) 2 (0.0) | 6.436 4 (0.1) 6,432 (99.9) 4 (0.1) 2 (0.0) 2 (0.0) 3 (0.0) 2 (0.0) 2 (0.0) 4 (0.1) 4 (0.1) 4 (0.1) |
| adverse events                                                                                                                                                                            |                                                                                      |                                                                                                     |                                                                                           |                                                                                                    |
| with non-serious adverse events                                                                                                                                                           |                                                                                      |                                                                                                     |                                                                                           |                                                                                                    |
| with serious adverse events                                                                                                                                                               |                                                                                      |                                                                                                     |                                                                                           |                                                                                                    |
| with serious drug-related adverse events                                                                                                                                                  |                                                                                      |                                                                                                     |                                                                                           |                                                                                                    |
| with any dose modification due to an adverse event                                                                                                                                        |                                                                                      |                                                                                                     |                                                                                           |                                                                                                    |
| Pembrolizumab dose modification                                                                                                                                                           | 4 (0.9)                                                                              |                                                                                                     |                                                                                           |                                                                                                    |
| all regimen components dose modification                                                                                                                                                  | 4 (0.9)                                                                              |                                                                                                     | 2 (0.0)                                                                                   |                                                                                                    |
| who died                                                                                                                                                                                  | 1 (0.2)                                                                              |                                                                                                     | 0 (0.0)                                                                                   | 0 (0.0)                                                                                            |
| Who died due to a drug-related adverse event                                                                                                                                              | 1 (0.2)                                                                              | 0 (0.0)                                                                                             | 0 (0.0)                                                                                   | 0 (0.0)                                                                                            |
| discontinued any drug due to an adverse event                                                                                                                                             | 4 (0.9)                                                                              | 0 (0.0)                                                                                             | 0 (0.0)                                                                                   | 2 (0.0)                                                                                            |
| discontinued Pembrolizumab                                                                                                                                                                | 4 (0.9)                                                                              | 0 (0.0)                                                                                             | 0 (0.0)                                                                                   | 2 (0.0)                                                                                            |
| discontinued allregimen components                                                                                                                                                        | 3 (0.7)                                                                              | 0 (0.0)                                                                                             | 0 (0.0)                                                                                   | 2 (0.0)                                                                                            |
| discontinued any drug due to a drug- related adverse event                                                                                                                                | 4 (0.9)                                                                              | 0 (0.0)                                                                                             | 0 (0.0)                                                                                   | 2 (0.0)                                                                                            |
| discontinued Pembrolizumab                                                                                                                                                                | 4 (0.9)                                                                              | 0 (0.0)                                                                                             | 0 (0.0)                                                                                   | 2 (0.0)                                                                                            |
| discontinued allregimen components                                                                                                                                                        | 3 (0.7)                                                                              | 0 (0.0)                                                                                             | 0 (0.0)                                                                                   | 2 (0.0)                                                                                            |
| discontinued any drug due to a serious adverse event                                                                                                                                      | 4 (0.9)                                                                              | 0 (0.0)                                                                                             | 0 (0.0)                                                                                   | 0 (0.0)                                                                                            |
| discontinued Pembrolizumab                                                                                                                                                                | 4 (0.9)                                                                              | 0 (0.0)                                                                                             | 0 (0.0)                                                                                   | 0 (0.0)                                                                                            |
| discontinued allregimen components                                                                                                                                                        | 3 (0.7)                                                                              | 0 (0.0)                                                                                             | 0 (0.0)                                                                                   | 0 (0.0)                                                                                            |
| discontinued any drug due to a serious drug-related adverse event                                                                                                                         | 4 (0.9)                                                                              | 0 (0.0)                                                                                             | 0 (0.0)                                                                                   | 0 (0.0)                                                                                            |
| discontinued Pembrolizumab                                                                                                                                                                | 4 (0.9)                                                                              | 0 (0.0)                                                                                             | 0 (0.0)                                                                                   | 0 (0.0)                                                                                            |
| discontinued allregimen components                                                                                                                                                        | 3 (0.7)                                                                              | 0 (0.0)                                                                                             | 0 (0.0)                                                                                   | 0 (0.0)                                                                                            |

Non-serious adverse events up to 30 days following the last dose and serious adverse events up to 90 days following the last dose are included.

Defined as an action taken of dose reduced, drug interrupted or drug withdrawn.

IIncludes allsubjects who received atleast one dose of Pembrolizumab and/or Axitinib in KN426.

Includes all subjects who received at least one dose ofpembrolizumab in KN001 Part B1,B2,B3,D,C,F1,F2,F3,KN002 (original phase).KN006,KN010.KN012 Cohorts B and B2(HNSCC),KN013 Cohort 3 (Hodgkin Lymphoma).KN024,KN040. KN045, KN052, KN055 andKN087.

Includes allsubjects who received at least one dose of Sunitinib in KN426.

Includes all subjects who received atleast one dose ofpembrolizumab inKN001 Part B1,B2.B3.D,C,F1,F2,F3,KN002 （original phase),KN006,KN010,KN012 Cohorts B and B2(HNSCC),Cohort C (Urothelial Tract Cancer)and Cohort D (GastricCancer).KN013 Cohort 3 (HodgkinLymphoma)and Cohort 4A (MLBCL).KN017,KN024,KN028 Cohort B4, KN040,KN042,KN045,KN052,KN054,KN055,KN059 Cohort 1,KN087,KN158,KN164 Cohort A,KN170,KN224 and KN427 Cohort A.

Database cutoff date for Melanoma (KN001-Melanoma:18APR2014,KN002: 28FEB2015,KN006: 03MAR2015,KN054: 020CT2017)

Database cutoff date forLung (KN001-NSCLC: 23JAN2015,KN010: 30SEP2015,KN024: 10JUL2017,KN042: 26FEB2018)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN055: 22APR2016)

Database cutoff date for Gastric (KN012-Gastric: 26APR2016, KN059-Cohort 1: 21APR2017)

Database cutoff date for cHL (KN013-Cohort 3: 27SEP2016,KN087: 25SEP2016)

Database cutoff date for Bladder (KN012-Urothelial: 01SEP2015, KN045: 260CT2017, KN052: 09MAR2017)

Database cutoff date for Colorectal (KN164-Cohort A: 03AUG2016)

Database cutoff date for MLBCL (KN013-Cohort 4A: 04AUG2017, KN170: 19JAN2018)

Database cutoff date for Cervical (KN028-Cohort B4: 20FEB2017, KN158: 15JAN2018)

Database cutoff date for HCC (KN224:15MAY2018)

Database cutoff date forRCC (KN426: 24AUG2018,KN427-CohortA: 07SEP2018)

Database cutoff date for MCC (KN017: 06FEB2018)

Source: [ISS: adam-adsl; adae]

<div style=\"page-break-after: always\"></div>

Range

## Table 5.3.5.3.3-rcc1: 75

## Time to Onset and Duration of AEOSI - Myasthenic Syndrome (ASaT Population)

|                                                                           | KN426 Data for Pembrolizumab + Axiinibl n ()   | KN426 Sunitinib n (6)   | Reference Safety Dataset for Pembrolizumab Monotherapy' n (%)   | Cumulative Running Safety Dataset for Pembrolizumab Monotherapy (/)   |
|---------------------------------------------------------------------------|------------------------------------------------|-------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------------|
| Subjects in population                                                    | 429                                            | 425                     | 4439                                                            | 6436                                                                  |
| Subjects with Myasthenic Syndrome                                         | 4 (0.9)                                        | 0                       | 2 (0.0)                                                         | 4 (0.1)                                                               |
| Time to Onset of Fist Myasthenic Syndrome (days)f Mean (Std) Median Range | 40.5 (13.6) 40.5 24 to 57                      | 0 0.0 0 to 0            | 57.5 (23.3) 57.5 41 to 74                                       | 68.8 (40.5) 57.5 36 to 124                                            |
| Totalepisodes of Myasthenic Syndrome                                      | 4                                              | 0                       | 2                                                               | 6                                                                     |
| Avernge Episodes per patient                                              |                                                | 0                       |                                                                 |                                                                       |
| Episode duration (days)t                                                  | 1.00                                           |                         | 1.00                                                            | 1.50                                                                  |
| Median                                                                    | 343.0                                          | 0                       | 330.0                                                           | 330.0                                                                 |
|                                                                           | 28+ to 384                                     | 0 to 0                  | 255+ to 330                                                     |                                                                       |

(%) = Number of subjects with Myasthenic Syndrome / Number of subjects in population.

↑Time to onset statistics are based on mumber of subjects with Myasthenic Syndrome.

↑ From product-limit (Kaplan-Meier) method for censored data. If an adverse eventis not resolved at the time of analysis or the subject died without adverse event resolved, the duration is censored at either data cutoff date or date of death, whichever occured first.

+ indicates the AE episode is not recoveredlresolved by the time of the cutoff date or date of death.

Std = Standard Deviation

Grades are based on NCI CTCAE 4.0.

Includes all subjects who received at least one dose of Pembrolizumab and/or Axitinib in KN426.

Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 Cohonts B and B2 (HNSCC). KN013 Cohort 3 (Hodgkin Lymphoma). KN024.KN040. KN045.KN052. KN055 andKN087.

I Includes all subjects who received at least one dose of Sumitinib in KN426.

Inchudes all subjecis who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase). KN006, KN010, KN012 Cohorts B and B2 (HNSCC). KN045, KN052, KN054, KN055, KN059 Cohort 1, KN087, KN158, KN164 Cohort A, KN170, KN224 and KN427 Cohort A.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 020CT2017)

Database cutoff date for Lumg (KN001-NSCLC: 23IAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 26FEB2018)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016. KN040: 15MAY2017, KN055: 22APR2016)

Database cutoff date for Gastic (KN012-Gastric: 26APR2016, KN059-Cohort 1: 21APR2017)

Database cutoff date for cHL (KN013-Cohort 3: 27SEP2016, KN087: 25SEP2016)

Database cutoff date for Bladder (KN012-Urothelial: 01SEP2015, KN045: 26OCT2017,KN052: 09MAR2017)

Database cutoff date for Colorectal (KN164-Cohort A: 03AUG2016)

Database cutoff date for MLBCL (KN013-Cohort 4A:04AUG2017. KIN170: 19JAN2018)

Database cutoff date for Cervical (KN028-Cohort B4: 20FEB2017, KN158: 15JAN2018)

Database cutoff date for HCC (KN224: 15MAY2018)

Database cutoff date for RCC (KN426: 24AUG2018, KN427-Cohort A: 07SEP2018)

Database cutoff date for MCC (KN017: 06FEB2018)

Source: [ISS: adam-adsl; adae]

In the pembrolizub+axitinib arm, median time to Myasthenic syndrome AEOSI was 40.5 days (range, 24-57). An average of 1 episode was reported per patient with a median duration of 343 days. All subjects developing myasthenic syndrome were treated with concomitant corticosteroids (high doses 75%; low doses 25%).

8 to 376+

<div style=\"page-break-after: always\"></div>

## Table 5.3.5.3.3-rcc1: 86 Adverse Event Summary AEOSI - Nephritis (ASaT Population)

|                                                                   | KN426 Data for Pembrolizumnb + Axitinibl   | KN426 Sumitinib   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Cumulative Rumning Safety Dataset for Pembrolizumab Monotherapy'   | Cumulative Rumning Safety Dataset for Pembrolizumab Monotherapy'   |
|-------------------------------------------------------------------|--------------------------------------------|-------------------|----------------------------------------------------------|----------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|
|                                                                   | n ()                                       | ()                | n                                                        | ()                                                       |                                                                    | ()                                                                 |
| Subjects in population                                            | 429                                        | 425               | 4,439                                                    |                                                          | 6,436                                                              |                                                                    |
| with one or more adverse events                                   | 6 (1.4)                                    | 1 (0.2)           | 15                                                       | (0.3)                                                    | 21                                                                 | (0.3)                                                              |
| with no adverse event                                             | 423 (98.6)                                 | 424 (99.8)        | 4.424                                                    | (99.7)                                                   | 6,415                                                              | (99.7)                                                             |
| with drug-related adverse events                                  | 3 (0.7)                                    | 1 (0.2)           | 14                                                       | (0.3)                                                    | 20                                                                 | (0.3)                                                              |
| with toxicity grade 3-5 adverse events                            | 1 (0.2)                                    | 0 (0.0)           | 11                                                       | (0.2)                                                    | 14                                                                 | (0.2)                                                              |
| with toxicity grade 3-5 dnug-related adverse events               | 1 (0.2)                                    | 0 (0.0)           | 11                                                       | (0.2)                                                    | 14                                                                 | (0.2)                                                              |
| with non-serious adverse events                                   | 4 (0.9)                                    | 1 (0.2)           | 2                                                        | (0.0)                                                    | 4                                                                  | (0.1)                                                              |
| with serious adverse events                                       | 2 (0.5)                                    | 0 (0.0)           | 13                                                       | (0.3)                                                    | 17                                                                 | (0.3)                                                              |
| with serious dnug-related adverse events                          | 1 (0.2)                                    | 0 (0.0)           | 13                                                       | (0.3)                                                    | 17                                                                 | (0.3)                                                              |
| with any dose modification due to an adverse event                | 4 (0.9)                                    | 1 (0.2)           | 12                                                       | (0.3)                                                    | 16                                                                 | (0.2)                                                              |
| Pembrolizumab dose modification                                   | 2 (0.5)                                    | 0 (0.0)           | 12                                                       | (0.3)                                                    | 16                                                                 | (0.2)                                                              |
| all regimen components dose modification                          | 2 (0.5)                                    | 1 (0.2)           | 12                                                       | (0.3)                                                    | 16                                                                 | (0.2)                                                              |
| who died                                                          | 0 (0.0)                                    | 0 (0.0)           | 0                                                        | (0.0)                                                    | 0                                                                  | (0.0)                                                              |
| who died due to a drug-related adverse event                      | 0 (0.0)                                    | 0 (0.0)           | 0                                                        | (0.0)                                                    | 0                                                                  | (0.0)                                                              |
| discontinued any dnug due to an adverse event                     | 2 (0.5)                                    | 1 (0.2)           | 7                                                        | (0.2)                                                    | 9                                                                  | (0.1)                                                              |
| discontinued Pembrolizumab                                        | 1 (0.2)                                    | 0 (0.0)           | 7                                                        | (0.2)                                                    | 9                                                                  | (0.1)                                                              |
| discontinued allregimen components                                | (0.2)                                      | 1 (0.2)           | 7                                                        | (0.2)                                                    | 9                                                                  | (0.1)                                                              |
| discontinued any dnug due to a drug- related adverse event        | (0.2)                                      | (0.2)             | 7                                                        | (0.2)                                                    | 9                                                                  | (0.1)                                                              |
| discontinued Pembrolizumab                                        | 0 (0.0)                                    | 0 (0.0)           | 7                                                        | (0.2)                                                    | 9                                                                  | (0.1)                                                              |
| discontinued all regimen components                               | 0 (0.0)                                    | 1 (0.2)           | 7                                                        | (0.2)                                                    | 9                                                                  | (0.1)                                                              |
| discontinued any dnug due to a serious adverse event              | 2 (0.5)                                    | 0 (0.0)           | 6                                                        | (0.1)                                                    | 8                                                                  | (0.1)                                                              |
| discontinued Pembrolizumab                                        | 1 (0.2)                                    | 0 (0.0)           | 6                                                        | (0.1)                                                    | 8                                                                  | (0.1)                                                              |
| discontinued allregimen components                                | 1 (0.2)                                    | 0 (0.0)           | 6                                                        | (0.1)                                                    | 8                                                                  | (0.1)                                                              |
| discontimued any drug due to a serious dnug-related adverse event | 1 (0.2)                                    | 0 (0.0)           | 6                                                        | (0.1)                                                    | 8                                                                  | (0.1)                                                              |
| discontinued Pembrolizumab                                        | 0 (0.0)                                    | 0 (0.0)           | 6                                                        | (0.1)                                                    | 8                                                                  | (0.1)                                                              |

discontimued allregimen components

0

(0.0)

Determined by the investigator to be related to the drug.

Non-serious adverse events up to 30 days following the last dose and serious adverse events up to 90 days following the last dose are included.

0

(0.0)

I Defined as an action taken of dose reduced, drug intermupted or drug withdrawn.

IIncludes all subjects who received at least one dose of Pembrolizumab and/or Axitinib in KN426.

Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase). KN006, KN010. KN012 Cohorts B and B2 (HNSCC). KN013 Cohort 3 (Hodgkin Lymphoma). KN024, KN040. KN045, KN052, KN055 and KN087.

Includes all subjects who received at least one dose of Sunitinib in KN426.

*Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1. B2. B3. D, C. F1. F2, F3, KN002 (original phase).KN006, KN010, KN012 Cohorts B and B2 (HNSCC). Cohort C (Urothelial Tract Cancer) and Cohort D (Gastic Cancer). KN013 Cohort 3 (Hodgkin Lymphoma) and Cohort 4A (MLBCL). KN017, KN024, KN028 Cohort B4. KN040, KN042, KN045, KN052, KN054, KN055, KN059 Cohort 1, KN087, KN158, KN164 Cohort A, KN170, KN224 and KN427 Cohort A.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014,KN002: 28FEB2015,KN006:03MAR2015,KN054: 020CT2017)

Database cutoff date for Lung (KN001-NSCLC: 23IAN2015. KN010: 30SEP2015, KN024: 10JUL2017, KN042: 26FEB2018)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN055: 22APR2016)

Database cutoff date for Gastric (KN012-Gastric: 26APR2016, KN059-Cohort 1: 21APR2017)

Database cutoff date for cHL (KN013-Cohort 3: 27SEP2016, KN087: 25SEP2016)

Database cutoff date for Bladder (KN012-Urothelial: 01SEP2015, KN045: 260CT2017, KN052: 09MAR2017)

Database cutoff date for Colorectal (KN164-Cohort A: 03AUG2016)

Database cutoff date for MLBCL (KN013-Cohort 4A: 04AUG2017, KN170: 19JAN2018)

Database cutoff date for Cervical (KN028-Cohort B4: 20FEB2017, KN158: 15JAN2018)

Database cutoff date for HCC (KN224: 15MAY2018)

Database cutoff date for RCC (KN426: 24AUG2018, KN427-Cohort A: 07SEP2018)

Database cutoff date for MCC (KIN017: 06FEB2018)

Source: [ISS: adam-adsl; adae]

6

(0.1)

8

(0.1)

<div style=\"page-break-after: always\"></div>

Table 5.3.5.3.3-rcc1: 87

Time to Onset and Duration of AEOSI - Nephritis (ASaT Population)

|                                                                  | KN426 Data for Pembrolizmab + Axitinibl (%)   | KN426 Sunitinib (%)    | Reference Safety Dataset for Pembrolizumab Monotherapy n (%)   | CumulativeRunningSafety Dataset for Pembrolizumab Monotherapy' Ⅱ (2-)   |
|------------------------------------------------------------------|-----------------------------------------------|------------------------|----------------------------------------------------------------|-------------------------------------------------------------------------|
| Subjects in population                                           | 429                                           | 425                    | 4439                                                           | 6436                                                                    |
| Subjects with Nephritis                                          | 6 (1.4)                                       | 1 (0.2)                | 15 (0.3)                                                       | 21 (0.3)                                                                |
| Time to Onset of First Nephritis (days)t Mean (Std) Median Range | 227.2 (177.6) 206.0 42 to 505                 | 238.0 238.0 238 to 238 | 146.1 (129.6) 150.0 12 to 388                                  | 172.1 (141.7) 150.0 12 to 424                                           |
| Total episodes of Nephritis                                      | 6                                             | 1                      | 15                                                             | 21                                                                      |
| Average Episodes per patient Episode duration (days)t            | 1.00                                          | 1.00                   | 1.00                                                           | 1.00                                                                    |
| Median                                                           | 46.0                                          | Not reached            | 57.0                                                           | 57.0                                                                    |

<!-- image -->

Source[ISS·adam-adl· adael

In the pembrolizub+axitinib arm, median time to Nephritis AEOSI was 206 days (range, 42-505). An average of 1 episode was reported per patient with a median duration of 46 days.  Corticosteroids were given at high doses in 66.7%.

<div style=\"page-break-after: always\"></div>

## Pneumonitis

Table 5.3.5.3.3-rcc1: 94

## Adverse Event Summary AEOSI-Pneumonitis (ASaT Population)

|                                                                   | KN426 Data for Pembrolizumab + Axitinibl   | KN426 Sumitinibt   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Cumulative Running Safety Dataset for Pembrolizmab Monotherapy'   | Cumulative Running Safety Dataset for Pembrolizmab Monotherapy'   |
|-------------------------------------------------------------------|--------------------------------------------|--------------------|----------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------------|
|                                                                   | n (%)                                      | n (%)              | n                                                        | ()                                                       | n                                                                 | (%)                                                               |
| Subjects in population with one or more adverse events            | 429 12 (2.8)                               | 425 1 (0.2)        | 4,439 166                                                | (3.7)                                                    | 6,436 254                                                         | (3.9)                                                             |
| with no adverse event                                             | 417 (97.2)                                 | 424 (99.8)         | 4,273                                                    | (96.3)                                                   | 6,182                                                             | (96.1)                                                            |
| with drug-related adverse events                                  | 12 (2.8)                                   | 1 (0.2)            | 152                                                      | (3.4)                                                    | 231                                                               | (3.6)                                                             |
| with toxicity grade 3-5 adverse events                            | 2 (0.5)                                    | 0 (0.0)            | 60                                                       | (1.4)                                                    | 92                                                                | (1.4)                                                             |
| with toxicity grade 3-5 drug-related adverse events               | 2 (0.5)                                    | 0 (0.0)            | 55                                                       | (1.2)                                                    | 85                                                                | (1.3)                                                             |
| with non-serious adverse events                                   | 6 (1.4)                                    | 1 (0.2)            | 89                                                       | (2.0)                                                    | 136                                                               | (2.1)                                                             |
| with serious adverse events                                       | 6 (1.4)                                    | 0 (0.0)            | 87                                                       | (2.0)                                                    | 133                                                               | (2.1)                                                             |
| with serious drug-related adverse events                          | 6 (1.4)                                    | 0 (0.0)            | 81                                                       | (1.8)                                                    | 125                                                               | (1.9)                                                             |
| with any dose modification due to an adverse event                | 8 (61)                                     | 0 (0.0)            | 111                                                      | (2.5)                                                    | 176                                                               | (2.7)                                                             |
| Pembrolizumab dose modification                                   | 7 (1.6)                                    | 0 (0.0)            | 111                                                      | (2.5)                                                    | 176                                                               | (2.7)                                                             |
| allregimen components dose modification                           | 4 (0.9)                                    | 0 (0.0)            | 111                                                      | (2.5)                                                    | 176                                                               | (2.7)                                                             |
| who died                                                          | 1 (0.2)                                    | 0 (0.0)            | 7                                                        | (0.2)                                                    | 9                                                                 | (0.1)                                                             |
| who died due to a drug-related adverse event                      | 1 (0.2)                                    | 0 (0.0)            | 7                                                        | (0.2)                                                    |                                                                   | (0.1)                                                             |
| discontinued any drug due to an adverse event                     | 3 (0.7)                                    | 0 (0.0)            | 67                                                       | (1.5)                                                    | 101                                                               | (1.6)                                                             |
| discontinued Pembrolizumab                                        | 3 (0.7)                                    | 0 (0.0)            | 67                                                       | (1.5)                                                    | 101                                                               | (1.6)                                                             |
| discontinued allregimen components                                | 0 (0.0)                                    | 0 (0.0)            | 67                                                       | (1.5)                                                    | 101                                                               | (1.6)                                                             |
| discontinued any drug due to a drug- related adverse event        | 3 (0.7)                                    | 0 (0.0)            | 66                                                       | (1.5)                                                    | 100                                                               | (1.6)                                                             |
| discontinued Pembrolizumab                                        | 3 (0.7)                                    | 0 (0.0)            | 66                                                       | (1.5)                                                    | 100                                                               | (1.6)                                                             |
| discontinued allregimen components                                | 0 (0.0)                                    | 0 (0.0)            | 66                                                       | (1.5)                                                    | 100                                                               | (1.6)                                                             |
| discontinued any drug due to a serious adverse event              | 3 (0.7)                                    | 0 (0.0)            | 54                                                       | (1.2)                                                    | 78                                                                | (1.2)                                                             |
| discontinued Pembrolizumab                                        | 3 (0.7)                                    | 0 (0.0)            | 54                                                       | (1.2)                                                    | 78                                                                | (1.2)                                                             |
| discontinued allregimen components                                | 0 (0.0)                                    | 0 (0.0)            | 54                                                       | (1.2)                                                    | 78                                                                | (1.2)                                                             |
| discontinued any dnug due to a serious drug-related adverse event | 3 (0.7)                                    | 0 (0.0)            | 53                                                       | (1.2)                                                    | 77                                                                | (1.2)                                                             |
| discontinued Pembrolizumab                                        | 3 (0.7)                                    | 0 (0.0)            | 53                                                       | (1.2)                                                    | 77                                                                | (1.2)                                                             |
| discontinued all regimen components                               | 0 (0.0)                                    | 0 (0.0)            | 53                                                       | (1.2)                                                    | 77                                                                | (1.2)                                                             |

Determined by the investigator to be related to the drug.

asop ise[ aq Sumonoy sfiep 06 ol dn sjuana asianpe snouas pue asop ise[ aq zuymoloy sfep oe oi dn sjuana asranpe snoyes-uon are included.

I Defined as an action taken of dose reduced, drug intemupted or drug withdrawn.

Inchudes all subjects who received at least one dose of Pembrolizumab and/or Axitinib in KN426.

Includes allsubjects who received at least one dose ofpembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase). KN006, KN010, KN012 Cohorts B and B2 (HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040. KN045, KN052, KN055 and KN087.

+Includes all subjects who received at least one dose of Sunitinib in KN426.

Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, Fl, F2, F3. KN002 (original phase). KN006, KN010, KN012 Cohorts B and B2 (HNSCC), Cohort C (Urothelial Tract Cancer) and Cohort D (Gastric Cancer), KN013 Cohort 3 (Hodgkin Lymphoma) and Cohort 4A (MLBCL). KN017, KN024, KN028 Cohort B4, KN040, KN042, KN045. KN052, KN054, KN055. KN059 Cohort 1, KN087, KN158, KN164 Cohort A, KN170, KN224 and KN427 Cohort A.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014.KN002: 28FEB2015. KN006: 03MAR2015. KN054: 020CT2017)

Database cutoff date for Lumg (KN001-NSCLC: 23IAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 26FEB2018)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN055: 22APR2016)

Database cutoff date for Gastric (KN012-Gastric: 26APR2016, KN059-Cohort 1: 21APR2017)

Database cutoff date for cHL (KN013-Cohort 3:27SEP2016.KN087:25SEP2016)

Database cutoff date for Bladder (KN012-Urothelial: 01SEP2015.KN045: 260CT2017, KN052: 09MAR2017)

Database cutoff date for Colorecial (KN164-Cohort A: 03AUG2016)

Database cutoff date for MLBCL (KN013-Cohort 4A: 04AUG2017, KN170: 19IAN2018)

Database cutoff date for Cervical (KIN028-Cohort B4: 20FEB2017, KN158: 15IAN2018)

Database cutoff date for HCC (KIN224: 15MAY2018)

Database cutoff date for RCC (KN426: 24AUG2018, KN427-Cohort A: 07SEP2018)

Database cutoff date for MCC (KN017: 06FEB2018)

Source: [ISS: adam-adsl; adae]

<div style=\"page-break-after: always\"></div>

## Table 5.3.5.3.3-rcc1:95

## TimetoOnset andDurationofAEOSI-Pneumonitis

## (ASaT Population)

|                                                                    | KN426 Data for Pembrolizumab + Axitinib n (%)   | KN426 Sunitinib n (%)   | Reference Safety Dataset for Pembrolizumab Monotherapy n (%)   | Cumulative Running Safety Dataset forPembrolizumab Monotherapy\" n (%)   |
|--------------------------------------------------------------------|-------------------------------------------------|-------------------------|----------------------------------------------------------------|-------------------------------------------------------------------------|
| Subjects in population                                             | 429                                             | 425                     | 4439                                                           | 6436                                                                    |
| Subjects with Pneumonitis                                          | 12 (2.8)                                        | 1 (0.2)                 | 166 (3.7)                                                      | 254 (3.9)                                                               |
| Time to Onset of First Pneumonitis (days)t Mean (Std) Median Range | 261.3 (133.2) 199.0 126 to 527                  | 169.0 169.0 169 to 169  | 157.7 (150.9) 111.5 2 to 647                                   | 154.4 (152.6) 102.0 2 to 816                                            |
| Total episodes of Pneumonitis                                      | 12                                              |                         | 183                                                            | 295                                                                     |
| Average Episodes per patient Episode duration (days)t              | 1.00                                            | 1.00                    | 1.10                                                           | 1.16                                                                    |
| Median                                                             | 91.0                                            | Notreached              | 64.0                                                           | 61.0                                                                    |
| Range                                                              | 16+ to 260                                      | 46+ to 46+              | 1 to 771+                                                      | 1 to 771+                                                               |

(%/) = Number of subjects with Pneumonitis / Number of subjects in population.

↑ Time to onset statistics are based on number of subjects with Pneumonitis.

From product-limit (Kaplan-Meier) method for censored data.If an adverse eventis notresolved at the time of analysis or the subject died without adverse eventresolved, the duration is censored at either data cutoff date or date of death, whichever occured first.

+ indicates the AE episode is not recovered/resolved by the time of the cutoff date or date of death.

Std = Standard Deviation.

Includes allsubjects who received atleast one dose of Pembrolizumab and/or Axitinib inKN426.

Grades are based on NCICTCAE 4.0.

Includes all subjects who received at least one dose of Sunitinib in KN426.

ncludes all subjects whoreceivedatleast one dose ofpembrolizumab inKN001 PartB1.B2B3,D.C,F1,F2,F3,KN002(original phase)KN006,KN010,KN012 Cohorts B and B2 (HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma),KN024, KN040, KN045,KN052,KN055 and KN087.

Includes all subjects who received atleast one dose ofpembrolizumabinKN001PartB1B2B3DCF1.F2.F3.KN002(original phase）KN006.KN010.KN012 Cohorts B andB2(HNSCC) Cohort C (Urothelial Tract Cancer) and Cohort D (Gastric Cancer),KN013 Cohort3 (Hodgkin Lymphoma) and Cohort 4A (MLBCL).KN017,KN024,KN028 Cohort B4,KN040,KN042. KN045,KN052,KN054,KN055,KN059 Cohort 1,KN087,KN158,KN164 Cohort A,KN170,KN224 andKN427 Cohort A.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014,KN002: 28FEB2015, KN006: 03MAR2015, KN054: 02OCT2017)

Database cutoff date forLung (KN001-NSCLC: 23JAN2015,KN010: 30SEP2015,KN024: 10JUL2017,KN042: 26FEB2018)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016,KN040: 15MAY2017, KN055: 22APR2016)

Database cutoff date for Gastic (KN012-Gastic: 26APR2016,KN059-Cohort 1: 21APR2017)

Databasecutoff date forBladder(KN012-Urothelial:01SEP2015,KN045: 26OCT2017,KN052:09MAR2017)

Database cutoff date forcHL(KN013-Cohort3: 27SEP2016,KN087:25SEP2016)

Database cutoff date for Colorectal (KN164-Cohort A: 03AUG2016)

Database cutoff date for MLBCL (KN013-Cohort 4A:04AUG2017,KN170: 19JAN2018)

Database cutoff date forCervical (KN028-Cohort B4: 20FEB2017,KN158: 15IAN2018)

Database cutoff date forHCC(KN224: 15MAY2018)

Database cutoff date for RCC (KN426: 24AUG2018,KN427-Cohort A: 07SEP2018)

Database cutoff date for MCC (KN017: 06FEB2018)

Source: [ISS: adam-adsl; adae]

In the pembrolizub+axitinib arm, median time to Pneumonitis AEOSI was 199 days (range, 126-527). An average of 1 episode was reported per patient with a median duration of 91 days. Corticosteroids were given at high doses in 58.3% and low doses in 16.7%.

<div style=\"page-break-after: always\"></div>

## Thyroiditis

## Table 5.3.5.3.3-rcc1: 110 Adverse Event Summary AEOSI- Thyroiditis (ASaT Population)

|                                                                   | KN426 Data for Peubrolizumab + Axitinibl   | KN426 Sumitinib   | Reference Safety Dataset for Pembrolizumnb Monotherapy   | Reference Safety Dataset for Pembrolizumnb Monotherapy   | Cumulative Rumning Safety Dataset for Pembrolizumab Monotherapy'   | Cumulative Rumning Safety Dataset for Pembrolizumab Monotherapy'   |
|-------------------------------------------------------------------|--------------------------------------------|-------------------|----------------------------------------------------------|----------------------------------------------------------|--------------------------------------------------------------------|--------------------------------------------------------------------|
|                                                                   | n ()                                       |                   | (26)                                                     | n (%)                                                    |                                                                    | (6)                                                                |
| Subjects in population                                            | 429 12                                     | 425 2             | (0.5)                                                    | 4,439 30 (0.7)                                           | 6,436 65                                                           | (1.0)                                                              |
| with one or more adverse events with no adverse event             | (2.8) 417 (97.2)                           | 423               | (99.5)                                                   | 4,409 (99.3)                                             | 6,371                                                              | (99.0)                                                             |
| with drug-related adverse events                                  | 11 (2.6)                                   | 1                 | (0.2)                                                    | 30 (0.7)                                                 | 64                                                                 | (1.0)                                                              |
| with toxicity grnade 3-5 adverse events                           | 1 (0.2)                                    | 0                 | (0.0)                                                    | 1 (0.0)                                                  | 2                                                                  | (0.0)                                                              |
| with toxicity grade 3-5 drug-related adverse events               | 1 (0.2)                                    | 0                 | (0.0)                                                    | 1 (0.0)                                                  | 2                                                                  | (0.0)                                                              |
| with non-serious adverse events                                   | 12 (2.8)                                   | 2                 | (0.5)                                                    | 28 (0.6)                                                 | 61                                                                 | (0.9)                                                              |
| with serious adverse events                                       | 0 (0.0)                                    | 0                 | (0.0)                                                    | 2 (0.0)                                                  | 5                                                                  | (0.1)                                                              |
| with serious drug-related adverse events                          | 0 (0.0)                                    | 0                 | (0.0)                                                    | 2 (0.0)                                                  | 5                                                                  | (0.1)                                                              |
| with any dose modification due to an adverse event                | 4 (0.9)                                    | 0                 | (0.0)                                                    | 2 (0.0)                                                  | 7                                                                  | (0.1)                                                              |
| Pembrolizumab dose modification                                   | 3 (0.7)                                    | 0                 | (0.0)                                                    | 2 (0.0)                                                  | 7                                                                  | (0.1)                                                              |
| all regimen components dose modification                          | 2 (0.5)                                    | 0                 | (0.0)                                                    | 2 (0.0)                                                  | 7                                                                  | (0.1)                                                              |
| who died                                                          | 0 (0.0)                                    | 0                 | (0.0)                                                    | 0 (0.0)                                                  | 0                                                                  | (0.0)                                                              |
| who died due to a drug-related adverse event                      | 0 (0.0)                                    | 0                 | (0.0)                                                    | 0 (0.0)                                                  | 0                                                                  | (0.0)                                                              |
| discontinued any dnug due to an adverse event                     | 0 (0.0)                                    | 0                 | (0.0)                                                    | 0 (0.0)                                                  | 0                                                                  | (0.0)                                                              |
| discontinued Pembrolizumab                                        | 0 (0.0)                                    | 0                 | (0.0)                                                    | 0 (0.0)                                                  | 0                                                                  | (0.0)                                                              |
| discontinued allregimen components                                | 0 (0.0)                                    | 0                 | (0.0)                                                    | 0 (0.0)                                                  | 0                                                                  | (0.0)                                                              |
| discontinued any drug due to a drug- related adverse event        | 0 (0.0)                                    | 0                 | (0.0)                                                    | 0 (0.0)                                                  | 0                                                                  | (0.0)                                                              |
| discontinued Pembrolizumab                                        | 0 (0.0)                                    | 0                 | (0.0)                                                    | 0 (0.0)                                                  | 0                                                                  | (0.0)                                                              |
| discontinued allregimen components                                | 0 (0.0)                                    | 0                 | (0.0)                                                    | 0 (0.0)                                                  | 0                                                                  | (0.0)                                                              |
| discontinued any dnug due to a serious adverse event              | (0.0)                                      |                   | (0.0)                                                    | (0.0)                                                    | 0                                                                  | (0.0)                                                              |
| discontinued Pembrolizumab                                        | 0 (0.0)                                    | 0                 | (0.0)                                                    | 0 (0.0)                                                  | 0                                                                  | (0.0)                                                              |
| discontinued allregimen components                                | 0 (0.0)                                    | 0                 | (0.0)                                                    | 0 (0.0)                                                  | 0                                                                  | (0.0)                                                              |
| discontinued any drug due to a serious dnug-related adverse event | 0 (0.0)                                    | 0                 | (0.0)                                                    | 0 (0.0)                                                  | 0                                                                  | (0.0)                                                              |
| discontinued Pembrolizumab                                        | 0 (0.0)                                    | 0                 | (0.0)                                                    | 0 (0.0)                                                  | 0                                                                  | (0.0)                                                              |
| discontinued all regimen components                               | 0 (0.0)                                    | 0                 | (0.0)                                                    | 0 (0.0)                                                  | 0                                                                  | (0.0)                                                              |

Defined as an action taken of dose reduced, drug intermupted or dnug withdrawn.

Determined by the investigator to be related to the drug.

Non-serious adverse events up to 30 days following the last dose and serious adverse events up to 90 days following the lhst dose are included.

Includes allsubjects who received at least one dose of Pembrolizumab and/or Axitinib in KN426.

- Includes allsubjects who received at least one dose of pembrolizumab in KN001 Paut Bl, B2, B3, D, C, F1, F2, F3, KN002 (original phase). KN006, KN010, KN012 Cohorts B and B2 (HNSCC). KN013 Cohort 3 (Hodgkin Lymphoma). KN024, KN040. KN045.RIN052,KN055and KN087.

I Includes all subjects who received at least one dose of Sumitinib in KN426.

- Includes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2,B3. D, C, F1, F2. F3.KN002 (original phase). KN006, KN010, KN012 Cohorts B and B2 (HNSCC). Cohort C (Urothelial Tract Cancer) and Cohort D (Gastric Cancer).KN013 Cohort 3 (Hodgkin Lymphoma） and Cohort 4A (MLBCL).KN017, KN024, KN028 Cohort B4. KN040, KN042,KN045,KN052,KN054, KN055, KN059 Cohort 1,KN087,KN158, KN164 Cohort A,KN170.KN224 and KN427 Cohort A.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 020CT2017)

Database cutoff date for Lung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 26FEB2018)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN055: 22APR2016)

Database cutoff date for Gastric (KN012-Gastric: 26APR2016. KN059-Cohort 1: 21APR2017)

Database cutoff date for cHL (KN013-Cohort 3: 27SEP2016, KN087: 25SEP2016)

Database cutoff date for Bladder (KN012-Urothelial: 01SEP2015, KN045: 260CT2017, KN052: 09MAR2017)

Database cutoff date for Colorectal (KN164-Cohort A: 03AUG2016)

Database cutoff date for MLBCL (KN013-Cohort 4A: 04AUG2017, KN170: 19IAN2018)

Database cutoff date for Cervical (KN028-Cohort B4: 20FEB2017, KN158: 15IAN2018)

Database cutoff date for HCC (KN224: 15MAY2018)

Database cutoff date forRCC （KN426:24AUG2018,KN427-Cohort A:07SEP2018)

Database cutoff date for MCC (KN017: 06FEB2018)

Souce: [ISS: adam-adsl; adae]

<div style=\"page-break-after: always\"></div>

Range

Table 5.3.5.3.3-rcc1: 111 Time to Onset and Duration of AEOSI - Thyroiditis

## (ASaT Population)

|                                                                   | KN426 Data for Pembrolizumab + Axiinibl (%)   | KN426 Sunitinib n (%)    | Reference Safety Dataset for Pembrolizumab Monotherapy n (%)   | CumulativeRunning Safety Dataset for Pembrolizumab Monotherapy' n (%)   |
|-------------------------------------------------------------------|-----------------------------------------------|--------------------------|----------------------------------------------------------------|-------------------------------------------------------------------------|
| Subjects in population                                            | 429                                           | 425                      | 4439                                                           | 6436                                                                    |
| Subjects with Thyroiditis                                         | 12 (2.8)                                      | 2 (0.5)                  | 30 (0.7)                                                       | 65 (1.0)                                                                |
| Time to Onset of First Thyroiditis (days) Mean (Std) Median Range | 71.7 (57.0) 61.0 22 to 224                    | 71.0 (0.0) 71.0 71 to 71 | 69.2 (56.4) 63.5 15 to 260                                     | 67.6 (51.1) 63.0 7 to 260                                               |
| Total episodes of Thyroiditis                                     | 12                                            | 2                        | 30                                                             | 69                                                                      |
| Average Episodes per patient                                      | 1.00                                          | 1.00                     | 1.00                                                           | 1.06                                                                    |
| Episode duration(days)I Median                                    | Not reached                                   | 23.0                     | 462.0                                                          | 188.0                                                                   |

22to508+

(%/) = Number of subjects with Thyroiditis/ Number of subjects in population.

↑ Time to onset statistics are based on number of subjects with Thyroiditis.

↑ From product-limit (Kaplan-Meier) method for censored data. If an adverse eventis notresolvedatthe tine of analysis or the subject died without adverse event resolved, the dwation is censored at either data cutoff date or date of death, whichever occured first.

+ indicates the AE episode is notrecovered/resolved by the time of the cutoff date or date of death.

Std = Standard Deviation.

Grades are based on NCI CTCAE 4.0.

Includes all subjects who received at least one dose of Sunitinib in KN426.

IIncludes al subjects who received at least one dose of Pembrolizumab and/or Axitinib in KN426.

Includes allsubjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C,F1, F2, F3, KN002 (original phase), KN006, KN010,KN012 Cohorts B and B2 (HNSCC). KN013 Cohort 3 (Hodgkin Lymphoma).KN024,KN040,KN045,KN052,KN055 and KN087.

Includes all subjects who received at least one dose ofpembrolizumab in KN001 Part B1, B2, B3, D, C,F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 Cohorts B and B2 (HNSCC). Cohort C(UrothelialTract Cancer）and CohortD（Gastic Cancer),KN013Cohort3(HodgkinLymphoma)andCohort 4A (MLBCL),KN017,KN024,KN028 CohortB4,KN040.KN042 KN045,KN052,KN054,KN055,KN059 Cohort i,KN087,KN158,KN164 Cohort A,KN170,KN224 and KN427 Cohort A.

Database cutoff date for Melanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015, KN054: 02OCT2017)

Database cutoff date forLumg (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015,KN024: 10JUL2017,KN042: 26FEB2018)

Database cutoff date forHNSCC (KN012-HNSCC: 26APR2016,KN040: 15MAY2017, KN055: 22APR2016)

Database cutoff date for Gastic (KN012-Gastric: 26APR2016, KN059-Cohort 1: 21APR2017)

Database cutoff date for Bladder (KN012-Urothelial: 01SEP2015,KN045: 26OCT2017,KN052: 09MAR2017)

Database cutoff date for cHL (KN013-Cohort3: 27SEP2016,KN087: 25SEP2016)

Database cutoff date for Colorectal (KN164-Cohort A: 03AUG2016)

Database cutoff date for MLBCL (KN013-Cohort 4A: 04AUG2017, KN170: 19JAN2018)

Database cutoff date for Cervical (KN028-Cohort B4: 20FEB2017, KN158: 15JAN2018)

Database cutoff date for HCC (KN224: 15MAY2018)

Database cutoff date for RCC (KN426: 24AUG2018,KN427-Cohort A: 07SEP2018)

Database cutoff date for MCC (KN017: 06FEB2018)

Souwce: [ISS: adam-adsl; adae]

In the pembrolizub+axitinib arm, median time to Thyroiditis AEOSI was 61 days (range, 22-224). An average of 1 episode was reported per patient with a not reached median duration (range, 22-508+). None of the subjects presenting with thyroiditis in either treatment arms received corticosteroids.

## Hepatic Adverse Events

A higher than expected incidence of Grade 3 or 4 hepatic AEs was observed during the conduct of this study via medical monitoring and was confirmed at IA1. In order to better understand treatment-emergent hepatic events, a formal analysis plan was developed to accurately quantify and characterize these events. A combined list of preferred AE terms from 3 MedDRA hepatic SMQs and the hepatitis AEOSI were predefined as hepatic AEs in the Hepatic Events Analysis Plan in the sSAP. A Hepatic Events Analysis Set (HEAS) was identified to include any participant who had received at least 1 dose of study  treatment  and  experienced  any  treatment-emergent  AE  matching  a  hepatic  AE  PT  from  the pre-selected list.

## Demography and Baseline Disease Characteristics of the HEAS

A total of 287 participants (174 in the pembrolizumab+axitinib group, 113 in the sunitinib arm) were included in the HEAS. Participant demographics were generally similar to those reported for the ITT population. Comparison between study arms shows comparable characteristics, except for proportion of subjects aged &gt;65 years (pembrolizumab+axitinib 44.3%, sunitinib 31.9%). Also, disease characteristics were comparable in the two treatment arms. Liver metastases were described in 15.5% and 14.2% of subjects treated with pembrolizumab+axitinib and sunitinib, respectively. Subject characteristics in the pembrolizumab+axitinib arm were generally similar for the HEAS population (n=174) compared to those reported for the non-HEAS population (n=255); however a slightly higher proportion of Asian population was reported for the HEAS (19.5%) compared to the non-HEAS population (12.5%); the proportion of

15 to 31

15 to 785+

2 to 785+

<div style=\"page-break-after: always\"></div>

patient with liver metastasis was 15% in both groups.

## Overall hepatic AEs and most common PTs

Table 12-14 Overall Hepatic Adverse Event Summary (ASaT Population)

|                                                                                                                                                                            | Pembrolizumab+Axitinib                                                                                                                                                     | Pembrolizumab+Axitinib                                                                                                                                                     | Sunitinib                                                                                                                                                                  | Sunitinib                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                            | n                                                                                                                                                                          | (%)                                                                                                                                                                        | n                                                                                                                                                                          | (%)                                                                                                                                                                        |
| Subjects in population                                                                                                                                                     | 429                                                                                                                                                                        |                                                                                                                                                                            | 425                                                                                                                                                                        |                                                                                                                                                                            |
| with one or more hepatic adverse events                                                                                                                                    | 174                                                                                                                                                                        | (40.6)                                                                                                                                                                     | 113                                                                                                                                                                        | (26.6)                                                                                                                                                                     |
| with no hepatic adverse event                                                                                                                                              | 255                                                                                                                                                                        | (59.4)                                                                                                                                                                     | 312                                                                                                                                                                        | (73.4)                                                                                                                                                                     |
| with drug-related hepatic adverse events                                                                                                                                   | 147                                                                                                                                                                        | (34.3)                                                                                                                                                                     | 88                                                                                                                                                                         | (20.7)                                                                                                                                                                     |
| with toxicity grade 3-5 hepatic adverse events                                                                                                                             | 16                                                                                                                                                                         | (21.2)                                                                                                                                                                     | 26                                                                                                                                                                         | (6.1)                                                                                                                                                                      |
| with toxicity grade 3-5 drug-related hepatic adverse events                                                                                                                | 81                                                                                                                                                                         | (18.9)                                                                                                                                                                     | 17                                                                                                                                                                         | (4.0)                                                                                                                                                                      |
| with serious hepatic adverse events                                                                                                                                        | 30                                                                                                                                                                         | (7.0)                                                                                                                                                                      | 4                                                                                                                                                                          | (0.9)                                                                                                                                                                      |
| with seriousdrug-relatedhepatic adverseevents                                                                                                                              | 27                                                                                                                                                                         | (6.3)                                                                                                                                                                      | 2                                                                                                                                                                          | (0.5)                                                                                                                                                                      |
| who died due to a hepatic adverse event                                                                                                                                    | 0                                                                                                                                                                          | (0.0)                                                                                                                                                                      | 1                                                                                                                                                                          | (0.2)                                                                                                                                                                      |
| who died due to a drug-related hepatic adverse event                                                                                                                       | 0                                                                                                                                                                          | (0.0)                                                                                                                                                                      | 1                                                                                                                                                                          | (0.2)                                                                                                                                                                      |
| discontinued any dug due to a hepatic adverse event                                                                                                                        | 57                                                                                                                                                                         | (13.3)                                                                                                                                                                     | 2                                                                                                                                                                          | (0.5)                                                                                                                                                                      |
| discontinued Pembrolizumab                                                                                                                                                 | 43                                                                                                                                                                         | (10.0)                                                                                                                                                                     | 0                                                                                                                                                                          | (0.0)                                                                                                                                                                      |
| discontinued Axitinib                                                                                                                                                      | 29                                                                                                                                                                         | (6.8)                                                                                                                                                                      | 0                                                                                                                                                                          | (0.0)                                                                                                                                                                      |
| discontinued BothPembrolizumabandAxitinib                                                                                                                                  | 13                                                                                                                                                                         | (3.0)                                                                                                                                                                      | 0                                                                                                                                                                          | (0.0)                                                                                                                                                                      |
| discontinued any drug due to a drug-related hepatic adverse event                                                                                                          | 56                                                                                                                                                                         | (13.1)                                                                                                                                                                     | 2                                                                                                                                                                          | (0.5)                                                                                                                                                                      |
| discontinued Pembrolizumab                                                                                                                                                 | 42                                                                                                                                                                         | (9.8)                                                                                                                                                                      | 0                                                                                                                                                                          | (0.0)                                                                                                                                                                      |
| discontinued Axitinib                                                                                                                                                      | 29                                                                                                                                                                         | (6.8)                                                                                                                                                                      | 0                                                                                                                                                                          | (0.0)                                                                                                                                                                      |
| discontinuedBothPembrolizumabandAxitinib                                                                                                                                   | 13                                                                                                                                                                         | (3.0)                                                                                                                                                                      | 0                                                                                                                                                                          | (0.0)                                                                                                                                                                      |
| discontinued any drug due to a senious hepatic adverse event                                                                                                               | 21                                                                                                                                                                         | (4.9)                                                                                                                                                                      | 1                                                                                                                                                                          | (0.2)                                                                                                                                                                      |
| discontinued Pembrolizumab                                                                                                                                                 | 18                                                                                                                                                                         | (4.2)                                                                                                                                                                      | 0                                                                                                                                                                          | (0.0)                                                                                                                                                                      |
| discontinued Axitinib                                                                                                                                                      |                                                                                                                                                                            | (2.6)                                                                                                                                                                      | 0                                                                                                                                                                          | (0.0)                                                                                                                                                                      |
| discontinued BothPembrolizumabandAxitinib                                                                                                                                  | 8                                                                                                                                                                          | (6'1)                                                                                                                                                                      | 0                                                                                                                                                                          | (0.0)                                                                                                                                                                      |
| discontinued any drug due to a senious drug-related hepatic adverse event                                                                                                  | 20                                                                                                                                                                         | (4.7)                                                                                                                                                                      | 1                                                                                                                                                                          | (0.2)                                                                                                                                                                      |
| discontinuedPembrolizumab                                                                                                                                                  | 17                                                                                                                                                                         | (4.0)                                                                                                                                                                      | 0                                                                                                                                                                          | (0.0)                                                                                                                                                                      |
| discontinuedAxitinib                                                                                                                                                       |                                                                                                                                                                            | (2.6)                                                                                                                                                                      | 0                                                                                                                                                                          | (0.0)                                                                                                                                                                      |
| discontinuedBothPembrolizumabandAxitinib                                                                                                                                   | 8                                                                                                                                                                          | (61)                                                                                                                                                                       | 0                                                                                                                                                                          | (0.0)                                                                                                                                                                      |
| Determined by the investigator to be related to the drug.                                                                                                                  | Determined by the investigator to be related to the drug.                                                                                                                  | Determined by the investigator to be related to the drug.                                                                                                                  | Determined by the investigator to be related to the drug.                                                                                                                  | Determined by the investigator to be related to the drug.                                                                                                                  |
| Refer to Hepatic Events Analysis Plan in KEYNOTE 426 sSAP regarding hepatic events PT terms search shrategy and fullisting of hepatic PT terms included for this analysis. | Refer to Hepatic Events Analysis Plan in KEYNOTE 426 sSAP regarding hepatic events PT terms search shrategy and fullisting of hepatic PT terms included for this analysis. | Refer to Hepatic Events Analysis Plan in KEYNOTE 426 sSAP regarding hepatic events PT terms search shrategy and fullisting of hepatic PT terms included for this analysis. | Refer to Hepatic Events Analysis Plan in KEYNOTE 426 sSAP regarding hepatic events PT terms search shrategy and fullisting of hepatic PT terms included for this analysis. | Refer to Hepatic Events Analysis Plan in KEYNOTE 426 sSAP regarding hepatic events PT terms search shrategy and fullisting of hepatic PT terms included for this analysis. |
| Grades are based on NCI CTCAE version 4.0.                                                                                                                                 | Grades are based on NCI CTCAE version 4.0.                                                                                                                                 | Grades are based on NCI CTCAE version 4.0.                                                                                                                                 | Grades are based on NCI CTCAE version 4.0.                                                                                                                                 | Grades are based on NCI CTCAE version 4.0.                                                                                                                                 |
| Non-senious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included. Database CutoffDate: 24Aug2018.                  | Non-senious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included. Database CutoffDate: 24Aug2018.                  | Non-senious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included. Database CutoffDate: 24Aug2018.                  | Non-senious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included. Database CutoffDate: 24Aug2018.                  | Non-senious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included. Database CutoffDate: 24Aug2018.                  |

Sowrce: [P426V01MK3475: adam-adsl; adae]

<div style=\"page-break-after: always\"></div>

Table 12-15 Subjects With Hepatic Adverse Events by Decreasing Incidence (Incidence &gt; 0% in One or More Treatment Groups) (ASaT Population)

|                                         | Pembrolizumab + Axitinib   | Pembrolizumab + Axitinib   | Sunitinib   | Sunitinib   |
|-----------------------------------------|----------------------------|----------------------------|-------------|-------------|
|                                         | n                          | (%)                        | n           | (%)         |
| Subjects in population                  | 429                        |                            | 425         |             |
| with one or more hepatic adverse events | 174                        | (40.6)                     | 113         | (26.6)      |
| with nohepatic adverse events           | 255                        | (59.4)                     | 312         | (73.4)      |
| Alanine aminotransferase increased      | 115                        | (26.8)                     | 64          | (15.1)      |
| Aspartate aminotransferase increased    | 112                        | (26.1)                     | 69          | (16.2)      |
| Blood bilirubinincreased                | 28                         | (6.5)                      | 24          | (5.6)       |
| Hepaticfunction abnormal                | 15                         | (3.5)                      | 7           | (1.6)       |
| Gamma-glutamylhransferase increased     | 8                          | (61)                       | 4           | (0.9)       |
| Hepatitis                               | 7                          | (1.6)                      | 1           | (0.2)       |
| Hyperbilirubinaemia                     | 7                          | (1.6)                      | 8           | (1.9)       |
| Liver function test increased           | 5                          | (71)                       | 1           | (0.2)       |
| Hepatocellular injuy                    | 4                          | (0.9)                      | 4           | (0.9)       |
| Hepatotoxicity                          | 4                          | (0.9)                      | 0           | (0.0)       |
| Autoimmune hepatitis                    | 3                          | (0.7)                      | 0           | (0.0)       |
| Bilirubin conjugated increased          | 3                          | (0.7)                      | 4           | (0.9)       |
| Hepatic steatosis                       | 3                          | (0.7)                      | 0           | (0.0)       |
| Ascites                                 | 2                          | (0.5)                      | 3           | (0.7)       |
| Hepatic enzyme increased                | 2                          | (0.5)                      | 2           | (0.5)       |
| Liver disorder                          | 2                          | (0.5)                      | 0           | (0.0)       |
| Transaminases increased                 | 2                          | (0.5)                      | 2           | (0.5)       |
| Blood bilirubin unconjugated increased  | 1                          | (0.2)                      | 1           | (0.2)       |
| Drug-induced liver injuy                | 1                          | (0.2)                      | 0           | (0.0)       |
| Hepatic cinhosis                        | 1                          | (0.2)                      | 0           | (0.0)       |
| Hepatic pain                            | 1                          | (0.2)                      | 2           | (0.5)       |
| Immune-mediated hepatitis               | 1                          | (0.2)                      | 0           | (0.0)       |
| Liver injwy                             | 1                          | (0.2)                      | 0           | (0.0)       |
|                                         | 0                          |                            | 1           |             |

Hepatitis fulminant

(0.0)

(0.2)

Every subjectis counted a single time for each applicable row and column.

A system organ class or specific adverse event appears on this report only ifits incidence in one or more of the columns meets the incidence criterion in the report title, afterrounding.

Non-serious adverse events up to 30 days oflast dose and senious adverse events up to 90 days of last dose are included.

The adverse events are ordered decreasingly by the incidence in the fiurst column.

Database Cutoff Date: 24Aug2018.

ource: [P426V01MK3475: adam-adsl; adae]

<div style=\"page-break-after: always\"></div>

## Grade 3 to 5 hepatic AEs

Table 12-16 Subjects With Grade 3-5 Hepatic Adverse Events by Decreasing Incidence (Incidence &gt; 0% in One or More Treatment Groups) (ASaT Population)

|                                         | Pembrolizumab + Axitinib   | Pembrolizumab + Axitinib   | Sunitinib   | Sunitinib   |
|-----------------------------------------|----------------------------|----------------------------|-------------|-------------|
|                                         | n                          | (%)                        | n           | (%)         |
| Subjects in population                  | 429                        |                            | 425         |             |
| with one or more hepatic adverse events | 91                         | (21.2)                     | 26          | (6.1)       |
| with no hepatic adverse events          | 338                        | (78.8)                     | 399         | (93.9)      |
| Alanine aminotransferase increased      | 57                         | (13.3)                     | 13          | (3.1)       |
| Aspartate aminotransferase increased    | 30                         | (7.0)                      | 10          | (2.4)       |
| Hepaticfunction abnormal                | 7                          | (9:1)                      | 0           | (0.0)       |
| Hepatitis                               | 6                          | (1.4)                      | 0           | (0.0)       |
| Blood bilinubin increased               | 4                          | (0.9)                      | 3           | (0.7)       |
| Gamma-glutamyltransferase increased     | 4                          | (0.9)                      | 2           | (0.5)       |
| Hepatotoxicity                          | 4                          | (0.9)                      | 0           | (0.0)       |
| Hepatocellular injuy                    | 3                          | (0.7)                      | 3           | (0.7)       |
| Liver function test increased           | 3                          | (0.7)                      | 0           | (0.0)       |
| Autoimmune hepatitis                    | 2                          | (0.5)                      | 0           | (0.0)       |
| Hepatic enzyme increased                | 2                          | (0.5)                      | 0           | (0.0)       |
| Transaminases increased                 | 2                          | (0.5)                      | 0           | (0.0)       |
| Ascites                                 | 1                          | (0.2)                      | 2           | (0.5)       |
| Drug-induced liver injuy                | 1                          | (0.2)                      | 0           | (0.0)       |
| Hepatic cinhosis                        | 1                          | (0.2)                      | 0           | (0.0)       |
| Hepatic pain                            | 1                          | (0.2)                      | 1           | (0.2)       |
| Immune-mediated hepatitis               | 1                          | (0.2)                      | 0           | (0.0)       |
| Bilirubin conjugated increased          | 0                          | (0.0)                      | 2           | (0.5)       |
| Hepatitis fulminant                     | 0                          | (0.0)                      | 1           | (0.2)       |
| Hyperbilirubinaemia                     | 0                          | (0.0)                      |             | (0.2)       |

Every subjectis counted a single time foreach applicablerow and column.

A system organ class or specific adverse event appears on this report only ifits incidence in one or more of the columns meets the incidence critenion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and senious adverse events up to 90 days of last dose are included.

The adverse events are ordered decreasingly by the incidence in the first column. DatabaseCutoff Date:24Aug2018.

Source: [P426V01MK3475: adam-adsl; adae]

<div style=\"page-break-after: always\"></div>

## Drug-related hepatic AEs

Table 12-17 Subjects With Drug-Related Hepatic Adverse Events by DecreasingIncidence (Incidence &gt; 0% in One or More Treatment Groups) (ASaT Population)

|                                         | Pembrolizumab + Axitinib   | Pembrolizumab + Axitinib   | Sunitinib   | Sunitinib   |
|-----------------------------------------|----------------------------|----------------------------|-------------|-------------|
|                                         | n                          | (%)                        | n           | (%)         |
| Subjects in population                  | 429                        |                            | 425         |             |
| with one or more hepatic adverse events | 147                        | (34.3)                     | 88          | (20.7)      |
| with nohepatic adverse events           | 282                        | (65.7)                     | 337         | (79.3)      |
| Alanine aminotransferase increased      | 102                        | (23.8)                     | 54          | (12.7)      |
| Aspartate aminotransferase increased    | 97                         | (22.6)                     | 59          | (13.9)      |
| Blood bilirubin increased               | 19                         | (4.4)                      | 20          | (4.7)       |
| Hepatic function abnormal               | 13                         | (3.0)                      | 6           | (1.4)       |
| Hepatitis                               | 6                          | (1.4)                      | 1           | (0.2)       |
| Hyperbilirubinaemia                     | 5                          | (7)                        | 6           | (1.4)       |
| Hepatocellular injuy                    | 4                          | (0.9)                      | 3           | (0.7)       |
| Hepatotoxicity                          | 4                          | (0.9)                      | 0           | (0.0)       |
| Bilirubin conjugated increased          | 3                          | (0.7)                      | 2           | (0.5)       |
| Gamma-glutamylhransferaseincreased      | 3                          | (0.7)                      | 4           | (0.9)       |
| Liver function test increased           | 3                          | (0.7)                      | 1           | (0.2)       |
| Autoimmune hepatitis                    | 2                          | (0.5)                      | 0           | (0.0)       |
| Hepatic enzyme increased                | 2                          | (0.5)                      | 1           | (0.2)       |
| Liver disorder                          | 2                          | (0.5)                      | 0           | (0.0)       |
| Transaminases increased                 | 2                          | (0.5)                      | 1           | (0.2)       |
| Blood bilirubin unconjugated increased  | 1                          | (0.2)                      | 1           | (0.2)       |
| Drug-induced liver injuy                | 1                          | (0.2)                      | 0           | (0.0)       |
| Hepatic steatosis                       | 1                          | (0.2)                      | 0           | (0.0)       |
| Immune-mediated hepatitis               | 1                          | (0.2)                      | 0           | (0.0)       |
| Liver injury                            | 1                          | (0.2)                      | 0           | (0.0)       |
| Hepatitis fulminant                     | 0                          | (0.0)                      | 1           | (0.2)       |

Every subject is counted a single time for each applicable rowand column.

A system organ class or specific adverse event appears on this report only ifits incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-senious adverse events up to 30 days of last dose and senious adverse events up to 90 days of last dose are included.

The adverse events are ordered decreasingly by the incidence in the first column.

DatabaseCutoffDate:24Aug2018

Source: [P426V01MK3475: adam-adsl; adae]

<div style=\"page-break-after: always\"></div>

## Grade 3 to 5 drug-related hepatic AEs

Table 12-18 Subjects With Drug-Related Grade 3-5 Hepatic Adverse Events by Decreasing Incidence (Incidence &gt; 0% in One or More Treatment Groups) (ASaT Population)

|                                      | Pembrolizumab + Axitinib   | Pembrolizumab + Axitinib   | Sunitinib   | Sunitinib   |
|--------------------------------------|----------------------------|----------------------------|-------------|-------------|
|                                      | n                          | (%)                        | n           | (%)         |
| Subjects in population               | 429                        |                            | 425         |             |
| withoneormorehepaticadverseevents    | 81                         | (18.9)                     | 17          | (4.0)       |
| with no hepatic adverse events       | 348                        | (81.1)                     | 408         | (96.0)      |
| Alanine aminotransferase increased   | 52                         | (12.1)                     | 11          | (2.6)       |
| Aspartate aminotransferase increased | 29                         | (6.8)                      | 7           | (1.6)       |
| Hepatic function abnormal            | 6                          | (1.4)                      | 0           | (0.0)       |
| Hepatitis                            | 6                          | (1.4)                      | 0           | (0.0)       |
| Hepatotoxicity                       | 4                          | (0.9)                      | 0           | (0.0)       |
| Hepatocellular injuy                 | 3                          | (0.7)                      | 2           | (0.5)       |
| Liver function test increased        | 3                          | (0.7)                      | 0           | (0.0)       |
| Blood bilirubin increased            | 2                          | (0.5)                      | 1           | (0.2)       |
| Hepatic enzyme increased             | 2                          | (0.5)                      | 0           | (0.0)       |
| Transaminases increased              | 2                          | (0.5)                      | 0           | (0.0)       |
| Autoimmunehepatitis                  | 1                          | (0.2)                      | 0           | (0.0)       |
| Drug-induced liver injuy             | 1                          | (0.2)                      | 0           | (0.0)       |
| Gamma-glutamylhransferase increased  | 1                          | (0.2)                      | 2           | (0.5)       |
| Immune-mediated hepatitis            | 1                          | (0.2)                      | 0           | (0.0)       |
| Hepatitis fulminant                  | 0                          | (0.0)                      | 1           | (0.2)       |
| Hyperbilirubinaemia                  | 0                          | (0.0)                      |             | (0.2)       |

Every subject is counted a single time for each applicable row and column.

A system organ class or specific adverse event appears on this report only ifits incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-senious adverse events up to 30 days of last dose and senious adverse events up to 90 days of last dose are included.

The adverse events are ordered decreasingly by the incidence in the first column.

Database Cutoff Date: 24Aug2018.

5ource:[P426V01MK3475:adam-adsl; adae]

<div style=\"page-break-after: always\"></div>

## Table Subjects in the HEAS Population With Serious Hepatic Adverse Events by Decreasing Incidence

## (Incidence &gt; 0% in One or More Treatment Groups) (ASaT Population)

|                                         | Pembrolizumab + Axitinib   | Pembrolizumab + Axitinib   | Sunitinib   | Sunitinib   |
|-----------------------------------------|----------------------------|----------------------------|-------------|-------------|
|                                         | n                          | (%)                        | n           | (%)         |
| Subjects in population                  | 429                        |                            | 425         |             |
| with one or more hepatic adverse events | 30                         | (7.0)                      | 4           | (0.9)       |
| with no hepatic adverse events          | 399                        | (93.0)                     | 421         | (99.1)      |
| Alanine aminotransferase increased      | 6                          | (1.4)                      | 0           | (0.0)       |
| Aspartate aminotransferase increased    | 5                          | (1.2)                      | 0           | (0.0)       |
| Hepatic function abnormal               | 5                          | (1.2)                      | 0           | (0.0)       |
| Hepatitis                               | 3                          | (0.7)                      | 0           | (0.0)       |
| Hepatocellular injury                   | 3                          | (0.7)                      | 1           | (0.2)       |
| Autoimmune hepatitis                    | 2                          | (0.5)                      | 0           | (0.0)       |
| Hepatic enzyme increased                | 2                          | (0.5)                      | 0           | (0.0)       |
| Liver function test increased           | 2                          | (0.5)                      | 0           | (0.0)       |
| Transaminases increased                 | 2                          | (0.5)                      | 0           | (0.0)       |
| Blood bilirubin increased               | 1                          | (0.2)                      | 0           | (0.0)       |
| Drug-induced liver injury               | 1                          | (0.2)                      | 0           | (0.0)       |
| Hepatic cirrhosis                       | 1                          | (0.2)                      | 0           | (0.0)       |
| Hepatotoxicity                          | 1                          | (0.2)                      | 0           | (0.0)       |
| Immune-mediated hepatitis               | 1                          | (0.2)                      | 0           | (0.0)       |
| Ascites                                 | 0                          | (0.0)                      | 1           | (0.2)       |
| Hepatic pain                            | 0                          | (0.0)                      | 1           | (0.2)       |
| Hepatitis fulminant                     | 0                          | (0.0)                      | 1           | (0.2)       |

Every subject is counted a single time for each applicable row and column.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

MedDRA preferred terms \"Neoplasm progression\", \"Malignant neoplasm progression\" and \"Disease progression\" not related to the drug are excluded.

The adverse events are ordered decreasingly by the incidence in the first column.

Database Cutoff Date: 24Aug2018.

Source:  [P426V01MK3475: adam-adsl; adae]

(0.9)

(99.1)

(0.0)

(0.0)

(0.0)

(0.0)

(0.2)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

(0.2)

(0.2)

(0.2)

<div style=\"page-break-after: always\"></div>

## Table Subjects in the HEAS Population With Hepatic Adverse Events Resulting in Treatment Discontinuation By Decreasing Incidence (Incidence &gt; 0% in One or More Treatment Groups) (ASaT Population)

(0.5)

(99.5)

(0.2)

(0.2)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

(0.0)

(0.2)

(0.2)

|                                         | Pembrolizumab + Axitinib   | Pembrolizumab + Axitinib   | Sunitinib   | Sunitinib   |
|-----------------------------------------|----------------------------|----------------------------|-------------|-------------|
|                                         | n                          | (%)                        | n           | (%)         |
| Subjects in population                  | 429                        |                            | 425         |             |
| with one or more hepatic adverse events | 57                         | (13.3)                     | 2           | (0.5)       |
| with no hepatic adverse events          | 372                        | (86.7)                     | 423         | (99.5)      |
| Alanine aminotransferase increased      | 31                         | (7.2)                      | 1           | (0.2)       |
| Aspartate aminotransferase increased    | 20                         | (4.7)                      | 1           | (0.2)       |
| Hepatic function abnormal               | 6                          | (1.4)                      | 0           | (0.0)       |
| Hepatitis                               | 4                          | (0.9)                      | 0           | (0.0)       |
| Hepatotoxicity                          | 4                          | (0.9)                      | 0           | (0.0)       |
| Hepatocellular injury                   | 3                          | (0.7)                      | 0           | (0.0)       |
| Autoimmune hepatitis                    | 2                          | (0.5)                      | 0           | (0.0)       |
| Liver function test increased           | 2                          | (0.5)                      | 0           | (0.0)       |
| Blood bilirubin unconjugated increased  | 1                          | (0.2)                      | 0           | (0.0)       |
| Drug-induced liver injury               | 1                          | (0.2)                      | 0           | (0.0)       |
| Hepatic enzyme increased                | 1                          | (0.2)                      | 0           | (0.0)       |
| Immune-mediated hepatitis               | 1                          | (0.2)                      | 0           | (0.0)       |
| Transaminases increased                 | 1                          | (0.2)                      | 0           | (0.0)       |
| Hepatitis fulminant                     | 0                          | (0.0)                      | 1           | (0.2)       |
| Hyperbilirubinaemia                     | 0                          | (0.0)                      | 1           | (0.2)       |

Every subject is counted a single time for each applicable row and column.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

The adverse events are ordered decreasingly by the incidence in the first column. Database Cutoff Date: 24Aug2018.

Source:  [P426V01MK3475: adam-adsl; adae]

Overall, 15 participants discontinued both pembrolizumab + axitinib due to hepatic AEs; 11 (73.3%) of these participants received subsequent anti-cancer treatment, with a median interval from last dose of study treatment to first dose of subsequent treatment of 44 days (range 29 days to 252 days); 9 of these participants were alive at the time of data cutoff (02-JAN-2019). In context, 88 of 176 (50%) of participants who discontinued pembrolizumab + axitinib for any reason received a subsequent anti-cancer treatment therapy. Four participants who discontinued pembrolizumab + axitinib due to hepatic AEs did not receive subsequent anti-cancer treatments. Of those, 3 participants were alive at the time of data cutoff.

<div style=\"page-break-after: always\"></div>

Table Recovery from the First ALT or AST ≥3 × ULN Events and Steroid Use during the First Events (HEAS Population from Pembrolizumab + Axitinib Arm)

44

28

17.5 (3 to 43)

6

22.5 (16 to 64)

22.0 13 to 44)

3

0

0

|                                                 | First ALT or AST ≥3 × ULN events categories (N = 120)   | First ALT or AST ≥3 × ULN events categories (N = 120)   |
|-------------------------------------------------|---------------------------------------------------------|---------------------------------------------------------|
|                                                 | Group1 †                                                | Group2 ‡                                                |
| Subjects with events                            | 76                                                      | 44                                                      |
| Recovered, n (%)                                | 71 (93.4)                                               | 41 (93.2)                                               |
| Received steroid during the 1st event, n (%)    | 42 (59.2)                                               | 34 (82.9)                                               |
| Received high dose*, n                          | 28                                                      | 28                                                      |
| Time to recovery (days), median (range)         | 10.0 (5 to 176)                                         | 17.5 (3 to 43)                                          |
| Received low dose, n                            | 12                                                      | 6                                                       |
| Time to recovery (days), median (range)         | 11.5 (5 to 73)                                          | 22.5 (16 to 64)                                         |
| Received no steroid during the 1st event, n (%) | 29                                                      | 7                                                       |
| Time to recovery (days), median (range)         | 8.0 (4 to 71)                                           | 22.0 13 to 44)                                          |
| Not recovered, n (%)                            | 5 (6.6)                                                 | 3 (6.8)                                                 |
| Received steroid during the 1st event, n (%)    | 1 (20.0)                                                | 3 (100.0)                                               |
| Received high dose, n                           | 1                                                       | 3                                                       |
| Received low dose, n                            | 0                                                       | 0                                                       |
| Received no steroid during the 1st event, n (%) | 4 (80.0)                                                | 0                                                       |

Database Cutoff Date: 24Aug2018.

## Laboratory findings

In pembrolizumab+axitinib arm the following were the most common laboratory abnormalities: Glucose increased (61.9%), ALT  increased (59.6%), AST  increased (56.7%), Creatinine  increased (43.0%), Sodium  decreased (35.0%), Potassium  increased (34.1%), Lymphocyte  decreased (33.3%),  and Albumin decreased (31.9%).

In comparison of the sunitinib arm, the proportion of subjects with abnormal laboratory findings was higher in the pembrolizumab+axitinib arm for: ALT increased (59.6% vs 44.4%; grade 3-4 20.1% vs 5.5%), AST increased (56.7% and 55.6%; grade 3-4 13.2% vs 4.5%), Bilirubin increased (22.0% vs 21.1%), Calcium increased (26.6% vs 15.3%). While similar proportions across study arms were found for and Creatinine increased (43% and 40%), sunitinib-treated participants had lower frequency of the following: Potassium increased (34.1% vs 22%), Hemoglobin dec reased (28.7% vs 65.3%; grade 3-4 8.9%  vs  3.2%), Leukocytes  decreased (13.9%  vs  71.8%;  grade  3-4  1.4%  vs  7.8%), Neutrophils decreased (26.6% vs 49%; 1.2% vs 18.8%), Phosphate decreased (26.2% vs 77.7%; grade 3-4 6.4% vs 17.5%), Platelet decreased (26.6% vs 77.7%; grade 3-4 1.4% vs 14.5%).

<div style=\"page-break-after: always\"></div>

## Hepatic Laboratory Analysis

## Subjects With Liver Function Laboratory Findings That Met Predetermined Criteria

Table 12-19 (ASaT Population)

|                                                                      | Pembrolizumab +Axitinib                                              | Pembrolizumab +Axitinib                                              | Sunitinib                                                            | Sunitinib                                                            |
|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|
| Criteria                                                             | n/m                                                                  | (%)                                                                  | n/m                                                                  | (%)                                                                  |
| Subjects in population                                               | 429                                                                  |                                                                      | 425                                                                  |                                                                      |
| AlanineAminotransferase                                              | AlanineAminotransferase                                              |                                                                      |                                                                      |                                                                      |
| ≥3 xULN                                                              | 119/425                                                              | (28.0)                                                               | 42/419                                                               | (10.0)                                                               |
| ≥5 xULN                                                              | 85/425                                                               | (20.0)                                                               | 23/419                                                               | (5.5)                                                                |
| ≥10 xULN                                                             | 37/425                                                               | (8.7)                                                                | 6/419                                                                | (1.4)                                                                |
| ≥20 x ULN                                                            | 13/425                                                               | (3.1)                                                                | 2/419                                                                | (0.5)                                                                |
| Aspartate Aminotransferase                                           | Aspartate Aminotransferase                                           |                                                                      |                                                                      |                                                                      |
| ≥3xULN                                                               | 101/425                                                              | (23.8)                                                               | 36/419                                                               | (8.6)                                                                |
| ≥5 xULN                                                              | 57/425                                                               | (13.4)                                                               | 19/419                                                               | (4.5)                                                                |
| >10 x ULN                                                            | 28/425                                                               | (6.6)                                                                | 7/419                                                                | (1.7)                                                                |
| ≥20 x ULN                                                            | 9/425                                                                | (2.1)                                                                | 2/419                                                                | (0.5)                                                                |
| Aminotransferase (ALT or AST)                                        | Aminotransferase (ALT or AST)                                        |                                                                      |                                                                      |                                                                      |
| 3xULN                                                                | 123/425                                                              | (28.9)                                                               | 51/418                                                               | (12.2)                                                               |
| ≥5 xULN                                                              | 87/425                                                               | (20.5)                                                               | 26/418                                                               | (6.2)                                                                |
| ≥10 xULN                                                             | 44/425                                                               | (10.4)                                                               | 7/418                                                                | (1.7)                                                                |
| ≥20 x ULN                                                            | 13/425                                                               | (3.1)                                                                | 3/418                                                                | (0.7)                                                                |
| Bilirubin                                                            | Bilirubin                                                            |                                                                      |                                                                      |                                                                      |
| ≥2 xULN                                                              | 21/425                                                               | (4.9)                                                                | 29/418                                                               | (6.9)                                                                |
| Alkaline Phosphatase                                                 | Alkaline Phosphatase                                                 | Alkaline Phosphatase                                                 | Alkaline Phosphatase                                                 | Alkaline Phosphatase                                                 |
| ≥1.5xULN                                                             | 75/424                                                               | (17.7)                                                               | 70/416                                                               | (16.8)                                                               |
| Aminotransferase (ALT or AST) and Bilirubin                          | Aminotransferase (ALT or AST) and Bilirubin                          | Aminotransferase (ALT or AST) and Bilirubin                          | Aminotransferase (ALT or AST) and Bilirubin                          | Aminotransferase (ALT or AST) and Bilirubin                          |
| AT≥3xULNandBILI≥l.5 x ULN                                            | 23/425                                                               | (5.4)                                                                | 10/417                                                               | (2.4)                                                                |
| AT≥3 x ULNand BILI≥2x ULN                                            | 15/425                                                               | (3.5)                                                                | 7/417                                                                | (1.7)                                                                |
| Aminotransferase (ALT or AST) and Bilirubin and Alkaline Phosphatase | Aminotransferase (ALT or AST) and Bilirubin and Alkaline Phosphatase | Aminotransferase (ALT or AST) and Bilirubin and Alkaline Phosphatase | Aminotransferase (ALT or AST) and Bilirubin and Alkaline Phosphatase | Aminotransferase (ALT or AST) and Bilirubin and Alkaline Phosphatase |

Source: [P426V01MK3475: adam-adsl; addili]

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 12-20 HEAS Subjects With Liver Function Laboratory Findings That Met Predetermined Criteria (ASaT Population)

<!-- image -->

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Pembrolizumab+Axitinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Pembrolizumab+Axitinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Sunitinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Sunitinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Criteria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | n/m                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | n/m                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Subjects in population                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 429                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 425                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Alanine Aminotransferase                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| ≥3xULN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 116/425                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (27.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 35/419                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (8.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 25xULN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 83/425                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (19.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 18/419                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (4.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| ≥10xULN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 37/425                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (8.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 4/419                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | (1.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| ≥20 x ULN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 13/425                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (3.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 2/419                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | (0.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Aspartate Aminotransferase                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| ≥3xULN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 100/425                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (23.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 27/419                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (6.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| ≥5xULN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 56/425                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (13.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 13/419                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (3.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| 210xULN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 28/425                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (6.6)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 5/419                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | (1.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| ≥20 xULN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 9/425                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | (2.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 1/419                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | (0.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Aminotransferase (ALT or AST)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| ≥3xULN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 120/425                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | (28.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 41/418                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (9.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| ≥5xULN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 85/425                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (20.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 20/418                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (4.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| ≥10 xULN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 44/425                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (10.4)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 5/418                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | (1.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| ≥20 x ULN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 13/425                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (3.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 2/418                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | (0.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Bilirubin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| ≥2xULN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 20/425                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (4.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 20/418                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (4.8)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Alkaline Phosphatase                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| ≥1.5 xULN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 41/424                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (9.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 31/416                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (7.5)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Aminotransferase(ALT or AST) and Bilirubin                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Aminotransferase(ALT or AST) and Bilirubin                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| AT ≥3 x ULN and BILI≥l.5 x ULN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 22/425                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (5.2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 7/417                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | (1.7)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| AT≥3xULNandBILI≥2x ULN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 14/425                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | (3.3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 4/417                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | (1.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Aminotransferase (ALT or AST) and Bilirubin and Alkaline Phosphatase                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Aminotransferase (ALT or AST) and Bilirubin and Alkaline Phosphatase                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Aminotransferase (ALT or AST) and Bilirubin and Alkaline Phosphatase                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Aminotransferase (ALT or AST) and Bilirubin and Alkaline Phosphatase                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Aminotransferase (ALT or AST) and Bilirubin and Alkaline Phosphatase                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Aminotransferase (ALT or AST) and Bilirubin and Alkaline Phosphatase                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Aminotransferase (ALT or AST) and Bilirubin and Alkaline Phosphatase                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Aminotransferase (ALT or AST) and Bilirubin and Alkaline Phosphatase                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Aminotransferase (ALT or AST) and Bilirubin and Alkaline Phosphatase                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Aminotransferase (ALT or AST) and Bilirubin and Alkaline Phosphatase                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| AT≥3xULNandBILI≥2x ULN and ALP<2 xULN                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 9/425                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | (2.1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 0/417                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | (0.0)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| n = Number of HEAS Subjects with postbaseline test results (or combination of test results from the same day) that met predetermined criteria. m = Number of Subjects with at least one postbaseline test result or combination of test results firom the same day. ALP = Alkaline phosphatase; ALT = Alanine aminotransferase; AST = Aspartate aminotransferase; AT = Aminotransferase (ALT or AST); BILI = Bilirubin; ULN = Upper limit of normal range. Laboratory records up to 90 days of last dose are included. | n = Number of HEAS Subjects with postbaseline test results (or combination of test results from the same day) that met predetermined criteria. m = Number of Subjects with at least one postbaseline test result or combination of test results firom the same day. ALP = Alkaline phosphatase; ALT = Alanine aminotransferase; AST = Aspartate aminotransferase; AT = Aminotransferase (ALT or AST); BILI = Bilirubin; ULN = Upper limit of normal range. Laboratory records up to 90 days of last dose are included. | n = Number of HEAS Subjects with postbaseline test results (or combination of test results from the same day) that met predetermined criteria. m = Number of Subjects with at least one postbaseline test result or combination of test results firom the same day. ALP = Alkaline phosphatase; ALT = Alanine aminotransferase; AST = Aspartate aminotransferase; AT = Aminotransferase (ALT or AST); BILI = Bilirubin; ULN = Upper limit of normal range. Laboratory records up to 90 days of last dose are included. | n = Number of HEAS Subjects with postbaseline test results (or combination of test results from the same day) that met predetermined criteria. m = Number of Subjects with at least one postbaseline test result or combination of test results firom the same day. ALP = Alkaline phosphatase; ALT = Alanine aminotransferase; AST = Aspartate aminotransferase; AT = Aminotransferase (ALT or AST); BILI = Bilirubin; ULN = Upper limit of normal range. Laboratory records up to 90 days of last dose are included. | n = Number of HEAS Subjects with postbaseline test results (or combination of test results from the same day) that met predetermined criteria. m = Number of Subjects with at least one postbaseline test result or combination of test results firom the same day. ALP = Alkaline phosphatase; ALT = Alanine aminotransferase; AST = Aspartate aminotransferase; AT = Aminotransferase (ALT or AST); BILI = Bilirubin; ULN = Upper limit of normal range. Laboratory records up to 90 days of last dose are included. |

Source:[P426V01MK3475: adam-adsl; addili]

<div style=\"page-break-after: always\"></div>

Figure12-6 OverallPeakALT/ULN RatioOver theWholeStudyDuration vs. OverallPeakTotalBilirubin/ULNRatioOver theWholeStudyDuration (ASaT Population) Pembrolizumab +Axitinib Arm (N=429)

<!-- image -->

PeakALT in multiplies of ULN-Log Scale

+ Gubject Ilad Concomitant ALT &gt;= JxULN and Total Dilirubin &gt;= 2ULN

Figure 12-7 Overall Peak ALT/ULN Ratio Over theWholeStudyDuration vs. OverallPeakTotalBilirubin/ULNRatioOvertheWholeStudyDuration (HEAS Population) Pembrolizumab + Axitinib Arm (N=174)

<!-- image -->

+ Gubject I lad Concomitant ALT &gt;= 3xULN and Total Dilirubin &gt;= 2xULN

<div style=\"page-break-after: always\"></div>

## Characterization of ALT ≥3 x ULN Events in the HEAS

Table 12-21 Time to Onset of the First ALT ≥ 3xULN Events (HEAS Population)

|                                                                                                                                          | Pembrolizumab +Axitinib N=429 (ASaT)                                                                                                     |
|------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| Subjects in HEAS population                                                                                                              | 174                                                                                                                                      |
| Subjects in HEAS population with treatment-emergent ALT ≥ 3xULN events                                                                   | 116                                                                                                                                      |
| Time to onset of the first ALT > 3xULN events since the first study treatment (days)                                                     |                                                                                                                                          |
| Mean                                                                                                                                     | 103.3                                                                                                                                    |
| SD                                                                                                                                       | 93.59                                                                                                                                    |
| Median                                                                                                                                   | 70.5                                                                                                                                     |
| Range                                                                                                                                    | 7 to 603                                                                                                                                 |
| Analysis of time to onset of the first ALT ≥ 3xULN events is based on all HEAS subjects with ALT ≥ 3xULN events. SD: standard deviation. | Analysis of time to onset of the first ALT ≥ 3xULN events is based on all HEAS subjects with ALT ≥ 3xULN events. SD: standard deviation. |

Source:[P426V01MK3475: adam-adsl; adheas]

## Recovery from the First ALT ≥ 3xULN Events and Study Treatment Status after the First Events (HEAS Population from Pembrolizumab + Axitinib Arm)

12

0

|                                                                                      | First ALT ≥ 3xULN events † categories   | First ALT ≥ 3xULN events † categories   | First ALT ≥ 3xULN events † categories   | First ALT ≥ 3xULN events † categories   | First ALT ≥ 3xULN events † categories       |
|--------------------------------------------------------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|-----------------------------------------|---------------------------------------------|
|                                                                                      | ALT ≥ 3xULN                             | ALT ≥ 5xULN                             | ALT ≥ 10xULN                            | ALT ≥ 20xULN                            | ALT ≥ 3xULN with concurrent T- bili ≥ 2xULN |
| Subjects with any events With ALT recovered to < 3xULN from the first event, n (%) ‡ | 116 109 (94.0)                          | 74 72 (97.3)                            | 34 32 (94.1)                            | 11 9 (81.8)                             | 12 10 (83.3)                                |
| Immunosuppressive use during the first event                                         |                                         |                                         |                                         |                                         |                                             |
| Received systemic steroid, n (%) §                                                   | 65 (59.6)                               | 53 (73.6)                               | 25 (78.1)                               | 7 (77.8)                                | 8 (80.0)                                    |
| Received other systemic immunosuppressive, n (%) §                                   | 0                                       | 0                                       | 0                                       | 0                                       | 0                                           |
| Study treatment status after recovery from the first event                           |                                         |                                         |                                         |                                         |                                             |
| Received no more study treatment after recovery, n (%) § ¶                           | 17 (15.6)                               | 14 (19.4)                               | 10 (31.3)                               | 6 (66.7)                                | 4 (40.0)                                    |
| Received any study treatment on/after recovery, n (%) §                              | 92 (84.4)                               | 58 (80.6)                               | 22 (68.8)                               | 3 (33.3)                                | 6 (60.0)                                    |
| Received axitinib monotherapy on/after recovery, n (%) §                             | 34 (31.2)                               | 31 (43.1)                               | 15 (46.9)                               | 1 (11.1)                                | 4 (40.0)                                    |
| Duration of treatment after recovery in days #                                       |                                         |                                         |                                         |                                         |                                             |
| Median                                                                               | 155.0                                   | 152.0                                   | 152.0                                   | 342.0                                   | 80.5                                        |
| Range                                                                                | 15 to 543                               | 15 to 543                               | 22 to 416                               | 342 to 342                              | 49 to 404                                   |
| Received pembro monotherapy on/after recovery, n (%) §                               | 3 (2.8)                                 | 2 (2.8)                                 | 1 (3.1)                                 | 1 (11.1)                                | 1 (10.0)                                    |
| Duration of treatment after recovery in days                                         |                                         |                                         |                                         |                                         |                                             |
| Median                                                                               | 28.0                                    | 15.0                                    | 28.0                                    | 28.0                                    | 28.0                                        |
| Range                                                                                | 2 to 57                                 | 2 to 28                                 | 28 to 28                                | 28 to 28                                | 28 to 28                                    |
| Received pembro and axitinib on/after recovery, n (%) §                              | 55 (50.5)                               | 25 (34.7)                               | 6 (18.8)                                | 1 (11.1)                                | 1 (10.0)                                    |
| Duration of treatment after recovery in days                                         |                                         |                                         |                                         |                                         |                                             |
| Median                                                                               | 263.0                                   | 257.0                                   | 408.5                                   | 499.0                                   | 85.0                                        |
| Range                                                                                | 8 to 525                                | 22 to 525                               | 154 to 525                              | 499 to 499                              | 85 to 85                                    |

| With ALTnot recovered to <3xULN from the first event,n（%)   | 7 (6.0)   | 2 (2.7)   | 2 (5.9)   | 2 (18.2)   | 2 (16.7)   |
|-------------------------------------------------------------|-----------|-----------|-----------|------------|------------|
| Steroiduseduingthefirstevent                                |           |           |           |            |            |
| Received systemic steroid, n (%)                            | 3 (42.9)  | 2 (100.0) | 2 (100.0) | 2 (100.0)  | 2 (100.0)  |
| Received other systemic immumosuppressive, n (%)            | 0         | 0         | 0         | 0          | 0          |

Source:[P426V01MK3475: adam-adsl; adheas]

<div style=\"page-break-after: always\"></div>

Table 14.4-8 Outcome of Rechallenge after Recovery from the First ALT ≥ 3xULN Events (HEAS Population from Pembrolizumab + Axitinib Arm)

|                                     | Received any study treatment after recovery!   | Received axitinib only after recovery   | Received pembrolizumab only after recovery   | Received both axitinib and pembrolizumab after recovery   |
|-------------------------------------|------------------------------------------------|-----------------------------------------|----------------------------------------------|-----------------------------------------------------------|
| Subjects in population              | 92                                             | 34                                      | 3                                            | 55                                                        |
| With no ALT ≥ 3xULN recuured        | 51 (55.4)                                      | 18 (52.9)                               | 2 (66.7)                                     | 31 (56.4)                                                 |
| With ALT≥3xULN recuredand recovered | 41 (44.6)                                      | 16 (47.1)                               | 1 (33.3)                                     | 24 (43.6)                                                 |
| WithALT>3xULNrecuredand no recovery | 0 (0.0)                                        | 0 (0.0)                                 | 0 (0.0)                                      | 0 (0.0)                                                   |

Souce:[P426V01MK3475:adam-adsl; adheas]

## Table: Summary of Steroid Use in Subjects with Recurrence of ALT ≥3 × ULN following

## Rechallenge in the Combination Arm (HEAS Population from Pembrolizumab + Axitinib Arm)

24

12

|                                                            |   Received any study treatment after recovery |   Received axitinib only after recovery |   Received pembrolizumab only after recovery |   Received both axitinib and pembrolizumab after recovery |
|------------------------------------------------------------|-----------------------------------------------|-----------------------------------------|----------------------------------------------|-----------------------------------------------------------|
| Subjects with ALT ALT ≥ 3xULN recurred after rechallenge † |                                            41 |                                      16 |                                            1 |                                                        24 |
| With steroid use ‡                                         |                                            23 |                                      10 |                                            1 |                                                        12 |

Database Cutoff Date: 24Aug2018.

## Table:  Outcome of Rechallenge after Recovery from the First ALT ≥ 3xULN Events for Subjects with ALT≥5xULN during the First Event (HEAS Population from Pembrolizumab + Axitinib Arm)

|                                             | Receivedanystudy treatmentafter recoveryt   | Received axitinib only after recoveryt   | Received pembrolizumabonly after recovery   | Receivedbothaxitinib andpembrolizumab afterrecovery   |
|---------------------------------------------|---------------------------------------------|------------------------------------------|---------------------------------------------|-------------------------------------------------------|
| Subjects in population                      | 58                                          | 31                                       | 2                                           | 25                                                    |
| WithnoALT≥3xULNrecurred                     | 32 (55.2)                                   | 17 (54.8)                                | 2 (100.0)                                   | 13 (52.0)                                             |
| WithALT≥3xULNrecurred+andrecovereds         | 26 (44.8)                                   | 14 (45.2)                                | 0 (0.0)                                     | 12 (48.0)                                             |
| With ALT ≥ 3xULN recurred+ and no recoverys | 0 (0.0)                                     | 0 (0.0)                                  | 0 (0.0)                                     | 0 (0.0)                                               |

DatabaseCutoffDate:24Aug2018

## Specific Hepatic Events Subgroups in the Pembrolizumab + Axitinib Group

As specified in the in the Hepatic Events Analysis Plan in the supplemental Statistical Analysis Plan, narratives of the following subgroups of hepatic events have been medically reviewed:

· Group A: Summary of Concurrent ALT or AST ≥3 x ULN and Total Bilirubin ≥2 x ULN

15  of  the  429  (3.5%)  participants  in  the  pembrolizumab  +  axitinib  group  were  identified  with concurrent ALT &gt;3 × ULN and total bilirubin ≥2 × ULN. Of these 15 participants, 5 participants were

<div style=\"page-break-after: always\"></div>

identified  as  having  elevated  ALT  with  concurrent  hepatic  dysfunction.  Of  the  remaining  10 participants,  4  participants  lacked  sufficient  information  to  determine  if  hepatic  dysfunction  was present; 4 participants had laboratory values that were not consistent with hepatic dysfunction (eg, elevated indirect bilirubin); and 2 participants were determined to have elevated ALT related to other causes (ie, acute cholecystitis, multi-organ failure following myocarditis).

All  but  two  participants  with  hepatic  AEs  recovered  to  Grade  1  or  Grade  0  (1  participant  with concurrent hepatic dysfunction recovered from Grade 4 to Grade 3, but died subsequently due to drug-related  necrotizing  fasciitis;  1  participant  in  whom  hepatic  dysfunction  could  not  be  fully established, continued to increase after study treatment discontinuation. This participant died due to disease progression).

## · Group B: Summary of ALT ≥20 x ULN

Overall, 13 participants (3.1%) from the pembrolizumab + axitinib group were identified with peak ALT ≥20 × ULN. Five participants had concurrent total bilirubin ≥2 × ULN, and are included in Group A. Of the remaining 8 cases, five had onset ALT ≥20 x ULN (Grade 4) a nd the remaining 3 participants had onset ALT ≥3 x ULN but &lt;5 x ULN (Grade 2) and of these, 2 participants had ALT increased to ≥20 x  ULN  after  rechallenge.  In  all  8  participants,  ALT  elevations  recovered  to  &lt;3  ×  ULN  with corticosteroid use (n=6) or no corticosteroid use (n=2).

- Group C: Participants with Treatment-emergent ALT ≥3 x ULN Without Recovery to ALT &lt;3 x ULN

Seven participants with treatmentemergent ALT elevation ≥3 × ULN did not demonstrate recovery of ALT &lt;3 × ULN at the time of data cutoff [Table 4.5.22].

- o 2 participants had concurrent ALT ≥3 x ULN, total bilirubin ≥2 x ULN, and peak ALT ≥20 x ULN.
- o 1  participant  had  ALT  elevation  that  decreased  from  Grade  4  to  low  Grade  3  after discontinuation of both study treatments and initiation of steroid treatment. This participant subsequently died due to drug-related necrotizing fasciitis.
- o 1 participant with elevated ALT, AST, ALP, and total bilirubin continued to increase after study treatment discontinuation and steroid treatment. This participant subsequently died due to disease progression without further follow-up data
- o 5 participants had peak ALT ≥3 x ULN but &lt;5 x ULN without concurrent total bilirubin elevation (Grad 2).
- o 3 participants discontinued study treatment due to disease progression with no follow-up data at the 90 day cutoff for this lab data analysis.
- o 1 participant had onset of ALT elevation (Grade 2) 15 days prior to data cutoff and was still in study treatment and at the time of the cutoff was being followed for this event.
- o 1 participant with no follow-up ALT data provided died due to myasthenia gravis that was considered by the investigator to be related to treatment.

<div style=\"page-break-after: always\"></div>

Table: Study Treatment Received After Recovery from the Second Episode of ALT ≥3 × ULN Events

| Study treatment received following recovery from the second episode of ALT ≥ 3xULN event   | ALT based on peak value of the 2 nd episode   | ALT based on peak value of the 2 nd episode   | ALT based on peak value of the 2 nd episode   | ALT based on peak value of the 2 nd episode   | ALT based on peak value of the 2 nd episode   |
|--------------------------------------------------------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|
| Study treatment received following recovery from the second episode of ALT ≥ 3xULN event   | Total                                         | ALT × ULN ≥3 to < 5                           | ALT × ULN ≥5 to < 10                          | ALT × ULN ≥10 to < 20                         | ALT × ULN ≥20                                 |
| Participants recovered from the second episode, n                                          | 44                                            | 21                                            | 16                                            | 5                                             | 2                                             |
| Received any study drug, n                                                                 | 37                                            | 20                                            | 10                                            | 5                                             | 2                                             |
| Received both pembrolizumab and axitinib, n                                                | 17                                            | 11                                            | 3                                             | 3                                             | 0                                             |
| Received pembrolizumab only, n                                                             | 6                                             | 2                                             | 2                                             | 1                                             | 1                                             |
| Received axitinib only, n                                                                  | 14                                            | 7                                             | 5                                             | 1                                             | 1                                             |
| Received neither study drug, n                                                             | 7                                             | 1                                             | 6                                             | 0                                             | 0                                             |
| Data cutoff: 02Jan2019                                                                     | Data cutoff: 02Jan2019                        | Data cutoff: 02Jan2019                        | Data cutoff: 02Jan2019                        | Data cutoff: 02Jan2019                        | Data cutoff: 02Jan2019                        |

<div style=\"page-break-after: always\"></div>

## Cardiac Arrythmias/Atrial Fibrillation

During the evaluation the MAH provided in depth analysis of Atrial Fibrillation and more generally Cardiac Arrythmias SMQ AEs within the KN-426 study, as well as out an overall Safety Database Review to identify any reported event from all types of sources.

Table 2 OverallSummaryofCardiacArrhythmiaAdverseEvents(ASaTPopulation)

|                                                                                     | Pembrolizumab + Axitinib   | Pembrolizumab + Axitinib   | Sunitinib   | Sunitinib   |
|-------------------------------------------------------------------------------------|----------------------------|----------------------------|-------------|-------------|
|                                                                                     | n                          | (%)                        | n           | (%)         |
| Subjects in population                                                              | 429                        |                            | 425         |             |
| with one or more cardiacarrhythmia adverse eventss                                  | 25                         | (5.8)                      | 10          | (2.4)       |
| with no cardiac arrhythmia adverse event                                            | 404                        | (94.2)                     | 415         | (97.6)      |
| with drug-related+ cardiac arrhythmia adverse events                                | 10                         | (2.3)                      | 1           | (0.2)       |
| with toxicity grade 3-5 cardiac arrhythmia adverse events                           | 5                          | (1.2)                      | 1           | (0.2)       |
| with toxicity grade 3-5 drug-related cardiac arrhythmia adverse events              | 3                          | (0.7)                      | 0           | (0.0)       |
| with serious cardiac arrhythmia adverse events                                      | 6                          | (1.4)                      | 1           | (0.2)       |
| with serious drug-related cardiac arrhythmia adverse events                         | 4                          | (0.9)                      | 0           | (0.0)       |
| who died due to a cardiac arrhythmia adverse event                                  | 0                          | (0.0)                      | 0           | (0.0)       |
| who died due to a drug-related cardiacarrhythmia adverse event                      | 0                          | (0.0)                      | 0           | (0.0)       |
| discontinued any drug due to a cardiacarrhythmia adverse event                      | 1                          | (0.2)                      | 0           | (0.0)       |
| discontinued Pembrolizumab                                                          | 0                          | (0.0)                      | 0           | (0.0)       |
| discontinued Axitinib                                                               | 1                          | (0.2)                      | 0           | (0.0)       |
| discontinued Both Pembrolizumab and Axitinib                                        | 0                          | (0.0)                      | 0           | (0.0)       |
| discontinued any drug due to a drug-related cardiac arrhythmia adverse event        | 1                          | (0.2)                      | 0           | (0.0)       |
| discontinued Pembrolizumab                                                          | 0                          | (0.0)                      | 0           | (0.0)       |
| discontinued Axitinib                                                               | 1                          | (0.2)                      | 0           | (0.0)       |
| discontinued Both Pembrolizumab and Axitinib                                        | 0                          | (0.0)                      | 0           | (0.0)       |
| discontinuedanydrugduetoaseriouscardiacarrhythmia adverseevent                      | 1                          | (0.2)                      | 0           | (0.0)       |
| discontinued Pembrolizumab                                                          | 0                          | (0.0)                      | 0           | (0.0)       |
| discontinued Axitinib                                                               | 1                          | (0.2)                      | 0           | (0.0)       |
| discontinued Both Pembrolizumab and Axitinib                                        | 0                          | (0.0)                      | 0           | (0.0)       |
| discontinued any drug due toa serious drug-related cardiac arrhythmia adverse event | 1                          | (0.2)                      |             | (0.0)       |
| discontinued Pembrolizumab                                                          | 0                          | (0.0)                      | 0           | (0.0)       |
| discontinued Axitinib                                                               | 1                          | (0.2)                      | 0           | (0.0)       |
| discontinued Both Pembrolizumab and Axitinib                                        | 0                          | (0.0)                      | 0           | (0.0)       |

Pembrolizumab + Axitinib

n

(%)

Sunitinib

+Determined by the investigatorto be related to the drug.

Grades are based on NCI CTCAE version 4.0.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded. Database Cutoff Date:24Aug2018.

n

(%)

<div style=\"page-break-after: always\"></div>

## Table 3 SubjectsWith CardiacArrhythmia Adverse EventsbyDecreasing Incidence (Incidence&gt;O% in One or More Treatment Groups) (ASaT Population)

|                                                    | Pembrolizumab + Axitinib   | Pembrolizumab + Axitinib   | Sunitinib   | Sunitinib   |
|----------------------------------------------------|----------------------------|----------------------------|-------------|-------------|
|                                                    | n                          | (%)                        | n           | (%)         |
| Subjects in population                             | 429                        |                            | 425         |             |
| with one or more cardiac arrhythmia adverse events | 25                         | (5.8)                      | 10          | (2.4)       |
| with no cardiac arrhythmia adverse events          | 404                        | (94.2)                     | 415         | (97.6)      |
| Atrial fibrillation                                | 7                          | (1.6)                      | 1           | (0.2)       |
| Sinus tachycardia                                  | 4                          | (0.9)                      | 3           | (0.7)       |
| Sinus bradyca rdia                                 | 3                          | (0.7)                      | 1           | (0.2)       |
| Supraventricular tachycardia                       | 2                          | (0.5)                      | 0           | (0.0)       |
| Ventricular extrasystoles                          | 2                          | (0.5)                      | 1           | (0.2)       |
| Arrhythmia supraventricular                        | 1                          | (0.2)                      | 0           | (0.0)       |
| Atrial flutter                                     | 1                          | (0.2)                      | 1           | (0.2)       |
| Atrial tachycardia                                 | 1                          | (0.2)                      | 0           | (0.0)       |
| Atrioventricular block                             | 1                          | (0.2)                      | 1           | (0.2)       |
| Bradyarrhythmia                                    | 1                          | (0.2)                      | 0           | (0.0)       |
| Bundle branch block right                          | 1                          | (0.2)                      | 1           | (0.2)       |
| Electrocardiogram QT prolonged                     | 1                          | (0.2)                      | 0           | (0.0)       |
| Sinus node dysfunction                             | 1                          | (0.2)                      | 0           | (0.0)       |
| Ventricular arrhythmia                             | 1                          | (0.2)                      | 0           | (0.0)       |
| Arrhythmia                                         | 0                          | (0.0)                      | 1           | (0.2)       |
| Rhythm idioventricular                             | 0                          | (0.0)                      | 1           | (0.2)       |

Every subject is counted a single time for each applicable row and column.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

The adverse events are ordered decreasingly by the incidence in the first column. Database Cutoff Date: 24Aug2018.

<div style=\"page-break-after: always\"></div>

## Table 4

## Exposure-Adjusted Cardiac Arrhythmias Adverse Events (Including Multiple Occurrences of Events)

(Incidence &gt;0% In One or More Treatment Groups) (By Decreasimg Frequency of Preferred Term) (Asat Population)

|                              | Event Count and Rate (Events/l00 person-months)   | Event Count and Rate (Events/l00 person-months)   | Event Count and Rate (Events/l00 person-months)         | Event Count and Rate (Events/l00 person-months)                  |
|------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------------|------------------------------------------------------------------|
|                              | KN426 Data for Pembrolizuwab+ Axitinib            | KN426 Sunitimibf                                  | Reference Safety Dataset for Pembrolizummab Monotherapy | Cumulative Rurming Safety Dataset for Pembrolizummab Monotherapy |
| Number ofsubjects exposed    | 429                                               | 425                                               | 4439                                                    | 6436                                                             |
| Total exposure person-months | 4766.94                                           | 3924.64                                           | 32354.30                                                | 49189.73                                                         |
| Total events (rate)          | 28 (0.59)                                         | 11 (0.28)                                         | 181 (0.56)                                              | 244 (0.50)                                                       |
| SMQ Cardiac Arrhythmia       | 28 (0.6)                                          | 11 (0.3)                                          | 181 (0.6)                                               | 244 (0.5)                                                        |

Non-serious adverse events up to 30 day's oflast dose and serious adverse events up to 90 days of last dose are included.

Preferred terms Neoplasm progression', Malignant neoplasm pro gression' and Disease pro gression' not related to the drug are excluded. Ineludes all subjects who received at least one doseof Pembrolizumab and/or Axitiwib in KN426.

t Includes allsubjects who received at leastone doseof Sunitinib in KN426.

phase), KN006, KN010, KN012 Cohorts B and B2 (HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN045, KN052, KN055 andKN087.

Includes all subjeets who received at leastone dose of pembrolizumab in KN001 Part B1, B2, B3,D, C, F1, F2, F3, KN002 (original phase), KN006, KN0 10, KN012 Cohorts B and B2 (HNSCC), Cohort C (Urofhelial Tract Cancer) and Cohort D (Gastric Cancer), KN013 Cohort 3 (Hodgkin Lymphoma) and Cohort 4A (MLBCL), KN01 7, KN024, KN028 Cohort B4, KN040, KN042, KN045, KN052, KN054, KN055, KN059 Cohort 1, KN087,KN158, KN164 Cohort A, KN170, KN224 and KN427 Cohort .A.

Database cutoff dateforMelanoma (KN001-Melanoma: 18APR2014, KN002 : 28FEB2015, KN006 : 03MAR2015 ,KN054: 02OCT2017)

Database cutoff dateforLung (KN001-NSCLC: 23JAN20 15, KN0 10: 30SEP2015, KN024: 10JUL201 7, KN042: 26FEB2018)

Database cutoff dateforHNSCC (KN0 12-HNSCC: 26APR2016, KN040: 15MA Y2017, KN055: 22APR20 16)

Database cutoff dateforGastmic (KN012-Gastric: 26APR2016, KN059-Cohort 1: 21APR2017)

Database cutoff dateforcHI (KN013-Cohort 3 : 27SEP2016, KN087 : 25SEP2016)

Database cutoff dateforBladde (KN012-Urothelial: 01SEP2015, KN045: 26OCT2017, KN052: 09MAR2017)

Database cutoff datefor Colorectal (KN164-Cohort A: 03AUG2016)

Database cutoff dateforMLBCL (KN013-Cohort 4A: 04AUG2017, KN170: 19JAN20 18)

Database cutoff datefor Cervical (KN028-Cohort B4 : 20FEB2017, KN158: 15JAN2018)

Database cutoff dateforHCC (KN224 : 15MAY2018)

Database cutoff dateforRCC (KN426: 24AUG2018, KN427-Cohort A: 07SEP2018)

Database cutoff dateforMCC (KN017:06FEB2018)

<!-- image -->

Source:[ISS:adwm-adl:adae]

<div style=\"page-break-after: always\"></div>

Table 5

Exposure-Adjusted CardiacArrhythmias Adverse Events

(Including Multiple Occurrences ofEvents)

(Incidence&gt;0%InOne orMoreTreatment Groups)

(By DecreasingFrequency ofPreferred Term) (ASAT POPULATION)

|                                             | Event Count and Rate (Events/100 person-months)   | Event Count and Rate (Events/100 person-months)   | Event Count and Rate (Events/100 person-months)         | Event Count and Rate (Events/100 person-months)                |
|---------------------------------------------|---------------------------------------------------|---------------------------------------------------|---------------------------------------------------------|----------------------------------------------------------------|
|                                             | KN426 Data for Bembralizumah+ Axitioib            | KN426Sunitinib                                    | Reference Safety Dataset for Pembrolizummab Monotherapy | CumulativeRunming Safety Dataset for Pembrolizumab Monotherapy |
| Number ofsubjects exposed                   | 429                                               | 425                                               | 4439                                                    | 6436                                                           |
| Total exposure person-months                | 4766.94                                           | 3924.64                                           | 32354.30                                                | 49189.73                                                       |
| Total events (rate)                         | 28 (0.59)                                         | 11 (0.28)                                         | 181 (0.56)                                              | 244 (0.50)                                                     |
| Atrial fibrillation                         | 8 (0.2)                                           | 1 (0.0)                                           | 63 (0.2)                                                | 83 (0.2)                                                       |
| Sinus tachycardia                           | 4 (0.1)                                           | 3 (0.1)                                           | 37 (0.1)                                                | 45 (0.1)                                                       |
| Sinus bradycardia                           | 3 (0.1)                                           | 1 (0.0)                                           | 14 (0.0)                                                | 21 (0.0)                                                       |
| Supraventricular tachycardia                | 2 (0.0)                                           | 0 (0.0)                                           | 18 (0.1)                                                | 26 (0.1)                                                       |
| Ventricularextrasystoles                    | 2 (0.0)                                           | 1 (0.0)                                           | 3 (0.0)                                                 | 4 (0.0)                                                        |
| Arrhythmiasupraventricular                  | 1 (0.0)                                           | 0 (0.0)                                           | 1 (0.0)                                                 | 1 (0.0)                                                        |
| Atrial flutter                              | 1 (0.0)                                           | 1 (0.0)                                           | 16 (0.0)                                                | 18 (0.0)                                                       |
| Atrial tachycardia                          | 1 (0.0)                                           | 0 (0.0)                                           | 1 (0.0)                                                 | 1 (0.0)                                                        |
| Atrioventicularblock                        | 1 (0.0)                                           | 1 (0.0)                                           | 1 (0.0)                                                 | 2 (0.0)                                                        |
| Bradyarrhythmia                             | 1 (0.0)                                           | 0 (0.0)                                           | 0 (0.0)                                                 | 0 (0.0)                                                        |
| Bundle branch block right                   | 1 (0.0)                                           | 1 (0.0)                                           | 3 (0.0)                                                 | 3 (0.0)                                                        |
| Electrocardiogram QT prolonged              | 1 (0.0)                                           | 0 (0.0)                                           | 9 (0.0)                                                 | 10 (0.0)                                                       |
| Sinus node dysfumction                      | 1 (0.0)                                           | 0 (0.0)                                           | 0 (0.0)                                                 | 0 (0.0)                                                        |
| Ventriculararrhythmia                       | 1 (0.0)                                           | 0 (0.0)                                           | 0 (0.0)                                                 | 1 (0.0)                                                        |
| Adams-Stokes syndlrome                      | 0 (0.0)                                           | 0 (0.0)                                           | 0 (0.0)                                                 | 1 (0.0)                                                        |
| Arrhythmia                                  | 0 (0.0)                                           | 1 (0.0)                                           | 4 (0.0)                                                 | 6 (0.0)                                                        |
| Atrioventricularblock complete              | 0 (0.0)                                           | 0 (0.0)                                           | 1 (0.0)                                                 | 1 (0.0)                                                        |
| Atrioventmicularblock first degree          | 0 (0.0)                                           | 0 (0.0)                                           | 4 (0.0)                                                 | 4 (0.0)                                                        |
| Bundle branch block lef                     | 0 (0.0)                                           | 0 (0.0)                                           | 1 (0.0)                                                 | 3 (0.0)                                                        |
| Electrocardiogramtenolarisation abnormality | 0 (0.0)                                           | 0 (0.0)                                           | 1 (0.0)                                                 | 1 (0.0)                                                        |
| Heartrate irregular                         | 0 (0.0)                                           | 0 (0.0)                                           | 1 (0.0)                                                 | 1 (0.0)                                                        |
| Paroxysmal arrhythmia                       | 0 (0.0)                                           | 0 (0.0)                                           | 0 (0.0)                                                 | 1 (0.0)                                                        |
| Rhythm idioventricular                      | 0 (0.0)                                           | 1 (0.0)                                           | 0 (0.0)                                                 | 0 (0.0)                                                        |
| Supraventricular extrasystoles              | 0 (0.0)                                           | 0 (0.0)                                           | 2 (0.0)                                                 | 4 (0.0)                                                        |
| Tachyarrhythmia                             | 0 (0.0)                                           | 0 (0.0)                                           | 0 (0.0)                                                 | 1 (0.0)                                                        |
| Ventricularfibrillation                     | 0 (0.0)                                           | 0 (0.0)                                           | 1 (0.0)                                                 | 2 (0.0)                                                        |
| Ventriculartachycardlia                     | 0 (0.0)                                           | 0 (0.0)                                           | 0 (0.0)                                                 | 3 (0.0)                                                        |
| Wolff-Parkinson-White syndrome              | 0 (0.0)                                           | 0 (0.0)                                           | 0 (0.0)                                                 | 1(0.0)                                                         |

| Event Count and Rate(Events/100person-months)   | Event Count and Rate(Events/100person-months)   | Event Count and Rate(Events/100person-months)          | Event Count and Rate(Events/100person-months)                  |
|-------------------------------------------------|-------------------------------------------------|--------------------------------------------------------|----------------------------------------------------------------|
| KN426 Data for Bembraliamah+ Axitinib!          | KN426Sunitinib                                  | Reference Safety Dataset for Pembrolizumab Monotherapy | Cumulative Ruming Safety Dataset for Pembrolizumab Monotherapy |

Preferredl terms Neoplasm progression', Malignant neoplasm progression' and Disease progression' notrelatedl to the drug are excluded.

↑ Includles allsubjects who received at least one doseof Sunitinib in KN426.

Includes allsubjects who received at least one doseofPembrolizumab and/orAxjtioib in KN426.

phase), KN006,KN010, KN012 Cohorts B andB2 (HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma), KN024,KN040,KN045, KN052, KN055 andKN087.

Includes all subjects whoreceivedat leastone dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 Cohorts B andB2 (HNSCC), Cohort C(Urothelial Tract Cancer) and Cohort D (Gastric Cancer), KN013 Cohort3 (HodgkinLymphoma) and Cohort 4A (MLBCL),KN017,KN024,KN028 CohortB4,KN040,KN042,KN045, KN052, KN054, KN055, KN059 Cohort 1, KN087,KN158, KN164 Cohort A, KN170,KN224 and KN427 Cohort A.

Database cutbf dateforMelanoma (KN001-Melanoma: 18APR2014, KN002: 28FEB2015, KN006: 03MAR2015,KN054: 02OCT2017)

Database cutbff dateforLung (KN001-NSCLC: 23JAN2015, KN010: 30SEP2015, KN024: 10JUL2017, KN042: 26FEB2018)

Database cutoff dateforHNSCC (KN012-HNSCC: 26APR2016, KN040: 15MA Y2017, KN055: 22APR2016)

Database cutbff dateforGastmic (KN012-Gastric: 26APR2016,KN059-Cohort 1: 21APR2017)

Database cutbof dateforcHI (KN013-Cohort3:27SEP2016, KN087: 25SEP2016)

Database cutbff dateforBladder (KN012-Urothelial: 01SEP2015, KN045: 26OCT2017, KN052: 09MAR2017)

Database cutbff dateforColorectal (KN164-Cohort A: 03AUG2016)

Database cutboff dateforMLBCL (KN013-Cohort 4A: 04AUG2017, KN170: 19JAN2018)

Database cutoff datefor Cervical (KN028-Cohort B4 : 20FEB2017, KN158: 15JAN2018)

Database cutbff dateforHCC(KN224: 15MAY2018)

Database cutbffdateforRCC (KN426:24AUG2018,KN427-CohortA:07SEP2018)

Database cutbff dateforMCC (KN017:06FEB2018)

Source:[ISS:ada-adsl:adae]

<div style=\"page-break-after: always\"></div>

The pembrolizumab OASE is the largest source of unblinded aggregate (i.e. across indications) safety data from pembrolizumab monotherapy including all open-label, unmasked, or completed randomized study for which there has been a database lock on or before 31-Mar--2018 (n=9118). Pooled data from all studies using chemotherapy comparators (all cytotoxic treatments combined, N=1324) is provided in this response for context and comparison.

The OASE database was queried to identify participants with AEs (including AE count and frequency) from the MedDRA sub-SMQ Cardiac arrhythmias (including bradyarrhythmias and tachyarrhythmias).

[lable / Adverse Event Summary By Treatment Group in the OASE Preferred Terms for the SMQ of Cardiac Arrhythmia (APaT Population)

|                                                                                           | All MK-3475 Combined                                                                      | All MK-3475 Combined                                                                      | Chemotherapy                                                                              | Chemotherapy                                                                              |
|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
|                                                                                           | n                                                                                         | (%)                                                                                       |                                                                                           | (%)                                                                                       |
| Subjects in population                                                                    | 9,118                                                                                     | 9,118                                                                                     | 1,324                                                                                     | 1,324                                                                                     |
| with one or more adverse events                                                           | 297                                                                                       | (3.3)                                                                                     |                                                                                           | (2.6)                                                                                     |
| with no adverse event                                                                     | 8,821                                                                                     | (96.7)                                                                                    | 1,290                                                                                     | (97.4)                                                                                    |
| with drug-related# adverse events                                                         | 22                                                                                        | (0.2)                                                                                     | 6                                                                                         | (0.5)                                                                                     |
| with toxicity grade 3-5 adverse events                                                    | 65                                                                                        | (0.7)                                                                                     | 12                                                                                        | (0.9)                                                                                     |
| with toxicity grade 3-5 drug-related adverse events                                       | 5                                                                                         | (0.1)                                                                                     | 2                                                                                         | (0.2)                                                                                     |
| with non-serious adverse events                                                           |                                                                                           | (2.6)                                                                                     | 27                                                                                        | (2.0)                                                                                     |
| with serious adverse events                                                               | 63                                                                                        | (0.7)                                                                                     | 10                                                                                        | (0.8)                                                                                     |
| with serious drug-related adverse events                                                  | 3                                                                                         | (0.0)                                                                                     | 1                                                                                         | (0.1)                                                                                     |
| who died                                                                                  |                                                                                           | (0.0)                                                                                     | 0                                                                                         | (0.0)                                                                                     |
| who died due to a drug-related adverse event                                              | 0                                                                                         | (0.0)                                                                                     | 0                                                                                         | (0.0)                                                                                     |
| discontinued drug due to an adverse event                                                 | 7                                                                                         | (0.1)                                                                                     | 1                                                                                         | (0.1)                                                                                     |
| discontinued drug due to a drug-related adverse event                                     | 2                                                                                         | (0.0)                                                                                     | 0                                                                                         | (0.0)                                                                                     |
| discontinued drug due to a serious adverse event                                          | 7                                                                                         | (0.1)                                                                                     | 1                                                                                         | (0.1)                                                                                     |
| discontinued drug due to a serious drug-related adverse event                             | 2                                                                                         | (0.0)                                                                                     | 0                                                                                         | (0.0)                                                                                     |
| Determined by the investigator to be related to the drug. MedDRA version 21.0 is applied. | Determined by the investigator to be related to the drug. MedDRA version 21.0 is applied. | Determined by the investigator to be related to the drug. MedDRA version 21.0 is applied. | Determined by the investigator to be related to the drug. MedDRA version 21.0 is applied. | Determined by the investigator to be related to the drug. MedDRA version 21.0 is applied. |

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | All MK-3475 Combined                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | All MK-3475 Combined                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Chemotherapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Chemotherapy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | I                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | (%)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| (MK-3475 KN059 Database Cutoff Date: 21APR2017). (MK-3475 KN061 Database Cutoff Date: 26OCT2017). (MK-3475 KN086 Database Cutoff Date: 10NOV2017). (MK-3475 KN087 Database Cutoff Date: 21MAR2017). (MK-3475 KN100 Database Cutoff Date: 02JAN2017). (MK-3475 KN151 Database Cutoff Date: 27DEC2017). (MK-3475 KN158 Database Cutoff Date: 15JAN2018). (MK-3475 KN164 Database Cutoff Date for Cohort A and CohortB: 12SEP2017). (MK-3475 KN170 Database Cutoff Date for the PMBCL Cohort: 19JAN2018). (MK-3475 KN180 Database Cutoff Date: 18SEP2017). (MK-3475 KN199 Database Cutoff Date: 13OCT2017). (MK-3475 KN224 Database Cutoff Date: 13FEB2018). | (MK-3475 KN059 Database Cutoff Date: 21APR2017). (MK-3475 KN061 Database Cutoff Date: 26OCT2017). (MK-3475 KN086 Database Cutoff Date: 10NOV2017). (MK-3475 KN087 Database Cutoff Date: 21MAR2017). (MK-3475 KN100 Database Cutoff Date: 02JAN2017). (MK-3475 KN151 Database Cutoff Date: 27DEC2017). (MK-3475 KN158 Database Cutoff Date: 15JAN2018). (MK-3475 KN164 Database Cutoff Date for Cohort A and CohortB: 12SEP2017). (MK-3475 KN170 Database Cutoff Date for the PMBCL Cohort: 19JAN2018). (MK-3475 KN180 Database Cutoff Date: 18SEP2017). (MK-3475 KN199 Database Cutoff Date: 13OCT2017). (MK-3475 KN224 Database Cutoff Date: 13FEB2018). | (MK-3475 KN059 Database Cutoff Date: 21APR2017). (MK-3475 KN061 Database Cutoff Date: 26OCT2017). (MK-3475 KN086 Database Cutoff Date: 10NOV2017). (MK-3475 KN087 Database Cutoff Date: 21MAR2017). (MK-3475 KN100 Database Cutoff Date: 02JAN2017). (MK-3475 KN151 Database Cutoff Date: 27DEC2017). (MK-3475 KN158 Database Cutoff Date: 15JAN2018). (MK-3475 KN164 Database Cutoff Date for Cohort A and CohortB: 12SEP2017). (MK-3475 KN170 Database Cutoff Date for the PMBCL Cohort: 19JAN2018). (MK-3475 KN180 Database Cutoff Date: 18SEP2017). (MK-3475 KN199 Database Cutoff Date: 13OCT2017). (MK-3475 KN224 Database Cutoff Date: 13FEB2018). | (MK-3475 KN059 Database Cutoff Date: 21APR2017). (MK-3475 KN061 Database Cutoff Date: 26OCT2017). (MK-3475 KN086 Database Cutoff Date: 10NOV2017). (MK-3475 KN087 Database Cutoff Date: 21MAR2017). (MK-3475 KN100 Database Cutoff Date: 02JAN2017). (MK-3475 KN151 Database Cutoff Date: 27DEC2017). (MK-3475 KN158 Database Cutoff Date: 15JAN2018). (MK-3475 KN164 Database Cutoff Date for Cohort A and CohortB: 12SEP2017). (MK-3475 KN170 Database Cutoff Date for the PMBCL Cohort: 19JAN2018). (MK-3475 KN180 Database Cutoff Date: 18SEP2017). (MK-3475 KN199 Database Cutoff Date: 13OCT2017). (MK-3475 KN224 Database Cutoff Date: 13FEB2018). | (MK-3475 KN059 Database Cutoff Date: 21APR2017). (MK-3475 KN061 Database Cutoff Date: 26OCT2017). (MK-3475 KN086 Database Cutoff Date: 10NOV2017). (MK-3475 KN087 Database Cutoff Date: 21MAR2017). (MK-3475 KN100 Database Cutoff Date: 02JAN2017). (MK-3475 KN151 Database Cutoff Date: 27DEC2017). (MK-3475 KN158 Database Cutoff Date: 15JAN2018). (MK-3475 KN164 Database Cutoff Date for Cohort A and CohortB: 12SEP2017). (MK-3475 KN170 Database Cutoff Date for the PMBCL Cohort: 19JAN2018). (MK-3475 KN180 Database Cutoff Date: 18SEP2017). (MK-3475 KN199 Database Cutoff Date: 13OCT2017). (MK-3475 KN224 Database Cutoff Date: 13FEB2018). |

Source:[1Q20180ASE: adaw-iadxl: iadae]

Table 8 Subjects with Adverse Events (Incidence &gt;0% in One or More Treatment Groups) By Treatment Group in the OASE Preferred Terms for the SMQ of Cardiac Arrhythmias Sorted by Decreasing Incidence (APaT Population)

|                                              | All MK-3475 Combinedt   | All MK-3475 Combinedt   | Chemotherapy   | Chemotherapy   |
|----------------------------------------------|-------------------------|-------------------------|----------------|----------------|
|                                              | n                       | (%)                     | n              | (%)            |
| Subjects in population                       | 9,118                   |                         | 1,324          |                |
| with one or more adverse events              | 297                     | (3.3)                   | 34             | (2.6)          |
| with no adverse events                       | 8,821                   | (96.7)                  | 1,290          | (t6)           |
| Atrial fibrillation                          | 96                      | (1.1)                   | 13             | (1.0)          |
| Sinus tachycardia                            | 85                      | (0.9)                   | 8              | (0.6)          |
| Sinus bradycardia                            | 26                      | (0.3)                   | 2              | (0.2)          |
| Supraventrieular tachycardia                 |                         | (0.3)                   | 2              | (0.2)          |
| Atrial flutter                               | 21                      | (0.2)                   | 1              | (0.1)          |
| Electrocardiogram QT prolonged               | 13                      | (0.1)                   | 0              | (0.0)          |
| Arrhythmia                                   | 10                      | (0.1)                   | 4              | (0.3)          |
| Ventricular tachycardia                      | 6                       | (0.1)                   | 0              | (0.0)          |
| Bundle branch block right                    | 5                       | (0.1)                   | 0              | (0.0)          |
| Atrioventricular block first degree          | 4                       | (0.0)                   | 0              | (0.0)          |
| Ventricular extrasystoles                    | 4                       | (0.0)                   | 1              | (0.1)          |
| Atrioventricular block complete              | 3                       | (0.0)                   | 0              | (0.0)          |
| Heart rate irregular                         | 3                       | (0.0)                   | 0              | (0.0)          |
| Supraventrieular extrasystoles               | E                       | (0.0)                   | 0              | (0.0)          |
| Ventricular fibrillation                     | E                       | (0.0)                   | 1              | (0.1)          |
| Atrial tachyeardia                           | 2                       | (0.0)                   | 0              | (0.0)          |
| Arrhythmia supraventricular                  | 1                       | (0.0)                   | 0              | (0.0)          |
| Atrioventrieular block                       | 1                       | (0.0)                   | 2              | (0.2)          |
| Bundle branch block                          | 1                       | (0.0)                   | 0              | (0.0)          |
| Bundle branch block left                     | 1                       | (0.0)                   | 1              | (0.1)          |
| Electrocardiogram tepolarisation abnormality | 1                       | (0.0)                   | 0              | (0.0)          |

<div style=\"page-break-after: always\"></div>

|                               | All MK-3475 Combimed   | Chemotherapy   |
|-------------------------------|------------------------|----------------|
|                               | (%)                    | n (%6)         |
| Extrasystoles                 | 1 (0.0)                | 0 (0.0)        |
| Pulseless electrical activity | 1 (0.0)                | 0 (0.0)        |
| Sinus arrhythmia              | 1 (0.0)                | 0 (0.0)        |
| Tachyarrhythmia               | 1 (0.0)                | 1 (0.1)        |
| Ventricular arrhythmia        | 1 (0.0)                | 0 (0.0)        |
| Conduction disorder           | 0 (0.0)                | 1 (0.1)        |

<!-- image -->

Source:[1Q2018OASE: adaw-iadxl: iadae]

The risk of all cardiac arrhythmias in the pooled pembrolizumab monotherapy dataset shown by age categories is depicted in the Table below.

<div style=\"page-break-after: always\"></div>

## Table 10

## Subjects With Adverse Events (Incidence &gt; 0% in One or More Treatment Groups) By Age Category (years)

## Preferred Terms for the SMQ of Cardiac Arrhythrmia Sorted by Decreasing Frequency

(APaT Population)

|                                                        | <50      | <50    | 50 to ≤60   | 50 to ≤60   | 60 to ≤70   | 60 to ≤70   | 70 to ≤80   | 70 to ≤80   | 08=<   | 08=<   |
|--------------------------------------------------------|----------|--------|-------------|-------------|-------------|-------------|-------------|-------------|--------|--------|
|                                                        | n        | (%)    | n           | (%)         |             | (%)         | I           | (%)         |        | (%)    |
| Subjeets in population with one or more adverse events | 1,894 41 | (2.2)  | 2,073 52    | (2.5)       | 2,862 91    | (3.2)       | 1,881 87    | (4.6)       | 807 26 | (6.4)  |
| with no adverse events                                 | 1,853    | (97.8) | 2,021       | (97.5)      | 2,771       | (96.8)      | 1,794       | (95.4)      | 382    | (93.6) |
| Sinus tachycardia                                      | 27       | (1.4)  | 16          | (0.8)       | 27          | (0.9)       | 13          | (0.7)       | 2      | (0.5)  |
| Atrial fibrillation                                    |          | (0.2)  | 9           | (0.4)       | 31          | (1.1)       | 8           | (2.0)       | 14     | (3.4)  |
| Sinus bradyeardia                                      | 3        | (0.2)  | 5           | (0.2)       | 5           | (0.2)       | 10          | (0.5)       | 3      | (0.7)  |
| Supraventrieular tachycardia                           |          | (0.2)  | 5           | (0.2)       | 7           | (0.2)       | 5           | (0.3)       |        | (1.0)  |
| Atrial flutter                                         | 2        | (0.1)  | 5           | (0.2)       | 10          | (0.3)       | 4           | (0.2)       | 0      | (0.0)  |
| Electrocardiogram QT prolonged                         | 1        | (0.1)  | 3           | (0.1)       | 3           | (0.1)       | 5           | (0.3)       | 1      | (0.2)  |
| Extrasystoles                                          | 1        | (0.1)  | 0           | (0.0)       | 0           | (0.0)       | 0           | (0.0)       | 0      | (0.0)  |
| Heart rate irregular                                   | 1        | (0.1)  | 1           | (0.0)       | 0           | (0.0)       | 1           | (0.1)       | 0      | (0.0)  |
| Tachyarrhythmia                                        | 1        | (0.1)  | 0           | (0.0)       | 0           | (0.0)       | 0           | (0.0)       | 0      | (0.0)  |
| Ventricular tachycardia                                | 1        | (0.1)  | 2           | (0.1)       | 2           | (0.1)       | 0           | (0.0)       | 1      | (0.2)  |
| Arrhythmia                                             | 0        | (0.0)  | 1           | (0.0)       |             | (0.1)       | 7           | (0.4)       | 0      | (0.0)  |
| Arrhythmia supraventricular                            | 0        | (0.0)  | 0           | (0.0)       | 1           | (0.0)       | 0           | (0.0)       | 0      | (0.0)  |
| Atrial tachyeardia                                     | 0        | (0.0)  | 0           | (0.0)       | 0           | (0.0)       | 1           | (0.1)       | 1      | (0.2)  |
| Atrioventricular block                                 | 0        | (0.0)  | 0           | (0.0)       | 1           | (0.0)       | 0           | (0.0)       | 0      | (0.0)  |
| Atioventricular block complete                         | 0        | (0.0)  | 1           | (0.0)       | 1           | (0.0)       | 1           | (0.1)       | 0      | (0.0)  |
| Atrioventricular block first degree                    | 0        | (0.0)  | 1           | (0.0)       | 1           | (0.0)       | 2           | (0.1)       | 0      | (0.0)  |
| Bundle branch block                                    | 0        | (0.0)  | 1           | (0.0)       | 0           | (0.0)       | 0           | (0.0)       | 0      | (0.0)  |
| Bundle branch block left                               | 0        | (0.0)  | 0           | (0.0)       | 1           | (0.0)       | 0           | (0.0)       | 0      | (0.0)  |
| Bundle branch block right                              | 0        | (0.0)  | 2           | (0.1)       | 2           | (0.1)       | 0           | (0.0)       | 1      | (0.2)  |
| Electrocardiogram tenolarisation abnormality           | 0        | (0.0)  | 1           | (0.0)       | 0           | (0.0)       | 0           | (0.0)       | 0      | (0.0)  |
| Pulseless electrical aetivity                          | 0        | (0.0)  | 1           | (0.0)       | 0           | (0.0)       | 0           | (0.0)       | 0      | (0.0)  |
| Sinus arrhythmia                                       | 0        | (0.0)  | 0           | (0.0)       | 0           | (0.0)       | 1           | (0.1)       | 0      | (0.0)  |
| Supraventricular extrasystoles                         | 0        | (0.0)  | 0           | (0.0)       | 1           | (0.0)       | 2           | (0.1)       | 0      | (0.0)  |
| Ventrieular arrhythmia                                 | 0        | (0.0)  | 0           | (0.0)       | 0           | (0.0)       | 1           | (0.1)       | 0      | (0.0)  |
| Ventricular extrasystoles                              | 0        | (0.0)  | 2           | (0.1)       | 0           | (0.0)       | 2           | (0.1)       | 0      | (0.0)  |
| Ventricular fibrillation                               | 0        | (0.0)  | 0           | (0.0)       | 1           | (0.0)       | 2           | (0.1)       | 0      | (0.0)  |

Every subject is counted a single time for each applicable row and column.

A system organ class or specific adverse event appears on this report only if its incidence in one or more of the columns meets the incidence criterion in the report title, after rounding.

MedDRA version 21.0 is applied.

Ineludes the following subjeets on MK-3475 monotherapy: 1) all subjeets in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN012, KN013 HL and PMBCL Cohorts, KN013 non-Hodgkin Lymphoma Cohorts with PD-L1 positive (4B), with relapsed/refractory Follieular Lymphoma (4C) and with relapsed/refractory Diffuse Large B-Cell Lymphoma (4D), PMBCL, KN180, KN199 and KN224, 2) all subjects in KN002 treated with pembrolizumab in the original phase, and 3) all subjects treated with pembrolizumab monotherapy in KN006, KN010, KN024, KN040, KN045, KN054, KN059 and KN061.

<div style=\"page-break-after: always\"></div>

Source: [1Q2018OASE: adaw-iadxl: iadae]

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Immunogenicity

Table 4.5.25: Overview of Impact of ADA on Adverse Events Incidence after Pembrolizumab Combination Therapy, 200 mg Pembrolizumab Q3W + 5 mg Axitinib BID (KN426)

|                                                           | negative   | negative   | non-TE nAB Neg   | non-TE nAB Neg   | non-TEnAB Pos   | non-TEnAB Pos   | TE nAB Neg   | TE nAB Neg   | TE nAB Pos   | TE nAB Pos   |
|-----------------------------------------------------------|------------|------------|------------------|------------------|-----------------|-----------------|--------------|--------------|--------------|--------------|
|                                                           | n          | (%)        | n                | (%)              | n               | (%)             | n            | (%)          | n            | (%)          |
| Subjects in population                                    | 358        |            | 5                |                  | 2               |                 | 21           |              | 3            |              |
| with one or more adverse events                           | 354        | (98.9)     | 5                | (100.0)          | 2               | (100.0)         | 21           | (100.0)      | 3            | (100.0)      |
| with no adverse event                                     | 4          | (1.1)      | 0                | (0.0)            | 0               | (0.0)           | 0            | (0.0)        | 0            | (0.0)        |
| withdrug-relatedfadverse events                           | 349        | (97.5)     | 4                | (80.0)           | 2               | (100.0)         | 21           | (100.0)      | 3            | (100.0)      |
| withtoxicitygrade3-5adverse events                        | 269        | (75.1)     | 4                | (80.0)           | 2               | (100.0)         | 17           | (81.0)       | 3            | (100.0)      |
| with toxicity grade 3-5 drug-related adverse events       | 221        | (61.7)     | 3                | (60.0)           | 2               | (100.0)         | 16           | (76.2)       | 2            | (66.7)       |
| with serious adverse events                               | 147        | (41.1)     | 3                | (60.0)           | 1               | (50.0)          | 10           | (47.6)       | 2            | (66.7)       |
| with serious drug-related adverse events                  | 84         | (23.5)     | 3                | (60.0)           | 1               | (50.0)          | 6            | (28.6)       | 1            | (33.3)       |
| who died                                                  | 13         | (3.6)      | 0                | (0.0)            | 0               | (0.0)           | 0            | (0.0)        | 0            | (0.0)        |
| whodied due to a drug-related adverseevent                | 2          | (0.6)      | 0                | (0.0)            | 0               | (0.0)           | 0            | (0.0)        | 0            | (0.0)        |
| discontinueddrugdueto an adverseevent                     | 100        | (27.9)     | 3                | (60.0)           | 2               | (100.0)         | 11           | (52.4)       | 1            | (33.3)       |
| discontinued drug due toa drug-related adverse event      | 81         | (22.6)     | 1                | (20.0)           | 2               | (100.0)         | 9            | (42.9)       | 1            | (33.3)       |
| discontinueddiugduetoaseriousadverseevent                 | 61         | (17.0)     | 2                | (40.0)           | 1               | (50.0)          | 5            | (23.8)       | 1            | (33.3)       |
| discontinueddrugdue toa seriousdrug-related adverse event | 41         | (11.5)     | 1                | (20.0)           | 1               | (50.0)          | 3            | (14.3)       | 1            | (33.3)       |

Non-serious adverse events up to30days of lastdose andserious adverse eventsupto90days oflast dose areincluded.

DatabaseCutoff Date:24Aug2018.

Subjects with inconclusive ADA results are excluded

## Safety in special populations

## Intrinsic Factors

Age

Table 5.3.5.3.3-rcc1: 122

Adverse Event Summary by Age Category (&lt;65, 65-74, 75-84, &gt;= 85) (ASaT Population)

|                                                                   | KN426 Data for Pembrolizumab + Axitinibl   | KN426 Data for Pembrolizumab + Axitinibl   | KN426 Data for Pembrolizumab + Axitinibl   | KN426 Data for Pembrolizumab + Axitinibl   | KN426 Data for Pembrolizumab + Axitinibl   | KN426 Data for Pembrolizumab + Axitinibl   | KN426 Sumitinibll   | KN426 Sumitinibll   | KN426 Sumitinibll   | KN426 Sumitinibll   | KN426 Sumitinibll   | KN426 Sumitinibll   | KN426 Sumitinibll   |
|-------------------------------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|---------------------|
|                                                                   | 65                                         | 65                                         | 65-74                                      | 65-74                                      | 75-84                                      | 75-84                                      | =85                 | 65                  | 65                  | 65-74               | 75-84 >=85          | 75-84 >=85          |                     |
|                                                                   |                                            | (%)                                        |                                            | (%)                                        | n                                          | (%)                                        | (%)                 | (%)                 |                     | (%)                 | (%)                 | (%)                 |                     |
| Subjects in population                                            | 257                                        |                                            | 136                                        |                                            | 34                                         | 2                                          |                     | 277                 | 111                 |                     | 35                  | 2                   |                     |
| with one or more adverse events                                   | 253                                        | (98.4)                                     | 133                                        | (97.8)                                     | 34 (100.0)                                 | 2                                          | (100.0) 275         | (E66)               | 111                 | (100.0)             | 35 (100.0)          | 2 (100.0)           |                     |
| with no adverse event                                             | 4                                          | (1.6)                                      | 3                                          | (2.2)                                      | 0 (0.0)                                    | 0 (0.0)                                    | 2                   | (0.7)               | 0                   | (0.0)               | 0 (0.0)             | 0 (0.0)             |                     |
| with crnug-related adverse events                                 | 247                                        | (96.1)                                     | 131                                        | (96.3)                                     | 34 (100.0)                                 | 1                                          | (50.0) 270          | (97.5)              | 108                 | (97.3)              | 35 (100.0)          | 2 (100.0)           |                     |
| with toxicity grade 3-5 adverse events                            | 177                                        | (68.9)                                     | 116                                        | (85.3)                                     | 30 (88.2)                                  | 2                                          | (100.0)             | 181 (65.3)          | 89                  | (80.2)              | 28 (80.0)           | 2 (100.0)           |                     |
| with toxicity grade 3-5 drug-related adverse events               | 144                                        | (56.0)                                     | 96                                         | (70.6)                                     | 29 (85.3)                                  |                                            | (50.0)              | 145 (52.3)          | 75                  | (67.6)              | 25 (71.4)           | 2 (100.0)           |                     |
| with serious adverse events                                       | 95                                         | (37.0)                                     | 57                                         | (41.9)                                     | 19 (55.9)                                  |                                            | (100.0)             | 68 (24.5)           | 49                  | (44.1)              | 15 (42.9)           | (50.0)              |                     |
| with serious dnug-related adverse events                          | 56                                         | (21.8)                                     | 35                                         | (25.7)                                     | 10 (29.4)                                  | (50.0)                                     | 26                  | (9.4)               | 24                  | (21.6)              | 9 (25.7)            | (50.0)              |                     |
| who died                                                          | 3                                          | (7D)                                       | 4                                          | (2.9)                                      | 3 (8.8)                                    | 1 (50.0)                                   |                     | 7                   | 6                   | (5.4)               | 2 (5.7)             | 0 (0.0)             |                     |
| who died due to a dnug-related aciverse event                     | 1                                          | (0.4)                                      | 2                                          | (1.5)                                      | 1 (2.9)                                    | 0                                          | (0.0)               | 2                   | (2.5) (0.7) 4       | (3.6)               | 1 (2.9)             | 0 (0.0)             |                     |
| discontinued any drug due to an adverse event                     | 70                                         | (27.2)                                     | 47                                         | (34.6)                                     | 13 (38.2)                                  | 1                                          | (50.0)              | 30                  | (10.8) 22           | (8'61)              | 7 (20.0)            | 0 (0.0)             |                     |
| dliscontinued Pembrolizuab                                        | 49                                         | (19.1)                                     | 28 (20.6)                                  |                                            | 11 (32.4)                                  | 1 (50.0)                                   |                     | 0 (0.0)             | 0                   | (0.0)               | 0 (0.0)             | 0 (0.0)             |                     |
| discontinued all regimen components                               | 16                                         | (6.2)                                      | 11                                         | (8.1)                                      | 5 (14.7)                                   | 1                                          | (50.0)              | 30 (10.8)           | 22                  | (19.8)              | 7 (20.0)            | 0 (0.0)             |                     |
| discontinued any drug due to a dnug-related adverse event         | 63                                         | (24.5)                                     | 37                                         | (27.2)                                     | 11 (32.4)                                  | 0 (0.0)                                    |                     | 22 (6L)             | 15                  | (13.5)              | 6 (17.1)            | 0 (0.0)             |                     |
| discontinuedPembrolizumab                                         | 48                                         | (18.7)                                     | 23                                         | (16.9)                                     | 9 (26.5)                                   | 0 (0.0)                                    | 0                   | (0.0)               | 0                   | (0.0)               | 0 (0.0)             | 0 (0.0)             |                     |
| dliscontinued all regimen components                              | 16                                         | (6.2)                                      | 8                                          | (5.9)                                      | 3 (8.8)                                    | 0 (0.0)                                    | 22                  | (6L)                | 15                  | (13.5)              | 6 (17.1)            | 0 (0.0)             |                     |
| discontinued any drug due to a serious adverse event              | 35                                         | (13.6)                                     | 30                                         | (22.1)                                     | 7 (20.6)                                   | (50.0)                                     | 23                  | (8.3)               | 14                  | (12.0)              | 5 (14.3)            | 0 (0.0)             |                     |
| discontinuedPembrolizumab                                         | 24                                         | (9.3)                                      | 18                                         | (13.2)                                     | 7 (20.6)                                   | (50.0)                                     | 0                   | (0.0)               | 0                   | (0.0)               | 0 (0.0)             | 0 (0.0)             |                     |
| dliscontinued all regimen components                              | 12                                         | (4.7)                                      | 9                                          | (6.6)                                      | 3 (8.8)                                    | (50.0)                                     | 23                  | (8.3)               | 14                  | (12.0)              | 5 (14.3)            | 0 (0.0)             |                     |
| discontinued any drug due to a serious dnug-related adverse event | 29                                         | (11.3)                                     | 19                                         | (14.0)                                     | 5 (14.7)                                   | 0 (0.0)                                    | 16                  | (5.8)               | 8                   | (7L)                | 4 (11.4)            | 0 (0.0)             |                     |
| discontinued Pembrolizumab                                        | 24                                         | (9.3)                                      | 13                                         | (9:6)                                      | 5 (14.7)                                   | 0 (0.0)                                    | 0                   | (0.0)               | 0                   | (0.0)               | 0 (0.0)             | 0 (0.0)             |                     |

<div style=\"page-break-after: always\"></div>

Souce:[ISS:adam-adsl; adae]

<!-- image -->

Table 5.3.5.3.3-rcc1: 123

## Adverse Event Summary by Age Category (&lt;65, 65-74, 75-84, &gt;= 85) (ASaT Population)

|                                                                   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Cumulative Rumning Safety Dataset for Pembrolizmab Monotherapy   | Cumulative Rumning Safety Dataset for Pembrolizmab Monotherapy   | Cumulative Rumning Safety Dataset for Pembrolizmab Monotherapy   | Cumulative Rumning Safety Dataset for Pembrolizmab Monotherapy   | Cumulative Rumning Safety Dataset for Pembrolizmab Monotherapy   | Cumulative Rumning Safety Dataset for Pembrolizmab Monotherapy   | Cumulative Rumning Safety Dataset for Pembrolizmab Monotherapy   | Cumulative Rumning Safety Dataset for Pembrolizmab Monotherapy   |
|-------------------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|
|                                                                   | 65                                                       | 65                                                       | 65-74                                                    | 65-74                                                    | 75-84                                                    | 75-84                                                    | =85                                                      | <65                                                              | <65                                                              | 65-74                                                            | 65-74                                                            | 75-84                                                            | 75-84                                                            | =85                                                              | =85                                                              |
|                                                                   |                                                          | (%)                                                      | n                                                        | (%)                                                      | n (%6)                                                   | n (%6)                                                   | (%)                                                      | (%6)                                                             | (%6)                                                             | (%)                                                              | (%)                                                              | n (%)                                                            | n (%)                                                            | n (%)                                                            | n (%)                                                            |
| Subjects in population                                            | 2,453                                                    |                                                          | 1,333                                                    |                                                          | 563                                                      |                                                          | 90                                                       | 3,709                                                            |                                                                  | 1,897                                                            |                                                                  | 722                                                              |                                                                  | 108                                                              |                                                                  |
| with one or more adverse events                                   | 2,381                                                    | (97.1)                                                   | 1,292                                                    | (96.9)                                                   | 551                                                      | (97.9)                                                   | 89 (98.9)                                                | 3,579                                                            | (96.5)                                                           | 1,836                                                            | (96.8)                                                           | 703                                                              | (97.4)                                                           | 107                                                              | (99.1)                                                           |
| with no adverse event                                             | 72                                                       | (2.9)                                                    | 41                                                       | (3.1)                                                    | 12                                                       | (2.1)                                                    | 1 (1.1)                                                  | 130                                                              | (3.5)                                                            | 61                                                               | (3.2)                                                            | 19                                                               | (2.0)                                                            | 1                                                                | (0.9)                                                            |
| with drug-related adverse events                                  | 1,716                                                    | (70.0)                                                   | 951                                                      | (71.3)                                                   | 405                                                      | (71.9)                                                   | 68 (75.6)                                                | 2,570                                                            | (69.3)                                                           | 1,351                                                            | (7IL)                                                            | 508                                                              | (70.4)                                                           | 83                                                               | (76.9)                                                           |
| with toxicity grade 3-5 adverse events                            | 1,111                                                    | (45.3)                                                   | 681                                                      | (51.1)                                                   | 307                                                      | (54.5)                                                   | 54 (60.0)                                                | 1,669                                                            | (45.0)                                                           | 964                                                              | (50.8)                                                           | 410                                                              | (56.8)                                                           | 64                                                               | (59.3)                                                           |
| with toxicity grade 3-5 dnug-related adverse events               | 318                                                      | (13.0)                                                   | 227                                                      | (17.0)                                                   | 100                                                      | (17.8)                                                   | 15 (16.7)                                                | 509                                                              | (13.7)                                                           | 349                                                              | (18.4)                                                           | 139                                                              | (19.3)                                                           | 21                                                               | (19.4)                                                           |
| with serious adverse events                                       | 865                                                      | (35.3)                                                   | 561                                                      | (42.1)                                                   | 261                                                      | (46.4)                                                   | 42 (46.7)                                                | 1,301                                                            | (35.1)                                                           | 780                                                              | (41.1)                                                           | 339                                                              | (47.0)                                                           | 52                                                               | (48.1)                                                           |
| with serious dnug-related adverse events                          | 228                                                      | (9.3)                                                    | 156                                                      | (11.7)                                                   | 71                                                       | (12.6)                                                   | 9 (10.0)                                                 | 370                                                              | (10.0)                                                           | 243                                                              | (12.8)                                                           | 6                                                                | (12.9)                                                           | 14                                                               | (13.0)                                                           |
| who died                                                          | 95                                                       | (3.9)                                                    | 70                                                       | (5.3)                                                    | 38                                                       | (6.7)                                                    | 8 (8.9)                                                  | 149                                                              | (4.0)                                                            | 111                                                              | (5.9)                                                            | 59                                                               | (8.2)                                                            | 10                                                               | (9.3)                                                            |
| who died due toa cinug-related adverse event                      | 11                                                       | (0.4)                                                    | 7                                                        | (0.5)                                                    | 3                                                        | (0.5)                                                    | 1 (1.1)                                                  | 20                                                               | (0.5)                                                            | 14                                                               | (0.7)                                                            | 6                                                                | (0.8)                                                            | 1                                                                | (0.9)                                                            |
| discontinued any dnug due to an adiverse event                    | 255                                                      | (10.4)                                                   | 176                                                      | (13.2)                                                   | 99                                                       | (17.6)                                                   | 8 (8.9)                                                  | 415                                                              | (11.2)                                                           | 263                                                              | (13.9)                                                           | 137                                                              | (19.0)                                                           | 13                                                               | (12.0)                                                           |
| discontinued Pembrolizuab                                         | 255                                                      | (10.4)                                                   | 176                                                      | (13.2)                                                   | 99                                                       | (17.6)                                                   | 8 (8.9)                                                  | 415                                                              | (11.2)                                                           | 263                                                              | (13.9)                                                           | 137                                                              | (0'61)                                                           | 13                                                               | (12.0)                                                           |
| discontimed allregimen components                                 | 255                                                      | (10.4)                                                   | 176                                                      | (13.2)                                                   | 99                                                       | (17.6)                                                   | 8 (8.9)                                                  | 415                                                              | (11.2)                                                           | 263                                                              | (13.9)                                                           | 137                                                              | (19.0)                                                           | 13                                                               | (12.0)                                                           |
| discontimued any dnug due to a dnug-related adverse event         | 114                                                      | (4.6)                                                    | 93                                                       | (0'L)                                                    | 49                                                       | (8.7)                                                    | 3 (3.3)                                                  | 210                                                              | (5.7)                                                            | 142                                                              | (7.5)                                                            | 64                                                               | (8.9)                                                            | 7                                                                | (6.5)                                                            |
| discontinued Pembrolizumab                                        | 114                                                      | (4.6)                                                    | 93                                                       | (0L)                                                     | 49                                                       | (8.7)                                                    | 3 (3.3)                                                  | 210                                                              | (5.7)                                                            | 142                                                              | (7.5)                                                            | 64                                                               | (8.9)                                                            | 7                                                                | (6.5)                                                            |
| discontimued allregimen components                                | 114                                                      | (4.6)                                                    | 93                                                       | (0'L)                                                    | 49                                                       | (8.7)                                                    | 3 (3.3)                                                  | 210                                                              | (5.7)                                                            | 142                                                              | (7.5)                                                            | 64                                                               | (8.9)                                                            | 7                                                                | (6.5)                                                            |
| discontimued any drug dne to a serious adverse event              | 198                                                      | (8.1)                                                    | 127                                                      | (9.5)                                                    | 76                                                       | (13.5)                                                   | 6 (6.7)                                                  | 303                                                              | (8.2)                                                            | 188                                                              | (9.9)                                                            | 107                                                              | (14.8)                                                           | 10                                                               | (9.3)                                                            |
| discontinued Pembrolizuab                                         | 198                                                      | (8.1)                                                    | 127                                                      | (56)                                                     | 76                                                       | (13.5)                                                   | 6 (6.7)                                                  | 303                                                              | (8.2)                                                            | 188                                                              | (6'6)                                                            | 107                                                              | (14.8)                                                           | 10                                                               | (9.3)                                                            |
| discontimuedallregimencomponents                                  | 198                                                      | (8.1)                                                    | 127                                                      | (9.5)                                                    | 76                                                       | (13.5)                                                   | 6 (6.7)                                                  | 303                                                              | (8.2)                                                            | 188                                                              | (9.9)                                                            | 107                                                              | (14.8)                                                           | 10                                                               | (E'6)                                                            |
| discontimued any dnug che to a serious drug-related adverse event | 79                                                       | (3.2)                                                    | 59                                                       | (4.4)                                                    | 33                                                       | (5.9)                                                    | 1 (1.1)                                                  | 128                                                              | (3.5)                                                            | 87                                                               | (4.0)                                                            | 42                                                               | (5.8)                                                            | 4                                                                | (3.7)                                                            |
| discontinued Pembrolizmmab                                        | 79                                                       | (3.2)                                                    | 59                                                       | (4.4)                                                    | 33                                                       | (5.9)                                                    | 1 (1.1)                                                  | 128                                                              | (3.5)                                                            | 87                                                               | (4.0)                                                            | 42                                                               | (5.8)                                                            | 4                                                                | (3.7)                                                            |

<div style=\"page-break-after: always\"></div>

## Adverse Event Summary by Age Category (&lt;65, 65-74, 75-84, &gt;= 85) (ASaT Population)

|                                     | Reference Safety Dataset for Pembrolizumab Monotherapy   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Reference Safety Dataset for Pembrolizumab Monotherapy   | Cuulative Rumming SafetyDataset for Pembrolizumab Monotherapy   | Cuulative Rumming SafetyDataset for Pembrolizumab Monotherapy   | Cuulative Rumming SafetyDataset for Pembrolizumab Monotherapy   | Cuulative Rumming SafetyDataset for Pembrolizumab Monotherapy   |
|-------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|
|                                     | ≤65                                                      | 65-74                                                    | 75-84                                                    | >=85                                                     | ≤65                                                             | 65-74                                                           | 75-84                                                           | >=85                                                            |
|                                     | (%6)                                                     | (%6)                                                     | (%)                                                      | (%)                                                      | (%) (3.5)                                                       | (96)                                                            | (%6)                                                            | n (%6)                                                          |
| discoutinued all regimen components | 79 (3.2)                                                 | 59 (4.4)                                                 | 33 (5.9)                                                 | 1 (1.1)                                                  | 128                                                             | 87 (4.6)                                                        | 42 (5.8)                                                        | 4 (3.7)                                                         |

Souce: [ISS: adam-adsl; adke]

<!-- image -->

Table 4.5.28: Adverse Event Summary for Elderly Subjects by Age

|                                      | Age (Years)              | Age (Years)              | Age (Years)              | Age (Years)              | Age (Years)              | Age (Years)              | Age (Years)              | Age (Years)              | Age (Years)   | Age (Years)   | Age (Years)   | Age (Years)   | Age (Years)   | Age (Years)   | Age (Years)   | Age (Years)   |
|--------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|
|                                      | Pembrolizumab + Axitinib | Pembrolizumab + Axitinib | Pembrolizumab + Axitinib | Pembrolizumab + Axitinib | Pembrolizumab + Axitinib | Pembrolizumab + Axitinib | Pembrolizumab + Axitinib | Pembrolizumab + Axitinib | Sunitinib     | Sunitinib     | Sunitinib     | Sunitinib     | Sunitinib     | Sunitinib     | Sunitinib     | Sunitinib     |
|                                      | <65                      | <65                      | 65-74                    | 65-74                    | 75-84                    | 75-84                    | ≥85                      | ≥85                      | <65           | <65           | 65-74         | 65-74         | 75-84         | 75-84         | ≥85           | ≥85           |
|                                      | n                        | (%)                      | n                        | (%)                      | n                        | (%)                      | n                        | (%)                      | n             | (%)           | n             | (%)           | n             | (%)           | n             | (%)           |
| Subjects in Population               | 257                      |                          | 136                      |                          | 34                       |                          | 2                        |                          | 277           |               | 111           |               | 35            |               | 2             |               |
| with one or more adverse             | 253                      | (98.4)                   | 133                      | (97.8)                   | 34                       | (100.0)                  | 2                        | (100.0)                  | 275           | (99.3)        | 111           | (100.0)       | 35            | (100.0)       | 2             | (100.0)       |
| events                               |                          |                          |                          |                          |                          |                          |                          |                          |               |               |               |               |               |               |               |               |
| who died                             | 3                        | (1.2)                    | 4                        | (2.9)                    | 3                        | (8.8)                    | 1                        | (50.0)                   | 7             | (2.5)         | 6             | (5.4)         | 2             | (5.7)         | 0             | (0.0)         |
| with serious adverse events          | 95                       | (37.0)                   | 57                       | (41.9)                   | 19                       | (55.9)                   | 2                        | (100.0)                  | 68            | (24.5)        | 49            | (44.1)        | 15            | (42.9)        | 1             | (50.0)        |
| discontinued due to an adverse event | 70                       | (27.2)                   | 47                       | (34.6)                   | 13                       | (38.2)                   | 1                        | (50.0)                   | 30            | (10.8)        | 22            | (19.8)        | 7             | (20.0)        | 0             | (0.0)         |
| CNS                                  | 72                       | (28.0)                   | 45                       | (33.1)                   | 19                       | (55.9)                   | 1                        | (50.0)                   | 21            | (7.6)         | 7             | (6.3)         | 3             | (8.6)         | 0             | (0.0)         |
| (confusion/extrapyramidal)           |                          |                          |                          |                          |                          |                          |                          |                          |               |               |               |               |               |               |               |               |
| AE related to falling                | 16                       | (6.2)                    | 14                       | (10.3)                   | 7                        | (20.6)                   | 0                        | (0.0)                    | 16            | (5.8)         | 10            | (9.0)         | 4             | (11.4)        | 1             | (50.0)        |
| CV events                            | 127                      | (49.4)                   | 79                       | (58.1)                   | 21                       | (61.8)                   | 1                        | (50.0)                   | 142           | (51.3)        | 71            | (64.0)        | 17            | (48.6)        | 0             | (0.0)         |
| Cerebrovascular events               | 8                        | (3.1)                    | 2                        | (1.5)                    | 0                        | (0.0)                    | 0                        | (0.0)                    | 4             | (1.4)         | 7             | (6.3)         | 1             | (2.9)         | 1             | (50.0)        |
| Infections                           | 105                      | (40.9)                   | 64                       | (47.1)                   | 21                       | (61.8)                   | 2                        | (100.0)                  | 108           | (39.0)        | 48            | (43.2)        | 16            | (45.7)        | 1             | (50.0)        |

AEs were followed 30 after last dose of study treatment; SAEs were followed 90 after last dose of study treatment.

MedDRA preferred terms \"Neoplasm progression\", \"Malignant neoplasm progression\" and \"Disease progression\" not related to the drug are excluded. DatabaseCutoffDate:24Aug2018.

<div style=\"page-break-after: always\"></div>

## Gender

Table 5.3.5.3.3-rcc1: 124

## Adverse Event Summary by Gender (ASaT Population)

|                                                                   | KN426 Data for Pembrolizumab + Axitinibl   | KN426 Data for Pembrolizumab + Axitinibl   | KN426 Data for Pembrolizumab + Axitinibl   | KN426 Data for Pembrolizumab + Axitinibl   | KN426 Sumitinibl   | KN426 Sumitinibl   | KN426 Sumitinibl   | KN426 Sumitinibl   | Reference SafetyDatasetfor Pembrolizumab Monotherapy   | Reference SafetyDatasetfor Pembrolizumab Monotherapy   | Reference SafetyDatasetfor Pembrolizumab Monotherapy   | Reference SafetyDatasetfor Pembrolizumab Monotherapy   | CumulativeRumningSafetyDataset for PembrolizuabMonotherapy   | CumulativeRumningSafetyDataset for PembrolizuabMonotherapy   | CumulativeRumningSafetyDataset for PembrolizuabMonotherapy   | CumulativeRumningSafetyDataset for PembrolizuabMonotherapy   |
|-------------------------------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------|--------------------|--------------------|--------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|
|                                                                   | M                                          | M                                          | F                                          | F                                          | M                  | M                  | F                  | F                  | M                                                      | M                                                      | F                                                      | F                                                      | M                                                            | M                                                            | F                                                            | F                                                            |
|                                                                   |                                            | (%)                                        |                                            | (%)                                        | n                  | (%)                |                    | (%)                |                                                        | (%)                                                    |                                                        | (%)                                                    |                                                              | (%)                                                          |                                                              | (%)                                                          |
| Subjects in population                                            | 306                                        |                                            | 123                                        |                                            | 318                |                    | 107                |                    | 2,869                                                  |                                                        | 1,570                                                  |                                                        | 4,159                                                        |                                                              | 2,277                                                        |                                                              |
| with one or more adverse events                                   | 301                                        | (98.4)                                     | 121                                        | (98.4)                                     | 316                | (99.4)             | 107                | (100.0)            | 2,788                                                  | (97.2)                                                 | 1,525                                                  | (97.1)                                                 | 4,020                                                        | (96.7)                                                       | 2,205                                                        | (96.8)                                                       |
| with no aciverse event                                            | 5                                          | (91)                                       | 2                                          | (1.6)                                      | 2                  | (0.0)              | 0                  | (0.0)              | 81                                                     | (2.8)                                                  | 45                                                     | (2.9)                                                  | 139                                                          | (3.3)                                                        | 72                                                           | (3.2)                                                        |
| with drug-relatedadverse events                                   | 293                                        | (95.8)                                     | 120                                        | (97.6)                                     | 309                | (97.2)             | 106                | (99.1)             | 2,030                                                  | (70.8)                                                 | 1,110                                                  | (70.7)                                                 | 2.903                                                        | (69.8)                                                       | 1,609                                                        | (70.7)                                                       |
| with toxicity grade 3-5 adverse events                            | 223                                        | (72.9)                                     | 102                                        | (82.9)                                     | 210                | (66.0)             | 90                 | (84.1)             | 1,414                                                  | (49.3)                                                 | 739                                                    | (47.1)                                                 | 2,035                                                        | (48.9)                                                       | 1,072                                                        | (47.1)                                                       |
| with toxicity grade 3-5 drug-related adverse events               | 182                                        | (59.5)                                     | 88                                         | (71.5)                                     | 166                | (52.2)             | 81                 | (75.7)             | 446                                                    | (15.5)                                                 | 214                                                    | (13.6)                                                 | 696                                                          | (16.7)                                                       | 322                                                          | (14.1)                                                       |
| with serious adverse events                                       | 128                                        | (41.8)                                     | 45                                         | (36.6)                                     | 103                | (32.4)             | 30                 | (28.0)             | 1,152                                                  | (40.2)                                                 | 577                                                    | (36.8)                                                 | 1,635                                                        | (39.3)                                                       | 837                                                          | (36.8)                                                       |
| with serious drug-related aciverse events                         | 73                                         | (23.9)                                     | 29                                         | (23.6)                                     | 43                 | (13.5)             | 17                 | (15.9)             | 316                                                    | (11.0)                                                 | 148                                                    | (9.4)                                                  | 493                                                          | (11.9)                                                       | 227                                                          | (10.0)                                                       |
| who died                                                          | 10                                         | (3.3)                                      | 1                                          | (0.8)                                      | 13                 | (4.1)              | 2                  | (1.9)              | 146                                                    | (5.1)                                                  | 65                                                     | (4.1)                                                  | 235                                                          | (5.7)                                                        | t6                                                           | (4.1)                                                        |
| who died due to a dnug-related adverse event                      | 3                                          | (1.0)                                      | 1                                          | (0.8)                                      | 6                  | (61)               | 1                  | (0.9)              | 15                                                     | (0.5)                                                  | 7                                                      | (0.4)                                                  | 28                                                           | (0.7)                                                        | 13                                                           | (0.6)                                                        |
| discontinued any dnug dueto an adverse event                      | 92                                         | (30.1)                                     | 39                                         | (31.7)                                     | 41                 | (12.9)             | 18                 | (16.8)             | 352                                                    | (12.3)                                                 | 186                                                    | (11.8)                                                 | 551                                                          | (13.2)                                                       | 277                                                          | (771)                                                        |
| dliscontinued Pembrolizmab                                        | 60                                         | (19.6)                                     | 29                                         | (23.6)                                     | 0                  | (0.0)              | 0                  | (0.0)              | 352                                                    | (12.3)                                                 | 186                                                    | (11.8)                                                 | 551                                                          | (13.2)                                                       | 277                                                          | (12.2)                                                       |
| discontinued all regimen components                               | 23                                         | (7.5)                                      | 10                                         | (8.1)                                      | 41                 | (12.9)             | 18                 | (16.8)             | 352                                                    | (12.3)                                                 | 186                                                    | (11.8)                                                 | 551                                                          | (13.2)                                                       | 277                                                          | (12.2)                                                       |
| discontinued any drug due to a dnug-related aciverse event        | 78                                         | (25.5)                                     | 33                                         | (26.8)                                     | 29                 | (9.1)              | 14                 | (13.1)             | 176                                                    | (6.1)                                                  | 83                                                     | (5.3)                                                  | 286                                                          | (6.9)                                                        | 137                                                          | (6.0)                                                        |
| dliscontinued Pembrolizmab                                        | 56                                         | (18.3)                                     | 24                                         | (19.5)                                     | 0                  | (0.0)              | 0                  | (0.0)              | 176                                                    | (6.1)                                                  | 83                                                     | (5.3)                                                  | 286                                                          | (6.9)                                                        | 137                                                          | (6.0)                                                        |
| discontinued allregimen components                                | 19                                         | (6.2)                                      | 8                                          | (6.5)                                      | 29                 | (9.1)              | 14                 | (13.1)             | 176                                                    | (6.1)                                                  | 83                                                     | (5.3)                                                  | 286                                                          | (6.9)                                                        | 137                                                          | (6.0)                                                        |
| discontimued any drug due to a serious adiverse event             | 53                                         | (17.3)                                     | 20                                         | (16.3)                                     | 31                 | (9.7)              | 11                 | (10.3)             | 271                                                    | (9.4)                                                  | 136                                                    | (8.7)                                                  | 410                                                          | (9.9)                                                        | 198                                                          | (8.7)                                                        |
| dliscontinued Pembrolizmab                                        | 37                                         | (12.1)                                     | 13                                         | (10.6)                                     | 0                  | (0.0)              | 0                  | (0.0)              | 271                                                    | (9.4)                                                  | 136                                                    | (8.7)                                                  | 410                                                          | (6'6)                                                        | 198                                                          | (8.7)                                                        |
| discontinued allregimen components                                | 20                                         | (6.5)                                      | 5                                          | (4.1)                                      | 31                 | (9.7)              | 11                 | (10.3)             | 271                                                    | (9.4)                                                  | 136                                                    | (8.7)                                                  | 410                                                          | (66)                                                         | 198                                                          | (8.7)                                                        |
| discontimued any drug due to a serious drug-related adverse event | 39                                         | (12.7)                                     | 14                                         | (11.4)                                     | 21                 | (6.0)              | 7                  | (6.5)              | 119                                                    | (4.1)                                                  | 53                                                     | (3.4)                                                  | 181                                                          | (4.4)                                                        | 80                                                           | (3.5)                                                        |
| dliscontinued Pembrolizwab                                        | 33                                         | (10.8)                                     | 9                                          | (7.3)                                      | 0                  | (0.0)              | 0                  | (0.0)              | 119                                                    | (4.1)                                                  | 53                                                     | (3.4)                                                  | 181                                                          | (4.4)                                                        | 80                                                           | (3.5)                                                        |

discoutiuued allregimen components

16

(5.2)

Determined by the investigator to be related to the dnug.

3

(2.4)

21

(6.6)

7

(6.5)

119

(4.1)

Non-serious adverse events up to 30 days following the last dose and serious adverse events up to 90 days following the last dose are included.

IIncludes all subjects who received at least one dose of Pembrolizumab and/or Axitinib in KN426.

Includes allsubjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 Cohorts B and B2 (HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN045, KN052, KN055 and KN087.

' Includes allsubjects who received at least one dose of Sumitinib in KN426.

Includes all subjects who received atleast one dose ofpembrolizumab in KN001 Part B1, B2,B3,D, C,F1,F2,F3, KN002(original phase),KN006,KN010, KN012 Cohorts B and B2 (HNSCC), Cohort C (Urothelial Tract Cancer) and Cohort D (GastricCancer),KN013 Cohort3(Hodgkin Lymphoma) and Cohort 4A (MLBCL),KN017,KN024,KN028 Cohort B4,KN040,KN042, KN045,KN052,KN054,KN055,KN059 Cohort 1,KN087,KN158,KN164CohortA,KN170,KN224 andKN427 Cohort A.

Database cutoff date forMelanoma (KN001-Melanoma:18APR2014,KN002: 28FEB2015,KN006:03MAR2015,KN054:02OCT2017)

Database cutoff date for Lumg (KN001-NSCLC: 23IAN2015, KN010: 30SEP2015,KN024: 10JUL2017, KN042: 26FEB2018)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN055: 22APR2016)

Database cutoff date forGastric (KN012-Gastric:26APR2016,KN059-Cohort 1: 21APR2017)

Database cutoff date for cHL(KN013-Cohort 3: 27SEP2016,KN087:25SEP2016)

Database cutoff date for Bladder (KN012-Urothelial: 01SEP2015,KN045: 26OCT2017, KN052: 09MAR2017)

Database cutoff date for Colorectal (KN164-Cohort A: 03AUG2016)

Database cutoff date for MLBCL (KN013-Cohort 4A: 04AUG2017,KN170: 19JAN2018)

Database cutoff date for Cervical (KN028-Cohort B4: 20FEB2017, KN158:15JAN2018)

Database cutoff date for HCC (KN224:15MAY2018)

Database cutoff date for RCC (KN426: 24AUG2018,KN427-Cohort A: 07SEP2018)

Database cutoff dateforMCC(KN017:06FEB2018)

Souce:[ISS: adam-adsl; adae]

53

(3.4)

181

(4.4)

80

(3.5)

<div style=\"page-break-after: always\"></div>

## Table 1 Adverse Event Summary by KPS Range (ASaT Population)

|                                                               | Pembrolizumab + Axitinib   | Pembrolizumab + Axitinib   | Pembrolizumab + Axitinib   | Pembrolizumab + Axitinib   | Sunitinib   | Sunitinib   | Sunitinib   | Sunitinib   |
|---------------------------------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|-------------|-------------|-------------|-------------|
|                                                               | 90/100                     | 90/100                     | 70/80                      | 70/80                      | 90/100      | 90/100      | 70/80       | 70/80       |
|                                                               | n                          | (%)                        | n                          | (%)                        | n           | (%)         | n           | (%)         |
| Subjects in population                                        | 345                        |                            | 84                         |                            | 339         |             | 86          |             |
| with one or more adverse events                               | 340                        | (98.6)                     | 82                         | (97.6)                     | 337         | (99.4)      | 86          | (100.0)     |
| with no adverse event                                         | 5                          | (1.4)                      | 2                          | (2.4)                      | 2           | (0.6)       | 0           | (0.0)       |
| with drug-related † adverse events                            | 336                        | (97.4)                     | 77                         | (91.7)                     | 332         | (97.9)      | 83          | (96.5)      |
| with toxicity grade 3-5 adverse events                        | 263                        | (76.2)                     | 62                         | (73.8)                     | 230         | (67.8)      | 70          | (81.4)      |
| with toxicity grade 3-5 drug-related adverse events           | 223                        | (64.6)                     | 47                         | (56.0)                     | 192         | (56.6)      | 55          | (64.0)      |
| with serious adverse events                                   | 136                        | (39.4)                     | 37                         | (44.0)                     | 94          | (27.7)      | 39          | (45.3)      |
| with serious drug-related adverse events                      | 86                         | (24.9)                     | 16                         | (19.0)                     | 42          | (12.4)      | 18          | (20.9)      |
| who died                                                      | 9                          | (2.6)                      | 2                          | (2.4)                      | 6           | (1.8)       | 9           | (10.5)      |
| who died due to a drug-related adverse event                  | 3                          | (0.9)                      | 1                          | (1.2)                      | 2           | (0.6)       | 5           | (5.8)       |
| discontinued drug due to an adverse event                     | 106                        | (30.7)                     | 25                         | (29.8)                     | 40          | (11.8)      | 19          | (22.1)      |
| discontinued drug due to a drug-related adverse event         | 92                         | (26.7)                     | 19                         | (22.6)                     | 29          | (8.6)       | 14          | (16.3)      |
| discontinued drug due to a serious adverse event              | 59                         | (17.1)                     | 14                         | (16.7)                     | 26          | (7.7)       | 16          | (18.6)      |
| discontinued drug due to a serious drug-related adverse event | 44                         | (12.8)                     | 9                          | (10.7)                     | 16          | (4.7)       | 12          | (14.0)      |

† Determined by the investigator to be related to the drug.

Grades are based on NCI CTCAE version 4.0.

Non-serious adverse events up to 30 days of last dose and serious adverse events up to 90 days of last dose are included.

MedDRA preferred terms \"Neoplasm Progression\", \"Malignant Neoplasm Progression\" and \"Disease Progression\" not related to the drug are excluded.

Database Cutoff Date: 24Aug2018.

(100.0)

(0.0)

(96.5)

(81.4)

(64.0)

(45.3)

(20.9)

(10.5)

(5.8)

(22.1)

(16.3)

(18.6)

(14.0)

<div style=\"page-break-after: always\"></div>

## Extrinsic Factors

Region

Table 5.3.5.3.3-rcc1: 126

Adverse Event Summary by Region (ASaT Population)

|                                                                  | KN426DataforPembrolizumab+ Axiinibl   | KN426DataforPembrolizumab+ Axiinibl   | KN426DataforPembrolizumab+ Axiinibl   | KN426DataforPembrolizumab+ Axiinibl   | KN426 Sumitinibl!   | KN426 Sumitinibl!   | KN426 Sumitinibl!   | KN426 Sumitinibl!   | Reference Safety Dataset for PembrolizmabMonotherapy   | Reference Safety Dataset for PembrolizmabMonotherapy   | Reference Safety Dataset for PembrolizmabMonotherapy   | Reference Safety Dataset for PembrolizmabMonotherapy   | CuumulativeRumningSafetyDataset forPembrolizumabMonotherapy   | CuumulativeRumningSafetyDataset forPembrolizumabMonotherapy   | CuumulativeRumningSafetyDataset forPembrolizumabMonotherapy   | CuumulativeRumningSafetyDataset forPembrolizumabMonotherapy   |
|------------------------------------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------|---------------------|---------------------|---------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
|                                                                  | EU                                    | EU                                    | Ex-EU                                 | Ex-EU                                 | EU                  | EU                  | Ex-EU               | Ex-EU               | EU                                                     | EU                                                     | Ex-EU                                                  | Ex-EU                                                  | EU                                                            | EU                                                            | Ex-EU                                                         | Ex-EU                                                         |
|                                                                  | n (%6)                                | n (%6)                                | (%)                                   | (%)                                   | (%6)                | (%6)                | (%)                 | (%)                 | (%6)                                                   | (%6)                                                   | (%)                                                    | (%)                                                    | n (%)                                                         | n (%)                                                         | (%)                                                           | (%)                                                           |
| Subjects in population                                           | 161                                   |                                       | 268                                   |                                       | 154                 |                     | 271                 |                     | 1,537                                                  |                                                        | 2,902                                                  |                                                        | 2,298                                                         |                                                               | 4,138                                                         |                                                               |
| with one or more adverse events                                  | 156                                   | (96.9)                                | 266                                   | (99.3)                                | 154                 | (100.0)             | 269                 | (99.3)              | 1,480                                                  | (96.3)                                                 | 2,833                                                  | (97.6)                                                 | 2,211                                                         | (96.2)                                                        | 4,014                                                         | (97.0)                                                        |
| with no adverse event                                            | 5                                     | (3.1)                                 | 2                                     | (0.7)                                 | 0                   | (0.0)               | 2                   | (0.7)               | 57                                                     | (3.7)                                                  | 69                                                     | (2.4)                                                  | 87                                                            | (3.8)                                                         | 124                                                           | (3.0)                                                         |
| with dnug-related adverse events                                 | 152                                   | (94.4)                                | 261                                   | (97.4)                                | 151                 | (98.1)              | 264                 | (97.4)              | 1,048                                                  | (68.2)                                                 | 2,092                                                  | (72.1)                                                 | 1,583                                                         | (68.9)                                                        | 2,929                                                         | (70.8)                                                        |
| with toxicity grade 3-5 adverse events                           | 126                                   | (78.3)                                | 199                                   | (74.3)                                | 115                 | (74.7)              | 185                 | (68.3)              | 732                                                    | (47.6)                                                 | 1,421                                                  | (49.0)                                                 | 1,077                                                         | (46.9)                                                        | 2,030                                                         | (49.1)                                                        |
| with toxicity grade 3-5 dnug-related adverse events              | 104                                   | (64.6)                                | 166                                   | (61.9)                                | 89                  | (57.8)              | 158                 | (58.3)              | 235                                                    | (15.3)                                                 | 425                                                    | (14.6)                                                 | 364                                                           | (15.8)                                                        | 654                                                           | (15.8)                                                        |
| with serious adverse events                                      | 77                                    | (47.8)                                | 96                                    | (35.8)                                | 60                  | (39.0)              | 73                  | (26.9)              | 618                                                    | (40.2)                                                 | 1,111                                                  | (38.3)                                                 | 885                                                           | (38.5)                                                        | 1,587                                                         | (38.4)                                                        |
| with serious drug-related adverse events                         | 41                                    | (25.5)                                | 61                                    | (22.8)                                | 31                  | (20.1)              | 29                  | (10.7)              | 181                                                    | (11.8)                                                 | 283                                                    | (9.8)                                                  | 273                                                           | (11.9)                                                        | 447                                                           | (10.8)                                                        |
| who died                                                         | 7                                     | (4.3)                                 | 4                                     | (1.5)                                 | 7                   | (4.5)               | 8                   | (3.0)               | 80                                                     | (5.2)                                                  | 131                                                    | (4.5)                                                  | 114                                                           | (5.0)                                                         | 215                                                           | (5.2)                                                         |
| who died due to a dnug-related adverse event                     | 1                                     | (0.6)                                 | 3                                     | (1.1)                                 | 4                   | (2.0)               | 3                   | (1.1)               | 10                                                     | (0.7)                                                  | 12                                                     | (0.4)                                                  | 14                                                            | (0.6)                                                         | 27                                                            | (0.7)                                                         |
| discontinued any dnug due to an adverse event                    | 59                                    | (36.6)                                | 72                                    | (26.9)                                | 27                  | (17.5)              | 32                  | (11.8)              | 178                                                    | (11.6)                                                 | 360                                                    | (12.4)                                                 | 288                                                           | (12.5)                                                        | 540                                                           | (13.0)                                                        |
| discoutinued Pembrolizwab                                        | 43                                    | (26.7)                                | 46                                    | (17.2)                                | 0                   | (0.0)               | 0                   | (0.0)               | 178                                                    | (11.6)                                                 | 360                                                    | (12.4)                                                 | 288                                                           | (12.5)                                                        | 540                                                           | (13.0)                                                        |
| discontinued all regimen components                              | 18                                    | (11.2)                                | 15                                    | (5.0)                                 | 27                  | (17.5)              | 32                  | (11.8)              | 178                                                    | (11.6)                                                 | 360                                                    | (12.4)                                                 | 288                                                           | (12.5)                                                        | 540                                                           | (13.0)                                                        |
| discontinued any drug dhe to a drug-related adverse event        | 47                                    | (29.2)                                | 64                                    | (23.9)                                | 21                  | (13.6)              | 22                  | (8.1)               | 6                                                      | (6.1)                                                  | 165                                                    | (5.7)                                                  | 158                                                           | (6.9)                                                         | 265                                                           | (6.4)                                                         |
| discoutinued Pembrolizumab                                       | 35                                    | (21.7)                                | 45                                    | (16.8)                                | 0                   | (0.0)               | 0                   | (0.0)               | 6                                                      | (6.1)                                                  | 165                                                    | (5.7)                                                  | 158                                                           | (6.9)                                                         | 265                                                           | (6.4)                                                         |
| discontinued allregimen components                               | 12                                    | (7.5)                                 | 15                                    | (5.0)                                 | 21                  | (13.6)              | 22                  | (8.1)               | t6                                                     | (6.1)                                                  | 165                                                    | (5.7)                                                  | 158                                                           | (6.9)                                                         | 265                                                           | (6.4)                                                         |
| discontinued any dnug cdhe to a serious adverse event            | 33                                    | (20.5)                                | 40                                    | (14.9)                                | 19                  | (12.3)              | 23                  | (8.5)               | 142                                                    | (9.2)                                                  | 265                                                    | (9.1)                                                  | 207                                                           | (0'6)                                                         | 401                                                           | (9.7)                                                         |
| discoutinued Pembrolizuab                                        | 22                                    | (13.7)                                | 28                                    | (10.4)                                | 0                   | (0.0)               | 0                   | (0.0)               | 142                                                    | (9.2)                                                  | 265                                                    | (9.1)                                                  | 207                                                           | (0'6)                                                         | 401                                                           | (9.7)                                                         |
| discontinued allregimen components                               | 13                                    | (8.1)                                 | 12                                    | (4.5)                                 | 19                  | (12.3)              | 23                  | (8.5)               | 142                                                    | (9.2)                                                  | 265                                                    | (9.1)                                                  | 207                                                           | (9.0)                                                         | 401                                                           | (9.7)                                                         |
| discontinued any dnug de to a serious drug-related adverse event | 20                                    | (12.4) (9.3)                          | 33                                    | (12.3)                                | 13 0                | (8.4)               | 15                  | (5.5)               | 67                                                     | (4.4)                                                  | 105 105                                                | (3.0) (3.0)                                            | 93                                                            | (4.0)                                                         | 168                                                           | (4.1)                                                         |
| discoutinuedPembrolizumab                                        | 15                                    |                                       | 27                                    | (10.1)                                |                     | (0.0)               | 0                   | (0.0)               | 67                                                     | (4.4)                                                  |                                                        |                                                        | 93                                                            | (4.0)                                                         | 168                                                           | (4.1)                                                         |

discoutinued all regimen components

7

(4.3)

Detenmined by the investigator to be related to the drug.

12

(4.5)

13

(8.4)

15

(5.5)

67

(4.4)

Non-serious adverse events up to 30 days following the last dose and serious adverse events up to 90 days following the last dose are included.

ncludes all subjects who received at least one dose of Pembrolizmab and/or Axitinib in KN426.

ncludes all subjects who received at least one dose of pembrolizuab in KN001 Part B1, B2, B3, D,C, F1, F2, F3, KN002 (original phase), KN006, KN010, KN012 Cohorts B and B2 (HNSCC), KN013 Cohort 3 (Hodgkin Lymphoma), KN024, KN040, KN045, KN052, KN055 and KN087.

I Includes all subjects who received at least one dose of Sumitinib in KN426.

mcludes all subjects who received at least one dose of pembrolizumab in KN001 Part B1, B2, B3, D, C, F1, F2, F3, KN002 (oniginal phase), KN006, KN010, KN012 Cohorts B and B2 (HNSCC), Cohort C（UrothelialTractCancer)and Cohort D（GasticCamcer),KN013 Cohort 3(HodgkinLymphoma)and Cohort 4A（MLBCL),KN017,KN024,KN028Cohort B4,KN040,KN042 KN045, KN052, KN054, KN055, KN059 Cohort 1, KN087, KN158, KN164 Cohort A, KN170, KN224 and KN427 Cohort A.

DatabasecutofdateforMelanoma(KN001-Melanoma:18APR2014,KN002:28FEB2015,KN006:03MAR2015,KN054:02OCT2017)

Database cutoff date forLumg(KN001-NSCLC: 23JAN2015,KN010:30SEP2015,KN024:10JUL2017,KN042:26FEB2018)

Database cutoff date for HNSCC (KN012-HNSCC: 26APR2016, KN040: 15MAY2017, KN055: 22APR2016)

Database cutoff date for Gastic (KN012-Gastric: 26APR2016, KN059-Cohort 1: 21APR2017)

Database cutoff date for cHL(KN013-Cohort 3: 27SEP2016,KN087: 25SEP2016)

Database cutoff date for Bladder (KN012-Urothelial: 01SEP2015,KN045: 26OCT2017,KN052:09MAR2017)

Database cutoff date for Colorectal (KN164-Cohort A: 03AUG2016)

Database cutoff date for MLBCL (KN013-Cohort 4A: 04AUG2017, KN170: 19JAN2018)

Database cutof date for Cervical (KN028-Cohort B4: 20FEB2017,KN158: 15JAN2018)

Database cutoff dateforHCC(KN224:15MAY2018)

Database cutof date for RCC(KN426: 24AUG2018,KN427-Cohort A: 07SEP2018)

Database cutoff date for MCC (KN017: 06FEB2018)

Souce:[ISS: adam-adsl; adae]

105

(3.6)

93

(4.0)

168

(4.1)

<div style=\"page-break-after: always\"></div>

## Adverse Reactions supporting Table 2 in Section 4.8 of the SmPC

## Adverse Reactions in Patients Treated with Pembrolizumab in Combination with Axitinib (KEYNOTE-426 version)

(Support for Table 2 of the SmPC)

|                                             | Combination with axitinib                            | Frequency All Grades %(n)                | Grade of Severity (Grade 3-5) %(n)   |
|---------------------------------------------|------------------------------------------------------|------------------------------------------|--------------------------------------|
| Infections and                              | infestations                                         |                                          |                                      |
| Common                                      | pneumonia                                            | 3.5% (15)                                | 0.9% (4)                             |
| Blood and lymphatic system disorders        |                                                      |                                          |                                      |
| Common                                      | anaemia neutropaenia leukopaenia thrombocytopaenia   | 7.9% (34) 1.9% (8) 1.4% (6) 2.6% (11)    | 0.7% (3) 0.2% (1) 0 0                |
| Uncommon                                    |                                                      | 0.9% (4)                                 |                                      |
|                                             | lymphopaenia eosinophilia                            | 0.7% (3)                                 | 0.2% (1) 0                           |
| Immune system disorders                     |                                                      |                                          |                                      |
| Common                                      | infusion related reaction a                          | 1.2% (5)                                 | 0.2% (1)                             |
| Endocrine disorders                         |                                                      |                                          |                                      |
| Very common                                 | hyperthyroidism b                                    | 12.8% (55)                               | 1.2% (5)                             |
|                                             | hypothyroidism                                       | 35.4% (152)                              | 0.2% (1)                             |
| Common                                      | hypophysitis c                                       | 1.2% (5)                                 | 0.9% (4)                             |
|                                             | thyroiditis d                                        | 2.8% (12)                                | 0.2% (1) 0.7% (3)                    |
|                                             | adrenal insufficiency                                | 2.8% (12)                                |                                      |
| Metabolism and nutrition disorders          |                                                      |                                          |                                      |
| Very common                                 | decreased appetite                                   | 29.6% (127)                              | 2.8% (12)                            |
| Common                                      | hypokalaemia hyponatraemia hypocalcaemia             | 4.7% (20) 4.9% (21) 1.4% (6)             | 0.9% (4) 2.3% (10) 0                 |
| Uncommon                                    | type 1 diabetes mellitus e                           | 0.2%                                     | 0.2% (1)                             |
| Psychiatric disorders Common                |                                                      | (1)                                      |                                      |
|                                             | insomnia                                             | 8.4% (36)                                | 0                                    |
| Nervous system disorders Very common Common | headache dysgeusia dizziness lethargy neuropathy     | 15.9% (68) 11.0% (47) 5.1% (22) 2.1% (9) | 0.9% (4) 0.2% (1) 0 0                |
| Uncommon                                    |                                                      | 1.2% (5)                                 | 0                                    |
| Eye disorders                               | myasthenic                                           |                                          |                                      |
|                                             | peripheral                                           |                                          |                                      |
|                                             | syndrome g                                           |                                          |                                      |
|                                             |                                                      |                                          | 0.5% (2)                             |
|                                             |                                                      | 0.9% (4)                                 |                                      |
| Common Uncommon                             | dry eye uveitis h                                    | 1.9% (8) 0.5% (2)                        | 0                                    |
| Cardiac disorders                           |                                                      |                                          | 0                                    |
| Common                                      | cardiac arrhythmia † (including atrial fibrillation) | 5.8% (25)                                | 1.2% (5)                             |
| Uncommon                                    |                                                      | 0.5% (2)                                 |                                      |
| Vascular disorders                          | myocarditis                                          |                                          | 0.5% (2)                             |
|                                             | hypertension                                         | 44.5% (191)                              | 22.1% (95)                           |
| Very common                                 |                                                      |                                          | 1.6% (7)                             |
|                                             | pneumonitis i                                        |                                          | 0.5% (2)                             |
| mediastinal disorders                       |                                                      |                                          |                                      |
|                                             |                                                      | 2.8% (12)                                |                                      |
|                                             |                                                      | 25.4% (109)                              |                                      |
|                                             |                                                      | 16.1% (69)                               |                                      |
| Respiratory,                                |                                                      |                                          |                                      |
| Very common                                 | cough                                                |                                          | 0.2%                                 |
| Common                                      |                                                      | 21.2% (91)                               |                                      |
|                                             |                                                      |                                          | 0.2%                                 |
| Gastrointestinal disorders                  |                                                      |                                          |                                      |
|                                             |                                                      |                                          | (1)                                  |
|                                             | dysphonia                                            |                                          |                                      |
|                                             |                                                      |                                          | (1)                                  |
|                                             | dyspnoea                                             |                                          |                                      |
|                                             | thoracic and                                         |                                          |                                      |

<div style=\"page-break-after: always\"></div>

|                                                    | Combination with axitinib                                                      | Frequency All Grades %(n)                             | Grade of Severity (Grade 3-5)             |
|----------------------------------------------------|--------------------------------------------------------------------------------|-------------------------------------------------------|-------------------------------------------|
| Very common                                        | diarrhoea abdominal pain j nausea vomiting                                     | 54.3% (233) 19.3% (83) 27.7% (119) 15.2% (65)         | %(n) 9.1% (39) 2.1% (9) 0.9% (4) 0.2% (1) |
| Common                                             | constipation colitis k                                                         | 20.7% (89) 2.6% (11)                                  | 0 1.9% 0                                  |
|                                                    | dry mouth                                                                      | 5.8% (25)                                             | (8)                                       |
| Uncommon                                           | pancreatitis l                                                                 | 0.5% (2)                                              | 0.5% (2)                                  |
| Hepatobiliary disorders                            |                                                                                |                                                       |                                           |
| Common                                             | hepatitis m                                                                    | 2.8% (12)                                             | 2.3% (10)                                 |
| Skin and subcutaneous tissue disorders Very common |                                                                                | 28.0% (120)                                           |                                           |
|                                                    | palmar-plantar erythrodysaesthesia syndrome rash n pruritus o p                | 20.5% (88) 16.6% (71) 2.1% (9)                        | 5.1% (22) 0 0 1.4% (6)                    |
| Common                                             | severe skin reactions dermatitis acneiform dermatitis dry skin alopecia eczema | 1.6% (7) 1.9% (8) 6.8% (29) 3.5% (15) 1.2% (5)        | 0.2% (1) 0.2% (1) 0.2% (1) 0 0            |
| Uncommon                                           | erythema hair colour changes lichenoid keratosis r papule psoriasis            | 3.0% (13) 0.5% (2) 0.2% (1) 0.7% (3)                  | 0 0 0                                     |
| Musculoskeletal and connective tissue disorders    | vitiligo q                                                                     | 0.7% (3)                                              | 0 0                                       |
|                                                    | musculoskeletal pain s arthralgia                                              | 0.2% (1) 21.4% (92)                                   | 0 1.9% (8)                                |
| Very common                                        | pain in extremity myositis t arthritis u v                                     | 18.2% (78) 11.9% (51) 9.8% (42)                       | 0.9% (4) 0.9% (4) 0.5% (2) 0.5% (2)       |
| Common                                             |                                                                                | 2.1% (9)                                              | 0                                         |
|                                                    | tenosynovitis                                                                  |                                                       |                                           |
| Renal and urinary disorders Common                 | nephritis w acute kidney injury fatigue asthenia pyrexia x                     | 1.2% (5) 3.3% (14) 4.0% (17)                          | 0.5% (2) 1.9% (8)                         |
| General disorders and                              | oedema influenza like chills                                                   | 38.5% (165) 15.2% (65) 12.8% (55) 8.2% (35) 3.3% (14) | 2.8% (12) 2.6% (11) 0                     |
| administration site conditions Very common         | illness                                                                        | 4.9% (21)                                             | 0.2% (1) 0.2%                             |
| Common                                             |                                                                                |                                                       | (1) 0                                     |
| Investigations                                     |                                                                                |                                                       |                                           |
| Very common                                        | alanine                                                                        | 26.8% 26.1%                                           |                                           |
|                                                    | aminotransferase increased                                                     | (115) (112)                                           | 13.3% (57)                                |
|                                                    |                                                                                |                                                       | 7.0% (30)                                 |
|                                                    | aspartate aminotransferase                                                     |                                                       |                                           |
|                                                    |                                                                                |                                                       | 0.5% (2)                                  |
|                                                    | increased blood creatinine increased                                           | 11.2% (48)                                            |                                           |

<div style=\"page-break-after: always\"></div>

|          | Combination with axitinib            | Frequency All Grades %(n)   | Grade of Severity (Grade 3-5) %(n)   |
|----------|--------------------------------------|-----------------------------|--------------------------------------|
| Common   | blood alkaline phosphatase increased | 6.3% (27)                   | 1.2% (5)                             |
| Common   | hypercalcaemia                       | 4.0% (17)                   | 0.5% (2)                             |
| Common   | blood bilirubin increased            | 6.5% (28)                   | 0.9% (4)                             |
| Uncommon | amylase increased                    | 0.2% (1)                    | 0                                    |

*Adverse reaction frequencies presented in Table 2 may not be fully attributable to pembrolizumab alone but may contain contributions from the underlying disease or from other medicinal products used in a combination.

† Based upon a standard query including bradyarrhythmias and tachyarrhythmias.

The following terms represent a group of related events that describe a medical condition rather than a single event.

- a. infusion-related reaction (drug hypersensitivity, anaphylactic reaction, anaphylactoid reaction, hypersensitivity and cytokine release syndrome)
- b. hypothyroidism (myxoedema)
- c. hypophysitis (hypopituitarism)
- d. thyroiditis (autoimmune thyroiditis and thyroid disorder)
- e. type 1 diabetes mellitus (diabetic ketoacidosis)
- f. Guillain-Barré syndrome (axonal neuropathy and demyelinating polyneuropathy)
- g. myasthenic syndrome (myasthenia gravis, including exacerbation)
- h. uveitis (iritis and iridocyclitis)
- i. pneumonitis (interstitial lung disease)
- j. abdominal pain (abdominal discomfort, abdominal pain upper and abdominal pain lower)
- k. colitis (colitis microscopic, enterocolitis, enterocolitis haemorrhagic, and autoimmune colitis)
- l. pancreatitis (autoimmune pancreatitis and pancreatitis acute)
- m. hepatitis (autoimmune hepatitis, immune-mediated hepatitis and drug induced liver injury)
- n. rash (rash erythematous, rash follicular, rash generalised, rash macular, rash maculo-papular, rash papular, rash pruritic, rash vesicular and genital rash)
- o. pruritus (urticaria, urticaria papular, pruritus generalised and pruritus genital)
- p. severe skin reactions (dermatitis bullous, dermatitis exfoliative, erythema multiforme, exfoliative rash, pemphigus, skin necrosis, toxic skin eruption and Grade ≥ 3 of the following: acute febrile neutropaenic dermatosis, contusion, decubitus ulcer, dermatitis psoriasiform, drug eruption, jaundice, pemphigoid, pruritus, pruritus generalised, rash, rash erythematous, rash generalised, rash maculo-papular, rash pruritic, rash pustular and skin lesion)
- q. vitiligo (skin depigmentation, skin hypopigmentation and hypopigmentation of the eyelid)
- r. lichenoid keratosis (lichen planus and lichen sclerosus)
- s. musculoskeletal pain (musculoskeletal discomfort, back pain, musculoskeletal stiffness, musculoskeletal chest pain and torticollis)
- t. myositis (myalgia, myopathy, polymyalgia rheumatica and rhabdomyolysis)
- u. arthritis (joint swelling, polyarthritis and joint effusion)
- v. tenosynovitis (tendonitis, synovitis and tendon pain)
- w. nephritis (nephritis autoimmune, tubulointerstitial nephritis and renal failure, renal failure acute, or acute kidney injury with evidence of nephritis, nephrotic syndrome)
- x. oedema (oedema peripheral, generalised oedema, fluid overload, fluid retention, eyelid oedema and lip oedema, face oedema, localised oedema and periorbital oedema)

<div style=\"page-break-after: always\"></div>

## Safety related to drug-drug interactions and other interactions

As pembrolizumab is an IgG antibody that is administered parenterally and cleared by catabolism, food and DDI are not anticipated to influence exposure. Drugs that affect the cytochrome P450 enzymes, and other metabolizing enzymes, are not expected to interfere with the metabolism of an IgG antibody. The IgG antibodies, in general, do not directly regulate the expression of cytochrome P450 enzymes, other enzymes, or transporters involved in drug elimination. Therefore, no dedicated DDI studies have been performed. In addition, in vitro experiments and studies conducted in preclinical species have been shown to have limited value in predicting DDI potential in humans [Ref. 5.4: 03JJPS]. Therefore, no preclinical pharmacokinetic studies were conducted to assess the propensity of pembrolizumab to be a victim or perpetrator of pharmacokinetic DDIs. Similarly, the potential of a DDI between pembrolizumab and a TKI is expected to be low due to differences in metabolic pathways.

Studies evaluating pharmacodynamics drug interactions with pembrolizumab have not been conducted. However, as systemic corticosteroids may be used in combination with pembrolizumab to ameliorate potential  side  effects,  the  potential  for  a  pharmacokinetic  DDI  with  pembrolizumab  as  a  victim  was assessed as part of the population pharmacokinetic analysis. No relationship was observed between prolonged use of systemic corticosteroids and pembrolizumab exposure. Systemic corticosteroids, or other  immunosuppressants,  can  be  used  during  pembrolizumab  treatment  to  treat  immune-related adverse reactions.

## Discontinuation due to adverse events

## Discontinuation Due to AEs

Table 5.3.5.3.3-rcc1: 26 Subjects With Drug-Related Adverse Events Resulting in Any Treatment Discontinuation (Incidence &gt; 1% in Preferred Term) By Decreasing Frequency of Preferred Term (ASaT Population) (modified by the Assessor)

|                                                                         | KN426 Data for Pembrolizumab + Axitinibl   | KN426Sumitinib           | Reference Safety Dataset for Pembrolizmab Monotherapy   | Cumlative Rumning Safety Dataset for Pembrolizuab Mouotherapy   |
|-------------------------------------------------------------------------|--------------------------------------------|--------------------------|---------------------------------------------------------|-----------------------------------------------------------------|
| Subjects in population withoneormoreadverseevents withno adverse evenis | 429 111 (25.9) 318 (74.1)                  | 425 43 (10.1) 382 (89.9) | 4,439 259 (5.8) 4,180 (94.2)                            | 6,436 423 (6.6) 6,013 (93.4)                                    |
|                                                                         | 31                                         | 1 (0.2)                  | (0.2)                                                   | 19                                                              |
| Alamine aminohansferaseincreased                                        | (7.2)                                      |                          | 7                                                       | (0.3)                                                           |
| Aspartate aminotransferase increased                                    | 20 (4.7)                                   | (0.2)                    | 10 (0.2)                                                | 18 (0.3)                                                        |
| Hepatic fiwction abnonmal                                               | 6 (1.4)                                    | 0 (0.0)                  | 0 (0.0)                                                 | 2 (0.0)                                                         |

Aside from ALT and AST increased as well as Hepatic function abnormal occurring among AEs leading to treatment discontinuation with frequencies &gt;1%, Decreased appetite, Diarrhoea, Hepatitis, Hepatotoxicity, and Myasthenia gravis were documented in 4 patients each, and Acute kidney injury, Cerebrovascular accident, Hepatocellular injury, Palmar-plantar erythrodysaesthesia Syndrome, Proteinuria, Pulmonary embolism were found in 3 subjects each.

<div style=\"page-break-after: always\"></div>

Table 14.3-41 Subjects With Adverse Events Resulting in Treatment Discontinuation By Decreasing Incidence (Incidence &gt; 1% in One or More Treatment Groups) (ASaT Population) (modified by the Assessor)

|                                    | Pembrolizumab+Axitinib                        | Pembrolizumab+Axitinib                        | Pembrolizumab+Axitinib                    | Pembrolizumab+Axitinib                    | Pembrolizumab+Axitinib        | Pembrolizumab+Axitinib        | Pembrolizumab+Axitinib   | Pembrolizumab+Axitinib   | Suitinib   |
|------------------------------------|-----------------------------------------------|-----------------------------------------------|-------------------------------------------|-------------------------------------------|-------------------------------|-------------------------------|--------------------------|--------------------------|------------|
|                                    | Pembrolizumab and/or Axitinib Discontinuation | Pembrolizumab and/or Axitinib Discontinuation | Pembrolizumaband Axitinib Discontinuation | Pembrolizumaband Axitinib Discontinuation | Pembrolizumab Discontinuation | Pembrolizumab Discontinuation | Axitinib Discontinuation | Axitinib Discontinuation |            |
|                                    | n                                             | (%)                                           | n                                         | (%)                                       | n                             | (%)                           | n                        | (%) n                    | (%)        |
| Subjectsinpopulation               | 429                                           |                                               | 429                                       |                                           | 429                           |                               | 429                      | 425                      |            |
| withone ormoreadverseevents        | 131                                           | (30.5)                                        | 33                                        | (7.7)                                     | 89                            | (20.7)                        | 88                       | (20.5) 59                | (13.9)     |
| with no adverseevents              | 298                                           | (69.5)                                        | 396                                       | (92.3)                                    | 340                           | (79.3)                        | 341                      | (79.5) 366               | (86.1)     |
| Alanineaminotransferaseincreased   | 31                                            | (7.2)                                         |                                           | (71)                                      | 20                            | (4.7)                         | 16                       | (3.7)                    | (0.2)      |
| Aspartateaminotransferaseincreased | 20                                            | (4.7)                                         | 3                                         | (0.7)                                     | 16                            | (3.7)                         | 7                        | (1.6) 1                  | (0.2)      |
| Hepaticfinctionabnormal            | 6                                             | (1.4)                                         | 3                                         | (0.7)                                     | 4                             | (0.9)                         |                          | (1.2) 0                  | (0.0)      |

In the combination arm, discontinuation of both drugs due to drug-related AEs was found in 27 subjects with a median time to event of 63.0 days. Discontinuation of pembrolizumab was reported for 80 participants after a similar time on treatment (median 65 days).

Table 14.3-45 Time to Discontinuation of Both Drugs in Pembrolizumab + Axitinib Arm Due to Drug-related Adverse Events (ASaT Population)

|                                                                                                                                                                     | Pembrolizumab + Axitinib N =429 (ASaT)                                                                                                                              |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Subjects with discontinuation of both drugs due to drug-related adverse events                                                                                      | 27                                                                                                                                                                  |
| Time to discontinuation of both drugs due to drug-related adverse events (days)f Median                                                                             | 63.0                                                                                                                                                                |
| Time to discontinuation of both drugs due to drug-related adverse events = last dose date of both drugs - first dose date + 1 day. Database Cutoff Date: 24Aug2018. | Time to discontinuation of both drugs due to drug-related adverse events = last dose date of both drugs - first dose date + 1 day. Database Cutoff Date: 24Aug2018. |

Source: [P426V01MK3475: adam-adsl; adae; adpm]

Table 14.3-46 Time to Discontinuation of Pembrolizumab Due to Drug-related Adverse Events

## (ASaT Population)

|                                                                                                                                                                         | Pembrolizumab +Axitinib N =429 (ASaT)                                                                                                                                   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Subjects with discontinuation of Pembrolizumab due to diug-related adverse events                                                                                       | 80                                                                                                                                                                      |
| Time to discontinuation of Pembrolizumab due to drug-related adverse events (days) Median                                                                               | 65.0                                                                                                                                                                    |
| Time to discontinuation of Pembrolizumab due to drug-related adverse events = last dose date of Pembrolizumab - first dose date + 1 day. DatabaseCutoff Date:24Aug2018. | Time to discontinuation of Pembrolizumab due to drug-related adverse events = last dose date of Pembrolizumab - first dose date + 1 day. DatabaseCutoff Date:24Aug2018. |

Source: [P426V01MK3475: adam-adsl; adae; adpm]

## Interruption Due to Adverse Events

Table 14.3-47 Subjects With Adverse Events Resulting in Treatment Interruption By Decreasing Incidence (Incidence &gt; 10% in Preferred Term)

(ASaT Population)

( modified by Assessor )

|                                      | Pembrolizumab+Axitinib                     | Pembrolizumab+Axitinib                     | Pembrolizumab+Axitinib                | Pembrolizumab+Axitinib                | Pembrolizumab+Axitinib   | Pembrolizumab+Axitinib   | Pembrolizumab+Axitinib   | Pembrolizumab+Axitinib   | Sunitinib   | Sunitinib   |
|--------------------------------------|--------------------------------------------|--------------------------------------------|---------------------------------------|---------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|-------------|-------------|
|                                      | Pembrolizumab and/or Axitinmib Intemuption | Pembrolizumab and/or Axitinmib Intemuption | Pembrolizumab and AxitinibIntemuption | Pembrolizumab and AxitinibIntemuption | Pembrolizmab Intemuption | Pembrolizmab Intemuption | AxitinibIntenuption      | AxitinibIntenuption      |             |             |
|                                      | 1                                          | (%)                                        | 1                                     | (%)                                   | n                        | (%)                      | 1                        | (%)                      | n           | (%)         |
| Subjectsin population                | 429                                        |                                            | 429                                   |                                       | 429                      |                          | 429                      |                          | 425         |             |
| with one or more adverse events      | 300                                        | (69.9)                                     | 153                                   | (35.7)                                | 216                      | (50.3)                   | 274                      | (63.9)                   | 212         | (49.9)      |
| with no adverse events               | 129                                        | (30.1)                                     | 276                                   | (64.3)                                | 213                      | (49.7)                   | 155                      | (36.1)                   | 213         | (50.1)      |
| Dianhoea                             | 70                                         | (16.3)                                     | 31                                    | (7.2)                                 | 41                       | (9.6)                    | 63                       | (14.7)                   | 21          | (4.9)       |
| Alanine aminotransferaseincreased    | 60                                         | (14.0)                                     | 31                                    | (7.2)                                 | 41                       | (9.6)                    | 52                       | (12.1)                   | 12          | (2.8)       |
| Aspartate aminotransferase imcreased | 57                                         | (13.3)                                     | 29                                    | (6.8)                                 | 37                       | (8.6)                    | 50                       | (11.7)                   | 8           | (1.9)       |
| Hypertension                         | 57                                         | (13.3)                                     | 3                                     | (0.7)                                 | 3                        | (0.7)                    | 57                       | (13.3)                   | 34          | (8.0)       |

<div style=\"page-break-after: always\"></div>

## Dose Reduction Due to Adverse Events

Number  of  subjects  with  dose  change  from  initial  dose  were  similar  in  the  two  treatment  arms (pembrolizumab+axitinib  429  [100%];  sunitinib  425  [1005]).  In  the  combination  arm  69  subjects (16.1%) had Dose Escalation from Initial Dose, while 284 (66.2%) had Dose Reduction from Initial Dose. In the axitinib arm, none of the participants had Dose Escalation from Initial Dose, while 207 (48.7%) had Dose Reduction from Initial Dose.

<div style=\"page-break-after: always\"></div>

## Subjects With Adverse Events Resulting in Dose Reduction By Decreasing Incidence

Table 14.3-52 (Incidence &gt; 1% in Preferred Term)* (ASaT Population) ( modified by Assessor )

Table 14.3-54

|                                             | Pembrolizumab+ Axitinib   | Pembrolizumab+ Axitinib   | Sunitinib   | Sunitinib   |
|---------------------------------------------|---------------------------|---------------------------|-------------|-------------|
|                                             | Ⅱ                         | (%6)                      |             | (%6)        |
| Subjects inpopulation                       | 429                       |                           | 425         |             |
| Withoneormoreadverseevents                  | 87                        | (20.3)                    | 128         | (30.1)      |
| withnoadverseevents                         | 342                       | (79.7)                    | 297         | (69.9)      |
| Hypertension                                | 17                        | (4.0)                     | 15          | (3.5)       |
| Diamhoea                                    | 14                        | (3.3)                     | 13          | (3.1)       |
| Palmar-plantar erythrodysaesthesia syndrome | 9                         | (2.1)                     | 15          | (3.5)       |
| Fatigule                                    | 7                         | (1.6)                     | 17          | (4.0)       |

Subjects With Drug-Related Adverse Events Resulting in Dose Reduction By Decreasing Incidence

(Incidence &gt; 1% in Preferred Term)*

(ASaT Population) ( modified by Assessor )

Table 14.3-56

|                                             | Pembrolizumab + Axitinib   | Pembrolizumab + Axitinib   | Sunitinib   | Sunitinib   |
|---------------------------------------------|----------------------------|----------------------------|-------------|-------------|
|                                             | Ⅱ                          | (%6)                       |             | (%6)        |
| Subjectsinpopulation                        | 429                        |                            | 425         |             |
| with one ormore adverse events              | 86                         | (20.0)                     | 121         | (28.5)      |
| withno adverseevents                        | 343                        | (80.0)                     | 304         | (71.5)      |
| Hypertension                                | 17                         | (4.0)                      | 14          | (3.3)       |
| Dianhoea                                    | 14                         | (3.3)                      | 13          | (3.1)       |
| Palmar-plantar erythrodysaesthesia syndrome |                            | (2.1)                      | 15          | (3.5)       |
| Fatigue                                     | 7                          | (1.6)                      | 15          | (3.5)       |

Subjects With Grade 3-5 Adverse Events Resulting in Dose Reduction By Decreasing Incidence

(Incidence &gt; 1% in Preferred Term)*

(ASaT Population) (modified by Assessor )

|                                           | Pembrolizmab+ Axitinib   | Pembrolizmab+ Axitinib   | Sunitinib   | Sunitinib   |
|-------------------------------------------|--------------------------|--------------------------|-------------|-------------|
|                                           |                          | (%6)                     |             | (96)        |
| Subjectsinpopulation                      | 429                      |                          | 425         |             |
| withoneormoreadverseevents                | 44                       | (10.3)                   | 61          | (14.4)      |
| withnoadverseevents                       | 385                      | (89.7)                   | 364         | (85.6)      |
| Hypertension                              | 11                       | (2.6)                    | 7           | (1.6)       |
| Diarhoea                                  | 7                        | (1.6)                    |             | (1.2)       |
| Fatigue                                   |                          | (1.2)                    | 6           | (1.4)       |
| Palmar-plantarerythrodysaesthesiasyndrome |                          | (1.2)                    | 4           | (0.9)       |

## Post marketing experience

The safety profile of pembrolizumab was summarized in the PSUR covering the period 04-MAR-2018 through 03-SEP-2018. No revocation or withdrawal of pembrolizumab registration for safety reasons has occurred in any country.

## 2.5.1. Discussion on clinical safety

The claimed indication of pembrolizumab in combination with axitinib for 1L treatment of subjects with advanced RCC is based on safety data from the IA1 on the ASaT population of KEYNOTE-426, which is an

<div style=\"page-break-after: always\"></div>

ongoing,  Phase 3,  randomized,  open-label,  multicenter,  global  study  (data  cut-off  24  Aug  2018). Submitted side-by-side  safety  tables  show  data  from  the  pembrolizumab+axitinib  (N=429)  and  the sunitinib (N=425) arms. In addition, the pooled Pembrolizumab Monotherapy Reference SD (N=4439) is provided to compare safety data from KN426 with the established safety profile for pembrolizumab monotherapy across indications approved in the EU, and the Cumulative Running Safety Dataset for Pembrolizumab Monotherapy (including all pembrolizumab monotherapy indications globally) is provided to evaluate consistency of the pembrolizumab safety profile across indications. Finally, as supportive safety  information  data  from  the Axitinib  monotherapy arm  of  Phase  3  Study A4061051  for  the  1L treatment of metastatic RCC (data cut-off 27 July 2012; N=189) and the Pembrolizumab monotherapy Cohort A of KEYNOTE-427 study for the 1L treatment of advanced ccRCC (data cut-off 07 Sept 2018; N=110) are presented. The safety data from the 52 participants enrolled in the Phase 1b study (Study A4061079)  of  pembrolizumab+axitinib  were  presented  separately  in  the  dossier.  Safety  data  from KEYNOTE-427  Cohort A  (subjects  treated  with  pembrolizumab  monotherapy  for  1L  treatment  of advanced ccRCC) has been provided either pooled within the Cumulative Running Safety Dataset for Pembrolizumab  Monotherapy  (including  all  pembrolizumab  monotherapy  indications  globally)  or separately in the CSR P427V01MK3475.

Demographics of KN426 study population depict mainly White (80%) subjects of male gender (70-75%) with mean age of 61 years. Two thirds of participants were enrolled outside the EU. Regarding previous RCC treatments approximately 83% had undergone prior nephrectomy and 9% previous radiotherapy, with similar proportions in study arms. With the exception of proportion of subjects aged &gt;65, that was slightly increased in the pembrolizumab+axitinib group if compared to the sunitinib group (40.1% vs 34.8%, respectively), patient demographics and disease characteristics were quite well balanced among the two KN426 treatment arms. In the experimental arm there were few more women (28.7% vs 25.4%) than in the control arm. Liver metastases were found in approximately 15% of subjects of both arms. In respect to the Pembrolizumab Monotherapy RSD and as expected for RCC patients, KN426 participants were more often male gender than in the reference dataset (73% vs 65%, respectively). The other demographics were consistent between the pivotal trial and the pooled dataset.

With regards to duration of exposure , median time on therapy was longer in the pembrolizumab+axitinib arm (10.42 months), when compared to the sunitinib arm (7.82 months) and the Pembrolizumab Monotherapy RSD (4.17 months), which is likely associated with the OS benefit as compared to the control arm and the 2L settings for the indications in the pembrolizumab monotherapy RSD.  Similarly,  proportion  of  subjects  with  exposures  for  &gt;6  or  &gt;12  months  were  higher  in  the pembrolizumab+axitinib arm (77.9% and 40.3%), followed by the sunitinib arm (63.5% and 25.4%) and the  Pembrolizumab  Monotherapy  RSD  (40.9%  and  19.2%).  Mean  number  of  pembrolizumab administrations were higher in the pembrolizumab+axitinib arm (13.8+8.04) than in the Pembrolizumab Monotherapy RSD (10.7+9.56). This finding could be related to the disease setting (1L treatment of RCC) where the drug combination has been studied.

Based on the safety summary overall AEs were observed in similar proportions in subjects receiving pembrolizumab+axitinib compared to those treated with sunitinib. However, the following AE categories were reported more frequently in the experimental combination arm: Grade 3-5 AEs (75.8% vs 70.6%), Grade 3-5 drug-related AEs (62.9% vs 58.1%), SAEs (40.3% vs 31.3%), drug-related SAEs (23.8% vs 14.1%), and drug discontinuations due to AEs (30.5% vs 13.5%), to drug-related AEs (25.9% vs 10.1%), to SAEs (17.0% vs 9.9%), or to drug-related SAEs (12.4% vs 6.6%). Even adjusting for exposure and including  multiple  event  occurrences,  the  increased  rate  of  drug-related  SAEs  (2.87  vs  1.99/100 person-months, respectively) and of drug discontinuations due to AEs (3.78 vs 1.66/100 person-months, respectively),  to  drug-related  AEs  (3.19  vs  1.2/100  person-months,  respectively),  to  SAEs  (1.68  vs 1.1/100  person-months,  respectively),  or  to  drug-related  SAEs  (1.24  vs  0.71/100  person-months,

<div style=\"page-break-after: always\"></div>

respectively) is observed. These data suggest that the tolerability of the combination is poor with a much higher rate of treatment discontinuation due to AEs, drug-related AEs and drug-related AEs compared to sunitinib and to what observed so far with pembrolizumab monotherapy.

In KN426, at least one AE was found in almost all participants (98.4% in pembrolizumab+axitinib and 99.5% in sunitinib) and PTs most commonly (incidence &gt;30%) reported for the pembrolizumab+axitinib arm, in some cases occurred with similar frequencies as in the sunitinib arm: Diarrhea (54.3%  and  44.9%,  respectively), Hypertension (44.5%  and  45.4%), Fatigue (38.5%  and 37.9%), and Hypothyroidism (35.4% and 31.5%). Between-treatment comparisons showed increased risk in the pembrolizumab-axitinib arm (risk with 95%CI exceeding 0) for Dysphonia , Arthralgia , ALT increased, AST increased, Diarrhea, Pruritus, Hyperthyroidism, Cough, Weight decreased, Proteinuria, Constipation, Dyspnea, Abdominal pain , while the sunitinib arm was in disadvantage for blood system disorders, Palmar-plantar erythrodysesthesia syndrome , Dysgeusia , Mucosal Inflammation and  some gastrointestinal disorders. When looking at exposure-adjusted SOCs incidence, a slightly higher rate of Respiratory, thoracic and mediastinal disorders was found for the group treated with pembrolizumab+axitinib  in  respect  to  that  receiving  sunitinib  (10.5  vs  8.0/100  p-m),  that  could  be related to higher Dysphonia rates. Most of other SOCs were reported either less often for the combination treatment  versus  controls  ( Blood  and  lymphatic  disorders 1.9  vs  14.7/100  p-m, Gastrointestinal disorders 29.4  vs  35.9/100  p-m, General  disorders 13.0  vs  18.1/100  p-m, Investigations 18.1  vs 24.1/100 p-m, Nervous system disorders 6.8 vs 10.7/100 p-m, Skin and subcutaneous tissue disorders 11.6 vs 16.3/100 p-m), or  similarly frequent in the two study arms ( Endocrine disorders 5.8 and 5.0/100 p-m, Hepatobiliary disorders 1.3 and 1.2/100 p-m , Infections and infestations 7.6 and 6.8/100 p-m , Renal and urinary disorders 4.5 and 4.0/100 p-m). When looking at exposure periods, in both treatment arms most event rates were the highest during the first months. Based on indirect comparison of data from Study KN-426, Study A4061051 (Axitinib monotherapy) and available data for pembrolizumab monotherapy, it is observed that the combination is associated with an increased frequency of some AEs compared to what previously observed with monotherapies, such as Diarrhoea, Hypothiroidism, ALT increased, AST increased, Fatigue, Nausea, Proteinuria, Hyperthyroidism . Grade 3-5 AEs were reported in 75.8% of subjects treated with pembrolizumab+axitinib and in 70.6% of those receiving sunitinib. PTs with  incidence  rates  &gt;5%  in  the  combination  treatment  were Hypertension (22.1%), ALT increased (13.3%), Diarrhea (9.1%), AST  increased (7.0%), Palmar-plantar  erythrodysaesthesia  syndrome (5.1%), while in the sunitinib arm the following were reported: Hypertension (19.3%), Platelet count decreased (7.3%), Neutrophil  count  decreased (6.8%), Neutropenia (6.6%), Fatigue (6.6%)  and Thrombocytopenia (5.9%).  Between-treatment  risk  differences  with  95%CI  exceeding  0  showed advantage of controls over the combination treatment for ALT increased, AST increased and Diarrhea ; while  pembrolizumab+axitinib  arm  was  in  favor  for  most  Grade  3-5  myelotoxicity  AEs  and Fatigue . Although  median  time  to  first  Grade  3-5  AE  was  shorter  for  the  sunitinib  arm  when  compared  to pembrolizumab+axitinib arm (10.1 vs 13.1 weeks, respectively), no statistically significant difference was documented.

With regards to drug-related AEs , similar overall proportions were reported across study arms (96.3% in pembrolizumab+axitinib and 97.6% in sunitinib). Type and frequency of the most common events (&gt;30% incidence) in subjects receiving the combination treatment mirrored the expected safety profile of drug components, and, apart from Diarrhoea, were not substantially dissimilar from those reported for sunitinib-treated participants ( Diarrhea 49.0%  and 41.2%; Hypertension 41.7%  and 43.3%, Hypothyroidism 31.5% and 28.0%, and Fatigue 30.3% and 33.4%, respectively). Among events with incidence &gt;20%, ALT increased (23.8% vs 12.7%), AST increased (22.6% vs 13.9%), and Dysphonia (22.8% vs 2.8%) were all more often found in the combination arm when compared to sunitinib. Analysis of between-treatment difference was in agreement with the results found for overall AEs by showing increased risks for the pembrolizumab+axitinib arm of Dysphonia , ALT increased, Hyperthyroidism, AST increased, Arthralgia, Pruritus, Diarrhea, Proteinuria, and Cough , and for the sunitinib arm of Dysgeusia ,

<div style=\"page-break-after: always\"></div>

Thrombocytopenia , Neutropenia , Platelet count decreased , Anemia , Palmar-plantar erythrodysesthesia syndrome , Neutrophil  count  decreased , Dyspepsia , White  blood  cell  count  decreased , Mucosal inflammation , Leukopenia , Gastroesophageal reflux disease , Stomatitis , and Vomiting AEs. Based on indirect comparison of data from Study KN-426, Study A4061051 (Axitinib monotherapy) and available data for pembrolizumab monotherapy, it is observed that the combination is associated with an increased frequency of some drug-related AEs compared to what previously observed with monotherapies, such as Diarrhoea,  Hypothiroidism,  ALT  increased,  AST  increased,  Fatigue,  Nausea,  Proteinuria,  Arthralgia, Hyperthyroidism . Proportions of overall grade 3-5 drug-related AEs were somehow increased in the pembrolizumab+axitinib arm if compared to the sunitinib arm (62.9% vs 58.1%, respectively). Based on investigator's judgments, within the combination arm, the grade 3-5 drug-related AEs were considered related to axitinib (56.9%), to pembrolizumab (37.1%) or to both the compounds (26.1%). Grade 5 drug-related AEs were reported in 4 subjects of the pembrolizumab+axitinib arm (0.9%; all considered related  to  pembrolizumab  by  investigators)  and  7  subjects  (1.6%)  of  the  sunitinib  arm.  PTs  with difference &gt;2% between treatment arms and higher proportions in the pembrolizumab+axitinib than in the  sunitinib  group  were: Hypertension (21.2%  vs  18.4%,  respectively), ALT  increased (12.1%  vs 18.4%), Diarrhea (7.2% vs 4.5%), and AST increased (6.8% vs 1.6%). Differently, the sunitinib-treated group  had  enlarged  proportions  for Thrombocytopenia (5.2%  vs  0.0%,  respectively), Platelet  count decreased (7.3% vs 0.2%), Neutropenia (6.6% vs 0.2%), Hypophosphatasemia (2.6% vs 0.5%).

More subjects in the pembrolizumab+axitinib arm compared to the sunitinib arm were found with SAEs (40.3% vs 31.3%, respectively). Most often reported events for pembrolizumab+axitinib arm were: Diarrhea (2.8%), Acute kidney injury (1.6%), ALT increased (1.4%), Dehydration (1.4%), AST increased (1.2%), Hepatic function abnormal (1.2%), Pneumonitis (1.2% ) .  Between-treatment comparisons of SAEs  showed  sunitinib  being  in  favor  for Diarrhea , ALT  increased,  Pneumonitis, Hepatic  function abnormal, AST increased , while combination treatment did not result of advantage for any event. Also, drug-related  SAEs were more often reported for the combination arm than for controls (23.8% vs 14.1%, respectively). Aside from the gastrointestinal ( Diarrhea 1.9%; Colitis 0.8%)  and  respiratory events ( Pneumonitis 1.2%; Pulmonary embolism 0.8%), drug-related SAEs due to Hepatobiliar disorders were the most frequent and were reported in 31 subjects (7.2%): ALT increased (6 subjects) ,  AST increased (5 subjects) , Hepatic function abnormal (4 subjects), Hepatitis (3 subjects), Hepatocellular injury (3 subjects), Hepatic enzyme increased (2 subjects), Liver function test increased (2 subjects), Transaminases increased (2 subjects), Autoimmune hepatitis (1 subject), Blood bilirubin increased (1 subject), Hepatotoxicity (1 subject), Immune mediated hepatitis (1 subject). Serious drug-related Acute kidney injury and Myasthenia gravis were reported in 4 subjects each, while Cerebrovascular event in 3. When  drug-related  SAEs  are  analyzed  by  SOCs, Gastrointestinal  disorders (4.2%), Hepatobiliary disorders (3.5%) and Investigations (3%, mainly liver tests) were the most frequently reported. Cardiac disorders, whilst having rates of 0.4% for pembrolizumab monotherapy, are reported at 1.6% for the pembrolizumab+axitinib arm (most common PTs: Atrial  fibrillation and Myocarditis in  2  cases  each; 0.5%) and 1.4% the sunitinib arm.

With  regard  to  cardiac  disorders,  while  myocarditis  is  a  known  side  effect  of  pembrolizumab,  atrial fibrillation is not reported in Pembrolizumab SmPC, nor in axitinib one. Further, analysis of aggregated Cardiac  arrhythmias  SMQ  confirmed  an  increased  proportion  of  events  in  subjects  treated  with pembrolizumab+axitinib compared to those receiving sunitinib (5.8% vs 2.4%, respectively), and similar differences for drug-related AEs (2.3% vs 0.2%) and SAEs (1.4% vs 0.2%). Based on these findings, the MAH was asked to provide further information and, if applicable, to propose modifications to the SmPC. Cardiac arrhythmias SMQ (0.59 vs 0.28/100 person-months, respectively) and Atrial fibrillation PT (0.2 vs  0.0/100  person-months,  respectively),  clearly  show  higher  exposure-adjusted  rates  in  KN-426 pembrolizumab+axitinib-treated subjects when compared to those receiving sunitinib. Exposure-adjusted event rates in RCC patients treated with pembrolizumab combo were similar to those

<div style=\"page-break-after: always\"></div>

observed in subjects receiving pembrolizumab monotherapy across indications of the Reference safety Dataset, suggesting no additional safety issues when pembrolizumab is combined with axitinib. The query of  the  OASE database aimed at comparing safety data of pembrolizumab monotherapy including all open-label, unmasked, or completed randomized study for which there has been a database lock on or before 31-Mar--2018 (n=9118) with that of all cytotoxic treatments from all studies using chemotherapy comparators combined (N=1324) did not find differences in frequency or in exposure-adjusted rates of overall and drug-related MedDRA sub-SMQ Cardiac arrhythmias, as well as related PTs. When analyzing Atrial fibrillation by age strata, as expected, the risk significantly increases in higher age groups treated with  pembrolizumab  (0.2-0.4%  in  subjects  &lt;60  y  vs  1.1-3.4%  in  subjects  &gt;60  y).  Review  of  the Company's global safety Database (MARRS) identified 725 arrhythmia events (atrial fibrillation in 46.76% of  cases)  occurring  in  665  subjects  (approximately  90%  SAEs),  having  characteristics  as  expected (higher prevalence in males and more aged subjects). While a relatively short elapse of time between treatment start and AE occurrence is noted (median 56 days for atrial fibrillation, 33 days for fatal cases), the high frequency of concurrent morbidity acts as confounder in causality analysis. The MAH stated that there  is  insufficient  evidence  to  suggest  a  causal  relationship  between  pembrolizumab  and  cardiac arrhythmia, however, this is not agreed, and as a drug/class-induced safety issue cannot be ruled out. The MAH was requested to add atrial fibrillation/cardiac arrhythmias to ADRs in Section 4.8 of the SmPC. (See SmPC 4.8)

In addition, a trend toward higher incidences of severe and serious Acute kidney injury was notable in the pembrolizumab+axitinib group compared to the sunitinib arm, although the numbers are likely to small to draw  definitive  conclusion.  The  incidences  of  serious  AEs  were  1.6%  [n=7]  vs  0.7%  [n=3],  (risk difference not statistically significant); incidences of drug-related SAEs were 0.9% for pembrolizumab+axitinib and 0.2% for both sunitinib and the RSD; Grade 3 to 5 events were 1.9% for pembrolizumab+axitinib vs 1.2% for sunitinib and 0.9% for the RSD and drug-related Grade 3 to 5 AEs were 0.9% [n=4] vs 0.2% [n=1] for pembrolizumab+axitinib compared to sunitinib. The (higher) rates of Nephritis and Creatinine increased (compared to the RSD) are depicted in the SmPC. Review of the renal toxicity,  showed    a  higher  proportion  of  Renal  Adverse  Events  (40.3%  vs.  29.4%,  respectively),  in particular of drug-related and of more severe renal AEs, for the pembrolizumab+axitinib in respect to the SOC arm. PTs with largest difference between study treatments were the following: Proteinuria, Acute renal failure,  Renal  failure and Renal impairment .  The  well-known association of diarrhea and acute kidney failure occurred only in few participants. No modifications to the SmPC are needed, as Acute Kidney Injury is already included in Table 2 of Section 4.8 and Proteinuria rates appear overall similar to those reported for axitinib monotherapy.

Subjects with AEs leading to deaths up to 90 days of last dose were quite comparable among study arms with 11 (2.6%) subjects in the pembrolizumab+axitinib and 15 (3.5%) in the sunitinib arm. In the combination arm reported reasons for death were: Cardiac arrest, Death, Myasthenia gravis, Myocarditis, Necrotizing fasciitis, Plasma cell myeloma, Pneumonitis, Pulmonary embolism, Pulmonary thrombosis, and Respiratory failure (all registered in one case each). In the combination treatment, 4 fatal events were judged by the investigator to be associated with pembrolizumab: Myasthenia gravis, Myocarditis, Necrotizing fasciitis, and Pneumonitis. With regard to the AEs leading to death considered pembrolizumab-related by investigator, Pneumonitis , Myastenic syndrome and Myocarditis are already reported in Keytruda SmPC. After additional review of Necrotizing fasciitis as possibly immune-related event, based on available information it is agreed with the MAH that data are currently insufficient to support  an  update  of  the  SmPC  and  that  these  AEs  will  be  further  monitored  through  routine pharmacovigilance activities. Though it is noted that in 6 out of the 11 patients who died following AEs, there was an history of hepatic toxicity during treatment exposure (Grade 4 in 1 case, Grade 3 in 4 cases and Grade 1 in the remaining case) and that in two instances (ID numbers redacted) the time between

<div style=\"page-break-after: always\"></div>

hepatic AE and death is rather short, based on patient history review,  a relationship between the liver toxicity and the fatal outcome is considered unlikely.

In the group treated with pembrolizumab-axitinib, the proportions of overall AEOSIs (51.3% vs 36.2%) and  of  all  event  categories  (except  deaths)  were  increased  in  respect  to  the  sunitinib  group.  Dose modifications  and  treatment  discontinuations  due  to  AEOSIs  were  much  more  frequent  with  the combination  compared  to  sunitib  and  pembrolizumab  monotherapy  (Reference  safety  dataset).  A difference of &gt;2% in frequencies between study arms were found for Adrenal insufficiency (3.0% vs 0.2% in pembrolizumab-axitinib and sunitinib groups respectively), Hepatitis (2.8% vs 0.5%), Hyperthyroidism (12.8%  vs  3.8%), Pneumonitis (2.8%  vs  0.2%),  and Thyroiditis (2.8%  vs  0.5%).  Notably,  similar proportions across study arms were reported for Hypothyroidism and Nephritis . AEOSIs with Grade 3-5 in severity were documented in 10.7% of subjects treated with combination treatment and in only 1.9% of those receiving sunitinib. Distribution of outcomes of AEOSIs were similar in KN426 study arms, with approximately one third that resolved without sequelae. Fatal events were Pneumonitis, Myasthenic Syndrome, Myocarditis in one case each of the combination arm and Hepatitis in the sunitinib arm. With regard to Myositis , the MAH adapted Table 2 and classified the AE of myositis in the same frequency category for pembrolizumab monotherapy and the combination with axitinib.

Out  of  the  12 Hepatitis AEOSIs,  that  presented  after  a  median  of  54  days,  10  were  judged  to  be drug-related (9 Grade 3-5) and 9 were classified as SAEs. Overall, 67% of patients were treated with corticosteroids, and, except 1 that developed sequelae, all resolved (9 subjects; 75%) or were resolving at the time of data cut-off (2 subjects; 16.7%).

With regards to thyroid AEOSIs, in the safety profile of pembrolizumab+axitinib an exceeding frequency of Hypothyroidism as  well  as  of Hyperthyroidism is  noted  in  respect  to  known  pembrolizumab monotherapy safety. Furthermore, a slight increase in Thyroiditis is also found (2.8% in pembrolizumab+axitinib vs 0.5% in sunitinib). Although these are expected ADR of both pembrolizumab and axitinib, the frequencies appear relevant, in particular for hyperthyroidism. Median time to onset was approximately  similar  among  combination  treatment  and  pembrolizumab  monotherapy.  Regarding outcomes, while most of hypothyroidism events did not resolve (62.5%) (and are treated with continued hormone replacement therapy), most of the hyperthyroidism events (85.5%) reassuringly did resolve. It is agreed not to add the information regarding high rate of thyroid disturbances when pembrolizumab is used in combination with axitinib in Section 4.4 of the SmPC, as frequencies [very common] are provided in Table 2 of Section 4.8.

With regards to laboratory findings, in the pembrolizumab+axitinib arm the following were the most common abnormalities: Glucose increased (61.9%), ALT increased (59.6%), AST increased (56.7%), Creatinine increased (43.0%), Sodium decreased (35.0%), Potassium increased (34.1%), Lymphocyte decreased (33.3%), and Albumin decreased (31.9%). When comparing study arms, pembrolizumab+axitinib had higher liver test abnormalities, while the sunitinib arm showed increased myelotoxicity abnormalities.

Analysis of treatment-emergent Hepatic Adverse Events , defined by 3 MedDRA SMQs and hepatitis AEOSI and assessed in the overall study population and in the Hepatic Events Analysis Set (HEAS; n=287), showed in the pembrolizumab+axitinib arm when compared to sunitinib controls increased proportions of overall hepatic events (40.6% vs 26.6%), drug-related hepatic AEs (34.3% vs 20.7%), grade 3-5 hepatic AEs (21.2% vs 6.1%), grade 3-5 drug-related hepatic AEs (18.9% vs 4.0%), serious hepatic  AEs  (7.0%  vs  0.9%),  serious  drug-related  hepatic  AEs  (6.3%  vs  0.5%),  and  of  drug discontinuation due to hepatic AEs (13.3% vs 0.5%), to drug-related hepatic AEs (13.1% vs 0.5%), to serious hepatic AEs (4.9% vs 0.2%), and to serious drug-related hepatic AEs (4.7% vs 0.2%). Most

<div style=\"page-break-after: always\"></div>

common (&gt;1% incidence) PTs for hepatic AEs were principally ALT increased (26.8%; grade 3-5 13.3%; drug-related 23.8%) and AST increased (26.1%; grade 3-5 7.0%; drug-related 22.6%), followed by Blood bilirubin increased (6.5%; grade 3-5 0.9%; drug-related 4.4%), Hepatic function abnormal (3.5%; grade  3-5  1.6%;  drug-related  3.0%), γ -GT  increased (1.9%;  grade  3-5  0.9%;  drug-related  0.7%), Hepatitis (1.6%;  grade  3-5  1.4%;  drug-related  1.4%), Hyperbilirubinemia (1.6%;  grade  3-5  0%; drug-related 1.2%), Liver function test increased (1.2%; grade 3-5 0.7%; drug-related 0.7%). Subjects treated  with  pembrolizumab+axitinib  in  comparison  to  those  receiving  sunitinib,  showed  higher proportions in ALT and AST increased. Additionally, ALT or AST elevation concurrent with total bilirubin elevation  (+/-  ALP  elevation)  was  more  common  in  the  pembrolizumab+axitinib  arm.Evaluation  of Drug-Induced Serious Hepatotoxicity (eDISH) plots displayed subjects (n=15) in the Hy's Law quadrant, raising the concern of Drug-Induced Liver Injury with pembrolizumab+axitinib. First treatment-emergent ALT &gt;3xULN events, that occurred after a mean of 103 days of exposure and was treated with systemic steroids  in  62-100%  of  cases  (growing  frequency  with  increasing  severity),  resolved  in  82-94%  of subjects with decreasing frequency based on highest level reached. Based on ALT increase category (≥3 x ULN, ≥5 x ULN, ≥10 x ULN and ≥20 x ULN), re -challenge with combination treatment was carried out in 51-11% of cases, with further ALT elevation (&gt;3xULN) event in 43.6% with consequent recovery in all (guidance  for  evaluation  and  management  of  patients  with  AST/ALT  elevation,  including  algorithms regarding study drug rechallenge, were progressively updated during the study conduction). In only 7 patients ALT did not recover to Grade 0-1 after the first hepatic event (ALT ≥ 3xULN). For most of these patients, non-recovery appeared to be related to limited follow-up (lack of follow-up data, death, event 15 days prior to data cutoff). No correlation could be determined with lack of corticosteroid treatment based on this limited number. 41 patients (45%) had a recurrence of ALT elevation after rechallenge with treatment and all recovered (see Table 4.5.23). In the pembrolizumab + axitinib arm 92 participants received study treatment following recovery of the first ALT ≥ 3 x ULN. Of these 41 participants (44.6%) had a second episode of ALT ≥ 3xULN, 23 (56%) received steroids, and all recovered to &lt;3xULN prior to the data cutoff. Considering that 44% of patients (18/41) recovered also from the second hepatic event without corticosteroid treatment it is not justified to recommend corticosteroids as mandatory.

Within the HEAS popu lation, ALT≥3xULN occurrence seems not associated with clinically relevant patient or  disease  characteristics  or  use  of  potentially  concomitant  hepatotoxic  medications.  Due  to  first ALT≥3xULN event, median treatment delay was of 37.5 days, and subjects per manently discontinuing pembrolizumab+axitinib due to hepatic toxicity in 73% of cases subsequently received antineoplastic therapy.

With regard to corticosteroid treatment for hepatic AEs, it is notable that the lack of immunosuppressive therapy did not appear to have had a negative impact on the rate of recovery and only 62% received systemic steroids for ALT ≥ 3 x ULN, 76% for ALT ≥ 5 x ULN and 84.4% for ALT ≥ 10 x ULN, although systemic  corticosteroids  had  been  recommended  in  the  protocol  for  Grade ≥ 2  AEs  in  line  with recommendations  in  the  SmPC.  The  MAH  clarified  that  Management  guidelines  implemented  in  the protocol (Amendment 8) recommended to promptly interrupt both study drugs if ALT/AST elevations &gt;3×ULN were observed and initiate steroids only if the elevations did not resolve promptly without corticosteroid treatment (recommendations based on the difference in half-life of axitinib (~6 hours) and pembrolizumab  (3  to  4  weeks).  Further,  the  MAH  provided  data  to  support  that  the  frequency  of corticosteroid  use  for  hepatic  AEs  in  KEYNOTE-426  is  generally  consistent  with  the  frequency  of corticosteroid  use  for  the  adverse  event  of  special  interest  (AEOSI)  of  hepatitis  across  the  entire pembrolizumab  program  (that  means  that  despite  the  recommendations  in  the  SmPC  to  initiate corticosteroid treatment for hepatic AEs ≥ 2, corticosteroids are applied in a lower proportion in clinical practice). Data for rechallenge of patients with more severe ALT elevations (ALT ≥10 × ULN, ALT ≥20 × ULN, and ALT ≥3 × ULN as sociated with bilirubin ≥2 × ULN) were provided and show, although based on limited  patient  numbers,  that  even  in  these  patients  subsequent  recurrences  following  re-challenge recovered again. In the SmPC, for subjects with ' ALT or AST ≥ 10 times ULN or &gt; 3 times ULN with

<div style=\"page-break-after: always\"></div>

concurrent  total  bilirubin ≥ 2  times  ULN,  both  KEYTRUDA  and  axitinib  should  be  permanently discontinued and corticosteroid therapy may be considered' according to the SmPC which is endorsed.

In section 4.2 of the SmPC, ' rechallenge with a single medicine or sequential rechallenge with both medicines after recovery may be considered ' if ALT or AST ≥ 3 times ULN but &lt; 10 times ULN. According to Table 4.5.23 the choice of retreatment after recovery did not appear to influence the probability of a second hepatic AE (nearly 50%). However only 3 patients received pembrolizumab monotherapy after recovery  and  median  duration  of  treatment  after  recovery  was  only  28  days  for  pembro  mono  (as opposed to 155 days for axitinib monotherapy in 34 patients and 263 days for pembrolizumab + axitinib in 55 patients). Drug discontinuation was due to PD in 2 out of 3 cases. In view of these limited data the recommendation of a rechallenge with pembrolizumab as monotherapy appears somewhat questionable, but from provided updated data it appears to be no profound rationale to assume that a re-challenge with pembrolizumab mono would not be a reasonable option for patients with axitinib related AEs or that one sequence of re-challenge would be more preferable.

In  the  same  SmPC  section,  the  MAH  provided  dosing  guidelines  for  liver  enzyme  elevations  when Keytruda is combined with axitinib:

| In patients with RCC being treated with KEYTRUDA in combination with axitinib:                                                                                                                                                                                                                                  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| If ALT or AST > 3 times ULN but < 10 times ULN, both KEYTRUDA and axitinib should be withheld until these adverse reactions recover to Grades O-1. Corticosteroid therapy may be considered. Rechallenge with a single medicine or sequential rechallenge with both medicines after recovery may be considered. |
| If ALT or AST > 10 times ULN or > 3 times ULN with concurrent total bilirubin >2 times ULN, both KEYTRUDA and axitinib should be permanently discontinued and corticosteroid therapy may be considered.                                                                                                         |

In participants with ALT or AST ≥ 3 × ULN to &lt;10 × ULN, without concurrent total bilirubin elevation a higher  proportion  of  patients  without  steroids  did  not  recover  (14%;  4/29)  compared  to  those  that received high or low dose steroids (2%; 1/42). However, most of the patients without steroid treatment recovered (86%; 25/29), time to recovery was similar for all patients and numbers for non-recovered patients after the first AE are too small to draw definitive conclusions and justify steroid treatment for all patients treated with the combination therapy. In participants with ALT or AST ≥ 10 × ULN, or ALT/AST ≥ 3 × ULN with concurrent total bilirubin ≥ 2 × ULN most of the patients received steroids (34/44) and 6.8% (3/44) patients did not recover from the first events, but all received steroid treatment. In view of these data, the very general recommendation for patients with liver enzyme elevations 'corticosteroid therapy may be considered' can be considered acceptable.

The rewording of the text applicable to RCC patients in Table 1 of Section 4.2 of the SmPC is endorsed (see  SmPC),  but  the  different  approach  used  with  regards  to  subjects  with  ALT  &gt;5  times  ULN, (permanently discontinue for all indications while could be rechallenged in RCC) might be misleading as in  section  4.4  ( Immune-related  hepatitis )  it  is  stated  that  'Corticosteroid  should  be  administered'. Concerning  this,  the  MAH  clarified  that  the  provided  information  is  meant  to  be  understood  as complementary in view of the different underlying pathophysiologic mechanisms of both drugs. This is acceptable.

In addition, the MAH  provided data for 37 patients with a second re-challenge (with pembrolizumab alone,  axitinib  alone  or  both  pembrolizumab  and  axitinib).  A  total  of  12  participants  had  another recurrence of ALT ≥ 3 × ULN, most of these subsequent ALT elevations (7 out of 12) were ≥ 3 to &lt;5 × ULN and all these recurrent ALT elevations subsequently resolved. Despite the limited patient numbers, it is agreed that data support the safety of multiple re-challenges. Based on provided updated data including results for a second re-challenge of study drugs, there appears to be no profound rationale to assume that a re-challenge with pembrolizumab mono would not be a reasonable option for patients with axitinib related AEs or that one sequence of re-challenge would be more preferable. The MAH further clarifies that the recommendation to discontinue pembrolizumab permanently for recurrent Grade 3 adverse reactions

<div style=\"page-break-after: always\"></div>

applies also for the combination therapy but only for immune-related (hepatic) events. This is further clarified in the SmPC by:

' KEYTRUDA, as monotherapy or as combination therapy, should be permanently discontinued for Grade 4 or recurrent Grade 3 immune-related adverse reactions, unless otherwise specified in Table 1 '.

In section 4.4, the MAH added the following paragraph:

Use ofpembrolizumabin combinationwith axitinibfor first-line treatment of patients with RCC When pembrolizumab is given with axitinib, higher than expected frequencies of Grades 3 and 4 ALT and AST elevations have been reported in patients with advanced RCC (see section 4.8). Liver enzymes should be monitored before initiation of and periodically throughout treatment. More frequent monitoring of liver enzymes as compared to when the medicines are used in monotherapy may be considered. Medical management guidelines for both medicines should be followed (see section 4.2 and refer to the Summary of Product Characteristics for axitinib).

The inclusion of this paragraph and its wording is supported, as it is agreed that an increased incidence of elevated ALT and AST represents the most frequent observed hepatic AEs, and reflects the hepatic AE profile associated with the combination of pembrolizumab+axitinib most appropriately. Although, 'more frequent monitoring' may be considered an unclear indication, as in the SmPCs of pembrolizumab and axitinib there an exact frequency of monitoring is not stated, the MAH argues that the frequency of liver function monitoring depends on the clinical circumstances and that a more definitive recommendation would not be considered helpful to address this variability, and this is agreed.

KN426  safety  analyses  did  show  more  subjects  receiving  pembrolizumab+axitinib  having drug discontinuation due to AEs than those treated with sunitinib (25.9% vs 10.1%, respectively). The observed incidence of AEs leading to the discontinuation of any drug was 30.5%  in the pembrolizumab+axitinib group, but simultaneous discontinuation of both drugs in the pembrolizumab+axitinib  group  (7.7%)  was  lower  compared  with  AEs  leading  to  discontinuation  of sunitinib (13.9%). The most common reason for stopping study drug in the combination arm was ALT increased (31 subjects, [7.2 %]) AST increased (20 subjects, [4.7%]), and Hepatic function abnormal (6 subjects, [1.4%]). When looking at frequency and reasons for specific study drug discontinuation, no relevant differences could be found between pembrolizumab and axitinib. Median time to discontinuation is  around  60  days.  Overall interruption  of  study  drugs due  to  AEs was  reported  in  69.9%  for pembrolizumab  and/or  axitinib  (pembrolizumab  and  axitinib  35.7%,  pembrolizumab  50.3%,  axitinib 63.9%) and in 49.9% for sunitinib.  Among  reasons,  diarrhoea  and  transaminase  elevation  were  as frequently  recorded  for  pembrolizumab  and  axitinib,  this  latter  was  interrupted  more  often  due  to Hypertension (13.3% vs 0.7%, respectively) and Palmar-plantar erythrodysaesthesia syndrome (6.8% vs  0.5%,  respectively).  Compared  to  sunitinib,  in  the  pembrolizumab+axitinib  arm  an  overall  lower proportion  of  subjects  with  dose  reduction  due  to  AEs (20.3%  vs  30.1%,  respectively),  due  to drug-related AEs (20% vs 28.5%), or due to grade 3-5 AEs (10.3% vs 14.4%) were found.

AEs summary by subgroups shows an increase in incidences of all AEs categories for elderly across treatments,  with  a  more  pronounced  difference  between  younger  and  older  age  categories  in pembrolizumab+axitinib-treated subjects than in those receiving suntinib. Between-treatment comparisons showed the largest differences in AEs frequencies among the 75-84 age group. With only 36 participants ≥75 years in the pembrolizumab + axitinib group the safety data were insufficient for a thorough characterization in this age group, and this has been reflected in the SmPC.

At gender analyses, female subjects had higher proportions of grade 3-5 AEs (82.9% vs 72.9%) and of drug-related grade 3-5 AEs (71.5% vs 59.5%), while SAE, drug-related SAEs compared to males, while discontinuations were not dissimilar between subgroups. Also, in the sunitinib arm, a higher frequency of grade 3-5 AEs and grade 3-5 drug-related AEs was found in females compared to males. Frequency of AEs

<div style=\"page-break-after: always\"></div>

leading to death was slightly higher in males (3.3%) than in females (0.8%), in accordance with that found in the Pembrolizumab Monotherapy RSD (5.1%). AEs summary table by KPS ranges (90/100 vs 70/80) did not show relevant differences in safety profiles among groups With regards to extrinsic factors, the  safety  profile  of  pembrolizumab+axitinib  was  comparable  between  geographical  regions  of enrollment.

Immunogenicity  assessment in  pembrolizumab+axitinib-treated  subjects  documented  treatment emergent ADA in 6.2% (1.4-3.8% for pembrolizumab monotherapy across indications) and incidence of treatment-emergent neutralizing positive status in 0.8% (0.2-1.6% for pembrolizumab monotherapy). Due to limited number of patients with treatment-emergent ADA, it is difficult to draw conclusions on the impact on safety profile or to merit further investigations regarding possible confounding factors.

## Comparison of AEs for pembrolizumab+axitinib in KN426 versus axitinib in study A4061051

There  is  no  direct  comparison  between  pembrolizumab+axitinib  and  axitinib  alone.  Therefore,  the assessment of safety should take into account the limitation of indirect comparison between different studies.  Based  on  the  data  provided,  proportions  of  subjects  with  overall  AEs  (98.4%  vs  88.9%, respectively) and of drug-related AEs (96.3% vs 86.2%, respectively) were higher in pembrolizumab combination treatment in respect to axitinib when used for RCC treatment. The pattern of most common PTs found for the combination treatment was similar to that reported for axitinib monotherapy: Diarrhea (54.3% and 49.7%, respectively) Hypertension (44.5% and 48.7%, respectively), Fatigue (38.5% and 32.8%, respectively), Decreased appetite (29.6% and 28.6%, respectively), Palmar-plantar erythrodysaesthesia  syndrome (28%  and  26.5%), Dysphonia (25.4%  and  23.3%,  respectively). Compared to axitinib, in pembrolizumab+axitinib-treated subjects, increased proportions of thyroid AEs ( Hypothyroidism 35.4%  vs  20.6%; Hyperthyroidism 12.8%  vs  3.2%,  respectively)  as  well  as  of hepatotoxicity  ( ALT  increased 26.8%  vs  10.6%; AST  increased 26.1%  vs  7.9%,  respectively)  were reported. Incidences of Grade 3 to 5 hypertension, ALT increased, and AST increased were higher in pembrolizumab+axitinib as expected based on the safety profile for axitinib monotherapy; Hypertension is a known AE for axitinib, but the reason for the higher incidence of Grade 3 to 5 hypertension (22.1%) in the pembrolizumab + axitinib group relative to what was observed for axitinib in Study A4061051 (13.8%) remains unclear; however apart from one Grade 4 event (hypertensive crisis), all events were Grade 3 and only 1 participant discontinued either pembrolizumab or axitinib due to hypertension.

Noteworthy the incidence of drug-related SAEs in the pembrolizumab + axitinib group (23.8%) was four times higher relative to what was observed for axitinib monotherapy in Study A4061051 (5.3%). While the incidence of Diarrhoea was similar to what was observed for axitinib in Study A4061051 (2.8% versus 2.6%, respectively), the rates of hepatic SAEs as well as of ALT increased and AST increased , in particular Grade 3 to 4 elevations, in the pembrolizumab + axitinib group were higher than would be expected from the combination of pembrolizumab and axitinib monotherapies.

## Comparison of AEs for pembrolizumab+axitinib in KN426 versus pembrolizumab monotherapy in KN427 study

In the indirect comparison between the KN426 and the KN427, both conducted for treatment of RCC, whilst similar proportions of subjects with overall AEs in the two treatment strategies, drug-related AEs were more often found in pembrolizumab combination treatment compared to monotherapy (96.3% vs 80.9%, respectively). The frequency of almost all most common (&gt;30% incidence) PTs reported for in pembrolizumab+axitinib resulted higher than that found with pembrolizumab monotherapy: Diarrhea (54.3%  vs  22.7%,  respectively), Hypertension (44.5%  vs  8.2%,  respectively), Fatigue (38.5%  vs 38.2%, respectively), Hypothyroidism (35.4% vs 11.2%, respectively).

## Comparison  of  KN426  study  with  pooled  Pembrolizumab  Monotherapy  Reference  Safety Dataset

<div style=\"page-break-after: always\"></div>

In comparison with the pooled reference dataset for pembrolizumab monotherapy across indications, the KN426 AEs summary highlights a clearly worse safety profile for pembrolizumab when associated with axitinib. Indeed, higher incidence of drug-related AEs (96.3% vs 70.7%, respectively), Grade 3-5 AEs (75.8% vs 48.5%), Grade 3-5 drug-related AEs (62.9% vs 14.9%) and drug-related SAEs (23.8% vs 10.5%) were found. Furthermore, while AEs leading to deaths were similar in pembrolizumab+axitinib-treated subjects of KN426 and the pooled monotherapy dataset, a considerably higher proportion of subjects experienced overall and drug-related AEs leading to drug discontinuation, interruption or dose modification with the combination.  With regards to AEOSIs, a higher proportion of subjects with at least one event was found in the combination arm compared to pembrolizumab monotherapy for overall and all event categories (overall 51.3% vs 22.7%, drug-related events 47.1% vs 19.4%, grade 3-5 events 10.7% vs 5.7%, grade 3-5 drug-related events 8.9% vs 4.9%, and SAEs (9.8% vs 5.8%). Adrenal Insufficiency (3.0% vs 0.8%), Hepatitis (2.8% vs 0.7%), Hyperthyroidism (12.8% vs 3.3%), Hypothyroidism (35.4% vs 9.9%), Nephritis (1.4% vs 0.3%), Thyroiditis (2.8% vs 0.7%) all had a &gt;1% higher incidence in the combination treatment when compared to pembrolizumab monotherapy. Median time to first AEOSI tended to be shorter in the combination treatment than in the pembrolizumab monotherapy dataset for the following events: Hepatitis (54 vs 61 days, respectively), Hypothyroidism (94 vs 105 days), and Myasthenic syndrome (40.5 vs 57.5 days). Compared to pembrolizumab monotherapy, a higher incidence of adrenal insufficiency is noted in subjects treated with pembrolizumab combined with axitinib, however rates are low and possibly related to longer exposure in RCC setting than in other indications.

## 2.5.2. Conclusions on clinical safety

Overall, the safety assessment of the combination of pembrolizumab+axitinib is partially hampered by the lack of a direct comparison with axitinib in particular within a single study. For 1L treatment of subjects with advanced RCC, the overall safety profile of pembrolizumab+axitinib compares less favourable to sunitinib, but demonstrated as apparently overall manageable. In KEYNOTE-426, a higher rate of all adverse event categories (particularly grade 3-5 AES, SAEs and drug discontinuations due to AEs) for the combination of pembrolizumab with axitinib. Even adjusting for exposure an increased rate of drug-related SAEs and of drug discontinuations due to AEs is observed.

Based on indirect comparison the combination has a clearly worst safety profile compare to monotherapies. Many of the observed toxicities (i.e. diarrhea, hypertension, dysphonia, fatigue, palmar-plantar erythrodysaestesia syndrome) mirror the known individual safety profiles of axitinib and pembrolizumab, although with a higher incidence for some of them. The high occurrence of hepatic adverse events has been addressed in the SmPC (sections 4.2, 4.4. 4.8). A higher frequency Cardiac Arrythmias SMQ/Atrial Fibrillation is observed in the pembrolizumab/axitinib arm compared to the sunitinib arm in KN-426 trial. As causal relationship with pembrolizumab cannot be ruled out, the MAH has added atrial fibrillation/cardiac arrhythmias to ADRs in Section 4.8 of the SmPC.

## 2.5.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.6. Risk management plan

The PRAC considered that the risk management plan version 25.0 is acceptable.

The CHMP endorsed the Risk Management Plan version 25.0 with the following content:

<div style=\"page-break-after: always\"></div>

## Safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                                                        |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Immune-Related Adverse Reactions (including immune related pneumonitis, colitis,hepatitis, nephritis, and endocrinopathies)                                                                                                                                                                                       |
| Important potential risks    | For hematologic malignancies: increased risk of severe complications of allogeneic stem cell transplantation (SCT) in patients who have previously received pembrolizumab Graft versus host disease (GVHD) after pembrolizumab administration in patients with a history of allogeneic stem cell transplant (SCT) |
| Missing information          | Long term safety                                                                                                                                                                                                                                                                                                  |

No changes to the list of safety concerns were made as a result of this extension of indication.

## Pharmacovigilance plan

## Table: On-going and planned additional pharmacovigilance activities

| Study Status                                                  | Study/activity Type, title and category                                                                                                                                                                                                                     | Summary of Objectives                                                                                                                                                                                                                                                                     | Safety concerns addressed                                                                                                                                                                                                | Milestones                                                    | Due dates                                                     |
|---------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|---------------------------------------------------------------|
| Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                               | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                                             | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                            | Category 3 - Required additional pharmacovigilance activities | Category 3 - Required additional pharmacovigilance activities |
| Started                                                       | Clinical trial A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) versus Platinum Based Chemotherapy in Treatment Naïve Subjects with PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (KN042) | To evaluate the overall survival (OS) and progression free survival (PFS) and to examine the safety and tolerability profile of pembrolizumab in subjects with PD-L1 positive 1L advanced/metastatic NSCLC, treated with pembrolizumab compared to standard of care (SOC) chemotherapies. | -Important identified risks (Immune-related adverse reactions) -Important potential risks (GVHD after pembrolizumab administration in patients with a history of allogeneic SCT) -Missing information (Long term safety) | Final Study Report                                            | Dec 2019                                                      |

<div style=\"page-break-after: always\"></div>

## Table: On-going and planned additional pharmacovigilance activities

| Study Status   | Study/activity Type, title and category                                                                                                                    | Summary of Objectives                                                                                                                                                                                                                                                                                     | Safety concerns addressed                                                                                                                                                                                                                                                                                                        | Milestones         | Due dates   |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|-------------|
| Started        | Clinical Trial A Phase Ib Multi-Cohort Trial of MK-3475 (pembrolizumab) in Subjects with Hematologic Malignancies (KN013)                                  | To examine the safety and tolerability of pembrolizumab in subjects with hematologic malignancies including, Hodgkin lymphoma, mediastinal large B cell lymphoma (MLBCL), relapsed/refractory non-Hodgkin lymphoma (NHL), myelodysplastic syndrome (MDS) and multiple myeloma.                            | -Important identified risks (Immune-related adverse reactions) -Important potential risks (For hematologic malignancies: increased risk of severe complications of allogeneic SCT in patients who have previously received pembrolizumab ; GVHD after pembrolizumab administration in patients with a history of allogeneic SCT) | Final Study Report | Mar 2019    |
| Started        | Clinical Trial A Phase II Clinical Trial of MK-3475 (Pembrolizumab) in Subjects with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL) (KN087) | To determine the safety and tolerability of pembrolizumab in subjects with relapsed or refractory classical Hodgkin Lymphoma (cHL) and to evaluate overall response rate (ORR), progression free survival (PFS), duration of response (DOR) and overall survival (OS) of pembrolizumab in study subjects. | -Important identified risks (Immune-related adverse reactions) -Important potential risks (For hematologic malignancies: increased risk of severe complications of allogeneic SCT in patients who have previously received pembrolizumab ; GVHD after pembrolizumab administration in patients with a history of allogeneic SCT) | Final Study Report | Aug 2021    |

<div style=\"page-break-after: always\"></div>

## Table: On-going and planned additional pharmacovigilance activities

| Study Status   | Study/activity Type, title and category                                                                                                                                                                      | Summary of Objectives                                                                                                                                                                                                                                                    | Safety concerns addressed                                                                                                                                                                                                                                                                                                        | Milestones         | Due dates   |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|-------------|
| Started        | Clinical Trial A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma (KN204)              | To compare overall survival (OS), progression free survival (PFS) and overall response rate (ORR) of pembrolizumab when compared to Brentuximab Vedotin in subjects with relapsed or refractory cHL and to examine the safety and tolerability between treatment groups. | -Important identified risks (Immune-related adverse reactions) -Important potential risks (For hematologic malignancies: increased risk of severe complications of allogeneic SCT in patients who have previously received pembrolizumab ; GVHD after pembrolizumab administration in patients with a history of allogeneic SCT) | Final Study Report | Apr 2021    |
| Planned        | Cumulative review of literature, clinical trial and post-marketing cases for the risks of encephalitis, sarcoidosis and GVHD after pembrolizumab administration in patients with a history of allogeneic SCT | To monitor, identify and evaluate reports of encephalitis, sarcoidosis and GVHD after pembrolizumab administration in patients with a history of allogeneic SCT.                                                                                                         | Important potential risk of GVHD after pembrolizumab administration in patients with a history of allogeneic SCT                                                                                                                                                                                                                 | PSUR               | 2019        |
| Started        | Clinical trial A Phase I/II Study of MK-3475 in Combination with Chemotherapy or Immunotherapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma (KN021)                         | To determine the recommended Phase II dose for MK-3475 in combination with chemotherapy or immunotherapy in subjects with unresectable or metastatic NSCLC.                                                                                                              | -Important identified risks (Immune-related adverse reactions) -Important potential risks (GVHD after pembrolizumab administration in patients with a history of allogeneic SCT)                                                                                                                                                 | Final Study Report | Apr 2020    |

<div style=\"page-break-after: always\"></div>

## Table: On-going and planned additional pharmacovigilance activities

| Study Status   | Study/activity Type, title and                                                                                                                                                                                                                                                                                                                                                                        | Summary of Objectives                                                                                                                                                                                                                                                                                               | Safety concerns addressed                                                                                                                                                        | Milestones         | Due dates   |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|-------------|
| Started        | category Clinical Trial A Randomized, Double-Blind, Phase III Study of Platinum+ Pemetrexed Chemotherapy with or without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KN189)                                                                                                                                                                    | To evaluate the antitumor activity of pembrolizumab in combination with chemotherapy compared with saline placebo in combination with chemotherapy and to evaluate the antitumor activity of pembrolizumab in combination with chemotherapy compared with saline placebo in combination with chemotherapy using OS. | -Important identified risks (Immune-related adverse reactions) -Important potential risks (GVHD after pembrolizumab administration in patients with a history of allogeneic SCT) | Final Study Report | Jun 2021    |
| Started        | Clinical Trial A randomized, active-controlled, multicenter, open-label Phase III clinical trial to examine the efficacy and safety of Pembrolizumab versus the choice of 3 different standard treatment options in subjects with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) whose disease has progressed on or after prior platinum-containing chemotherapy (KN040) | To compare the overall survival (OS) in subjects with R/M HNSCC treated with pembrolizumab compared to standard treatment.                                                                                                                                                                                          | -Important identified risks (Immune-related adverse reactions) -Important potential risks (GVHD after pembrolizumab administration in patients with a history of allogeneic SCT) | Final Study Report | May 2020    |
| Started        | Clinical Trial A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KN426)                                                                                                                         | To evaluate and compare PFS per RECIST 1.1 as assessed by BICR and OS in subjects treated with pembrolizumab plus axitinib versus sunitinib monotherapy.                                                                                                                                                            | -Important identified risks (Immune-related adverse reactions) -Important potential risks (GVHD after pembrolizumab administration in patients with a history of allogeneic SCT) | Final Study Report | March 2021  |

<div style=\"page-break-after: always\"></div>

Study KEYNOTE 426 was added to the pharmacovigilance plan in order to address existing safety concerns in the new indication (first line treatment of advanced or metastatic renal cell carcinoma).

## Risk minimisation measures

No changes to the risk minimisation measures were made as a result of this extension of indication.

## 2.7. Update of the Product information

As a result of this variation, section(s) 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are being updated.

The MAH provided supporting extensive summary tables for section 4.8 of the SmPC. The MAH provided a summary Table of ADRs with related frequencies (all grades and grade 3-5) to support the new column for the use of pembrolizumab in combination with axitinib.

The package leaflet has been updated accordingly in section 1. The base file for the revised Product Information in the current submission is the final Product Information from variations EMEA/H/C/3820/II/058 &amp; II/047 and PSUSA/00010403/201803.

## 2.7.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the applicant and has been found acceptable for the following reasons: The proposed changes in the context of this extension of indication do not involve a relevant impact on the PIL.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

This extension of indication of Keytruda is for the first line treatment of advanced or metastatic renal cell carcinoma (RCC) in combination with axitinib.

## 3.1.2. Available therapies and unmet medical need

In the EU, the following agents targeting the VEGF/VEGFR signaling pathway are approved for the 1L treatment of advanced RCC: sunitinib, pazopanib, bevacizumab + IFNα, tivozanib and cabozantinib (in patients who are considered to be intermediate and poor risk).

In addition to agents that target VEGFR and VEGF, other approved agents for advanced RCC include the mTOR inhibitor temsirolimus for patients considered to be poor risk (per the MSKCC risk category) in the 1L setting and the mTOR inhibitor everolimus

Recently, the combination of nivolumab + ipilimumab was approved in the EU for use in treatment-naïve patients with advanced RCC who were considered to be intermediate or poor risk per the IMDC criteria.

According to the main guidelines (RCC: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, update January 2019; NCCN Clinical Practice Guidelines in Oncology: kidney cancer: version 3.2019) tumor histology and risk stratification is important in treatment selection. A prognostic model

<div style=\"page-break-after: always\"></div>

derived from a population of patients with metastatic RCC treated with VEGF-targeted treatment has been more recently developed, known as International Metastatic RCC Database Consortium (IMDC) score: this model take into consideration six clinical parameters to stratify patients into favourable, intermediate and poor prognosis groups: interval from diagnosis to treatment less than 1 year, Karnofski PS&lt;80%, corrected serum calcium&gt;ULN, serum hemoglobin&lt;ULN, absolute neutrophil count&gt;ULN and platelets&gt;ULN. The IMDC model has been derived from a retrospective study of 645 patients treated with VEGF-targeted agents (Heng DY, et al. J Clin Oncol 2009), and validated in an independent dataset (Heng DY, et al.Lancet Oncol 2013). The 2-year OS ranges from 75% in the favourable risk group (none of the 6 factors identified) to 7% in the poor-risk group (3 to 6 factors identified).

## 3.1.3. Main clinical studies

The application is based upon the interim analysis 1 of KEYNOTE-426 Study, is an ongoing, Phase 3, randomized, multicenter, active-controlled, 2 arms, open-label clinical study in first line adult patients with advanced renal cell carcinoma (RCC), comparing the combination of pembrolizumab 200mg Q3W + axitinib 5 mg BID with sunitinib 50 mg QD 4 weeks on 2 weeks off.

The primary objectives of the study were to compare the OS and PFS per RECIST 1.1 by BICR in participants treated with pembrolizumab  + axitinib vs sunitinib. ORR, DCR, DoR, safety and tolerability profile of pembrolizumab, PFS and OS rate at 12, 24 and 18 months, and PROs were secondary objectives.

A total of 861 patients were randomly allocated in one of the 2 arms from 24-OCT-2016 to 24-JAN-2018 across 124 global study sites in 16 countries.

## 3.2. Favourable effects

- A statistically significant benefit in OS has been observed for pembrolizumab + axitinib over sunitinib (HR of 0.53, 95% CI 0.38, 0.74; p=0.00005);
- A statistically significant benefit in PFS has been also observed for pembrolizumab + axitinib over sunitinib (HR of 0.69, 95% CI 0.57, 0.84; p=0.00014);
- Objective response rate based on BICR assessment were observed in 59.3% (95% CI 54.5,63.9) of the patients treated with the combination compared to 35.7% (95% CI 31.1,40.4) in the control arm. The median time to response is similar in the two arms, while the duration of response tend to be longer in the experimental arm with 70.6% of patients still in response at 12 months in the control arm vs 61.6% in the control arm.
- Updated data confirmed the OS benefit in the overall population, as well as in the IDMC poor (HR= 0.50, 95%CI 0.29,0.87) and intermediate (HR= 0.52, 95%CI 0.36,0.75) risk categories.
- Updated PFS data show a trend to an improved effect in the IDMC favourable risk subgroup compared to data initially submitted.
- Permanent discontinuation treatment due to AEs does not seem to negatively affect neither the outcome of patients on subsequent treatments nor their prognosis if left untreated.

## 3.3. Uncertainties and limitations about favourable effects

- The immaturity of efficacy data that do not allow to draw any sound conclusion with regard to the IMDC favourable risk group (HR 0.94, 95%CI 0.43, 2.07). The OS KM curves in this subgoup are

<div style=\"page-break-after: always\"></div>

superimposable at this stage. The final CSR should be provided post-approval, in particular to further characterize the benefit of the combination treatment.

- The lack of monotherapy experimental arms in study KN-426 hampers the assessment of the contribution of each component of the combination treatment. However, a positive contribution of each component can be assumed on the basis of the plausible mechanism of action of the two agents in the combination, evidence of single-agent activity, high activity of the combination in terms of ORR and PFS compared to monotherapy albeit in indirect comparisons, and the established contribution of these agents in different tumour types.

## 3.4. Unfavourable effects

Overall, the safety assessment of the combination of pembrolizumab+axitinib is partially hampered by the lack of a direct comparison within a single study. In the pembrolizumab+axitinib arm when compared to the sunitinib arm, the following were found:

- Increased frequencies of all AE categories, except for deaths;
- Confirmed higher risk for drug-related SAE (2.87 vs 1.99/100 p-m, respectively) and for all types of AEs leading to drug discontinuation when exposure-adjusted rates were considered;
- Increased risk of drug-related transaminase elevation and drug-related dysphonia;
- Overall AEOSIs frequency of 51.3% vs 36.2%;
- Overall treatment-emergent Hepatic Adverse Events frequency of 40.6% vs 26.6%;
- Non-fatal Drug-Induced Liver Injury in 15 subjects;
- High frequency of thyroid adverse events: Hyperthyroidism 12.8% vs 3.8%, Hypothyroidism 35.4% vs 31.5% , Thyroiditis 2.8% vs 0.5%;
- The incidences of ALT increased and AST increased, in particular Grade 3 to 4 elevations, were higher than would be expected from the combination of pembrolizumab and axitinib monotherapies; the incidences of the PTs ALT and AST increased were 26.8% and 26.1%, respectively in the pembrolizumab+axitinib group, 6.0% and 6.2% in the RSD, and 10.6% and 7.9% for axitinib in Study A4061051.
- Incidences of Grade 3 to 5 hypertension (22.1%) and hyperthyroidism (12.8%) in the pembrolizumab + axitinib group were higher compared to those for sunitinib, pembrolizumab monotherapy, and axitinib. However both AEs were clinically manageable.
- A trend toward higher incidences of severe and serious acute kidney injury was notable in the pembrolizumab + axitinib group; however absolute numbers were small (Grade 3 to 5 events 1.9%, SAEs 1.6).
- Among-drug related SAEs, it is noted that cardiac disorders, whilst having rates of 0.4% for pembrolizumab monotherapy, are reported at 1.6% for the pembrolizumab+axitinib arm (1.4% the  sunitinib  arm).  Cardiac  arrhythmias  SMQ  showed  an  increased  proportion  of  events  in subjects treated with pembrolizumab+axitinib compared to those receiving sunitinib (5.8% vs 2.4%, respectively), and  similar  differences  for  drug-related  AEs  (2.3%  vs  0.2%)  and  SAEs (1.4% vs 0.2%). Similarly, subjects with Atrial Fibrillation were 1.6% vs 0.2%, respectively. Cardiac arrhythmias SMQ also show higher exposure-adjusted rates pembrolizumab+axitinib-treated subjects when compared to those receiving sunitinib (0.6 in

<div style=\"page-break-after: always\"></div>

pembro combo vs 0.3/100 person-months in sunitinib). Cardiac arrhythmias (including atrial fibrillation) has been included as ADR in the Keytruda SmPC.

The safety profile of pembrolizumab in combination with axitinib compares unfavourable to sunitinib in 1L RCC treatment.

## 3.5. Uncertainties and limitations about unfavourable effects

- Safety data in the age group ≥75 years are limited. This is reflected in the SmPC.

## 3.6. Effects Table

Table 2. Effects Table for KN426 Trial. Data cut-off: 24-AUG-2018 (database lock 24 August 2018)

| Effect                           | Short description                                                                            | Unit                 | Pembro+ axitinib                                       | Sunitinib                                              | Uncertainties / Strength of evidence                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|----------------------------------|----------------------------------------------------------------------------------------------|----------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Favourable Effects               | Favourable Effects                                                                           | Favourable Effects   | Favourable Effects                                     | Favourable Effects                                     | Favourable Effects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| OS (ITT)                         | Time from randomization to death due to any cause                                            | Months HR (95% CI)   | NR vs NR HR of 0.53, (95% CI 0.38, 0.74; p=0.00005)    | NR vs NR HR of 0.53, (95% CI 0.38, 0.74; p=0.00005)    | Dual Primary Endpoints ITT: statistically significant data from IA1 too immature to assess the B/R in all relevant subgroups Lack of direct comparison with monotherapies hampers the assessment of the contribution of each component. Updated descriptive results (data cut-off date 2 Jan 2019) confirmed OS, PFS and ORR benefit of the combination. Updated PFS in the IDMC favourable risk group showed a trend toward improved effect compared to prior data, with ORR advantage. No apparent detrimental effect is seen in OS, although data are quite immature. |
| PFS per RECIST 1.1 by BICR (ITT) | Time from randomization to first PD (per RECIST 1.1 based on BICR) or death due to any cause | Months HR (95% CI)   | 15.1 vs 11.0 HR of 0.69 (95% CI 0.56, 0.84; p=0.00012) | 15.1 vs 11.0 HR of 0.69 (95% CI 0.56, 0.84; p=0.00012) |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| ORR per RECIST 1.1 by BICR (ITT) | proportion of patients who achieved complete or partial response (secondary endpoint)        | %                    | 59.3%                                                  | 35.7%                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Unfavourable Effects             | Unfavourable Effects                                                                         | Unfavourable Effects | Unfavourable Effects                                   | Unfavourable Effects                                   | Unfavourable Effects                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|                                  | Drug-related G 3-5 AEs                                                                       | %                    | 62.9                                                   | 58.1                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                                  | Drug-related SAEs                                                                            | %                    | 40.3                                                   | 31.3                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                                  | Discontinuation due                                                                          | %                    | 30.5                                                   | 13.5                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                                  | Discontinuation due to AEs                                                                   | %                    | 25.9                                                   | 10.1                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                                  | Discontinuation due to drug-related SAEs                                                     | %                    | 17.0                                                   | 9.9                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|                                  | Cardiac Arrythmias SMQ                                                                       | %                    | 5.8                                                    | 2.4                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The combination of pembrolizumab and axitinib demonstrated superiority vs sunitinib in terms of PFS and OS in patients with advanced RCC, supported by an advantage in terms of ORR. Based on updated data, a benefit in PFS and ORR is observed across all IMDC risk group, with no apparent detrimental OS effect in the favourable risk.

For 1L treatment of subjects with advanced RCC, the overall safety profile of pembrolizumab+axitinib compares less favourable to sunitinib, but demonstrated as apparently overall manageable. In KEYNOTE-426, a higher rate of all adverse event categories (particularly grade 3-5 AES, SAEs and drug discontinuations due to AEs) for the combination of pembrolizumab with axitinib. Even adjusting for exposure an increased rate of drug-related SAEs and of drug discontinuations due to AEs is observed.

Concerns were raised regarding high occurrence of hepatic adverse events, which are addressed in the SmPC. Taking into account the worse safety profile of the combination compared to sunitinib, it is reassuring that permanent discontinuation treatment due to AEs does not seem to negatively affect neither the outcome of patients on subsequent treatments nor their prognosis if left untreated.

## 3.7.2. Balance of benefits and risks

Overall, a benefit in terms of PFS and ORR was observed across all IMDC risk group with pembrolizumab and axitinib compared to sunitinib. Although the safety profile of the combination compares less favourable to sunitinib, it appears overall manageable. The benefits of the combination treatment are considered to outweigh the risks.

## 3.7.3. Additional considerations on the benefit-risk balance

None.

## 3.8. Conclusions

The overall B/R of pembrolizumab in the first line treatment of advanced or metastatic renal cell carcinoma, in combination with axitinib, is positive.

The CHMP considers the following measures necessary to address issues related to clinical efficacy:

The final CSR of the pivotal Keynote-426 study should be provided post-approval as Annex II condition, in particular to further characterize the benefit of the combination treatment in the favourable IDMC risk group with longer follow-up.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following

<div style=\"page-break-after: always\"></div>

change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II and IIIB     |

Extension of Indication to include first line treatment of advanced or metastatic renal cell carcinoma (RCC) as combination therapy of pembrolizumab together with axitinib based on the results of the first Interim Analysis (IA1) from the pivotal study, KN426, an ongoing, Phase 3, randomized, open-label, multicenter, global study, to evaluate the efficacy and safety of pembrolizumab in combination with axitinib versus sunitinib in previously untreated subjects with advanced/metastatic RCC. It also includes supportive data from KEYNOTE-427 Cohort A (pembrolizumab monotherapy) and a Sponsored Study A4061051 (axitinib monotherapy). As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance.

The MAH took the opportunity to update the educational materials in Annex II of the Product Information in relation to the adopted variation procedure EMEA/H/C/003820/II/0068. Furthermore, the due date of the Post-authorisation efficacy study P361 is updated to 2Q 2020.

In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet.

The risk management plan (RMP) Version 25 is submitted.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk management plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

In addition, an updated RMP should be submitted:

At the request of the European Medicines Agency;

Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

<div style=\"page-break-after: always\"></div>

## Obligation to conduct post-authorisation measures

The MAH shall complete, within the stated timeframe, the below measures:

| Description                                                                                                                                                                                                                                                                                                                                                   | Due date   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| Post-authorisation efficacy study (PAES): The MAH should submit the final study report for study P426: A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) | 1Q 2021    |

## Paediatric data

Furthermore, the CHMP reviewed the available paediatric data of studies subject to the agreed Paediatric Investigation Plan PIP P/0043/2018 and the results of these studies are reflected in the Summary of Product Characteristics (SmPC) and, as appropriate, the Package Leaflet.

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Extension of Indication to include first line treatment of advanced or metastatic renal cell carcinoma (RCC) as combination therapy of pembrolizumab together with axitinib based on the results of the first Interim Analysis (IA1) from the pivotal study, KN426, an ongoing, Phase 3, randomized, open-label, multicenter, global study, to evaluate the efficacy and safety of pembrolizumab in combination with axitinib versus sunitinib in previously untreated subjects with advanced/metastatic RCC. It also includes supportive data from KEYNOTE-427 Cohort A (pembrolizumab monotherapy) and a Sponsored Study A4061051 (axitinib monotherapy). As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance.

The MAH took the opportunity to update the educational materials in Annex II of the Product Information in relation to the adopted variation procedure EMEA/H/C/003820/II/0068. Furthermore, the due date of the Post-authorisation efficacy study P361 is updated to 2Q 2020.

In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet.

The risk management plan (RMP) Version 25 is submitted.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Summary

Please refer to the Scientific Discussion EMEA/H/C/003820/II/0069.